Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 8, 2021, is named 070413_20615_SL.txt and is 3,009,383 bytes in size.

FIELD OF THE INVENTION

The present invention relates to antibodies directed to epitopes of SARS-CoV-2 Coronavirus 2 (“SARS-CoV-2”). The present invention further relates to the preparation and use of broadly neutralizing antibodies directed to the SARS-CoV-2 spike (S) glycoproteins for the prevention and treatment of SARS-CoV-2 infection.

BACKGROUND OF THE INVENTION

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). It contains four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Among them, S protein plays the most important roles in viral attachment, fusion, and entry, and it serves as a target for development of antibodies, entry inhibitors, and vaccines. The S protein mediates viral entry into host cells by first binding to a host receptor through the receptor-binding domain (RBD) in the S1 subunit and then fusing the viral and host membranes through the S2 subunit. SARS-CoV and MERS-CoV RBDs recognize different receptors. SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as its receptor, whereas MERS-CoV recognizes dipeptidyl peptidase 4 (DPP4) as its receptor. Similar to SARS-CoV, SARS-CoV-2 also recognizes ACE2 as its host receptor binding to viral S protein.

As of Apr. 25, 2020, a total of 2.84 million confirmed cases of COVID-19 were reported, including 199,000 deaths, in the United States and at least 85 other countries and/or territories. Currently, the intermediate host of SARS-CoV-2 is still unknown, and no effective prophylactics or therapeutics are available. This calls for the immediate development of vaccines and antiviral drugs for prevention and treatment of COVID-19.

In addition, due to the ability of SARS-CoV-2 to be spread through an airborne route, SARS-CoV-2 presents a particular threat to the health of large populations of people throughout the world. Accordingly, methods to immunize people before infection, diagnose infection, immunize people during infection, and treat infected persons infected with SARS-CoV-2 are urgently needed.

SUMMARY OF THE INVENTION

This disclosure addresses the need mentioned above in a number of aspects by providing broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof.

In one aspect, this disclosure provides an isolated anti-SARS-CoV-2 antibody or antigen-binding fragment thereof that binds specifically to a SARS-CoV-2 antigen. In some embodiments, the SARS-CoV-2 antigen comprises a Spike (S) polypeptide, such as a S polypeptide of a human or an animal SARS-CoV-2. In some embodiments, the SARS-CoV-2 antigen comprises the receptor-binding domain (RBD) of the S polypeptide. In some embodiments, the RBD comprises amino acids 319-541 of the S polypeptide.

In some embodiments, the antibody or antigen-binding fragment thereof is capable of neutralizing a plurality of SARS-CoV-2 strains.

In some embodiments, the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDRs) (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region having an amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) of a light chain variable region having the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise respective amino acid sequences of (i) SEQ ID NOs: 2878, 2880, 2882, 2890, 2892, and 2894; or (ii) SEQ ID NOs: 2902, 2904, 2906, 2914, 2916, and 2918.

In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region having an amino acid sequence with at least 75% identity to SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; or (ii) a light chain variable region having an amino acid sequence with at least 75% identity to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region having an amino acid sequence with at least 75% identity to SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; and (ii) a light chain variable region having an amino acid sequence with at least 75% identity to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region having the amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; or (ii) a light chain variable region having the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region having the amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; and (ii) a light chain variable region having the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region that comprise the respective amino acid sequences of SEQ ID NOs: 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44, 45-46, 47-48, 49-50, 51-52, 53-54, 55-56, 57-58, 59-60, 61-62, 63-64, 65-66, 67-68, 69-70, 71-72, 73-74, 75-76, 77-78, 79-80, 81-82, 83-84, 85-86, 87-88, 89-90, 91-92, 93-94, 95-96, 97-98, 99-100, 101-102, 103-104, 105-106, 107-108, 109-110, 111-112, 113-114, 115-116, 117-118, 119-120, 121-122, 123-124, 125-126, 127-128, 129-130, 131-132, 133-134, 135-136, 137-138, 139-140, 141-142, 143-144, 145-146, 147-148, 149-150, 151-152, 153-154, 155-156, 157-158, 159-160, 161-162, 163-164, 165-166, 167-168, 169-170, 171-172, 173-174, 175-176, 177-178, 179-180, 181-182, 183-184, 185-186, 187-188, 2876 and 2888, or 2900 and 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region that comprise the respective amino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56, 57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain/light chain sequence pair of SEQ ID NOs: 2886/2898, 2887/2899, 2910/2921, or 2911/2922.

In some embodiments, the antibody or antigen-binding fragment thereof is a multivalent antibody that comprises (a) a first target binding site that specifically binds to an epitope within the S polypeptide, and (b) a second target binding site that binds to a different epitope on the S polypeptide or a different molecule. In some embodiments, the multivalent antibody is a bivalent or bispecific antibody.

In some embodiments, the antibody or the antigen-binding fragment thereof further comprises a variant Fc constant region. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a chimeric antibody, a humanized antibody, or a humanized monoclonal antibody. In some embodiments, the antibody is a single-chain antibody, Fab or Fab2 fragment.

In some embodiments, the antibody or antigen-binding fragment thereof is detectably labeled or conjugated to a toxin, a therapeutic agent, a polymer, a receptor, an enzyme or a receptor ligand. In some embodiments, the polymer is polyethylene glycol (PEG).

For example, an antibody of the invention may be coupled to a toxin. Such antibodies may be used to treat animals, including humans, that are infected with the virus that is etiologically linked to SARS-CoV-2. For example, an antibody that binds to the spike protein of the coronavirus that is etiologically linked to SARS-CoV-2 may be coupled to a tetanus toxin and administered to an animal suffering from infection by the aforementioned virus. The toxin-coupled antibody is thought to bind to a portion of a spike protein presented on an infected cell, and then kill the infected cell.

An antibody of the invention may be coupled to a detectable tag. Such antibodies may be used within diagnostic assays to determine if an animal, such as a human, is infected with SARS-CoV-2. Examples of detectable tags include fluorescent proteins (i.e., green fluorescent protein, red fluorescent protein, yellow fluorescent protein), fluorescent markers (i.e., fluorescein isothiocyanate, rhodamine, texas red), radiolabels (i.e., 3H, 32P, 125I), enzymes (i.e., β-galactosidase, horseradish peroxidase, β-glucuronidase, alkaline phosphatase), or an affinity tag (i.e., avidin, biotin, streptavidin).

In another aspect, this disclosure provides a pharmaceutical composition comprising: the antibody or antigen-binding fragment thereof of any one of the preceding claims and optionally a pharmaceutically acceptable carrier or excipient.

In some embodiments, the pharmaceutical comprises two or more of the antibody or antigen-binding fragment thereof of described above, such as any combinations of the antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain that comprise the respective amino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56, 57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912.

In some embodiments, the two or more of the antibody or antigen-binding fragment thereof comprise: (1) a first antibody set comprising: (i) a first antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 57-58; and (ii) a second antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 1-2, 55-56, 57-58, 65-66, 81-82, or 85-86; or (2) a second antibody set comprising: (a) a third antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of of SEQ ID NOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912; and (b) a fourth antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of of SEQ ID NOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912, wherein the third antibody is different from the fourth antibody.

In some embodiments, the pharmaceutical composition further comprises a second therapeutic agent. In some embodiments, the second therapeutic agent comprises an anti-inflammatory drug or an antiviral compound. In some embodiments, the antiviral compound comprises: a nucleoside analog, a peptoid, an oligopeptide, a polypeptide, a protease inhibitor, a 3C-like protease inhibitor, a papain-like protease inhibitor, or an inhibitor of an RNA dependent RNA polymerase. In some embodiments, the antiviral compound may include: acyclovir, gancyclovir, vidarabine, foscarnet, cidofovir, amantadine, ribavirin, trifluorothymidine, zidovudine, didanosine, zalcitabine or an interferon. In some embodiments, the interferon is an interferon-α or an interferon-β.

Also within the scope of this disclosure is use of the pharmaceutical composition, as described above, in the preparation of a medicament for the diagnosis, prophylaxis, treatment, or combination thereof of a condition resulting from a SARS-CoV-2.

In another aspect, this disclosure also provides (i) a nucleic acid molecule encoding a polypeptide chain of the antibody or antigen-binding fragment thereof described above; (ii) a vector comprising the nucleic acid molecule as described; and (iii) a cultured host cell comprising the vector as described. Also provided is a method for producing a polypeptide, comprising: (a) obtaining the cultured host cell as described; (b) culturing the cultured host cell in a medium under conditions permitting expression of a polypeptide encoded by the vector and assembling of an antibody or fragment thereof; and (c) purifying the antibody or fragment from the cultured cell or the medium of the cell.

In another aspect, this disclosure provides a kit comprising a pharmaceutically acceptable dose unit of the antibody or antigen-binding fragment thereof of or the pharmaceutical composition as described above. Also within the scope of this disclosure is a kit for the diagnosis, prognosis or monitoring the treatment of SARS-CoV-2 in a subject, comprising: the antibody or antigen-binding fragment thereof as described; and a least one detection reagent that binds specifically to the antibody or antigen-binding fragment thereof.

In yet another aspect, this disclosure further provides a method of neutralizing SARS-CoV-2 in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment thereof or a therapeutically effective amount of the pharmaceutical composition, as described above.

In yet another aspect, this disclosure additionally provides a method of preventing or treating a SARS-CoV-2 infection, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment thereof or a therapeutically effective amount of the pharmaceutical composition, as described above.

In some embodiments, the method of neutralizing SARS-CoV-2 in a subject comprises administering to a subject in need thereof a therapeutically effective amount of a first antibody or antigen-binding fragment thereof and a second antibody or antigen-binding fragment thereof of the antibody or antigen-binding fragment or a therapeutically effective amount of the pharmaceutical composition described above, as described above, wherein the first antibody or antigen-binding fragment thereof and the second antibody or antigen binding fragment thereof exhibit synergistic activity.

In some embodiments, the method of preventing or treating a SARS-CoV-2 infection, comprising administering to a subject in need thereof a therapeutically effective amount of a first antibody or antigen-binding fragment thereof and a second antibody or antigen-binding fragment thereof of the antibody or antigen-binding fragment or a therapeutically effective amount of the pharmaceutical composition described above, as described above, wherein the first antibody or antigen-binding fragment thereof and the second antibody or antigen binding fragment thereof exhibit synergistic activity. In some embodiments, the first antibody or antigen-binding fragment thereof is administered before, after, or concurrently with the second antibody or antigen-binding fragment thereof.

In some embodiments, the first antibody or antigen-binding fragment thereof and the second antibody or antigen-binding fragment thereof can be any combinations of the antibody or antigen-binding fragment thereof comprising a heavy chain and a light chain that comprise the respective amino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56, 57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912.

In some embodiments, the first antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 57-58 and the second antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 1-2, 55-56, 57-58, 65-66, 81-82, or 85-86.

In some embodiments, the first antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912, and the second antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912, wherein the first antibody and the second antibody are different.

In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a second therapeutic agent or therapy. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 57-58; and the second therapeutic agent or therapy comprises an antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region that comprise the respective amino acid sequences of SEQ ID NOs: 1-2, 55-56, 57-58, 65-66, 81-82, or 85-86.

In some embodiments, the second therapeutic agent comprises an anti-inflammatory drug or an antiviral compound. In some embodiments, the antiviral compound comprises a nucleoside analog, a peptoid, an oligopeptide, a polypeptide, a protease inhibitor, a 3C-like protease inhibitor, a papain-like protease inhibitor, or an inhibitor of an RNA dependent RNA polymerase. In some embodiments, the antiviral compound may include: acyclovir, gancyclovir, vidarabine, foscarnet, cidofovir, amantadine, ribavirin, trifluorothymidine, zidovudine, didanosine, zalcitabine or an interferon. In some embodiments, the interferon is an interferon-α or an interferon-β.

In some embodiments, the antibody or antigen-binding fragment thereof is administered before, after, or concurrently with the second therapeutic agent or therapy. In some embodiments, the antibody or antigen-binding fragment thereof is administered to the subject intravenously, subcutaneously, or intraperitoneally. In some embodiments, the antibody or antigen-binding fragment thereof is administered prophylactically or therapeutically.

In another aspect, this disclosure further provides a method for detecting the presence of SARS CoV-2 in a sample comprising the steps of: (i) contacting a sample with the antibody or antigen-binding fragment thereof described above; and (ii) determining binding of the antibody or antigen-binding fragment to one or more SARS CoV-2 antigens, wherein binding of the antibody to the one or more SARS CoV-2 antigens is indicative of the presence of SARS CoV-2 in the sample. In some embodiments, the sample is a blood sample.

In some embodiments, the SARS-CoV-2 antigen comprises a S polypeptide, such as a S polypeptide of a human or an animal SARS-CoV-2. In some embodiments, the SARS-CoV-2 antigen comprises the receptor-binding domain (RBD) of the S polypeptide. In some embodiments, the RBD comprises amino acids 319-541 of the S polypeptide.

In some embodiments, the antibody or antigen-binding fragment thereof is conjugated to a label. In some embodiments, the step of detecting comprises contacting a secondary antibody with the antibody or antigen-binding fragment thereof and wherein the secondary antibody comprises a label. In some embodiments, the label includes a fluorescent label, a chemiluminescent label, a radiolabel, and an enzyme.

In some embodiments, the step of detecting comprises detecting fluorescence or chemiluminescence. In some embodiments, the step of detecting comprises a competitive binding assay or ELISA.

In some embodiments, the method further comprises binding the sample to a solid support. In some embodiments, the solid support includes microparticles, microbeads, magnetic beads, and an affinity purification column.

The foregoing summary is not intended to define every aspect of the disclosure, and additional aspects are described in other sections, such as the following detailed description. The entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. Other features and advantages of the invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the disclosure, are given by way of illustration only, because various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B are a set of graphs showing the results of monoclonal antibodies for neutralization of SARS-CoV-2 pseudovirus expressing nanoluciferase.

FIGS. 2A and 2B (collectively “FIG. 2”) are a set of graphs showing the results of monoclonal antibodies in ELISA for binding to the Receptor Binding Domain (RBD) of the virus Spike protein.

FIGS. 3A, 3B, 3C, 3D, 3E, 3F, 3G, and 3H (collectively “FIG. 3”) are a set of graphs showing results of ELISAs measuring plasma reactivity to RBD (FIGS. 3A and 3B) and S protein (FIGS. 3C and 3D). Left shows optical density units at 450 nm (OD, Y axis) and reciprocal plasma dilutions (X axis). Negative controls in black; individuals 21, and 47 in blue and red lines and arrowheads, respectively. Right shows normalized area under the curve (AUC) for 8 controls and each of 149 individuals in the cohort. FIG. 3E shows symptom (Sx) onset to time of sample collection in days (X axis) plotted against normalized AUC for IgM binding to RBD (Y axis); r=0.5517 and p=<0.0001. FIG. 3F shows participant age in years (X axis) plotted against normalized AUC for IgG binding to RBD (Y axis); r=0.1827 and p=0.0258. The r and p values for the correlations in FIGS. 3E and 3F were determined by two-tailed Spearman's. FIG. 3G shows normalized AUC of anti-RBD IgG ELISA for outpatients (n=138) and hospitalized (n=11) individuals; p=0.0178. FIG. 3H shows normalized AUC of anti-RBD IgG ELISA for males (n=83) and females (n=66); p=0.0063. For FIGS. 3G and 3H, horizontal bars indicate median values. Statistical significance was determined using two-tailed Mann-Whitney U test.

FIGS. 4A, 4B, 4C, 4D, 4E, and 4F (collectively “FIG. 4”) are a set of graphs showing neutralization of SARS-CoV-2 pseudovirus by plasma. FIG. 4A shows normalized relative luminescence values (RLU, Y axis) in cell lysates of 293 T_ACE2cells 48 hours after infection with nanoluc-expressing SARS-CoV-2 pseudovirus in the presence of increasing concentrations of plasma (X axis) derived from 149 participants (grey, except individuals 21 and 47 in blue and red lines, bars and arrowheads, respectively) and 3 negative controls (black lines). Mean of duplicates; representative of two independent experiments. FIG. 4B shows ranked average half-maximal inhibitory plasma neutralizing titer (NT₅₀) for the 59 of 149 individuals with NT₅₀s>500 and individual 107. Asterisks indicate donors from which antibody sequences were derived. FIG. 4C shows normalized AUC for anti-RBD IgG ELISA (X axis) plotted against NT₅₀(Y axis); r=0.6432, p=<0.0001. FIG. 4D shows normalized AUC for anti-S IgG ELISA (X axis) plotted against NT₅₀(Y axis); r=0.6721, p=<0.0001. The r and p values for the correlations in FIGS. 4C and 4D were determined by two-tailed Spearman's. FIG. 4E shows NT₅₀for outpatients (n=138) and hospitalized (n=11) individuals; p=0.0495. FIG. 4F shows NT₅₀for males (n=83) and females (n=66) in the cohort; p=0.0031. Statistical significance in e and f was determined using two-tailed Mann-Whitney U test and horizontal bars indicate median values. Dotted lines in FIGS. 4E and 4F (NT₅₀=5) represents lower limit of detection (LLOD). Samples with neutralizing titers below 1:50 were plotted at LLOD.

FIGS. 5A, 5B, 5C, and 5D (collectively “FIG. 5”) are a set of graphs showing activities of anti-SARS-CoV-2 RED antibodies. FIG. 5A shows representative flow cytometry plots displaying dual AF647- and PE-RBD binding B cells in control and 6 study individuals (for gating strategy see FIG. 12). Percentages of antigen specific B cells are indicated. Control is a healthy control sample obtained pre-COVID-19. FIG. 5B is a set of pie charts depicting the distribution of antibody sequences from 6 individuals. The number in the inner circle indicates the number of sequences analyzed for the individual denoted above the circle. White indicates sequences isolated only once, and grey or colored pie slices are proportional to the number of clonally related sequences. Red, blue, orange, and yellow pie slices indicate clones that share the same IGHV and IGLV genes. FIG. 5C is circos plot showing sequences from all 6 individuals with clonal relationships depicted as in FIG. 5B. Interconnecting lines indicate the relationship between antibodies that share V and J gene segment sequences at both IGH and IGL. Purple, green, and gray lines connect related clones, clones and singles, and singles to each other, respectively. FIG. 5D shows sample sequence alignment for antibodies originating from different individuals that display highly similar IGH V(D)J and IGL VJ sequences including CDR3s. Amino acid differences in CDR3s to the bolded reference sequence above are indicated in red and dots represent identities. FIG. 5D discloses SEQ ID NOS 598, 602, 1434, 1438, 2445, 2449, 578, 582, 586, 1754, 1758, 600, 600, 1436, 600, 2487, 600, 580, 584, 580, 580, and 580, respectively, in order of column.

FIGS. 6A, 6B, 6C, 6D, 6E, 6F, 6G, 6H, 6I, 6J, 6K, 6L, 6M, 6N, 6O, 6P, 6Q, and 6R (collectively “FIG. 6”) are a set of graphs showing anti-SARS-CoV-2 RBD antibody reactivity. FIG. 6A is a graph showing the results of ELISA assays measuring monoclonal antibody binding to RBD. Optical density units at 450 nm (OD, Y axis) vs. antibody concentrations (X axis); 94 samples and 1 isotype control. C121, C135 C144 and isotype control in red, green, purple, and black respectively, in all panels. FIG. 6B is a graph showing normalized relative luminescence values (RLU, Y axis) in cell lysates of 293T_ACE2cells 48 hours after infection with SARS-CoV-2 pseudovirus in the presence of increasing concentrations of monoclonal antibodies (X axis). 89 samples and 1 isotype control. FIG. 6C shows normalized RLU for SARS-CoV-2 pseudovirus neutralization (Y axis) vs. titration of monoclonal antibodies C121, C135 and C144. FIG. 6D shows SARS-CoV-2 real virus neutralization assay. Normalized infected cells (Y axis, determined by dividing the amount of infection per well by the average of control wells infected in the absence of antibodies) vs. titration of monoclonal antibodies C121, C135, and C144. FIGS. 6A, 6B, 6C, and 6D show a representative of two independent experiments. In FIG. 6B and FIG. 6C is mean of duplicates and in FIG. 6D is mean with a standard deviation of triplicates. FIG. 6E shows IC₅₀s for antibodies assayed in FIGS. 6B and 6D, the average value of at least two experiments is shown. Samples with IC₅₀s above 1 mg/ml were plotted at 1 μg/ml; n=89 (pseudovirus) and n=3 (virus), respectively. FIG. 6F is a diagrammatic representation of biolayer interferometry experiment. FIG. 6G is a graph showing binding of C144, C101, C121, C009, C135, and CR3022 to RBD. FIGS. 6H, 6I, 6J, 6K, 6L, 6M, and 6N shows secondary antibody binding to preformed IgG-RBD complexes (Ab1). The table displays the shift in nanometers after second antibody (Ab2) binding to the antigen in the presence of the first antibody (Ab1). Values are normalized by the subtraction of the autologous antibody control. Representative of two experiments. FIGS. 6O, 6P, and 6Q show representative 2D-class averages and 3D reconstructed volumes for SARS-CoV-S 2P trimers complexed with C002, C119, and C121 Fabs. 2D class averages with observable Fab density are boxed. FIG. 6R shows overlay of S-Fab complexes with fully-occupied C002 (blue), C121 (magenta) and C119 (orange) Fabs. The SARS-CoV-2 S model from PDB 6VYB was fit into the density and the SARS-CoV mAb S230 (PDB 6NB6) is shown as a reference (green ribbon).

FIGS. 7A, 7B, 7C, 7D, 7E, 7F, 7G, 7H, 7I, 7J, 7K, and 7L (collectively “FIG. 7”) are a set of graphs showing clinical correlates. FIG. 7A shows summary of the cohort's characteristics. FIG. 7B shows age distribution (Y axis) for all males (n=83) and females (n=66) in the cohort; p=0.2074. FIG. 7C shows duration of symptoms in days (Y axis) for all males (n=83) and females (n=66) in the cohort; p=0.8704. FIG. 7D shows time between symptom onset and plasma collection (Y axis) for all males (n=83) and females (n=66) in the cohort; p=0.5514. FIG. 7E shows subjective symptom severity on a scale of 0-10 (Y axis) for all males (n=83) and females (n=66) in the cohort; p=0.1888. FIG. 7F shows age distribution (Y axis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.0305. FIG. 7G shows duration of symptoms in days (Y axis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.1241. FIG. 7H shows time between symptom onset and plasma collection in days (Y axis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.1589. FIG. 7I shows symptom severity (Y axis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.0550. FIG. 7J shows age distribution (Y axis) for all outpatient (n=138) and hospitalized (n=11) participants; p=0.0024. FIG. 7K shows duration of symptoms in days (Y axis) for all outpatient (n=138) and hospitalized (n=11) participants in the cohort; p=<0.0001. FIG. 7L shows time between symptom onset and plasma collection in days (Y axis) for all outpatient (n=138) and hospitalized (n=11) participants in the cohort; p=0.0001. Horizontal bars indicate median values. Statistical significance was determined using two-tailed Mann-Whitney U test.

FIGS. 8A, 8B, 8C, 8D, 8E, 8F, 8G, 8H, 8I, and 8J (collectively “FIG. 8”) are a set of graphs showing clinical correlates of plasma antibody titers. FIG. 8A shows normalized AUC for IgG anti-RBD (Y axis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.0107. FIG. 8B shows normalized AUC for IgM anti-RBD (Y axis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.5371. FIG. 8C shows normalized AUC for IgG anti-S (Y axis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.0135. FIG. 8D shows normalized AUC for IgM anti-S(Y axis) for all cases (n=111) and contacts (n=38) in the cohort; p=0.7838. FIG. 8E shows normalized AUC for IgM anti-RBD (Y axis) for all males (n=83) and females (n=66) in the cohort; p=0.9597. FIG. 8F shows normalized AUC for IgG anti-S (Y axis) for all males (n=83) and females (n=66) in the cohort; p=0.0275. FIG. 8E shows normalized AUC for IgM anti-S (Y axis) for all males (n=83) and females (n=66) in the cohort; p=0.5363. FIG. 8H shows normalized AUC for IgM anti-RBD (Y axis) for all outpatient (=138) and hospitalized (n=11) participants in the cohort; p=0.0059. FIG. 8I shows normalized AUC for IgG anti-S (Y axis) for all outpatient (=138) and hospitalized (=11) participants in the cohort; p=0.0623. FIG. 8J shows normalized AUC for IgM anti-S (Y axis) for all outpatient (=138) and hospitalized (=11) participants in the cohort; p=0.2976. Horizontal bars indicate median values. Statistical significance was determined using two-tailed Mann-Whitney U test.

FIGS. 9A, 9B, 9C, 9D, 9E, 9F, 9G, 9H, 9I, 9J, 9K, 9L, 9M, and 9N (collectively “FIG. 9”) are a set of graphs showing additional clinical correlates of plasma antibody titers. FIG. 9A shows time between symptom onset and plasma collection in days (X axis) plotted against normalized AUC for IgG anti-RBD (Y axis); r=−0.0261 p=0.7533. FIG. 9B shows time between symptom onset and plasma collection in days (X axis) plotted against normalized AUC for IgG anti-S(Y axis); r=−0.1495 p=0.0697. FIG. 9C shows time between symptom onset and plasma collection in days (X axis) plotted against normalized AUC for IgM anti-S (Y axis); r=0.1496 p=0.0695. FIG. 9D shows age (X axis) plotted against AUC for IgM anti-RBD (Y axis); r=0.0172 p=0.8355. FIG. 9E shows age (X axis) plotted against normalized AUC for IgG anti-S (Y axis); r=0.1523 p=0.0638. FIG. 9F shows age (X axis) plotted against normalized AUC for IgM anti-S (Y axis); r=0.0565 p=0.4934. FIG. 9G shows duration of symptoms in days (X axis) plotted against normalized AUC for IgG anti-RBD (Y axis); r=0.1525, p=0.0633. FIG. 9H shows duration of symptoms in days (X axis) plotted against normalized AUC for IgM anti-RBD (Y axis); r=−0.3187, p=<0.0001. FIG. 9I shows duration of symptoms in days (X axis) plotted against normalized AUC for IgG anti-S (Y axis); r=0.0329, p=0.6904. FIG. 9J shows duration of symptoms in days (X axis) plotted against normalized AUC for IgM anti-S (Y axis); r=0.0824, p=0.3177. FIG. 9K shows severity of symptoms (X axis) plotted against normalized AUC for IgG anti-RBD (Y axis); r=0.2679 p=0.0010. FIG. 9L shows severity of symptoms (X axis) plotted against normalized AUC for IgM anti-RBD (Y axis); r=−0.1943 p=0.0176. FIG. 9M shows severity of symptoms (X axis) plotted against normalized AUC for IgG anti-S (Y axis); r=0.1187 p=0.1492. FIG. 9N shows severity of symptoms (X axis) plotted against normalized AUC for IgM anti-S (Y axis); r=0.1597 p=0.0517. All correlations were analyzed by two-tailed Spearman's.

FIGS. 10A, 10B, and 10C (collectively “FIG. 10”) show a diagrammatic representation of the SARS-CoV2-Strunc luciferase assay. FIG. 10A shows that co-transfection of pNL4-3ΔEnv-nanoluc and pSARS-CoV-2 spike vectors into 293T cells (ATCC) leads to production of SARS-CoV-2 Spike-pseudotyped HIV-1 particles (SARS-CoV-2 pseudovirus) carrying the Nanoluc gene. FIG. 10B shows that SARS-CoV-2 pseudovirus was incubated for 1 h at 37° C. with plasma or monoclonal antibody dilutions. The virus-antibody mixture is used to infect ACE2-expressing 293T cells, which will express nanoluc Luciferase upon infection. FIG. 10C shows relative luminescence units (RLU) reads from lysates of ACE2-expressing 293T cells infected with increasing amounts of SARS-CoV-2 pseudovirus. Error bars represent standard deviation of triplicates, two experiments.

FIGS. 11A, 11B, 11C, 11D, 11E, and 11F (collectively “FIG. 11”) are a set of graphs showing clinical correlates of neutralization. FIG. 11A shows normalized AUC for anti-RBD IgM (X axis) plotted against NT₅₀(Y axis); r=0.3119, p=0.0001. FIG. 11B shows normalized AUC for anti-S IgM (X axis) plotted against NT₅₀(Y axis); r=0.3211, p=<0.0001. FIG. 11C shows duration of symptoms in days (X axis) plotted against NT₅₀(Y axis); r=0.1997, p=0.0146. FIG. 11D shows time between symptom onset and plasma collection in days (X axis) plotted against NT₅₀(Y axis); r=−0.1344, p=0.1033. FIG. 11E shows symptom severity (X axis) plotted against NT₅₀(Y axis); r=0.2234, p=0.0062. FIG. 11F shows age (X axis) plotted against NT₅₀(Y axis); r=0.3005, p=0.0002. All correlations were analyzed by two-tailed Spearman's. Dotted line (NT₅₀=5) represents lower limit of detection (LLOD) of pseudovirus neutralization assay. Samples with neutralizing titers below 1:50 were plotted at LLOD.

FIG. 12 shows the results of flow cytometry and gating strategy used for cell sorting. Gating was on singlets that were CD20⁺ and CD3⁻CD8⁻CD16⁻Ova⁻. Sorted cells were RBD-PE⁺ and RBD-AF647⁺.

FIG. 13 shows frequency distributions of human V genes. The two-tailed t test with unequal variance was used to compare the frequency distributions of human V genes of anti-SARS-CoV-2 antibodies from this study to Sequence Read Archive SRP010970 (Rubelt, F. et al. PLoS One).

FIGS. 14A, 14B, and 14C (collectively “FIG. 14”) show the analysis of antibody somatic hypermutation and CDR3 length. FIG. 14A shows that for each individual, the number of somatic nucleotide mutations (Y axis) at the IGVH and IGVL are shown on the left panel, and the amino acid length of the CDR3s (Y axis) are shown on the right panel. The horizontal bars indicate the mean. The number of antibody sequences (IGVH and IGVL) evaluated in each participant are n=118 (COV107), n=127 (COV21), n=79 (COV47), n=54 (COV57), n=78 (COV72), n=78 (COV96). FIG. 14B is the same as in FIG. 14A but for all antibodies combined (n=534 for both IGVH and IGVL). FIG. 14C shows distribution of the hydrophobicity GRAVY scores at the IGH CDR3 in antibody sequences from this study compared to a public database (see Methods for statistical analysis in EXAMPLE 1). The box limits are at the lower and upper quartiles, the center line indicates the median, the whiskers are 1.5× interquartile range, and the dots represent outliers.

FIGS. 15A, 15B, 15C, 15D, and 15E (collectively “FIG. 15”) show Binding of the monoclonal antibodies to the RBD of SARS-CoV-2 and cross-reactivity to SARS-CoV. FIG. 15A shows EC₃₀values for binding to the RBD of SARS-CoV-2. Average of two or more experiments; n=89. FIGS. 15B and 15C show binding curves and EC₃₀values (average of two experiments) for binding to the RBD of SARS-CoV; n=20 and n=17 (excluding isotype and CR3022), respectively. FIGS. 15D and 15E show SARS-CoV pseudovirus neutralization curves and IC₅₀values. Shown in FIG. 15D are the standard deviations of duplicates for one representative experiment and in FIG. 15E is the average of two experiments (n=10, excluding CR3022). Samples with IC₅₀s above 1 μg/ml were plotted at 1 μg/ml.

FIG. 16 shows the results of the biolayer interferometry experiment that depicts binding of antibodies C144, C101, C002, C121, C009, C119. Graphs show secondary antibody binding to preformed C121 IgG-RBD complexes. The table displays the shift in nanometers after second antibody (Ab2) binding to the antigen in the presence of the first antibody (Ab1). Values are normalized by the subtraction of the autologous antibody control.

FIGS. 17A, 17B, and 17C (collectively “FIG. 17”) are a set of diagrams depicting that coronavirus S proteins show localized regions of conservation and variability. FIG. 17A is a schematic of SARS-CoV-2 S protein domain architecture. The 51 and S2 subunits are indicated, with scissors representing the locations of proteolytic cleavage sites required for S priming prior to fusion. UH=upstream helix, FP=fusion peptide, HR1=heptad repeat 1, CH=central helix, BH=β-hairpin, HR2=heptad repeat 2, TM=transmembrane region, CT=cytoplasmic tail. FIG. 17B shows phylogenetic trees of selected coronaviruses based on protein sequences of S proteins and RBD/S1B domains. FIG. 17C shows sequence conservation of 7 human coronaviruses plotted as a surface. The sequence alignment was generated using SARS-CoV-2 (GenBank MN985325.1), SARS-CoV (AAP13441.1), MERS-CoV (JX869059.2), HCoV-OC43 (AAT84362.1), HCoV-229E (AAK32191.1), HCoV-NL63 (AAS58177.1), and HCoV-HKU1 (QOZME7.1). Conservation was calculated by ConSurf Database (Landau et al., 2005) and displayed using a surface representation of the structure of the SARS-CoV-2 S protein (PDB code 6VXX).

FIGS. 18A, 18B, and 18C (collectively “FIG. 18”) are a set of diagrams showing that plasma Fabs bind to SARS-CoV-2 S protein. FIG. 18A shows a schematic of polyclonal IgG and Fab purification from human plasma for nsEMPEM protocol. FIG. 18B shows an SEC profile of Fabs (left) and SDS-PAGE of purified IgGs and Fabs (right) from COV21, COV57, and COV107 plasma samples. FIG. 18C shows SEC demonstration that plasma-derived Fabs from COV21 and COV57 shift the SARS-CoV-2 S protein trimer to a higher apparent molecular weight. No shift was observed when Fabs from COV107 were analyzed by SEC with S protein. Fractions pooled and concentrated for nsEMPEM are boxed. See also FIG. 24.

FIGS. 19A, 19B, 19C, 19D, 19E, 19F, 19G, and 19H (collectively “FIG. 19”) show convalescent plasma IgG and Fab binding properties demonstrating recognition of diverse coronaviruses and effects of avidity. Results from ELISAs assessing binding of IgGs and Fabs purified from plasmas from 10 COVID-19 individuals (X-axis) presented as area under the curve (AUC; shown as mean±S.D. of values derived from experiments conducted in triplicate). FIGS. 19A, 19B, 19C, 19D, 19E, and 19F show that binding was assessed against S and RBD proteins for SARS-CoV-2 (FIG. 19A), SARS-CoV (FIG. 19B), MERS-CoV (FIG. 19C), HCoV-NL63 (FIG. 19D), HCoV-OC43 (FIG. 19E), and HCoV-229E (FIG. 19F). Polyclonal IgGs or Fabs were evaluated at a top concentration of 50 μg/mL and 7 additional 4-fold serial dilutions. Binding of the IgG and Fab from IOMA, an antibody against HIV-1 (Gristick et al., 2016), was used as a control in each assay. FIG. 19G shows in vitro neutralization assays comparing the potencies of purified plasma IgGs and purified plasma Fabs. COV21, COV57, and COV107 plasma Fabs and IgGs are highlighted in the indicated colors; curves for 10 other plasmas (listed in FIG. 19H) are gray. FIG. 19H shows molar IC₅₀values for purified plasma IgGs and Fabs for the indicated plasmas are listed with the molar ratio for IC₅₀(Fab) to IC₅₀(IgG) shown in the right column. See also FIGS. 25 and 26.

FIGS. 20A, 20B, and 20C (collectively “FIG. 20”) show the results of the EM study that reveals distinct predominant epitopes targeted by convalescent plasma antibodies. FIG. 20A shows side and top views for representative 3D reconstructions of four nsEMPEM datasets (S protein alone, S+COV21 Fabs, S+COV57 Fabs, S+COV107 Fabs). Bound Fabs observed in reconstructions from COV21 and COV57 plasmas are highlighted with false coloring as orange and green, respectively. No Fabs were observed in the reconstruction of COV107 Fabs plus S protein. Refined 3D models for SARS-CoV-2 S trimer-polyclonal Fab complexes from COV21 (panel B), and COV57 (panel C) were rigid-body fit with reference structures in Chimera (Goddard et al., 2007; Pettersen et al., 2004), displayed as cartoons (S1^A: blue, S1^B: red, S2: gray). FIG. 20B shows that for COV21, the volume was best-fitted with PDB 6VYB (SARS-CoV-2, one “up” S1^Bconformation, inset). Overlay of PDB 6NB6 showed similarities in S1^Bepitope targeting of COV21 Fab (orange) and the human SARS-CoV neutralizing antibody, S230 (magenta, cartoon). FIG. 20C shows that COV57 was fitted with PDB 6VXX (closed, prefusion conformation, inset). Fab density (green) was focused on the S1^Adomain. See also FIG. 27.

FIGS. 21A, 21B, 21C, 21D, 21E, and 21F (collectively “FIG. 21”) show a cryo-EM structure of a monoclonal Fab-S protein complex that resembles the COV21 Fab(s)-S reconstruction. FIG. 21A shows reconstructed volumes for mAb C105 bound to SARS-CoV-2 S trimers in state 1 (two “up” RBDs, two bound Fabs) and state 2 (three “up” RBDs, three bound Fabs). FIG. 21B shows cartoon representation of VH-VL domains of C105 bound to an RBD (left panel) and CDR loops of C105 overlaid on surface representation of the RBD (shown as a gray surface) (right panel). FIG. 21C shows RBD surface showing contacts by C105 VH-VL (contacts defined as an RBD residue within 7 Å of a VH or VL residue Ca atom). FIG. 21D shows RBD surface fitted with volume representing the variable domains of the COV21 Fab(s) nsEMPEM reconstruction. FIG. 21E shows CDR loops of B38 mAb overlaid on surface representation of the RBD (from PDB code 7BZ5). FIG. 21F shows RBD surface showing contacts by ACE2 (contacts defined as an RBD residue within 7 Å of an ACE2 residue Ca atom) (from PDB code 6VW1). See also FIGS. 29 and 30.

FIGS. 22A, 22B, and 22C (collectively “FIG. 22”) show identified S mutations that are unlikely to affect epitopes revealed by nsEMPEM and single-particle cryo-EM. FIGS. 22A and 22B show the refined 3D model of SARS-CoV-2 S trimer alone that was fitted with a reference structure (PDB 6VYB; gray cartoon) with locations of mutations observed in circulating SARS-CoV-2 isolates (Table 17) highlighted (red spheres). Residues affected by mutations that are disordered in the SARS-CoV-2 S structure (V483A) or in regions that are not included in the S ectodomain (signal sequence or cytoplasmic tail) are not shown. Densities corresponding to Fabs were separated, colored, and displayed on the same 3D volume. FIG. 22C shows C105-RBD interaction from the cryo-EM structure of the C105-S complex (FIG. 21), showing locations of RBD mutations. V483 is ordered in this structure. See also Table 17.

FIGS. 23A, 23B, and 23C (collectively “FIG. 23”) show S protein epitopes that offer different possibilities for avidity effects during IgG and receptor binding. FIG. 23A, left panel, shows a model of two adjacent S trimers separated by ˜15 nm, as seen on coronaviruses by cryo-electron tomography (Neuman et al., 2011), demonstrating that the orientation of COV21 Fab(s) on S could accommodate inter-spike crosslinking by a single IgG. The Fc portion of the IgG (PDB code 1IGT) was modeled assuming flexibility between the Fabs and the Fc (Sandin et al., 2004) and with the hinge region indicated by a dotted line since it is disordered in crystal structures of intact IgGs (Harris et al., 1992; Harris et al., 1998; Saphire et al., 2001). FIG. 23A, right panel, shows an example of a model of two adjacent S trimers with bound Fab(s) in the orientation observed in the COV57 Fab(s)-S reconstruction demonstrating that inter-spike crosslinking is unlikely due to the “downward” orientation of the Fab(s), which does not permit linking by an Fc region, and predicted steric clashes between adjacent Fabs. Inter-spike crosslinking is also not possible for other orientations of two adjacent COV57 Fab(s)-S complexes (not shown). FIG. 23B show a model of S trimers with two RBDs in an “up” position based on a cryo-EM structure of SARS-CoV S trimer (Kirchdoerfer et al., 2018) (PDB code 6CRX) interacting with full-length ACE2 receptors from the cryo-EM structure of soluble SARS-CoV-2 RBDs bound to the dimeric membrane form of ACE2 (Yan et al., 2020) (PDB code 6M17). Inter-spike crosslinking is possible if ACE2 dimers cluster in the membrane. FIG. 23C shows a model of intra-spike crosslinking between dimeric ACE2 and an S protein trimer with two RBDs in an “up” position. The RBDs were rotated by ˜180 about their long axes to allow binding of the ACE2 ectodomains. Rotation of the RBD is a possibility since its position is flexible with respect to the remaining part of the S trimer (Walls et al., 2019). In this model, RBDs from a single S trimer could bind the ACE2 dimer in the same configuration as seen in the B^oAT1-ACE2-SARS-CoV-2 RBD structure (PDB code 6M17).

FIGS. 24A, 24B, 24C, 24D, 24E, 24F, 24G, 24H, 24I, 24J, 24K, and 24L (collectively “FIG. 24”) show SEC-MALS characterization of purified proteins (related to FIGS. 18 and 19). FIGS. 24A, 24B, 24C, 24G, 24H, 24I show the SEC-MALS results of CoV S trimers, and FIGS. 24D, 24E, 24F, 24J, 24K, and 24L show corresponding representative nsEM. Scale bar on micrographs represents 50 nm.

FIGS. 25A, 25B, 25C, 25D, 25E, and 25F (collectively “FIG. 25”) show SARS-CoV-2, SARS-CoV, MERS-CoV and common cold coronavirus ELISA curves (related to FIG. 19). Anti-S IgG (left panel), Anti-S Fab (middle left panel), Anti-RBD/S1^BIgG (middle right panel), and Anti-RBD/S1^BFab (right panel) ELISA binding data for (FIG. 25A) SARS-CoV-2, (FIG. 25B) SARS-CoV, (FIG. 25C) MERS-CoV, (FIG. 25D) HCoV-NL63, (FIG. 25E) HCoV-OC43, and (FIG. 25F) HCoV-229E. COV21: red curves; COV57: green curves; COV107: magenta curves. Curves for other plasmas are in gray. Each curve represents the average of three independent experiments. Binding of the IgG and Fab from IOMA, an antibody against HIV-1 (Gristick et al., 2016), was used as a control in each assay.

FIGS. 26A, 26B, 26C, 26D, 26E, and 26F (collectively “FIG. 26”) show RBD adsorption experiments to assess degrees of cross-reactive RBD recognition by plasma IgGs (related to FIG. 19). Purified IgGs from COVID-19 plasmas (indicated by numbers) and control plasmas (indicated as “con”) were adsorbed with one of two resins: a SARS-CoV-2 RBD resin (IgGs remaining after RBD adsorption; light gray bars) and a 2G12 mAb control resin (IgGs remaining after control adsorption; dark gray bars). IgGs remaining after adsorption were evaluated in ELISAs against the indicated RBD (or S1^B) domains. Binding of IgGs after adsorption to IOMA, an antibody against HIV-1 (Gristick et al., 2016), was used as a control in each assay. Results are presented as area under the curve (AUC; shown as mean of experiments conducted in duplicate).

FIGS. 27A, 27B, 27C, 27D, 27E, and 27F (collectively “FIG. 27”) show representative 2D class-averages and 3D models from nsEMPEM of human convalescent plasma (related to FIG. 20). FIGS. 27A, 27C, and 27E show representative reference-free 2D class-averages obtained from EM data collections of (FIG. 27A) SARS-CoV-2 S trimers alone, (FIG. 27C) SARS-CoV-2 S complexed with COV21 polyclonal Fabs, and (FIG. 27E) SARS-CoV-2 S complexed with COV57 polyclonal Fabs. For COV21 and COV57, class-averages demonstrating extra density beyond the S trimer core are highlighted (red boxes). For COV107, no extra density was observed in class averages or a 3D construction. FIGS. 27B, 27D, and 27F show refined 3D models after iterative rounds of 2D and 3D classification. Features corresponding to Fabs are denoted.

FIGS. 28A, 28B, and 28C (collectively “FIG. 28”) show data collection and processing pipeline for the cryo-EM structure of the C105-SARS-CoV-2 S complex (related to FIG. 21). FIG. 28A shows a representative micrograph of C105-S complex in vitreous ice. Power spectrum of micrograph determined during CTF estimation showing Thon rings to 3.2 Å is shown in the inset. FIG. 28B shows reference-free 2D classification of extracted particles. FIG. 28C shows workflow for classification and refinement of selected particles. Briefly, after selection of good 2D class averages, an ab initio model was generated, which was then homogeneously refined before further 3D classification. To improve features at the SARS-CoV-2 RBD-C105 Fab interface, particles from states 1 and 2 were combined and used for nonuniform, focused refinement to yield a state 1-like reconstruction to an FSC=0.143 resolution of 3.4 Å.

FIGS. 29A, 29B, 29C, 29D, and 29E (collectively “FIG. 29”) show cryo-EM structure validation (related to FIG. 21). FIG. 29A shows fourier shell correlation (FSC) plots calculated from half-maps of state 1 (black), state 1 after focused refinement (blue) and state 2 (red). Dotted lines for FSC values of 0.5 and 0.143 are shown. FIGS. 29B and 29C show 2D angular distribution plot for state 1 (FIG. 29B) and state 2 (FIG. 29C) reconstructions. FIG. 29D shows local resolution estimations for states 1 and 2 and at the RBD-C105 Fab interface. FIG. 29E shows representative density from S trimer and Fab regions of the state 1 reconstructed volume. Maps are contoured at 6σ.

FIGS. 30A and 30B (collectively “FIG. 30”) show CDRH3 length distributions (related to FIG. 21). FIG. 30A shows the CDRH3 lengths (IMGT definition) (Lefranc et al., 2015) of anti-SARS-CoV-2 RBD-binding mAbs (Robbiani et al., 2020) are shown in three groups: all 534 mAbs (dark gray), those derived from VH3-53 (red), and those derived from VH3-66 (green). For comparison, the CDRH3 length distribution from the human antibody repertoire (Briney et al., 2019) is also shown (normalized to the same total count as the set of 534). The CDRH3 length of mAb B38 is indicated with an arrow. FIG. 30B shows the length of CDRH3s in human antibodies versus predicted clashes with SARS-CoV-2 RBD if binding in the orientation observed for the mAbs B38 and C105. The VH domains of 1364 human antibody structures with resolutions of ≤3.5 Å downloaded from SAbDab (Dunbar et al., 2014) were aligned to the B38 VH domain in complex with SARS-CoV-2 RBD (PDB code 7BZ5) (Wu et al., 2020c). In cases in which there was more than one Fab in the crystallographic asymmetric unit, each VH was evaluated and enumerated separately. CDRH3 clashes were defined if any CDRH3 atom was within 2.0 Å of an atom in the RBD, a stringent criterion devised to account for not allowing CDR flexibility or different side chain rotamer conformations.

FIGS. 31A, 31B, 31C, and 31D are a set of diagrams showing SARS-CoV-2 pseudovirus neutralization of C135 and C144′. FIGS. 31A and 31B show the titration curves (FIG. 31A) and IC50 and IC90 values (FIG. 31B) of C135 and C144′ from different lots (also see Table 14 for the sequences). FIG. 31C shows the titration curves of C135, C144′, and C135 combined with C144′ from the GMP lots, with the IC50 and IC90 values summarized in FIG. 31D.

DETAILED DESCRIPTION OF THE INVENTION

SARS-CoV-2 represents a serious public health concern. Methods to diagnose and treat persons who are infected with SARS-CoV-2 provide the opportunity to either prevent or control further spread of infection by SARS-CoV-2. These methods are especially important due to the ability of SARS-CoV-2 to infect persons through an airborne route.

This invention is based, at least in part, on unexpected broadly neutralizing activities of the disclosed anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. These antibodies and antigen-binding fragments constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.

A. BROADLY NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIES

a. Antibodies

The invention disclosed herein involves broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. These antibodies refer to a class of neutralizing antibodies that neutralize multiple SARS-CoV-2 virus strains. The antibodies are able to protect a subject prophylactically and therapeutically against a lethal challenge with a SARS-CoV-2 virus.

In one aspect, this disclosure provides an isolated anti-SARS-CoV-2 antibody or antigen-binding fragment thereof that binds specifically to a SARS-CoV-2 antigen. In some embodiments, the SARS-CoV-2 antigen comprises a portion of a Spike (S) polypeptide, such as a S polypeptide of a human or an animal SARS-CoV-2. In some embodiments, the SARS-CoV-2 antigen comprises the receptor-binding domain (RBD) of the S polypeptide. In some embodiments, the RBD comprises amino acids 319-541 of the S polypeptide. In some embodiments, the antibody or antigen-binding fragment thereof is capable of neutralizing a plurality of SARS-CoV-2 strains.

In some embodiments, the antibody or antigen-binding fragment thereof is capable of neutralizing a SARS-CoV-2 virus at an IC50 concentration of less than 50 μg/ml.

The spike protein is important because it is present on the outside of intact SARS-CoV-2. Thus, it presents a target that can be used to inhibit or eliminate an intact virus before the virus has an opportunity to infect a cell. A representative amino acid sequence is provided below:

(Accession ID: NC_045512.2; SEQ ID NO: 2927)

MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHS

TQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNI

IRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNK

SWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGY

FKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLT

PGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETK

CTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASV

YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSF

VIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYN

YLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPT

NGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTG

VLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITP

GTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCL

IGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLG

AENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECS

NLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGF

NFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLI

CAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAM

QMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQD

VVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGR

LQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLM

SFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGT

HWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKE

ELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDL

QELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSC

GSCCKFDEDDSEPVLKGVKLHYT

Listed below in TABLES 4-5 and 7-14 are amino acid sequences of the heavy chain (HC) variable regions and light chain (LC) variable regions of exemplary antibodies.

HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprising respective amino acid sequences of (i) SEQ ID NOs: 2878, 2880, 2882, 2890, 2892, and 2894; or (ii) SEQ ID NOs: 2902, 2904, 2906, 2914, 2916, and 2918.

In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region having an amino acid sequence with at least 75% identity to SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; and (ii) a light chain variable region having an amino acid sequence with at least 75% identity to SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a heavy chain variable region having the amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 2876, or 2900; and (ii) a light chain variable region having the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 2888, or 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprise the respective amino acid sequences of SEQ ID NOs: 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44, 45-46, 47-48, 49-50, 51-52, 53-54, 55-56, 57-58, 59-60, 61-62, 63-64, 65-66, 67-68, 69-70, 71-72, 73-74, 75-76, 77-78, 79-80, 81-82, 83-84, 85-86, 87-88, 89-90, 91-92, 93-94, 95-96, 97-98, 99-100, 101-102, 103-104, 105-106, 107-108, 109-110, 111-112, 113-114, 115-116, 117-118, 119-120, 121-122, 123-124, 125-126, 127-128, 129-130, 131-132, 133-134, 135-136, 137-138, 139-140, 141-142, 143-144, 145-146, 147-148, 149-150, 151-152, 153-154, 155-156, 157-158, 159-160, 161-162, 163-164, 165-166, 167-168, 169-170, 171-172, 173-174, 175-176, 177-178, 179-180, 181-182, 183-184, 185-186, 187-188, 2876 and 2888, or 2900 and 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain that comprise the respective amino acid sequences of SEQ ID NOs: 1-2; 13-14; 25-26; 49-50, 55-56, 57-58, 65-66, 81-82, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912.

In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain/light chain sequence pair of SEQ ID NOs: 2886/2898, 2887/2899, 2910/2921, or 2911/2922.

In some embodiments, the antibody or antigen-binding fragment thereof comprises (a) a first target binding site that specifically binds to an epitope within the S polypeptide, and (b) a second target binding site that binds to a different epitope on the S polypeptide or on a different molecule. In some embodiments, the multivalent antibody is a bivalent or bispecific antibody.

In some embodiments, the antibody or the antigen-binding fragment thereof further comprises a variant Fc constant region. The antibody can be a monoclonal antibody. In some embodiments, the antibody can be a chimeric antibody, a humanized antibody, or humanized monoclonal antibody. In some embodiments, the antibody can be a single-chain antibody, Fab or Fab2 fragment.

In some embodiments, the antibody or antigen-binding fragment thereof can be detectably labeled or conjugated to a toxin, a therapeutic agent, a polymer (e.g., polyethylene glycol (PEG)), a receptor, an enzyme or a receptor ligand. For example, an antibody of the present invention may be coupled to a toxin (e.g., a tetanus toxin). Such antibodies may be used to treat animals, including humans, that are infected with the virus that is etiologically linked to SARS-CoV-2. The toxin-coupled antibody is thought to bind to a portion of a spike protein presented on an infected cell, and then kill the infected cell.

In another example, an antibody of the present invention may be coupled to a detectable tag. Such antibodies may be used within diagnostic assays to determine if an animal, such as a human, is infected with SARS-CoV-2. Examples of detectable tags include: fluorescent proteins (i.e., green fluorescent protein, red fluorescent protein, yellow fluorescent protein), fluorescent markers (i.e., fluorescein isothiocyanate, rhodamine, texas red), radiolabels (i.e., 3H, 32P, 125I), enzymes (i.e., β-galactosidase, horseradish peroxidase, β-glucuronidase, alkaline phosphatase), or an affinity tag (i.e., avidin, biotin, streptavidin). Methods to couple antibodies to a detectable tag are known in the art. Harlow et al., Antibodies: A Laboratory Manual, page 319 (Cold Spring Harbor Pub. 1988).

b. Fragment

In some embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab′, Fab′-SH, F(ab′)2, Fv, and single-chain Fv (scFv) fragments, and other fragments described below, e.g., diabodies, triabodies tetrabodies, and single-domain antibodies. For a review of certain antibody fragments, see Hudson et al., Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab′)2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.

Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).

Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In some embodiments, a single-domain antibody is a human single-domain antibody (DOMANTIS, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516).

Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g., E. coli or phage), as described herein.

c. Chimeric and Humanized Antibodies

In some embodiments, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

In some embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and are further described, e.g., in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing “resurfacing”); Dall'Acqua et al., Methods 36:43-60 (2005) (describing “FR shuffling”); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the “guided selection” approach to FR shuffling).

Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the “best-fit” method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996)).

d. Human Antibodies

In some embodiments, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art or using techniques described herein. Human antibodies are described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).

Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 describing XENOMOUSE technology; U.S. Pat. No. 5,770,429 describing HUMAB technology; U.S. Pat. No. 7,041,870 describing K-M MOUSE technology, and U.S. Patent Application Publication No. US 2007/0061900, describing VELOCIMOUSE technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.

Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Pat. No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005).

Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.

Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al., in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., 2001) and further described, e.g., in the McCafferty et al., Nature 348:552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marks and Bradbury, in Methods in Molecular Biology 248:161-175 (Lo, ed., Human Press, Totowa, N.J., 2003); Sidhu et al., J. Mol. Biol. 338(2): 299-310 (2004); Lee et al., J. Mol. Biol. 340(5): 1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2): 119-132 (2004).

In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., Ann. Rev. Immunol., 12: 433-455 (1994). Phage typically display antibody fragments, either as scFv fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self-antigens without any immunization as described by Griffiths et al., EMBO J, 12: 725-734 (1993). Finally, naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Pat. No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360. Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

e. Variants

In some embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen binding.

Substitution, Insertion, and Deletion Variants

In some embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are defined herein. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Accordingly, an antibody of the invention can comprise one or more conservative modifications of the CDRs, heavy chain variable region, or light variable regions described herein. A conservative modification or functional equivalent of a peptide, polypeptide, or protein disclosed in this invention refers to a polypeptide derivative of the peptide, polypeptide, or protein, e.g., a protein having one or more point mutations, insertions, deletions, truncations, a fusion protein, or a combination thereof. It substantially retains the activity to of the parent peptide, polypeptide, or protein (such as those disclosed in this invention). In general, a conservative modification or functional equivalent is at least 60% (e.g., any number between 60% and 100%, inclusive, e.g., 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, and 99%) identical to a parent. Accordingly, within the scope of this invention are heavy chain variable region or light variable regions having one or more point mutations, insertions, deletions, truncations, a fusion protein, or a combination thereof, as well as antibodies having the variant regions.

As used herein, the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology=# of identical positions/total # of positions×100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.

The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

Additionally or alternatively, the protein sequences of the present invention can further be used as a “query sequence” to perform a search against public databases to, for example, identify related sequences. Such searches can be performed using the XBLAST program (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the antibody molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. (See www.ncbi.nlm.nih.gov).

As used herein, the term “conservative modifications” refers to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include: (i) amino acids with basic side chains (e.g., lysine, arginine, histidine), (ii) acidic side chains (e.g., aspartic acid, glutamic acid), (iii) uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), (iv) nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), (v) beta-branched side chains (e.g., threonine, valine, isoleucine), and (vi) aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described in, e.g., Hoogenboom et al., in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, N.J., (2001). Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

Glycosylation Variants

In some embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites are created or removed.

For example, an aglycoslated antibody can be made (i.e., the antibody lacks glycosylation). Glycosylation can be altered to, for example, increase the affinity of the antibody for antigen. Such carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in elimination of one or more variable region framework glycosylation sites to thereby eliminate glycosylation at that site. Such aglycosylation may increase the affinity of the antibody for antigen. Such an approach is described in further detail in U.S. Pat. Nos. 5,714,350 and 6,350,861 by Co et al.

Glycosylation of the constant region on N297 may be prevented by mutating the N297 residue to another residue, e.g., N297A, and/or by mutating an adjacent amino acid, e.g., 298 to thereby reduce glycosylation on N297.

Additionally or alternatively, an antibody can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNac structures. Such altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies. Such carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies described herein to thereby produce an antibody with altered glycosylation. For example, EP 1,176,195 by Hanai et al. describes a cell line with a functionally disrupted FUT8 gene, which encodes a fucosyltransferase, such that antibodies expressed in such a cell line exhibit hypofucosylation. PCT Publication WO 03/035835 by Presta describes a variant Chinese Hamster Ovary cell line, Led 3 cells, with reduced ability to attach fucose to Asn(297)-linked carbohydrates, also resulting in hypofucosylation of antibodies expressed in that host cell (see also Shields, R. L. et al. (2002) J. Biol. Chem. 277:26733-26740). PCT Publication WO 99/54342 by Umana et al. describes cell lines engineered to express glycoprotein-modifying glycosyltransferases (e.g., beta(1,4)-N-acetylglucosaminyltransferase III (GnTIII)) such that antibodies expressed in the engineered cell lines exhibit increased bisecting GlcNac structures which result in increased ADCC activity of the antibodies (see also Umana et al. (1999) Nat. Biotech. 17: 176-180).

Fc Region Variants

The variable regions of the antibody described herein can be linked (e.g., covalently linked or fused) to an Fc, e.g., an IgG1, IgG2, IgG3 or IgG4 Fc, which may be of any allotype or isoallotype, e.g., for IgG1: Glm, Glm1(a), Glm2(x), Glm3(f), Glm17(z); for IgG2: G2m, G2m23(n); for IgG3: G3m, G3m21(g1), G3m28(g5), G3m11(b0), G3m5(b1), G3m13(b3), G3m14(b4), G3m10(b5), G3m15(s), G3m16(t), G3m6(c3), G3m24(c5), G3m26(u), G3m27(v); and for K: Km, Km1, Km2, Km3 (see, e.g., Jefferies et al. (2009) mAbs 1: 1). In some embodiments, the antibodies variable regions described herein are linked to an Fc that binds to one or more activating Fc receptors (FcγI, FcγIIa or FcγIIIa), and thereby stimulate ADCC and may cause T cell depletion. In some embodiments, the antibody variable regions described herein are linked to an Fc that causes depletion.

In some embodiments, the antibody variable regions described herein may be linked to an Fc comprising one or more modifications, typically to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and/or antigen-dependent cellular cytotoxicity. Furthermore, an antibody described herein may be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or be modified to alter its glycosylation, to alter one or more functional properties of the antibody. The numbering of residues in the Fc region is that of the EU index of Kabat.

The Fc region encompasses domains derived from the constant region of an immunoglobulin, preferably a human immunoglobulin, including a fragment, analog, variant, mutant or derivative of the constant region. Suitable immunoglobulins include IgG1, IgG2, IgG3, IgG4, and other classes such as IgA, IgD, IgE and IgM, The constant region of an immunoglobulin is defined as a naturally-occurring or synthetically-produced polypeptide homologous to the immunoglobulin C-terminal region, and can include a CH1 domain, a hinge, a CH2 domain, a CH3 domain, or a CH4 domain, separately or in combination. In some embodiments, an antibody of this invention has an Fc region other than that of a wild type IgA1. The antibody can have an Fc region from that of IgG (e.g., IgG1, IgG2, IgG3, and IgG4) or other classes such as IgA2, IgD, IgE, and IgM. The Fc can be a mutant form of IgA1.

The constant region of an immunoglobulin is responsible for many important antibody functions, including Fc receptor (FcR) binding and complement fixation. There are five major classes of heavy chain constant region, classified as IgA, IgG, IgD, IgE, IgM, each with characteristic effector functions designated by isotype. For example, IgG is separated into four subclasses known as IgG1, IgG2, IgG3, and IgG4.

Ig molecules interact with multiple classes of cellular receptors. For example, IgG molecules interact with three classes of Fcγ receptors (FcγR) specific for the IgG class of antibody, namely FcγRI, FcγRII, and FcγRIIL. The important sequences for the binding of IgG to the FcγR receptors have been reported to be located in the CH2 and CH3 domains. The serum half-life of an antibody is influenced by the ability of that antibody to bind to an FcR.

In some embodiments, the Fc region is a variant Fc region, e.g., an Fc sequence that has been modified (e.g., by amino acid substitution, deletion and/or insertion) relative to a parent Fc sequence (e.g., an unmodified Fc polypeptide that is subsequently modified to generate a variant), to provide desirable structural features and/or biological activity. For example, one may make modifications in the Fc region in order to generate an Fc variant that (a) has increased or decreased ADCC, (b) increased or decreased CDC, (c) has increased or decreased affinity for Clq and/or (d) has increased or decreased affinity for an Fc receptor relative to the parent Fc. Such Fc region variants will generally comprise at least one amino acid modification in the Fc region. Combining amino acid modifications is thought to be particularly desirable. For example, the variant Fc region may include two, three, four, five, etc. substitutions therein, e.g., of the specific Fc region positions identified herein.

A variant Fc region may also comprise a sequence alteration wherein amino acids involved in disulfide bond formation are removed or replaced with other amino acids. Such removal may avoid reaction with other cysteine-containing proteins present in the host cell used to produce the antibodies described herein. Even when cysteine residues are removed, single chain Fc domains can still form a dimeric Fc domain that is held together non-covalently. In other embodiments, the Fc region may be modified to make it more compatible with a selected host cell. For example, one may remove the PA sequence near the N-terminus of a typical native Fc region, which may be recognized by a digestive enzyme in E. coli such as proline iminopeptidase. In other embodiments, one or more glycosylation sites within the Fc domain may be removed. Residues that are typically glycosylated (e.g., asparagine) may confer cytolytic response. Such residues may be deleted or substituted with unglycosylated residues (e.g., alanine). In other embodiments, sites involved in interaction with complement, such as the Clq binding site, may be removed from the Fc region. For example, one may delete or substitute the EKK sequence of human IgG1. In some embodiments, sites that affect binding to Fc receptors may be removed, preferably sites other than salvage receptor binding sites. In other embodiments, an Fc region may be modified to remove an ADCC site. ADCC sites are known in the art; see, for example, Molec. Immunol. 29 (5): 633-9 (1992) with regard to ADCC sites in IgG1. Specific examples of variant Fc domains are disclosed, for example, in WO 97/34631 and WO 96/32478.

In one embodiment, the hinge region of Fc is modified such that the number of cysteine residues in the hinge region is altered, e.g., increased or decreased. This approach is described further in U.S. Pat. No. 5,677,425 by Bodmer et al. The number of cysteine residues in the hinge region of Fc is altered to, for example, facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody. In one embodiment, the Fc hinge region of an antibody is mutated to decrease the biological half-life of the antibody. More specifically, one or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc-hinge fragment such that the antibody has impaired Staphylococcal protein A (SpA) binding relative to native Fc-hinge domain SpA binding. This approach is described in further detail in U.S. Pat. No. 6,165,745 by Ward et al.

In yet other embodiments, the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector function(s) of the antibody. For example, one or more amino acids selected from amino acid residues 234, 235, 236, 237, 297, 318, 320 and 322 can be replaced with a different amino acid residue such that the antibody has an altered affinity for an effector ligand but retains the antigen-binding ability of the parent antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the CI component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260, both by Winter et al.

In another example, one or more amino acids selected from amino acid residues 329, 331 and 322 can be replaced with a different amino acid residue such that the antibody has altered Clq binding and/or reduced or abolished CDC. This approach is described in further detail in U.S. Pat. No. 6,194,551 by Idusogie et al.

In another example, one or more amino acid residues within amino acid positions 231 and 239 are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in PCT Publication WO 94/29351 by Bodmer et al.

In yet another example, the Fc region may be modified to increase ADCC and/or to increase the affinity for an Fcγ receptor by modifying one or more amino acids at the following positions: 234, 235, 236, 238, 239, 240, 241, 243, 244, 245, 247, 248, 249, 252, 254, 255, 256, 258, 262, 263, 264, 265, 267, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 299, 301, 303, 305, 307, 309, 312, 313, 315, 320, 322, 324, 325, 326, 327, 329, 330, 331, 332, 333, 334, 335, 337, 338, 340, 360, 373, 376, 378, 382, 388, 389, 398, 414, 416, 419, 430, 433, 434, 435, 436, 437, 438 or 439. Exemplary substitutions include 236A, 239D, 239E, 268D, 267E, 268E, 268F, 324T, 332D, and 332E. Exemplary variants include 239D/332E, 236A/332E, 236A/239D/332E, 268F/324T, 267E/268F, 267E/324T, and 267E/268F7324T. Other modifications for enhancing FcγR and complement interactions include but are not limited to substitutions 298A, 333A, 334A, 326A, 2471, 339D, 339Q, 280H, 290S, 298D, 298V, 243L, 292P, 300L, 396L, 3051, and 396L. These and other modifications are reviewed in Strohl, 2009, Current Opinion in Biotechnology 20:685-691.

Fc modifications that increase binding to an Fcγ receptor include amino acid modifications at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 255, 256, 258, 265, 267, 268, 269, 270, 272, 279, 280, 283, 285, 298, 289, 290, 292, 293, 294, 295, 296, 298, 301, 303, 305, 307, 312, 315, 324, 327, 329, 330, 335, 337, 3338, 340, 360, 373, 376, 379, 382, 388, 389, 398, 414, 416, 419, 430, 434, 435, 437, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in abat (WO00/42072).

Other Fc modifications that can be made to Fcs are those for reducing or ablating binding to FcγR and/or complement proteins, thereby reducing or ablating Fc-mediated effector functions such as ADCC, antibody-dependent cellular phagocytosis (ADCP), and CDC. Exemplary modifications include but are not limited substitutions, insertions, and deletions at positions 234, 235, 236, 237, 267, 269, 325, and 328, wherein numbering is according to the EU index. Exemplary substitutions include but are not limited to 234G, 235G, 236R, 237K, 267R, 269R, 325L, and 328R, wherein numbering is according to the EU index. An Fc variant may comprise 236R/328R. Other modifications for reducing FcγR and complement interactions include substitutions 297A, 234A, 235A, 237A, 318A, 228P, 236E, 268Q, 309L, 330S, 331S, 220S, 226S, 229S, 238S, 233P, and 234V, as well as removal of the glycosylation at position 297 by mutational or enzymatic means or by production in organisms such as bacteria that do not glycosylate proteins. These and other modifications are reviewed in Strohl, 2009, Current Opinion in Biotechnology 20:685-691.

Optionally, the Fc region may comprise a non-naturally occurring amino acid residue at additional and/or alternative positions known to one skilled in the art (see, e.g., U.S. Pat. Nos. 5,624,821; 6,277,375; 6,737,056; 6,194,551; 7,317,091; 8,101,720; WO00/42072; WO01/58957; WO02/06919; WO04/016750; WO04/029207; WO04/035752; WO04/074455; WO04/099249; WO04/063351; WO05/070963; WO05/040217, WO05/092925 and WO06/020114). Fc variants that enhance affinity for an inhibitory receptor FcγRIIb may also be used. Such variants may provide an Fc fusion protein with immune-modulatory activities related to FcγRIIb cells, including, for example, B cells and monocytes. In one embodiment, the Fc variants provide selectively enhanced affinity to FcγRIIb relative to one or more activating receptors. Modifications for altering binding to FcγRIIb include one or more modifications at a position selected from the group consisting of 234, 235, 236, 237, 239, 266, 267, 268, 325, 326, 327, 328, and 332, according to the EU index. Exemplary substitutions for enhancing FcγRIIb affinity include but are not limited to 234D, 234E, 234F, 234W, 235D, 235F, 235R, 235Y, 236D, 236N, 237D, 237N, 239D, 239E, 266M, 267D, 267E, 268D, 268E, 327D, 327E, 328F, 328W, 328Y, and 332E. Exemplary substitutions include 235Y, 236D, 239D, 266M, 267E, 268D, 268E, 328F, 328W, and 328Y. Other Fc variants for enhancing binding to FcγRllb include 235Y/267E, 236D/267E, 239D/268D, 239D/267E, 267E/268D, 267E/268E, and 267E/328F.

The affinities and binding properties of an Fc region for its ligand may be determined by a variety of in vitro assay methods (biochemical or immunological based assays) known in the art including but not limited to, equilibrium methods (e.g., ELISA, or radioimmunoassay), or kinetics (e.g., BIACORE analysis), and other methods such as indirect binding assays, competitive inhibition assays, fluorescence resonance energy transfer (FRET), gel electrophoresis and chromatography (e.g., gel filtration). These and other methods may utilize a label on one or more of the components being examined and/or employ a variety of detection methods including but not limited to chromogenic, fluorescent, luminescent, or isotopic labels. A detailed description of binding affinities and kinetics can be found in Paul, W. E., ed., Fundamental Immunology, 4th Ed., Lippincott-Raven, Philadelphia (1999), which focuses on antibody-immunogen interactions.

In some embodiments, the antibody is modified to increase its biological half-life. Various approaches are possible. For example, this may be done by increasing the binding affinity of the Fc region for FcRn. For example, one or more of the following residues can be mutated: 252, 254, 256, 433, 435, 436, as described in U.S. Pat. No. 6,277,375. Specific exemplary substitutions include one or more of the following: T252L, T254S, and/or T256F. Alternatively, to increase the biological half-life, the antibody can be altered within the CH1 or CL region to contain a salvage receptor binding epitope taken from two loops of a CH2 domain of an Fc region of an IgG, as described in U.S. Pat. Nos. 5,869,046 and 6,121,022 by Presta et al. Other exemplary variants that increase binding to FcRn and/or improve pharmacokinetic properties include substitutions at positions 259, 308, 428, and 434, including for example 2591, 308F, 428L, 428M, 434S, 434H, 434F, 434Y, and 434M. Other variants that increase Fc binding to FcRn include: 250E, 250Q, 428L, 428F, 250Q/428L (Hinton et al, 2004, J. Biol. Chem. 279(8): 6213-6216, Hinton et al. 2006 Journal of Immunology 176:346-356), 256A, 272A, 286A, 305A, 307A, 307Q, 311A, 312A, 376A, 378Q, 380A, 382A, 434A (Shields et al, Journal of Biological Chemistry, 2001, 276(9):6591-6604), 252F, 252T, 252Y, 252W, 254T, 256S, 256R, 256Q, 256E, 256D, 256T, 309P, 311S, 433R, 433S, 4331, 433P, 433Q, 434H, 434F, 434Y, 252Y/254T/256E, 433K/434F/436H, 308T/309P/311S (Dall Acqua et al. Journal of Immunology, 2002, 169:5171-5180, Dall'Acqua et al., 2006, Journal of Biological Chemistry 281:23514-23524). Other modifications for modulating FcRn binding are described in Yeung et al., 2010, J Immunol, 182:7663-7671. In some embodiments, hybrid IgG isotypes with particular biological characteristics may be used. For example, an IgG1/IgG3 hybrid variant may be constructed by substituting IgG 1 positions in the CH2 and/or CH3 region with the amino acids from IgG3 at positions where the two isotypes differ. Thus a hybrid variant IgG antibody may be constructed that comprises one or more substitutions, e.g., 274Q, 276K, 300F, 339T, 356E, 358M, 384S, 392N, 397M, 4221, 435R, and 436F. In other embodiments described herein, an IgG1/IgG2 hybrid variant may be constructed by substituting IgG2 positions in the CH2 and/or CH3 region with amino acids from IgG1 at positions where the two isotypes differ. Thus a hybrid variant IgG antibody may be constructed chat comprises one or more substitutions, e.g., one or more of the following amino acid substitutions: 233E, 234L, 235L, 236G (referring to an insertion of a glycine at position 236), and 321 h.

Moreover, the binding sites on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn have been mapped and variants with improved binding have been described (see Shields, R. L. et al. (2001) J. Biol. Chem. 276:6591-6604). Specific mutations at positions 256, 290, 298, 333, 334, and 339 were shown to improve binding to FcγRIII Additionally, the following combination mutants were shown to improve FcγRIII binding: T256A/S298A, S298A/E333A, S298A/K224A, and S298A/E333A/K334A, which has been shown to exhibit enhanced FcγRIIIa binding and ADCC activity (Shields et al., 2001). Other IgG1 variants with strongly enhanced binding to FcγRIIIa have been identified, including variants with S239D/I332E and S239D/I332E/A330L mutations which showed the greatest increase in affinity for FcγRIIIa, a decrease in FcγRIIb binding, and strong cytotoxic activity in cynomolgus monkeys (Lazar et al., 2006). Introduction of the triple mutations into antibodies such as alemtuzumab (CD52-specific), trastuzumab (HER2/neu-specific), rituximab (CD20-specific), and cetuximab (EGFR-specific) translated into greatly enhanced ADCC activity in vitro, and the S239D/I332E variant showed an enhanced capacity to deplete B cells in monkeys (Lazar et al., 2006). In addition, IgG1 mutants containing L235V, F243L, R292P, Y300L and P396L mutations which exhibited enhanced binding to FcγRIIIa and concomitantly enhanced ADCC activity in transgenic mice expressing human FcγRIIIa in models of B cell malignancies and breast cancer have been identified (Stavenhagen et al., 2007; Nordstrom et al., 2011). Other Fc mutants that may be used include: S298A/E333A/L334A, S239D/I332E, S239D/I332E/A330L, L235V/F243L/R292P/Y300L/P396L, and M428L/N434S.

In some embodiments, an Fc is chosen that has reduced binding to FcγRs. An exemplary Fc, e.g., IgGl Fc, with reduced FcγR binding, comprises the following three amino acid substitutions: L234A, L235E, and G237A.

In some embodiments, an Fc is chosen that has reduced complement fixation. An exemplary Fc, e.g., IgG1 Fc, with reduced complement fixation, has the following two amino acid substitutions: A330S and P331S.

In some embodiments, an Fc is chosen that has essentially no effector function, i.e., it has reduced binding to FcγRs and reduced complement fixation. An exemplary Fc, e.g., IgGl Fc, that is effectorless, comprises the following five mutations: L234A, L235E, G237A, A330S, and P331S.

When using an IgG4 constant domain, it is usually preferable to include the substitution S228P, which mimics the hinge sequence in IgG1 and thereby stabilizes IgG4 molecules.

f. Multivalent Antibodies

In one embodiment, the antibodies of the invention may be monovalent or multivalent (e.g., bivalent, trivalent, etc.). As used herein, the term “valency” refers to the number of potential target binding sites associated with an antibody. Each target binding site specifically binds one target molecule or specific position or locus on a target molecule. When an antibody is monovalent, each binding site of the molecule will specifically bind to a single antigen position or epitope. When an antibody comprises more than one target binding site (multivalent), each target binding site may specifically bind the same or different molecules (e.g., may bind to different ligands or different antigens, or different epitopes or positions on the same antigen). See, for example, U.S.P.N. 2009/0129125. In each case, at least one of the binding sites will comprise an epitope, motif or domain associated with a DLL3 isoform.

In one embodiment, the antibodies are bispecific antibodies in which the two chains have different specificities, as described in Millstein et al., 1983, Nature, 305:537-539. Other embodiments include antibodies with additional specificities such as trispecific antibodies. Other more sophisticated compatible multispecific constructs and methods of their fabrication are set forth in U.S.P.N. 2009/0155255, as well as WO 94/04690; Suresh et al., 1986, Methods in Enzymology, 121:210; and WO96/27011.

As stated above, multivalent antibodies may immunospecifically bind to different epitopes of the desired target molecule or may immunospecifically bind to both the target molecule as well as a heterologous epitope, such as a heterologous polypeptide or solid support material. In some embodiments, the multivalent antibodies may include bispecific antibodies or trispecific antibodies. Bi specific antibodies also include cross-linked or “heteroconjugate” antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

In some embodiments, antibody variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobulin constant domain sequences, such as an immunoglobulin heavy chain constant domain comprising at least part of the hinge, CH2, and/or CH3 regions, using methods well known to those of ordinary skill in the art.

g. Antibody Derivatives

An antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water-soluble polymers.

Non-limiting examples of water-soluble polymers include, but are not limited to, PEG, copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.

In another embodiment, conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody-nonproteinaceous moiety are killed.

Another modification of the antibodies described herein is pegylation. An antibody can be pegylated to, for example, increase the biological (e.g., serum) half-life of the antibody. To pegylate an antibody, the antibody, or fragment thereof, typically is reacted with PEG, such as a reactive ester or aldehyde derivative of PEG, under conditions in which one or more PEG groups become attached to the antibody or antibody fragment. Preferably, the pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive PEG molecule (or an analogous reactive water-soluble polymer). As used herein, the term “polyethylene glycol” is intended to encompass any of the forms of PEG that have been used to derivatize other proteins, such as mono (CI-CIO) alkoxy- or aryloxy-polyethylene glycol or polyethylene glycol-maleimide. In some embodiments, the antibody to be pegylated is an aglycosylated antibody. Methods for pegylating proteins are known in the art and can be applied to the antibodies described herein. See, for example, EP 0 154 316 by Nishimura et al. and EP0401384 by Ishikawa et al.

The present invention also encompasses a human monoclonal antibody described herein conjugated to a therapeutic agent, a polymer, a detectable label or enzyme. In one embodiment, the therapeutic agent is a cytotoxic agent. In one embodiment, the polymer is PEG.

h. Nucleic Acids, Expression Cassettes, and Vectors

The present invention provides isolated nucleic acid segments that encode the polypeptides, peptide fragments, and coupled proteins of the invention. The nucleic acid segments of the invention also include segments that encode for the same amino acids due to the degeneracy of the genetic code. For example, the amino acid threonine is encoded by ACU, ACC, ACA, and ACG and is therefore degenerate. It is intended that the invention includes all variations of the polynucleotide segments that encode for the same amino acids. Such mutations are known in the art (Watson et al., Molecular Biology of the Gene, Benjamin Cummings 1987). Mutations also include alteration of a nucleic acid segment to encode for conservative amino acid changes, for example, the substitution of leucine for isoleucine and so forth. Such mutations are also known in the art. Thus, the genes and nucleotide sequences of the invention include both the naturally occurring sequences as well as mutant forms.

The nucleic acid segments of the invention may be contained within a vector. A vector may include, but is not limited to, any plasmid, phagemid, F-factor, virus, cosmid, or phage in a double- or single-stranded linear or circular form which may or may not be self transmissible or mobilizable. The vector can also transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extra-chromosomally (e.g., autonomous replicating plasmid with an origin of replication).

Preferably the nucleic acid segment in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in vitro or in a host cell, such as a eukaryotic cell, or a microbe, e.g., bacteria. The vector may be a shuttle vector that functions in multiple hosts. The vector may also be a cloning vector that typically contains one or a small number of restriction endonuclease recognition sites at which foreign DNA sequences can be inserted in a determinable fashion. Such insertion can occur without loss of essential biological function of the cloning vector. A cloning vector may also contain a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Examples of marker genes are tetracycline resistance or ampicillin resistance. Many cloning vectors are commercially available (Stratagene, New England Biolabs, Clonetech).

The nucleic acid segments of the invention may also be inserted into an expression vector. Typically an expression vector contains prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance gene to provide for the amplification and selection of the expression vector in a bacterial host; regulatory elements that control initiation of transcription such as a promoter; and DNA elements that control the processing of transcripts such as introns, or a transcription termination/polyadenylation sequence.

Methods to introduce nucleic acid segment into a vector are available in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001)). Briefly, a vector into which a nucleic acid segment is to be inserted is treated with one or more restriction enzymes (restriction endonuclease) to produce a linearized vector having a blunt end, a “sticky” end with a 5′ or a 3′ overhang, or any combination of the above. The vector may also be treated with a restriction enzyme and subsequently treated with another modifying enzyme, such as a polymerase, an exonuclease, a phosphatase or a kinase, to create a linearized vector that has characteristics useful for ligation of a nucleic acid segment into the vector. The nucleic acid segment that is to be inserted into the vector is treated with one or more restriction enzymes to create a linearized segment having a blunt end, a “sticky” end with a 5′ or a 3′ overhang, or any combination of the above. The nucleic acid segment may also be treated with a restriction enzyme and subsequently treated with another DNA modifying enzyme. Such DNA modifying enzymes include, but are not limited to, polymerase, exonuclease, phosphatase or a kinase, to create a nucleic acid segment that has characteristics useful for ligation of a nucleic acid segment into the vector.

The treated vector and nucleic acid segment are then ligated together to form a construct containing a nucleic acid segment according to methods available in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001)). Briefly, the treated nucleic acid fragment, and the treated vector are combined in the presence of a suitable buffer and ligase. The mixture is then incubated under appropriate conditions to allow the ligase to ligate the nucleic acid fragment into the vector.

The invention also provides an expression cassette which contains a nucleic acid sequence capable of directing expression of a particular nucleic acid segment of the invention, either in vitro or in a host cell. Also, a nucleic acid segment of the invention may be inserted into the expression cassette such that an anti-sense message is produced. The expression cassette is an isolatable unit such that the expression cassette may be in linear form and functional for in vitro transcription and translation assays. The materials and procedures to conduct these assays are commercially available from Promega Corp. (Madison, Wis.). For example, an in vitro transcript may be produced by placing a nucleic acid sequence under the control of a T7 promoter and then using T7 RNA polymerase to produce an in vitro transcript. This transcript may then be translated in vitro through use of a rabbit reticulocyte lysate. Alternatively, the expression cassette can be incorporated into a vector allowing for replication and amplification of the expression cassette within a host cell or also in vitro transcription and translation of a nucleic acid segment.

Such an expression cassette may contain one or a plurality of restriction sites allowing for placement of the nucleic acid segment under the regulation of a regulatory sequence. The expression cassette can also contain a termination signal operably linked to the nucleic acid segment as well as regulatory sequences required for proper translation of the nucleic acid segment. The expression cassette containing the nucleic acid segment may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Expression of the nucleic acid segment in the expression cassette may be under the control of a constitutive promoter or an inducible promoter, which initiates transcription only when the host cell is exposed to some particular external stimulus.

The expression cassette may include in the 5′-3′ direction of transcription, a transcriptional and translational initiation region, a nucleic acid segment and a transcriptional and translational termination region functional in vivo and/or in vitro. The termination region may be native with the transcriptional initiation region, may be native with the nucleic acid segment, or may be derived from another source.

The regulatory sequence can be a polynucleotide sequence located upstream (5′ non-coding sequences), within, or downstream (3′ non-coding sequences) of a coding sequence, and which influences the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences can include, but are not limited to, enhancers, promoters, repressor binding sites, translation leader sequences, introns, and polyadenylation signal sequences. They may include natural and synthetic sequences as well as sequences, which may be a combination of synthetic and natural sequences. While regulatory sequences are not limited to promoters, some useful regulatory sequences include constitutive promoters, inducible promoters, regulated promoters, tissue-specific promoters, viral promoters, and synthetic promoters.

A promoter is a nucleotide sequence that controls the expression of the coding sequence by providing the recognition for RNA polymerase and other factors required for proper transcription. A promoter includes a minimal promoter, consisting only of all basal elements needed for transcription initiation, such as a TATA-box and/or initiator that is a short DNA sequence comprised of a TATA-box and other sequences that serve to specify the site of transcription initiation, to which regulatory elements are added for control of expression. A promoter may be derived entirely from a native gene, or be composed of different elements derived from different promoters found in nature, or even be comprised of synthetic DNA segments. A promoter may contain DNA sequences that are involved in the binding of protein factors that control the effectiveness of transcription initiation in response to physiological or developmental conditions.

The invention also provides a construct containing a vector and an expression cassette. The vector may be selected from, but not limited to, any vector previously described. Into this vector may be inserted an expression cassette through methods known in the art and previously described (Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2001)). In one embodiment, the regulatory sequences of the expression cassette may be derived from a source other than the vector into which the expression cassette is inserted. In another embodiment, a construct containing a vector and an expression cassette is formed upon insertion of a nucleic acid segment of the invention into a vector that itself contains regulatory sequences. Thus, an expression cassette is formed upon insertion of the nucleic acid segment into the vector. Vectors containing regulatory sequences are available commercially, and methods for their use are known in the art (Clonetech, Promega, Stratagene).

i. Methods of Production

Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one embodiment, an isolated nucleic acid encoding an antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g., a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

For recombinant production of an antibody, a nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254, describing expression of antibody fragments in E. coli.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-1414 (2004), and Li et al., Nat. Biotech. 24:210-215 (2006).

Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified, which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES technology for producing antibodies in transgenic plants).

Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include CHO cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0, and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).

B. COMPOSITIONS AND FORMULATIONS

The antibodies of this invention represent an excellent way for the development of antiviral therapies either alone or in antibody cocktails with additional anti-SARS-CoV-2 virus antibodies for the treatment of human SARS-CoV-2 infections in humans.

In another aspect, the present invention provides a pharmaceutical composition comprising the antibodies of the present invention described herein formulated together with a pharmaceutically acceptable carrier. The composition may optionally contain one or more additional pharmaceutically active ingredients, such as another antibody or a therapeutic agent.

In some embodiments, the two or more of the antibody or antigen-binding fragment thereof comprise: (1) a first antibody set comprising: (i) a first antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 57-58; and (ii) a second antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 1-2, 55-56, 57-58, 65-66, 81-82, or 85-86; or (2) a second antibody set comprising: (a) a third antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of of SEQ ID NOs: 13-14, 49-50, 85-86113-114, 125-126, 2876 and 2888, or 2900 and 2912; and (b) a fourth antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of of SEQ ID NOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912, wherein the third antibody is different from the fourth antibody.

The pharmaceutical compositions of the invention also can be administered in a combination therapy with, for example, another immune-stimulatory agent, an antiviral agent, or a vaccine, etc. In some embodiments, a composition comprises an antibody of this invention at a concentration of at least 1 mg/ml, 5 mg/ml, 10 mg/ml, 50 mg/ml, 100 mg/ml, 150 mg/ml, 200 mg/ml, 1-300 mg/ml, or 100-300 mg/ml.

In some embodiments, the second therapeutic agent comprises an anti-inflammatory drug or an antiviral compound. In some embodiments, the antiviral compound comprises: a nucleoside analog, a peptoid, an oligopeptide, a polypeptide, a protease inhibitor, a 3C-like protease inhibitor, a papain-like protease inhibitor, or an inhibitor of an RNA dependent RNA polymerase. In some embodiments, the antiviral compound may include: acyclovir, gancyclovir, vidarabine, foscarnet, cidofovir, amantadine, ribavirin, trifluorothymidine, zidovudine, didanosine, zalcitabine or an interferon. In some embodiments, the interferon is an interferon-α or an interferon-β.

Also within the scope of this disclosure is use of the pharmaceutical composition in the preparation of a medicament for the diagnosis, prophylaxis, treatment, or combination thereof of a condition resulting from a SARS-CoV-2.

The pharmaceutical composition can comprise any number of excipients. Excipients that can be used include carriers, surface-active agents, thickening or emulsifying agents, solid binders, dispersion or suspension aids, solubilizers, colorants, flavoring agents, coatings, disintegrating agents, lubricants, sweeteners, preservatives, isotonic agents, and combinations thereof. The selection and use of suitable excipients is taught in Gennaro, ed., Remington: The Science and Practice of Pharmacy, 20th Ed. (Lippincott Williams & Wilkins 2003), the disclosure of which is incorporated herein by reference.

Preferably, a pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound can be coated in a material to protect it from the action of acids and other natural conditions that may inactivate it. The phrase “parenteral administration” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, an antibody of the present invention described herein can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, e.g., intranasally, orally, vaginally, rectally, sublingually or topically.

The pharmaceutical compositions of the invention may be prepared in many forms that include tablets, hard or soft gelatin capsules, aqueous solutions, suspensions, and liposomes and other slow-release formulations, such as shaped polymeric gels. An oral dosage form may be formulated such that the antibody is released into the intestine after passing through the stomach. Such formulations are described in U.S. Pat. No. 6,306,434 and in the references contained therein.

Oral liquid pharmaceutical compositions may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid pharmaceutical compositions may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.

An antibody can be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dosage form in ampules, prefilled syringes, small volume infusion containers or multi-dose containers with an added preservative. The pharmaceutical compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical compositions suitable for rectal administration can be prepared as unit dose suppositories. Suitable carriers include saline solution and other materials commonly used in the art.

For administration by inhalation, an antibody can be conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, an antibody may take the form of a dry powder composition, for example, a powder mix of a modulator and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator. For intra-nasal administration, an antibody may be administered via a liquid spray, such as via a plastic bottle atomizer.

Pharmaceutical compositions of the invention may also contain other ingredients such as flavorings, colorings, anti-microbial agents, or preservatives. It will be appreciated that the amount of an antibody required for use in treatment will vary not only with the particular carrier selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient. Ultimately the attendant health care provider may determine proper dosage. In addition, a pharmaceutical composition may be formulated as a single unit dosage form.

The pharmaceutical composition of the present invention can be in the form of sterile aqueous solutions or dispersions. It can also be formulated in a microemulsion, liposome, or other ordered structure suitable to high drug concentration.

An antibody of the present invention described herein can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the antibody in the patient. In general, human antibodies show the longest half-life, followed by humanized antibodies, chimeric antibodies, and nonhuman antibodies. The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time. Some patients continue to receive treatment for the rest of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably, until the patient shows partial or complete amelioration of symptoms of disease. Thereafter, the patient can be administered a prophylactic regime.

The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated and the particular mode of administration and will generally be that amount of the composition, which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.01% to about 99% of active ingredient, preferably from about 0.1% to about 70%, most preferably from about 1% to about 30% of active ingredient in combination with a pharmaceutically acceptable carrier.

Dosage regimens can be adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus can be administered, several divided doses can be administered over time or the dose can be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Alternatively, the antibody can be administered as a sustained release formulation, in which case less frequent administration is required. For administration of the antibody, the dosage ranges from about 0.0001 to 800 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight. For example dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg. An exemplary treatment regime entails administration once per week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months or once every three to 6 months. Preferred dosage regimens for an antibody of the invention include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, with the antibody being given using one of the following dosing schedules: (i) every four weeks for six dosages, then every three months; (ii) every three weeks; (iii) 3 mg/kg body weight once followed by 1 mg/kg body weight every three weeks. In some methods, dosage is adjusted to achieve a plasma antibody concentration of about 1-1000 μg/ml and in some methods about 25-300 μg/ml. A “therapeutically effective dosage” of an antibody of the invention preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. For example, for the treatment of SARS-CoV-2 infection in a subject, a “therapeutically effective dosage” preferably inhibits SARS-CoV-2 virus replication or uptake by host cells by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. A therapeutically effective amount of a therapeutic compound can neutralize SARS-CoV-2 virus, or otherwise ameliorate symptoms in a subject, which is typically a human or can be another mammal.

The pharmaceutical composition can be a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

Therapeutic compositions can be administered via medical devices such as (1) needleless hypodermic injection devices (e.g., U.S. Pat. Nos. 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; and 4,596,556); (2) micro-infusion pumps (U.S. Pat. No. 4,487,603); (3) transdermal devices (U.S. Pat. No. 4,486,194); (4) infusion apparati (U.S. Pat. Nos. 4,447,233 and 4,447,224); and (5) osmotic devices (U.S. Pat. Nos. 4,439,196 and 4,475,196); the disclosures of which are incorporated herein by reference.

In some embodiments, the human monoclonal antibodies of the invention described herein can be formulated to ensure proper distribution in vivo. For example, to ensure that the therapeutic compounds of the invention cross the blood-brain barrier, they can be formulated in liposomes, which may additionally comprise targeting moieties to enhance selective transport to specific cells or organs. See, e.g., U.S. Pat. Nos. 4,522,811; 5,374,548; 5,416,016; and 5,399,331; V. V. Ranade (1989) Clin. Pharmacol. 29:685; Umezawa et al., (1988) Biochem. Biophys. Res. Commun. 153:1038; Bloeman et al. (1995) FEBS Lett. 357:140; M. Owais et al. (1995) Antimicrob. Agents Chemother. 39:180; Briscoe et al. (1995) Am. Physiol. 1233:134; Schreier et al. (1994). Biol. Chem. 269:9090; Keinanen and Laukkanen (1994) FEBS Lett. 346:123; and Killion and Fidler (1994) Immunomethods 4:273.

In some embodiments, the initial dose may be followed by administration of a second or a plurality of subsequent doses of the antibody or antigen-binding fragment thereof in an amount that can be approximately the same or less than that of the initial dose, wherein the subsequent doses are separated by at least 1 day to 3 days; at least one week, at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks.

Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor-mediated endocytosis (see, e.g., Wu et al. (1987) J. Biol. Chem. 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. The pharmaceutical composition can also be delivered in a vesicle, in particular, a liposome (see, for example, Langer (1990) Science 249: 1527-1533).

The use of nanoparticles to deliver the antibodies of the present invention is also contemplated herein. Antibody-conjugated nanoparticles may be used both for therapeutic and diagnostic applications. Antibody-conjugated nanoparticles and methods of preparation and use are described in detail by Arruebo, M., et al. 2009 (“Antibody-conjugated nanoparticles for biomedical applications” in J. Nanomat. Volume 2009, Article ID 439389), incorporated herein by reference. Nanoparticles may be developed and conjugated to antibodies contained in pharmaceutical compositions to target cells. Nanoparticles for drug delivery have also been described in, for example, U.S. Pat. No. 8,257,740, or U.S. Pat. No. 8,246,995, each incorporated herein in its entirety.

In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used. In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose.

The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous, intracranial, intraperitoneal and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by methods publicly known. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled in an appropriate ampoule.

A pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition of the present invention. Examples include, but certainly are not limited to AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Burghdorf, Switzerland), HUMALOG MIX 75/25™ pen, HUMALOG™ pen, HUMALIN 70/30™ pen (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, N.J.), OPTIPEN™, OPTIPEN PRO™, OPTIPEN STARLET™, and OPTICLIK™ (Sanofi-Aventis, Frankfurt, Germany), to name only a few. Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present invention include, but certainly are not limited to the SOLOSTAR™ pen (Sanofi-Aventis), the FLEXPEN™ (Novo Nordisk), and the KWIKPEN™ (Eli Lilly), the SURECLICK™ Autoinjector (Amgen, Thousand Oaks, Calif.), the PENLET™ (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L. P.) and the HUMIRA™ Pen (Abbott Labs, Abbott Park, Ill.), to name only a few.

Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the antibody contained is generally about 5 to about 500 mg per dosage form in a unit dose; especially in the form of injection, it is preferred that the antibody is contained in about 5 to about 300 mg and in about 10 to about 300 mg for the other dosage forms.

C. METHODS AND USES

a. Methods of Treatment

The antibodies, compositions, and formulations described herein can be used to neutralize SARS-CoV-2 virus and thereby treating or preventing SARS-CoV-2 infections.

Accordingly, in one aspect, this disclosure further provides a method of neutralizing SARS-CoV-2 in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment thereof or a therapeutically effective amount of the pharmaceutical composition, as described above.

In another aspect, this disclosure additionally provides a method of preventing or treating a SARS-CoV-2 infection, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment thereof or a therapeutically effective amount of the pharmaceutical composition, as described above.

The neutralizing of the SARS-CoV-2 virus can be done via (i) inhibiting SARS-CoV-2 virus binding to a target cell; (ii) inhibiting SARS-CoV-2 virus uptake by a target cell; (iii) inhibiting SARS-CoV-2 virus replication; and (iv) inhibiting SARS-CoV-2 virus particles release from infected cells. One skilled in the art possesses the ability to perform any assay to assess neutralization of SARS-CoV-2 virus.

Notably, the neutralizing properties of antibodies may be assessed by a variety of tests, which all may assess the consequences of (i) inhibition of SARS-CoV-2 virus binding to a target cell; (ii) inhibition of SARS-CoV-2 virus uptake by a target cell; (iii) inhibition of SARS-CoV-2 virus replication; and (iv) inhibition of SARS-CoV-2 virus particles release from infected cells. In other words, implementing different tests may lead to the observation of the same consequence, i.e., the loss of infectivity of the SARS-CoV-2 virus. Thus, in one embodiment, the present invention provides a method of neutralizing SARS-CoV-2 virus in a subject comprising administering to the subject a therapeutically effective amount of the antibody of the present invention described herein.

Another aspect of the present invention provides a method of treating a SARS-CoV-2-related disease. Such a method includes therapeutic (following SARS-CoV-2 infection) and prophylactic (prior to SARS-CoV-2 exposure, infection or pathology). For example, therapeutic and prophylactic methods of treating an individual for a SARS-CoV-2 infection include treatment of an individual having or at risk of having a SARS-CoV-2 infection or pathology, treating an individual with a SARS-CoV-2 infection, and methods of protecting an individual from a SARS-CoV-2 infection, to decrease or reduce the probability of a SARS-CoV-2 infection in an individual, to decrease or reduce susceptibility of an individual to a SARS-CoV-2 infection, or to inhibit or prevent a SARS-CoV-2 infection in an individual, and to decrease, reduce, inhibit or suppress transmission of a SARS-CoV-2 from an infected individual to an uninfected individual. Such methods include administering an antibody of the present invention or a composition comprising the antibody disclosed herein to therapeutically or prophylactically treat (vaccinate or immunize) an individual having or at risk of having a SARS-CoV-2 infection or pathology. Accordingly, methods can treat the SARS-CoV-2 infection or pathology, or provide the individual with protection from infection (e.g., prophylactic protection).

In one embodiment, a method of treating a SARS-CoV-2-related disease comprises administering to an individual in need thereof an antibody or therapeutic composition disclosed herein in an amount sufficient to reduce one or more physiological conditions or symptoms associated with a SARS-CoV-2 infection or pathology, thereby treating the SARS-CoV-2-related disease.

In one embodiment, an antibody or therapeutic composition disclosed herein is used to treat a SARS-CoV-2-related disease. Use of an antibody or therapeutic composition disclosed herein treats a SARS-CoV-2-related disease by reducing one or more physiological conditions or symptoms associated with a SARS-CoV-2 infection or pathology. In aspects of this embodiment, administration of an antibody or therapeutic composition disclosed herein is in an amount sufficient to reduce one or more physiological conditions or symptoms associated with a SARS-CoV-2 infection or pathology, thereby treating the SARS-CoV-2-based disease. In other aspects of this embodiment, administration of an antibody or therapeutic composition disclosed herein is in an amount sufficient to increase, induce, enhance, augment, promote or stimulate SARS-CoV-2 clearance or removal; or decrease, reduce, inhibit, suppress, prevent, control, or limit transmission of SARS-CoV-2 to another individual.

One or more physiological conditions or symptoms associated with a SARS-CoV-2 infection or pathology will respond to a method of treatment disclosed herein. The symptoms of SARS-CoV-2 infection or pathology vary, depending on the phase of infection.

In some embodiments, the method of neutralizing SARS-CoV-2 in a subject comprises administering to a subject in need thereof a therapeutically effective amount of a first antibody or antigen-binding fragment thereof and a second antibody or antigen-binding fragment thereof of the antibody or antigen-binding fragment or a therapeutically effective amount of the pharmaceutical composition, as described above, wherein the first antibody or antigen-binding fragment thereof and the second antibody or antigen binding fragment thereof exhibit synergistic activity.

In some embodiments, the method of preventing or treating a SARS-CoV-2 infection, comprising administering to a subject in need thereof a therapeutically effective amount of a first antibody or antigen-binding fragment thereof and a second antibody or antigen-binding fragment thereof of the antibody or antigen-binding fragment or a therapeutically effective amount of the pharmaceutical composition, as described above, wherein the first antibody or antigen-binding fragment thereof and the second antibody or antigen binding fragment thereof exhibit synergistic activity. In some embodiments, the first antibody or antigen-binding fragment thereof is administered before, after, or concurrently with the second antibody or antigen-binding fragment thereof.

In some embodiments, the first antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912, and the second antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of SEQ ID NOs: 13-14, 49-50, 85-86, 113-114, 125-126, 2876 and 2888, or 2900 and 2912, wherein the first antibody and the second antibody are different.

The antibodies described herein can be used together with one or more of other anti-SARS-CoV-2 virus antibodies to neutralize SARS-CoV-2 virus and thereby treating SARS-CoV-2 infections.

b. Combination Therapies

Combination therapies may include an anti-SARS-CoV-2 antibody of the invention and any additional therapeutic agent that may be advantageously combined with an antibody of the invention or with a biologically active fragment of an antibody of the invention. The antibodies of the present invention may be combined synergistically with one or more drugs or therapy used to treat a disease or disorder associated with a viral infection, such as a SARS-CoV-2 infection. In some embodiments, the antibodies of the invention may be combined with a second therapeutic agent to ameliorate one or more symptoms of said disease. In some embodiments, the antibodies of the invention may be combined with a second antibody to provide synergistic activity in ameliorating one or more symptoms of said disease. In some embodiments, the first antibody or antigen-binding fragment thereof is administered before, after, or concurrently with the second antibody or antigen-binding fragment thereof.

For example, the antibody described herein can be used in various detection methods for use in, e.g., monitoring the progression of a SARS-CoV-2 infection; monitoring patient response to treatment for such an infection, etc. The present disclosure provides methods of detecting a neuraminidase polypeptide in a biological sample obtained from an individual. The methods generally involve: a) contacting the biological sample with a subject anti-neuraminidase antibody; and b) detecting binding, if any, of the antibody to an epitope present in the sample. In some instances, the antibody comprises a detectable label. The level of neuraminidase polypeptide detected in the biological sample can provide an indication of the stage, degree, or severity of a SARS-CoV-2 infection. The level of the neuraminidase polypeptide detected in the biological sample can provide an indication of the individual's response to treatment for a SARS-CoV-2 infection.

In some embodiments, the second therapeutic agent is another antibody to a SARS-COV-2 protein or a fragment thereof. It is contemplated herein to use a combination (“cocktail”) of antibodies with broad neutralization or inhibitory activity against SARS-COV-2. In some embodiments, non-competing antibodies may be combined and administered to a subject in need thereof. In some embodiments, the antibodies comprising the combination bind to distinct non-overlapping epitopes on the protein. In some embodiments, the second antibody may possess longer half-life in human serum.

As used herein, the term “in combination with” means that additional therapeutically active component(s) may be administered prior to, concurrent with, or after the administration of the anti-SARS-COV-2 antibody of the present invention. The term “in combination with” also includes sequential or concomitant administration of an anti-SARS-COV-2 antibody and a second therapeutic agent.

The additional therapeutically active component(s) may be administered to a subject prior to administration of an anti-SARS-COV-2 antibody of the present invention. For example, a first component may be deemed to be administered “prior to” a second component if the first component is administered 1 week before, 72 hours before, 60 hours before, 48 hours before, 36 hours before, 24 hours before, 12 hours before, 6 hours before, 5 hours before, 4 hours before, 3 hours before, 2 hours before, 1 hour before, 30 minutes before, 15 minutes before, 10 minutes before, 5 minutes before, or less than 1 minute before administration of the second component. In other embodiments, the additional therapeutically active component(s) may be administered to a subject after administration of an anti-SARS-COV-2 antibody of the present invention. For example, a first component may be deemed to be administered “after” a second component if the first component is administered 1 minute after, 5 minutes after, 10 minutes after, 15 minutes after, 30 minutes after, 1 hour after, 2 hours after, 3 hours after, 4 hours after, 5 hours after, 6 hours after, 12 hours after, 24 hours after, 36 hours after, 48 hours after, 60 hours after, 72 hours after administration of the second component. In yet other embodiments, the additional therapeutically active component(s) may be administered to a subject concurrent with administration of an anti-SARS-COV-2 antibody of the present invention. “Concurrent” administration, for purposes of the present invention, includes, e.g., administration of an anti-SARS-COV-2 antibody and an additional therapeutically active component to a subject in a single dosage form, or in separate dosage forms administered to the subject within about 30 minutes or less of each other. If administered in separate dosage forms, each dosage form may be administered via the same route (e.g., both the anti-SARS-COV-2 antibody and the additional therapeutically active component may be administered intravenously, etc.); alternatively, each dosage form may be administered via a different route (e.g., the anti-SARS-COV-2 antibody may be administered intravenously, and the additional therapeutically active component may be administered orally). In any event, administering the components in a single dosage from, in separate dosage forms by the same route, or in separate dosage forms by different routes are all considered “concurrent administration,” for purposes of the present disclosure. For purposes of the present disclosure, administration of an anti-SARS-COV-2 antibody “prior to,” “concurrent with,” or “after” (as those terms are defined hereinabove) administration of an additional therapeutically active component is considered administration of an anti-SARS-COV-2 antibody “in combination with” an additional therapeutically active component.

The present invention includes pharmaceutical compositions in which an anti-SARS-COV-2 antibody of the present invention is co-formulated with one or more of the additional therapeutically active component(s) as described elsewhere herein.

c. Administration Regimens

According to certain embodiments, a single dose of an anti-SARS-COV-2 antibody of the invention (or a pharmaceutical composition comprising a combination of an anti-SARS-COV-2 antibody and any of the additional therapeutically active agents mentioned herein) may be administered to a subject in need thereof. According to certain embodiments of the present invention, multiple doses of an anti-SARS-COV-2 antibody (or a pharmaceutical composition comprising a combination of an anti-SARS-COV-2 antibody and any of the additional therapeutically active agents mentioned herein) may be administered to a subject over a defined time course. The methods according to this aspect of the invention comprise sequentially administering to a subject multiple doses of an anti-SARS-COV-2 antibody of the invention. As used herein, “sequentially administering” means that each dose of anti-SARS-COV-2 antibody is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present invention includes methods which comprise sequentially administering to the patient a single initial dose of an anti-SARS-COV-2 antibody, followed by one or more secondary doses of the anti-SARS-COV-2 antibody, and optionally followed by one or more tertiary doses of the anti-SARS-COV-2 antibody.

The terms “initial dose,” “secondary doses,” and “tertiary doses,” refer to the temporal sequence of administration of the anti-SARS-COV-2 antibody of the invention. Thus, the “initial dose” is the dose which is administered at the beginning of the treatment regimen (also referred to as the “baseline dose”); the “secondary doses” are the doses which are administered after the initial dose; and the “tertiary doses” are the doses which are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of anti-SARS-COV-2 antibody, but generally may differ from one another in terms of frequency of administration. In some embodiments, however, the amount of anti-SARS-COV-2 antibody contained in the initial, secondary and/or tertiary doses varies from one another (e.g., adjusted up or down as appropriate) during the course of treatment. In some embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered at the beginning of the treatment regimen as “loading doses” followed by subsequent doses that are administered on a less frequent basis (e.g., “maintenance doses”).

In certain exemplary embodiments of the present invention, each secondary and/or tertiary dose is administered 1 to 48 hours (e.g., 1, 1½, 2, 2½, 3, 3½, 4, 4½, 5, 5½, 6, 6½, 7, 7½, 8, 8½, 9, 9½, 10, 10½, 11, 11½, 12, 12½, 13, 13½, 14, 14½, 15, 15½, 16, 16½, 17, 17½, 18, 18½, 19, 19½, 20, 20½, 21, 21½, 22, 22½, 23, 23½, 24, 24½, 25, 25½, 26, 26½, or more) after the immediately preceding dose. The phrase “the immediately preceding dose,” as used herein, means, in a sequence of multiple administrations, the dose of anti-SARS-COV-2 antibody, which is administered to a patient prior to the administration of the very next dose in the sequence with no intervening doses.

The methods, according to this aspect of the invention, may comprise administering to a patient any number of secondary and/or tertiary doses of an anti-SARS-COV-2 antibody. For example, In some embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to the patient. Likewise, In some embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to the patient.

In some embodiments of the invention, the frequency at which the secondary and/or tertiary doses are administered to a patient can vary over the course of the treatment regimen. The frequency of administration may also be adjusted during the course of treatment by a physician depending on the needs of the individual patient following clinical examination.

d. Diagnostic Uses of the Antibodies

The anti-SARS-COV-2 antibodies of the present invention may be used to detect and/or measure SARS-COV-2 in a sample, e.g., for diagnostic purposes. Some embodiments contemplate the use of one or more antibodies of the present invention in assays to detect a SARS-COV-2-associated-disease or disorder. Exemplary diagnostic assays for SARS-COV-2 may comprise, e.g., contacting a sample, obtained from a patient, with an anti-SARS-COV-2 antibody of the invention, wherein the anti-SARS-COV-2 antibody is labeled with a detectable label or reporter molecule or used as a capture ligand to selectively isolate SARS-COV-2 from patient samples. Alternatively, an unlabeled anti-SARS-COV-2 antibody can be used in diagnostic applications in combination with a secondary antibody, which is itself detectably labeled. The detectable label or reporter molecule can be a radioisotope, such as H, C, P, S, or I; a fluorescent or chemiluminescent moiety such as fluorescein isothiocyanate, or rhodamine; or an enzyme such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure SARS-COV-2 in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (MA), and fluorescence-activated cell sorting (FACS).

In some embodiments, the step of detecting comprises detecting fluorescence or chemiluminescence. In some embodiments, the step of detecting comprises a competitive binding assay or ELISA.

Samples that can be used in SARS-COV-2 diagnostic assays according to the present invention include any tissue or fluid sample obtainable from a patient, which contains detectable quantities of either SARS-COV-2 protein, or fragments thereof, under normal or pathological conditions. Generally, levels of SARS-COV-2 protein in a particular sample obtained from a healthy patient (e.g., a patient not afflicted with a disease associated with SARS-COV-2) will be measured to initially establish a baseline, or standard, level of SARS-COV-2. This baseline level of SARS-COV-2 can then be compared against the levels of SARS-COV-2 measured in samples obtained from individuals suspected of having a SARS-COV-2-associated condition, or symptoms associated with such condition.

The antibodies specific for SARS-COV-2 protein may contain no additional labels or moieties, or they may contain an N-terminal or C-terminal label or moiety. In one embodiment, the label or moiety is biotin. In a binding assay, the location of a label (if any) may determine the orientation of the peptide relative to the surface upon which the peptide is bound. For example, if a surface is coated with avidin, a peptide containing an N-terminal biotin will be oriented such that the C-terminal portion of the peptide will be distal to the surface.

D. KITS

In some embodiments, the kit also includes a container that contains the composition and optionally informational material. The informational material can be descriptive, instructional, marketing or other material that relates to the methods described herein and/or the use of the agents for therapeutic benefit. In an embodiment, the kit also includes an additional therapeutic agent, as described above. For example, the kit includes a first container that contains the composition and a second container for the additional therapeutic agent.

The informational material of the kits is not limited in its form. In some embodiments, the informational material can include information about production of the composition, concentration, date of expiration, batch or production site information, and so forth. In one embodiment, the informational material relates to methods of administering the composition, e.g., in a suitable dose, dosage form, or mode of administration (e.g., a dose, dosage form, or mode of administration described herein), to treat a subject in need thereof. In one embodiment, the instructions provide a dosing regimen, dosing schedule, and/or route of administration of the composition or the additional therapeutic agent. The information can be provided in a variety of formats, including printed text, computer-readable material, video recording, or audio recording, or information that contains a link or address to substantive material.

The kit can include one or more containers for the composition. In some embodiments, the kit contains separate containers, dividers or compartments for the composition and informational material. For example, the composition can be contained in a bottle or vial, and the informational material can be contained in a plastic sleeve or packet. In other embodiments, the separate elements of the kit are contained within a single, undivided container. For example, the composition is contained in a bottle or vial that has attached thereto the informational material in the form of a label. In some embodiments, the kit includes a plurality (e.g., a pack) of individual containers, each containing one or more unit dosage forms (e.g., a dosage form described herein) of the agents.

The kit optionally includes a device suitable for administration of the composition or other suitable delivery device. The device can be provided pre-loaded with one or both of the agents or can be empty, but suitable for loading. Such a kit may optionally contain a syringe to allow for injection of the antibody contained within the kit into an animal, such as a human.

E. DEFINITIONS

To aid in understanding the detailed description of the compositions and methods according to the disclosure, a few express definitions are provided to facilitate an unambiguous disclosure of the various aspects of the disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

The term “antibody” as referred to herein includes whole antibodies and any antigen-binding fragment or single chains thereof. Whole antibodies are glycoproteins comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The heavy chain variable region CDRs and FRs are HFR1, HCDR1, HFR2, HCDR2, HFR3, HCDR3, HFR4. The light chain variable region CDRs and FRs are LFR1, LCDR1, LFR2, LCDR2, LFR3, LCDR3, LFR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (CIq) of the classical complement system.

The term “antigen-binding fragment or portion” of an antibody (or simply “antibody fragment or portion”), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., a Spike or S protein of SARS-CoV-2 virus). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen-binding fragment or portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fab′ fragment, which is essentially a Fab with part of the hinge region (see, FUNDAMENTAL IMMUNOLOGY (Paul ed., 3rd ed. 1993)); (iv) a Fd fragment consisting of the VH and CHI domains; (v) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (vi) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; (vii) an isolated CDR; and (viii) a nanobody, a heavy chain variable region containing a single variable domain and two constant domains. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv or scFv); see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding fragment or portion” of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

An “isolated antibody,” as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to a Spike or S protein of SARS-CoV-2 virus is substantially free of antibodies that specifically bind antigens other than the neuraminidase). An isolated antibody can be substantially free of other cellular material and/or chemicals.

The terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.

The term “human antibody” is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences. The human antibodies of the invention can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term “human antibody,” as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

The term “human monoclonal antibody” refers to antibodies displaying a single binding specificity, which have variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. In one embodiment, the human monoclonal antibodies can be produced by a hybridoma that includes a B cell obtained from a transgenic nonhuman animal, e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.

The term “recombinant human antibody,” as used herein, includes all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom (described further below), (b) antibodies isolated from a host cell transformed to express the human antibody, e.g., from a transfectoma, (c) antibodies isolated from a recombinant, combinatorial human antibody library, and (d) antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable regions in which the framework and CDR regions are derived from human germline immunoglobulin sequences. In some embodiments, however, such recombinant human antibodies can be subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.

The term “isotype” refers to the antibody class (e.g., IgM or IgG1) that is encoded by the heavy chain constant region genes. The phrases “an antibody recognizing an antigen” and “an antibody specific for an antigen” are used interchangeably herein with the term “an antibody which binds specifically to an antigen.”

The term “human antibody derivatives” refers to any modified form of the human antibody, e.g., a conjugate of the antibody and another agent or antibody. The term “humanized antibody” is intended to refer to antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. Additional framework region modifications can be made within the human framework sequences.

The term “chimeric antibody” is intended to refer to antibodies in which the variable region sequences are derived from one species, and the constant region sequences are derived from another species, such as an antibody in which the variable region sequences are derived from a mouse antibody, and the constant region sequences are derived from a human antibody. The term can also refer to an antibody in which its variable region sequence or CDR(s) is derived from one source (e.g., an IgA1 antibody) and the constant region sequence or Fc is derived from a different source (e.g., a different antibody, such as an IgG, IgA2, IgD, IgE or IgM antibody).

The invention encompasses isolated or substantially purified nucleic acids, peptides, polypeptides or proteins. In the context of the present invention, an “isolated” nucleic acid, DNA or RNA molecule or an “isolated” polypeptide is a nucleic acid, DNA molecule, RNA molecule, or polypeptide that exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid, DNA molecule, RNA molecule or polypeptide may exist in a purified form or may exist in a non-native environment such as, for example, a transgenic host cell. A “purified” nucleic acid molecule, peptide, polypeptide or protein, or a fragment thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In one embodiment, an “isolated” nucleic acid is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. A protein, peptide or polypeptide that is substantially free of cellular material includes preparations of protein, peptide or polypeptide having less than about 30%, 20%, 10%, or 5% (by dry weight) of contaminating protein. When the protein of the invention, or biologically active portion thereof, is recombinantly produced, preferably culture medium represents less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or non-protein-of-interest chemicals.

The terms polypeptide, peptide, and protein are used interchangeably herein.

The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, pegylation, or any other manipulation, such as conjugation with a labeling component. As used herein, the term “amino acid” includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.

A peptide or polypeptide “fragment” as used herein refers to a less than full-length peptide, polypeptide or protein. For example, a peptide or polypeptide fragment can have is at least about 3, at least about 4, at least about 5, at least about 10, at least about 20, at least about 30, at least about 40 amino acids in length, or single unit lengths thereof. For example, fragment may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or more amino acids in length. There is no upper limit to the size of a peptide fragment. However, in some embodiments, peptide fragments can be less than about 500 amino acids, less than about 400 amino acids, less than about 300 amino acids or less than about 250 amino acids in length. Preferably the peptide fragment can elicit an immune response when used to inoculate an animal. A peptide fragment may be used to elicit an immune response by inoculating an animal with a peptide fragment in combination with an adjuvant, a peptide fragment that is coupled to an adjuvant, or a peptide fragment that is coupled to arsanilic acid, sulfanilic acid, an acetyl group, or a picryl group. A peptide fragment can include a non-amide bond and can be a peptidomimetic.

As used herein, the term “conjugate” or “conjugation” or “linked” as used herein refers to the attachment of two or more entities to form one entity. A conjugate encompasses both peptide-small molecule conjugates as well as peptide-protein/peptide conjugates.

The term “recombinant,” as used herein, refers to antibodies or antigen-binding fragments thereof of the invention created, expressed, isolated or obtained by technologies or methods known in the art as recombinant DNA technology which include, e.g., DNA splicing and transgenic expression. The term refers to antibodies expressed in a non-human mammal (including transgenic non-human mammals, e.g., transgenic mice), or a cell (e.g., CHO cells) expression system or isolated from a recombinant combinatorial human antibody library.

A “nucleic acid” or “polynucleotide” refers to a DNA molecule (for example, but not limited to, a cDNA or genomic DNA) or an RNA molecule (for example, but not limited to, an mRNA), and includes DNA or RNA analogs. A DNA or RNA analog can be synthesized from nucleotide analogs. The DNA or RNA molecules may include portions that are not naturally occurring, such as modified bases, modified backbone, deoxyribonucleotides in an RNA, etc. The nucleic acid molecule can be single-stranded or double-stranded.

The term “substantial identity” or “substantially identical,” when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 90%, and more preferably at least about 95%, 96%, 97%, 98% or 99% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or GAP, as discussed below. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule may, in certain instances, encode a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

As applied to polypeptides, the term “substantial similarity” or “substantially similar” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 90% sequence identity, even more preferably at least 95%, 98% or 99% sequence identity. Preferably, residue positions, which are not identical, differ by conservative amino acid substitutions. A “conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331, which is herein incorporated by reference. Examples of groups of amino acids that have side chains with similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic-hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartate and glutamate, and 7) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256: 1443 45, herein incorporated by reference. A “moderately conservative” replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For instance, GCG software contains programs such as GAP and BESTFIT, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, e.g., GCG Version 6.1. Polypeptide sequences also can be compared using FASTA with default or recommended parameters; a program in GCG Version 6.1. FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (2000) supra). Another preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program BLAST, especially BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each of which is herein incorporated by reference.

As used herein, the term “affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein.

The term “specifically binds,” or “binds specifically to,” or the like, refers to an antibody that binds to a single epitope, e.g., under physiologic conditions, but which does not bind to more than one epitope. Accordingly, an antibody that specifically binds to a polypeptide will bind to an epitope that present on the polypeptide, but which is not present on other polypeptides. Specific binding can be characterized by an equilibrium dissociation constant of at least about 1×10-8 M or less (e.g., a smaller KD denotes a tighter binding). Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. As described herein, antibodies have been identified by surface plasmon resonance, e.g., BIACORE™, which bind specifically to a Spike or S protein of SARS-CoV-2 virus.

Preferably, the antibody binds to a Spike or S protein with “high affinity,” namely with a KD of 1×10−7 M or less, more preferably 5×10−8 M or less, more preferably 3×10−8 M or less, more preferably 1×10−8 M or less, more preferably 5×10−9 M or less or even more preferably 1×10−9 M or less, as determined by surface plasmon resonance, e.g., BIACORE. The term “does not substantially bind” to a protein or cells, as used herein, means does not bind or does not bind with a high affinity to the protein or cells, i.e., binds to the protein or cells with a KD of 1×10−6 M or more, more preferably 1×10−5 M or more, more preferably 1×10−4 M or more, more preferably 1×10−3 M or more, even more preferably 1×10−2 M or more.

The term “Kassoc” or “Ka,” as used herein, is intended to refer to the association rate of a particular antibody-antigen interaction, whereas the term “Kdis” or “Kd,” as used herein, is intended to refer to the dissociation rate of a particular antibody-antigenn interaction. The term “KD,” as used herein, is intended to refer to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e., Kd/Ka) and is expressed as a molar concentration (M). KD values for antibodies can be determined using methods well established in the art. A preferred method for determining the KD of an antibody is by using surface plasmon resonance, preferably using a biosensor system such as a BIACORE system.

Antibodies that “compete with another antibody for binding to a target” refer to antibodies that inhibit (partially or completely) the binding of the other antibody to the target. Whether two antibodies compete with each other for binding to a target, i.e., whether and to what extent one antibody inhibits the binding of the other antibody to a target, may be determined using known competition experiments. In some embodiments, an antibody competes with, and inhibits binding of another antibody to a target by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The level of inhibition or competition may be different depending on which antibody is the “blocking antibody” (i.e., the cold antibody that is incubated first with the target). Competition assays can be conducted as described, for example, in Ed Harlow and David Lane, Cold Spring Harb Protoc; 2006 or in Chapter 11 of “Using Antibodies” by Ed Harlow and David Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA 1999. Competing antibodies bind to the same epitope, an overlapping epitope or to adjacent epitopes (e.g., as evidenced by steric hindrance). Other competitive binding assays include: solid phase direct or indirect radioimmunoassay (MA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see Stahli et al., Methods in Enzymology 9:242 (1983)); solid phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614 (1986)); solid phase direct labeled assay, solid phase direct labeled sandwich assay (see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1988)); solid phase direct label RIA using 1-125 label (see Morel et al., Mol. Immunol. 25(1):7 (1988)); solid phase direct biotin-avidin EIA (Cheung et al., Virology 176:546 (1990)); and direct labeled RIA. (Moldenhauer et al., Scand. J. Immunol. 32:77 (1990)).

The term “epitope” as used herein refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects. The term “epitope” also refers to a site on an antigen to which B and/or T cells respond. It also refers to a region of an antigen that is bound by an antibody. Epitopes may be defined as structural or functional. Functional epitopes are generally a subset of the structural epitopes and have those residues that directly contribute to the affinity of the interaction. Epitopes may also be conformational, that is, composed of non-linear amino acids. In some embodiments, epitopes may include determinants that are chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, In some embodiments, may have specific three-dimensional structural characteristics, and/or specific charge characteristics. An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation. Methods for determining what epitopes are bound by a given antibody (i.e., epitope mapping) are well known in the art and include, for example, immunoblotting and immune-precipitation assays, wherein overlapping or contiguous peptides from a Spike or S protein are tested for reactivity with a given antibody. Methods of determining spatial conformation of epitopes include techniques in the art and those described herein, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E. Morris, Ed. (1996)).

The term “epitope mapping” refers to the process of identification of the molecular determinants for antibody-antigen recognition.

The term “binds to an epitope” or “recognizes an epitope” with reference to an antibody or antibody fragment refers to continuous or discontinuous segments of amino acids within an antigen. Those of skill in the art understand that the terms do not necessarily mean that the antibody or antibody fragment is in direct contact with every amino acid within an epitope sequence.

The term “binds to the same epitope” with reference to two or more antibodies means that the antibodies bind to the same, overlapping or encompassing continuous or discontinuous segments of amino acids. Those of skill in the art understand that the phrase “binds to the same epitope” does not necessarily mean that the antibodies bind to or contact exactly the same amino acids. The precise amino acids that the antibodies contact can differ. For example, a first antibody can bind to a segment of amino acids that is completely encompassed by the segment of amino acids bound by a second antibody. In another example, a first antibody binds one or more segments of amino acids that significantly overlap the one or more segments bound by the second antibody. For the purposes herein, such antibodies are considered to “bind to the same epitope.”

As used herein, the term “immune response” refers to a biological response within a vertebrate against foreign agents, which response protects the organism against these agents and diseases caused by them. An immune response is mediated by the action of a cell of the immune system (for example, a T lymphocyte, B lymphocyte, natural killer (NK) cell, macrophage, eosinophil, mast cell, dendritic cell or neutrophil) and soluble macromolecules produced by any of these cells or the liver (including antibodies, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and/or elimination from the vertebrate's body of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues. An immune reaction includes, e.g., activation or inhibition of a T cell, e.g., an effector T cell or a Th cell, such as a CD4+ or CD8+ T cell, or the inhibition of a Treg cell.

The term “detectable label” as used herein refers to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorescers, chemiluminescers, chromophores, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, chromophores, dyes, metal ions, metal sols, ligands (e.g., biotin, avidin, streptavidin or haptens), intercalating dyes and the like. The term “fluorescer” refers to a substance or a portion thereof that is capable of exhibiting fluorescence in the detectable range.

In many embodiments, the terms “subject” and “patient” are used interchangeably irrespective of whether the subject has or is currently undergoing any form of treatment. As used herein, the terms “subject” and “subjects” may refer to any vertebrate, including, but not limited to, a mammal (e.g., cow, pig, camel, llama, horse, goat, rabbit, sheep, hamsters, guinea pig, cat, dog, rat, and mouse, a non-human primate (for example, a monkey, such as a cynomolgus monkey, chimpanzee, etc.) and a human). The subject may be a human or a non-human. In more exemplary aspects, the mammal is a human. As used herein, the expression “a subject in need thereof” or “a patient in need thereof” means a human or non-human mammal that exhibits one or more symptoms or indications of disorders (e.g., neuronal disorders, autoimmune diseases, and cardiovascular diseases), and/or who has been diagnosed with inflammatory disorders. In some embodiments, the subject is a mammal. In some embodiments, the subject is human.

As used herein, the term “disease” is intended to be generally synonymous and is used interchangeably with, the terms “disorder” and “condition” (as in medical condition), in that all reflect an abnormal condition (e.g., inflammatory disorder) of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.

As used herein, the term “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment, “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the patient. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.

The terms “prevent,” “preventing,” “prevention,” “prophylactic treatment” and the like refer to reducing the probability of developing a disorder or condition in a subject, who does not have, but is at risk of or susceptible to developing a disorder or condition.

The terms “decrease,” “reduced,” “reduction,” “decrease,” or “inhibit” are all used herein generally to mean a decrease by a statistically significant amount. However, for avoidance of doubt, “reduced,” “reduction” or “decrease” or “inhibit” means a decrease by at least 10% as compared to a reference level, for example, a decrease by at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% decrease (e.g., absent level as compared to a reference sample), or any decrease between 10-100% as compared to a reference level.

As used herein, the term “agent” denotes a chemical compound, a mixture of chemical compounds, a biological macromolecule (such as a nucleic acid, an antibody, a protein or portion thereof, e.g., a peptide), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. The activity of such agents may render it suitable as a “therapeutic agent,” which is a biologically, physiologically, or pharmacologically active substance (or substances) that acts locally or systemically in a subject.

As used herein, the terms “therapeutic agent,” “therapeutic capable agent,” or “treatment agent” are used interchangeably and refer to a molecule or compound that confers some beneficial effect upon administration to a subject. The beneficial effect includes enablement of diagnostic determinations; amelioration of a disease, symptom, disorder, or pathological condition; reducing or preventing the onset of a disease, symptom, disorder, or condition; and generally counteracting a disease, symptom, disorder or pathological condition.

The term “therapeutic effect” is art-recognized and refers to a local or systemic effect in animals, particularly mammals, and more particularly humans caused by a pharmacologically active substance.

The term “effective amount,” “effective dose,” or “effective dosage” is defined as an amount sufficient to achieve or at least partially achieve a desired effect. A “therapeutically effective amount” or “therapeutically effective dosage” of a drug or therapeutic agent is any amount of the drug that, when used alone or in combination with another therapeutic agent, promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. A “prophylactically effective amount” or a “prophylactically effective dosage” of a drug is an amount of the drug that, when administered alone or in combination with another therapeutic agent to a subject at risk of developing a disease or of suffering a recurrence of disease, inhibits the development or recurrence of the disease. The ability of a therapeutic or prophylactic agent to promote disease regression or inhibit the development or recurrence of the disease can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.

Doses are often expressed in relation to bodyweight. Thus, a dose which is expressed as [g, mg, or other unit]/kg (or g, mg etc.) usually refers to [g, mg, or other unit] “per kg (or g, mg etc.) bodyweight,” even if the term “bodyweight” is not explicitly mentioned.

As used herein, the term “composition” or “pharmaceutical composition” refers to a mixture of at least one component useful within the invention with other components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of one or more components of the invention to an organism.

As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the composition, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

As used herein, the term “pharmaceutically acceptable carrier” includes a pharmaceutically acceptable salt, pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a compound(s) of the present invention within or to the subject such that it may perform its intended function. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each salt or carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; diluent; granulating agent; lubricant; binder; disintegrating agent; wetting agent; emulsifier; coloring agent; release agent; coating agent; sweetening agent; flavoring agent; perfuming agent; preservative; antioxidant; plasticizer; gelling agent; thickener; hardener; setting agent; suspending agent; surfactant; humectant; carrier; stabilizer; and other non-toxic compatible substances employed in pharmaceutical formulations, or any combination thereof. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of one or more components of the invention, and are physiologically acceptable to the subject. Supplementary active compounds may also be incorporated into the compositions.

“Combination” therapy, as used herein, unless otherwise clear from the context, is meant to encompass administration of two or more therapeutic agents in a coordinated fashion and includes, but is not limited to, concurrent dosing. Specifically, combination therapy encompasses both co-administration (e.g., administration of a co-formulation or simultaneous administration of separate therapeutic compositions) and serial or sequential administration, provided that administration of one therapeutic agent is conditioned in some way on the administration of another therapeutic agent. For example, one therapeutic agent may be administered only after a different therapeutic agent has been administered and allowed to act for a prescribed period of time. See, e.g., Kohrt et al. (2011) Blood 117:2423.

As used herein, the term “co-administration” or “co-administered” refers to the administration of at least two agent(s) or therapies to a subject. In some embodiments, the co-administration of two or more agents/therapies is concurrent. In other embodiments, a first agent/therapy is administered prior to a second agent/therapy. Those of skill in the art understand that the formulations and/or routes of administration of the various agents/therapies used may vary.

As used herein, the term “contacting,” when used in reference to any set of components, includes any process whereby the components to be contacted are mixed into the same mixture (for example, are added into the same compartment or solution), and does not necessarily require actual physical contact between the recited components. The recited components can be contacted in any order or any combination (or sub-combination) and can include situations where one or some of the recited components are subsequently removed from the mixture, optionally prior to addition of other recited components. For example, “contacting A with B and C” includes any and all of the following situations: (i) A is mixed with C, then B is added to the mixture; (ii) A and B are mixed into a mixture; B is removed from the mixture, and then C is added to the mixture; and (iii) A is added to a mixture of B and C.

“Sample,” “test sample,” and “patient sample” may be used interchangeably herein. The sample can be a sample of serum, urine plasma, amniotic fluid, cerebrospinal fluid, cells, or tissue. Such a sample can be used directly as obtained from a patient or can be pre-treated, such as by filtration, distillation, extraction, concentration, centrifugation, inactivation of interfering components, addition of reagents, and the like, to modify the character of the sample in some manner as discussed herein or otherwise as is known in the art. The terms “sample” and “biological sample” as used herein generally refer to a biological material being tested for and/or suspected of containing an analyte of interest such as antibodies. The sample may be any tissue sample from the subject. The sample may comprise protein from the subject.

As used herein, the term “in vitro” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within a multi-cellular organism.

As used herein, the term “in vivo” refers to events that occur within a multi-cellular organism, such as a non-human animal.

As used herein, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.

As used herein, the terms “including,” “comprising,” “containing,” or “having” and variations thereof are meant to encompass the items listed thereafter and equivalents thereof as well as additional subject matter unless otherwise noted.

As used herein, the phrases “in one embodiment,” “in various embodiments,” “in some embodiments,” and the like are used repeatedly. Such phrases do not necessarily refer to the same embodiment, but they may unless the context dictates otherwise.

As used herein, the terms “and/or” or “/” means any one of the items, any combination of the items, or all of the items with which this term is associated.

As used herein, the word “substantially” does not exclude “completely,” e.g., a composition which is “substantially free” from Y may be completely free from Y. Where necessary, the word “substantially” may be omitted from the definition of the invention.

As used herein, the term “each,” when used in reference to a collection of items, is intended to identify an individual item in the collection but does not necessarily refer to every item in the collection. Exceptions can occur if explicit disclosure or context clearly dictates otherwise.

As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In some embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value). Unless indicated otherwise herein, the term “about” is intended to include values, e.g., weight percents, proximate to the recited range that are equivalent in terms of the functionality of the individual ingredient, the composition, or the embodiment.

As disclosed herein, a number of ranges of values are provided. It is understood that each intervening value, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither, or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

All methods described herein are performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. In regard to any of the methods provided, the steps of the method may occur simultaneously or sequentially. When the steps of the method occur sequentially, the steps may occur in any order, unless noted otherwise. In cases in which a method comprises a combination of steps, each and every combination or sub-combination of the steps is encompassed within the scope of the disclosure, unless otherwise noted herein.

Each publication, patent application, patent, and other reference cited herein is incorporated by reference in its entirety to the extent that it is not inconsistent with the present disclosure. Publications disclosed herein are provided solely for their disclosure prior to the filing date of the present invention. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

F. EXAMPLES
Example 1

This example describes the materials, methods, and instrumentation used in EXAMPLE 2.

Study participants. Study participants were recruited at the Rockefeller University Hospital in New York from April 1 through May 8, 2020. Eligible participants were adults aged 18-76 years who were either diagnosed with SARS-CoV-2 infection by RT-PCR and were free of symptoms of COVID-19 for at least 14 days (cases), or who were close contacts (e.g., household, co-workers, members of the same religious community) with someone who had been diagnosed with SARS-CoV-2 infection by RT-PCR and were free of symptoms suggestive of COVID-19 for at least 14 days (contacts). Exclusion criteria included the presence of symptoms suggestive of active SARS-CoV-2 infection, or hemoglobin <12 g/dL for males and <11 g/dL for females.

Most study participants were residents of the Greater New York City tri-state region and were enrolled sequentially according to eligibility criteria. Participants were first interviewed by phone to collect information on their clinical presentation and subsequently presented to the Rockefeller University Hospital for a single blood sample collection. Participants were asked to rate the highest severity of their symptoms on a numeric rating scale ranging from 0 to 10. The score was adapted from the pain scale chart, where 0 was the lack of symptoms, 4 were distressing symptoms (e.g., fatigue, myalgia, fever, cough, shortness of breath) that interfered with daily living activities, 7 were disabling symptoms that prevented the performance of daily living activities, and 10 were unimaginable/unspeakable discomfort (in this case, distress due to shortness of breath). All participants provided written informed consent before participation in the study, and the study was conducted in accordance with Good Clinical Practice, and clinical data collection and management was with software iRIS by iMedRIS. The study was performed in compliance with all relevant ethical regulations, and the protocol for human subject studies was approved by the Institutional Review Board (IRB) of the Rockefeller University.

Blood samples processing and storage. Peripheral Blood Mononuclear Cells (PBMCs) were obtained by gradient centrifugation and stored in liquid nitrogen in the presence of FCS and DMSO. Heparinized plasma and serum samples were aliquoted and stored at −20° C. or less. Prior to experiments, aliquots of plasma samples were heat-inactivated (56C for 1 hour) and then stored at 4C.

Cloning, expression, and purification of recombinant coronavirus proteins. Codon-optimized nucleotide sequences encoding the SARS-CoV-2 S ectodomain (residues 16-1206) and receptor-binding domain (RBD; residues 331-524) were synthesized and subcloned into the mammalian expression pTwist-CMV BetaGlobin vector by Twist Bioscience Technologies based on an early SARS-CoV-2 sequence isolate (GenBank MN985325.1). The SARS-CoV-2 RBD construct included an N-terminal human IL-2 signal peptide and dual C-terminal tags ((GGGGS)₂-HHHHHHHH (SEQ ID NO: 3233) (octa-histidine), and GLNDIFEAQKIEWHE (SEQ ID NO: 3234) (AviTag)). In addition, the corresponding S1^Bor receptor binding domains for SARS-CoV (residues 318-510; GenBank AAP13441.1), MERS-CoV (residues 367-588; GenBank JX869059.2), HCoV-NL63 (residues 481-614; GenBank AAS58177.1), HCoV-OC43 (residues 324-632; GenBank AAT84362.1), and HCoV-229E (residues 286-434; GenBank AAK32191.1) were synthesized with the same N- and C-terminal extensions as the SARS-CoV-2 RBD construct and subcloned into the mammalian expression pTwist-CMV BetaGlobin vector (Twist Bioscience Technologies). The SARS-CoV-2 S ectodomain was modified as previously described (Walls, A. C. et al. Cell 181, 281-292 e286 (2020).). Briefly, the S ectodomain construct included an N-terminal mu-phosphatase signal peptide, 2P stabilizing mutations (K986P and V987P), mutations to remove the S1/S2 furin cleavage site (₆₈₂RRAR₆₈₅(SEQ ID NO: 3235) to GSAS (SEQ ID NO: 3236)), a C-terminal extension (IKGSG-RENLYFQG (SEQ ID NO: 3237) (TEV protease site), GGGSG-YIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO: 3238) (foldon trimerization motif), G-HHHHHHHH (SEQ ID NO: 3239) (octa-histidine tag), and GLNDIFEAQKIEWHE (SEQ ID NO: 3234) (AviTag)). The SARS-CoV-2 S 2P ectodomain and RBD constructs were produced by transient transfection of 500 mL of Expi293F cells (Thermo Fisher) and purified from clarified transfected cell supernatants four days post-transfection using Ni²⁺-NTA affinity chromatography (GE Life Sciences). Affinity-purified proteins were concentrated and further purified by size-exclusion chromatography (SEC) using a Superdex200 16/60 column (GE Life Sciences) running in 1×TBS (20 mM Tris-HCl pH 8.0, 150 mM NaCl, and 0.02% NaN3). Peak fractions were analyzed by SDS-PAGE, and fractions corresponding to soluble S 2P trimers or monomeric RBD proteins were pooled and stored at 4° C.

ELISAs. Validated ELISAs to evaluate antibodies binding to SARS-CoV-2 RBD and trimeric spike proteins, and to SARS-CoV RBD, were performed by coating of high binding 96 half well plates (Corning #3690) with 50 μL per well of a 1 μg/mL protein solution in PBS overnight at 4° C. (Amanat, F. et al. Nat Med, doi:10.1038/s41591-020-0913-5 (2020); Grifoni, A. et al. Cell, doi:10.1016/j.cell.2020.05.015 (2020)). Plates were washed 6 times with washing buffer (1×PBS with 0.05% Tween 20 (Sigma-Aldrich)) and incubated with 170 μL per well blocking buffer (1×PBS with 2% BSA and 0.05% Tween20 (Sigma)) for 1 hour at room temperature (RT). Immediately after blocking, monoclonal antibodies or plasma samples were added in PBS and incubated for 1 hr at RT. Plasma samples were assayed at a 1:200 starting dilution and seven additional 3-fold serial dilutions. Monoclonal antibodies were tested at 10 μg/ml starting concentration and 10 additional 4-fold serial dilutions. Plates were washed 6 times with washing buffer and then incubated with anti-human IgG or IgM secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson Immuno Research 109-036-088 and 109-035-129) in blocking buffer at a 1:5000 dilution. Plates were developed by addition of the HRP substrate, TMB (ThermoFisher) for 10 minutes, then the developing reaction was stopped by adding 50 μl 1M H₂SO₄and absorbance was measured at 450 nm with an ELISA microplate reader (FluoStar Omega, BMG Labtech) with Omega and Omega MARS software for analysis. For plasma samples, a positive control (plasma from patient COV21, diluted 200-fold in PBS) and negative control historical plasma samples were added in duplicate to every assay plate for validation. The average of its signal was used for normalization of all the other values on the same plate with Excel software prior to calculating the area under the curve using Prism 8 (GraphPad). For monoclonal antibodies, the half-maximal effective concentration (EC₅₀) was determined using 4-parameter nonlinear regression (GraphPad Prism).

293T_ACE2cells. For constitutive expression of ACE2 in 293T cells, a cDNA encoding ACE2, carrying two inactivating mutations in the catalytic site (H374N & H378N), was inserted into CSIB 3′ to the SFFV promoter (Kane, M. et al. Cell Host Microbe 20, 392-405 (2016).). 293T_ACE2cells were generated by transduction with CSIB based virus followed by selection with 5 μg/ml Blasticidin.

SARS-CoV-2 and SARS-CoV pseudotyped reporter viruses. A plasmid expressing a C-terminally truncated SARS-CoV-2 S protein (pSARS-CoV2-S_trunc) was generated by insertion of a human-codon optimized cDNA encoding SARS-CoV-2 S lacking the C-terminal 19 codons (GENEART) into pCR3.1. The S ORF was taken from “Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1” (NC_045512). For expression of full-length SARS-CoV S protein, “Human SARS coronavirus Spike glycoprotein Gene ORF cDNA clone expression plasmid (Codon Optimized)” (here referred to as pSARS—CoV-S) was obtained from SinoBiological (Cat: VG40150-G-N). An env-inactivated HIV-1 reporter construct (pNL4-3ΔFnv-nanoluc) was generated from pNL4-3 by introducing a 940 bp deletion 3′ to the vpu stop-codon, resulting in a frameshift in env (Adachi, A. et al. J Virol 59, 284-291 (1986).). The human codon-optimized nanoluc Luciferase reporter gene (Nluc, Promega) was inserted in place of nucleotides 1-100 of the nef-gene. To generate pseudotyped viral stocks, 293T cells were transfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV2-S_truncor pSARS—CoV-S using polyethyleneimine. Co-transfection of pNL4-3ΔFnv-nanoluc and S-expression plasmids leads to production of HIV-1-based virions carrying either the SARS-CoV-2 or SARS-CoV spike protein on the surface. Eight hours after transfection, cells were washed twice with PBS, and fresh media was added. Supernatants containing virions were harvested 48 hours post transfection, filtered, and stored at −80° C. Infectivity of virions was determined by titration on 293T_ACE2cells. See also https://www.biorxiv.org/content/10.1101/2020.06.08.140871v1.

Pseudotyped virus neutralization assay. Five-fold serially diluted plasma from COVID-19 convalescent individuals and healthy donors or four-fold serially diluted monoclonal antibodies were incubated with the SARS-CoV-2 or SARS-CoV pseudotyped virus for 1 hour at 37° C. degrees. The mixture was subsequently incubated with 293T_ACE2cells for 48 hours, after which cells were washed twice with PBS and lysed with Luciferase Cell Culture Lysis 5× reagent (Promega). Nanoluc Luciferase activity in lysates was measured using the Nano-Glo Luciferase Assay System (Promega) with Modulus II Microplate Reader User interface (TURNER BioSystems). Relative luminescence units obtained were normalized to those derived from cells infected with SARS-CoV-2 or SARS-CoV pseudotyped virus in the absence of plasma or monoclonal antibodies. The half-maximal inhibitory concentration for plasma (NT₅₀) or monoclonal antibodies (IC₅₀) was determined using 4-parameter nonlinear regression (GraphPad Prism).

Cell lines, virus, and virus titration. VeroE6 kidney epithelial cells (Chlorocebus sabaeus; ATCC) and Huh-7.5 hepatoma cells (H. sapiens; Dr. Charles Rice, Laboratory of Virology and Infectious Disease, The Rockefeller University) were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 1% nonessential amino acids (NEAA) and 10% fetal bovine serum (FBS) at 37° C. and 5% CO₂. All cell lines have been tested negative for contamination with mycoplasma and were obtained from the ATCC (with the exception for Huh-7.5). SARS-CoV-2, strain USA-WA1/2020, was obtained from BEI Resources and amplified in VeroE6 cells at 33° C. Viral titers were measured on Huh-7.5 cells by standard plaque assay (PA). Briefly, 500 μL of serial 10-fold virus dilutions in Opti-MEM were used to infect 400,000 cells seeded the day prior in a 6-well plate format. After 90 min adsorption, the virus inoculum was removed, and cells were overlayed with DMEM containing 10% FBS with 1.2% microcrystalline cellulose (Avicel). Cells were incubated for five days at 33° C., followed by fixation with 3.5% formaldehyde and crystal violet staining for plaque enumeration. All experiments were performed in a biosafety level 3 laboratory.

Microscopy-based neutralization assay of authentic SARS-CoV-2. The day prior to infection, VeroE6 cells were seeded at 12,500 cells/well into 96-well plates. Antibodies were serially diluted in BA-1, mixed with a constant amount of SARS-CoV-2 (grown in VeroE6), and incubated for 60 min at 37° C. The antibody-virus-mix was then directly applied to VeroE6 cells (MOI of ˜0.1 PFU/cell). Cells were fixed 18 hours post infection by adding an equal volume of 7% formaldehyde to the wells, followed by permeabilization with 0.1% Triton X-100 for 10 min. After extensive washing, cells were incubated for 1 hour at room temperature with blocking solution of 5% goat serum in PBS (catalog no. 005-000-121; Jackson ImmunoResearch). A rabbit polyclonal anti-SARS-CoV-2 nucleocapsid antibody (catalog no. GTX135357; GeneTex) was added to the cells at 1:500 dilution in blocking solution and incubated at 4° C. overnight. A goat anti-rabbit AlexaFluor 594 (catalog no. A-11012; Life Technologies) at a dilution of 1:2,000 was used as a secondary antibody. Nuclei were stained with Hoechst 33342 (catalog no. 62249; Thermo Scientific) at a 1:1,000 dilution. Images were acquired with a fluorescence microscope and analyzed using ImageXpress Micro XLS and MetaXpress software (Molecular Devices, Sunnyvale, Calif.). All statistical analyses were done using Prism 8 software (GraphPad).

Biotinylation of viral protein for use in flow cytometry. Purified and Avi-tagged SARS-CoV-2 RBD was biotinylated using the Biotin-Protein Ligase-BIRA kit according to manufacturer's instructions (Avidity). Ovalbumin (Sigma, A5503-1G) was biotinylated using the EZ-Link Sulfo-NHS-LC-Biotinylation kit according to the manufacturer's instructions (Thermo Scientific). Biotinylated Ovalbumin was conjugated to streptavidin-BV711 (BD biosciences, 563262) and RBD to streptavidin-PE (BD biosciences, 554061) and streptavidin-Alexa Fluor 647 (AF647, Biolegend, 405237) respectively (Wang, Z. et al. J Immunol Methods 478, 112734, (2020)).

Single cell sorting by flow cytometry. PBMCs were enriched for B cells by negative selection using a pan B cell isolation kit according to the manufacturer's instructions (Miltenyi Biotec, 130-101-638). The enriched B cells were incubated in FACS buffer (1×Phosphate-buffered Saline (PBS), 2% calf serum, 1 mM EDTA) with the following anti-human antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41), anti-CD8-APC-eFluro 780 (Invitrogen, 47-0086-42), anti-CD16-APC-eFluro 780 (Invitrogen, 47-0168-41), anti-CD14-APC-eFluro 780 (Invitrogen, 47-0149-42), as well as Zombie NIR (BioLegend, 423105), and fluorophore-labeled RBD and Ovalbumin for 30 minutes on ice (Wang, Z. et al. J Immunol Methods 478, 112734 (2020).). Single CD3⁻CD8⁻CD16⁻CD20⁺Ova⁻RBD-PE⁺RBD-AF647⁺ B cells were sorted into individual wells of 96-well plates containing 4 μl of lysis buffer (0.5×PBS, 10 mM DTT, 3000 units/mL RNasin Ribonuclease Inhibitors (Promega, N2615) per well using a FACS Aria III and FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis. The sorted cells were frozen on dry ice, and then stored at −80° C. or immediately used for subsequent RNA reverse transcription. Although cells were not stained for IgG expression, they are memory B cells based on the fact that they are CD20⁺ (a marker absent in plasmablasts) and they express IgG (since antibodies were amplified from these cells using IgG-specific primers).

Antibody sequencing, cloning, and expression. Antibodies were identified and sequenced as described previously (Robbiani, D. F. et al. Cell 169, 597-609 e511 (2017); Tiller, T. et al. J Immunol Methods 329, 112-124 (2008); von Boehmer, L. et al. Nat Protoc 11, 1908-1923 (2016)). Briefly, RNA from single cells was reverse-transcribed (SuperScript III Reverse Transcriptase, Invitrogen, 18080-044) and the cDNA stored at −20° C. or used for subsequent amplification of the variable IGH, IGL and IGK genes by nested PCR and Sanger sequencing (Tiller, T. et al. J Immunol Methods 329, 112-124 (2008)). Anti-Zika virus monoclonal antibody Z021 (Robbiani, D. F. et al. Cell 169, 597-609 e511 (2017)) was used as isotype control. Sequence analysis was with MacVector. Amplicons from the first PCR reaction were used as templates for Sequence- and Ligation-Independent Cloning (SLIC) into antibody expression vectors. Recombinant monoclonal antibodies and Fabs were produced and purified as previously described (Klein, F. et al. J Exp Med 211, 2361-2372 (2014); Schoofs, T. et al. Immunity 50, 1513-1529 (2019)).

Biolayer interferometry. BLI assays were performed on the Octet Red instrument (ForteBio) at 30° C. with shaking at 1,000 r.p.m. Epitope binding assays were performed with protein A biosensor (ForteBio 18-5010), following the manufacturer's protocol “classical sandwich assay.” (1) Sensor check: sensors immersed 30 sec in buffer alone (buffer ForteBio 18-1105). (2) Capture 1^stAb: sensors immersed 10 min with Ab1 at 40 μg/mL. (3) Baseline: sensors immersed 30 sec in buffer alone. (4) Blocking: sensors immersed 5 min with IgG isotype control at 50 μg/mL. (6) Antigen association: sensors immersed 5 min with RBD at 100 μg/mL. (7) Baseline: sensors immersed 30 sec in buffer alone. (8) Association Ab2: sensors immersed 5 min with Ab2 at 40 μg/mL. Curve fitting was performed using the Fortebio Octet Data analysis software (ForteBio).

Computational analyses of antibody sequences. Antibody sequences were trimmed based on quality and annotated using Igblastn v1.14.0 (Ye, J., et al. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res 41, W34-40 (2013)) with IMGT domain delineation system. Annotation was performed systematically using Change-0 toolkit v.0.4.5 (Gupta, N. T. et al. Bioinformatics 31, 3356-3358 (2015).). Heavy and light chains derived from the same cell were paired, and clonotypes were assigned based on their V and J genes using in-house R and Perl scripts (FIGS. 5B and 5C). All scripts and the data used to process antibody sequences are publicly available on GitHub (https://github.com/stratust/igpipeline).

The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study were compared to Sequence Read Archive SRP010970 (Rubelt, F. et al. PLoS One 7, e49774 (2012).). The V(D)J assignments were done using IMGT/High V-Quest, and the frequencies of heavy and light chain V genes were calculated for 14 and 13 individuals, respectively, using sequences with unique CDR3 s. The two-tailed t test with unequal variances was used to determine statistical significance (FIG. 13).

Nucleotide somatic hypermutation and CDR3 length were determined using in-house R and Perl scripts. For somatic hypermutations, IGHV and IGLV nucleotide sequences were aligned against their closest germlines using Igblastn, and the number of differences was considered nucleotide mutations. The average mutations for V genes were calculated by dividing the sum of all nucleotide mutations across all patients by the number of sequences used for the analysis. To calculate the GRAVY scores of hydrophobicity (Kyte, J. & Doolittle, R. F. J Mol Biol 157, 105-132 (1982).) we used Guy H. R. Hydrophobicity scale based on free energy of transfer (kcal/mole) (Guy, H. R. Biophys J 47, 61-70 (1985).) implemented by the R package Peptides available in the Comprehensive R Archive Network repository (https://journal.r-project.org/archive/2015/RJ-2015-001/RJ-2015-001.pdf). We used 533 heavy chain CDR3 amino acid sequences from this study (sequence COV047_P4_IgG_51-P1369 lacks CDR3 amino acid sequence) and 22,654,256 IGH CDR3 sequences from the public database of memory B-cell receptor sequences (DeWitt, W. S. et al. PLoS One 11, e0160853 (2016).). The Shapiro-Wilk test was used to determine whether the GRAVY scores are normally distributed. The GRAVY scores from all 533 IGH CDR3 amino acid sequences from this study were used to perform the test, and 5000 GRAVY scores of the sequences from the public database were randomly selected. The Shapiro-Wilk p-values were 6.896×10⁻³and 2.217×10′ for sequences from this study and the public database, respectively, indicating the data are not normally distributed. Therefore, we used the Wilcoxon non-parametric test to compare the samples, which indicated a difference in hydrophobicity distribution (p=5×10′; FIG. 14).

Negative-stain EM Data Collection and Processing. Purified Fabs (C002, C119, and C121) were complexed with SARS-CoV-2 S trimer at a 2-fold molar excess for 1 min and diluted to 40 μg/mL in TBS immediately before adding 3 μL to a freshly-glow discharged ultrathin, 400 mesh carbon-coated copper grid (Ted Pella, Inc.). Samples were blotted after a 1 min incubation period and stained with 1% uranyl formate for an additional minute before imaging. Micrographs were recorded on a Thermo Fisher Talos Arctica transmission electron microscope operating at 200 keV using a K3 direct electron detector (Gatan, Inc) and SerialEM automated image acquisition software (Mastronarde, D. N. J Struct Biol 152, 36-51 (2005).). Images were acquired at a nominal magnification of 28,000× (1.44 Å/pixel size) and a −1.5 to −2.0 μm defocus range. Images were processed in cryoSPARC, and reference-free particle picking was completed using a gaussian blob picker (Punjani, A., et al. Nat Methods 14, 290-296 (2017).). Reference-free 2D class averages and ab initio volumes were generated in cryoSPARC, and subsequently 3D-classified to identify classes of S-Fab complexes, that were then homogenously refined. Figures were prepared using UCSF Chimera (Goddard, T. D., et al. J Struct Biol 157, 281-287 (2007).). The resolutions of the final single particle reconstructions were ˜17-20 Å calculated using a gold-standard FSC (0.143 cutoff) and ˜24-28 Å using a 0.5 cutoff.

Example 2

During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-2 (Graham, R. L., et al. Nat Rev Microbiol 11, 836-848 (2013); Gralinski, L. E. & Baric, R. S. J Pathol 235, 185-195 (2015); Hoffmann, M. et al. Cell 181, 271-280 e278 (2020); Walls, A. C. et al. Cell 181, 281-292 (2020); Jiang, S., et al. Trends Immunol (2020).). This disclosure reports on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titers: less than 1:50 in 33% and below 1:1000 in 79%, while only 1% showed titers >1:5000. Antibody sequencing revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC₅₀s) as low as single-digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.

Between Apr. 1 and May 8, 2020, 157 eligible participants enrolled in the study. Of these, 111 (70.7%) were individuals diagnosed with SARS-CoV-2 infection by RT-PCR (cases), and 46 (29.3%) were close contacts of individuals diagnosed with SARS-CoV-2 infection (contacts). While inclusion criteria allowed for enrollment of asymptomatic participants, 8 contacts that did not develop symptoms were excluded from further analyses. The 149 cases and contacts were free of symptoms suggestive of COVID-19 for at least 14 days at the time of sample collection. Participant demographics and clinical characteristics are shown in Tables 2 and 3 and FIG. 7A. Only one individual who tested positive for SARS-CoV-2 infection by RT-PCR remained asymptomatic. The other 148 participants reported symptoms suggestive of COVID-19 with an average onset of approximately 39 days (range 17 to 67 days) before sample collection. In this cohort, symptoms lasted for an average of 12 days (0-35 days), and 11 (7%) of the participants were hospitalized. The most common symptoms were fever (83.9%), fatigue (71.1%), cough (62.4%), and myalgia (61.7%), while baseline comorbidities were infrequent (10.7%) (Tables 2 and 3). There were no significant differences in duration or severity (see Methods) of symptoms, or in time from onset of symptoms to sample collection between genders or between cases and contacts. There was no age difference between females and males in our cohort (FIG. 7).

Plasma samples were tested for binding to the SARS-CoV-2 RBD and trimeric spike (S) proteins by a validated ELISA using anti-IgG or -IgM secondary antibodies for detection (FIG. 7, Table 2, FIGS. 8 and 9) (Amanat, F. et al. Nat Med (2020); Grifoni, A. et al. Cell (2020).). Eight independent negative controls and the positive control plasma sample from participant 21 (COV21) were included for normalization of the area under the curve in all experiments (AUC). Overall, 78% and 70% of the plasma samples tested showed anti-RBD and anti-S IgG AUCs that were at least 2 standard deviations above the control (FIGS. 7A and 7B). In contrast, only 15% and 34% of the plasma samples showed IgM responses to anti-RBD and anti-S that were at least 2 standard deviations above control, respectively (FIGS. 7C and 7D). There was no positive correlation between anti-RBD or -S IgG or IgM levels and duration of symptoms or the timing of sample collection relative to the onset of symptoms (FIG. 3E and FIGS. 9A-9C and 9G-9J). On the contrary, as might be expected, anti-RBD IgM titers were negatively correlated with duration of symptoms and the timing of sample collection (FIG. 3E and FIG. 9H). Anti-RBD IgG levels were modestly correlated to age and the severity of symptoms including hospitalization (FIGS. 3F-3G and FIG. 9K). Interestingly, females had lower anti-RBD and -S IgG titers than males (FIG. 3H and FIG. 8F).

To measure the neutralizing activity in convalescent plasmas, we used HIV-1-based virions carrying a nanoluc luciferase reporter that was pseudotyped with the SARS-CoV-2 spike (SARS-CoV-2 pseudovirus, see Methods, FIG. 4 and FIG. 10). Negative (historical) and positive (COV21) controls were included in all experiments. The overall level of neutralizing activity in the cohort, as measured by the half-maximal neutralizing titer (NT₅₀) was generally low, with 33% less than 50 and 79% below 1,000 (FIGS. 4A and 4B). The geometric mean NT₅₀was 121 (arithmetic mean=714), and only 2 individuals reached NT₅₀s above 5,000 (FIGS. 4A and 4B and Table 2).

Notably, levels of anti-RBD- and -S IgG antibodies correlated strongly with NT₅₀(FIGS. 4C and 4D). The neutralizing activity also correlated with age, duration of symptoms, and symptom severity (FIG. 11). Consistent with this observation, hospitalized individuals with longer symptom duration showed slightly higher average levels of neutralizing activity than non-hospitalized individuals (p=0.0495, FIG. 4E). Finally, a significant difference in neutralizing activity between males and females (p=0.0031, FIG. 4F) was observed. The difference between males and females was consistent with higher anti-RBD and -S IgG titers in males, and could not be attributed to age, severity, timing of sample collection relative to the onset of symptoms or duration of symptoms (FIG. 3H and FIGS. 8A-8D and 8F).

To determine the nature of the antibodies elicited by SARS-CoV-2 infection, flow cytometry was used to isolate individual B lymphocytes with receptors that bound to RBD from the blood of 6 selected individuals, including the 2 top and 4 high to intermediate neutralizers (FIG. 5). The frequency of antigen-specific B cells, identified by their ability to bind to both Phycoerythrin (PE)- and AF647-labeled RBD, ranged from 0.07 to 0.005% of all circulating B cells in COVID-19 convalescents but they were undetectable in pre-COVID-19 controls (FIG. 5A and FIG. 12). 534 paired IgG heavy and light chain (IGH and IGL) sequences were obtained by reverse transcription and subsequent PCR from individual RBD-binding B cells from the 6 convalescent individuals (see Methods and Tables 4-5 and 7-14). When compared to the human antibody repertoire, several IGHV and IGLV genes were significantly over-represented (FIG. 13). The average number of V genes nucleotide mutations for IGH and IGL was 4.2 and 2.8, respectively (FIG. 14), which is lower than in antibodies cloned from individuals suffering from chronic infections such as Hepatitis B or HIV-1, and similar to antibodies derived from primary malaria infection or non-antigen-enriched circulating IgG memory cells (Scheid, J. F. et al. Nature 458, 636-640 (2009); Tiller, T. et al. Immunity 26, 205-213 (2007); Murugan, R. et al. Sci Immunol 3 (2018); Wang, Q. et al. Cell Host Microbe, doi:10.1016/j.chom.2020.05.010 (2020).). Among other antibody features, IGH CDR3 length was indistinguishable from the reported norm, and hydrophobicity was below average (FIG. 14) (Briney, B., et al. Nature 566, 393-397 (2019).).

As is the case with other human pathogens, there were expanded clones of viral antigen binding B cells in all COVID-19 individuals tested (see Methods and FIGS. 5B and 5C). Overall, 32.2% of the recovered IGH and IGL sequences were from clonally expanded B cells (range 21.8-57.4% across individuals, FIG. 5B). Antibodies that shared specific combinations of IGHV and IGLV genes in different individuals comprised 14% of all the clonal sequences (colored pie slices in FIGS. 5B and 5C). Remarkably, the amino acid sequences of some antibodies found in different individuals were nearly identical (FIGS. 5D and 5E). For example, antibodies expressed by clonally expanded B cells with IGHV1-58/IGKV3-20 and IGHV3-30-3/IGKV1-39 found repeatedly in different individuals had amino acid sequence identities of up to 99% and 92%, respectively (FIG. 5D and Table 4). It was concluded that the IgG memory response to the SARS-CoV-2 RBD is rich in recurrent and clonally expanded antibody sequences.

To examine the binding properties of anti-SARS-CoV-2 antibodies, 94 representative antibodies, 67 from clones and 27 from singlets (Tables 4 and 5), were expressed. ELISA assays showed that 95% (89 out of 94) of the antibodies tested including clonal and unique sequences bound to the SARS-CoV-2 RBD with an average half-maximal effective concentration (EC₅₀) of 6.9 ng/mL (FIG. 6A and FIG. 15A). A fraction of these (7 out of 77 that were tested, or 9%) cross-reacted with the RBD of SARS-CoV with EC₅₀s below 1 mg/mL (FIGS. 15B and 15C). No significant cross-reactivity was noted to the RBDs of MERS, HCoV-OC43, HCoV-229E or HCoV-NL63.

To determine whether the monoclonal antibodies have neutralizing activity, we tested them against the SARS-CoV-2 pseudovirus (FIG. 6 and Table 6). Among 89 RBD binding antibodies tested, it was found 52 that neutralized SARS-CoV-2 pseudovirus with nanogram per milliliter half-maximal inhibitory concentrations (IC₅₀s) ranging from 3 to 709 (FIGS. 6B, 6C, and 6E; Table 6). A subset of the most potent of these antibodies was also tested against authentic SARS-CoV-2 and neutralized with IC₅₀s of less than 5 ng/ml (FIGS. 6D and 6E). Only two of the antibodies which cross-reacted with the RBD of SARS-CoV showed significant neutralizing activity against SARS-CoV pseudovirus (FIGS. 15D and 15E).

Potent neutralizing antibodies were found in individuals irrespective of their plasma NT₅₀s. For example, C121, C144, and C135 with IC₅₀s of 1.64, 2.55 and 2.98 ng/mL against authentic SARS-CoV-2, respectively, were obtained from individuals COV107, COV47, and COV72 whose plasma NT₅₀values were of 297, 10,433 and 3,138, respectively (FIG. 4B and FIG. 6). Finally, clones of antibodies with shared IGHV and IGLV genes were among the best neutralizers, e.g., antibody C002 composed of IGHV3-30/IGKV1-39 is shared by the 2 donors with the best plasma neutralizing activity (red pie slice in FIGS. 5B and 6). It was concluded that even individuals with modest plasma neutralizing activity harbor rare IgG memory B cells that produce potent SARS-CoV-2 neutralizing antibodies.

To determine whether human anti-SARS-CoV-2 monoclonal antibodies with neutralizing activity can bind to distinct domains on the RBD, we performed bilayer interferometry experiments in which a preformed antibody-RBD immune complex was exposed to a second monoclonal. The antibodies tested comprised 3 groups, all of which differ in their binding properties from CR3022, an antibody that neutralizes SARS-CoV and binds to, but does not neutralize SARS-CoV-2 (ter Meulen, J. et al. PLoS Med 3, e237(2006); Yuan, M. et al. Science 368, 630-633 (2020).). Representatives of each of the 3 groups include: C144 and C101 in Group 1; C121 and C009 in Group 2; C135 in Group 3. All of these antibodies can bind after CR3022. Groups 1 and 2 also bind after Group 3, and Groups 1 and 2 differ in that Group 1 can bind after Group 2 but not vice versa (FIGS. 6F-6N). It was concluded that similar to SARS-CoV, there are multiple distinct neutralizing epitopes on the RBD of SARS-CoV-2.

To further define the binding characteristics of Groups 1 and 2 antibodies, SARS-CoV-2 S-Fab complexes were imaged by negative stain electron microscopy (nsEM) using C002 (Group 1, an IGHV3-30/IGKV1-39 antibody, which is clonally expanded in 2 donors), C119 and C121 (both in Group 2) Fabs (FIGS. 6F-6R and FIG. 16). Consistent with the conformational flexibility of the RBD, 2D class averages showed heterogeneity in both occupancy and orientations of bound Fabs for both groups (FIGS. 40-6Q). The low resolution of NS EM reconstructions precludes detailed binding interpretations, but the results are consistent with Fabs from both groups being able to recognize “up” and “down” states of the RBD, as previously described for some antibodies targeting this epitope (Walls, A. C. et al. Cell 176, 1026-1039 (2019); Pinto, D. et al. Nature, doi:10.1038/s41586-020-2349-y (2020).). The 3D reconstructions are also consistent with competition measurements indicating that Groups 1 and 2 antibodies bind a RBD epitope distinct from antibody CR3022 (FIGS. 6F-6N) and with a single-particle cryo-EM structure of a C105-S complex (https://www.biorxiv.org/content/10.1101/2020.05.28.121533v1.full.pdf). In addition, the structures suggest that the antibodies bind the RBD with different angles of approach, with Group 1 antibodies more similar to the approach angle of the SARS-CoV antibody S230 (Zhu, Z. et al. Proc Natl Acad Sci USA 104, 12123-12128 (2007).) (FIG. 6R).

Human monoclonal antibodies with neutralizing activity against pathogens ranging from viruses to parasites have been obtained from naturally infected individuals by single cell antibody cloning. Several have been shown to be effective in protection and therapy in model organisms and in early phase clinical studies, but only one antiviral monoclonal is currently in clinical use (Salazar, G., et al. NPJ Vaccines 2, 19 (2017).). Antibodies are relatively expensive and more difficult to produce than small molecule drugs. However, they differ from drugs in that they can engage the host immune system through their constant domains that bind to Fc gamma receptors on host immune cells (Bournazos, S. & Ravetch, J. V. Immunol Rev 275, 285-295 (2017).). These interactions can enhance immunity and help clear the pathogen or infected cells, but they can also lead to disease enhancement during Dengue (Feinberg, M. B. & Ahmed, R. Science 358, 865-866 (2017)) and possibly coronavirus infections (Iwasaki, A. & Yang, Y. Nat Rev Immunol, doi:10.1038/s41577-020-0321-6 (2020).). This problem has impeded Dengue vaccine development but would not interfere with the clinical use of potent neutralizing antibodies that can be modified to prevent Fc gamma receptor interactions and remain protective against viral pathogens (Van Rompay, K. K. A. et al. Proc Natl Acad Sci USA 117, 7981-7989 (2020).).

Antibodies are essential elements of most vaccines and will likely be a crucial component of an effective vaccine against SARS-CoV-2 (Plotkin, S. A. Clin Vaccine Immunol 17, 1055-1065 (2010); Yu, J. et al. Science, doi:10.1126/science.abc6284 (2020); Chandrashekar, A. et al. Science, doi:10.1126/science.abc4776 (2020).). Recurrent antibodies have been observed in other infectious diseases and vaccinal responses (Wang, Q. et al. Cell Host Microbe, doi:10.1016/j.chom.2020.05.010 (2020); Scheid, J. F. et al. Science 333, 1633-1637 (2011); Robbiani, D. F. et al. Cell 169, 597-609 e511(2017); Ehrhardt, S. A. et al. Nat Med 25, 1589-1600 (2019); Pappas, L. et al. Nature 516, 418-422 (2014).). The observation that plasma neutralizing activity is low in most convalescent individuals, but that recurrent anti-SARS-CoV-2 RBD antibodies with potent neutralizing activity can be found in individuals with unexceptional plasma neutralizing activity suggests that humans are intrinsically capable of generating anti-RBD antibodies that potently neutralize SARS-CoV-2. Thus, vaccines that selectively and efficiently induce antibodies targeting the SARS-CoV-2 RBD may be especially effective.

Example 3

This example describes the materials, methods, and instrumentation used in EXAMPLE 4.

Human subjects. Samples of peripheral blood were obtained upon written consent from community participants under protocols approved by the Institutional Review Board of the Rockefeller University (DRO-1006). Details on the demographics of the cohort are provided in (Robbiani et al., 2020).

Cell lines. HEK293T cells for pseudovirus production and HEK293TACE2 cells for pseudovirus neutralization experiments were cultured at 37° C. and 5% CO2 in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich) and 5 μg/ml Gentamicin (Sigma-Aldrich). The medium for the 293TAce2 cells additionally contained 5 μg/ml Blasticidin (Gibco). For constitutive expression of ACE2 in 293T cells, a Cdna encoding ACE2, carrying two inactivating mutations in the catalytic site (H374N & H378N), was inserted into CSIB 3′ to the SFFV promoter (Kane et al., 2016). 293TACE2 cells were generated by transduction with CSIB based virus followed by selection with 5 μg/ml Blasticidin (Gibco). Expi293F cells (Gibco) for protein expression were maintained at 37° C. and 8% CO2 in Expi293 Expression medium (Gibco), transfected using Expi293 Expression System Kit (Gibco) and maintained under shaking at 130 rpm. The gender of the HEK293T, HEK293TACE2 and Expi293F cell lines is female. Cell lines were not specifically authenticated.

Bacteria. E. coli DH5α (Zymo Research) for propagation of expression plasmids were cultured at 37° C. in LB broth (Sigma-Aldrich) with shaking at 250 rpm.

Viruses. To generate pseudotyped viral stocks, HEK293T cells were transfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV2-Strunc (Robbiani et al., 2020) using polyethyleneimine, leading to production of HIV-1-based virions carrying the SARS-CoV-2 S protein at the surface. Eight hours after transfection, cells were washed twice with PBS and fresh media was added. Supernatants containing virions were harvested 48 hours post transfection, filtered and stored at −80° C. Infectivity of virions was determined by titration on 293TACE2 cells.

Collection of human samples. Convalescent and healthy donor plasma samples were collected and processed as described (Robbiani et al., 2020). The convalescent plasma samples used for nsEMPEM were from residents in the State of New York: COV21 (a 54-year-old male Hispanic, collection 27 days after symptom onset), COV57 (a 66-year-old male Caucasian, collection 21 days after symptom onset), and COV107 (a 53-year-old female Caucasian, collection 29 days after symptom onset). An analysis of SARS-CoV-2 genomes in the GISAID database with sample collection dates in March 2020 (contemporaneous with the infections of individuals COV21, COV57, and COV107) was performed to identify any viral spike mutations likely to have been present. For SARS-CoV-2 genomes of New York State residents from March 2020, 468 of 475 contained the D614G mutation. Thus, based on state-level mutant frequencies, these individuals were likely to have been infected with D614G-containing viruses. All other spike mutations in these genomes had a frequency below 2%. All participants provided written informed consent before sample collection at the Rockefeller University Hospital and the study was conducted in accordance with Good Clinical Practice. Anti-coagulated plasma was heat-inactivated (56° C. for 1 hour) prior to shipment to Caltech and stored at 4° C. thereafter (Robbiani et al., 2020).

Phylogenetic trees. Sequence alignments of S proteins and RBD/S1^Bdomains were made with Clustal Omega (Sievers et al., 2011). Phylogenetic trees were calculated from these amino acid alignments using PhyML 3.0 (Guindon et al., 2010) and visualized with PRESTO (http://www.atgc-montpellier.fr/presto).

Cloning and expression of recombinant CoV proteins. Codon-optimized nucleotide sequences encoding the SARS-CoV-2 S ectodomain (residues 161206 of an early SARS-CoV-2 sequence isolate; GenBank MN985325.1, which has an Asp at position 614, so does not include the D614G mutation described as possibly more transmissible in (Korber et al., 2020)), SARS-CoV S (residues 12-1193; GenBank AAP13441.1), MERS-CoV S (residues 19-1294; GenBank JX869059.2), HCoV-OC43 (residues 15-1263; GenBank AAT84362.1), HCoV-NL63 (residues 16-1291; GenBank AAS58177.1), and HCoV-229E (residues 17-1113; GenBank AAK32191.1) were synthesized and subcloned into the mammalian expression pTwist-CMV BetaGlobin vector by Twist Bioscience Technologies. The S proteins were modified as previously described (Li et al., 2019; Tortorici et al., 2019; Walls et al., 2020). Briefly, the S ectodomain constructs included an N-terminal mu-phosphatase signal peptide, 2P stabilizing mutations (Pallesen et al., 2017) and a C-terminal extension (GSG-RENLYFQG (SEQ ID NO: 3240) (TEV protease site), GGGSG-YIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO: 3238) (foldon trimerization motif), G-HHHHHHH (SEQ ID NO: 3239) (octa-histidine tag), and GLNDIFEAQKIEWHE (SEQ ID NO: 3234) (AviTag)). For SARS-CoV-2, MERS-CoV, HCoV-NL63 and HCoV-OC43 mutations to remove the S1/S2 furin cleavage site were introduced.

Codon-optimized nucleotide sequences encoding the receptor binding domain (RBD) for SARS-CoV-2 (residues 331-524) SARS-CoV S (residues 318-510), MERS-CoV S (residues 367-588), HCoV-NL63 (residues 481-614), and corresponding S1^Bdomains for HCoV-OC43 (residues 324-632), and HCoV-229E (residues 286-434) were synthesized and subcloned into the mammalian expression pTwist-CMV BetaGlobin vector by Twist Bioscience Technologies. The RBD/S1^Bconstructs included an N-terminal human IL-2 signal peptide and dual C-terminal tags (G-HHHHHHH (SEQ ID NO: 3239) (octa-histidine), and GLNDIFEAQKIEWHE (SEQ ID NO: 3234) (AviTag)).

The S protein and RBD/S1^Bconstructs were expressed by transient transfection of Expi293F cells (Gibco) and purified from clarified transfected cell supernatants four days post-transfection using HisTrap FF and HisTrap HP columns (GE Healthcare Life Sciences). After concentration, affinity-purified proteins were further purified by size-exclusion chromatography (SEC) using a HiLoad 16/600 Superdex 200 pg column (GE Healthcare Life Sciences) in 1×TBS (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02% NaN3). Peak fractions were analyzed by SDS-PAGE, and fractions corresponding to S trimers or monomeric RBD/S1^Bproteins were pooled and stored at 4° C.

SEC-MALS. Purified CoV-S trimers were concentrated to 1 mg/mL and loaded onto a Superose 6 Increase 10/300 GL column (GE Healthcare Life Sciences) and passed through a Wyatt DAWN coupled to a Wyatt UT-rEX differential refractive index detector (Wyatt Technology). Data were analyzed using Astra 6 software (Wyatt Technology) to determine glycoprotein molecular weights.

Purification of plasma IgGs and Fabs. IgGs were purified from plasma samples using 5-mL HiTrap MabSelect SuRe columns (GE Healthcare Life Sciences). Heat-inactivated plasma was diluted 10-fold with cold PBS, and samples were applied to prepacked columns at 1 mL/min. Bound IgGs were washed with 10 column volumes (CV) PBS and eluted with 5 CV 0.1M glycine, 100 mM NaCl, pH 3.0 directly into 10% v/v 1M Tris-HCl, pH 8. To produce polyclonal Fab fragments, IgGs were buffer exchanged into PBS by centrifugation with 30 kDa MWCO membrane centrifugal filter units (Millipore). Fabs were generated by papain digestion using crystallized papain (Sigma-Aldrich) in 50 mM sodium phosphate, 2 mM EDTA, 10 mM L-cysteine, pH 7.4 for 30-60 min at 37° C. at a 1:100 enzyme:IgG ratio. To remove undigested IgGs and Fc fragments, digested products were applied to a 1-mL HiTrap MabSelect SuRe column (GE Healthcare Life Sciences) and the flow-through containing cleaved Fabs was collected. Fabs were further purified by SEC using a Superdex 200 Increase 10/300 column (GE Healthcare Life Sciences) in TBS, before concentrating and storage at 4° C.

To evaluate binding of purified polyclonal IgGs or Fabs to CoV proteins, purified S1^B/RBD or S proteins were biotinylated using the Biotin-Protein Ligase-BIRA kit according to manufacturer's instructions (Avidity). Biotinylated-CoV proteins were captured on streptavidin coated 96-well plates (Thermo Scientific) by incubating with 100 pL of 2 pg/mL protein solution in TBS overnight at 4° C. Plates were washed 3× in washing buffer (1×TBST: 20 mM Tris, 150 mM NaCl, 0.05% Tween20, pH 8.0) and blocked with 200 pL blocking buffer (TBST-MS: 1×TBST+1% w/v milk, 1% v/v goat serum (Gibco) for 1 h at RT. Immediately after blocking, polyclonal IgGs or Fabs were assayed for binding at a 50 pg/mL starting concentration and seven 4-fold serial dilutions in blocking buffer. After 2 h incubation at RT, plates were washed 5 times with washing buffer and incubated with goat-anti-human IgG or goat-anti-human IgG(H+L) secondary antibody conjugated to horseradish peroxidase (HRP) (SouthernBiotech) in blocking buffer at a 1:4000 or 1:2000 dilution, respectively. Plates were washed 5 times with washing buffer and developed by addition of 100 pL 1-Step™ Ultra TMB-ELISA Substrate Solution (Thermo Scientific) for 3 min. The developing reaction was quenched by addition of 100 pl 1N HCl and absorbance was measured at 450 nm using Gen5 software on a Synergy Neo2 Reader (BioTek).

RBD Adsorption ELISAs. Plasmids for SARS-CoV-2 RBD 6×HisTag constructs (residues 319-541, GenBank: MN908947.3) were a gift from the lab of Florian Krammer (Mount Sinai) (“6×HisTag” disclosed as SEQ ID NO: 3241). SARS-CoV-2 RBD 6×HisTag constructs (“6×HisTag” disclosed as SEQ ID NO: 3241) were expressed by transient transfection of Expi293F cells (Gibco) and purified using HisTrap FF and HisTrap HP columns (GE Healthcare Life Sciences), followed by SEC using a HiLoad 16/600 Superdex 200 pg column (GE Healthcare Life Sciences) against 1×TBS (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02% NaN3). Purified protein was concentrated and buffer exchanged into 100 mM Sodium Bicarbonate pH 8.3, 500 mM NaCl using a gravity-flow chromatography with a PD-10 desalting column (GE Healthcare Life Sciences). Buffer-exchanged RBD was concentrated to 5 mL and covalently coupled to a 5 mL HiTrap NETS-activated Sepharose column (GE Healthcare Life Sciences) according to the manufacturer's protocol. Control resin was made using the same procedure to covalently couple 2G12, an HIV-1 mAb, as described (Scharf et al., 2015).

For RBD-absorption ELISA experiments to evaluate binding of purified polyclonal IgGs to CoV S1^B/RBD proteins after absorption of SARS-CoV-2 RBD-specific antibodies, biotinylated-S1^B/RBD proteins were captured on high-capacity streptavidin coated 96-well plates (Thermo Scientific) by incubating with 100 μL of 2 μg/mL protein solution in TBS overnight at 4° C. Plates were washed 3× in washing buffer and blocked as described above. For absorption of RBD-specific antibodies, 100 μL of SARS-CoV-2 RBD-coupled resin or 2G12 control resin was incubated with 100 μL of purified IgGs diluted to −1 mg/mL for 1 h at RT with agitation. After incubation, SARS-CoV-2 RBD-coupled resin was gently centrifuged at 250×g for 2 min, and non-absorbed IgGs were removed by careful pipetting of the aqueous layer above the pelleted RBD-coupled resin. Unadsorbed and absorbed IgG samples were assayed at a 50 μg/mL starting concentration and seven 4-fold serial dilutions as described above.

Pseudotyped virus neutralization assays. Pseudoviruses based on HIV lentiviral particles were prepared as described (Robbiani et al., 2020). Four-fold serially diluted purified polyclonal IgGs and Fabs from COVID-19 plasmas were incubated with SARS-CoV-2 pseudotyped virus for 1 hour at 37° C. After incubation with 293TACE2 cells for 48 hours at 37° C., cells were washed twice with PBS, lysed with Luciferase Cell Culture Lysis 5× reagent (Promega), and NanoLuc Luciferase activity in lysates was measured using the Nano-Glo Luciferase Assay System (Promega). Relative luminescence units (RLUs) were normalized to values derived from cells infected with pseudotyped virus in the absence of purified plasma IgGs or Fabs. Half-maximal inhibitory concentrations _(IC50values) for purified plasma IgGs and Fabs were determined as molar concentrations (to account for the IgG versus Fab difference in molecular weight) using 4-parameter nonlinear regression (Prism, GraphPad).

Negative-stain electron microscopy (nsEM). Purified CoV-S trimers were adsorbed to freshly-glow discharged PureC 300 mesh carbon-coated copper grids (EMD Sciences) for 1 min followed by 2% uranyl formate staining. Micrographs were recorded using Digital Micrograph software on a 120 kV FEI Tecnai T12 equipped with a Gatan Ultrascan 2 k×2 k CCD at a 52,000× nominal magnification.

nsEMPEM. Methods were adapted from (Bianchi et al., 2018). To form polyclonal Fab-S complexes, 30 μg of SARS-CoV-2 S trimers were incubated overnight at RT with 30-50 mg/mL Fabs in 100 μL total volume (corresponding to ˜1000× the _EC50values for ELISAs using purified polyclonal Fabs), and the complexes were purified by SEC on a Superose 6 increase 10/300 GL column (GE Healthcare Life Sciences). Fractions containing complexes were pooled and concentrated to 50 μg/mL and passed through a 0.1 μm filter before deposition on 300 mesh carbon-coated copper grids (source?) and stained with 1% (w/v) uranyl formate (source?). Grids were imaged at 300 keV using a Titan Krios transmission electron microscope (Thermo Fisher) operating at RT, equipped with a K3 direct electron detector (Gatan) using SerialEM 3.7? (Mastronarde, 2005). Images were processed in cryoSPARC v 2.14, and a reference-free particle stack was generated using a Gaussian blob picker (Punjani et al., 2017). Particles corresponding to S-Fab complexes were identified by extensive 2D classification to identify class averages that displayed structural elements interpreted as Fab density and also represented different views. Extracted particles were used to generate ab initio models in cryoSPARC that were further processed by 3D classification to separate out complexes and S trimer structures alone. Figures were prepared using UCSF Chimera (Goddard et al., 2007; Pettersen et al., 2004).

X-ray crystallography. The Fab from the C105 monoclonal IgG was expressed, purified, and stored as described (Scharf et al., 2015; Schoofs et al., 2019). Crystallization trials were performed at room temperature using the sitting drop vapor diffusion method by mixing equal volumes of C105 Fab and reservoir using a TTP LabTech Mosquito robot and commercially-available screens (Hampton Research). After optimization of initial hits, crystals were obtained in 0.15 M lithium sulfate, 0.1 M citric acid pH 3.5, 18% v/v PEG 6000 at 20° C. Crystals were transferred stepwise to 20% glycerol cryoprotectant before being cryopreserved in liquid nitrogen.

X-ray diffraction data were collected for C105 Fab at the Stanford Synchroton Radiation Lightsource (SSRL) beamline 12-1 on a Pilatus 6M pixel detector (Dectris). Data from a single crystal were indexed and integrated in XDS (Kabsch, 2010) and merged using AIMLESS in CCP4 (Winn et al., 2011) (Table 16). The structure of C105 Fab was determined by molecular replacement in PHASER (McCoy et al., 2007) using the B38 Fab coordinates from PDB code 7BZ5 after removal of CDR loops as a search model. The C105 Fab coordinates were refined using Phenix (Adams et al., 2010) and cycles of manual building in Coot (Emsley et al., 2010) (Table 16).

Cryo-EM Sample Preparation. Purified C105 Fab was incubated with SARS-CoV-2 S trimer at a 2:1 molar ratio per protomer on ice for 30 minutes prior to purification by SEC on a Superose 6 Increase 10/300 GL column (GE Healthcare Life Sciences). Fab-S complexes were concentrated to 1.6 mg/ml in Tris-buffered saline (TB S). Immediately before deposition onto a 300 mesh, 1.2/1.3 AuUltraFoil grid (Electron Microscopy Sciences) that had been freshly glow-discharged for 1 min at 20 mA using a PELCO easiGLOW (Ted Pella), 3 μL of complex was mixed with 0.5 μL of a 0.5% w/v octyl-maltoside solution (Anatrace). Samples were vitrified in 100% liquid ethane using a Mark IV Vitrobot (Thermo Fisher) after blotting for 3 s with Whatman No. 1 filter paper at 22° C. and 100% humidity.

Cryo-EM Data Collection and Processing. For the C105-S trimer complex, micrographs were collected on a Titan Krios transmission electron microscope (Thermo Fisher) operating at 300 kV using SerialEM automated data collection software (Mastronarde, 2005). Movies were obtained on a Gatan K3 Summit direct electron detector operating in counting mode at a nominal magnification of 105,000× (super-resolution 0.418 Å/pixel) using a defocus range of −1 to −2.5 μm. Movies were collected with an 1.9 s exposure time with a rate of 22 eipix/s, which resulted in a total dose of ˜60 e−/Å²over 40 frames. The 5,940 cryo-EM movies were patch motion corrected for beam-induced motion including dose-weighting within cryoSPARC v2.15 (Punjani et al., 2017) after binning super resolution movies by 2 (0.836 Å/pixel). The non-dose-weighted images were used to estimate CTF parameters using CTFFIND4 (Rohou and Grigorieff, 2015), and micrographs with power spectra that showed poor CTF fits or signs of crystalline ice were discarded, leaving 5,316 micrographs. Particles were picked in a reference-free manner using Gaussian blob picker in cryoSPARC (Punjani et al., 2017). An initial 565,939 particle stack was extracted, binned ×2 (1.68 Å/pixel), and subjected to iterative rounds of reference-free 2D classification to identify class averages corresponding to intact S-trimer complexes with well-defined structural features. This routine resulted in a new particle stack of 71,289 particles, which were unbinned (0.836 Å/pixel) and re-extracted using a 352 box size. Two ab initio volumes were generated, with one class of 61,737 particles revealing an S-trimer complexed with two C105 Fabs.

Particles were further 3D classified (k=3) and heterogeneously refined to reveal two distinct states of the C105-S trimer complex. State 1 (37,615 particles) displaying 2 “up” RBD conformations bound by 2 C105 Fabs, and state 2 (14,119 particles) that displayed 3 “up” RBD conformations bound by 3 C105 Fabs. Particles from states 1 and 2 were separately refined using non-uniform 3D refinement imposing either C1 or C3 symmetry, respectively, to final resolutions of 3.6 Å (state 1; 37,615 particles) and 3.7 Å (state 2; 14,119 particles) according to the gold-standard FSC (Bell et al., 2016). Given that the RBD “up” conformations with C105 Fabs bound were similar in both states 1 and 2, improvements to the resolution at the RBD-C105 Fab interface were achieved by combining the entire particle stack (˜52 k particles) for a focused, non-uniform 3D refinement. A soft mask was generated from the state 1 volume (5-pixel extension, 10-pixel soft cosine edge) for the S1 subunits and C105 Fab variable domains. These efforts resulted in a modest improvement in the RBD-C105 Fab interface (FIG. 29D), and an overall resolution of 3.4 Å according to the gold-standard FSC.

Cryo-EM Structure Modeling and Refinement. Initial coordinates were generated by docking individual chains from reference structures into cryo-EM density using UCSF Chimera (Goddard et al., 2007). The following coordinates were used: SARS-CoV-2 S trimer: PDB code 6VYB, “up” RBD conformations: PDB code 7BZ5, C105 Fab: this study. These initial models were then refined into cryo-EM maps using one round of rigid body refinement followed by real space refinement. Sequence-updated models were built manually in Coot (Emsley et al., 2010) and then refined using iterative rounds of refinement in Coot and Phenix (Adams et al., 2010). Glycans were modeled at possible N-linked glycosylation sites (PNGSs) in Coot using ‘blurred’ maps processed with a variety of B-factors (Terwilliger et al., 2018). Validation of model coordinates was performed using MolProbity (Chen et al., 2010) and is reported in Table 17.

Structural Analyses. Structural figures were made using PyMOL (Version 1.8.2.1 Schrodinger, LLC) or UCSF Chimera (Goddard et al., 2007). Local resolution maps were calculated using cryoSPARC v 2.15 (Punjani et al., 2017).

Example 4

A newly-emergent betacoronavirus, SARS-CoV-2, resulted in a pandemic in 2020, causing the respiratory disease COVID-19 (Wu et al., 2020b; Zhou et al., 2020). SARS-CoV-2 is the third zoonotic betacoronavirus to infect humans this century, following SARS-CoV and MERS-CoV (Middle East Respiratory Syndrome) infections in 2003 and 2012, respectively (de Wit et al., 2016). In addition, four globally-distributed human coronaviruses, HCoV-OC43, HCoV-HKU1 (beta coronaviruses), and HCoV-NL63, HCoV-229E (alpha coronaviruses), contribute to 15-30% of common colds (Fung and Liu, 2019). The neutralizing antibody response to coronaviruses is primarily directed against the trimeric spike glycoprotein (S) on the viral membrane envelope, which serves as the machinery to fuse the viral and host cell membranes (Fung and Liu, 2019). Coronavirus S proteins contain three copies of an S1 subunit comprising the S1^Athrough S1^Ddomains, which mediates attachment to target cells, and three copies of an S2 subunit, which contains the fusion peptide and functions in membrane fusion (FIG. 17A). Neutralizing antibody responses against SARS-CoV-2, SARS-CoV, and MERS-CoV S proteins often target the receptor-binding domain (RBD; also called the S1^Bdomain) (Hwang et al., 2006; Pinto et al., 2020; Prabakaran et al., 2006; Reguera et al., 2012; Rockx et al., 2008; Walls et al., 2020; Walls et al., 2019; Widjaja et al., 2019; Wrapp and McLellan, 2019; Wrapp et al., 2020).

The S proteins of SARS-CoV-2 (1273 residues, strain Wuhan-Hu-1) and SARS-CoV (1255 residues, strain Urbani) share 77.5% amino acid sequence identity, while the S proteins of SARS-CoV-2 and MERS-CoV (1353 residues, strain EMC2012) are more distantly related, sharing only 31% identity (FIGS. 17B and 17C). Sequence identities between SARS-CoV-2 and common cold coronavirus S proteins are even lower, varying between 25% and 30%. Phylogenetic analyses confirm that SARS-CoV-2 and SARS-CoV are more closely related to each other than to other human coronaviruses (FIG. 1B). The RBD/S1^Bdomains show varying degrees of sequence identity, ranging from 13% (SARS-CoV-2 and HCoV-NL63) to 74% (SARS-CoV-2 and SARS-CoV). Nevertheless, the 3D structures of S protein trimer ectodomains are similar to each other and to other coronavirus S structures, including the finding of flexible RBDs (S1^Bdomains) that can be in various “up” conformations or in the “down” conformation of the closed pre-fusion trimer (Kirchdoerfer et al., 2016; Li et al., 2019; Walls et al., 2020; Walls et al., 2016; Wrapp et al., 2020; Yuan et al., 2017). Primary amino acid sequence differences in the RBDs of SARS-CoV-2 and SARS-CoV compared with MERS-CoV (FIG. 1B,C) result in binding to different host receptors: angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 and SARS-CoV (Hoffmann et al., 2020; Li et al., 2003; Zhou et al., 2020) and dipeptidyl peptidase 4 for MERS-CoV (Raj et al., 2013). One of the common cold coronaviruses, HCoV-NL63, also uses its RBD (S1^B) to bind ACE2, although its interactions differ structurally from RBD-ACE2 interactions of SARS-CoV-2 and SARS-CoV (Tortorici and Veesler, 2019), whereas HCoV-OC43 and HCoV-HKU1 uses their S1^Adomains to bind host receptors including 9-O-acetylated sialic acids (Tortorici et al., 2019).

Understanding the antibody response to SARS-CoV-2 S protein is of critical importance because correlates of protection for vaccines usually involve antibodies (Plotkin, 2001, 2008, 2010). Moreover, antibodies are being considered as therapeutics for COVID-19 patients (Zhou and Zhao, 2020). Relatively little is known about antibody recognition of SARS-CoV-2 S compared with other coronavirus S proteins (Graham et al., 2013; Gralinski and Baric, 2015; Wan et al., 2020). However, structures of S trimer, RBD-Fab, RBD-ACE2, and S trimer-Fab complexes for SARS-CoV-2 and other coronaviruses are informative for interpreting and understanding the antibody response to SARS-CoV-2 (Gui et al., 2017; Kirchdoerfer et al., 2020; Kirchdoerfer et al., 2016; Kirchdoerfer et al., 2018; Pallesen et al., 2017; Pinto et al., 2020; Shang et al., 2020; Shang et al., 2018; Walls et al., 2016; Walls et al., 2017; Walls et al., 2019; Wang et al., 2020; Xiong et al., 2018; Yuan et al., 2020).

Here, we analyzed purified IgG and Fabs from the plasmas of 10 COVID-19 convalescent individuals (Robbiani et al., 2020) for binding to trimeric S and monomeric RBD/S1^Bdomains of six human coronaviruses and for neutralization of SARS-CoV-2 pseudoviruses. To better understand the binding mechanism of polyclonal antibodies, we further characterized plasma Fabs from two individuals using negative-stain electron microscopy polyclonal epitope mapping (nsEMPEM), showing that the polyclonal landscape includes antibodies that target epitopes in both SARS-CoV-2 S1^Aand RBD domains. In addition, we solved a 3.4 Å single-particle cryo-EM structure of an S trimer bound to a neutralizing monoclonal antibody (mAb), which targeted an epitope on an “up” RBD that overlapped with the RBD epitope identified by nsEMPEM and would sterically block ACE2 receptor binding. The epitopes we found represent binding classes defined by distinct VH gene segments, suggesting that these recurring classes are commonly represented in neutralizing antibodies against SARS-CoV-2 and provide criteria for evaluating neutralizing antibodies raised by infection or vaccination. Finally, we used modeling to suggest that distinct binding orientations allow for differential avidity effects, demonstrating the potential for inter-spike crosslinking that would increase effective affinities for some anti-S IgGs on SARS-CoV-2 virions.

Convalescent plasma IgG and Fab binding properties demonstrate recognition of diverse coronaviruses and effects of avidity. Convalescent plasma samples were collected from individuals who had recovered from COVID-19 at Rockefeller University Hospital (Robbiani et al., 2020). We isolated polyclonal IgGs from 10 convalescent plasmas (FIG. 18), most of which had high neutralizing titers (Robbiani et al., 2020), and compared binding of their IgGs to purified S proteins from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, and HCoV-229E (FIG. 24) by ELISA (FIGS. 18 and 26). Purified plasma IgGs recognized S proteins from all coronaviruses evaluated, with weaker binding observed for most samples to MERS-CoV (FIG. 19C) and common cold coronavirus S proteins (FIGS. 19D-F).

Amongst the plasmas (COV21, COV57, and COV107) chosen for further analysis based on ELISA EC50 values and strong neutralization potencies (Robbiani et al., 2020), IgGs from COV21 and COV57 showed the strongest binding to the S proteins from SARS-CoV-2 and SARS-CoV, with only the COV57 IgGs showing measurable binding to MERS-CoV S protein. The COV107 IgGs showed intermediate binding to SARS-CoV-2 and SARS-CoV and no binding to MERS-CoV S proteins (FIGS. 19A-C).

ELISAs against RBD (or S1^Bdomain for two of the common cold coronavirus S proteins) showed the strongest binding to SARS-CoV-2 RBD for COV21, followed by COV57 and then COV107 IgGs, with the proportion of RBD versus S binding from COV21, COV72, and COV47 suggesting that the majority of the IgG responses from these plasmas were focused on the RBD, often a target of neutralizing antibodies in coronavirus infections (Hwang et al., 2006; Pinto et al., 2020; Prabakaran et al., 2006; Reguera et al., 2012; Rockx et al., 2008; Walls et al., 2020; Walls et al., 2019; Widjaja et al., 2019; Wrapp et al., 2020). The only appreciable reactivity with SARS-CoV and MERS-CoV RBDs was exhibited by COV21 IgG, which bound to SARS-CoV RBD (FIG. 19B). Although we cannot determine whether the same IgGs are binding all three S proteins, the potential for cross-reactive binding of SARS-CoV antibodies was demonstrated for a mAb that was isolated from a SARS-infected individual, which was shown to recognize SARS-CoV and SARS-CoV-2 RBDs (Pinto et al., 2020). No reactivity with MERS-CoV RBD was observed for any of the polyclonal IgGs (FIG. 19C). For most of the plasma IgGs, binding to the RBD was substantially weaker than binding to the counterpart S protein, with the exception of the strong COV21 and COV72 responses to the SARS-CoV-2 RBD. Most of the plasma IgGs exhibited stronger binding to the common cold S1^B/RBDs than to the counterpart S protein trimers (FIGS. 19D-F).

To assess the degree to which cross-reactive recognition contributed to binding of plasma IgGs to RBD/S1^Bdomains, we repeated the ELISAs before and after adsorption with SARS-CoV-2 RBD-coupled resin or a control resin for five plasma IgG samples (FIG. 26). As a positive control, purified IgGs incubated with the RBD resin showed little or no SARS-CoV-2 RBD binding (FIG. 26A). Binding to SARS-CoV RBD was also reduced for the IgGs remaining after SARS-CoV-2 RBD adsorption (FIG. 26B), suggesting cross-reactive recognition consistent with the 78% sequence conservation and structural homology of SARS-CoV-2 RBD and SARS-CoV RBD (Walls et al., 2020). By contrast, adsorption of plasma IgGs with SARS-CoV-2 RBD resins had only a modest effect on binding to common cold coronavirus RBDs (FIGS. 26D-F), consistent with little to no cross-reactive antibody recognition, likely due to the low conservation between the SARS-CoV-2 RBD and mild coronavirus RBDs (Premkumar et al., 2020). We also note that IgGs from control plasmas collected from individuals not exposed to SARS-CoV-2 exhibited binding to common cold coronavirus RBDs that was not affected by SARS-CoV-2 RBD adsorption (FIG. 26), again consistent with pre-exposure to mild coronaviruses rather than cross-reactivity with SARS-CoV-2 RBD.

Taken together, these results indicate: (i) The binding strengths and patterns of different coronavirus S protein recognition were diverse across COVID-19 individual plasma samples, (ii) Convalescent COVID-19 individuals harbor antibodies to the SARS-CoV-2 S protein, and to a lesser extent, the RBD/S1B, as well as reactivity to other coronaviruses, which likely represents previous exposure to common cold viruses, (iii) Polyclonal IgGs from individual plasma samples that bind to S proteins from MERS-CoV and/or SARS-CoV may display cross-reactive recognition, since the plasma donors were unlikely to have been infected with either of these coronaviruses, and (iv) Compared to the COV57 and COV107 plasmas, the COV21 IgG response had a higher proportion of IgGs that recognized the SARS-CoV-2 RBD.

We also evaluated the degree to which avidity effects contributed to the strength of binding of plasma IgGs to S proteins and RBDs by comparing the binding of bivalent polyclonal IgGs to monovalent Fabs, prepared by proteolytic cleavage of purified polyclonal IgGs (FIGS. 18B and 18C). Differential effects were evident in IgG to Fab comparisons: most of the SARS-CoV-2 anti-S response was reduced by at least 50% in the case of monovalent Fabs for all plasmas except for COV57 (FIG. 19A). Recognition of the other coronavirus S proteins was also diminished for Fabs compared to intact IgGs (FIGS. 19B-F). For the three plasma IgGs that were further evaluated, the largest relative differences in IgG versus Fab binding to SARS-CoV-2 S protein was observed for COV21 and COV107; the IgG versus Fab binding difference for COV57 was less pronounced (FIG. 19A). Notably, the SARS-CoV-2 S protein and RBD ELISAs showed that a higher fraction of the COV21 plasma IgGs were RBD-specific compared with the COV57 IgGs (FIGS. 19A and 19B) (Robbiani et al., 2020).

In summary, the ELISA data indicate that IgGs in plasma samples differ in their degree of focus upon epitopes within the S protein RBD/S1^Bdomain, their relative amounts of reactivity with SARS-CoV, MERS-CoV, and common cold coronaviruses, and the extent to which avidity effects contribute to the tighter binding of polyclonal bivalent IgGs as compared with monovalent Fab s.

Plasma IgGs are more potent neutralizers than plasma Fabs. To investigate whether the bivalent architecture or larger size of IgGs compared with Fabs resulted in increased neutralization potencies, we measured the potencies of purified plasma IgGs and Fabs using in vitro neutralization assays (FIG. 19G). SARS-CoV-2 pseudoviruses were constructed as described (Robbiani et al., 2020), and the concentrations of IgGs and Fabs at which 50% neutralization was achieved _(IC50values) were calculated. All tested plasma IgGs neutralized pseudoviruses at lower molar concentrations than their Fab counterparts, with increased potencies ranging from 6- to 100-fold (FIG. 19H). The increased potency of the IgGs compared to Fabs was statistically significant (p=0.0003), even when accounting for two Fabs per IgG. We conclude that bivalent IgGs more effectively neutralize SARS-CoV-2 pseudoviruses than monovalent Fabs.

EM reveals distinct predominant epitopes targeted by convalescent plasma antibodies. We next used negative stain polyclonal electron microscopy (nsEMPEM) (Bianchi et al., 2018; Nogal et al., 2020) to map epitopes from Fabs isolated from convalescent COVID-19 plasma IgGs onto the SARS-CoV-2 S protein. In this method, Fabs that bind to an antigenic target are separated from non-binding Fabs in a polyclonal mixture by size-exclusion chromatography (SEC), Fab-antigen complexes are imaged by EM, and 2D/3D classification were used to identify predominant epitopes (Bianchi et al., 2018; Nogal et al., 2020) (FIGS. 18A-C). Typically, Fabs are incubated at 1000-2000× above EC50 values calculated from binding assays (Bianchi et al., 2018; Nogal et al., 2020). For most COVID-19 plasmas, Anti-S Fab EC50 values were estimated to be >50 μg/mL (FIG. 25). However, purified polyclonal Fabs from COV21 and COV57 plasmas, which had approximate EC50s ranging from 20-50 μg/mL, showed stable binding by SEC after incubation with SARS-CoV-2 S trimers (FIG. 18D), and 2D class averages showed evidence of bound Fabs (FIG. 28). By contrast, purified Fabs from COV107 _(EC50>50 μg/mL) showed no evidence of binding to S by SEC (data not shown) or in a 3D reconstruction (FIG. 20A).

In order to verify that extra densities in nsEMPEM 3D reconstructions corresponded to bound Fab(s), we first solved a 3D reconstruction of SARS-CoV-2 S alone, revealing the expected low-resolution structure of the closed, prefusion S trimer (FIG. 20A). A 3D reconstruction of COV21 Fabs complexed with S showed recognizable density for the S trimer with a single extending density at the apex of the trimer corresponding to a Fab or mixture of Fabs bound to a similar epitope (FIG. 20A). The density could be fit to an S trimer with a Fab bound to a single RBD in an “up” position using coordinates from SARS-CoV-2 S trimer structures (Walls et al., 2020; Wrapp et al., 2020), consistent with ELISA results mapping the COV21 response to the SARS-CoV-2 RBD (FIG. 19A). The complex structure and the position of the COV21 Fab(s) closely resembled a structure of SARS-CoV S bound to a Fab from the S230 mAb isolated from a SARS-CoV-infected individual, whose epitope overlaps with the binding site for the ACE2 receptor (Walls et al., 2019) (FIG. 20B). Interestingly, S230 binding was shown to functionally mimic ACE2 binding, allowing cleavage of the SARS-CoV S protein to promote fusogenic conformational rearrangements (Walls et al., 2019). While the COV21 Fab complex reconstruction showed occupancy for one S-protomer with an RBD in an “up” position (FIG. 20A), COV21 Fab(s) could also bind analogous to the S230 Fab-SARS-Cov S complex, where classes of S trimer structures were found with two “up”/one “down” and three “up” RBD conformations (Walls et al., 2019).

Moreover, antibody S230, whose binding orientation resembles the position observed in the COV21 Fab(s) reconstruction (FIG. 20B), appears to be a member of a class of recurrent anti-SARS mAbs. It belongs to a set of 10 non-clonally-related VH3-30-derived mAbs isolated from an individual infected with SARS-CoV, which represented 40% of the clones isolated from this individual (Pinto et al., 2020). Notably, these clones contained similar 9 amino acid CDRL3 sequences (consensus sequence MQGTHWPPT (SEQ ID NO: 3656)), suggesting that this group of mAbs has a common mode of binding, partially dependent on VH3-30-derived features. RBD residues 473 and 475 contacted by the antibody heavy chain in the S230 Fab-SARS-CoV structure (Walls et al., 2019) are conserved between SARS-CoV and SARS-CoV-2, and these residues are in the vicinity of antibody heavy chain residues N57 and K58. The only VH gene segments encoding the N57/K58 pair are VH3-30, VH3-30-3, and VH3-33 (Lefranc et al., 2015). When mAbs were isolated after single B cell sorting using SARS-CoV-2 RBD as a bait, COV21 antibodies included heavy chains derived from IGHV3-30, which were also found in sequenced antibodies from five other donor plasmas (Robbiani et al., 2020). The similarity in binding orientation of COV21 Fab(s) with S230 (FIG. 20B) suggests that COV21 Fab(s) may be members of the S230 recurrent class. Consistent with this hypothesis, 38 of 127 sequenced antibodies from the COV21 donor were derived from VH3-30 or from the closely-related VH3-30-3 or VH3-33 VH gene segments (Robbiani et al., 2020).

The COV57 Fab(s)-S structure also showed recognizable density for both the S trimer and a single bound Fab(s) (FIG. 20C). However, in this complex, the S trimer appeared closed with no RBDs in an “up” position, and the Fab density was not associated with an RBD, but rather with one of the S1^Asubunits. In the complex, the Fab(s) pointed downwards (i.e., towards the viral membrane) rather that upwards (away from the viral membrane), as seen for the COV21 Fab(s). The COV57 Fab(s) density was in the vicinity of loops on the S1^Adomain that were disordered in SARS-CoV-2 S trimer structures (Walls et al., 2020; Wrapp et al., 2020). Such flexibility could explain the diffuse nature of the COV57 Fab(s) density in this reconstruction. Interestingly, characterization of COV57 neutralization showed less correlation with RBD-specific antibodies relative to COV21 (Robbiani et al., 2020), consistent with the ELISAs (FIG. 19A) and nsEMPEM characterizations (FIG. 20C) reported here. This suggests that targeting S1 regions outside of the RBD may represent alternative modes for potent neutralization of SARS-CoV-2, as found for neutralizing antibodies isolated after vaccination against MERS-CoV in nonhuman primates (Wang et al., 2015).

A cryo-EM structure of a monoclonal Fab-S protein complex resembles the COV21 Fab(s)-S reconstruction. Although we could not resolve densities for bound Fabs in the COV107-S nsEMPEM reconstruction (FIG. 20A), RBD-binding mAbs isolated from the COV107 individual were potently neutralizing (Robbiani et al., 2020). We determined a 3.4 Å single-particle cryo-EM structure of the complex of one such antibody (C105; IC₅₀for neutralization of SARS-CoV-2 pseudovirus=26.1 ng/mL) (Robbiani et al., 2020) bound to the SARS-CoV-2 S protein using a 1.8 Å crystal structure of the unbound C105 Fab for fitting to the cryo-EM density (FIGS. 21, 28, and 29; Tables 15 and 16).

We found two populations of C105 Fab-S complexes: an asymmetric S trimer with two “up” RBDs (state 1; 3.4 Å resolution), each of which was complexed with a Fab, and a symmetric trimer with three RBDs in the same “up” conformation (state 2; 3.7 Å resolution), again with each RBD complexed with a Fab (FIG. 21A). A subset of complexes in the cryo-EM structure of the S230 mAb bound to SARS-CoV S trimer were also found with three “up” RBDs bound to three Fabs (Walls et al., 2019), although in that structure, as in the C105-S structure, the majority of complexes had their RBDs in a two “up,” one “down” configuration.

The C105-RBD interfaces were similar across the five examples in the state 1 and state 2 complex structures (FIG. 28), thus we describe the interface for one of the Fab-RBD complexes in the state 1 complex in which the resolution at the interface was improved by performing a focused refinement (Punjani et al., 2017) on the C105 Fab-RBD portion of the complex (FIG. 28). The C105 Fab uses its three heavy chain complementarity determining regions (CDRH1, CDRH2, and CDRH3) and two of its light chain CDRs (CDRL1 and CDRL3) to rest against the receptor-binding ridge of the RBD (FIGS. 21B and 21C). The majority of the antibody contacts are made by CDRH1, CDRH2, and CDRL1, with CDRH3 and CDRL3 playing minor roles. The C105 epitope overlaps with the COV21 epitope defined by nsEMPEM, which also rests against the receptor-binding ridge in the RBD, although the Fab(s) in the COV21 reconstruction are predicted to adopt a different angle of approach (FIG. 21D). Interestingly, the C105-RBD interaction closely resembles the RBD interaction of another COVID-19 donor-derived neutralizing mAb, B38 (FIG. 21E), as reported in a recent Fab-RBD crystal structure (Wu et al., 2020c). The heavy chains of both B38 and C105 are derived from the VH3-53 gene segment, whereas the light chain gene segments differ: KVJ-9 for B38 (Wu et al., 2020c) and LV2-8 for C105 (Robbiani et al., 2020). Accordingly, the CDRH1 and CDRH2 loops of both neutralizing antibodies share similar conformations and contribute more to the antibody-RBD interface than their CDRH3 loops (FIGS. 21B and 21E).

The common epitope of C105 and B38 overlaps with the binding site for ACE2 (FIG. 21F), rationalizing their potent neutralizing activities (Robbiani et al., 2020; Wu et al., 2020c). Given that COV21 was one of the more potent neutralizing plasmas of the 149 that were collected (Robbiani et al., 2020), the overlap in the C105/B38 neutralizing epitope with the nsEMPEM-defined predominant COV21 epitope suggests that recognition of the COV21 epitope by S230-like antibodies would also be neutralizing.

CDRH3 length is a characteristic of the recurring VH3-53/VH3-66 class of anti-SARS-CoV-2 RBD neutralizing antibodies. The shared binding mode of B38 and C105, both VH3-53-derived mAbs, defines a recurrent class of anti-SARS-CoV-2 mAbs. Among a large set (n=534) of cloned anti-SARS-CoV-2 mAbs against the RBD, those derived from VH3-53 and VH3-66 were over-represented (Robbiani et al., 2020). Other studies have also reported anti-SARS-CoV-2 mAbs derived from these genes (Brouwer et al., 2020; Cao et al., 2020; Chi et al., 2020; Ju et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Wu et al., 2020c; Zost et al., 2020). These VH gene segments encode V regions that differ in only one amino acid position, which is not in a CDR. Thus, in terms of V-gene-determined mAb classes, they are functionally equivalent. When grouping VH3-53 and VH3-66, over-representation of VH3-53/VH3-66-derived mAbs is significant (p=0.035). A notable characteristic of the VH3-53/VH3-66-derived subset (75 mAbs) within the 534 anti-RBD mAbs (Robbiani et al., 2020) was a bias towards shorter CDRH3s (as defined by IMGT) (Lefranc et al., 2015): 75% had lengths between 9 and 12 residues, which is significantly different from the human repertoire and from the entire set of 534 anti-SARS-CoV-2 RBD mAbs (two sample Kolmogorov-Smirnov test, p<0.001) (FIG. 30A).

Superposition of VH domains from unrelated antibodies with longer CDRH3s suggests that RBD residues 456-457 and/or 484-493 present a steric barrier limiting the CDRH3 loop lengths that are compatible with this binding orientation (FIG. 30B). A recent report identified a clonally-unrelated group of VH3-53/VH3-66 anti-SARS-CoV-2 mAbs based on CDRH3 sequence similarity to the anti-SARS-CoV mAb m396 (derived from VH1-69) (Cao et al., 2020). The structure of a SARS-CoV RDB complex with m396 (PDB code 2DD8) (Prabakaran et al., 2006) shows that mAb m396 does not share the B38/C105 binding mode. We suggest that the key feature of the VH3-53/VH3-66 mAbs identified based on CDRH3 sequence similarity to m396 (Cao et al., 2020) is their CDRH3 length (11 residues), and that these mAbs will share the B38/C105 binding mode, not the m396 binding mode.

Identified S mutations are unlikely to affect epitopes revealed by nsEMPEM and single-particle cryo-EM. A recent report suggested that a mutation in the S protein (D614G) increases transmissibility of SARS-CoV-2 (Korber et al., 2020), and it has been speculated that this substitution, or others found in different S protein sequences, could affect antibody recognition. In cryo-EM structures of the prefusion S trimer (Walls et al., 2020; Wrapp et al., 2020) and in our C105-S complex (FIG. 21), S protein residue D614 is located in S1^D, where it makes contact with an adjacent protomer. To address whether the D614G mutation could affect binding of antibodies in COV21 and COV57 plasma samples, we marked the location of the D614 residues and other residues that were reported to mutate (Korber et al., 2020) on the COV21 and COV57 nsEMPEM reconstructions (FIGS. 22A and 22B) and on the C105-S cryo-EM structure (FIG. 22C). The RBD-binding COV21 Fab(s) and the C105 Fab are distant from residue D614 (FIGS. 22A and 22C). Therefore, if the COV21 reconstruction reflects the predominant epitope in the COV21 plasma, it is unlikely that antibodies elicited in the COV21 individual would be sensitive to the D614G substitution. Indeed, in the absence of large conformational changes, all anti-RBD antibodies, including C105 (Robbiani et al., 2020) and B38 (Wu et al., 2020c), would be unaffected by this substitution. Mutations in the SARS-CoV-2 RBD identified by genome sequencing also include N439K, V483A, and V367F (Tables S3,S4), but the affected residues are not within the epitopes of the COV21 Fab(s) (FIGS. 22A and 22B) or the C105 Fab (FIG. 22C), and residue 483 is disordered in unliganded S protein structures (Walls et al., 2020; Wrapp et al., 2020). The predominant epitope in the COV57 plasma is closer to S protein D614, but this residue appears to be outside of the binding interface. In addition, mutations in the S1^Adomain identified by genome sequencing (Tables S3,S4) reside outside of the COV57 Fab(s) epitope (FIGS. 22A and 22B). Thus in the absence of a major conformational change induced by mutation, the observed substitutions, particularly the D614G mutation, are unlikely to affect antibodies elicited in the COV21 or COV57 individuals or in RBD-binding antibodies such as C105.

S protein epitopes offer different possibilities for avidity effects during IgG and receptor binding. IgGs contain two identical antigen-binding Fabs, thus offering the opportunity to bind pathogens with regularly-spaced antigen sites using avidity effects, either through inter-spike crosslinking (binding the same epitope on adjacent spikes) and/or intra-spike crosslinking (binding the same epitope on identical subunits of a single multimeric spike) (Klein and Bjorkman, 2010).

To address whether inter-spike crosslinking by anti-SARS-CoV-2 IgGs could occur, we modeled adjacent S proteins on a virion membrane assuming a minimum inter-spike separation distance of ˜15 nm, as observed from cryo-electron tomography analyses of SARS-CoV and other coronaviruses (Neuman et al., 2011). By including a bound Fab on each S trimer in the position of the COV21 Fab(s) from the nsEMPEM reconstruction, we addressed whether the Fabs from a single IgG could bind to two adjacent S trimers. The modeling predicts that inter-spike crosslinking could occur for the COV21 epitope (FIG. 23A). By contrast, the downward-pointing Fab(s) in the COV57-S nsEMPEM reconstruction appear unlikely to participate in inter-spike crosslinking by an IgG due to the Fab orientations being unable to accommodate an Fc in a position that could join two Fabs (FIG. 23A). These predictions are consistent with ELISA results demonstrating diminished binding for COV21 Fabs compared with their IgG counterparts, but less pronounced differences for the Fab versus IgG comparison for COV57 (FIG. 18).

We also used modeling to predict whether avidity effects could influence the interaction between ACE2, an integral membrane protein that dimerizes on the target cell surface (Yan et al., 2020), with viral S trimers. Starting with a cryo-EM structure of dimeric full-length ACE2 associated with the integral membrane protein B^OAT1 bound to monomeric SARS-CoV-2 RBDs, we modeled bound S trimers from a cryo-EM structure of SARS-CoV S trimers with two RBDs in an “up” position (Kirchdoerfer et al., 2018). Assuming that there are adjacent ACE2-B^OAT1 complexes in the host cell membrane, the modeling predicts that inter-spike crosslinking is possible (FIG. 23B). Assuming rotation of the RBDs in a two “up”/one “down” S trimer, intra-spike cross-linking could also occur (FIG. 23C). If S trimers can indeed crosslink adjacent ACE2 receptors or bind as a single trimer to both ACE2 subunits in an ACE2 dimer, they could take advantage of avidity effects to bind more tightly than predicted from affinity measurements involving the interactions of monomeric ACE2 ectodomains to monomeric coronavirus RBDs (Shang et al., 2020; Walls et al., 2020; Wrapp et al., 2020).

The possibility of avidity effects during the interactions of SARS-CoV-2 S with ACE2 dimers has implications for interpretation of pseudovirus assays to measure coronavirus infectivity in the presence and absence of potential inhibitors such as antibodies. In vitro neutralization assays for SARS-CoV-2 include pseudoviruses based on HIV lentiviral particles (Chen et al., 2020; Crawford et al., 2020; Ou et al., 2020; Robbiani et al., 2020; Wu et al., 2020a), murine leukemia virus retroviral particles (Pinto et al., 2020; Quinlan et al., 2020), and vesicular stomatitis virus (Hoffmann et al., 2020; Nie et al., 2020; Xiong et al., 2020). Each of these pseudovirus types could potentially incorporate different numbers of spikes, in which case the overall spike density would alter sensitivity to antibody avidity. In any case, the effects of avidity on IgG binding to a tethered antigen are a complicated mixture of intrinsic Fab-antigen affinity, kinetics, input concentration, and incubation time (Klein and Bjorkman, 2010; Wu et al., 2005), thus neutralization potencies of some, but not all, IgGs could be affected in in vitro neutralization assays. In addition, when considering therapeutic applications of convalescent plasma or purified antibodies, avidity effects would be difficult to predict given uncertainties about antibody concentrations, viral titers, and potentially different S trimer spacings and densities on infectious virions.

The results, as presented above, provide a glimpse into diverse antibody responses in neutralizing plasmas from donors who recovered from COVID-19. We characterized polyclonal plasma IgGs that exhibited different degrees of cross-reactive binding between S proteins from SARS-CoV-2, SARS-CoV, and MERS-CoV and showed that the plasma IgGs also included non-cross-reactive antibodies against common cold virus RBDs. By mapping SARS-CoV-2 S epitopes targeted by convalescent plasma IgGs, we not only observed the expected targeting of the S protein RBD, but also discovered an epitope outside of the RBD, which may represent an alternative binding site for neutralizing antibodies. The RBD-binding Fab(s) from COV21 plasma resembled binding of S230, a VH3-30 mAb isolated from a SARS-CoV patient that blocks ACE2 receptor binding (Rockx et al., 2008). We found another type of ACE2 receptor-blocking anti-SARS-CoV-2 antibody in our analysis of a neutralizing mAb derived from the COV107 individual. In a 3.4 cryo-EM structure SARS-CoV-2 S protein bound to this mAb, C105, we observed an epitope on the RBD that overlapped with the binding site for COV21 Fab(s) and closely resembled the binding of another mAb, B38 (Wu et al., 2020c). Like C105, B38 is also derived from the VH3-53 VH gene segment. Our structural studies support the hypothesis that recurrent classes of anti-SARS-CoV-2 neutralizing antibodies derived from the VH3-53/VH3-66 and VH3-30 gene segments use the distinct RBD-binding modes of the B38/C105 and S230 mAbs, respectively, providing valuable information for evaluating antibodies raised by infection or vaccination by sequences alone. Finally, the RBD and S1^Aepitopes we mapped by nsEMPEM and single-particle cryo-EM are unlikely to be affected by common mutations in different SARS-CoV-2 isolates, offering hope that antibody therapeutics and/or a vaccine might be effective in combatting the current pandemic.

TABLE 1

Cohort characteristics

Average duration
Average
ELISA binding (AUC)

Average
Case/
Sx
Sx onset
Sx Severity
RBD
S
Neutralization

Gender
n
age
Contact
total
to visit
(0-10)
IgG
IgM
IgG
IgM
(NT50)

Male
83
45
65/18
12
39
5.8
2.44
1.61
4.65
1.62
867

(19-76)

(0-31)
(21-63)
(0-10)

Female
66
42
46/20
12
38
5.4
1.99
1.58
4.36
1.86
522

(19-75)

(1-35)
(17-67)
(1-9)

Sx = symptoms

TABLE 2

Individual participant demographics and clinical characteristics

Duration

ELISA

g p
(days)
Sx
binding (AUC)

p p
Case/
Sx
Sx onset
Severity
RBD
S
Neutralization

ID
Age
Gender
Race
Ethnicity
Contact
total
to visit
(0-10)
IgG
IgM
IgG
IgM
(NT50)

5
43
M
White
Non-Hispanic
Case
9
41
9
2.52
2.35
5.51
2.43
5.0

7
40
M
White
Non-Hispanic
Case
11
30
6
2.92
2.54
7.39
2.37
2730.4

8
37
M
White
Non-Hispanic
Case
3
57
5
2.11
0.81
4.46
0.88
5.0

9
35
F
White
Non-Hispanic
Case
12
54
5
2.90
1.07
4.44
2.80
5.0

12
27
F
White
Non-Hispanic
Contact
7
24
3
1.47
1.71
4.31
1.23
5.0

13
28
M
White
Non-Hispanic
Case
5
25
3
1.97
4.10
3.95
1.38
173.2

18
55
M
White
Non-Hispanic
Case
16
28
6
2.57
1.75
3.92
1.31
410.3

20
26
F
White
Non-Hispanic
Case
2
17
5
1.80
2.00
4.49
1.68
5.0

21
54
M
White
Hispanic
Contact
11
27
7
5.60
2.88
7.60
2.47
5052.7

24
34
M
White
Non-Hispanic
Case
15
30
4
2.29
1.97
4.36
1.45
280.7

26
66
M
White
Non-Hispanic
Case
2
35
3
1.67
1.86
4.00
1.58
276.1

27
26
M
White
Non-Hispanic
Case
9
32
4
1.79
1.64
4.41
1.30
739.3

28
26
M
White
Non-Hispanic
Case
7
21
4
2.39
2.25
4.93
1.66
888.9

29
26
F
White
Non-Hispanic
Contact
5
35
4
1.69
1.54
3.93
1.97
5.0

30
30
M
White
Non-Hispanic
Contact
3
35
4
3.07
2.55
4.86
1.34
5.0

31
51
M
White
Non-Hispanic
Case
9
33
3
1.29
1.60
4.69
1.20
192.3

32
46
F
White
Non-Hispanic
Case
8
32
3
1.30
2.18
3.79
0.83
47.4

37
27
M
White
Non-Hispanic
Case
6
26
6
2.13
1.52
4.11
1.04
286.3

38
57
F
White
Non-Hispanic
Case
10
38
4
1.87
2.02
4.30
1.12
518.9

40
44
M
White
Non-Hispanic
Case
7
23
5
1.72
1.50
3.81
1.47
42.1

41
35
M
White
Non-Hispanic
Contact
10
29
8
2.13
1.67
4.15
0.98
302.5

42
40
M
White
Non-Hispanic
Contact
20
36
8
2.37
1.50
5.82
1.43
627.1

45
55
F
White
Non-Hispanic
Case
7
46
6
1.95
0.97
3.53
0.75
5.0

46
39
M
White
Non-Hispanic
Case
6
30
2
2.68
1.45
4.14
1.29
59.2

47
43
F
White
Non-Hispanic
Case
11
33
5
3.02
2.30
6.23
2.66
10433.3

46
37
F
White
Non-Hispanic
Case
7
21
5
1.51
1.85
3.47
1.51
173.4

50
27
F
White
Non-Hispanic
Contact
7
28
4
1.64
2.32
5.42
1.45
924.7

51
21
M
White
Non-Hispanic
Contact
8
31
5
1.76
1.69
3.94
1.03
1499.2

54
40
F
White
Non-Hispanic
Contact
3
24
3
1.80
2.10
4.99
1.42
5.0

55
36
M
White
Non-Hispanic
Case
3
49
2
1.43
1.23
3.90
2.09
5.0

56
75
F
White
Non-Hispanic
Case
22
40
3
1.79
1.81
5.89
1.47
1388.4

57
66
M
White
Non-Hispanic
Case
6
21
5
1.54
2.10
4.33
1.00
2048.9

58
64
F
White
Non-Hispanic
Contact
1
32
2
1.20
1.71
3.95
1.21
5.0

64
28
F
White
Non-Hispanic
Contact
11
32
6
2.36
2.06
4.48
1.66
776.7

67
19
F
N/A
Hispanic
Case
5
29
6
2.56
1.98
5.48
1.32
2052.9

71
45
F
White
Non-Hispanic
Case
12
48
7
1.55
2.04
3.86
1.53
33.3

72
42
M
White
Non-Hispanic
Case
16
35
8
4.05
3.58
6.05
2.59
3136.2

75
46
F
White
Non-Hispanic
Case
10
36
4
1.64
2.37
3.98
1.20
271.5

76
49
F
White
Non-Hispanic
Case
28
34
4
1.88
1.65
5.17
0.97
219.8

77
37
M
White
Non-Hispanic
Contact
6
33
4
1.33
1.83
3.56
1.16
5.0

81
44
F
White
Non-Hispanic
Contact
3
35
2
1.58
1.73
3.82
1.10
5.0

82
46
M
N/A
Non-Hispanic
Case
0

0
2.19
1.92
5.41
1.81
130.7

88
41
M
White
Non-Hispanic
Case
7
23
4
1.82
3.32
4.97
1.37
424.7

95
44
M
White
Non-Hispanic
Case
9
36
6
2.61
1.62
6.03
1.62
961.9

96
48
F
White
Non-Hispanic
Case
9
30
3
3.93
1.93
6.25
2.26
927.7

97
39
M
White
Non-Hispanic
Case
9
31
3
1.58
1.61
4.03
2.33
202.7

98
35
F
White
Non-Hispanic
Case
2
24
4
1.78
1.47
5.38
1.22
249.0

99
36
F
White
Non-Hispanic
Case
13
29
5
2.50
3.27
4.38
2.49
1127.6

107
53
F
White
Non-Hispanic
Contact
10
29
4
1.74
1.41
4.66
0.90
297.5

108
75
M
White
Non-Hispanic
Case
16
41
7
1.37
0.88
3.47
1.36
557.5

110
27
M
White
Non-Hispanic
Case
1
25
1
1.30
1.60
4.00
0.93
5.0

114
30
F
White
Non-Hispanic
Case
15
36
7
1.65
1.92
3.53
1.55
110.9

115
65
F
White
Non-Hispanic
Contact
20
41
6
2.10
3.28
4.32
3.27
1127.7

119
56
M
White
Non-Hispanic
Case
13
48
3
1.36
1.26
4.41
1.59
650.3

120
56
F
White
Non-Hispanic
Case
26
48
6
0.99
0.97
3.65
1.21
100.6

121
19
M
White
Non-Hispanic
Contact
3
42
2
0.85
0.87
3.56
1.26
5.0

122
21
F
White
Non-Hispanic
Contact
3
36
1
1.44
0.94
3.39
1.22
5.0

123
26
M
White
Non-Hispanic
Contact
12
34
6
0.94
0.95
3.39
1.40
5.0

124
63
F
Asian
Non-Hispanic
Contact
4
37
3
1.58
2.06
3.49
1.32
5.0

125
51
F
White
Non-Hispanic
Case
10
26
3
1.92
3.49
3.86
1.24
126.5

127
24
F
White
Non-Hispanic
Case
10
43
6
1.80
2.50
4.37
2.41
883.5

130
39
M
White
Non-Hispanic
Contact
7
26
5
1.24
1.72
3.91
1.34
5.0

131
39
M
White
Non-Hispanic
Case
5
25
4
1.46
1.38
4.44
1.03
7.8

132
36
M
White
Non-Hispanic
Contact
10
50
6
2.15
1.76
4.84
1.97
5.0

134
27
F
White
Non-Hispanic
Contact
16
22
5
2.51
2.18
6.84
1.94
2700.6

135
62
F
White
Non-Hispanic
Case
8
31
6
2.20
2.02
3.80
1.13
350.0

140
63
F
White
Non-Hispanic
Case
28
47
1
1.05
1.24
3.58
1.28
52.4

149
41
M
White
Non-Hispanic
Contact
17
28
6
1.68
2.02
3.67
1.09
494.9

150
50
F
White
Non-Hispanic
Contact
12
45
7
1.15
0.43
3.18
1.82
5.0

154
66
M
Asian
Non-Hispanic
Case
16
30
9
3.19
2.19
4.85
1.29
928.2

157
50
M
White
Non-Hispanic
Case
10
32
8
2.40
2.86
3.90
2.06
741.7

166
28
F
White
Non-Hispanic
Case
13
45
2
1.27
0.66
3.45
0.94
5.0

167
50
F
White
Non-Hispanic
Contact
11
41
6
1.43
3.71
3.93
8.74
5.0

172
36
F
White
Non-Hispanic
Case
6
22
9
1.71
2.58
4.29
1.20
301.1

173
47
M
White
Non-Hispanic
Case
5
47
7
2.57
4.14
4.78
4.48
646.9

178
26
F
White
Non-Hispanic
Case
6
24
4
1.54
1.59
3.66
1.02
5.0

179
39
M
White
Non-Hispanic
Contact
10
37
3
1.89
2.25
3.83
1.73
370.1

182
44
F
White
Non-Hispanic
Contact
10
38
6
3.80
1.77
5.36
8.05
1503.7

183
43
F
White
Non-Hispanic
Case
13
44
8
1.56
1.02
3.88
1.55
240.1

185
54
M
White
Non-Hispanic
Case
11
44
8
3.51
1.39
5.55
2.11
1806.8

186
38
F
N/A
N/A
Case
8
26
2
1.73
2.47
4.37
1.23
296.9

190
54
F
White
Non-Hispanic
Case
18*
63
9
3.24
1.24
7.38
1.42
598.1

195
24
M
White
Non-Hispanic
Case
18
42
5
2.74
2.55
5.01
2.33
1315.1

200
60
F
White
Non-Hispanic
Case
17
39
7
2.40
1.00
4.38
1.51
1014.4

201
50
M
White
Non-Hispanic
Contact
15
33
6
4.37
2.57
6.15
1.57
3897.4

202
57
M
White
Non-Hispanic
Case
21
34
7
2.10
2.08
5.07
1.17
257.9

205
64
M
White
Non-Hispanic
Case
7
36
4
4.51
0.70
6.12
1.69
924.4

222
28
M
Asian
Non-Hispanic
Case
11
29
7
1.28
0.69
3.94
3.46
5.0

229
45
M
White
Non-Hispanic
Case
10
63
4
2.92
1.42
4.90
1.58
1272.9

230
50
M
White
Non-Hispanic
Case
18
33
7
3.80
0.47
3.48
0.88
5.0

232
38
F
White
Non-Hispanic
Case
13
43
7
1.57
0.70
4.24
5.70
94.3

233
55
M
White
Non-Hispanic
Case
20
41
3
2.07
2.11
4.51
1.07
173.2

241
36
M
White
Non-Hispanic
Case
12
30
7
2.27
2.66
4.54
1.46
923.1

242
59
M
White
Non-Hispanic
Case
10
42
6
4.91
1.94
4.81
2.16
1353.0

243
30
F
Asian
Non-Hispanic
Case
6
26
5
2.92
2.57
5.06
1.14
1300.2

246
44
F
White
Non-Hispanic
Case
10
38
7
2.05
2.79
6.09
1.32
566.0

255
33
M
White
Non-Hispanic
Case
14
44
6
2.14
0.70
4.20
1.24
172.5

256
63
F
White
Non-Hispanic
Case
27
42
6
1.72
1.96
4.26
7.79
141.6

258
52
M
White
Non-Hispanic
Contact
14
48
6
2.64
1.20
4.52
1.85
4145.9

279
41
M
White
Non-Hispanic
Case
7
38
8
1.68
2.13
3.77
1.90
308.9

280
59
M
White
Non-Hispanic
Case
6
32
7
2.53
3.07
4.61
1.19
1072.1

302
47
F
White
Non-Hispanic
Case
35*
49
7
1.48
0.97
4.06
1.26
5.0

310
34
F
White
Non-Hispanic
Case
17
35
5
3.95
1.24
9.44
3.07
485.5

314
46
M
White
Non-Hispanic
Case
11
38
7
2.12
0.88
4.56
1.51
667.1

315
29
F
White
Non-Hispanic
Case
15
42
8
3.02
0.69
3.98
1.03
376.5

319
50
M
White
Non-Hispanic
Case
5
38
6
3.71
2.28
3.79
1.05
5.0

323
39
F
White
Non-Hispanic
Case
7
45
7
1.05
1.03
3.53
1.42
5.0

325
52
M
White
Non-Hispanic
Case
16
38
8
2.25
1.47
4.83
2.28
1603.3

343
21
F
White
Non-Hispanic
Case
16
49
5
1.63
0.94
3.37
1.70
5.0

352
44
M
White
Non-Hispanic
Case
16
43
4
3.54
0.92
4.50
1.07
519.2

353
60
M
White
Non-Hispanic
Case
14
49
6
5.38
1.12
5.69
1.05
855.5

356
22
F
White
Non-Hispanic
Contact
16
38
3
1.37
0.61
2.98
1.09
5.0

357
27
F
White
Non-Hispanic
Contact
34
56
5
7.49
1.10
2.77
1.13
5.0

364
29
M
White
Non-Hispanic
Contact
14
49
6
0.97
0.58
2.90
0.89
5.0

366
41
F
White
Non-Hispanic
Contact
9
34
7
0.98
0.52
3.51
1.19
5.0

373
35
F
White
Non-Hispanic
Case
12
51
7
1.69
1.26
5.14
1.69
5.0

388
47
F
White
Non-Hispanic
Contact
14
41
9
1.57
1.06
3.61
1.69
5.0

393
69
M
White
Non-Hispanic
Case
23*
54
9
1.28
1.74
3.81
2.65
715.4

394
48
F
Multiple
Hispanic
Case
7
67
4
2.05
0.87
4.34
2.02
1281.5

397
52
M
White
Non-Hispanic
Case
22
45
8
3.32
0.59
5.01
0.87
1516.9

403
52
M
Asian
Non-Hispanic
Case
18*
39
10
5.36
1.09
10.01
1.36
3887.8

406
65
M
White
Non-Hispanic
Case
20
56
8
4.69
0.90
7.51
1.15
1288.7

410
34
M
White
Non-Hispanic
Case
12
46
8
1.06
0.56
3.95
0.76
5.0

421
62
F
White
Non-Hispanic
Contact
12
43
9
0.95
1.07
3.34
1.35
5.0

426
65
M
White
Non-Hispanic
Case
18
51
6
2.07
0.55
3.95
1.49
804.8

437
43
F
Asian
Non-Hispanic
Case
14
34
7
2.54
0.47
4.30
1.44
698.8

460
36
M
White
Non-Hispanic
Case
11
39
6
2.94
3.18
5.51
2.80
1906.7

461
49
M
White
Non-Hispanic
Case
7
39
5
3.38
0.94
4.67
2.02
1076.6

462
28
F
White
Non-Hispanic
Case
16
45
5
1.36
0.38
3.07
1.11
5.0

470
28
F
White
Non-Hispanic
Case
17
51
4
1.26
0.86
3.97
1.50
5.0

478
31
M
White
Non-Hispanic
Case
16
52
4
1.43
0.93
3.70
1.97
263.2

481
28
F
Asian
Non-Hispanic
Case
15
43
8
1.70
0.39
3.46
1.24
5.0

486
64
F
White
Non-Hispanic
Case
11
41
10
1.70
1.00
3.68
1.29
5.0

500
46
M
White
Non-Hispanic
Case
12
53
5
1.10
0.82
3.49
1.34
5.0

501
32
M
Asian
Non-Hispanic
Case
18*
53
10
2.62
0.65
4.51
1.21
718.8

502
52
M
White
Non-Hispanic
Case
16*
53
9
5.10
0.61
5.10
1.62
2171.8

506
46
M
White
Non-Hispanic
Case
12
59
9
0.84
0.81
3.13
1.21
5.0

507
39
M
White
Non-Hispanic
Case
15
60
8
1.92
0.96
4.56
1.52
5.0

509
36
M
White
Non-Hispanic
Case
11
50
5
1.99
1.01
3.99
1.45
5.0

526
49
M
Asian
Non-Hispanic
Case
11
34
7
3.36
1.45
5.88
1.57
4193.3

537
52
M
White
Non-Hispanic
Case
15
45
6
1.47
0.95
3.65
1.58
923.3

539
73
F
White
Non-Hispanic
Case
19*
54
10
2.82
0.63
4.46
1.45
487.9

547
59
M
White
Non-Hispanic
Case
15*
36
9
2.97
1.53
5.08
2.59
2900.6

587
54
M
PI
N/A
Case
17*
51
8
3.22
0.60
4.01
1.49
473.1

632
38
M
White
Non-Hispanic
Contact
10
43
6
2.49
0.86
4.50
1.63
572.3

633
39
M
White
Non-Hispanic
Contact
8
57
4
1.25
1.04
3.38
1.73
5.0

652
76
M
White
Non-Hispanic
Case
18*
56
10
4.75
1.46
8.96
3.80
2324.0

664
45
F
White
Non-Hispanic
Case
17*
42
10
1.68
0.43
3.93
1.32
5.0

675
47
M
White
Non-Hispanic
Contact
31
47
5
0.79
0.93
2.94
1.38
5.0

*hospitalized,

Sx = symptoms

q y y p

Participants

Symptom
(n = 149)
%

Fever
125
83.9

Fatigue
106
71.1

Cough
93
62.4

Myalgia
92
61.7

Shortness of breath
66
44.3

Headache
63
42.3

Loss of smell/taste
50
33.3

Sore throat
38
25.3

Diarrhea
32
21.3

Presence of
16
10.7

comorbidities (HTN,

CAD, DM, COPD,

asthma, cancer)

HTN (hypertension),

CAD (coronary artery disease),

DM (diabetes mellitus),

COPD (chronic obstructive pulmonary disease)

TABLE 4

Representative amino acid sequences of cloned recombinant antibodies

Old
SEQ

SEQ

Antibody
antibody
ID

ID

ID
ID
NO
IGH VDJ (aa)
NO
IGL VJ (aa)

C002
A-C002
1
EVQLVESGGGVVQPGRSLRLSCA
2
DIQLTQSPSSLSASVGDRVTITCRA

ASGFTFSIYGMHWVRQAPGKGLE

SQSISSYLNWYQQKPGKAPKLLIY

WAVISYDGSNKYYADSVKGRFTI

AASSLQSGVPSRFSGSGSGTDFTL

SRDNSKNTLYLQMNSLRAEDTAV

TISSLQPEDFATYYCQQSYSTPRT

YYCAKEGRPSDIVVVVAFDYWGQ

FGQGTKVEIK

GTLVTVSS

C003
A-C003
3
EVQLVESGGGLIQPGGSLRLSCA
4
EIVLTQSPGTLSLSPGERATLSCRA

ASGFTVSSNYMSWVRQAPGKGL

SQSVSSTYLAWYQQKPGQAPRLLI

EWVSVIYSGGSTYYADSVKGRFTI

YGASSRATGIPDRFSGSGSGTDFT

SRDNSKNTLYLQMNSLRAGDTAV

LTISRLEPEDFAVYYCQQYGSSPR

YYCARDYGDFYFDYWGQGTLVT

TFGQGTKLEIK

VSS

C004
A-C004
5
QVQLVQSGAEVKKPGASVKVSCK
6
AIRMTQSPSSLSASVGDRVTITCQ

ASGYTFTGYYMHWVRQAPGQGL

ASQDISNYLNWYQQKPGKAPKLLI

EWMGWINPISGGTNYAQKFQGR

YDASNLETGVPSRFSGSGSGTDFT

VTMTRDTSISTAYMELSRLRSDDT

FTISSLQPEDIATYYCQQYDNLPITF

AVYYCASPASRGYSGYDHGYYYY

GQGTRLEIK

MDVWGKGTTVTVSS

C005
A-C005
7
QVQLVQSGPEVKKPGTSVKVSCK
8
EIVLTQSPGTLSLSPGERATLSCRA

ASGFTFTSSAVQWVRQARGQRL

SQSVRSSYLAWYQQKPGQAPRLLI

EWIGWIVVGSGNTNYAQKFQERV

YGASSRATGIPDRFSGSGSGTDFT

TITRDMSTSTAYMELSSLRSEDTA

LTISRLEPEDFAVYYCQQYGSSPW

VYYCAAPHCSGGSCLDAFDIWGQ

TFGQGTKVEIK

GTMVTVSS

C006
A-C006
9
QVQLVESGGGLVKPGGSLRLSCA
10
QSVLTQPPSASGTPGQRVTVSCS

ASGFIFSDYCMSWIRRAPGKGLE

GSSSNIGSNTVNWYQQLPGTAPKL

WLSYISNSGTTRYYADSVKGRFTI

LIYSNNQRPSGVPDRFSGSKSGTS

SRDNGRNSLYLQMDSLSAEDTAV

ASLAISGLQSEDEADYFCAAWDDS

YYCARRGDGSSSIYYYNYMDVW

LNGPVFGGGTKLTVL

GKGTTVTVSS

C008
A-C008
11
EVQLVESGGGVVQPGRSLRLSCA
12
DIQMTQSPSTLSASVGDRVTITCR

ASGFTFSSYGMHWVRQAPGKGL

ANQSISSWLAWYQQKPGKAPKLLI

EWVTVISYDGRNKYYADSVKGRF

YKASSLESGVPSRFSGSGSGTEFT

TISRDNSKNTLYLQMNSLRAEDTA

LTISSLQPDDFATYYCQQYNSYWT

VYYCAREFGDPEWYFDYWGQGT

FGQGTKVEIK

LVTVSS

C009
A-C009
13
QVQLVQSGAEVKKPGASVKVSC
14
QSALTQPPSASGSPGQSVTISCTG

MASGYTFTGYYMHWVRQAPGQG

TSSDVGGYNYVSWYQQHPGKAPK

LEWMGWINPNSGGTNYAQKFQG

LMIYEVSKRPSGVPDRFSGSKSGN

RVTMTRDTSISTAYMELSRLRSDD

TASLTVSGLQAEDEAEYYCSSDAG

TAVYYCARDSPFSALGASNDYWG

SNNVVFGGGTKLTVL

QGTLVTVSS

C010
A-C010
15
EVQLVESGGGVVQPGRSLRLSCA
16
DIQLTQSPSSLSASVGDRVTITCRA

ASGFTFSSYAMHWVRQAPAKGLE

SQSISTYLNWYQQKPGKAPKLLIYA

WVAVILYDGSGKYYADSVKGRFTI

ASSLQSGVPSRFSGSGSGTDFTLT

SRDNSKNTLYLQMNSLRAEDTAV

ISSLQPEDFATYYCQQSYSTPPWT

YYCARDGIVDTALVTWFDYWGQG

FGQGTKVEIK

TLVTVSS

C013
A-C013
17
QVQLVQSGAEVKKPGSSVKVSCK
18
EIVLTQSPATLSLSPGERATLSCRA

ASGGTFSSYAISWVRQAPGQGLE

SQSVSSYLAWYQQKPGQAPRLLIY

WMGGIIPIFGTANYAQKFQGRVTI

DASNRATGIPARFSGSGSGTDFTL

TADESTSTAYMELSSLRSEDTAVY

TISSLEPEDFAVYYCQQRSNWPLT

YCARGNRLLYCSSTSCYLDAVRQ

FGGGTKVEIK

GYYYYYYMDVWGKGTTVTVSS

C016
A-C016
19
EVQLVESGGGVVQPGRSLRLSCA
20
AIRMTQSPSSLSASVGDRVTITCQ

ASGFTFSRYGMHWVRQAPGKGL

ASQDISNYLNWYQQKPGKAPKLLI

EWVAVISYDGSNKYYADSVKGRF

YDASNLETGVPSRFSGSGSGTDFT

TISRDNSKNTLYLQMNSLRAEDTA

FTINSLQPEDIATYYCQQYDNLPPT

VYYCAKVTAPYCSGGSCYGGNFD

FGGGTKVEIK

YWGQGTLVTVSS

C017
A-C017
21
EVQLVESGGGLVQPGRSLRLSCA
22
EIVLTQSPATLSLSPGERATLSCRA

ASGFTFDDYAMHWVRQAPGKGL

SQSVSSYLAWYQQKPGQAPRLLIY

EWVSGISWNSGTIGYADSVKGRF

DASNRATGIPARFSGSGSGTDFTL

TISRDNAKNSLYLQMNSLRAEDTA

TISSLEPEDFAVYYCQQRITFGQGT

FYYCAKAGVRGIAAAGPDLNFDH

RLEIK

WGQGTLVTVSS

C018
A-C018
23
EVQLVESGGGVVQPGRSLRLSCA
24
DIQLTQSPSSLSASVGDRVTITCRA

ASGFTFSNYAIHWVRQAPGKGLE

SQSIRSYLNWYQQKPGKAPKLLIY

WVAVISYDGSNKYYADSVKGRFTI

AASSLQSGVPSRFSGSGSGTDFTL

SRDNSKNTLYLQMNSLRAEDTAV

TISSLQPDDFATYYCQQSYSTPPA

YYCARDFDDSSFWAFDYWGQGT

TFGQGTKLEIK

LVTVSS

C019
A-C019
25
QVQLVQSGAEVKKPGASVKVSCK
26
SYELTQPPSVSVAPGKTARITCGE

ASGYTFTSYYMHWVRQAPGQGL

NNIGSKSVHWYQQKPGQAPVLVIY

EWMGIINPSGGSTSYAQKFQGRV

YDSDRPSGIPERFSGSNSGNTATL

TMTRDTSTSTVYMELSSLRSEDT

TINRVEAGDEADYYCQVWDSSSD

AVYYCARVPREGTPGFDPWGQG

HVVFGGGTKLTVL

TLVTVSS

C021
A-C021
27
QVQLQESGPGLVKPSQTLSLTCT
28
DIVMTQSPLSLPVTPGEPASISCRS

VSGGSISSGGYYWSWIRQHPGK

SQSLLHSNGYNYLDWYLQKPGQS

GLEWIGYIYYSGSTYYNPSLKSRV

PQLLIYLGSNRASGVPDRFSGSGS

TISVDTSKNQFSLKLSSVTAADTA

GTDFTLKISRVEAEDVGVYYCMQA

VYYCARVWQYYDSSGSFDYWGQ

LQTPFTFGPGTKVDIK

GTLVTVSS

C022
A-C022
29
QVQLQESGPGLVKPSETLSVTCT
30
DIQMTQSPSTLSASVGDSVTITCRA

VSGGSISSSRYYWGWIRQPPGKG

SQSISSWLAWYQQKPGKAPKLLIY

LEWIGSIYYSGSTYYNPSLKSRVTI

KASSLESGVPSRFSGSGSGTEFTL

SVDTSKNQFSLKLSSVTAADTAVY

TISSLQPDDFATYYCQQYNNYRYT

YCARHAAAYYDRSGYYFIEYFQH

FGQGTKLEIK

WGQGTLVTVSS

C027
A-C027
31
EVQLVESGGGVVQPGRSLRLSCA
32
DIQMTQSPSTLSASVGDRVTITCR

ASGFTFSSYGMHWVRQAPGKGL

ASQSISSWLAWYQQKPGKAPKLLI

EWVAVISYDGSNKYYADSVKGRF

YKASSLESGVPSRFSGSGSGTEFT

TISRDNSKNTLYLQMNSLRAEDTA

LTISSLQPDDFATYYCQQYNSYST

VYYCAKASGIYCSGGDCYSYYFD

FGQGTKVEIK

YWGQGTLVTVSS

C029
A-C029
33
QVQLQESGPGLVKPSQTLSLTCT
34
DIVMTQSPLSLPVTPGEPASISCRS

VSGGSISSGGYYWSWIRQHPGK

SQSLLHSNGYNYLDWYLQKPGQS

GLEWIGYIYYSGSTYYNPSLKSRV

PQLLIYLGSNRASGVPDRFSGSGS

TISVDTSKNQFSLKLSSVTAADTA

GTDFTLKISRVEAEDVGVYYCMQA

VYYCARTMYYYDSSGSFDYWGQ

LQTPHTFGGGTKVEIK

GTLVTVSS

C030
A-C030
35
EVQLVESGGGVVQPGRSLRLSCA
36
DIQMTQSPSTLSASVGDRVTITCR

ASGFTFSSYGMHVWRQAPGKGL

ASQSISSWLAWYQQKPGKAPKLLI

EWVAVISYDGSNKYYADSVKGRF

YKASSLESGVPSRFSGSGSGTEFT

TISRDNSKNTLYLQMNSLRAEDTA

LTISSLQPDDFATYYCQQYNSYST

VYYCAKASGIYCSGGNCYSYYFD

FGQGTKVEIK

YWGQGTLVTVSS

C031
A-C031
37
EVQLVESGGGLVQPGGSLRLSCA
38
DIQMTQSPSSLSASVGDRVTITCR

ASGFTFSSYDMHWVRQATGKGL

ASQSISSYLNWYQQKPGKAPKVLI

EWVSAIGTAGDTYYPGSVKGRFTI

YAASSLQSGVPSRFSGSGSGTDF

SRENAKNSLYLQMNSLRAGDTAV

TLTISSLQPEDFATYYCQQSYSTPP

YYCARVGYDSSGYSGWYFDLWG

LTFGGGTKVEIK

RGTLVTVSS

C032
A-C032
39
EVQLVQSGAEVKKPGESLKISCK
40
QSVLTQPPSVSGAPGQRVTISCTG

GSGYSFTSYWIGWVRQMPGKGL

SSSNIGAGYDVHWYQQLPGTAPK

EWMGIIYPGDSDTRYSPSFQGQV

LLIYGNSNRPSGVPDRFSGSKSGT

TISADKSISTAYLQWSSLKASDTA

SASLAITGLQAEDEADYYCQSYDS

MYYCARGVAVDWYFDLWGRGTL

SLSALYVFGTGTKVTVL

VTVSS

C036
A-C036
41
QVQLQQWGAGLLKPSETLSRTCA
42
DIVMTQSPLSLPVTPGEPASISCRS

VFGGSFTNYYWSWIRQSPGKGLE

SQSLLHRNGYNYLDWYLQKPGQS

WIGEINDSGITNYNPSLKSRVTISV

PQLLIYLGSNRASGVPDRFRGSGS

DTSKNQFSLSLRSVTAADTAVYYC

GTDFTLKISRVEAEDVGVYYCMQA

ARRRSFSRPSSIDYWGQGTLVTV

LQTLTFGQGTRLEIK

SS

C037
A-C037
43
QLVQSGPEVKKPGTSVKVSCKAS
44
EIVLTQSPGTLSLSPGERATLSCRA

GFTFTSSAMQWVRQARGQRLEW

SQSVSSSYLAWYQQKPGQAPRLLI

IGWIVVGSGNTNYAQKFQERVTIT

YGASSRATGIPDRFSGSGSGTDFT

RDMSTSTAYMELSSLRSEDTAVY

LTISRLEPEDFAVYYCQQYGSSPW

YCAAPYCSGGSCNDAFDIWGQG

TFGQGTKVEIK

TMVTVSS

C038
A-C038
45
VQLVESGGGVVQPGRSLRLSCAA
46
NFMLTQPHSVSESPGKTVTISCTG

SGFTFNRIAMYWVRQAPGKGLE

SSGSIASNYVQWYQQRPGSAPTT

WVAVISFDGSYEYYAESVKGRFAI

VIYEDTQRPSGVPDRFSGSIDSSS

SRDNSKNTLYLQMNSLRAEDTAV

NSASLTISGLKTEDEADYYCQSYDI

YYCAKSPMGYCTNGVCYPDSWG

NSRWVFGGGTKLTVL

QGTLVTVSS

C040
A-C040
47
EVQLVESGGGLVKPGGSLRLSCA
48
SYELTQPPSVSVAPGQTARITCGG

ASGFTFSNAWMSWVRQAPGKGL

NNIGSKSVHWYQQKPGQAPVLVV

EWVGRIKSKTDGGTTDYAAPVKG

YDDSDRPSGIPERFSGSNSGNTAT

RFTISRDDSKNTLYLQMNSLKTED

LTISRVEAGDEADYYCQVWDSSSD

TAVYYCTTDPHCSSTSCPIFYYYY

QGVFGGGTKLTVL

MDVWGKGTTVTVSS

C101
V-C001
49
QVQLVESGGGLIQPGGSLRLSCA
50
EIVLTQSPGTLSLSPGERATLSCRA

ASGFIVSSNYMSWVRQAPGKGLE

SQSVSSSYLAWYQQKPGQAPRLLI

WVSVIYSGGSTFYTDSVKGRFTIS

YGASSRATGIPDRFSGGGSETDFT

RDNSKNTLYLQMNSLRAEDTAVY

LTISRLEPEDCAVYYCQQYGSSPR

YCVRDYGDFYFDYWGQGTLVTV

TFGQGTKVEIK

SS

C102
V-C002
51
QVQLVESGGGLIQPGGSLRLSCA
52
EIVLTQSPGTLSLSPGERATLSCRA

ASGFIVSSNYMSWVRQAPGKGLE

SQSVSSSYLAWYQQKPGQAPRLLI

WVSVIYSGGSTFYADSVKGRFTIS

YGASSRATGIPDRFSGSGSGTDFT

RDNSKNTLYLQMNSLRAEDTAVY

LTISRLEPEDFAVYYCQQYGSSPR

YCARDYGDYYFDYWGQGTLVTV

TFGQGTKVEIK

SS

C103
V-C003
53
QVQLQQWGAGLLKPSETLSLTCA
54
EIVLTQSPGTLSLSPGERATLSCRA

VSGGSLSGFYWTWIRQPPGKGLE

SQTVTANYLAWYQQKPGQAPRLLI

WIGETNHFGSTGYKPSLKSRVTIS

YGASKRATGIPDRFSGSGSGTDFT

VDMSRNQFSLKVTSVTAADTAVY

LSISRLEPEDFAVYYCQQYTTTPRT

YCARKPLLYSDFSPGAFDIWGQG

FGGGTKVEIK

TMVTVSS

C104
V-C004
55
QVQLQQWGAGLLKPSETLSLSCA
56
EIVLTQSPGTVSLSPGERATLSCW

VYGGSLSGYYWSWIRQPPGKGL

ASQSVSASYLAWYQQKPGQAPRL

EWIGEINHFGSTGYNPSLKSRVTI

LIYGASSRATGIPDRFSGSGSGTD

SVDTSKSQFSVKLSSVTAADTAVY

FTLTISRLEPEDFAVYYCQQYGTTP

YCARKPLLYSNLSPGAFDIWGQG

RTFGGGTKVEIK

TMVTVSS

C105
V-C005
57
QVQLVESGGGLIQPGGSLRLSCA
58
QSALTQPPSASGSPGQSVTISCTG

ASGFTVSSNYMSWVRQAPGKGL

TSSDVGGYKYVSWYQQHPGKAPK

EWVSVIYSGGSTYYADSVKGRFTI

LMIYEVSKRPSGVPDRFSGSKSGN

SRDNSKNTLYLQMNSLRAEDTAV

TASLTVSGLQAEDEADYYCSSYEG

YYCARGEGWELPYDYWGQGTLV

SNNFVVFGGGTKLTVL

TVSS

C106
V-C006
59
QLQLQESGPGLVKPSETLSLTCTV
60
SYELTQPPSVSVAPGKTARITCGG

SGASVSSGSYYWSWIRQPPGKG

NNIGSKSVHWYQQKPGQAPVLVIY

LEWIGYIYYSGSTNYNPSLKSRVTI

FDSDRPSGIPERFSGSNSGNTATL

SVDTSKNQFSLKLSSVTAADTAVY

TISRVEAGDEADYYCQVWDSSRD

YCARERPGGTYSNTWYTPTDTN

HVVFGGGTKLTVL

WFDTWGQGTLVTVSS

C107
V-C007
61
QVQLVQSGAEVKKPGASVRVSCK
62
QSVLTQPPSASGTPGQRVTISCSG

ASGYTFTSYGFSWVRQAPGQGL

SSSNIGSNYVYWYQQLPGTAPKLL

EWMGWISAYNGNTNFAQKLQGR

IYRNNQRPSGVPDRFSGSKSGTSA

VTMTTDTSTSTAYMELRSLRSDD

SLAISGLRSEDEADYYCAAWDDSL

TAVYYCARGEAVAGTTGFFDYWG

SGFVVFGGGTKLTVL

QGTLVTVSS

C108
V-C008
63
QVQLQESGPGLVKPSGTLSLTCA
64
QSALTQPASVSGSPGQSITISCTGT

VSGGSISSTNWWSWVRQPPGKG

SSDVGGYNYVSWYQQHPGKAPKL

LEWIGEIYHTGSTNYNPSLKSRVTI

MIYDVSNRPSGVSNRFSGSKSGN

SVDKSKNQFSLKLSSVTAADTAVY

TASLTISGLQAEDEADYYCNSYTS

YCVRDGGRPGDAFDIWGQGTMV

SSTRVFGTGTKVTVL

TVSS

C110
V-C010
65
QVQLQQSGAEVKKPGESLKISCK
66
DIQMTQSPSTLSASVGDRVTITCR

GSGYSFTSYWIGWVRQMPGKGL

ASQSISYWLAWYQQKPGKAPKLLI

EWMGIIYPGDSDTRYSPSFQGQV

YQASSLESGVPSRFSGSESGTEFT

TISADKSISTAYMQWSSLKASDTA

LTISSLQPDDFATYYCQQYNSYPY

MYYCARSFRDDPRIAVAGPADAF

TFGQGTKLEIK

DIWGQGTMVTVSS

C112
V-C012
67
QVQLVESGGGVVQPGRSLRLSCA
68
QSALTQPASVSGSPGQSITISCTGT

ASGFTFSSHAMHWVRQAPGKGL

SSDVGGYNYVSWYQQHPGKAPKL

EWVAVISYDGSNKYYADSVKGRF

MIYDVSNRPSGVSNRFSGSKSGN

TISRDNSKNTLYLQMNSLRAEDTA

TASLTISGLQAEDEADYYCSSYTSS

VYYCAREDYYDSSGSFDYWGQG

STWVFGGGTKLTVL

TLVTVSS

C113
V-C013
69
QVQLVESGGGVVQPGRSLRLSCA
70
DIQMTQSPSTLSASVGDRVTITCR

ASGFTFSNFGMHWVRQAPGKGL

ASQSMSSWLAWYQQKPGNAPKLL

EWVAVIWYDGSNKYYADSVKGRF

IYKASSLESGVPSRFSGSGSGTEF

TISRDNSKNTLYLQMNSLRAEDTA

TLTISSLQPDDFATYYCQQHNSSP

VYYCARGVNPDDILTGVDAFDIW

LTFGGGTKVEIK

GQGTMVTVSS

C114
V-C014
71
QVQLVESGGGLIQPGGSLKLSCV
72
QSVLTQPPSVSGAPGQRVTISCTG

VSGFTVSKNYISWVRQAPGKGLE

TSSNIGAGYDVHWYQQLPGRAPK

WVSVIFAGGSTFYADSVKGRFAIS

VLISGNNIRPSEVPDRFSGSRSGT

RDNSNNTLFLQMNSLRVEDTAIYY

SASLAITSLQPEDEAQYYCQSYDS

CARGDGELFFDQWGQGTLVTVSS

SLYAVFGGGTKLTVL

C115
V-C015
73
QVQLVESGGGLIKPGRSLRLSCTA
74
DIVMTQSPLSLSVTPGEPASISCRS

SGFTFGDYAMTWFRQAPGKGLE

SQSLLHSNGNNYFDWYLQKPGQS

WVGFIRSKAYGGTTGYAASVKYR

PQLLIYLGSNRASGVPDRFSGSGS

FTISRDDSKSIAYLQMDSLKTEDT

GTDFTLKISRVEAEDVGVYYCMQV

AVYYCTRWDGWSQHDYWGQGT

LQIPYTFGQGTKLEIK

LVTVSS

C116
V-C016
75
QVQLVESGGGVVQPGRSLRLSCA
76
NFMLTQPHSVSESPGKTVTISCTG

ASGFTYSTYAMHWVRQAPGKGL

SSGSIASNYVQWYQQRPGSAPTT

EWVAFISYDGSNKYYADSVKGRF

VIYEDNQRPSGVPDRFSGSIDRSS

TISRDNSKNTLYLQMNSLRAEDTA

NSASLTISGLKTEDEADYYCQSYD

VYYCARDFYHNWFDPWGQGTLV

SGNHWVVFGGGTRLTVL

TVSS

C117
V-C017
77
QVQLVESGGGVVQPGRSLRLSCA
78
QSVLTQPPSVSAAPGQKVTISCSG

ASGFTFSTYAMHWVRQAPGEGL

SSSNIGNNLVSWYQQLPGTAPKLLI

EWVAVISYDGSNTYYADSVKGRF

YENNKRPSGIPDRFSGSKSGTSAT

TISRDNSKNTLYLQMNSLRAEDTA

LGITGLQTGDEADYYCGAWDSSLS

VYYCARDPIWFGELLSPPFVHFDY

AGGVYVFGTGTKVTVL

WGQGTLVTVSS

C118
V-C018
79
QVQLVESGGGVVQPGRSLRLSCA
80
QPVLTQSPSASASLGASVKLTCTL

ASGFTFSNYAMHWVRQAPGKGL

SSGHSSYAIAWHQQQPEKGPRYL

EWVAVISYDGSNKYYADSVKGRF

MKLNTDGSHSKGDGIPDRFSGSS

TISRDNSKNTLYLQMNSLRAEDTA

SGAERYLTISSLQSEDEADYYCQT

IYYCASGYTGYDYFVRGDYYGLD

WGTGILVFGGGTKLTVL

VWGQGTTVTVSS

C119
V-C019
81
QVQLVQSGAEVKKPGASVKVSCK
82
QSALTQPASVSGSPGQSITISCTGT

ASGYTFTSYYMHWVRQAPGQGL

SSDVGGYKYVSWYQRHPGKAPKL

EWMGIINPSGGSTSYAQKLQGRV

MIYDVSNRPSGVSNRFSGSKSGN

TMTRDTSTSTVYMELSSLRSEDT

TASLTISGLQAEDEADYYCSSYTSS

AVYYCARANHETTMDTYYYYYYM

STSVVFGGGTQLTVL

DVWGKGTTVTVSS

C120
V-C020
83
EVQLVESGGGLIQPGGSLRLSCA
84
AIRMTQSPSSLSASVGDTVTITCQA

ASGFTVSSNYMTWVRQAPGKGL

SQDISKYLNWYQQKPGKAPKLLIY

EWVSLIYPGGSTYYADSVKGRFTI

DASNLETGVPSRFSGSGSGTDFTF

SRDNSKNTLYLQMNSLRAEDTAV

TISSLQPEDIATYYCQQYDNLPQTF

YYCAREGMGMAAAGTWGQGTLV

GGGTKVEIK

TVSS

C121
V-C021
85
QVQLVQSGAEVKKPGASVKVSCK
86
QSALTQPASVSGSPGQSITISCTGT

ASGYTFTGYYMHWVRQAPGQGL

SSDVGSYNLVSWYQQHPGKAPKL

EWMGWISPVSGGTNYAQKFQGR

MIYEGSKRPSGVSNRFSGSKSGN

VTMTRDTSISTAYMELSRLRSDDT

TASLTISGLQAEDEADYYCCSYAG

AVYYCARAPLFPTGVLAGDYYYY

SSTLVFGGGTKLTVL

GMDVWGQGTTVTVSS

C122
V-C022
87
EVQLVESGGGLIQPGGSLRLSCA
88
DIQLTQSPSFLSASVGDRVTITCRA

ASGLTVSSNYMSWVRQAPGKGL

SQGISSYLAWYQQKPGKAPKLLIY

EWVSVLYSGGSSFYADSVKGRFT

AASTLQSGVPSRFSGSGSGTEFTL

ISRDNSKNTLYLQMNSLRAEDTAV

TISSLQPEDFATYYCQQLNSDSYT

YYCARESGDTTMAFDYWGQGTL

FGQGTKLEIK

VTVSS

C123
V-C023
89
EVQLVESGGGLIQPGGSLRLSCA
90
DIQLTQSPSFLSASVGDRVTITCRA

ASGVTVSRNYMSWVRQAPGKGL

SQGISSYLAWYQQKPGKAPKLLIY

EWVSVIYSGGSTYYADSVKGRFTI

AASTLQSGVPSRFSGSGSGTEFTL

SRDNSKNTLYLQMNSLRAEDTAV

TISSLQPEDFATYYCQQLNSYPPA

YYCARDLSAAFDIWGQGTMVTVSS

FGQGTRLEIK

C124
V-C024
91
EVQLVESGGGLVQPGGSLRLSCA
92
EIVLTQSPATLSLSPGERATLSCRA

ASGFTFSGYSMNWVRQAPGKGP

SQSFSSYLAWYQQKPGQAPRLLIY

EWVSYISRSSSTIYYADSVKGRFTI

DASNRATGIPARFSGSGSGTDFTL

SRDNAKNSLYLQMNSLRDEDTAV

TISSLEPEDFAVYYCQQRNNWPPE

YYCAREGARVGATYDTYYFDYW

WTFGQGTKVEIK

GQGTLVTVSS

C125
V-C025
93
QVQLVQSGPEVKKPGTSVKVSCK
94
EIVLTQSPGTLSLSPGERATLSCRA

ASGFTFTSSAVQWVRQARGQRL

SQSVSSSYLAWYQQKPGQAPRLLI

EWIGWIVVGSGNTNYAQKFQERV

YGASSRATGIPDRFSGSGSGTDFT

TITRDMSTSTAYMELSSLRSEDTA

LTISRLEPEDFAVYYCQQYGSSPW

VYYCAAPYCSGGSCSDAFDIWGQ

TFGQGTKVEIK

GTMVTVSS

C126
V-C026
95
QVQLQESGPGLVKPSETLSLSCA
96
NFMLTQPHSVSESPGKTVTISCTG

VSGGSIGSYFWSWIRQPPGKGLE

SSGSIASNYVQWYQQRPGSAPTT

WIGYLHYSGSTNYNPSLKSRVTIS

VINEDNQRPSGVPDRFSGSIDSSS

VDTSKNQFSLKLSSVTAADTAVYY

NSASLTISGLKTEDEADYYCQSYD

CARLQWLRGAFDIWGQGTMVTV

SSNLVFGGGTKLTVL

SS

C127
V-C027
97
QVQLVQSGAEVKKPGASVKVSCK
98
QSVLTQPPSASGTPGQRVTISCSG

ASGYTFTGYYMHWVRQAPGQGL

SSSNIGSNTVNWYQQLPGTAPKLL

EWMGWINPNSGGTNYAQKFQGR

IYSNNQRPSGVPDRFSGSKSGTSA

VTMTRDTSISTAYMELSRLRSDDT

SLAISGLQSEDEADYYCAAWDDSL

AVYYCATAHPRRIQGVFFLGPGV

NGVVFGGGTKLTVL

WGQGTTVTVSS

C128
V-C028
99
EVQLLESGGGLVQPGGSLRLSCA
100
EIVLTQSPGTLSLSPGERATLSCRA

ASGFTFSTYAMSWVRQAPGKGLE

SQSVNSRQLAWYQQKPGQAPRLL

WVSTITGSGRDTYYADSVKGRFTI

IYGASSRATGIPERFSGSGSGTDF

SRDNSKNTLFLQLNSLRAEDAAVY

TLTISRLESEDFAVYHCQQYGSSR

SCANHPLASGDDYYHYYMDVWG

ALTFGGGTKVEIK

KGTTVTVSS

C129
V-C029
101
QVQLVESGGGVVQPGRSLRLSCA
102
DIQMTQSPSSLSASVGDRVTITCQ

ASGFTFSSYGMNWVRQAPGKGL

ASQDISNYLNWYQQKPGKAPKLLI

EWVAVISYDGSNTYYTDSVKGRF

YDASNLETGVPSRFSGSESGTDFT

TISRDNSKNTLYLQMNSLRVDDTA

FTISSLQPEDIATYYCQQYDNLPITF

TYYCAKGPRFGWSYRGGSGFDI

GQGTRLEIK

WGQGTMVTVSS

C130
V-C030
103
QVQLVQSGAEVKKPGASVKVSCK
104
SYELTQPPSVSVAPGKTARITCGG

ASGYTFTNYYMHWVRQAPGQGL

NNIGSKSVHWYQQKPGQAPVLVIY

EWMGIINPSGGSTGYAQKFQGRV

YDSDRPSGIPERFSGSNSGNTATL

TMTRDTSTSTVYMELSSLRSEDT

TISRVEAGDEADYYCQVWDSSSD

AVYYCARSRPTPDWYFDLWGRG

HPGVVFGGGTKLTVL

TLVTVSS

C131
V-C031
105
QVQLVQSGSEVKKPGSSVKVSCK
106
EIVMTQSPATLSVSPGERATLSCR

ASGGTFSSYAFSWVRQAPGQGL

ASQSVSSNLAWYQQKPGQAPRLLI

EWMGRIIPILALANYAQKFQGRVTI

YGASTRATGIPARFSGSGSGTEFT

TADKSTSTAYMELSSLRSEDTAVY

LTISSLQSEDFAVYYCQQYNNWPI

YCARVNQAVTTPFSMDVWGQGT

TFGQGTRLEIK

TVTVSS

C132
V-C032
107
QVQLQESGPGLVKPSGTLSLTCA
108
QSALTQPASVSGSPGQSITISCTGT

VSGGSISSNNWWSCVRQPPGKG

SSDVGGYNYVSWYQQHPGKAPKL

LEWIGEIYHSGSTNYNPSLKSRVTI

MIYDVSNRPSGVSNRFSGSKSGN

SVDKSKNQFSLKLSSVTAADTAVY

TASLTISGLQAEDEADYYCSSYTSS

YCARGGDTAMGPEYFDYWGQGT

STLLFGGGTKLTVL

LVTVSS

C133
V-C033
109
QVQLVESGGGVVQPGRSLRLSCA
110
DIQMTQSPSSLSASVGDRVTITCR

ASGFTFSSYAMHWVRQAPGKGL

ASQSISSYLNWYQQKPGKAPKLLI

EWVAVILYDGSNKYYADSVKGRF

YAASSLQSGVPSRFSGSGSGTDF

TISRDNSKNTLYLQMNSLRAEDTA

TLTISSLQPEDFATYYCQQSYSTPP

VYYCARDSDVDTSMVTWFDYWG

WTFGQGTKVEIK

QGTLVTVSS

C134
V-C034
111
EVQLLESGGGLVQPGGSLRLSCA
112
SYELTQPPSVSVAPGKTARITCGG

ASGFTFSNYAMSWVRQAPGKGL

NNIGSKSVHWYQQKPGQAPVLVIY

EWVSAISGSDGSTYYAGSVKGRF

YDSDRPSGIPERFSGSNSGNTATL

TISRDNSKNTLYLQMNSLRAEDTA

TISRVEAGDEAEYHCQVWDSSSD

VYYCAKDPLITGPTYQYFHYWGQ

RPGVVFGGGTKLTVL

GTLVTVSS

C135
V-C035
113
QVQLVESGGGVVQPGRSLRLSCA
114
DIQMTQSPSTLSASVGDRVTITCR

ASGFTFSSYAMHWVRQAPGKGL

ASQSISNWLAWFQQKPGKAPKLLI

EWVAVIPFDGRNKYYADSVTGRF

YEASSLESGVPSRFSGSGSGTEFT

TISRDNSKNTLYLQMNSLRAEDTA

LTISSLQPDDFATYYCQQYNSYPW

VYYCASSSGYLFHSDYWGQGTLV

TFGQGTKVEIK

TVSS

C138
V-C038
115
EVQLVESGGGLVQPGGSLRLSCA
116
NFMLTQPHSVSESPGKTVTISCTG

ASGFTFSTYWMSWVRQPPGKGL

SSGSIASNYVQWYQQRPGSAPTT

EWVANIKQDGSEKYYVDSVKGRF

VIYEDNQRPSGVPDRFSGSIDSSS

TISRDNAKNSLYLQMNSLRADDTA

NSASLTISGLKTEDEADYYCQSYD

VYYCAGGTWLRSSFDYWGQGTL

SSNWVFGGGTKLTVL

VTVSS

C139
V-C039
117
EVQLVESGGGVVQPGRSLRLSCA
118
DIQMTQSPSSLSASVGDRVTITCQ

ASGFTFSSYAMHWVRQAPGKGL

ASQDISNYLNWYQQKPGKAPKLLI

EWVAVISYDGSNKYSADSVKGRF

YDASNLETGVPSRFSGSGSGTDFT

TISRDNSKNTLYLQMNSLRAEDTA

FTISSLQPEDIATYYCQQYDNLPLT

VYYCAKGGAYSYYYYMDVWGKG

FGGGTKVEIK

TTVTVSS

C140
V-C040
119
EVQLVESGGGLVQPGGSLRLSCA
120
DIQLTQSPSFLSASVGDRVTITCRA

ASGVTVSSNYMSWVRQAPGKGL

SQGISSYLAWYQQKPGKAPKLLIY

EWVSLIYSGGSTFYADSVKGRFTI

AASTLQSGVPSRFSGSGSGTEFTL

SRDNSENTLYLQMNTLRAEDTAV

TISSLQPEDFATYYCQQLNSYSYTF

YYCARDLYYYGMDVWGQGTTVT

GQGTKLEIK

VSS

C141
V-C041
121
EVQLVESGGGWQPGRSLRLSCA
122
NFMLTQPHSVSESPGKTVTISCTG

ASGFTFSSYAMFWVRQAPGKGLE

SSGSIASNYVQWYQQRPGSAPTT

WVAVISYDGSNKYYADSVKGRFTI

VIYEDNQRPSGVPDRFSGSIDSSS

SRDNSKNTLYLQMNSLRAEDTAV

NSASLTISGLKTEDEADYYCQSYD

YYCARADLGYCTNGVCYVDYWG

SSNWVFGGGTKLTVL

QGTLVTVSS

C143
V-C043
123
EVQLVESGGGLVQPGGSLRLSCA
124
QSALTQPASVSGSPGQSITISCTGT

ASGFSVSTKYMTWVRQAPGKGL

SNDVGSYTLVSWYQQYPGKAPKL

EWVSVLYSGGSDYYADSVKGRFT

LIFEGTKRSSGISNRFSGSKSGNTA

ISRDNSKNALYLQMNSLRVEDTG

SLTISGLQGEDEADYYCCSYAGAS

VYYCARDSSEVRDHPGHPGRSV

TFVFGGGTKLTVL

GAFDIWGQGTMVTVSS

C144
V-C044
125
EVQLVESGGGLIQPGGSLRLSCA
126
QSALTQPASVSGSPGQSITISCTGT

ASGFTVSNNYMSWVRQAPGKGL

SSDVGGYNYVSWYQQHPGKAPKL

EWVSVIYSGGSTYYADSVKGRFTI

MIYDVSNRPSGVSNRFSGSKSGN

SRDKSKNTLYLQMNRLRAEDTAV

TASLTISGLQAEDEADYYCSSYTSS

YYCAREGEVEGYNDFWSGYSRD

STRVFGTGTKVTVL

RYYFDYWGQGTLVTVSS

C145
V-C045
127
EVQLVESGGGLIQPGGSLRLSCA
128
QSALTQPASVSGSPGQSITISCTGT

ASGFSVSSNYMSWVRQAPGKGL

SSDVGGYNYVSWYQQHPGKAPKL

EWVSVIYSGGSTYYADSVKGRFTI

MIYDVSNRPSGVSNRFSGSKSGN

SRDNSKNTLYLQMNSLRAEDTAV

TASLTISGLQAEDEADYYCSSYTSS

YYCAREGEVEGYYDFWSGYSRD

TTRVFGTGTRVTVL

RYYFDYWGQGTLVTVSS

C146
V-C046
129
EVQLVESGGGLVKPGGSLRLSCA
130
QSALTQPASVSGSPGQSITISCTGT

ASGLTFTAYRMNWVRQAPGKGL

SSDIGVYNYISWSQQHPGKAPKVM

EWLSSISNTNGDIYYADSVKGRFT

IYDVTNRPSGVSNRFSGSKSGNTA

ISRDNAKNSLYLQMNSLRADDTAV

SLTISGLQAEDEADYYCSSYRGSS

YYCARDVASNYAYFDLWGQGTLV

TPYVFGTGTKVTVL

TVSS

C147
V-C047
131
EVQLVQSGAEVKKPGESLKISCK
132
QAVVTQEPSLTVSPGGTVTLTCGS

GSGYRFTNYWIGWVRQMPGKGL

STGAVTSGHYPYWFQQKSGQAPR

EWMGIIYPGDSDTRYSPSFQGQV

TLIYETSIKHSWTPARFSGSLLGGK

TISADKSITTAYLQWSSLKASDTA

AALTLSGAQPEDEADYYCLLSYSG

MYYCARLSDRWYSPFDPWGQGT

ARPVFGGGTKLTVL

LVTVSS

C148
V-C048
133
EVQLVESGGGLVQPGGSQRLSC
134
EIVMTQSPATLSVSPGERATLSCR

AASGFTVSSNYMSWIRQAPGKGL

ASQSVSSHLAWYQQKPGQAPRLLI

EWVSVIYSGGSAYYVDSVKGRFTI

YGASTRATGIPTRFSGSGSGTEFT

SRDNSKNTLYLQMNSLRPEDTAV

LTISSLQSEDFAVYYCQQYNNWPP

YYCARIANYMDVWGKGTTVTVSS

LTFGGGTKVEIK

C149
V-C049
135
QVQLVESGGGVVQPGRSLRLSCA
136
DIQMTQSPSSLSASVGDRVTITCR

ASGFTFSTYGMHWVRQAPGKGL

ASQSISSYLNWYQQKPGKVPKLLI

EWVAVISYDGSNKYFADSVKGRF

YAASSLQSGVPSRFSGSGSGTDF

TISRDNSKNTLYLQMNSLRPEDTA

TLTISSLQPEDFATYYCQQSYRTPL

VYYCAKVGMEYSSGWYGEEIDF

TFGGGTKVEIK

WGQGTLVTVSS

C150
V-C050
137
EVQLVESGGGLVQPGGSLRLSCV
138
QSALTQPASVSGSPGQSITISCTGT

ASGFTFSSYWMHWVRQVPGKGP

SSDVGYYNFVSWYQQHPGKAPKL

VWVSHINSEGSSTNYADSVRGRF

MIYEVSNRPSGVSNRFSGSKSGNT

TISRDNAKDTLYLQMNNLRAEDTA

ASLIISGLQAEDEADYYCSSYRSSS

VYYCARPTAVAAAGNYFYYYGMD

TLVFGGGTKLTVL

VWGQGTTVTVSS

C151
V-C051
139
EVQLVESGGGLVKPGGSLRLSCA
140
NFMLTQPHSVSESPGKTVTISCTG

ASGFTFSSYNMNWVRQAPGKGL

SSGSIASNYVQWYQQRPGSAPTT

EWVSCISSSSSYIYYADSVKGRFTI

VIYEDNQRPSGVPDRFSGSIDSSS

SRDNAKNSLYLQMNSLRAEDTAV

NSASLTISGLKTEDEADYYCQSYD

YYCARERGYDGGKTPPFLGGQG

SSNYWVFGGGTKLTVL

TLVTVSS

C152
V-C052
141
QVQLVQSGAEVKKPGASVKVSCK
142
DIQMTQSPSSLSASVGDRVTITCR

ASGYTFTSYGISWVRQAPGQGLE

ASQGISNYLAWYQQRPGKVPKLLI

WMGWISAYNGNTNYAQKLQGRV

FAASTLQSGVPSRFSGSGSGTDFT

TMTTDTSTSTAYMELRSLRSDDT

LTISSLQPEDVATYYCQKYNSAPR

AVFYCARDRGGHDFWSGYGFYY

TFGQGTKVEIK

YYGMDVWGQGTTVTVSS

C153
V-C053
143
EVQLVESGGGLIQPGGSLRLSCA
144
QSALTQPASVSGSPGQSITISCTGT

ASGFTVSSNYMSVWRQAPGKGL

SSDVGSYNLVSWYQQHPGKAPKL

EWVSVIYSGYSTYYVDSVKGRFTI

MIYEGSKRPSGVSNRFSGSKSGN

SRDNSKNTLYLQMNSLRAEDTAV

TASLTISGLQAEDEADYYCCSYAG

YYCARVGGAHSGYDGSFDYWGQ

SSTWVFGGGTKLTVL

GTLVTVSS

C154
V-C054
145
QVQLVESGGGVVQPGRSLRLSCA
146
DIQMTQSPSSLSASVGDRVTITCQ

ASGFTFSRYGMHWVRQAPGKGL

ASQGISNYLNWYQQKPGKAPKLLI

EWVAVMSYDGSSKYYADSVKGR

YDASNLETGVPSRFSGSGSGTDFT

FTISRDNSKNTLCLQMNSLRAEDT

FTISSLQPEDIATYYCQQYDNLPITF

AVYYCAKQAGPYCSGGSCYSAPF

GQGTRLEIK

DYWGQGTLVTVSS

C155
V-C055
147
EVQLVESGGGLIQPGGSLRLSCA
148
EIVMTQSPATLSVSPGERATLSCR

ASGFIVSSNYMSWVRQAPGKGLE

ASQSVSSNLAWYQQKPGQAPRLLI

WVSVIYSGGSTFYADSVKGRFTIS

YGASTRATAIPARFSGSGSGTEFT

RDNSKNTLYLQMNSLRAEDTAVY

LTISSLQSEDFAVYYCQQYNNWPR

YCARDFGEFYFDYWGQGTLVTVSS

TFGQGTKVEIK

C156
V-C056
149
QVQLVESGGGVVQPGRSLRLSCA
150
SYELTQPPSVSVAPGQTARISCGG

ASGFTFSNYGMHWVRQAPGKGL

NNIGSKNVHWYQQKPGQAPVLVV

EWVAVISYDGNNKYYADSVKGRF

YDDSDRPSGIPERFSGSNSGNTAT

TISRDNSKNTLYLQMNSLRAEDTA

LTISRVEAGDEADYYCQVWDSSSD

VYYCAKDPFPLAVAGTGYFDYWG

PWVFGGGTKLTVL

QGTLVTVSS

C160
V-C060
151
QVQLVQSGAEVKKPGASVKVSCK
152
SYELTQPPSVSVSPGQTARITCSG

ASGYTFTSYGISWVRQAPGQGLE

DALPKQYAYWYQQKPGQAPVLVIY

WMGWISAYNGNTNYAQKLQGRV

KDSERPSGIPERFSGSSSGTTVTL

TMTTDTSTSTAYMELRSLRSDDT

TISGVQAEDEADYYCQSADSSGTL

AVYYCARVPASYGDDDYYYYYG

VWFGGGTKLTVL

MDVWGQGTTVTVSS

C161
V-C061
153
QVQLQQWGAGLLKPSETLSLTCA
154
EIVLTQSPGTLSLSPGERATLSCRA

VSGGSLSGFYWTWIRQPPGKGLE

SQTLTANYLAWYQQKPGQAPRLLI

WIGETNHFGSTDYKPSLKSRVTIS

YGASKRATGIPDRFSGSGSGTDFT

VDMSRNQFSLIMTSVTAADTAVYY

LSISRLEPEDFAVYYCQQYGTTPR

CARKTLLFSDFSPGAFDIWGQGT

TFGGGTKVEI

MVTVSS

C162
V-C062
155
QVQLQQWGAGLLKPSETLSLTCA
156
EIVLTQSPGTLSLSPGERATLSCRA

VSGGSLSGFYWTWIRQPPGKGLE

SQTLTANYLAWYQQKPGQAPRLLI

WIGETNHFGSTDYKASLKSRVTIS

YGASKRAAGIPDRFSGSGSGTDFT

VGMSRNQFSLKVTSLTAADTAVY

LSITRLEPEDFAVYYCQQYHTTPRT

YCARKPLLYSDFSPGAFDVWGQG

FGGGTKVEI

TMVTVSS

C163
V-C063
157
QVQLQQWGAGLLKPSETLSLTCA
158
EIVLTQSPGTLSLSPGERATLSCRA

VSGGSLSGFYWTWIRQPPGKGLE

SQTVSANYLAWYQQKAGQAPRLLI

WIGETNHFGSTDYKPSLKSRVTIS

YGASKRATGIPDRFSGSGSGTDFT

VDMSRNQFSLKVTSVTAADTAVY

LSISRLEPEDFAVYYCQQYVTTPRT

YCARKPLLHSDLSPGAFDIWGQG

FGGGTKVEI

TMVTVSS

C164
V-C064
159
EVQLVESGGGLVQPGGSLRLSCA
160
QSALTQPASVSGSPGQSITISCTGT

ASGFSVSTKYMTWVRQAPGKGL

SNDVGSYTLVSWYQQYPGKAPKL

EWVSVLYSGGSDYYADSVKGRFT

LIFEVTKRSSGISNRFSGSKSGNTA

ISRDNSKNALYLQMNSLRVEDTG

SLTISGLQGEDEADYYCCSYAGAS

VYYCARDSSEVRDHPGHPGRSV

TFVFGGGTKLTVL

GAFDIWGQGTMVTVSS

C165
V-C065
161
QVQLVQSGAEVKKPGSSVKVSCK
162
EIVLTQSPGTLSLSPGERATLSCRA

ASGGTFSSYAINWVRQAPGQGLE

SQSVSSTYLAWYQQKPGQAPRLLI

WMGRHPIVGIANYAQKFQGRVTIT

YGASSRATGIPDRFSGSGSGTDFT

ADKSSSTAYMELSSLRSEDTAVY

LTISRLEPEDFAVYYCQQYGSSPW

YCARDLLDPQLDDAFDIWGQGTM

TFGQGTKVEIK

VTVSS

C201
M-C001
163
EVQLVESGGGLVQPGRSLRLSCA
164
IRMTQSPSSVSASVGDRVTITCRA

ASGFTFDDYAMHWVRQAPGKGL

SQGISSWLAWYQQKPGKAPKLLIY

EWVSGISWNSGSIGYADSVKGRF

VESSLQSGVPSRFSGSGSGTDFTL

TISRDNAKNSLYLQMNSLRAEDTA

TISSLQPEDFATYYCQQANSFPLTF

LYYCVKGVEYSSSSNFDYWGQG

GGGTKVEIK

TLVTVSS

C202
M-C002
165
EVQLVESGGGLVQPGGSLRLSCA
166
DIQLTQSPSSLSASVGDRVTITCQA

ASGFTVSSNYMSWVRQAPGKGL

SQDISNYLNWYQQKPGKAPKLLIY

EWVSLIYSGGSTYYADSVKGRFTI

DASNLETGVPSRFSGSGSGTDFTF

SRDNSKNTLYLQMNSLRAEDTAV

TISSLQPEDIATYYCQQYDNLPRSF

YYCARDTLGRGGDYWGQGTLVT

GQGTKLEIK

VSS

C204
M-C004
167
EVQLLESGGGLEQPGGSLRLSCA
168
DIQLTQSPSSLSASVGDRVTITCRA

ASGFTFSTYAMSWVRQAPGKGLE

SQSISSYLNWYQQKPGKAPKLLIY

WVSAISGSGAGTFYADSVKGRFTI

AASSLQSGVPSRFSGSGSGTDFTL

SRDNSKNTLYLQMNSLRAEDTAV

TISSLQPEDFATYYCQQSYSTPPW

YYCARESDCGSTSCYQVGWFDP

TFGQGTKVEIK

WGQGTLVTVSS

C205
M-C005
169
QVQLVQSGAEVKKPGASVKVSCK
170
EIVLTQSPGTLSLSPGERATLSCRA

ASGHTFTSYYMHWVRQAPGQGL

SQSVSSSYLAWYQQKPGQAPRLLI

EWMGIINPSGGSTSYAQKFQGRV

YGASSRATGIPDRFSGSGSGTDFT

TMTRDTSTSTVYMELSSLRSEDT

LTISRLEPEDFAVYYCQQYVSSPW

AVYYCARGPERGIVGATDYFDYW

TFGQGTKVEIK

GQGTLVTVSS

C207
M-C007
171
EVQLLESGGGLVQPGGSLRLSCA
172
EIVLTQSPATLSLSPGERATLSCRA

ASGFTFSSYAMSWVRQAPGKGL

SQSVSSYLAWYQQKPGQAPRLLIY

EWVSAISGSGGSTYYADSVKGRF

DASNRATGIPARFSGSGSGTDFTL

TISRDNSKNTLYLQMNSLRAEDTA

TISSLEPEDFAVYYCQQRSNWPRG

VYYCAKEPIGQPLLWWDYWGQG

FGQGTKVEIK

TLVTVSS

C208
M-C008
173
EVQLVQSGAEVKKPGESLKISCK
174
EIVLTQSPGTLSLSPGERATLSCRA

GSGYSFTSYWIGWVRQMPGKGL

SQSVSGSYLAWYQQRPGQAPRLL

EWMGIIYPGDSDTRYSPSFQGQV

IYGASSRATGIPDRFSGSGSGTDF

TISADKSISTAYLKWSSLKASDSA

TLTISRLEPEDFAVYYCQQYGSSLT

MYYCARGPNLQNWFDPWGQGTL

FGGGTKVEIK

VTVSS

C209
M-C009
175
QVQLVQSGAEVKKSGASVKVSCK
176
SYELTQPPSVSVAPGKTARITCGG

ASGYTFTSYDINWVRQATGQGLE

NNIGSKSVHWYQQKPGHAPVLVV

WMGWMNPNSGNTGYAQKFQGR

YDDSDRPSGIPERFSGSNSGNTAT

VTMTRNTSISTAYMXLSSLXSXXT

LTISRVEAGDEADYYCQVWDSTG

AVYYCAXGFSLTWYFDLWGRGXL

GHPDVVFGGGTKLTVL

VTXSS

C210
M-C010
177
EVQLVESGGGLIQPGGSLRLSCA
178
DIQLTQSPSFLSASVGDRVTITCRA

ASGFTVSSNYMSWVRQAPGKGL

SQGISSYLAWYQQKPGKAPKLLIY

EWVSVIYSGGSTFYADSVKGRFT

AASTLQSGVPSRFSGSGSGTEFTL

FSRDNSKNTLYLQMNSLRAEDTA

TISSLQPEDFATYYCQQLNSYPQG

VYYCARDLMAYGMDVWGQGTTV

TFGGGTKVEIK

TVSS

C211
M-C011
179
EVQLVESGGGLVQPGGSLRLSCA
180
EIVMTQSPATLSVSPGERATLSCR

ASEFTVSSNYMSWVRQAPGKGL

ASQSVSSNLAWYQQKPGQGPRLL

EWVSVIYSGGSTFYADSVKGRFTI

IYGASTRATGIPARFSGSGSGTEFT

SRDNSKNTLYLQMNSLRPEDTAV

LTISSLQSEDFAVYYCQQYNNWPR

YYCARDYGDFYFDFWGQGTLVTV

TFGQGTKVEIK

SS

C212
M-C012
181
QVQLVQSGAEVKKPGASVKVSCK
182
LTQPASVSGSPGQSITISCTGTSSD

ASGYTVTGYYIHWVRQAPGQGLE

VGSYNLVSWYQQHPGKAPKLMIY

WMGWISPNSGGTNYAQKFQGWV

EDSKRPSGVSNRFSGSKSGNTAS

TMTRDMSITTAYMELSRLRSDDTA

LTISGLQAEDEADYYCCSYAGSST

VYYCARERYFDLGGMDVWGQGT

RLFGGGTKLTVL

TVTVSS

C214
M-C014
183
QVQLVESGGGVVQPGRSLRLSCA
184
DIQLTQSPSSLSASVGDRVTITCRA

ASGFTFSSYGMHWVRQAPGKGL

SQSISSYLTWYQQKPGKAPKLLIYA

EWVAAIWYDGSNKHYADSVKGRF

ASSLQSGVPSRFSGSGSGTDFTLT

TISRDNSKNTLYLQMNSLRAEDTA

ISSLQPEDFATYYCQQSYSTPPWT

VYYCARDVGRVTTWFDPWGQGT

FGQGTKVEIK

LVTVSS

C215
M-C015
185
EVQLLESGGGLVQPGGSLRLSCA
186
DIQLTQSPSSLSASVGDRVTITCRA

ASGFTFSSYAMSWVRQAPGKGL

SQSISSYLNWYQQKPGKAPKLLIY

EWVSAITDSGDGTFYADSVKGRF

AASSLQSGVPSRFSGSGSGTDFTL

TISRDNSKNTLYLQMNSLRAEDTA

TISSLQPEDFATYYCQQSYSTPPW

VYYCASEEDYSNYVGWFDPWGQ

TFGQGTKVEIK

GTLVTVSS

C216
M-C016
187
EVQLVESGGGLVQPGGSLRLSCA
188
DIQLTQSPSSLSASVGDRVTITCRA

ASGFTFSSYDMHWVRQATGKGL

SQSISSYLNWYQQKPGKAPKLLIY

EWVSAIGTAGDTYYPDSVKGRFTI

VASSLQSGVPSRFSGSGSGTDFTL

SRENAKNSLYLQMNSLRAGDTAV

TISSLQPEDFATYYCQQSYSTPPIT

YYCARDRGSSGWYGWYFDLWG

FGQGTRLEIK

RGTLVTVSS

TABLE 5

Representative nucleotide sequences of cloned recombinant antibodies

Old

SEQ

SEQ

Antibody
antibody

ID

ID

ID
ID
IGH VDJ (nt)
NO
IGL VJ (nt)
NO

C002
A-C002
GAGGTGCAGCTGGTGGAGTCTGGGGG
189
GACATCCAGTTGACCCAGTCTCCATCCTC
190

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTCAGTATCTATGGCATGCACT

AGCAGCTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCAGTTATATCATAT

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

GATGGAAGTAATAAATACTATGCAGAC

CATCAAGGTTCAGTGGCAGTGGATCTGGG

TCCGTGAAGGGCCGATTCACCATCTCC

ACAGATTTCACTCTCACCATCAGCAGTCTG

AGAGACAATTCCAAGAACACGCTGTAT

CAACCTGAAGATTTTGCAACTTACTACTGT

CTGCAAATGAACAGCCTGAGAGCTGAG

CAACAGAGTTACAGTACCCCTCGGACGTT

GACACGGCTGTGTATTACTGTGCGAAA

CGGCCAAGGGACCAAGGTGGAAATCAAAC

GAGGGGAGACCATCTGATATTGTAGTG

GTGGTGGCCTTTGACTACTGGGGCCA

GGGAACCCTGGTCACCGTCTCCTCAG

C003
A-C003
GAGGTGCAGCTGGTGGAGTCTGGAGG
191
GAAATTGTGTTGACGCAGTCTCCAGGCAC
192

AGGCTTGATCCAGCCTGGGGGGTCCC

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCACCGTCAGTAGCAACTACATGAGCT

AGCAGCACCTACTTAGCCTGGTACCAGCA

GGGTCCGCCAGGCTCCAGGCAAGGGG

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

CTGGAGTGGGTCTCAGTTATTTATAGC

TCTATGGTGCATCCAGCAGGGCCACTGGC

GGTGGTAGCACATACTACGCAGACTCC

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

GTGAAGGGCCGATTCACCATCTCCAGA

TGGGACAGACTTCACTCTCACCATCAGCA

GACAATTCCAAGAACACGCTGTATCTT

GACTGGAGCCTGAAGATTTTGCAGTGTATT

CAAATGAACAGCCTGAGAGCCGGGGA

ACTGTCAGCAGTATGGTAGCTCACCTAGG

CACGGCCGTGTATTACTGTGCGAGGG

ACTTTTGGCCAGGGGACCAAGCTGGAGAT

ATTACGGTGACTTCTACTTTGACTACTG

CAAAC

GGGCCAGGGAACCCTGGTCACCGTCT

CCTCAG

C004
A-C004
CAGGTGCAGCTGGTGCAGTCTGGGGC
193
GCCATCCGGATGACCCAGTCTCCATCCTC
194

TGAGGTGAAGAAGCCTGGGGCCTCAG

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAAGGTCTCCTGCAAGGCTTCTGGAT

CCATCACTTGCCAGGCGAGTCAGGACATT

ACACCTTCACCGGCTACTATATGCACT

AGCAACTATTTAAATTGGTATCAGCAGAAA

GGGTGCGACAGGCCCCTGGACAAGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTTGAGTGGATGGGATGGATCAACCCT

CGATGCATCCAATTTGGAAACAGGGGTCC

ATCAGTGGTGGCACAAACTATGCACAG

CATCAAGGTTCAGTGGAAGTGGATCTGGG

AAGTTTCAGGGCAGGGTCACCATGACC

ACAGATTTTACTTTCACCATCAGCAGCCTG

AGGGACACGTCCATCAGCACAGCCTAC

CAGCCTGAAGATATTGCAACATATTACTGT

ATGGAGCTGAGCAGGCTGAGATCTGA

CAACAGTATGATAATCTCCCTATCACCTTC

CGACACGGCCGTGTATTACTGTGCGAG

GGCCAAGGGACACGACTGGAGATTAAAC

CCCAGCATCACGTGGATATAGTGGCTA

CGATCATGGGTACTACTACTACATGGA

CGTCTGGGGCAAAGGGACCACGGTCA

CCGTCTCCTCA

C005
A-C005
CAGGTGCAGCTGGTGCAGTCTGGGCC
195
GAAATTGTGTTGACGCAGTCTCCAGGCAC
196

TGAGGTGAAGAAGCCTGGGACCTCAG

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAAGGTCTCCTGCAAGGCTTCTGGAT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCACCTTTACTAGCTCTGCTGTGCAGT

AGAAGCAGCTACTTAGCCTGGTACCAGCA

GGGTGCGACAGGCTCGTGGACAACGC

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

CTTGAGTGGATAGGATGGATCGTCGTT

TCTATGGTGCATCCAGCAGGGCCACTGGC

GGCAGTGGTAACACAAACTACGCACAG

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

AAGTTCCAGGAAAGAGTCACCATTACC

TGGGACAGACTTCACTCTCACCATCAGCA

AGGGACATGTCCACAAGCACAGCCTAC

GACTGGAGCCTGAAGATTTTGCAGTGTATT

ATGGAGCTGAGCAGCCTGAGATCCGA

ACTGTCAGCAGTATGGTAGCTCACCGTGG

GGACACGGCCGTGTATTACTGTGCGG

ACGTTCGGCCAAGGGACCAAGGTGGAAAT

CTCCCCATTGTAGCGGTGGTAGCTGCC

CAAAC

TTGATGCTTTTGATATCTGGGGCCAAG

GGACAATGGTCACCGTCTCTTCAG

C006
A-C006
CAGGTGCAGCTGGTGGAGTCTGGGGG
197
CAGTCTGTGCTGACTCAGCCACCCTCAGC
198

AGGCTTGGTCAAGCCTGGAGGGTCCC

GTCTGGGACCCCCGGACAGAGGGTCACC

TGAGACTCTCCTGTGCAGCCTCTGGAT

GTCTCTTGTTCTGGAAGCAGCTCCAACATC

TCATCTTCAGTGACTACTGCATGAGCT

GGAAGCAATACTGTAAACTGGTACCAGCA

GGATCCGCCGGGCTCCAGGGAAGGGG

GCTCCCAGGAACGGCCCCCAAACTCCTCA

CTGGAATGGCTTTCATATATTAGTAATA

TCTATAGTAATAATCAGCGGCCCTCAGGG

GTGGTACCACCAGATACTACGCAGACT

GTCCCTGACCGATTCTCTGGCTCCAAGTC

CTGTGAAGGGCCGATTCACCATCTCCA

TGGCACCTCAGCCTCCCTGGCCATCAGTG

GGGACAACGGCAGGAACTCACTGTATC

GGCTCCAGTCTGAGGATGAGGCTGATTAT

TGCAAATGGACAGCCTGAGCGCCGAA

TTCTGTGCAGCATGGGATGACAGCCTGAA

GACACGGCCGTTTATTACTGTGCGAGA

TGGTCCGGTATTCGGCGGAGGGACCAAG

AGGGGGGACGGTAGCAGCTCGATCTA

CTGACCGTCCTAG

CTACTACAACTACATGGACGTCTGGGG

CAAAGGGACCACGGTCACCGTCTCCTCA

C008
A-C008
GAGGTGCAGCTGGTGGAGTCTGGGGG
199
GACATCCAGATGACCCAGTCTCCTTCCAC
200

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCCAATCAGAGTATT

TCACCTTCAGTAGCTATGGCATGCACT

AGTAGCTGGTTGGCCTGGTATCAGCAGAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

ACCAGGGAAAGCCCCTAAGCTCCTGATCT

CTGGAGTGGGTGACAGTTATTTCATAT

ATAAGGCGTCTAGTTTAGAAAGTGGGGTC

GATGGAAGGAATAAATACTATGCAGAC

CCATCAAGGTTCAGCGGCAGTGGATCTGG

TCCGTGAAGGGCCGATTCACCATCTCC

GACAGAATTCACTCTCACCATCAGCAGCC

AGAGACAACTCCAAGAACACGCTGTAT

TGCAGCCTGATGATTTTGCAACTTATTACT

CTGCAAATGAACAGCCTGAGAGCTGAG

GCCAACAGTATAATAGTTATTGGACGTTCG

GACACGGCTGTGTATTACTGTGCGAGA

GCCAAGGGACCAAGGTGGAAATCAAAC

GAATTCGGTGACCCCGAGTGGTACTTT

GACTACTGGGGCCAGGGAACCCTGGT

CACCGTCTCCTCAG

C009
A-C009
CAGGTGCAGCTGGTGCAGTCTGGGGC
201
CAGTCTGCCCTGACTCAGCCTCCCTCCGC
202

TGAGGTGAAGAAGCCTGGGGCCTCAG

GTCCGGGTCTCCTGGACAGTCAGTCACCA

TGAAGGTCTCCTGCATGGCTTCTGGAT

TCTCCTGCACTGGAACCAGCAGTGACGTT

ACACCTTCACCGGCTACTATATGCACT

GGTGGTTATAACTATGTCTCCTGGTACCAA

GGGTGCGACAGGCCCCTGGACAAGGG

CAGCACCCAGGCAAAGCCCCCAAACTCAT

CTTGAGTGGATGGGATGGATCAACCCT

GATTTATGAGGTCAGTAAGCGGCCCTCAG

AACAGTGGTGGCACAAACTATGCACAG

GGGTCCCTGATCGCTTCTCTGGCTCCAAG

AAGTTTCAGGGCAGGGTCACCATGACC

TCTGGCAACACGGCCTCCCTGACCGTCTC

AGGGACACGTCCATCAGCACAGCCTAC

TGGGCTCCAGGCTGAGGATGAGGCTGAG

ATGGAGCTGAGCAGGCTGAGATCTGA

TATTACTGCAGCTCAGATGCAGGCAGCAA

CGACACGGCCGTGTATTACTGTGCGAG

CAATGTGGTATTCGGCGGAGGGACCAAGC

AGACTCCCCATTTAGTGCTTTAGGGGC

TGACCGTCCTAG

CTCCAATGACTACTGGGGCCAGGGAA

CCCTGGTCACCGTCTCCTCAG

C010
A-C010
GAGGTGCAGCTGGTGGAGTCTGGGGG
203
GACATCCAGTTGACCCAGTCTCCATCCTC
204

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTCAGTAGCTATGCTATGCACT

AGCACCTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGCCAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCAGTTATATTATAT

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

GATGGAAGCGGTAAATACTACGCAGAC

CATCAAGGTTCAGTGGCAGTGGATCTGGG

TCCGTGAAGGGCCGATTCACCATCTCC

ACAGATTTCACTCTCACCATCAGCAGTCTG

AGAGACAATTCCAAGAACACGTTGTAT

CAACCTGAAGATTTTGCAACTTACTACTGT

CTGCAAATGAACAGCCTGAGAGCTGAG

CAACAGAGTTACAGTACCCCTCCGTGGAC

GACACGGCTGTGTATTACTGTGCGAGA

GTTCGGCCAAGGGACCAAGGTGGAGATCA

GACGGGATCGTGGATACAGCTCTGGTT

AAC

ACGTGGTTTGACTACTGGGGCCAGGG

AACCCTGGTCACCGTCTCCTCAG

C013
A-C013
CAGGTGCAGCTGGTGCAGTCTGGGGC
205
GAAATTGTGTTGACACAGTCTCCAGCCAC
206

TGAGGTGAAGAAGCCTGGGTCCTCGG

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAAGGTCTCCTGCAAGGCTTCTGGAG

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

GCACCTTCAGCAGCTATGCTATCAGCT

AGCAGCTACTTAGCCTGGTACCAACAGAA

GGGTGCGACAGGCCCCTGGACAAGGG

ACCTGGCCAGGCTCCCAGGCTCCTCATCT

CTTGAGTGGATGGGAGGGATCATCCCT

ATGATGCATCCAACAGGGCCACTGGCATC

ATCTTTGGTACAGCAAACTACGCACAG

CCAGCCAGGTTCAGTGGCAGTGGGTCTG

AAGTTCCAGGGCAGAGTCACGATTACC

GGACAGACTTCACTCTCACCATCAGCAGC

GCGGACGAATCCACGAGCACAGCCTA

CTAGAGCCTGAAGATTTTGCAGTTTATTAC

CATGGAGCTGAGCAGCCTGAGATCTGA

TGTCAGCAGCGTAGCAACTGGCCCCTCAC

GGACACGGCCGTGTATTACTGTGCGA

TTTCGGCGGAGGGACCAAGGTGGAGATCA

GAGGGAATCGACTACTTTATTGTAGTA

AAC

GTACCAGCTGCTATCTAGATGCGGTTA

GGCAGGGGTACTACTACTACTACTACA

TGGACGTCTGGGGCAAAGGGACCACG

GTCACCGTCTCCTCA

C016
A-C016
GAGGTGCAGCTGGTGGAGTCTGGGGG
207
GCCATCCGGATGACCCAGTCTCCATCCTC
208

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCAGGCGAGTCAGGACATT

TCACCTTCAGTAGATATGGCATGCACT

AGCAACTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCAGTTATATCATAT

CGATGCATCCAATTTGGAAACAGGGGTCC

GATGGAAGTAATAAATACTATGCAGAC

CATCAAGGTTCAGCGGAAGTGGATCTGGG

TCCGTGAAGGGCCGATTCACCATCTCC

ACAGATTTTACTTTCACCATCAACAGCCTG

AGAGACAATTCCAAGAACACGCTGTAT

CAGCCTGAAGATATTGCAACATATTACTGT

CTGCAAATGAACAGCCTGAGAGCTGAG

CAACAGTATGATAATCTCCCTCCTACTTTC

GACACGGCTGTGTATTACTGTGCGAAA

GGCGGAGGGACCAAGGTGGAGATCAAAC

GTGACCGCCCCTTATTGTAGTGGTGGT

AGCTGCTACGGAGGTAACTTTGACTAC

TGGGGCCAGGGAACCCTGGTCACCGT

CTCCTCAG

C017
A-C017
GAAGTGCAGCTGGTGGAGTCTGGGGG
209
GAAATTGTGTTGACACAGTCTCCAGCCAC
210

AGGCTTGGTACAGCCTGGCAGGTCCC

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCACCTTTGATGATTATGCCATGCACTG

AGCAGCTACTTAGCCTGGTACCAACAGAA

GGTCCGGCAAGCTCCAGGGAAGGGCC

ACCTGGCCAGGCTCCCAGGCTCCTCATCT

TGGAGTGGGTCTCAGGTATTAGTTGGA

ATGATGCATCCAACAGGGCCACTGGCATC

ATAGTGGTACCATAGGCTATGCGGACT

CCAGCCAGGTTCAGTGGCAGTGGGTCTG

CTGTGAAGGGCCGATTCACCATCTCCA

GGACAGACTTCACTCTCACCATCAGCAGC

GAGACAACGCCAAGAACTCCCTGTATC

CTAGAGCCTGAAGATTTTGCAGTTTATTAC

TGCAAATGAACAGTCTGAGAGCTGAGG

TGTCAGCAGCGTATCACCTTCGGCCAAGG

ACACGGCCTTTTATTACTGTGCAAAAG

GACACGACTGGAGATTAAAC

CGGGCGTAAGGGGTATAGCAGCAGCT

GGTCCCGACCTCAACTTCGACCACTGG

GGCCAGGGAACCCTGGTCACCGTCTC

CTCAG

C018
A-C018
GAGGTGCAGCTGGTGGAGTCTGGGGG
211
GACATCCAGTTGACCCAGTCTCCATCCTC
212

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCGTCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTCAGTAACTATGCTATACACTG

CGCAGCTATTTAAATTGGTATCAACAGAAA

GGTCCGCCAGGCTCCAGGCAAGGGGC

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

TGGAGTGGGTGGCAGTTATATCATATG

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

ATGGAAGCAATAAATACTACGCAGACT

CTTCAAGGTTCAGTGGCAGTGGATCTGGG

CCGTGAAGGGCCGATTCACCATCTCCA

ACAGATTTCACTCTCACCATCAGCAGTCTG

GAGACAATTCCAAGAACACGCTGTATC

CAACCTGATGATTTTGCAACTTACTACTGT

TGCAAATGAACAGCCTGAGAGCTGAGG

CAACAGAGTTACAGTACCCCTCCGGCCAC

ACACGGCTGTGTATTACTGTGCGAGAG

TTTTGGCCAGGGGACCAAGCTGGAGATCA

ATTTTGACGATAGTTCGTTCTGGGCGT

AAC

TTGACTACTGGGGCCAGGGAACCCTG

GTCACCGTCTCCTCAG

C019
A-C019
CAGGTGCAGCTGGTGCAGTCTGGGGC
213
TCCTATGAGCTGACACAGCCACCCTCAGT
214

TGAGGTGAAGAAGCCTGGGGCCTCAG

GTCAGTGGCCCCAGGAAAGACGGCCAGG

TGAAGGTTTCCTGCAAGGCATCTGGAT

ATTACCTGTGGGGAAAACAACATTGGAAG

ACACCTTCACCAGTTACTATATGCACTG

TAAAAGTGTGCACTGGTACCAGCAGAAGC

GGTGCGACAGGCCCCTGGACAAGGGC

CAGGCCAGGCCCCTGTGCTGGTCATCTAT

TTGAGTGGATGGGAATAATCAACCCTA

TATGATAGCGACCGGCCCTCAGGGATCCC

GTGGTGGTAGCACAAGCTACGCACAG

TGAGCGATTCTCTGGCTCCAACTCTGGGA

AAGTTCCAGGGCAGAGTCACCATGACC

ACACGGCCACCCTGACCATCAACAGGGTC

AGGGACACGTCCACGAGCACAGTCTA

GAAGCCGGGGATGAGGCCGACTATTACTG

CATGGAGCTGAGCAGCCTGAGATCTGA

TCAGGTGTGGGATAGTAGTAGTGATCATG

GGACACGGCCGTGTATTACTGTGCTAG

TGGTATTCGGCGGAGGGACCAAGCTGACC

AGTGCCCCGTGAGGGGACCCCAGGGT

GTCCTAG

TCGACCCCTGGGGCCAGGGAACCCTG

GTCACCGTCTCCTCAG

C021
A-C021
CAGGTGCAGCTGCAGGAGTCGGGCCC
215
GATATTGTGATGACTCAGTCTCCACTCTCC
216

AGGACTGGTGAAGCCTTCACAGACCCT

CTGCCCGTCACCCCTGGAGAGCCGGCCT

GTCCCTCACCTGCACTGTCTCTGGTGG

CCATCTCCTGCAGGTCTAGTCAGAGCCTC

CTCCATCAGCAGTGGTGGTTACTACTG

CTGCATAGTAATGGATACAACTATTTGGAT

GAGCTGGATCCGCCAGCACCCAGGGA

TGGTACCTGCAGAAGCCAGGGCAGTCTCC

AGGGCCTGGAGTGGATTGGGTACATCT

ACAGCTCCTGATCTATTTGGGTTCTAATCG

ATTACAGTGGGAGCACCTACTACAACC

GGCCTCCGGGGTCCCTGACAGGTTCAGT

CGTCCCTCAAGAGTCGAGTTACCATAT

GGCAGTGGATCAGGCACAGATTTTACACT

CAGTAGACACGTCTAAGAACCAGTTCT

GAAAATCAGCAGAGTGGAGGCTGAGGATG

CCCTGAAGCTGAGCTCTGTGACTGCCG

TTGGGGTTTATTACTGCATGCAAGCTCTAC

CGGACACGGCCGTGTATTACTGTGCGA

AAACTCCATTCACTTTCGGCCCTGGGACC

GAGTTTGGCAATACTATGATAGTAGTG

AAAGTGGATATCAAAC

GTTCCTTTGACTACTGGGGCCAGGGAA

CCCTGGTCACCGTCTCCTCAG

C022
A-C022
CAGGTGCAGTTGCAGGAGTCGGGCCC
217
GACATCCAGATGACCCAGTCTCCTTCCAC
218

AGGACTGGTGAAGCCTTCGGAGACCC

CCTGTCTGCATCTGTAGGAGACAGCGTCA

TGTCCGTCACTTGCACTGTCTCTGGTG

CCATCACTTGCCGGGCCAGTCAGAGTATT

GCTCCATCAGCAGTAGTAGGTACTACT

AGTAGCTGGTTGGCCTGGTATCAGCAGAA

GGGGCTGGATCCGCCAGCCCCCAGGG

ACCAGGGAAAGCCCCTAAGCTCCTGATCT

AAGGGGCTGGAGTGGATTGGGAGTAT

ATAAGGCGTCTAGTTTAGAAAGTGGGGTC

CTATTATAGTGGGAGCACCTACTACAA

CCATCAAGGTTCAGCGGCAGTGGATCTGG

CCCGTCCCTCAAGAGTCGAGTCACCAT

GACAGAATTCACTCTCACCATCAGCAGCC

ATCCGTGGACACGTCCAAGAACCAGTT

TGCAGCCTGATGATTTTGCAACTTATTACT

CTCCCTGAAGCTGAGCTCTGTGACCGC

GCCAACAGTATAATAATTACCGGTACACTT

CGCAGACACGGCTGTGTATTACTGTGC

TTGGCCAGGGGACCAAGCTGGAGATCAAAC

GAGACATGCGGCAGCATACTATGATAG

AAGTGGTTATTATTTCATCGAATACTTC

CAGCACTGGGGCCAGGGCACCCTGGT

CACCGTCTCCTCAG

C027
A-C027
GAGGTGCAGCTGGTGGAGTCTGGGGG
219
GACATCCAGATGACCCAGTCTCCTTCCAC
220

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCCAGTCAGAGTATT

TCACCTTCAGTAGCTATGGCATGCACT

AGTAGCTGGTTGGCCTGGTATCAGCAGAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

ACCAGGGAAAGCCCCTAAGCTCCTGATCT

CTGGAGTGGGTGGCAGTTATATCATAT

ATAAGGCGTCTAGTTTAGAAAGTGGGGTC

GATGGAAGTAATAAATACTATGCAGAC

CCATCAAGGTTCAGCGGCAGTGGATCTGG

TCCGTGAAGGGCCGATTCACCATCTCC

GACAGAATTCACTCTCACCATCAGCAGCC

AGAGACAATTCCAAGAACACGCTGTAT

TGCAGCCTGATGATTTTGCAACTTATTACT

CTGCAAATGAACAGCCTGAGAGCTGAG

GCCAACAGTATAATAGTTATTCGACGTTCG

GACACGGCTGTGTATTACTGTGCGAAA

GCCAAGGGACCAAGGTGGAAATCAAAC

GCAAGTGGAATTTATTGTAGTGGTGGA

GACTGCTACTCATACTACTTTGACTACT

GGGGCCAGGGAACCCTGGTCACCGTC

TCCTCAG

C029
A-C029
CAGGTGCAGCTGCAGGAGTCGGGCCC
221
GATATTGTGATGACTCAGTCTCCACTCTCC
222

AGGACTGGTGAAGCCTTCACAGACCCT

CTGCCCGTCACCCCTGGAGAGCCGGCCT

GTCCCTCACCTGCACTGTCTCTGGTGG

CCATCTCCTGCAGGTCTAGTCAGAGCCTC

CTCCATCAGCAGTGGTGGTTACTACTG

CTGCATAGTAATGGATACAACTATTTGGAT

GAGCTGGATCCGCCAGCACCCAGGGA

TGGTACCTGCAGAAGCCAGGGCAGTCTCC

AGGGCCTGGAGTGGATTGGGTACATCT

ACAGCTCCTGATCTATTTGGGTTCTAATCG

ATTACAGTGGGAGCACCTACTACAACC

GGCCTCCGGGGTCCCTGACAGGTTCAGT

CGTCCCTCAAGAGTCGAGTTACCATAT

GGCAGTGGATCAGGCACAGATTTTACACT

CAGTAGACACGTCTAAGAACCAGTTCT

GAAAATCAGCAGAGTGGAGGCTGAGGATG

CCCTGAAGCTGAGCTCTGTGACTGCCG

TTGGGGTTTATTACTGCATGCAAGCTCTAC

CGGACACGGCCGTGTATTACTGTGCGA

AAACTCCTCACACTTTCGGCGGAGGGACC

GAACAATGTATTACTATGATAGTAGTGG

AAGGTGGAGATCAAAC

TTCCTTTGACTACTGGGGCCAGGGAAC

CCTGGTCACCGTCTCCTCAG

C030
A-C030
GAGGTGCAGCTGGTGGAGTCTGGGGG
223
GACATCCAGATGACCCAGTCTCCTTCCAC
224

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCCAGTCAGAGTATT

TCACCTTCAGTAGCTATGGCATGCACT

AGTAGCTGGTTGGCCTGGTATCAGCAGAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

ACCAGGGAAAGCCCCTAAGCTCCTCATCT

CTGGAGTGGGTGGCAGTTATATCATAT

ATAAGGCGTCTAGTTTAGAAAGTGGGGTC

GATGGAAGTAATAAATACTATGCAGAC

CCATCAAGGTTCAGCGGCAGTGGATCTGG

TCCGTGAAGGGCCGATTCACCATCTCC

GACAGAATTCACTCTCACCATCAGCAGCC

AGAGACAATTCCAAGAACACGCTGTAT

TGCAGCCTGATGATTTTGCAACTTATTACT

CTGCAAATGAACAGCCTGAGAGCTGAG

GCCAACAGTATAATAGTTATTCGACGTTCG

GACACGGCTGTGTATTACTGTGCGAAA

GCCAAGGGACCAAGGTGGAAATCAAAC

GCAAGTGGAATATATTGTAGTGGTGGT

AACTGCTACTCATACTACTTTGACTACT

GGGGCCAGGGAACCCTGGTCACCGTC

TCCTCAG

C031
A-C031
GAGGTGCAGCTGGTGGAGTCTGGGGG
225
GACATCCAGATGACCCAGTCTCCATCCTC
226

AGGCTTGGTACAGCCTGGGGGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTCAGTAGCTACGACATGCACT

AGCAGCTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAAGCTACAGGAAAAGGT

CCAGGGAAAGCCCCTAAGGTCCTGATCTA

CTGGAGTGGGTCTCAGCTATTGGTACT

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

GCTGGTGACACATACTATCCAGGCTCC

CATCAAGGTTCAGTGGCAGTGGATCTGGG

GTGAAGGGCCGATTCACCATCTCCAGA

ACAGATTTCACTCTCACCATCAGCAGTCTG

GAAAATGCCAAGAACTCCTTGTATCTTC

CAACCTGAAGATTTTGCAACTTACTACTGT

AAATGAACAGCCTGAGAGCCGGGGAC

CAACAGAGTTACAGTACCCCTCCGCTCAC

ACGGCTGTGTATTACTGTGCAAGAGTA

TTTCGGCGGAGGGACCAAGGTGGAGATCA

GGGTATGATAGTAGTGGTTATTCGGGC

AAC

TGGTACTTCGATCTCTGGGGCCGTGGC

ACCCTGGTCACCGTCTCCTCAG

C032
A-C032
GAGGTGCAGCTGGTGCAGTCTGGAGC
227
CAGTCTGTGCTGACTCAGCCGCCCTCAGT
228

AGAGGTGAAAAAGCCCGGGGAGTCTC

GTCTGGGGCCCCAGGGCAGAGGGTCACC

TGAAGATCTCCTGTAAGGGTTCTGGAT

ATCTCCTGCACTGGGAGCAGCTCCAACAT

ACAGCTTTACCAGCTACTGGATCGGCT

CGGGGCAGGTTATGATGTACACTGGTACC

GGGTGCGCCAGATGCCCGGGAAAGGC

AGCAGCTTCCAGGAACAGCCCCCAAACTC

CTGGAGTGGATGGGGATCATCTATCCT

CTCATCTATGGTAACAGCAATCGGCCCTC

GGTGACTCTGATACCAGATACAGCCCG

AGGGGTCCCTGACCGATTCTCTGGCTCCA

TCCTTCCAAGGCCAGGTCACCATCTCA

AGTCTGGCACCTCAGCCTCCCTGGCCATC

GCCGACAAGTCCATCAGCACCGCCTAC

ACTGGGCTCCAGGCTGAGGATGAGGCTG

CTGCAGTGGAGCAGCCTGAAGGCCTC

ATTATTACTGCCAGTCCTATGACAGCAGCC

GGACACCGCCATGTATTACTGTGCGAG

TGAGTGCCCTTTATGTCTTCGGAACTGGG

AGGGGTAGCAGTGGACTGGTACTTCG

ACCAAGGTCACCGTCCTAG

ATCTCTGGGGCCGTGGCACCCTGGTC

ACCGTCTCCTCAG

C036
A-C036
CAGGTGCAGCTACAGCAGTGGGGCGC
229
GATATTGTGATGACTCAGTCTCCACTCTCC
230

AGGACTGTTGAAGCCTTCGGAGACCCT

CTGCCCGTCACCCCTGGAGAGCCGGCCT

GTCCCGCACCTGCGCTGTCTTTGGTGG

CCATCTCCTGCAGGTCTAGTCAGAGCCTC

GTCCTTCACTAATTACTACTGGAGTTG

CTGCATAGAAATGGATACAACTATTTGGAT

GATCCGCCAGTCCCCAGGGAAGGGGC

TGGTACCTGCAGAAGCCAGGGCAGTCTCC

TGGAGTGGATTGGGGAAATCAATGATA

ACAGCTCCTGATCTATTTGGGTTCCAATCG

GTGGAATCACCAACTACAACCCGTCCC

GGCCTCCGGGGTCCCTGACAGGTTCAGG

TCAAGAGTCGAGTCACCATCTCAGTAG

GGCAGTGGATCAGGCACAGATTTCACACT

ACACGTCCAAGAACCAGTTCTCCCTGA

GAAAATCAGCAGAGTGGAGGCTGAGGATG

GCCTGAGGTCTGTGACCGCCGCGGAC

TTGGGGTTTATTACTGCATGCAAGCTCTAC

ACGGCTGTGTATTACTGTGCCAGAAGG

AAACTCTCACCTTCGGCCAAGGGACACGA

AGGTCCTTCTCTCGTCCTTCGTCTATC

CTGGAGATTAAAC

GACTACTGGGGCCAGGGAACCCTGGT

CACCGTCTCCTCAG

C037
A-C037
TGCAGCTGGTGCAGTCTGGGCCTGAG
231
GAAATTGTGTTGACGCAGTCTCCAGGCAC
232

GTGAAGAAGCCTGGGACCTCAGTGAA

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

GGTCTCCTGCAAGGCTTCTGGATTCAC

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

CTTTACTAGCTCTGCTATGCAGTGGGT

AGCAGCAGCTACTTAGCCTGGTACCAGCA

GCGACAGGCTCGTGGACAACGCCTTG

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

AGTGGATAGGATGGATCGTCGTTGGCA

TCTATGGTGCATCCAGCAGGGCCACTGGC

GTGGTAACACAAACTACGCACAGAAGT

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

TCCAGGAAAGAGTCACCATTACCAGGG

TGGGACAGACTTCACTCTCACCATCAGCA

ACATGTCCACAAGCACAGCCTACATGG

GACTGGAGCCTGAAGATTTTGCAGTGTATT

AGCTGAGCAGCCTGAGATCCGAGGAC

ACTGTCAGCAGTATGGTAGCTCACCGTGG

ACGGCCGTGTATTACTGTGCGGCCCCA

ACGTTCGGCCAAGGGACCAAGGTGGAAAT

TATTGTAGTGGTGGTAGCTGCAATGAT

CAAAC

GCTTTTGATATCTGGGGCCAAGGGACA

ATGGTCACCGTCTCTTCAG

C038
A-C038
AGGTGCAGCTGGTGGAGTCTGGGGGA
233
AATTTTATGCTGACTCAGCCCCACTCTGTG
234

GGCGTGGTCCAGCCTGGGAGGTCCCT

TCGGAGTCTCCGGGGAAGACGGTTACCAT

GAGACTCTCCTGTGCAGCCTCTGGATT

CTCCTGCACCGGCAGCAGTGGCAGCATTG

CACCTTCAATAGAATTGCCATGTACTG

CCAGCAACTATGTGCAGTGGTACCAGCAG

GGTCCGCCAGGCTCCAGGCAAGGGGC

CGCCCGGGCAGTGCCCCCACCACTGTGA

TGGAATGGGTGGCAGTTATATCATTTG

TCTATGAAGATACCCAAAGACCCTCTGGG

ATGGAAGTTATGAATACTATGCAGAGT

GTCCCTGATCGGTTCTCTGGCTCCATCGA

CCGTGAAGGGCCGGTTCGCCATCTCC

CAGCTCCTCCAATTCTGCCTCCCTCACCAT

AGAGACAATTCCAAGAACACGCTGTAT

CTCTGGACTGAAGACTGAGGACGAGGCTG

CTACAGATGAACAGCCTGAGAGCTGAG

ACTACTACTGTCAGTCTTATGATATCAACA

GACACGGCTGTCTATTACTGTGCGAAA

GTCGTTGGGTGTTCGGCGGAGGGACCAA

AGTCCGATGGGTTATTGCACTAATGGT

GCTGACCGTCCTA

GTATGCTATCCTGACTCCTGGGGCCAG

GGAACCCTGGTCACCGTCTCCTCAG

C040
A-C040
GAGGTGCAGCTGGTGGAGTCTGGGGG
235
TCCTATGAGCTGACTCAGCCACCCTCGGT
236

AGGCTTGGTAAAGCCTGGGGGGTCCC

GTCAGTGGCCCCAGGACAGACGGCCAGG

TTAGACTCTCCTGTGCAGCCTCTGGAT

ATTACCTGTGGGGGAAACAACATTGGAAG

TCACTTTCAGTAACGCCTGGATGAGCT

TAAAAGTGTGCACTGGTACCAGCAGAAGC

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAGGCCAGGCCCCTGTGCTGGTCGTCTAT

CTGGAGTGGGTTGGCCGTATTAAAAGC

GATGATAGCGACCGGCCCTCAGGGATCCC

AAAACTGATGGTGGGACAACAGACTAC

TGAGCGATTCTCTGGCTCCAACTCTGGGA

GCTGCACCCGTGAAAGGCAGATTCACC

ACACGGCCACCCTGACCATCAGCAGGGTC

ATCTCAAGAGATGATTCAAAAAACACG

GAAGCCGGGGATGAGGCCGACTATTACTG

CTGTATCTGCAAATGAACAGCCTGAAA

TCAGGTGTGGGATAGTAGTAGTGATCAGG

ACCGAGGACACAGCCGTGTATTACTGT

GGGTATTCGGCGGAGGGACCAAGCTGAC

ACCACAGATCCCCATTGTAGTAGTACC

CGTCCTAG

AGCTGCCCCATTTTTTACTACTACTACA

TGGACGTCTGGGGCAAAGGGACCACG

GTCACCGTCTCCTCAG

C101
V-C001
CAGGTGCAGCTGGTGGAGTCTGGAGG
237
GAAATTGTGTTGACGCAGTCTCCAGGCAC
238

AGGCTTGATCCAGCCTGGGGGGTCCC

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCATCGTCAGTAGCAACTACATGAGCT

AGCAGCAGCTACTTAGCCTGGTACCAGCA

GGGTCCGCCAGGCTCCAGGGAAGGGG

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

CTGGAGTGGGTCTCAGTTATTTATAGC

TCTATGGTGCATCCAGCAGGGCCACTGGC

GGTGGTAGCACATTCTACACAGACTCC

ATCCCAGACAGGTTCAGTGGCGGTGGGTC

GTGAAGGGCCGATTCACCATCTCCAGA

TGAGACAGACTTCACTCTCACCATCAGCA

GACAATTCCAAGAACACTCTGTATCTTC

GACTGGAGCCTGAAGATTGTGCAGTGTAT

AAATGAACAGCCTGAGAGCCGAGGAC

TACTGTCAGCAGTATGGTAGCTCACCCCG

ACGGCCGTGTATTACTGTGTGCGGGAC

GACGTTCGGCCAAGGGACCAAGGTGGAA

TACGGTGACTTCTACTTTGACTACTGG

ATCAAAC

GGCCAGGGAACCCTGGTCACCGTCTC

CTCAG

C102
V-C002
CAGGTGCAGCTGGTGGAGTCTGGAGG
239
GAAATTGTGTTGACGCAGTCTCCAGGCAC
240

AGGCTTGATCCAGCCTGGGGGGTCCC

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCATCGTCAGTAGCAACTACATGAGCT

AGCAGCAGCTACTTAGCCTGGTACCAGCA

GGGTCCGCCAGGCTCCAGGGAAGGGG

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

CTGGAGTGGGTCTCAGTTATTTATAGC

TCTATGGTGCATCCAGCAGGGCCACTGGC

GGTGGTAGCACATTCTACGCAGACTCC

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

GTGAAGGGCCGATTCACCATCTCCAGA

TGGGACAGACTTCACTCTCACCATCAGCA

GACAATTCCAAGAACACGCTGTATCTT

GACTGGAGCCTGAAGATTTTGCAGTCTATT

CAAATGAACAGCCTGAGAGCCGAGGA

ACTGTCAGCAGTATGGTAGCTCACCTCGG

CACGGCCGTGTATTACTGTGCGAGGG

ACGTTCGGCCAAGGGACCAAGGTGGAAAT

ACTACGGTGACTACTACTTTGACTACT

CAAAC

GGGGCCAGGGAACCCTGGTCACCGTC

TCCTCAG

C103
V-C003
CAGGTGCAGCTACAGCAGTGGGGCGC
241
GAAATTGTGTTGACGCAGTCTCCAGGCAC
242

AGGACTGTTGAAGCCTTCGGAGACCCT

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

GTCCCTCACCTGCGCTGTCTCTGGTGG

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

GTCACTCAGTGGTTTCTACTGGACCTG

ACCGCCAACTACTTAGCCTGGTACCAGCA

GATCCGCCAGCCCCCAGGAAAGGGGC

GAAACCTGGCCAGGCTCCCAGACTCCTCA

TGGAGTGGATTGGGGAAACCAATCATT

TCTATGGTGCATCCAAGAGGGCCACTGGC

TTGGAAGCACCGGCTACAAGCCGTCC

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

CTCAAGAGTCGAGTCACCATATCAGTA

TGGGACAGACTTCACTCTCAGCATCAGCA

GACATGTCCAGGAACCAGTTCTCCCTG

GACTGGAGCCTGAAGATTTTGCAGTGTATT

AAGGTGACCTCTGTGACCGCCGCGGA

ACTGTCAGCAGTATACTACTACACCTCGGA

CACGGCTGTGTATTACTGTGCGAGAAA

CTTTCGGCGGAGGGACCAAGGTGGAGAT

GCCCCTCCTCTACAGTGACTTCTCTCC

CAAAC

TGGTGCTTTTGATATCTGGGGCCAAGG

GACAATGGTCACCGTCTCTTCAG

C104
V-C004
CAGGTGCAGCTACAGCAGTGGGGCGC
243
GAAATTGTGTTGACGCAGTCTCCAGGCAC
244

AGGACTGTTGAAGCCTTCGGAGACCCT

CGTGTCTTTGTCTCCAGGGGAAAGAGCCA

GTCCCTCTCCTGCGCTGTCTATGGTGG

CCCTCTCCTGCTGGGCCAGTCAGAGTGTT

GTCCCTCAGTGGTTACTACTGGAGCTG

AGCGCCAGCTACTTAGCCTGGTACCAGCA

GATCCGCCAGCCCCCAGGGAAGGGGC

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

TGGAGTGGATTGGGGAGATCAATCATT

TCTATGGTGCATCCAGCAGGGCCACTGGC

TTGGAAGCACCGGCTACAACCCGTCCC

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

TCAAGAGTCGAGTCACCATCTCCGTGG

TGGGACAGACTTCACTCTCACCATCAGTA

ACACGTCCAAGAGCCAGTTCTCCGTGA

GACTGGAGCCTGAAGATTTTGCAGTATATT

AGCTGAGCTCTGTGACCGCCGCGGAC

ACTGTCAGCAGTACGGTACTACACCTCGG

ACGGCTGTCTATTACTGCGCGAGAAAG

ACTTTCGGCGGAGGGACCAAGGTGGAGAT

CCCCTCCTCTACAGTAACTTATCCCCT

CAAAC

GGTGCTTTTGATATCTGGGGCCAAGGG

ACAATGGTCACCGTCTCTTCAG

C105
V-C005
CAGGTGCAGCTGGTGGAGTCTGGAGG
245
CAGTCTGCCCTGACTCAGCCTCCCTCCGC
246

AGGCTTGATCCAGCCTGGGGGGTCCC

GTCCGGGTCTCCTGGACAGTCAGTCACCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

TCTCCTGCACTGGAACCAGCAGTGACGTT

TCACCGTCAGTAGCAACTACATGAGCT

GGTGGTTATAAGTATGTCTCCTGGTACCAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAGCACCCAGGCAAAGCCCCCAAACTCAT

CTGGAGTGGGTCTCAGTTATTTATAGC

GATTTATGAGGTCAGTAAGCGGCCCTCAG

GGTGGTAGTACATACTACGCAGACTCC

GGGTCCCTGATCGCTTCTCTGGCTCCAAG

GTGAAGGGCCGATTCACCATCTCCAGA

TCTGGCAACACGGCCTCCCTGACCGTTTC

GACAATTCCAAGAACACGCTGTATCTT

TGGGCTCCAGGCTGAGGATGAGGCTGATT

CAAATGAACAGCCTGAGAGCCGAGGA

ATTACTGCAGCTCATATGAAGGCAGCAAC

CACGGCCGTGTATTACTGTGCGAGAG

AATTTTGTGGTATTCGGCGGAGGGACCAA

GCGAGGGGTGGGAGCTACCATACGAC

GCTGACCGTCCTAG

TACTGGGGCCAGGGAACCCTGGTCAC

CGTCTCCTCAG

C106
V-C006
CAGCTGCAGCTGCAGGAGTCGGGCCC
247
TCCTATGAGCTGACACAGCCACCCTCAGT
248

AGGACTGGTGAAGCCTTCGGAGACCC

GTCAGTGGCCCCAGGAAAGACGGCCAGG

TGTCCCTCACCTGCACTGTCTCTGGTG

ATTACCTGTGGGGGAAACAACATTGGAAG

CCTCCGTCAGCAGTGGTAGTTACTACT

TAAAAGTGTGCACTGGTACCAGCAGAAGC

GGAGCTGGATCCGGCAGCCCCCAGGG

CAGGCCAGGCCCCTGTGCTGGTCATCTAT

AAGGGACTGGAATGGATTGGGTATATC

TTTGATAGCGACCGGCCCTCAGGGATCCC

TATTACAGTGGGAGCACCAACTACAAC

TGAGCGATTCTCTGGCTCCAACTCTGGGA

CCCTCCCTCAAGAGTCGAGTCACCATA

ACACGGCCACCCTGACCATCAGCAGGGTC

TCAGTGGACACGTCCAAGAACCAGTTC

GAAGCCGGGGATGAGGCCGACTATTACTG

TCCCTGAAGCTGAGCTCTGTGACCGCT

TCAGGTGTGGGATAGTAGTCGTGATCATG

GCGGACACGGCCGTGTATTACTGTGC

TGGTATTCGGCGGAGGGACCAAGCTGACC

GAGAGAGCGGCCCGGTGGAACGTATA

GTCCTAG

GCAACACCTGGTACACCCCAACCGATA

CCAACTGGTTCGACACCTGGGGCCAG

GGAACCCTGGTCACCGTCTCCTCAG

C107
V-C007
CAGGTTCAGCTGGTGCAGTCTGGAGCT
249
CAGTCTGTGCTGACTCAGCCACCCTCAGC
250

GAGGTGAAGAAGCCTGGGGCCTCAGT

GTCTGGGACCCCCGGGCAGAGGGTCACC

GAGGGTCTCCTGCAAGGCTTCTGGTTA

ATCTCTTGTTCTGGAAGCAGCTCCAACATC

CACCTTTACCAGCTATGGTTTCAGCTG

GGAAGTAATTATGTATACTGGTACCAGCAG

GGTGCGACAGGCCCCTGGACAAGGGC

CTCCCAGGAACGGCCCCCAAACTCCTCAT

TTGAGTGGATGGGATGGATCAGCGCTT

CTATAGGAATAATCAGCGGCCCTCAGGGG

ACAATGGTAACACAAACTTTGCACAGA

TCCCTGACCGATTCTCTGGCTCCAAGTCT

AGCTCCAGGGCAGAGTCACCATGACC

GGCACCTCAGCCTCCCTGGCCATCAGTGG

ACAGACACATCCACGAGCACAGCCTAC

GCTCCGGTCCGAGGATGAGGCTGATTATT

ATGGAGCTGAGGAGCCTGAGATCTGA

ACTGTGCAGCATGGGATGACAGCCTGAGT

CGACACGGCCGTGTATTACTGTGCGAG

GGTTTTGTGGTATTCGGCGGAGGGACCAA

AGGGGAAGCAGTGGCTGGTACAACCG

GCTGACCGTCCTAG

GTTTTTTTGACTACTGGGGCCAGGGAA

CCCTGGTCACCGTCTCCTCAG

C108
V-C008
CAGGTGCAGCTGCAGGAGTCGGGCCC
251
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
252

AGGACTGGTGAAGCCTTCGGGGACCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGTCCCTCACCTGCGCTGTCTCTGGTG

TCTCCTGCACTGGAACCAGCAGTGACGTT

GCTCCATCAGCAGTACTAACTGGTGGA

GGTGGTTATAACTATGTCTCCTGGTACCAA

GTTGGGTCCGCCAGCCCCCAGGGAAG

CAACACCCAGGCAAAGCCCCCAAACTCAT

GGGCTGGAGTGGATTGGGGAAATCTAT

GATTTATGATGTCAGTAATCGGCCCTCAG

CATACTGGGAGCACCAACTACAACCCG

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

TCCCTCAAGAGTCGAGTCACCATATCA

CTGGCAACACGGCCTCCCTGACCATCTCT

GTAGACAAGTCCAAGAACCAGTTCTCC

GGGCTCCAGGCTGAGGACGAGGCTGATT

CTGAAGCTGAGCTCTGTGACCGCCGC

ATTACTGCAACTCATATACAAGCAGCAGCA

GGACACGGCCGTGTATTACTGTGTGAG

CTCGAGTCTTCGGAACTGGGACCAAGGTC

AGATGGAGGACGACCCGGGGATGCTT

ACCGTCCTAG

TTGATATCTGGGGCCAAGGGACAATGG

TCACCGTCTCTTCAG

C110
V-C010
CAGGTACAGCTGCAGCAGTCTGGAGC
253
GACATCCAGATGACCCAGTCTCCTTCCAC
254

AGAGGTGAAAAAGCCCGGGGAGTCTC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAAGATCTCCTGTAAGGGTTCTGGAT

CCATCACTTGCCGGGCCAGTCAGAGTATT

ACAGCTTTACCAGCTACTGGATCGGCT

AGTTACTGGTTGGCCTGGTATCAGCAGAA

GGGTGCGCCAGATGCCCGGGAAAGGC

ACCAGGGAAAGCCCCTAAGCTCCTGATCT

CTGGAGTGGATGGGGATCATCTATCCT

ATCAGGCGTCTAGTTTAGAAAGTGGGGTC

GGTGACTCTGATACCAGATACAGCCCG

CCGTCAAGGTTCAGCGGCAGTGAGTCTGG

TCCTTCCAAGGCCAGGTCACCATCTCA

GACAGAATTCACTCTCACCATCAGCAGCC

GCCGACAAGTCCATCAGCACCGCCTAC

TGCAGCCTGATGATTTTGCAACTTATTACT

ATGCAGTGGAGCAGCCTGAAGGCCTC

GCCAACAGTATAATAGTTACCCGTACACTT

GGACACCGCCATGTATTACTGTGCGAG

TTGGCCAGGGGACCAAGCTGGAGATCAAAC

ATCGTTCCGGGACGACCCCCGTATAGC

AGTGGCTGGCCCGGCTGATGCTTTTGA

TATCTGGGGCCAAGGGACAATGGTCAC

CGTCTCTTCAG

C112
V-C012
CAGGTGCAGCTGGTGGAGTCTGGGGG
255
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
256

AGGCGTGGTCCAGCCTGGGAGGTCCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

TCTCCTGCACCGGAACCAGCAGTGACGTT

TCACCTTCAGTAGCCATGCTATGCACT

GGTGGTTATAACTATGTCTCCTGGTACCAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CAACACCCAGGCAAAGCCCCCAAACTCAT

CTGGAGTGGGTGGCAGTTATATCATAT

GATTTATGATGTCAGTAATCGGCCCTCAG

GATGGAAGCAATAAATACTACGCAGAC

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

TCCGTGAAGGGCCGATTCACCATCTCC

CTGGCAACACGGCCTCCCTGACCATCTCT

AGAGACAATTCCAAGAACACGCTGTAT

GGGCTCCAGGCTGAGGACGAGGCTGATT

CTGCAAATGAACAGCCTGAGAGCTGAG

ATTACTGCAGCTCATATACAAGCAGCAGCA

GACACGGCTGTGTATTACTGTGCGAGA

CTTGGGTGTTCGGCGGAGGGACCAAGCT

GAGGATTACTATGATAGTAGTGGTTCTT

GACCGTCCTAG

TTGACTACTGGGGCCAGGGAACCCTG

GTCACCGTCTCCTCAG

C113
V-C013
CAGGTGCAGCTGGTGGAGTCTGGGGG
257
GACATCCAGATGACCCAGTCTCCTTCCAC
258

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCCAGTCAGAGTATG

TCACCTTCAGTAACTTTGGCATGCACT

AGTAGCTGGTTGGCCTGGTATCAGCAGAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

ACCAGGGAACGCCCCTAAGCTCCTGATCT

CTGGAGTGGGTGGCAGTTATATGGTAT

ATAAGGCGTCTAGTTTAGAAAGTGGGGTC

GATGGAAGTAATAAATACTATGCAGAC

CCATCAAGGTTCAGCGGCAGTGGATCTGG

TCCGTGAAGGGCCGATTCACCATCTCC

GACAGAATTCACTCTCACCATCAGCAGCC

AGAGACAATTCCAAGAACACGCTGTAT

TGCAGCCTGATGATTTTGCAACTTATTACT

CTGCAAATGAACAGCCTGAGAGCCGA

GCCAACAGCATAATAGTTCCCCGCTCACTT

GGACACGGCTGTGTATTACTGTGCGAG

TCGGCGGAGGGACCAAGGTGGAGATCAA

AGGAGTAAACCCCGACGATATTTTGAC

AC

TGGCGTAGATGCTTTTGATATCTGGGG

CCAAGGGACAATGGTCACCGTCTCTTC

AG

C114
V-C014
CAGGTGCAGCTGGTGGAGTCTGGAGG
259
CAGTCTGTGCTGACTCAGCCGCCCTCAGT
260

AGGGTTGATCCAGCCTGGGGGGTCCC

GTCTGGGGCCCCAGGGCAGAGGGTCACC

TGAAACTCTCCTGTGTAGTCTCTGGGT

ATCTCCTGCACTGGGACCAGTTCCAACAT

TCACCGTCAGTAAGAACTACATCAGTT

CGGGGCAGGTTATGATGTGCACTGGTACC

GGGTCCGCCAGGCTCCAGGCAAGGGG

AGCAACTTCCTGGAAGAGCCCCCAAAGTC

CTGGAATGGGTCTCAGTTATTTTTGCC

CTCATCTCTGGAAACAACATTCGGCCCTCA

GGTGGTAGTACATTCTACGCAGACTCC

GAGGTCCCTGACCGATTCTCTGGCTCCAG

GTTAAGGGCCGATTCGCCATCTCCAGA

GTCTGGCACCTCAGCCTCCCTGGCCATCA

GACAACTCCAACAACACGCTGTTTCTT

CTAGTCTCCAGCCTGAGGATGAGGCTCAA

CAAATGAACAGCCTGAGAGTCGAGGAC

TATTACTGTCAGTCTTATGACAGCAGTCTC

ACGGCCATTTATTACTGTGCGAGAGGG

TATGCGGTGTTCGGCGGAGGGACCAAGCT

GACGGGGAGTTATTCTTTGACCAATGG

GACCGTCCTA

GGCCAGGGAACCCTGGTCACCGTCTC

CTCAG

C115
V-C015
CAGGTGCAGCTGGTGGAGTCTGGGGG
261
GATATTGTGATGACTCAGTCTCCACTCTCC
262

AGGCTTGATAAAGCCAGGGCGGTCCC

CTGTCCGTCACCCCTGGAGAGCCGGCCTC

TGAGACTCTCTTGTACAGCCTCTGGAT

CATCTCCTGCAGGTCTAGTCAGAGCCTCC

TCACCTTTGGTGATTATGCTATGACCTG

TGCATAGTAATGGAAACAACTATTTCGATT

GTTCCGCCAGGCTCCAGGGAAGGGGC

GGTACCTGCAGAAGCCAGGGCAGTCTCCA

TGGAGTGGGTAGGTTTCATTAGAAGTA

CAGCTCCTGATCTATTTGGGTTCTAATCGG

AAGCTTATGGTGGGACAACAGGATACG

GCCTCCGGGGTCCCTGACAGGTTCAGTG

CCGCGTCTGTGAAATACAGATTTACCA

GCAGTGGATCAGGCACAGATTTTACACTG

TCTCAAGAGATGATTCCAAAAGCATCG

AAGATCAGCAGAGTGGAGGCTGAGGATGT

CCTATCTGCAAATGGACAGCCTGAAAA

TGGGGTTTATTACTGCATGCAAGTTCTACA

CCGAGGACACAGCCGTGTATTACTGTA

AATTCCGTACACTTTTGGCCAGGGGACCA

CTAGGTGGGACGGGTGGAGTCAACAT

AGCTGGAGATCAAAC

GACTATTGGGGCCAGGGAACCCTGGT

CACCGTCTCCTCAG

C116
V-C016
CAGGTGCAGCTGGTGGAGTCTGGGGG
263
AATTTTATGCTGACTCAGCCCCACTCTGTG
264

AGGCGTGGTCCAGCCTGGGAGGTCCC

TCGGAGTCTCCGGGGAAGACGGTAACCAT

TGAGACTCTCCTGTGCAGCCTCTGGAT

CTCCTGCACCGGCAGCAGTGGCAGCATTG

TCACCTACAGTACCTATGCTATGCACT

CCAGCAACTATGTGCAGTGGTACCAGCAG

GGGTCCGCCAGGCTCCAGGCAAGGGG

CGCCCGGGCAGTGCCCCCACCACTGTGA

CTGGAGTGGGTGGCATTTATATCATAT

TCTATGAGGATAACCAAAGACCCTCTGGG

GATGGAAGCAATAAATACTACGCAGAC

GTCCCTGATCGGTTCTCTGGCTCCATCGA

TCCGTGAAGGGCCGATTCACCATCTCC

CAGGTCCTCCAACTCTGCCTCCCTCACCA

AGAGACAATTCCAAGAACACGCTGTAT

TCTCTGGACTGAAGACTGAGGACGAGGCT

CTGCAAATGAACAGCCTGAGAGCTGAG

GACTACTACTGTCAGTCTTATGATAGCGGC

GACACGGCTGTGTATTACTGTGCGAGA

AATCATTGGGTGGTATTCGGCGGAGGGAC

GATTTCTACCATAACTGGTTCGACCCC

CAGGCTGACCGTCCTAG

TGGGGCCAGGGAACCCTGGTCACCGT

CTCCTCAG

C117
V-C017
CAGGTGCAGCTGGTGGAGTCTGGGGG
265
CAGTCTGTGCTGACTCAGCCGCCCTCAGT
266

AGGCGTGGTCCAGCCTGGGAGGTCCC

GTCTGCGGCCCCAGGACAGAAGGTCACC

TGAGACTCTCCTGTGCAGCCTCTGGAT

ATCTCCTGCTCTGGAAGCAGCTCCAACATT

TCACCTTCAGTACCTATGCTATGCACT

GGGAATAATTTGGTATCCTGGTACCAGCA

GGGTCCGCCAGGCTCCAGGCGAGGG

GCTCCCAGGAACAGCCCCCAAACTCCTCA

GCTGGAGTGGGTGGCAGTTATTTCATA

TCTATGAAAATAATAAGCGACCCTCAGGGA

TGATGGAAGCAATACATACTACGCAGA

TTCCTGACCGATTCTCTGGCTCCAAGTCTG

CTCCGTGAAGGGCCGATTCACCATCTC

GCACGTCAGCCACCCTGGGCATCACCGG

CAGAGACAATTCCAAGAACACGCTGTA

ACTCCAGACTGGGGACGAGGCCGATTATT

TCTGCAAATGAACAGCCTGAGAGCTGA

ACTGCGGAGCATGGGATAGCAGCCTGAGT

AGACACGGCTGTGTATTACTGTGCGAG

GCTGGCGGGGTTTATGTCTTCGGAACTGG

AGATCCCATATGGTTCGGGGAGTTATT

GACCAAGGTCACCGTCCTAG

ATCTCCTCCTTTTGTTCACTTTGACTAC

TGGGGCCAGGGAACCCTGGTCACCGT

CTCCTCAG

C118
V-C018
CAGGTGCAGCTGGTGGAGTCTGGGGG
267
CAGCCTGTGCTGACTCAATCGCCCTCTGC
268

AGGCGTGGTCCAGCCTGGGAGGTCCC

CTCTGCCTCCCTGGGAGCCTCGGTCAAGC

TGAGACTCTCCTGTGCAGCCTCTGGAT

TCACCTGCACTCTGAGCAGTGGGCACAGC

TCACCTTCAGTAACTATGCTATGCACTG

AGCTACGCCATCGCATGGCATCAGCAGCA

GGTCCGCCAGGCTCCAGGCAAGGGGC

GCCAGAGAAGGGCCCTCGGTACTTGATGA

TGGAGTGGGTGGCAGTTATATCATATG

AGCTTAACACTGATGGCAGCCACAGCAAG

ATGGAAGCAATAAATACTACGCAGACT

GGGGACGGGATCCCTGATCGCTTCTCAGG

CCGTGAAGGGCCGATTCACCATCTCCA

CTCCAGCTCTGGGGCTGAGCGCTACCTCA

GAGACAATTCCAAGAACACGCTGTATC

CCATCTCCAGCCTCCAGTCTGAGGATGAG

TGCAAATGAACAGCCTGAGAGCTGAGG

GCTGACTATTACTGTCAGACCTGGGGCAC

ACACGGCTATTTATTACTGTGCGAGTG

TGGCATTCTCGTATTCGGCGGAGGGACCA

GATATACTGGCTACGATTATTTTGTGCG

AGCTGACCGTCCTAG

GGGGGACTACTACGGTCTGGACGTCT

GGGGCCAAGGGACCACGGTCACCGTC

TCCTCA

C119
V-C019
CAGGTCCAGCTGGTACAGTCTGGGGC
269
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
270

TGAGGTGAAGAAGCCTGGGGCCTCAG

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAAGGTTTCCTGCAAGGCATCTGGAT

TCTCCTGCACTGGAACCAGCAGTGACGTT

ACACCTTCACCAGCTACTATATGCACT

GGTGGTTATAAGTATGTCTCCTGGTACCAA

GGGTGCGACAGGCCCCTGGACAAGGG

CGGCACCCAGGCAAAGCCCCCAAACTCAT

CTTGAGTGGATGGGAATAATCAACCCT

GATATATGATGTCAGTAATCGGCCCTCAG

AGTGGTGGTAGCACAAGCTACGCACA

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

GAAGTTACAGGGCAGAGTCACCATGAC

CTGGCAACACGGCCTCCCTGACCATCTCT

CAGGGACACGTCCACGAGCACAGTCT

GGGCTCCAGGCTGAGGACGAGGCTGATT

ACATGGAGCTGAGCAGCCTGAGATCTG

ATTACTGCAGCTCATACACAAGCAGCAGC

AGGACACGGCCGTGTATTACTGTGCGA

ACTTCTGTGGTGTTCGGCGGAGGGACCCA

GAGCCAATCATGAAACAACTATGGACA

GCTGACCGTCCTAG

CTTACTACTACTACTACTACATGGACGT

CTGGGGCAAAGGGACCACGGTCACCG

TCTCCTCA

C120
V-C020
GAGGTGCAGCTGGTGGAGTCTGGAGG
271
GCCATCCGGATGACCCAGTCTCCATCCTC
272

AGGCTTGATCCAGCCTGGGGGGTCCC

CCTGTCTGCATCTGTAGGAGACACAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

CCATCACTTGCCAGGCGAGTCAGGACATT

TCACCGTCAGTAGCAACTACATGACCT

AGCAAGTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTCTCACTTATTTATCCC

CGATGCATCCAATTTGGAAACAGGGGTCC

GGTGGTAGCACATACTACGCAGACTCC

CATCAAGGTTCAGTGGAAGTGGATCTGGG

GTGAAGGGCCGATTCACCATCTCCAGA

ACAGATTTTACTTTCACCATCAGCAGCCTG

GACAATTCCAAGAACACGCTGTATCTT

CAGCCTGAAGATATTGCAACATATTACTGT

CAAATGAACAGCCTGAGAGCCGAGGA

CAACAGTATGATAATCTCCCTCAGACTTTC

CACGGCCGTCTATTACTGTGCGAGAGA

GGCGGAGGGACCAAGGTGGAGATCAAAC

GGGTATGGGTATGGCAGCAGCTGGTA

CGTGGGGCCAGGGAACCCTGGTCACC

GTCTCCTCAG

C121
V-C021
CAGGTGCAGCTGGTGCAGTCTGGGGC
273
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
274

TGAGGTGAAGAAGCCTGGGGCCTCAG

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAAGGTCTCCTGCAAGGCTTCTGGAT

TCTCCTGCACTGGAACCAGCAGTGATGTT

ACACCTTCACCGGCTACTATATGCACT

GGGAGTTATAACCTTGTCTCCTGGTACCAA

GGGTGCGACAGGCCCCTGGACAAGGG

CAGCACCCAGGCAAAGCCCCCAAACTCAT

CTTGAGTGGATGGGATGGATCAGCCCT

GATTTATGAGGGCAGTAAGCGGCCCTCAG

GTCAGTGGTGGCACAAACTATGCACAG

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

AAGTTTCAGGGCAGGGTCACCATGACC

CTGGCAACACGGCCTCCCTGACAATCTCT

AGGGACACGTCCATCAGCACAGCCTAC

GGACTCCAGGCTGAGGACGAGGCTGATTA

ATGGAGCTGAGCAGGCTGAGATCTGA

TTACTGCTGCTCATATGCAGGTAGTAGCAC

CGACACGGCCGTGTATTACTGTGCGAG

TTTGGTATTCGGCGGAGGGACCAAGCTGA

AGCCCCACTGTTCCCCACAGGGGTGC

CCGTCCTAG

TAGCTGGGGACTACTACTACTACGGTA

TGGACGTCTGGGGCCAAGGGACCACG

GTCACCGTCTCCTCA

C122
V-C022
GAGGTGCAGCTGGTGGAGTCTGGAGG
275
GACATCCAGTTGACCCAGTCTCCATCCTTC
276

AGGCTTGATCCAGCCTGGGGGGTCCC

CTGTCTGCATCTGTAGGAGACAGAGTCAC

TGAGACTCTCCTGTGCAGCCTCTGGGC

CATCACTTGCCGGGCCAGTCAGGGCATTA

TCACCGTCAGTAGCAACTACATGAGCT

GCAGTTATTTAGCCTGGTATCAGCAAAAAC

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAGGGAAAGCCCCTAAGCTCCTGATCTAT

CTGGAGTGGGTCTCAGTTCTTTATAGC

GCTGCATCCACTTTGCAAAGTGGGGTCCC

GGTGGTAGCTCATTCTACGCAGACTCC

ATCAAGGTTCAGCGGCAGTGGATCTGGGA

GTGAAGGGCCGATTCACCATCTCCAGA

CAGAATTCACTCTCACAATCAGCAGCCTG

GACAATTCCAAGAACACGCTGTATCTT

CAGCCTGAAGATTTTGCAACTTATTACTGT

CAAATGAACAGCCTGAGAGCCGAAGAC

CAACAGCTTAATAGTGACTCGTACACTTTT

ACGGCCGTGTATTACTGTGCGAGAGAA

GGCCAGGGGACCAAGCTGGAGATCAAAC

AGTGGGGATACAACTATGGCCTTTGAC

TACTGGGGCCAGGGAACCCTGGTCAC

CGTCTCCTCAG

C123
V-C023
GAGGTGCAGCTGGTGGAGTCTGGAGG
277
GACATCCAGTTGACCCAGTCTCCATCCTTC
278

AGGCTTGATCCAGCCTGGGGGGTCCC

CTGTCTGCATCTGTAGGAGACAGAGTCAC

TGAGACTCTCCTGTGCAGCCTCTGGGG

CATCACTTGCCGGGCCAGTCAGGGCATTA

TCACCGTCAGTAGGAACTACATGAGCT

GCAGTTATTTAGCCTGGTATCAGCAAAAAC

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAGGGAAAGCCCCTAAGCTCCTGATCTAT

CTGGAGTGGGTCTCAGTTATTTATAGC

GCTGCATCCACTTTGCAAAGTGGGGTCCC

GGTGGTAGCACATACTACGCAGACTCC

ATCAAGGTTCAGCGGCAGTGGATCTGGGA

GTGAAGGGCCGATTCACCATCTCCAGA

CAGAATTCACTCTCACAATCAGCAGCCTG

GACAATTCCAAGAACACGCTGTATCTT

CAGCCTGAAGATTTTGCAACTTATTACTGT

CAAATGAACAGCCTGAGAGCCGAGGA

CAACAGCTTAATAGTTACCCTCCAGCCTTC

CACGGCCGTGTATTACTGTGCGAGAGA

GGCCAAGGGACACGACTGGAGATTAAAC

TCTATCTGCTGCTTTTGATATCTGGGG

CCAAGGGACAATGGTCACCGTCTCTTC

AG

C124
V-C024
GAGGTGCAGCTGGTGGAGTCTGGGGG
279
GAAATTGTGTTGACACAGTCTCCAGCCAC
280

AGGCTTGGTACAGCCTGGGGGGTCCC

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCCTCTCCTGCAGGGCCAGTCAGAGTTTT

TCACCTTCAGTGGCTATAGCATGAACT

AGCAGCTACTTAGCCTGGTACCAACAGAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

ACCTGGCCAGGCTCCCAGGCTCCTCATCT

CCGGAGTGGGTTTCATACATTAGTAGG

ATGATGCATCCAACAGGGCCACTGGCATC

AGTAGTAGTACCATATACTACGCAGAC

CCAGCCAGGTTCAGTGGCAGTGGGTCTG

TCTGTGAAGGGCCGATTCACCATCTCC

GGACAGACTTCACTCTCACCATCAGCAGC

AGAGACAATGCCAAGAACTCACTGTAT

CTAGAGCCTGAAGATTTTGCAGTTTATTAC

CTGCAAATGAACAGCCTGAGAGACGAG

TGTCAGCAGCGTAACAACTGGCCTCCCGA

GACACGGCTGTGTATTACTGTGCGAGA

GTGGACGTTCGGCCAAGGGACCAAGGTG

GAAGGGGCTAGAGTGGGAGCTACATA

GAAATCAAAC

TGACACGTACTACTTTGACTACTGGGG

CCAGGGAACCCTGGTCACCGTCTCCTC

AG

C125
V-C025
CAGGTGCAGCTGGTGCAGTCTGGGCC
281
GAAATTGTGTTGACGCAGTCTCCAGGCAC
282

TGAGGTGAAGAAGCCTGGGACCTCAG

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAAGGTCTCCTGCAAGGCTTCTGGAT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCACCTTTACTAGCTCTGCTGTGCAGT

AGCAGCAGCTACTTAGCCTGGTACCAGCA

GGGTGCGACAGGCTCGTGGACAACGC

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

CTTGAGTGGATAGGATGGATCGTCGTT

TCTATGGTGCATCCAGCAGGGCCACTGGC

GGCAGTGGTAACACAAACTACGCACAG

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

AAGTTCCAGGAAAGAGTCACCATTACC

TGGGACAGACTTCACTCTCACCATCAGCA

AGGGACATGTCCACAAGCACAGCCTAC

GACTGGAGCCTGAAGATTTTGCAGTGTATT

ATGGAGCTGAGCAGCCTGAGATCCGA

ACTGTCAGCAGTATGGTAGCTCACCGTGG

GGACACGGCCGTGTATTACTGTGCGG

ACGTTCGGCCAAGGGACCAAGGTGGAAAT

CACCTTATTGTAGTGGTGGTAGCTGCT

CAAAC

CTGATGCTTTTGATATCTGGGGCCAAG

GGACAATGGTCACCGTCTCTTCAG

C126
V-C026
CAGGTGCAGCTGCAGGAGTCGGGCCC
283
AATTTTATGCTGACTCAGCCCCACTCTGTG
284

AGGACTGGTGAAGCCTTCGGAGACCC

TCGGAGTCTCCGGGGAAGACGGTAACCAT

TGTCCCTCTCCTGCGCTGTCTCTGGTG

CTCCTGCACCGGCAGCAGTGGCAGCATTG

GCTCCATCGGTAGTTACTTCTGGAGCT

CCAGCAACTATGTGCAGTGGTACCAGCAG

GGATCCGGCAGCCCCCAGGGAAGGGA

CGCCCGGGCAGTGCCCCCACCACTGTGA

CTGGAGTGGATTGGATATCTCCATTAC

TCAATGAAGATAACCAAAGACCCTCTGGG

AGTGGGAGCACCAACTACAACCCCTCC

GTCCCTGATCGGTTCTCTGGCTCCATCGA

CTGAAGAGTCGAGTCACCATATCAGTA

CAGCTCCTCCAACTCTGCCTCCCTCACCA

GACACGTCCAAGAATCAGTTCTCCCTG

TCTCTGGACTGAAGACTGAGGACGAGGCT

AAGCTGAGCTCTGTGACCGCTGCGGA

GACTACTACTGTCAGTCTTATGATAGCAGC

CACGGCCGTGTATTACTGTGCGAGATT

AATTTGGTATTCGGCGGAGGGACCAAGCT

GCAGTGGCTACGCGGAGCTTTTGATAT

GACCGTCCTAG

CTGGGGCCAAGGGACAATGGTCACCG

TCTCTTCAG

C127
V-C027
CAGGTGCAGCTGGTGCAGTCTGGGGC
285
CAGTCTGTGCTGACTCAGCCACCCTCAGC
286

TGAGGTGAAGAAGCCTGGGGCCTCAG

GTCTGGGACCCCCGGGCAGAGGGTCACC

TGAAGGTCTCCTGCAAGGCTTCTGGAT

ATCTCTTGTTCTGGAAGCAGCTCCAACATC

ACACCTTCACCGGCTACTATATGCACT

GGAAGTAATACTGTAAACTGGTACCAGCA

GGGTGCGACAGGCCCCTGGACAAGGG

GCTCCCAGGAACGGCCCCCAAACTCCTCA

CTTGAGTGGATGGGATGGATCAACCCT

TCTATAGTAATAATCAGCGGCCCTCAGGG

AACAGTGGTGGCACAAACTATGCACAG

GTCCCTGACCGATTCTCTGGCTCCAAGTC

AAGTTTCAGGGCAGGGTCACCATGACC

TGGCACCTCAGCCTCCCTGGCCATCAGTG

AGGGACACGTCCATCAGCACAGCCTAC

GGCTCCAGTCTGAGGATGAGGCTGATTAT

ATGGAGCTGAGCAGGCTGAGATCTGA

TACTGTGCAGCATGGGATGACAGCCTGAA

CGACACGGCCGTGTATTACTGTGCGAC

TGGCGTGGTATTCGGCGGAGGGACCAAG

GGCGCACCCCCGGAGGATCCAAGGGG

CTGACCGTCCTAG

TATTTTTTTTGGGGCCGGGCGTCTGGG

GCCAAGGGACCACGGTCACCGTCTCC

TCA

C128
V-C028
GAGGTGCAGCTGTTGGAGTCTGGGGG
287
GAAATTGTGTTGACGCAGTCTCCAGGCAC
288

AGGCTTGGTACAGCCTGGGGGGTCCC

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCACCTTTAGCACCTATGCCATGAGTT

AACAGCAGGCAGTTAGCCTGGTACCAGCA

GGGTCCGCCAGGCTCCAGGGAAGGGG

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

CTGGAGTGGGTCTCAACTATTACTGGT

TCTATGGTGCGTCCAGCAGGGCCACTGGC

AGTGGTCGTGACACATACTACGCAGAC

ATCCCAGAGAGGTTCAGTGGCAGTGGATC

TCCGTGAAGGGCCGGTTCACCATCTCC

TGGGACAGACTTCACTCTCACCATCAGCA

AGAGACAATTCCAAGAACACGCTGTTT

GACTGGAGTCTGAAGATTTTGCAGTGTATC

CTGCAACTGAACAGCCTGAGAGCCGA

ACTGTCAGCAATATGGTAGCTCAAGGGCG

GGACGCGGCCGTGTATTCCTGTGCGA

CTCACTTTCGGCGGAGGGACCAAGGTGGA

ACCACCCTCTGGCATCAGGCGACGACT

GATCAAAC

ACTACCACTACTACATGGACGTCTGGG

GCAAAGGGACCACGGTCACCGTCTCC

TCA

C129
V-C029
CAGGTGCAGCTGGTGGAGTCTGGGGG
289
GACATCCAGATGACCCAGTCTCCATCCTC
290

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCAGGCGAGTCAGGACATT

TCACCTTCAGTAGCTATGGCATGAACT

AGCAACTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCAGTTATATCATAT

CGATGCATCCAATTTGGAAACAGGGGTCC

GATGGAAGTAATACATACTATACAGACT

CATCAAGGTTCAGTGGAAGTGAATCTGGG

CCGTGAAGGGCCGATTCACCATCTCCA

ACAGATTTTACTTTCACCATCAGCAGCCTG

GAGACAATTCCAAGAACACGCTGTATC

CAGCCTGAAGATATTGCAACATATTACTGT

TGCAAATGAACAGCCTGAGAGTTGACG

CAACAGTATGATAATCTCCCGATCACCTTC

ACACGGCTACATATTACTGTGCGAAAG

GGCCAAGGGACACGACTGGAGATTAAAC

GGCCCCGGTTTGGCTGGAGCTATAGA

GGGGGGTCTGGTTTTGATATCTGGGG

CCAAGGGACAATGGTCACCGTCTCTTC

AG

C130
V-C030
CAGGTGCAGCTGGTGCAGTCTGGGGC
291
TCCTATGAGCTGACACAGCCACCCTCAGT
292

TGAGGTGAAGAAGCCTGGGGCCTCAG

GTCAGTGGCCCCAGGAAAGACGGCCAGG

TGAAGGTTTCCTGCAAGGCATCTGGAT

ATTACCTGTGGGGGAAACAACATTGGAAG

ACACCTTCACCAACTACTATATGCACTG

TAAAAGTGTGCACTGGTACCAGCAGAAGC

GGTGCGACAGGCCCCTGGACAAGGGC

CAGGCCAGGCCCCTGTGCTGGTCATCTAT

TTGAGTGGATGGGAATAATCAACCCTA

TATGATAGCGACCGGCCCTCAGGGATCCC

GTGGTGGTAGCACAGGCTACGCACAG

TGAGCGATTCTCTGGCTCCAACTCTGGGA

AAGTTCCAGGGCAGAGTCACCATGACC

ACACGGCCACCCTGACCATCAGCAGGGTC

AGGGACACGTCCACGAGCACAGTCTA

GAAGCCGGGGATGAGGCCGACTATTACTG

CATGGAGCTGAGCAGCCTGAGATCTGA

TCAGGTGTGGGATAGTAGTAGTGATCATC

GGACACGGCCGTGTATTACTGTGCGA

CGGGGGTGGTATTCGGCGGAGGGACCAA

GATCCCGACCGACTCCTGACTGGTACT

GCTGACCGTCCTAG

TCGATCTCTGGGGCCGTGGCACCCTG

GTCACCGTCTCCTCAG

C131
V-C031
CAGGTGCAGCTGGTGCAGTCTGGGTC
293
GAAATAGTGATGACGCAGTCTCCAGCCAC
294

TGAGGTGAAGAAGCCTGGGTCCTCGG

CCTGTCTGTGTCTCCAGGGGAAAGAGCCA

TGAAGGTCTCCTGCAAGGCTTCTGGAG

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

GCACCTTCAGCAGCTATGCTTTCAGCT

AGCAGCAACTTAGCCTGGTACCAGCAGAA

GGGTGCGACAGGCCCCTGGACAAGGG

ACCTGGCCAGGCTCCCAGGCTCCTCATCT

CTTGAGTGGATGGGAAGGATCATCCCT

ATGGTGCATCCACCAGGGCCACTGGTATC

ATCCTTGCTTTAGCAAACTACGCACAG

CCAGCCAGGTTCAGTGGCAGTGGGTCTG

AAGTTCCAGGGCAGAGTCACGATTACC

GGACAGAGTTCACTCTCACCATCAGCAGC

GCGGACAAATCCACGAGCACAGCCTA

CTGCAGTCTGAAGATTTTGCAGTTTATTAC

CATGGAGCTGAGCAGCCTGAGATCTGA

TGTCAGCAGTATAATAACTGGCCGATCAC

GGACACGGCCGTGTATTACTGTGCGA

CTTCGGCCAAGGGACACGACTGGAGATTA

GAGTCAATCAAGCAGTAACTACTCCCT

AAC

TCTCCATGGACGTCTGGGGCCAAGGG

ACCACGGTCACCGTCTCCTCA

C132
V-C032
CAGGTGCAGCTGCAGGAGTCGGGCCC
295
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
296

AGGACTGGTGAAGCCTTCGGGGACCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGTCCCTCACCTGCGCTGTCTCTGGTG

TCTCCTGCACTGGAACCAGCAGTGACGTT

GCTCCATCAGCAGTAATAACTGGTGGA

GGTGGTTATAACTATGTCTCCTGGTACCAA

GTTGTGTCCGCCAGCCCCCAGGGAAG

CAACACCCAGGCAAAGCCCCCAAACTCAT

GGGCTGGAGTGGATTGGGGAAATCTAT

GATTTATGATGTCAGTAATCGGCCCTCAG

CATAGTGGGAGCACCAACTACAACCCG

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

TCCCTCAAGAGTCGAGTCACCATATCA

CTGGCAACACGGCCTCCCTGACCATCTCT

GTAGACAAGTCCAAGAACCAGTTCTCC

GGGCTCCAGGCTGAGGACGAGGCTGATT

CTGAAGCTGAGCTCTGTGACCGCCGC

ATTACTGCAGCTCATATACAAGCAGCAGCA

GGACACGGCCGTGTATTACTGTGCGA

CTCTTTTGTTCGGCGGAGGGACCAAGCTG

GAGGGGGGGATACAGCTATGGGCCCC

ACCGTCCTAG

GAATACTTTGACTACTGGGGCCAGGGA

ACCCTGGTCACCGTCTCCTCAG

C133
V-C033
CAGGTGCAGCTGGTGGAGTCTGGGGG
297
GACATCCAGATGACCCAGTCTCCATCCTC
298

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTCAGTAGCTATGCTATGCACT

AGCAGCTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCAGTTATATTATAT

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

GATGGAAGCAATAAATACTACGCAGAC

CATCAAGGTTCAGTGGCAGTGGATCTGGG

TCCGTGAAGGGCCGATTCACCATCTCC

ACAGATTTCACTCTCACCATCAGCAGTCTG

AGAGACAATTCCAAGAACACGCTGTAT

CAACCTGAAGATTTTGCAACTTACTACTGT

CTGCAAATGAACAGCCTGAGAGCTGAG

CAACAGAGTTACAGTACCCCTCCGTGGAC

GACACGGCTGTGTATTACTGTGCGAGA

GTTCGGCCAAGGGACCAAGGTGGAAATCA

GATTCGGACGTAGATACATCTATGGTT

AAC

ACTTGGTTCGACTACTGGGGCCAGGG

AACCCTGGTCACCGTCTCCTCAG

C134
V-C034
GAGGTGCAGCTGTTGGAGTCTGGGGG
299
TCCTATGAGCTGACACAGCCACCCTCAGT
300

AGGCTTGGTACAGCCTGGGGGGTCCC

GTCAGTGGCCCCAGGAAAGACGGCCAGG

TGAGACTCTCCTGTGCAGCCTCTGGAT

ATTACCTGTGGGGGAAACAACATTGGAAG

TCACCTTTAGCAACTATGCCATGAGCT

TAAAAGTGTGCACTGGTACCAGCAGAAGC

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAGGCCAGGCCCCTGTGCTGGTCATCTAT

CTGGAGTGGGTCTCAGCTATTAGTGGT

TATGATAGCGACCGGCCCTCAGGGATCCC

AGTGATGGTAGCACATACTACGCAGGC

TGAGCGATTCTCTGGCTCCAACTCTGGGA

TCCGTGAAGGGCCGGTTCACCATCTCC

ACACGGCCACCCTGACCATCAGCAGGGTC

AGAGACAATTCCAAGAACACACTGTAT

GAAGCCGGGGATGAGGCCGAATATCACTG

CTGCAAATGAACAGCCTGAGAGCCGA

TCAGGTGTGGGATAGTAGTAGTGATCGTC

GGACACGGCCGTATATTACTGTGCGAA

CGGGGGTGGTTTTCGGCGGAGGGACCAA

AGATCCCCTTATAACTGGACCTACCTAT

GCTGACCGTCCTAG

CAATACTTTCACTACTGGGGCCAGGGA

ACCCTGGTCACCGTCTCCTCAG

C135
V-C035
CAGGTGCAGCTGGTGGAGTCTGGGGG
301
GACATCCAGATGACCCAGTCTCCTTCCAC
302

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCCAGTCAGAGTATT

TCACCTTCAGTAGCTATGCTATGCACT

AGTAACTGGTTGGCCTGGTTTCAGCAGAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

ACCAGGGAAAGCCCCTAAGCTCCTGATCT

CTGGAGTGGGTGGCAGTTATACCATTT

ATGAGGCGTCTAGTTTAGAAAGTGGGGTC

GATGGAAGAAATAAGTACTACGCAGAC

CCATCAAGGTTCAGCGGCAGTGGATCTGG

TCCGTGACGGGCCGATTCACCATCTCC

GACAGAATTCACTCTCACCATCAGCAGCC

AGAGACAATTCCAAGAACACACTGTAT

TGCAGCCTGATGATTTTGCAACTTATTACT

CTGCAAATGAACAGCCTGAGAGCTGAG

GCCAACAGTATAATAGTTATCCGTGGACGT

GACACGGCTGTGTATTACTGTGCGAGT

TCGGCCAAGGGACCAAGGTGGAGATCAAAC

AGTAGTGGTTATCTTTTCCACTCTGACT

ACTGGGGCCAGGGAACCCTGGTCACC

GTCTCCTCAG

C138
V-C038
GAGGTGCAGCTGGTGGAGTCTGGGGG
303
AATTTTATGCTGACTCAGCCCCACTCTGTG
304

AGGCTTGGTCCAGCCTGGGGGGTCCC

TCGGAGTCTCCGGGGAAGACGGTAACCAT

TGAGACTCTCCTGTGCAGCCTCTGGAT

CTCCTGCACCGGCAGCAGTGGCAGCATTG

TCACCTTTAGTACCTATTGGATGAGCT

CCAGCAACTATGTGCAGTGGTACCAGCAG

GGGTCCGCCAGCCTCCAGGGAAGGGG

CGCCCGGGCAGTGCCCCCACCACTGTGA

CTGGAGTGGGTGGCCAACATAAAGCAA

TCTATGAGGATAACCAAAGACCCTCTGGG

GATGGAAGTGAGAAATACTATGTGGAT

GTCCCTGATCGGTTCTCTGGCTCCATCGA

TCTGTGAAGGGCCGATTCACCATCTCC

CAGCTCCTCCAACTCTGCCTCCCTCACCA

AGAGACAACGCCAAGAACTCACTGTAT

TCTCTGGACTGAAGACTGAGGACGAGGCT

CTGCAAATGAACAGCCTGAGAGCCGAC

GACTACTACTGTCAGTCTTATGATAGCAGC

GACACGGCCGTGTATTACTGTGCCGG

AATTGGGTGTTCGGCGGAGGGACCAAGCT

GGGGACATGGCTACGATCCTCTTTTGA

GACCGTCCTA

CTACTGGGGCCAGGGAACCCTGGTCA

CCGTCTCCTCAG

C139
V-C039
GAGGTGCAGCTGGTGGAGTCTGGGGG
305
GACATCCAGATGACCCAGTCTCCATCCTC
306

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCAGGCGAGTCAGGACATT

TCACCTTCAGTAGCTATGCCATGCACT

AGCAACTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCAGTTATATCATAT

CGATGCATCCAATTTGGAAACAGGGGTCC

GATGGAAGTAATAAATACTCTGCAGAC

CATCAAGGTTCAGTGGAAGTGGATCTGGG

TCCGTGAAGGGCCGATTCACCATCTCC

ACAGATTTTACTTTCACCATCAGCAGCCTG

AGAGACAATTCCAAGAACACGCTGTAT

CAGCCTGAAGATATTGCAACATATTACTGT

CTGCAAATGAACAGCCTGAGAGCTGAG

CAACAGTATGATAATCTCCCGCTCACTTTC

GACACGGCTGTGTATTACTGTGCGAAA

GGCGGAGGGACCAAGGTGGAAATCAAAC

GGGGGGGCCTACAGCTACTACTACTAC

ATGGACGTCTGGGGCAAAGGGACCAC

GGTCACCGTCTCCTCA

C140
V-C040
GAGGTGCAGCTGGTGGAGTCTGGGGG
307
GACATCCAGTTGACCCAGTCTCCATCCTTC
308

AGGCTTGGTCCAGCCTGGGGGGTCCC

CTGTCTGCATCTGTAGGAGACAGAGTCAC

TGAGACTCTCCTGTGCAGCCTCTGGAG

CATCACTTGCCGGGCCAGTCAGGGCATTA

TCACCGTCAGTAGCAACTACATGAGCT

GCAGTTATTTAGCCTGGTATCAGCAAAAAC

GGGTCCGCCAGCCTCCAGGGAAGGGG

CAGGGAAAGCCCCTAAGCTCCTGATCTAT

CTGGAGTGGGTCTCACTTATTTATAGC

GCTGCATCCACTTTGCAAAGTGGGGTCCC

GGTGGTAGCACATTCTACGCAGACTCC

ATCAAGGTTCAGCGGCAGTGGATCTGGGA

GTGAAGGGCAGATTCACCATCTCCAGA

CAGAATTCACTCTCACAATCAGCAGCCTG

GACAATTCCGAGAACACGCTGTATCTT

CAGCCTGAAGATTTTGCAACTTATTACTGT

CAAATGAACACCCTGAGAGCCGAGGA

CAACAGCTTAATAGTTACTCTTACACTTTT

CACGGCTGTGTATTACTGTGCGAGAGA

GGCCAGGGGACCAAGCTGGAGATCAAAC

TCTGTATTACTACGGTATGGACGTCTG

GGGCCAAGGGACCACGGTCACCGTCT

CCTCA

C141
V-C041
GAGGTGCAGCTGGTGGAGTCTGGGGG
309
AATTTTATGCTGACTCAGCCCCACTCTGTG
310

AGGCGTGGTCCAGCCTGGGAGGTCCC

TCGGAGTCTCCGGGGAAGACGGTAACCAT

TGAGACTCTCCTGTGCAGCCTCTGGAT

CTCCTGCACCGGCAGCAGTGGCAGCATTG

TCACCTTCAGTAGCTATGCTATGTTCTG

CCAGCAACTATGTGCAGTGGTACCAGCAG

GGTCCGCCAGGCTCCGGGCAAGGGGC

CGCCCGGGCAGTGCCCCCACCACTGTGA

TGGAGTGGGTGGCAGTTATATCATATG

TCTATGAGGATAACCAAAGACCCTCTGGG

ATGGAAGCAATAAATACTACGCAGACT

GTCCCTGATCGGTTCTCTGGCTCCATCGA

CCGTGAAGGGCCGATTCACCATCTCCA

CAGCTCCTCCAACTCTGCCTCCCTCACCA

GAGACAATTCCAAGAACACGCTGTATC

TCTCTGGACTGAAGACTGAGGACGAGGCT

TGCAAATGAACAGCCTGAGAGCTGAGG

GACTACTACTGTCAGTCTTATGATAGCAGC

ACACGGCTGTGTATTACTGTGCGAGGG

AATTGGGTGTTCGGCGGAGGGACCAAGCT

CGGATTTAGGATATTGTACTAATGGTGT

GACCGTCCTAG

ATGCTATGTTGACTACTGGGGCCAGGG

AACCCTGGTCACCGTCTCCTCA

C143
V-C043
GAGGTGCAGCTGGTGGAGTCTGGGGG
311
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
312

AGGCTTGGTCCAGCCGGGGGGGTCCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

TCTCCTGCACTGGAACCAGCAATGATGTT

TCAGTGTCAGCACCAAGTACATGACAT

GGGAGTTATACCCTTGTCTCCTGGTACCA

GGGTCCGTCAGGCTCCAGGGAAGGGG

ACAGTACCCAGGCAAAGCCCCCAAACTCT

CTGGAGTGGGTCTCAGTTCTTTACAGC

TAATTTTTGAGGGCACTAAGCGGTCCTCA

GGTGGTAGTGATTACTACGCAGACTCC

GGGATTTCTAATCGCTTCTCTGGTTCCAAG

GTGAAGGGCAGATTCACCATCTCCAGA

TCTGGCAACACGGCCTCCCTGACAATCTC

GACAATTCCAAGAACGCTTTATATCTTC

TGGGCTCCAGGGTGAAGACGAGGCTGATT

AAATGAACAGCTTGAGAGTCGAGGACA

ATTATTGCTGCTCATATGCAGGTGCTAGCA

CGGGTGTTTATTACTGTGCCAGAGACT

CTTTCGTGTTCGGCGGAGGGACCAAGCTG

CGTCGGAAGTCCGTGACCACCCCGGG

ACCGTCCTAG

CACCCAGGGCGCTCGGTGGGGGCTTT

TGATATCTGGGGCCAAGGGACAATGGT

CACCGTCTCTTCAG

C144
V-C044
GAGGTGCAGCTGGTGGAGTCTGGAGG
313
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
314

AGGCTTGATCCAGCCTGGGGGGTCCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

TCTCCTGCACTGGAACCAGCAGTGACGTT

TCACCGTCAGTAACAACTACATGAGCT

GGTGGTTATAACTATGTCTCCTGGTACCAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAACACCCAGGCAAAGCCCCCAAACTCAT

CTGGAGTGGGTCTCAGTTATTTATAGC

GATTTATGATGTCAGTAATCGGCCCTCAG

GGTGGTAGCACATACTACGCAGACTCC

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

GTGAAGGGCCGATTCACCATCTCCAGA

CTGGCAACACGGCCTCCCTGACCATCTCT

GACAAATCCAAGAACACGCTGTATCTT

GGGCTCCAGGCTGAGGACGAGGCTGATT

CAAATGAACAGGCTGAGAGCCGAGGA

ATTACTGCAGCTCATATACAAGCAGCAGCA

CACGGCCGTGTATTATTGTGCGAGAGA

CTCGAGTCTTCGGAACTGGGACCAAGGTC

AGGGGAGGTAGAAGGGTATAACGATTT

ACCGTCCTAG

TTGGAGTGGTTATTCTAGAGACCGTTA

CTACTTTGACTACTGGGGCCAGGGAAC

CCTGGTCACCGTCTCCTCAG

C145
V-C045
GAGGTGCAGCTGGTGGAGTCTGGAGG
315
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
316

AGGCTTGATCCAGCCTGGGGGGTCCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

TCTCCTGCACTGGAACCAGCAGTGACGTT

TCAGCGTCAGTAGCAACTACATGAGCT

GGTGGTTATAACTATGTCTCCTGGTACCAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAACACCCAGGCAAAGCCCCCAAACTCAT

CTGGAGTGGGTCTCAGTTATTTATAGC

GATTTATGATGTCAGTAATCGGCCCTCAG

GGTGGTAGTACATACTACGCAGACTCC

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

GTGAAGGGCCGATTCACCATCTCCAGA

CTGGCAACACGGCCTCCCTGACCATCTCT

GACAATTCCAAGAACACGCTGTATCTT

GGGCTCCAGGCTGAGGACGAGGCTGATT

CAAATGAACAGCCTGAGAGCCGAGGA

ATTACTGCAGCTCATATACAAGCAGCACCA

CACGGCCGTGTATTACTGTGCGAGAGA

CTCGAGTCTTCGGAACTGGGACCAGGGTC

AGGGGAGGTAGAAGGGTATTACGATTT

ACCGTCCTAG

TTGGAGTGGTTATTCTAGAGACCGTTA

CTACTTTGACTACTGGGGCCAGGGAAC

CCTGGTCACCGTCTCCTCAG

C146
V-C046
GAGGTGCAGCTGGTGGAGTCTGGGGG
317
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
318

AGGCCTGGTCAAGCCTGGGGGGTCCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAGACTCTCCTGTGCAGCCTCTGGAC

TCTCCTGCACTGGAACCAGCAGTGACATT

TCACCTTCACTGCCTATAGAATGAATTG

GGTGTTTATAACTATATCTCCTGGAGCCAA

GGTCCGCCAGGCTCCAGGGAAGGGGC

CAACACCCAGGCAAAGCCCCCAAAGTCAT

TGGAGTGGCTCTCATCAATTAGTAATA

GATTTATGATGTCACTAATCGGCCCTCAGG

CAAATGGCGACATATACTATGCAGACT

GGTTTCTAATCGCTTCTCTGGCTCCAAGTC

CAGTGAAGGGCCGATTCACCATCTCCA

TGGCAACACGGCCTCCCTGACCATCTCTG

GAGACAACGCCAAGAATTCTCTGTATC

GGCTCCAGGCTGAGGACGAGGCTGATTAT

TGCAAATGAACAGCCTGAGGGCCGAC

TATTGCAGCTCATATAGAGGCAGCAGCAC

GACACGGCTGTATATTACTGTGCGAGA

TCCCTATGTCTTCGGAACTGGGACCAAGG

GATGTTGCATCTAACTACGCTTACTTTG

TCACCGTCCTAG

ACCTTTGGGGCCAGGGAACCCTGGTC

ACCGTCTCCTCAG

C147
V-C047
GAGGTGCAGCTGGTGCAGTCTGGAGC
319
CAGGCTGTGGTGACCCAGGAGCCCTCACT
320

AGAGGTGAAAAAGCCCGGGGAGTCTC

GACTGTGTCCCCAGGAGGGACAGTCACTC

TGAAGATCTCCTGTAAGGGTTCTGGAT

TCACCTGTGGCTCCAGCACTGGAGCTGTC

ACAGATTTACCAACTACTGGATCGGCT

ACCAGTGGTCATTATCCCTACTGGTTCCAG

GGGTGCGCCAGATGCCCGGGAAAGGC

CAGAAGTCTGGCCAAGCCCCCAGGACACT

CTGGAGTGGATGGGGATCATCTATCCT

GATTTATGAAACAAGCATCAAACACTCCTG

GGTGACTCTGATACCAGATACAGCCCG

GACCCCTGCCCGGTTCTCAGGCTCCCTCC

TCCTTCCAAGGCCAGGTCACCATCTCA

TTGGGGGCAAAGCTGCCCTGACCCTTTCG

GCCGACAAGTCCATCACCACCGCCTAC

GGTGCGCAGCCTGAGGATGAGGCTGATTA

CTGCAGTGGAGCAGCCTGAAGGCCTC

TTACTGCTTGCTCTCCTATAGTGGTGCTCG

GGACACCGCCATGTATTACTGTGCGAG

GCCGGTGTTCGGCGGAGGGACCAAGCTG

ACTCAGTGACCGCTGGTACAGTCCGTT

ACCGTCCTAG

CGACCCCTGGGGCCAGGGAACCCTGG

TCACCGTCTCCTCAG

C148
V-C048
GAGGTGCAGCTGGTGGAGTCTGGGGG
321
GAAATAGTGATGACGCAGTCTCCAGCCAC
322

AGGCTTGGTCCAGCCTGGGGGGTCCC

CCTGTCTGTGTCTCCAGGGGAAAGAGCCA

AGAGACTCTCCTGTGCAGCCTCTGGAT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCACCGTCAGTAGCAATTACATGAGCT

AGCAGCCACTTAGCCTGGTACCAGCAGAA

GGATCCGCCAGGCTCCAGGGAAGGGG

ACCTGGCCAGGCTCCCAGGCTCCTCATCT

CTGGAGTGGGTCTCAGTTATTTATAGC

ATGGTGCATCCACCAGGGCCACTGGTATC

GGTGGTAGCGCATACTACGTAGACTCC

CCAACCAGGTTCAGTGGCAGTGGGTCTGG

GTGAAGGGCAGATTCACCATCTCCAGA

GACAGAGTTCACTCTCACCATCAGCAGCC

GACAATTCCAAGAACACCCTGTATCTT

TGCAGTCTGAAGATTTTGCAGTTTATTACT

CAAATGAACAGCCTGAGACCCGAGGA

GCCAGCAGTATAATAACTGGCCTCCGCTC

CACGGCTGTGTATTACTGTGCGAGAAT

ACTTTCGGCGGAGGGACCAAGGTGGAGAT

CGCAAACTACATGGACGTCTGGGGCAA

CAAAC

AGGGACCACGGTCACCGTCTCCTCA

C149
V-C049
CAGGTGCAGCTGGTGGAGTCTGGGGG
323
GACATCCAGATGACCCAGTCTCCATCCTC
324

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTCAGTACCTATGGCATGCACT

AGCAGTTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CCAGGGAAAGTCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCCGTTATATCATAT

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

GATGGAAGTAATAAATACTTTGCAGACT

CATCAAGGTTCAGTGGCAGTGGATCTGGG

CCGTGAAGGGCCGATTCACCATCTCCA

ACAGACTTCACTCTCACCATCAGCAGTCTG

GAGACAATTCCAAGAACACGCTTTATC

CAACCTGAAGATTTTGCAACTTACTACTGT

TGCAAATGAACAGCCTGAGACCTGAGG

CAACAGAGTTACAGAACCCCGCTCACTTT

ACACGGCTGTATATTACTGTGCGAAAG

CGGCGGAGGGACCAAGGTGGAGATCAAAC

TGGGGATGGAGTACAGCAGTGGCTGG

TACGGGGAAGAAATTGACTTCTGGGGC

CAGGGAACCCTGGTCACCGTCTCCTCAG

C150
V-C050
GAGGTGCAGCTGGTGGAGTCCGGGGG
325
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
326

AGGCTTAGTTCAGCCTGGGGGGTCCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAGACTCTCCTGTGTAGCCTCTGGAT

TCTCCTGCACTGGAACCAGCAGTGACGTT

TCACCTTCAGTAGCTACTGGATGCACT

GGTTATTATAACTTTGTCTCCTGGTACCAA

GGGTCCGCCAAGTCCCAGGGAAGGGG

CAACACCCAGGCAAAGCCCCCAAACTCAT

CCGGTGTGGGTCTCACATATTAACAGT

GATTTATGAGGTCAGTAATCGGCCCTCTG

GAAGGGAGTAGCACAAACTACGCGGA

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

CTCCGTGAGGGGCCGATTCACCATCTC

CTGGCAACACGGCCTCCCTGATCATCTCT

CAGAGACAACGCCAAGGACACGCTATA

GGGCTCCAGGCTGAGGACGAGGCTGATT

TCTTCAAATGAACAATCTGAGAGCCGA

ATTACTGCAGCTCATATAGAAGCAGCAGC

GGACACGGCTGTATATTACTGTGCAAG

ACTCTGGTGTTCGGCGGGGGGACCAAGC

ACCGACGGCTGTAGCAGCAGCTGGCA

TGACCGTCCTAG

ATTACTTCTACTACTACGGTATGGACGT

CTGGGGCCAAGGGACCACGGTCACCG

TCTCCTCA

C151
V-C051
CAGGTGCAGCTGGTGGAGTCTGGGGG
327
AATTTTATGCTGACTCAGCCCCACTCTGTG
328

AGGCCTGGTCAAGCCTGGGGGGTCCC

TCGGAGTCTCCGGGGAAGACGGTAACCAT

TGAGACTCTCCTGTGCAGCCTCTGGAT

CTCCTGCACCGGCAGCAGTGGCAGCATTG

TCACCTTCAGTAGCTATAACATGAACTG

CCAGCAACTATGTGCAGTGGTACCAGCAG

GGTCCGCCAGGCTCCAGGGAAGGGGC

CGCCCGGGCAGTGCCCCCACCACTGTGA

TGGAGTGGGTCTCATGCATTAGTAGTA

TCTATGAGGATAACCAAAGACCCTCTGGG

GTAGTAGTTACATATACTACGCAGACT

GTCCCTGATCGGTTCTCTGGCTCCATCGA

CAGTGAAGGGCCGATTCACCATCTCCA

CAGCTCCTCCAACTCTGCCTCCCTCACCA

GAGACAACGCCAAGAACTCACTGTATC

TCTCTGGACTGAAGACTGAGGACGAGGCT

TGCAAATGAACAGCCTGAGAGCCGAG

GACTACTACTGTCAGTCTTATGATAGCAGC

GACACGGCTGTGTATTACTGTGCGAGA

AATTATTGGGTGTTCGGCGGAGGGACCAA

GAGAGGGGGTATGACGGTGGTAAAAC

GCTGACCGTCCTAG

CCCCCCATTTCTTGGGGGCCAGGGAA

CCCTGGTCACCGTCTCCTCAG

C152
V-C052
CAGGTTCAGCTGGTGCAGTCTGGAGCT
329
GACATCCAGATGACCCAGTCTCCATCCTC
330

GAGGTGAAGAAGCCTGGGGCCTCAGT

CCTGTCTGCATCTGTAGGAGACAGAGTCA

GAAGGTCTCCTGCAAGGCTTCTGGTTA

CCATCACTTGCCGGGCGAGTCAGGGCATA

CACCTTTACCAGCTACGGTATCAGCTG

AGCAATTACTTAGCCTGGTATCAGCAGAG

GGTGCGACAGGCCCCTGGACAAGGGC

ACCAGGGAAAGTTCCTAAGCTCCTGATCTT

TTGAGTGGATGGGATGGATCAGCGCTT

TGCTGCATCCACTTTGCAATCAGGGGTCC

ACAATGGTAACACAAACTATGCACAGA

CATCTCGGTTCAGTGGCAGTGGATCTGGG

AGCTCCAGGGCAGAGTCACCATGACC

ACAGATTTCACTCTCACCATCAGCAGCCTG

ACAGACACATCCACGAGCACAGCCTAC

CAGCCTGAAGATGTTGCAACTTATTACTGT

ATGGAGCTGAGGAGCCTGAGATCTGA

CAAAAGTATAACAGTGCCCCTCGGACGTT

CGACACGGCCGTGTTTTACTGTGCGAG

CGGCCAAGGGACCAAGGTGGAAATCAAAC

AGATCGGGGGGGGCACGATTTTTGGA

GTGGTTATGGGTTCTACTACTACTACG

GTATGGACGTCTGGGGCCAAGGGACC

ACGGTCACCGTCTCCTCA

C153
V-C053
GAGGTGCAGCTGGTGGAGTCTGGAGG
331
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
332

AGGCTTGATCCAGCCTGGGGGGTCCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

TCTCCTGCACTGGAACCAGCAGTGATGTT

TCACCGTCAGTAGCAACTACATGAGCT

GGGAGTTATAACCTTGTCTCCTGGTACCAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAGCACCCAGGCAAAGCCCCCAAACTCAT

CTGGAGTGGGTCTCAGTTATTTATAGC

GATTTATGAGGGCAGTAAGCGGCCCTCAG

GGTTATAGCACATACTACGTAGACTCC

GGGTTTCTAATCGCTTCTCTGGCTCCAAGT

GTGAAGGGCCGATTCACCATCTCCAGA

CTGGCAACACGGCCTCCCTGACAATCTCT

GACAATTCCAAGAACACGCTGTATCTT

GGGCTCCAGGCTGAGGACGAGGCTGATT

CAAATGAACAGCCTGAGAGCCGAGGA

ATTACTGCTGCTCATATGCAGGTAGTAGCA

CACGGCCGTGTATTACTGTGCGAGAGT

CTTGGGTGTTCGGCGGAGGGACCAAGCT

GGGGGGAGCACATAGTGGCTACGACG

GACCGTCCTAG

GATCCTTTGACTACTGGGGCCAGGGAA

CCCTGGTCACCGTCTCCTCAG

C154
V-C054
CAGGTGCAGCTGGTGGAGTCTGGGGG
333
GACATCCAGATGACCCAGTCTCCATCCTC
334

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCAGGCGAGTCAGGGCATT

TCACCTTCAGTCGCTATGGCATGCACT

AGCAACTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCAGTTATGTCATAT

CGATGCATCCAATTTGGAAACAGGGGTCC

GATGGAAGTAGTAAATACTATGCAGAC

CATCAAGGTTCAGTGGAAGTGGATCTGGG

TCCGTGAAGGGCCGATTCACCATCTCC

ACAGATTTTACTTTCACCATCAGCAGCCTG

AGAGACAATTCCAAGAACACGCTGTGT

CAGCCTGAAGATATTGCAACATATTACTGT

CTGCAAATGAACAGCCTGAGAGCTGAG

CAACAGTATGATAATCTCCCGATCACCTTC

GACACGGCTGTGTATTACTGTGCGAAA

GGCCAAGGGACACGACTGGAGATTAAAC

CAGGCGGGCCCATATTGTAGTGGTGG

TAGCTGCTACTCCGCGCCCTTTGACTA

CTGGGGCCAGGGAACCCTGGTCACCG

TCTCCTCAG

C155
V-C055
GAGGTGCAGCTGGTGGAGTCTGGAGG
335
GAAATAGTGATGACGCAGTCTCCAGCCAC
336

AGGCTTGATCCAGCCTGGGGGGTCCC

CCTGTCTGTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGGGT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCATCGTCAGTAGCAACTACATGAGCT

AGCAGCAACTTAGCCTGGTACCAGCAGAA

GGGTCCGCCAGGCTCCAGGGAAGGGC

ACCTGGCCAGGCTCCCAGGCTCCTCATCT

CTGGAGTGGGTCTCAGTTATTTATAGC

ATGGTGCATCCACCAGGGCCACTGCTATC

GGTGGTAGCACATTCTACGCAGACTCC

CCAGCCAGGTTCAGTGGCAGTGGGTCTG

GTGAAGGGCCGATTCACCATCTCCAGA

GGACAGAGTTCACTCTCACCATCAGCAGC

GACAATTCCAAGAACACGCTGTATCTT

CTGCAGTCTGAAGATTTTGCAGTTTATTAC

CAAATGAACAGCCTGAGAGCCGAGGA

TGTCAGCAGTATAATAACTGGCCTCGGAC

CACGGCCGTGTATTACTGTGCGAGAGA

GTTCGGCCAAGGGACCAAGGTGGAGATCA

TTTTGGAGAGTTCTACTTTGACTACTGG

AAC

GGCCAGGGAACCCTGGTCACCGTCTC

CTCAG

C156
V-C056
CAGGTGCAGCTGGTGGAGTCTGGGGG
337
TCCTATGAGCTGACTCAGCCACCCTCGGT
338

AGGCGTGGTCCAGCCTGGGAGGTCCC

GTCAGTGGCCCCAGGACAGACGGCCAGG

TGAGACTCTCCTGTGCAGCCTCTGGAT

ATTTCCTGTGGGGGAAACAACATTGGAAG

TCACCTTCAGTAACTATGGCATGCACT

TAAAAATGTGCACTGGTACCAGCAGAAGC

GGGTCCGCCAGGCTCCAGGCAAGGGG

CAGGCCAGGCCCCTGTGCTGGTCGTCTAT

CTGGAGTGGGTGGCAGTTATATCATAT

GATGATAGCGACCGGCCCTCAGGGATCCC

GATGGAAATAATAAATACTATGCAGACT

TGAGCGATTCTCTGGCTCCAACTCTGGGA

CCGTGAAGGGCCGATTCACCATCTCCA

ACACGGCCACCCTGACCATCAGCAGGGTC

GAGACAATTCCAAGAACACGCTGTATC

GAAGCCGGGGATGAGGCCGACTATTACTG

TGCAAATGAACAGCCTGAGAGCTGAGG

TCAGGTGTGGGATAGTAGTAGTGATCCTT

ACACGGCTGTGTATTACTGTGCGAAAG

GGGTGTTCGGCGGAGGGACCAAGCTGAC

ATCCTTTCCCCTTAGCAGTGGCTGGGA

CGTCCTAG

CGGGCTACTTTGACTACTGGGGCCAG

GGAACCCTGGTCACCGTCTCCTCAG

C160
V-C060
CAGGTTCAGCTGGTGCAGTCTGGAGCT
339
TCCTATGAGCTGACACAGCCACCCTCGGT
340

GAGGTGAAGAAGCCTGGGGCCTCAGT

GTCAGTGTCCCCAGGACAGACGGCCAGG

GAAGGTCTCCTGCAAGGCTTCTGGTTA

ATCACCTGCTCTGGAGATGCATTGCCAAA

CACCTTTACCAGCTACGGTATCAGCTG

GCAATATGCTTATTGGTACCAGCAGAAGC

GGTGCGACAGGCCCCTGGACAAGGGC

CAGGCCAGGCCCCTGTGCTGGTGATATAT

TTGAGTGGATGGGATGGATCAGCGCTT

AAAGACAGTGAGAGGCCCTCAGGGATCCC

ACAATGGTAACACAAACTATGCACAGA

TGAGCGATTCTCTGGCTCCAGCTCAGGGA

AGCTCCAGGGCAGAGTCACCATGACC

CAACAGTCACGTTGACCATCAGTGGAGTC

ACAGACACATCCACGAGCACAGCCTAC

CAGGCAGAAGACGAGGCTGACTATTACTG

ATGGAGCTGAGGAGCCTGAGATCTGA

TCAATCAGCAGACAGCAGTGGTACTCTTT

CGACACGGCCGTGTATTACTGTGCGAG

GGGTGTTCGGCGGAGGGACCAAGCTGAC

AGTTCCCGCCTCGTACGGTGACGACG

CGTCCTAG

ATTACTACTACTACTACGGTATGGACGT

CTGGGGCCAAGGGACCACGGTCACCG

TCTCCTCA

C161
V-C061
CAGGTGCAGCTACAGCAGTGGGGCGC
341
GAAATTGTGTTGACGCAGTCTCCAGGCAC
342

AGGACTGTTGAAGCCTTCGGAGACCCT

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

GTCTCTCACCTGCGCTGTCTCTGGTGG

CCCTCTCCTGCAGGGCCAGTCAGACTCTT

GTCACTCAGTGGTTTCTACTGGACCTG

ACCGCCAACTACTTAGCCTGGTACCAGCA

GATCCGCCAGCCCCCCGGAAAGGGGC

GAAACCTGGCCAGGCTCCCAGACTCCTCA

TGGAGTGGATTGGGGAAACCAATCATT

TCTATGGTGCATCCAAGAGGGCCACTGGC

TTGGAAGCACCGACTACAAGCCGTCCC

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

TCAAGAGTCGAGTCACCATATCAGTAG

TGGGACAGACTTCACTCTCAGCATCAGCA

ACATGTCCAGGAACCAATTTTCCCTGA

GACTGGAGCCTGAAGATTTTGCAGTGTATT

TTATGACCTCTGTGACCGCCGCGGACA

ACTGTCAGCAGTATGGTACTACACCTCGG

CGGCTGTGTATTACTGTGCGAGAAAGA

ACTTTCGGCGGAGGGACCAAGGTGGAAAT

CCCTCCTCTTCAGTGACTTTTCTCCTG

CAA

GTGCTTTTGATATCTGGGGCCAAGGGA

CAATGGTCACCGTCTCTTCAG

C162
V-C062
CAGGTGCAGCTACAGCAGTGGGGCGC
343
GAAATTGTGTTGACGCAGTCTCCAGGCAC
344

AGGACTGTTGAAGCCTTCGGAGACCCT

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

GTCCCTCACCTGCGCTGTCTCTGGTGG

CCCTCTCCTGCAGGGCCAGTCAGACTCTT

GTCACTCAGTGGTTTCTACTGGACCTG

ACCGCCAACTACTTAGCCTGGTACCAGCA

GATCCGCCAGCCCCCAGGAAAGGGGC

GAAACCTGGCCAGGCTCCCAGACTCCTCA

TGGAGTGGATTGGGGAAACCAATCATT

TCTATGGTGCATCCAAGAGGGCCGCTGGC

TTGGAAGCACCGACTACAAGGCGTCCC

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

TCAAGAGTCGAGTCACCATATCAGTAG

TGGGACAGACTTCACTCTCAGCATCACCA

GCATGTCCAGGAACCAATTTTCCCTGA

GACTGGAGCCTGAAGATTTTGCAGTGTATT

AGGTGACTTCTCTGACCGCCGCGGAC

ACTGTCAGCAGTATCATACTACACCTCGGA

ACGGCTGTGTATTACTGCGCGAGAAAG

CTTTCGGCGGAGGGACCAAGGTGGAGAT

CCCCTCCTCTACAGTGACTTTTCTCCT

CAA

GGTGCTTTTGATGTCTGGGGCCAAGG

GACAATGGTCACCGTCTCTTCAG

C163
V-C063
CAGGTGCAGCTACAGCAGTGGGGCGC
345
GAAATTGTGTTGACGCAGTCTCCAGGCAC
346

AGGACTGTTGAAGCCTTCGGAGACCCT

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

GTCCCTCACCTGCGCTGTCTCTGGTGG

CCCTCTCCTGCAGGGCCAGTCAGACTGTT

GTCACTCAGTGGTTTCTACTGGACCTG

TCCGCCAACTACTTAGCCTGGTACCAGCA

GATCCGCCAGCCCCCAGGAAAGGGGC

GAAAGCTGGCCAGGCTCCCAGACTCCTCA

TGGAGTGGATTGGGGAAACCAATCATT

TCTATGGTGCATCCAAGAGGGCCACTGGC

TTGGAAGCACCGACTACAAGCCGTCCC

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

TCAAGAGTCGAGTCACCATATCAGTAG

TGGGACAGACTTCACTCTCAGCATCAGCA

ACATGTCCAGGAACCAGTTCTCCCTGA

GACTGGAGCCTGAAGATTTTGCTGTGTATT

AGGTGACCTCTGTGACCGCCGCGGAC

ACTGTCAGCAGTATGTTACTACACCTCGGA

ACGGCTGTTTATTACTGTGCGAGAAAG

CTTTCGGCGGAGGGACCAAGGTGGAAATC

CCCCTCCTCCACAGTGACTTATCTCCT

AA

GGTGCTTTTGATATCTGGGGCCAAGGG

ACAATGGTCACCGTCTCTTCAG

C164
V-C064
GAGGTGCAGCTGGTGGAGTCTGGGGG
347
CAGTCTGCCCTGACTCAGCCTGCCTCCGT
348

AGGCTTGGTCCAGCCGGGGGGGTCCC

GTCTGGGTCTCCTGGACAGTCGATCACCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

TCTCCTGCACTGGAACCAGCAATGATGTT

TCAGTGTCAGCACCAAGTACATGACAT

GGGAGTTATACCCTTGTCTCCTGGTACCA

GGGTCCGTCAGGCTCCAGGGAAGGGG

ACAGTACCCAGGCAAAGCCCCCAAGCTCT

CTGGAGTGGGTCTCAGTTCTTTACAGC

TAATTTTTGAGGTCACTAAGCGGTCCTCAG

GGTGGTAGTGATTACTACGCAGACTCC

GGATTTCTAATCGCTTCTCTGGTTCCAAGT

GTGAAGGGCAGATTCACCATCTCCAGA

CTGGCAACACGGCCTCCCTGACAATCTCT

GACAATTCCAAGAACGCTTTATATCTTC

GGGCTCCAGGGTGAAGACGAGGCTGATTA

AAATGAACAGCTTGAGAGTCGAGGACA

TTATTGCTGCTCATATGCAGGTGCTAGCAC

CGGGTGTTTATTACTGTGCCAGAGACT

TTTCGTGTTCGGCGGAGGGACCAAGCTGA

CGTCGGAAGTCCGTGACCACCCCGGG

CCGTCCTAG

CACCCAGGGCGCTCGGTGGGGGCTTT

TGATATCTGGGGCCAAGGGACAATGGT

CACCGTCTCTTCAG

C165
V-C065
CAGGTGCAGCTGGTGCAGTCTGGGGC
349
GAAATTGTGTTGACGCAGTCTCCAGGCAC
350

TGAGGTGAAGAAGCCTGGGTCGTCGG

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAAGGTCTCCTGCAAGGCTTCTGGAG

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

GCACCTTCAGTAGCTATGCTATCAACT

AGCAGCACCTACTTAGCCTGGTACCAGCA

GGGTGCGACAGGCCCCTGGACAAGGG

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

CTTGAGTGGATGGGAAGGATCATCCCT

TCTATGGTGCATCCAGCAGGGCCACTGGC

ATCGTTGGTATAGCAAACTACGCACAG

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

AAGTTCCAGGGCAGAGTCACGATTACG

TGGGACAGACTTCACTCTCACCATCAGCA

GCGGACAAATCCTCGAGCACAGCCTAC

GACTGGAGCCTGAAGATTTTGCAGTGTATT

ATGGAGCTGAGCAGCCTGAGATCTGA

ACTGTCAGCAGTATGGTAGCTCACCGTGG

GGACACGGCCGTGTATTACTGTGCGA

ACGTTCGGCCAAGGGACCAAGGTGGAAAT

GAGATCTCCTGGACCCCCAGCTAGATG

CAAAC

ATGCTTTTGATATCTGGGGCCAAGGGA

CAATGGTCACCGTCTCTTCAG

C201
M-C001
GAAGTGCAGCTGGTGGAGTCTGGGGG
351
CATCCGGATGACCCAGTCTCCATCTTCTGT
352

AGGCTTGGTACAGCCTGGCAGGTCCC

GTCTGCATCTGTAGGAGACAGAGTCACCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

TCACTTGTCGGGCGAGTCAGGGTATTAGC

TCACCTTTGATGATTATGCCATGCACTG

AGCTGGTTAGCCTGGTATCAGCAGAAACC

GGTCCGGCAAGCTCCAGGGAAGGGCC

AGGGAAAGCCCCTAAGCTCCTGATCTATG

TGGAGTGGGTCTCAGGTATTAGTTGGA

TTGAATCCAGTTTGCAAAGTGGGGTCCCA

ATAGTGGTAGTATAGGCTATGCGGACT

TCAAGGTTCAGCGGCAGTGGATCTGGGAC

CTGTGAAGGGCCGATTCACCATCTCCA

AGATTTCACTCTCACTATCAGCAGCCTGCA

GAGACAACGCCAAGAACTCCCTGTATC

GCCTGAAGATTTTGCAACCTACTATTGTCA

TGCAAATGAACAGTCTGAGAGCTGAGG

ACAGGCTAACAGTTTCCCTCTCACTTTCGG

AC

CGGAGGGACCAAGGTGGAAATCAAAC

ACGGCCTTGTATTACTGTGTAAAAGGG

GTCGAGTATAGCAGCTCGAGCAACTTT

GACTACTGGGGCCAGGGAACCCTGGT

CACCGTCTCCTCAG

C202
M-C002
GAGGTGCAGCTGGTGGAGTCTGGGGG
353
GACATCCAGTTGACCCAGTCTCCATCCTC
354

AGGCTTGGTCCAGCCTGGGGGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TAAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCAGGCGAGTCAGGACATT

TCACCGTCAGTAGCAACTACATGAGCT

AGCAACTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTCTCACTTATTTATAGC

CGATGCATCCAATTTGGAAACAGGGGTCC

GGTGGTAGCACATACTACGCAGACTCC

CATCAAGGTTCAGTGGAAGTGGATCTGGG

GTGAAGGGCCGATTCACCATCTCCAGA

ACAGATTTTACTTTCACCATCAGCAGCCTG

GACAATTCCAAGAACACGCTGTATCTT

CAGCCTGAAGATATTGCAACATATTACTGT

CAAATGAACAGCCTGAGAGCTGAGGAC

CAACAGTATGATAATCTCCCTCGGAGTTTT

ACGGCTGTGTATTACTGTGCGAGAGAT

GGCCAGGGGACCAAGCTGGAGATCAAAC

ACCCTTGGTAGGGGGGGCGACTACTG

GGGCCAGGGAACCCTGGTCACCGTCT

CCTCAG

C204
M-C004
GAGGTGCAGCTGTTGGAGTCTGGGGG
355
GACATCCAGTTGACCCAGTCTCCATCCTC
356

AGGCTTGGAACAGCCTGGGGGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACTTTTAGCACCTATGCCATGAGCT

AGCAGCTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTCTCAGCTATTAGTGGT

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

AGTGGTGCTGGCACATTCTACGCAGAC

CATCAAGGTTCAGTGGCAGTGGATCTGGG

TCCGTGAAGGGCCGGTTCACCATCTCC

ACAGATTTCACTCTCACCATCAGCAGTCTG

AGAGACAATTCCAAGAACACGCTGTAT

CAACCTGAAGATTTTGCAACTTACTACTGT

CTGCAAATGAACAGCCTGAGAGCCGA

CAACAGAGTTACAGTACCCCTCCGTGGAC

GGACACGGCCGTATATTACTGTGCGAG

GTTCGGCCAGGGGACCAAGGTGGAAATCA

AGAGAGCGATTGTGGTAGTACCAGCTG

AAC

CTATCAAGTCGGGTGGTTCGACCCCTG

GGGCCAGGGAACCCTGGTCACCGTCT

CCTCAG

C205
M-C005
CAGGTGCAGCTGGTGCAGTCTGGGGC
357
GAAATTGTGTTGACGCAGTCTCCAGGCAC
358

TGAGGTGAAGAAGCCTGGGGCCTCAG

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAAGGTTTCCTGCAAGGCATCTGGAC

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

ACACCTTCACCAGCTACTATATGCACT

AGCAGCAGCTACTTAGCCTGGTACCAGCA

GGGTGCGACAGGCCCCTGGACAAGGG

GAAACCTGGCCAGGCTCCCAGGCTCCTCA

CTTGAGTGGATGGGAATCATCAACCCT

TCTATGGTGCATCCAGCAGGGCCACTGGC

AGTGGTGGTAGCACAAGCTACGCACA

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

GAAGTTCCAGGGCAGAGTCACCATGAC

TGGGACAGACTTCACTCTCACCATCAGCA

CAGGGACACGTCCACGAGCACAGTCT

GACTGGAGCCTGAAGATTTTGCAGTGTATT

ACATGGAGCTGAGCAGCCTGAGATCTG

ACTGTCAGCAGTATGTTAGCTCACCGTGG

AGGACACGGCTGTGTATTACTGTGCTA

ACGTTCGGCCAAGGGACCAAGGTGGAGAT

GGGGGCCGGAACGGGGTATAGTGGGA

CAAAC

GCTACTGACTACTTTGACTACTGGGGC

CAGGGAACCCTGGTCACCGTCTCCTCAG

C207
M-C007
GAGGTGCAGCTGTTGGAGTCTGGGGG
359
GAAATTGTGTTGACACAGTCTCCAGCCAC
360

AGGCTTGGTACAGCCTGGGGGGTCCC

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCACCTTTAGCAGCTATGCCATGAGCT

AGCAGCTACTTAGCCTGGTACCAACAGAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

ACCTGGCCAGGCTCCCAGGCTCCTCATCT

CTGGAGTGGGTCTCAGCTATTAGTGGT

ATGATGCATCCAACAGGGCCACTGGCATC

AGTGGTGGTAGCACATACTACGCAGAC

CCAGCCAGGTTCAGTGGCAGTGGGTCTG

TCCGTGAAGGGCCGGTTCACCATCTCC

GGACAGACTTCACTCTCACCATCAGCAGC

AGAGACAATTCCAAGAACACGCTGTAT

CTAGAGCCTGAAGATTTTGCAGTTTATTAC

CTGCAAATGAACAGCCTGAGAGCCGA

TGTCAGCAGCGTAGCAACTGGCCCCGGG

GGACACGGCCGTATATTACTGTGCGAA

GGTTCGGCCAAGGGACCAAGGTGGAGAT

AGAACCCATCGGCCAGCCACTGCTATG

CAAAC

GTGGGACTACTGGGGCCAGGGAACCC

TGGTCACCGTCTCCTCAG

C208
M-C008
GAGGTGCAGCTGGTGCAGTCTGGAGC
361
GAAATTGTGTTGACGCAGTCTCCAGGCAC
362

AGAGGTGAAAAAGCCCGGGGAGTCTC

CCTGTCTTTGTCTCCAGGGGAAAGAGCCA

TGAAGATCTCCTGTAAGGGTTCTGGAT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

ACAGCTTTACCAGCTACTGGATCGGCT

AGCGGCAGCTACTTAGCCTGGTACCAGCA

GGGTGCGCCAGATGCCCGGGAAAGGC

GAGACCTGGCCAGGCTCCCAGGCTCCTCA

CTGGAGTGGATGGGGATCATCTATCCT

TCTATGGTGCTTCCAGCAGGGCCACTGGC

GGTGACTCTGATACCAGATACAGCCCG

ATCCCAGACAGGTTCAGTGGCAGTGGGTC

TCCTTCCAAGGCCAGGTCACCATCTCA

TGGGACAGACTTCACTCTCACCATCAGCA

GCCGACAAGTCCATCAGCACCGCCTAC

GACTGGAGCCTGAAGATTTTGCAGTGTATT

CTGAAGTGGAGCAGCCTGAAGGCCTC

ACTGTCAGCAGTATGGTAGCTCGCTCACT

GGACAGCGCCATGTATTACTGTGCGAG

TTCGGCGGGGGGACCAAGGTGGAGATCA

GGGGCCCAACCTCCAGAACTGGTTCG

AAC

ACCCCTGGGGCCAGGGAACCCTGGTC

ACCGTCTCCTCAG

C209
M-C009
CAGGTGCAGCTGGTGCAGTCTGGGGC
363
TCCTATGAGCTGACACAGCCACCCTCGGT
364

TGAGGTGAAGAAGTCTGGGGCCTCAG

GTCAGTGGCCCCAGGAAAGACGGCCAGG

TGAAGGTCTCCTGCAAGGCTTCTGGAT

ATTACCTGTGGGGGAAACAACATTGGAAG

ACACCTTCACCAGTTATGATATCAACTG

CAAAAGTGTGCACTGGTACCAGCAGAAGC

GGTGCGACAGGCCACTGGACAAGGGC

CAGGCCATGCCCCTGTACTGGTCGTCTAT

TTGAGTGGATGGGATGGATGAACCCTA

GATGATAGCGACCGGCCCTCAGGGATCCC

ACAGTGGTAACACAGGCTATGCACAGA

TGAGCGATTCTCTGGCTCCAACTCTGGGA

AGTTCCAGGGCAGAGTCACCATGACCA

ACACGGCCACCCTGACCATCAGCAGGGTC

GGAACACCTCCATAAGCACAGCCTACA

GAAGCCGGGGATGAGGCCGACTATTACTG

TGGANCTGAGCAGCCTGANATCTGANG

TCAGGTGTGGGATAGTACTGGTGGTCATC

ANACGGCCGTGTATTACTGTGCGANAG

CCGATGTGGTGTTCGGCGGAGGGACCAA

GGTTCAGCCTGACTTGGTACTTCGATC

GCTGACCGTCCTAG

TCTGGGGCCGTGGNNCCCTGGTCACC

GNCTCCTCAG

C210
M-C010
GAGGTGCAGCTGGTGGAGTCTGGAGG
365
GACATCCAGTTGACCCAGTCTCCATCCTTC
366

AGGCTTGATCCAGCCTGGGGGGTCCC

CTGTCTGCATCTGTAGGAGACAGAGTCAC

TGAGACTCTCCTGTGCAGCCTCTGGGT

CATCACTTGCCGGGCCAGTCAGGGCATTA

TCACCGTCAGTAGCAACTACATGAGCT

GCAGTTATTTAGCCTGGTATCAGCAAAAAC

GGGTCCGCCAGGCTCCAGGGAAGGGG

CAGGGAAAGCCCCTAAGCTCCTGATCTAT

CTGGAGTGGGTCTCAGTTATTTATAGC

GCTGCATCCACTTTGCAAAGTGGGGTCCC

GGTGGTAGTACATTCTACGCAGACTCC

ATCAAGGTTCAGCGGCAGTGGATCTGGGA

GTGAAGGGCCGATTCACCTTCTCCAGA

CAGAATTCACTCTCACAATCAGCAGCCTG

GACAATTCCAAGAACACGCTGTATCTT

CAGCCTGAAGATTTTGCAACTTATTACTGT

CAAATGAACAGCCTGAGAGCCGAGGA

CAACAGCTTAATAGTTACCCTCAGGGCACT

CACGGCCGTGTATTACTGTGCGAGAGA

TTCGGCGGAGGGACCAAGGTGGAAATCAA

TTTGATGGCCTACGGTATGGACGTCTG

AC

GGGCCAAGGGACCACGGTCACCGTCT

CCTCAG

C211
M-C011
GAGGTGCAGCTGGTGGAGTCTGGGGG
367
GAAATAGTGATGACGCAGTCTCCAGCCAC
368

AGGCTTGGTCCAGCCTGGGGGGTCCC

CCTGTCTGTGTCTCCAGGGGAAAGAGCCA

TGAGACTCTCCTGTGCAGCCTCTGAAT

CCCTCTCCTGCAGGGCCAGTCAGAGTGTT

TCACCGTCAGTAGCAACTACATGAGCT

AGCAGCAACTTAGCCTGGTACCAGCAGAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

ACCTGGCCAGGGTCCCAGGCTCCTCATCT

CTGGAGTGGGTCTCAGTTATTTATAGC

ATGGTGCATCCACCAGGGCCACTGGTATC

GGTGGTAGCACATTCTACGCAGACTCC

CCAGCCAGGTTCAGTGGCAGTGGGTCTG

GTGAAGGGCCGATTCACCATCTCCAGA

GGACAGAGTTCACTCTCACCATCAGCAGC

GACAATTCCAAGAACACGCTGTATCTT

CTGCAGTCTGAAGATTTTGCAGTTTATTAC

CAAATGAACAGCCTGAGACCTGAGGAC

TGTCAGCAGTATAATAACTGGCCCCGGAC

ACGGCTGTGTATTACTGTGCGAGAGAC

GTTCGGCCAAGGGACCAAGGTGGAGATCA

TACGGTGACTTCTACTTTGACTTCTGG

AAC

GGCCAGGGAACCCTGGTCACCGTCTC

CTCAG

C212
M-C012
CAGGTGCAGCTGGTGCAGTCTGGGGC
369
CTGACTCAGCCTGCCTCCGTGTCTGGGTC
370

TGAGGTGAAGAAGCCTGGGGCCTCAG

TCCTGGACAGTCGATCACCATCTCCTGCA

TGAAGGTCTCCTGCAAGGCTTCTGGAT

CTGGAACCAGCAGTGATGTTGGGAGTTAT

ACACCGTCACCGGCTATTATATACACT

AACCTTGTCTCCTGGTACCAACAGCACCC

GGGTGCGACAGGCCCCTGGACAAGGG

AGGCAAAGCCCCCAAACTCATGATTTATGA

CTTGAGTGGATGGGATGGATCAGCCCT

GGACAGTAAGCGGCCCTCAGGGGTTTCTA

AACAGTGGTGGCACAAACTATGCACAG

ATCGCTTCTCTGGCTCCAAGTCTGGCAAC

AAGTTTCAGGGCTGGGTCACCATGACC

ACGGCCTCCCTGACAATCTCTGGGCTCCA

AGGGACATGTCCATCACCACAGCCTAC

GGCTGAGGACGAGGCTGATTATTACTGCT

ATGGAGCTGAGTAGACTGAGATCTGAC

GCTCATATGCAGGTAGTAGCACTCGGCTA

GACACGGCCGTGTATTACTGTGCGAG

TTCGGCGGAGGGACCAAGCTGACCGTCCT

GGAACGATATTTTGACTTGGGTGGTAT

AG

GGACGTCTGGGGCCAAGGGACCACGG

TCACCGTCTCCTCAG

C214
M-C014
CAGGTGCAGCTGGTGGAGTCTGGGGG
371
GACATCCAGTTGACCCAGTCTCCATCCTC
372

AGGCGTGGTCCAGCCTGGGAGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCGTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTCAGTAGCTATGGCATGCACT

AGCAGCTATTTAACTTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGCAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTGGCAGCTATATGGTAT

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

GATGGAAGTAATAAACACTATGCAGAC

CATCAAGGTTCAGTGGCAGTGGATCTGGG

TCCGTGAAGGGCCGATTCACCATCTCC

ACAGATTTCACTCTCACCATCAGCAGTCTG

AGAGACAATTCCAAGAACACGCTGTAT

CAACCTGAAGATTTTGCAACTTACTACTGT

CTGCAAATGAACAGCCTGAGAGCCGA

CAACAGAGTTACAGTACCCCTCCGTGGAC

GGACACGGCTGTGTATTACTGTGCGAG

GTTCGGCCAAGGGACCAAGGTGGAGATCA

AGATGTAGGGCGGGTGACGACCTGGT

AAC

TCGACCCCTGGGGCCAGGGAACCCTG

GTCACCGTCTCCTCAG

C215
M-C015
GAGGTGCAGCTGTTGGAGTCTGGGGG
373
GACATCCAGTTGACCCAGTCTCCATCCTC
374

AGGCTTGGTACAGCCTGGGGGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTTAGCAGCTATGCCATGAGCT

AGCAGCTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAGGCTCCAGGGAAGGGG

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTCTCAGCTATTACTGAT

TGCTGCATCCAGTTTGCAAAGTGGGGTCC

AGTGGTGATGGCACATTCTACGCAGAC

CATCAAGGTTCAGTGGCAGTGGATCTGGG

TCCGTGAAGGGCCGGTTCACCATCTCC

ACAGATTTCACTCTCACCATCAGCAGTCTA

AGAGACAATTCCAAGAACACGCTGTAT

CAACCTGAAGATTTTGCAACTTACTACTGT

CTGCAAATGAACAGCCTGAGAGCCGA

CAACAGAGTTACAGTACCCCTCCGTGGAC

GGACACGGCCGTTTATTACTGTGCGTC

GTTCGGCCAAGGGACCAAGGTGGAAATCA

CGAAGAGGACTACAGTAACTACGTGGG

AAC

GTGGTTCGACCCCTGGGGCCAGGGAA

CCCTGGTCACCGTCTCCTCAG

C216
M-C016
GAGGTGCAGCTGGTGGAGTCTGGGGG
375
GACATCCAGTTGACCCAGTCTCCATCCTC
376

AGGCTTGGTACAGCCTGGGGGGTCCC

CCTGTCTGCATCTGTAGGAGACAGAGTCA

TGAGACTCTCCTGTGCAGCCTCTGGAT

CCATCACTTGCCGGGCAAGTCAGAGCATT

TCACCTTCAGTAGCTACGACATGCACT

AGCAGCTATTTAAATTGGTATCAGCAGAAA

GGGTCCGCCAAGCTACAGGAAAAGGT

CCAGGGAAAGCCCCTAAGCTCCTGATCTA

CTGGAGTGGGTCTCAGCTATTGGTACT

TGTTGCATCCAGTTTGCAAAGTGGGGTCC

GCTGGTGACACATACTATCCAGACTCC

CATCAAGGTTCAGTGGCAGTGGATCTGGG

GTGAAGGGCCGATTCACCATCTCCAGA

ACAGATTTCACTCTCACCATCAGCAGTCTG

GAAAATGCCAAGAACTCCTTGTATCTTC

CAACCTGAAGATTTTGCAACTTACTACTGT

AAATGAACAGCCTGAGAGCCGGGGAC

CAACAGAGTTACAGTACCCCCCCGATCAC

ACGGCTGTGTATTACTGTGCAAGAGAT

CTTCGGCCAAGGGACACGACTGGAGATTA

CGGGGAAGCAGTGGCTGGTACGGCTG

AAC

GTACTTCGATCTCTGGGGCCGTGGCAC

CCTGGTCACCGTCTCCTCAG

TABLE 6

Effective and inhibitory concentrations of the monoclonal antibodies

SARS-
SARS-

CoV-2
CoV

Participant
Antibody
SARS-CoV-2
SARS-CoV-2
SARS-CoV-2
SARS-CoV
RB
RBD

ID
ID
IC50 ng/ml
IC80 ng/ml
IC90 ng/ml
IC50 ng/ml
EC50 ng/ml
EC50 ng/ml

COV21
C002
8.88
21.95
37.61
NT
3.14
>1000

COV21
C003
313.79
992.62
>1000
NT
6.37
>1000

COV21
C004
10.67
41.08
91.71
NT
2.39
>1000

COV21
C005
60.49
130.65
205.20
NT
4.41
>1000

COV21
C006
321.51
>1000
>1000
NT
1.81
>1000

COV21
C008
625.46
>1000
>1000
NT
4.63
>1000

COV21
C009
4.82
14.54
29.34
NT
1.80
>1000

COV21
C010
>1000
>1000
>1000
>1000
5.44
>1000

COV21
C013
42.48
360.59
>1000
NT
2.59
>1000

COV21
C016
>1000
>1000
>1000
NT
7.41
>1000

COV21
C017
72.67
256.18
543.87
NT
1.63
>1000

COV21
C018
>1000
>1000
>1000
NT
1.53
>1000

COV21
C019
>1000
>1000
>1000
NT
11.85
>1000

COV21
C021
>1000
>1000
>1000
NT
1.25
>1000

COV21
C022
73.57
314.71
736.87
168.15
2.40
5.99

COV21
C027
>1000
>1000
>1000
>1000
2.65
696.05

COV21
C029
>1000
>1000
>1000
NT
4.13
>1000

COV21
C030
>1000
>1000
>1000
>1000
2.89
>1000

COV21
C031
>1000
>1000
>1000
NT
22.69
>1000

COV57
C032
>1000
>1000
>1000
NT
99.31
NT

COV57
C036
>1000
>1000
>1000
NT
64.10
NT

COV57
C037
155.78
488.45
>1000
NT
1.93
NT

COV57
C038
>1000
>1000
>1000
NT
4.69
NT

COV57
C040
>1000
>1000
>1000
NT
11.10
NT

COV107
C101
8.20
30.15
65.30
NT
1.51
>1000

COV107
C102
34.03
84.21
143.23
NT
4.54
>1000

COV107
C103
4.38
12.58
23.59
NT
3.77
>1000

COV107
C104
23.31
72.12
140.28
NT
8.31
>1000

COV107
C105
26.09
72.24
133.70
NT
5.20
>1000

COV107
C106
>1000
>1000
>1000
>1000
19.03
106.75

COV107
C107
>1000
>1000
>1000
NT
11.55
>1000

COV107
C108
480.69
>1000
>1000
NT
5.32
>1000

COV107
C110
18.44
45.11
77.28
NT
7.29
>1000

COV107
C112
111.79
701.99
>1000
NT
3.38
>1000

COV107
C113
>1000
>1000
>1000
NT
6.93
>1000

COV107
C114
>1000
>1000
>1000
NT
9.51
>1000

COV107
C115
198.33
958.18
>1000
NT
3.40
>1000

COV107
C116
>1000
>1000
>1000
NT
37.56
>1000

COV107
C117
348.00
>1000
>1000
NT
5.38
>1000

COV107
C118
103.69
417.76
>1000
138.36
3.45
3.82

COV107
C119
9.12
39.45
97.78
NT
3.57
>1000

COV107
C120
13.26
26.73
40.30
NT
1.41
>1000

COV107
C121
6.73
14.31
22.33
NT
2.85
>1000

COV107
C122
22.80
57.77
100.12
NT
2.67
>1000

COV107
C123
149.22
355.47
595.51
NT
1.92
>1000

COV107
C124
341.82
937.26
>1000
NT
2.23
>1000

COV107
C125
43.32
92.54
144.26
NT
1.87
>1000

COV107
C126
>1000
>1000
>1000
NT
4.78
>1000

COV107
C127
68.74
190.96
347.31
NT
2.62
>1000

COV072
C128
101.22
263.35
460.73
NT
1.95
>1000

COV072
C129
10.85
31.48
59.47
NT
1.16
NT

COV072
C130
>1000
>1000
>1000
NT
2.05
>1000

COV072
C131
30.52
178.90
759.11
NT
1.67
>1000

COV072
C132
708.67
>1000
>1000
NT
2.92
>1000

COV072
C133
>1000
>1000
>1000
NT
1.98
>1000

COV072
C134
>1000
>1000
>1000
NT
1.57
>1000

COV072
C135
16.61
32.81
48.90
NT
1.80
>1000

COV072
C138
>1000
>1000
>1000
NT
2.94
>1000

COV072
C139
>1000
>1000
>1000
NT
1.89
>1000

COV072
C140
23.88
66.24
120.69
NT
2.19
>1000

COV072
C141
>1000
>1000
>1000
>1000
1.71
>1000

COV047
C143
>1000
>1000
>1000
NT
3.66
>1000

COV047
C144
6.91
17.28
29.66
NT
3.24
>1000

COV047
C145
3.04
14.51
36.79
NT
3.86
>1000

COV047
C146
>1000
>1000
>1000
NT
>1000
>1000

COV047
C147
>1000
>1000
>1000
NT
>1000
>1000

COV047
C148
>1000
>1000
>1000
NT
64.69
>1000

COV047
C149
45.42
139.99
271.02
NT
1.79
NT

COV047
C150
>1000
>1000
>1000
NT
8.11
>1000

COV047
C151
31.79
363.97
>1000
NT
4.30
>1000

COV047
C152
22.27
122.06
330.67
NT
1.88
NT

COV047
C153
70.71
490.08
>1000
NT
3.17
>1000

COV047
C154
435.50
>1000
>1000
>1000
2.92
10.65

COV047
C155
11.00
35.75
77.01
NT
3.30
>1000

COV047
C156
>1000
>1000
>1000
NT
3.32
>1000

COV047
C160
>1000
>1000
>1000
NT
2.54
NT

COV107
C161
42.32
232.17
581.63
NT
1.63
NT

COV107
C162
14.44
59.81
138.75
NT
1.18
NT

COV107
C163
9.65
29.45
57.97
NT
1.77
NT

COV047
C164
239.15
865.40
>1000
NT
2.06
>1000

COV072
C165
40.81
138.66
297.38
NT
4.25
>1000

COV96
C201
>1000
>1000
>1000
NT
2.98
>1000

COV96
C202
>1000
>1000
>1000
NT
3.40
>1000

COV96
C204
>1000
>1000
>1000
>1000
3.73
9.41

COV96
C205
>1000
>1000
>1000
NT
>1000
>1000

COV96
C207
158.52
960.39
>1000
NT
1.87
>1000

COV96
C208
>1000
>1000
>1000
NT
>1000
>1000

COV96
C209
>1000
>1000
>1000
NT
3.79
>1000

COV96
C210
50.73
155.24
298.90
NT
2.83
>1000

COV96
C211
12.79
34.87
62.89
NT
2.82
>1000

COV96
C212
>1000
>1000
>1000
NT
>1000
>1000

COV96
C214
>1000
>1000
>1000
NT
5.75
>1000

COV96
C215
>1000
>1000
>1000
>1000
5.33
17.94

COV96
C216
>1000
>1000
>1000
NT
9.53
>1000

NT = not tested

TABLE 7

Anti-SARS-CoV-2 IgG antibodies from COV20

SEQ

SEQ

SEQUENCE_ID
ID NOS
aa
ID NOS
cdr3_aa

COVD20_P1_HC_B6-1369
377
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
378
TRDDSS

WMHWVRQAPGKGLVWVSRINSDGSRRAYA

WPHFF

TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV

DN

YYCTRDDSSWPHFFDNWGQGTLVTVSS

COVD20_P1_HC_D9-1369
381
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
382
TRDDSS

WMHWVRQAPGKGLVWVSRISSDGSRRAYAT

WPHFF

SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY

DN

YCTRDDSSWPHFFDNWGQGTLVTVSS

COVD20_P1_HC_D12-1369
385
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
386
TRDDSS

WMHWVRQAPGKGLVWVSRINSDGSRRAYA

WPHFF

TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV

DN

YYCTRDDSSWPHFFDNWGQGTLVTVSS

COVD20_P1_HC_E3-1369
389
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
390
TRDDSS

WMHWVRQAPGKGLVWVSRISSDGSRRAYAT

WPHFF

SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY

DN

YCTRDDSSWPHFFDNWGQGTLVTVSS

COVD20_P1_HC_G12-1369
393
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
394
TRDDSS

WMHWVRQAPGKGLVWVSRINSDGSRRAYA

WPHFF

TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV

DN

YYCTRDDSSWPHFFDNWGQGTLVTVSS

COVD20_P1_HC_H3-1369
397
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
398
TRDDSS

WMHWVRQAPGKGLVWVSRISSDGSRRAYAT

WPHFF

SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY

DN

YCTRDDSSWPHFFDNWGQGTLVTVSS

COVD20_P1_HC_H6-1369
401
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
402
TRDDSS

WMHWVRQAPGKGLVWVSRINSDGSRRAYA

WPHFF

TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV

DN

YFCTRDDSSWPHFFDNWGQGTLVTVSS

COVD20_P1_HC_H7-1369
405
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
406
TRDDSS

WMHWVRQAPGKGLVWVSRINTDGSRRAYA

WPHFF

TSVKGRFTISRDNAKNTVHLQMDSLRDEDTAV

DN

YFCTRDDSSWPHFFDNWGQGTLVTVSS

COVD20_P1_HC_H10-1369
409
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
410
TRDDSS

WMHWVRQAPGKGLVWVSRISSDGSRRAYAT

WPHFF

SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY

DN

YCTRDDSSWPHFFDNWGQGTLVTVSS

COVID020_Plate2_HC_19-
413
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
414
TRDDSS

P1369

WMHWVRQAPGKGLVWVSRINTDGSRRAYA

WPHFF

TSVKGRFTISRDNAKNTVHLQMDSLRDEDTAV

DN

YFCTRDDSSWPHFFDNWGQGTLVTVSS

COVID020_Plate2_HC_24-
417
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
418
TRDDSS

P1369

WMHWVRQAPGKGLVWVSRINSDGSRRAYA

WPHFF

TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV

DN

YYCTRDDSSWPHFFDNWGQGTLVTVSS

COVID020_Plate2_HC_36-
421
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
422
TRDDSS

P1369

WMHWVRQAPGKGLVWVSRISSDGSRRAYAT

WPHFF

SVKGRFTISRDNAKNTLYLQMDSLRDDDTAVY

DN

YCTRDDSSWPHFFDNWGQGTLVTVSS

COVID020_Plate2_HC_71-
425
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
426
TRDDSS

P1369

WMHWVRQAPGKGLVWVSRINSDGSRRAYA

WPHFF

TSVKGRFTISRDNAKNTLYLQMDSLRDEDTAV

DN

YFCTRDDSSWPHFFDNWGQGTLVTVSS

HEAVY

COVD20_P1_HC_F7-1369
429
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNY
430
ARGRG

DMHWVRQVTGEGLEWVSAIGTAGDTYYPGS

HCSSIS

VKGRFTISRENAKNSVFLQMNSLRAGDTAVYY

CLHSW

CARGRGHCSSISCLHSWFDSWGQGTLVTVSS

FDS

COVID020_Plate2_HC_48-
433
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNY
434
ARGRG

P1369

DMHWVRQATGEGLEWVSAIGTAGDTYYPGS

HCSSIS

VKGRFTISRENAKNSVFLQMNSLRAGDTAVYY

CLHSW

CARGRGHCSSISCLHSWFDSWGQGTLVTVSS

FDS

COVID020_Plate2_HC_63-
437
EVQLVESGGGLIQPGGSLRLSCAASGFTFNNY
438
ARGRG

P1369

DIHWVRQATGEGLEWVSAIGTAGDTYYPGSV

HCSSIS

KGRFTISRENAKNSVFLQMNSLRAGDTAVYYC

CLHSW

ARGRGHCSSISCLHSWFDSWGQGTLVTVSS

FDS

COVID020_Plate2_HC_66-
441
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNY
442
ARGRG

P1369

DIHWVRQATGEGLEWVSAIGTAGDTYYPGSV

HCSSIS

KGRFTISRENAKNSVFLQMNSLRAGDTAVYYC

CLHSW

ARGRGHCSSISCLHSWFDSWGQGTLVTVSS

FDS

COVD20_P1_HC_A5-1369
445
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDY
446
AKSGPY

AMHWVRQAPGKGLEWVSGISWNSGSIGYAD

PWAVY

SVKGRFTISRDNAKNSLYLQMNSLRAEDTALYY

YYGMD

CAKSGPYPWAVYYYGMDVWGQGTTVTVSS

V

COVD20_P1_HC_E10-1369
449
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDY
450
AKSGPY

AMHWVRQAPGKGLEWVSGISWNSGSIGYAD

PWAVY

SVKGRFTISRDNAKNSLYLQMNSLRAEDTALYY

YYGMD

CAKSGPYPWAVYYYGMDVWGQGTTVTVSS

V

COVID020_Plate2_HC_79-
453
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDY
454
AKSGPY

P1369

AMHWVRQAPGKGLEWVSGISWNSGSIGYAD

PWAVY

SVKGRFTISRDNAKNSLYLQMNSLRAEDTALYY

YYGMD

CAKSGPYPWAVYYYGMDVWGQGTTVTVSS

V

COVD20_P1_HC_H8-1369
457
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGY
458
ARDLTY

YVHWVRQAPGQGLEWMGWINPNSGGTNYT

GTVFY

QKFQGRVTMTRDRSISTAYMELSGLRSDDTAV

GMDV

YYCARDLTYGTVFYGMDVWGQGTTVTVSS

COVD20_P1_HC_B7-1369
461
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDY
462
ARGKW

YMSWIRQAPGKGLEWVSSISSSGSTIYYADSVK

LRGSFD

GRFTISRDNAKTSLYLQMNSLRAEDTAVYYCA

Y

RGKWLRGSFDYWGQGTLVTVSS

COVID020_Plate2_HC_33-
3186
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDY
466
ARGPSS

P1369

YMSWIRQAPGKGLEWVSYISSSSPYTNYADSV

THESRP

KGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC

RPFDY

ARGPSSTHESRPRPFDYWGQGTLVTVSS

COVID020_Plate2_HC_23-
3187
EVQLVESGGGLVKPGGSLRVSCAASGFTFTNA
470
TTSRG

P1369

WMSWVRQAPGKGLEWVGRIKSKTDGGTTDY

GDWP

AAPVKGRFTISRDDSKNTLYLQMNSLKTEDTA

VTDY

VYYCTTSRGGDWPVTDYWGQGTLVTVSS

COVID020_Plate2_HC_41-
469
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
474
AKDLEY

P1369

MSWVRQAPGKGLEWVSVISGSGGSTYYADSV

YDSSGY

KGRFTISRDNFKNTLYLQMNSLRAEDTAVYYC

PRPSEY

AKDLEYYDSSGYPRPSEYFQHWGQGTLVTVSS

FQH

COVID020_Plate2_HC_16-
3188
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
478
AKGGP

P1369

MSWVRQAPGKGLEWVSGISGSGGSTYYADSV

DYYDSS

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

GYIRSK

AKGGPDYYDSSGYIRSKPEYFQHWGQGTLVTV

PEYFQ

SS

H

COVID020_Plate2_HC_64-
473
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY
482
AKPTH

P1369

GMHWVRQAPGKGLEWVAVILYDGSNKYYAD

PGPSSE

SVKGRFTISRDNAKNTLYLQMNSLRAEDTAVY

YFQH

YCAKPTHPGPSSEYFQHWGQGTLVTVSS

COVD20_P1_HC_E1-1369
477
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY
486
AKPTH

GMHWVRQAPGKGLEWVAVISYDGSNKYYAD

PGPSSE

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY

YFQH

CAKPTHPGPSSEYFQHWGQGTLVTVSS

COVD20_P1_HC_H5-1369
481
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSY
490
AKKGG

GMHWVRQAPGKGLEWVAVISYDGSNKYYAD

LYGDYL

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY

NWFDP

CAKKGGLYGDYLNWFDPWGQGTLVTVSS

COVD20_P1_HC_G1-1369
485
QLQLQESGSGLVKPSQTLSLTCAVXGGSISSGG
3189
ARGPPI

YSWSWIRQPPGKGLEWIGYIYHSGSTYYNPSL

EGWLR

KSRVTISVDRSKNQFSLKLSSVTAADTAVYYCA

LGLGG

RGPPIEGWLRLGLGGGDWYFDLWGRGTLVTV

GDWYF

SS

DL

COVID020_Plate2_HC_83-
489
EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYW
3190
ARHDE

P1369

ISWVRQMPGKGLEWMGRIDPSDYYTNYSPSF

VDTAA

QGHVTISADKSISTAYLQWSSLKASDTAMYYC

GGY

ARHDEVDTAAGGYWGQGTLVTVSS

SEQ

SEQ

SEQUENCE_ID
ID NOS
aa
ID NOS
cdr3_aa

COVD20_P1_K_B6-1389
379
DIQMTQSPSSLSAFVGDRVTITCRASQ
380
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGSGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVD20_P1_K_D9-1389
383
DIQMTQSPSSLSAFVGDRVTITCRASQ
384
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGGGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVD20_P1_K_D12-1389
387
DIQMTQSPSSLSAFVGDRVTITCRASQ
388
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGSGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVD20_P1_K_E3-1389
391
DIQMTQSPSSLSAFVGDRVTITCRASQ
392
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGGGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVD20_P1_K_G12-1389
395
DIQMTQSPSSLSAFVGDRVTITCRASQ
396
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGSGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVD20_P1_K_H3-1389
399
DIQMTQSPSSLSAFVGDRVTITCRASQ
400
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGGGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVD20_P1_K_H6-1389
403
DIQMTQSPSSLSASVGDRVTITCRASQ
404
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGSGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVD20_P1_K_H7-1389
407
DIQMTQSPSSLSASVGDRVTITCRASQ
408
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGSGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVD20_P1_K_H10-1389
411
DIQMTQSPSSLSAFVGDRVTITCRASQ
412
QQ

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGGGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVID020_Plate2_Kappa_19-
415
DIQMTQSPSSLSASVGDRVTITCRASQ
416
QQ

P1389

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGSGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVID020_Plate2_Kappa_24-
419
DIQMTQSPSSLSASVGDRVTITCRASQ
420
QQ

P1389

SVANYLNWYQKKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGSGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVID020_Plate2_Kappa_36-
423
DIQMTQSPSSLSAFVGDRVTITCRASQ
424
QQ

P1389

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGGGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

COVID020_Plate2_Kappa_71-
427
DIQMTQSPSSLSASVGDRVTITCRASQ
428
QQ

P1389

SVANYLNWYQQKPGKAPKLLIYSASSL

SFIT

QSGVPSRFSGSGSGTDFSLTISSLQPED

PW

TATYYCQQSFITPWTFGQGTKVEIK

T

LAMBDA

COVD20_P1_L_F7-1409
431
QSVLTQPPSVSGAPGQRVTISCTGSSS
432
QSY

NIGAGSDVHWYQKLPGIAPKVLIYGYS

DTS

NRPSGVPDRFSGSKSGTSASLAITGLQA

LRV

EDEADYYCQSYDTSLRVVFGGGTKLTV

V

COVID020_Plate2_Lambda_48-
435
QSVLTQPPSVSGAPGQRVTISCTGSSS
436
QSY

P1409

NIGAGSDVHWYQKLPGTAPKVLIYGYS

DTS

NRPSGVPDRFSGSKSGTSASLAITGLQA

LRV

EDEADYYCQSYDTSLRVVFGGGTKLTV

V

COVID020_Plate2_Lambda_63-
439
QSVLTQPPSVSGAPGQRVTISCTGSSS
440
QSY

P1409

NIGAGSDVHWYQKLPGTAPKVLIYGYS

DTS

NRPSGVPDRFSGSKSGTSASLAITGLQA

LRV

EDEADYYCQSYDTSLRVVFGGGTKLTV

V

COVID020_Plate2_Lambda_66-
443
QSVLTQPPSVSGAPGQRVTISCTGSSS
444
QSY

P1409

NIGAGSDVHWYQKLPGTAPKVLIYGY

DTS

NNRPSGVPDRFSGSKSGTSASLAITGL

LRV

QAEDEADYYCQSYDTSLRVVFGGGTKL

V

TV

COVD20_P1_L_A5-1409
447
QSALTQPASVSGSPGQSITISCTGTSSD
448
SSY

VGGYNYVSWYQQHPGKAPKLMIYEVS

TSS

NRPSGVSNRFSGSKSGNTASLTISGLQ

STV

AEDEADYYCSSYTSSSTVFGGGTKLTVL

COVD20_P1_L_E10-1409
451
QSALTQPASVSGSPGQSITISCTGTSSD
452
SSY

VGGYNYVSWYQQHPGKAPKLMIYEVS

TSS

NRPSGVSNRFSGSKSGNTASLTISGLQ

STV

AEDEADYYCSSYTSSSTVFGGGTKLTVL

COVID020_Plate2_Lambda_79-
455
QSALTQPASVSGSPGQSITISCTGTSSD
456
SSY

P1409

VGGYNYVSWYQQHPGKAPKLMIYEVS

TSS

NRPSGVSNRFSGSKSGNTASLTISGLQ

STV

AEDEADYYCSSYTSSSTVFGGGTKLTVL

COVD20_P1_L_H8-1409
459
QSVLTQPPSVSGAPGQRVTISCTGSSS
460
QSY

NIGAGSDVHWYQKLPGTAPKVLIYGYS

DTS

NRPSGVPDRFSGSKSGTSASLAITGLQA

LRV

EDEADYYCQSYDTSLRVVFGGXXQAG

V

PS

KAPPA

COVD20_P1_K_B7-1389
463
EIVLTQSPATLSLSPGERATLSCRASQSV
464
QQ

SSYLAWYQQKPGQAPRLLIYDASNRAT

RSN

GIPARFSGSGSGTDFTLTISSLEPEDFAV

G

YYCQQRSNGFGGGTKVEIK

COVID020_Plate2_Kappa_33-
467
DIMTQSPSTLSASVGDRVTITCRASQ
468
QQ

P1389

SISSWLAWYQQKPGKAPKLLIYKASSLE

YNS

SGVPSRFSGSGSGTEFTLTISSLQPDDF

YSP

ATYYCQQYNSYSPGIFTFGQGTRLEIK

GIF

T

LAMBDA

COVID020_Plate2_Lambda_23-
471
QSVLTQPPSVSEAPRQRVTISCSGSSSN
472
AA

P1409

IGNNAVNWYQQLPGKAPKLLIYYDDLL

WD

PSGVSDRFSGSKSGTSASLAISGLQSED

DSL

EADYYCAAWDDSLNVWVFGGGTKLT

NV

VL

WV

COVID020_Plate2_Lambda_41-
475
QSVLTQPPSVSGAPGQRVTISCTGSSS
476
QSY

P1409

NIGAGYDVHWYQQLPGTAPKLLIYGN

DSS

SNRPSGVPDRFSGSKSGTSASLAITGLQ

LSG

AEDEADYYCQSYDSSLSGYVFGTGTKV

YV

TVL

COVID020_Plate2_Lambda_16-
479
QSVLTQPPSVSGAPGQRVTISCTGSSS
480
QSY

P1409

NIGAGYDVHWYQQLPGTAPKLLIYGN

DSS

SNRPSGVPDRFSGSKSGTSASLAITGLQ

LSV

AEDEADYYCQSYDSSLSVVFGGGTKLT

V

VL

KAPPA

COVID020_Plate2_Kappa_64-
483
AIQLTQSPSSLSASVGDRVTITCRASQG
484
QQ

P1389

ISSALAWYQQKPGKAPKLLIYDASSLES

FNS

GVPSRFSGSGSGTDFTLTISSLQPEDFA

YPL

TYYCQQFNSYPLTFGGGTKVEIK

T

COVD20_P1_K_E1-1389
487
AIQLTQSPSSLSAFVGDRVTITCRASQG
488
QQ

ISSALAWYQQKPGKAPKLLIYDASSLES

FNY

GVPSRFSGSGSGTDFTLTISSLQPEDFA

YPL

TYYCQQFNYYPLTFGGGTKVEIK

T

COVD20_P1_K_H5-1389
491
DIQMTQSPSSLSASVGDRVTITCQASQ
492
QQ

DISNYLNWYQQKPGKAPKLLIYDASNL

YD

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

NLP

ATYYCQQYDNLPLTFGGGTKVEIK

LT

LAMBDA

COVD20_P1_L_G1-1409
495
QSALTQPASVSGSPGQSITISCTGTSSD
496
SSY

VGGYNYVSWYQQHPGKAPKLMIYDV

TSS

SNRPSGVSNRFSGSKSGNTASLTISGLQ

STV

AEDEADYYCSSYTSSSTVVFGGGTKLTV

v

L

COVID020_Plate2_Lambda_83-
499
QSALTQPASVSGSPGQSITISCTGTSSD
500
SSY

P1409

VGGYNYVSWYQQHPGKAPKLMIYEVS

TSS

NRPSGVSNRFSGSKSGNTASLTISGLQ

SSY

AEDEADYYCSSYTSSSSYVFGTGTKVTV

V

L

TABLE 8

Anti-SARS-CoV-2 IgG antibodies from COV21

SEQ

SEQ

ID

ID

SEQUENCE_ID
NOS
aa
NOS
cdr3_aa

HEAVY

COVD21_P2_HC_A4-
501
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
502
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P2_HC_B5-
505
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
506
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P2_HC_C12-
509
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
510
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P2_HC_E4-
513
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
514
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P2_HC_F1-
517
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
518
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P1_HC_B7-
521
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
522
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P1_HC_B9-
525
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
526
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P1_HC_E1-
529
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
530
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P1_HC_E11-
533
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
534
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P1_HC_F6-
537
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
538
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P3_HC_A6-
541
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
542
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P3_HC_B12-
545
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
546
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P3_HC_B12-
549
QVQLVESGGGVVQPGRSLRLSCAASGFTFSIYG
550
AKEGRPS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DIVVVVA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KEGRPSDIVVVVAFDYWGQGTLVTVSS

COVD21_P2_HC_C8-
553
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
554
ASPASRG

p1369

MHWVRQAPGQGLEWMGWINPISGGTNYAQ

YSGYDHG

KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY

YYYYMDV

CASPASRGYSGYDHGYYYYMDVWGKGTTVTVS

S

COVD21_P2_HC_F12-
557
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
558
ASPASRG

p1369

MHWVRQAPGQGLEWMGWINPISGGTNYAQ

YSGYDHG

KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY

YYYYMDV

CASPASRGYSGYDHGYYYYMDVWGKGTTVTVS

S

COVD21_P1_HC_H9-
561
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
562
ASPASRG

p1369

MHWVRQAPGQGLEWMGWINPISGGTNYAQ

YSGYDHG

KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY

YYYYMDV

CASPASRGYSGYDHGYYYYMDVWGKGTTVTVS

S

COVD21_P1_HC_E5-
565
QVQLVESGGGLVKPGGSLRLSCAASGFIFSDYC
566
ARRGDGS

p1369

MSWIRRAPGKGLEWLSYISNSGTTRYYADSVKG

SSIYYYNY

RFTISRDNGRNSLYLQMDSLSAEDTAVYYCARR

MDV

GDGSSSIYYYNYMDVWGKGTTVTVSS

COVD21_P1_HC_F8-
569
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYC
570
ARRGDGS

p1369

MSWIRQAPGKGLEWLSYISNSGTTRYYADSVK

SSIYYYNY

GRFTISRDNGRNSLYLQMNSLSAEDTAVYYCAR

MDV

RGDGSSSIYYYNYMDVWGKGTTVTVSS

COVD21_P1_HC_G5-
573
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYC
574
ARRGDGS

p1369

MSWIRQAPGKGLEWLSYISNSGTTRYYADSVK

SSIYYYNY

GRFTISRDNGRNSLYLQMNSLSAEDTAVYYCAR

MDV

RGDGSSSIYYYNYMDVWGKGTTVTVSS

COVD21_P2_HC_A11-
577
QVQLVESGGGVVQPGRSLRLSCAASGFTYSGYA
578
ARDGIVD

p1369

MHWVRQAPGKGLEWVAVILDDGSNKYYADSV

TAMVTW

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

RDGIVDTAMVTWFDYWGQGTLVTVSS

COVD21_P2_HC_D1-
581
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
582
ARDQGM

p1369

MHWVRQAPGKGLEWVAVILYDGSNKYYADSV

ATTYFDY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

RDQGMATTYFDYWGQGTLVTVSS

COVD21_P2_HC_H7-
585
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
586
ARDGIVD

p1369

MHWVRQAPAKGLEWVAVILYDGSGKYYADSV

TALVTWF

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

DY

RDGIVDTALVTWFDYWGQGTLVTVSS

COVD21_P1_HC_B5-
589
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
590
ARDSPFS

p1369

MHWVRQAPGQGLEWMGWINPNSGGTNYA

GLGASND

QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY

Y

YCARDSPFSGLGASNDYWGQGTLVTVSS

COVD21_P3_HC_B5-
593
QVQLVQSGAEVKKPGASVKVSCMASGYTFTGY
594
ARDSPFS

p1369

YMHWVRQAPGQGLEWMGWINPNSGGTNYA

ALGASND

QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY

Y

YCARDSPFSALGASNDYWGQGTLVTVSS

COVD21_P2_HC_F9-
597
QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA
598
AAPHCSG

p1369

VQWVRQARGQRLEWIGWIVVGSGNTNYAQK

GSCLDAF

FQERVTITRDMSTSTAYMELSSLRSEDTAVYYCA

DI

APHCSGGSCLDAFDIWGQGTMVTVSS

COVD21_P1_HC_F10-
601
QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA
602
AAPHCSG

p1369

VQWVRQARGQRLEWIGWIVVGSGNTNYAQK

GSCYDAF

FQERVTITRDMSTSTAYMELSSLRSEDTAVYYCA

DI

APHCSGGSCYDAFDIWGQGTMVTVSS

COVD21_P2_HC_E9-
605
EVQLVESGGDLVKPGGSLRLSCAASGFTFNNA
606
TTGPHYD

p1369

WMSWVRQAPGKGLEWVGRIKDKSDGETTDY

SSGYSYT

AAPVQGRFTVSRDDSKNTLYLQMNSLKTEDTA

VDS

VYYCTTGPHYDSSGYSYTVDSWGQGTLVTVSS

COVD21_P2_HC_G2-
609
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW
610
TTGPHYD

p1369

MNWVRQAPGKGLEWVGRIKDKSDGGTIDYAA

DSGYSYT

PVQGRFTISRDDSKNTLYLQMNSLKTEDTAVYY

VDY

CTTGPHYDDSGYSYTVDYWGQGTLVTVSS

COVD21_P2_HC_G4-
613
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
614
AKASGIY

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

CSGGDCY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

SYYFDY

KASGIYCSGGDCYSYYFDYWGQGTLVTVSS

COVD21_P1_HC_B2-
617
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
618
AKASGIY

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

CSGGNCY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

SYYFDY

KASGIYCSGGNCYSYYFDYWGQGTLVTVSS

COVD21_P2_HC_F2-
621
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
622
AKGRVVY

p1369

MHWVRQAPGKGLEWVSGTSWNSGTIGYADS

AIDPDSV

VKGRFTISRDNAKNSLYLQMNSLRAEDTALYYC

SPFDY

AKGRVVYAIDPDSVSPFDYWGQGTLVTVSS

COVD21_P1_HC_E2-
625
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
626
AKPRKRG

p1369

MHWVRQAPGKGLEWVSGISWNSGSIGYADSV

DYYGSGS

KGRFTISRDNAKNSLYLQMNSLRAEDTALYYCA

YDY

KPRKRGDYYGSGSYDYWGQGTLVTVSS

COVD21_P2_HC_B10-
629
QLQLQESGPGLVKPSETLSVTCTVSGGSISSSRYY
630
ARHAAAY

p1369

WGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR

YDRSGYY

VTISVDTSKNQFSLKLSSVTAADTAVYYCARHAA

FIEYFQH

AYYDRSGYYFIEYFQHWGQGTLVTVSS

COVD21_P2_HC_H11-
633
QLQLQESGPGLVKPSETLSLTCTVSGGSISSSNYY
634
ARHAAAY

p1369

WGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR

YDRSGYY

VTISVDTSKNQFSLKVSSVTAADTAVYYCARHAA

FIEYFQH

AYYDRSGYYFIEYFQHWGXGTLVTVSS

COVD21_P3_HC_E4-
637
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNY
638
ARTDGTP

p1369

GISWVRQAPGQGLEWMGWNSAYNGNTNYA

AEYFQY

QKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVY

YCARTDGTPAEYFQYWGQGTLVTVSS

COVD21_P2_HC_G7-
641
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
642
ARGGQD

p1369

MHWVRQAPGQGLEWMGWINPNSGGTNYA

ELTGAFDI

QKFQGRVTMTRDTSISTAYMELSRLTSDDTAVY

YCARGGQDELTGAFDIWGQGTMVTVSS

COVD21_P1_HC_D10-
645
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
646
AKSPYYY

p1369

MHWVRQAPGQGLEWMGWINPISGGTNSAQ

DSSGYLG

KFQGRVTMTRDTSITTAYMELSSLRSDDTAVYH

GFDY

CAKSPYYYDSSGYLGGFDYWGQGTLVTVSS

COVD21_P1_HC_C7-
649
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
650
ARDLGYS

p1369

MHWVRQAPGQGLEWMGWINPNSGGRNYTQ

YVQGYFD

KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY

Y

CARDLGYSYVQGYFDYWGXGTLVTVSS

COVD21_P2_HC_B12-
653
QVQLVQSGAEVKKPGASVKVSCKASGYIFTGYY
654
ARDLGFS

p1369

MHWVRQAPGQGLEWMGWINPNSGGTNYA

RLQFLFD

QKFQGRVTMTRDTSISTVYMELSRLRSDDTAVY

Y

YCARDLGFSRLQFLFDYWGQGTLVTVSS

COVD21_P1_HC_F4-
657
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
658
ASTGYYIL

p1369

MHWVRQAPGQGLEWMGWINPNSGGTNYA

TGYEFGA

QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY

MDV

YCASTGYYILTGYEFGAMDVWGQGTTVTVSS

COVD21_P1_HC_D7-
661
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYY
662
ARDRPL

p1369

LHWVRQAPGQGLEWMGWINPTSGGTKYAQK

WFGVEY

FQGRVTMTRDTSITTAYMEVNRLRSDDTAVYY

GMDV

CARDRPLWFGVEYGMDVWGQGTTVTVSS

COVD21_P1_HC_C1-
665
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
666
ATTEGQQ

p1369

MHWVRQAPGQGLEWMGWINPNSGGTNYA

LPHPPYY

QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY

YYYYYMD

YCATTEGQQLPHPPYYYYYYYMDVWGKGTTVT

V

VSS

COVD21_P2_HC_G5-
669
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY
670
ARDRAET

p1369

MHWVRQAPGQGLEWIVIGIINPSGGSTTYAQK

EGSETYYY

FQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC

DSSGYYLL

ARDRAETEGSETYYYDSSGYYLLGYWGQGTLVT

GY

VSS

COVD21_P1_HC_D3-
673
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY
674
ARSSVTG

p1369

MHWVRQAPGQGLEWIVIGIINPSGGSTSYAQKF

TPPFDY

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA

RSSVTGTPPFDYWGQGTLVTVSS

COVD21_P2_HC_G8-
677
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY
678
ARVPREG

p1369

MHWVRQAPGQGLEWMGIINPSGGSTSYAQKF

TPGFDP

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA

RVPREGTPGFDPWGQGTLVTVSS

COVD21_P1_HC_E4-
681
QVQLVQSGAEVKKPGASVKVSCKAXGYTFTRX
682
LVGISTIV

p1369

HMQWVGQAPGQGLEWMGIINXSGGSTSYAQ

VVRPAV

KFQGRVTMARDTSTSSVXMELSSLRXRTRPCIT

WTS

VLVGISTIVVVRPAVWTSGAKGPRSPXX

COVD21_P1_HC_F12-
685
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
686
ARVLYYY

p1369

ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ

DSSGYPN

GRVTITADESTSTAYMELSSLRSEDTAVYYCARV

LEYFQH

LYYYDSSGYPNLEYFQHWGQGTLVTVSS

COVD21_P2_HC_B3-
689
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
690
ARGNRLL

p1369

ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ

YCSSTSCY

GRVTITADESTSTAYMELSSLRSEDTAVYYCARG

LDAVRQG

NRLLYCSSTSCYLDAVRQGYYYYYYMDVWGKG

YYYYYYM

TTVTVSS

DV

COVD21_P2_HC_B3-
693
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
694
ARGNRLL

p1369

ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ

YCSSTSCY

GRVTITADESTSTAYMELSSLRSEDTAVYYCARG

LDAVRQG

NRLLYCSSTSCYLDAVRQGYYYYYYMDVWGKG

YYYYYYM

TTVTVSS

DV

COVD21_P3_HC_C11-
697
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
698
ARVGYYY

p1369

ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ

DRSGFPR

GRVTITADKSTSTAYMELSSLRSEDTAVCYCARV

TEDYFDY

GYYYDRSGFPRTEDYFDYWGQGTLVTVSS

COVD21_P1_HC_G6-
701
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
702
ARDEGYC

p1369

ISWVRQAPGQGLEWMGGIIPIFYTANYAQKFQ

SGGSCYG

GRVTITADKSTSTAYMELSSLRSEDTAVYYCARD

YYYGMD

EGYCSGGSCYGYYYGMDVWGQGTTVTVSS

V

COVD21_P2_HC_B2-
705
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
706
ARGNRLL

p1369

ISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ

YCSSTSCY

GRVTITADESTSTAYMELSSLRSEDTAVYYCARG

LDAVRQG

NRLLYCSSTSCYLDAVRQGYYYYYYMDVWGKG

YYYYYYM

TTVTVSS

DV

COVD21_P1_HC_D2-
709
QVQLVESGGGLVKPGGSLRLSCAASGFIFSDYY
710
ARGLVYT

p1369

MSWIRQAPGKGLEWVSYISSSASTIYYADSVKG

PYRFGY

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG

LVYTPYRFGYWGQGTLVTVSS

COVD21_P3_HC_B4-
713
QVQLVESGGGLVKPGGSLRLSCAASGFTFIDYY
714
ARGRTW

p1369

MSWIRQAPGKGLEWVSYISSSGSTIYYADSVKG

ELVDY

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG

RTWELVDYWGQGTLVTVSS

COVD21_P1_HC_A12-
717
QVQLVESGGGLVKPGGSLRLSCAASGFTFIDYY
718
ARGKWL

p1369

MSWIRQAPGKGLEWVSYISSSGSTIYYADSVKG

RGSFDY

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG

RTWELVDYWGQGTLVTVSS

COVD21_P2_HC_A10-
721
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYD
722
ARVGYDS

p1369

MHWVRQATGKGLEWVSAIGTAGDTYYPGSVK

SGYSGW

GRFTISRENAKNSLYLQMNSLRAGDTAVYYCAR

YFDL

VGYDSSGYSGWYFDLWGRGTLVTVSS

COVD21_P3_HC_A2-
725
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYD
726
ARGGGET

p1369

MHWVRQATGKGLEWVSAIGTAGDTYYPDSVK

ITTVFDY

GRFTISRENAKNSLYLQMNSLRAGDTAVYYCAR

GGGETITTVFDYWGQGTLVTVSS

COVD21_P2_HC_D3-
729
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYD
730
ARGSYSN

p1369

MHWVRQATGKGLEWVSIIGTAGDTYYPGSVK

YVGYMD

GRFTISRENAKNSLYLQMNSLRAGDTAVYYCAR

V

GSYSNYVGYMDVWGKGTTVTVSS

COVD21_P2_HC_D10-
733
EVQLVESGGGLVKPGGSLRLSCAASGFTFSDAW
734
TTDQIYG

p1369

MSWVRQAPGKGLEWVGRLKSKTDGGTTDYAA

DYLRMPV

PVKGRFTISRDDSKNTLSLQMNSLKTEDTAVYYC

PFDY

TTDQIYGDYLRMPVPFDYWGQGTLVTVSS

COVD21_P3_HC_H6-
737
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW
738
TTGPQYD

p1369

MNWVRQAPGKGLEWIGRIKSNSDGGTTDYAA

DNGYSYT

PVQGRFTILRDDSKNTLYLQMTSLRTEDTAVYFC

VDY

TTGPQYDDNGYSYTVDYWGRGTLVTVSS

COVD21_P3_HC_D12-
741
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS
742
AREVKRV

p1369

MNWVRQAPGKGLEWVSSISSSSSYIYYADSVKG

VAAPEYY

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARE

FDY

VKRVVAAPEYYFDYWGQGXLVTVSS

COVD21_P3_HC_D11-
745
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS
746
AREVKRV

p1369

MNWVRQAPGKGLEWVSSISSSSSYIYYADSVKG

VAAPEYY

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARE

FDY

VKRVVAAPEYYFDYWGQGTLVTVSS

COVD21_P2_HC_C3-
749
EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYN
750
ARDRNRY

p1369

MNWVRQAPGKGLEWVSSITSSSSYIYYADSVK

DFWSGYY

GRFTISRDNAENSLYLQMNSLRAEDTAVYYCAR

RLVGFDP

DRNRYDFWSGYYRLVGFDPWGQGTLVTVSS

COVD21_P1_HC_F11-
753
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
754
AKVWSIS

p1369

MSWVRQAPGKGLEWVSGISDSGVSTYNADSV

LDAFDI

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

KVWSISLDAFDIWGQGTMVTVSS

COVD21_P2_HC_C4-
757
EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYA
758
AKDGGR

p1369

MSWVRQAPGKGLEWVSGISGSGDSTYYADSV

QWLVELL

KGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCA

DY

KDGGRQWLVELLDYWGHGTLVTVSS

COVD21_P2_HC_G9-
761
EVQLLESGGGLVQPGGSLRLSCAASRFTFSNYA
762
AKDRAAA

p1369

MSWVRQAPGKGLEWVSTISGSGGSTYYADSVK

HWATDY

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK

DRAAAHWATDYWGQGTLVTVSS

COVD21_P1_HC_F7-
765
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
766
AKDDSSG

p1369

MSWVRQAPGKGLEWVSAISGSGGSTYYADSV

YHYYFDY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

KDDSSGYHYYFDYWGQGTLVTVSS

COVD21_P1_HC_D1-
769
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
770
AKDSGTA

p1369

MSWVRQAPGKGLEWVSAISGSGDITYYADSVK

MVEIFDY

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK

DSGTAMVEIFDYWGQGTLVTVSS

COVD21_P3_HC_E1-
773
EVQLLESGGDLVQPGGSLRLSCAASGFTFSSYA
774
AKDLRST

p1369

MSWVRQAPGKGLEWVSAISGSGGSTYYADSV

TFYVYYF

KGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAK

DY

DLRSTTFYVYYFDYWGQGTLVTVSS

COVD21_P2_HC_F8-
777
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
778
AKVPIHY

p1369

MSWVRQAPGKGLEWVSAISGSGGTTYYADSV

CSNGVCY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

KVPIHYCSNGVCYFDYWGQGTLVTVSS

COVD21_P3_HC_D4-
781
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
782
AKVVGSG

p1369

MSWVRQAPGKGLEWVSAISGSGDSTYFADSVK

TPPDYYY

GRFTISRDNSKNTLYLHMNSLRAEDTAVYYCAK

YYYMDV

VVGSGTPPDYYYYYYMDVWGKGTTVTVSS

COVD21_P1_HC_D4-
785
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG
786
ARATCSG

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYFADSV

GSCLFGQ

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

NAFDI

RATCSGGSCLFGQNAFDIWGQGTMVTVSS

COVD21_P1_HC_G9-
789
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
790
ARDYGSS

p1369

MHWVRQAPGKGLEWVAVISYDGSSKFYADSV

WYQVPD

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

Y

RDYGSSWYQVPDYWGQGTLVTVSS

COVD21_P2_HC_H9-
793
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
794
AREFGDP

p1369

MHWVRQAPGKGLEWVTVISYDGRNKYYADSV

EWYFDY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

REFGDPEWYFDYWGQGTLVTVSS

COVD21_P1_HC_G8-
797
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
798
AKNQNSY

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

GYLSYFD

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

Y

KNQNSYGYLSYFDYWGQGTLVTVSS

COVD21_P1_HC_E12-
801
QVQLVESGGGVVQPGRSLRLSCAASGFTFRRYG
802
AKASGEY

p1369

IHWVRQAPGKGLEWVAVISYDGSNKYYADSVK

CGGGSCY

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK

RGVFDY

ASGEYCGGGSCYRGVFDYWGQGTLVTVSS

COVD21_P3_HC_H4-
805
QVQLVESGGGVVQPGRSLRLSCATSGFTFSSYG
806
AKVMGP

p1369

LHWVRQAPGKGLEWVALISYDGSDKYYADSVK

YCSGGSC

GRFTISRDTSKNTLFLQMNSLRAEDTAVYYCAKV

YSGYFDY

MGPYCSGGSCYSGYFDYWGQGTLVTVSS

COVD21_P1_HC_C4-
809
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
810
AKAGGPY

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

CSGGSCY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

SSYFDY

KAGGPYCSGGSCYSSYFDYWGQGTLVTVSS

COVD21_P1_HC_G2-
813
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
814
ARDCGG

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYSADSV

DCYPTTD

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

AFDI

RDCGGDCYPTTDAFDIWGQGTMVTVSS

COVD21_P2_HC_H10-
817
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
818
ARDHDY

p1369

MHWVRQAPGKGLEWVAVISYDGSSKYYADSV

GEIVDAF

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

DI

RDHDYGEIVDAFDIWGQGTMVTVSS

COVD21_P1_HC_B1-
821
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
822
ARDSEDC

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

SSTSCYLD

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

Y

RDSEDCSSTSCYLDYWGQGTLVTVSS

COVD21_P3_HC_E6-
825
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYV
826
ARGPGW

p1369

MNWVRQAPGKGLAWVAVISFDGSNKYYADSV

QWPELD

KGRFTVSRDNSKNTLYLQMNSLRAEDTALYYCA

Y

RGPGWQWPELDYWGQGTLVTVSS

COVD21_P3_HC_A5-
829
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
830
ATEDYYD

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

SSGSFDY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

TEDYYDSSGSFDYWGQGTLVTVSS

COVD21_P3_HC_C12-
833
QVQLVESGGGVVQPERSLRLSCAASGFTFSSYA
834
ARSKSYTS

p1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

WGYYHM

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

DV

RSKSYTSWGYYHMDVW

COVD21_P1_HC_D8-
837
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
838
ARDGTSI

p1369

IHWVRQAPGKGLEWVAVIWYDGSNKYYADSV

TLITEGDA

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDI

RDGTSITLITEGDAFDIWGQGTMVTVSS

COVD21_P2_HC_B11-
841
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
842
ARDPSVV

p1369

MHWVRQAPGKGLEWVAVIWHDGSNKYYADS

VTAIDFD

VKGRFTISRDNSKNTLYLQMNSLRAEDTALYYC

Y

ARDPSVWTAIDFDYWGQGTLVTVSS

COVD21_P2_HC_C9-
845
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
846
AREHTPT

p1369

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

DIVVVNV

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

EY

AREHTPTDIVVVNVEYWGQGTLVTVSS

COVD21_P3_HC_H8-
849
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYC
850
AREKDIV

p1369

MHWVRQAPGKGLEWVAVIWYDGNNKYYADS

ATDFDY

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

AREKDIVATDFDYWGQGTLVTVSS

COVD21_P1_HC_E10-
853
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
854
AREYFYD

p1369

IHWVRQAPGKGLEWVAVIWYDGSNKYYADSV

SSDYYFEY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

YFDY

REYFYDSSDYYFEYYFDYWGQGTLVTVSS

COVD21_P1_HC_A4-
857
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
858
ARDHSLG

p1369

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

VRGDGY

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

GMDV

ARDHSLGVRGDGYGMDVWGQGTTVTVSS

COVD21_P1_HC_G11-
861
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
862
ARDGAV

p1369

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

VRFLEWP

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

TVGYYYY

ARDGAVVRFLEWPTVGYYYYYMDVWGKGTTV

YMDV

TVSS

COVD21_P3_HC_G10-
865
QVQLVESGGGVVQPGRSLRLSCAASGFTFTSYG
866
ARDMMI

p1369

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

RGVAWY

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

YYMDV

ARDMMIRGVAWYYYMDVWGKGTTVTVSS

COVD21_P2_HC_H2-
869
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYS
870
ARDSGG

p1369

MNWVRQAPGKGLEWVSYISSSSSTIYYADSVK

DIVVIPAV

GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR

NGFDY

DSGGDIVVIPAVNGFDYWGQGTLVT

COVD21_P2_HC_A8-
873
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYS
874
AREAHD

p1369

MNWVRQAPGKGLEWVSYISSSSSTIYYADSVK

GALTDYG

GRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR

DYLNWF

EAHDGALTDYGDYLNWFDPWGQGTLVTVSS

DP

COVD21_P1_HC_A3-
877
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
878
ARDLYSS

p1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

GGTDI

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

DLYSSGGTDIWGQGTMVTVSS

COVD21_P3_HC_G1-
881
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
882
ARDLYSS

p1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

GGTDI

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

DLYSSGGTDIWGQGTMVTVSS

COVD21_P1_HC_A2-
885
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
886
ARGYGDY

p1369

MTWVRQAPGKGLEWVSLIYSGGSTFYADSVKG

YFDY

RFTISRDSSKNTLYLQMNSLRAEDTAVYYCARGY

GDYYFDYWGQGTLVTVSS

COVD21_P2_HC_F7-
889
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
890
ARDYGDF

p1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

YFDY

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

DYGDFYFDYWGQGTLVTVSS

COVD21_P1_HC_C8-
893
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
894
ARDWGD

p1369

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG

YYFDY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD

WGDYYFDYWGQGTLVTVSS

COVD21_P1_HC_A10-
897
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
898
ARDYGDF

p1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

YFDY

GRFTISRDNSKNTLYLQMNSLRAGDTAVYYCAR

DYGDFYFDYWGQGTLVTVSS

COVD21_P1_HC_B12-
901
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
902
ARDLSVF

p1369

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG

GMDV

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD

LSVFGMDVWGQGTTVTVSS

COVD21_P3_HC_C9-
905
EVQLVESGGGLIQPGGSLRVSCAASGFTVSSNY
906
ARDLGER

p1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

GMDV

GRFTISRDNSKNTLSLQMNSLRAEDTAVYYCAR

DLGERGMDVWGQGTTVTVSS

COVD21_P1_HC_H7-
909
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
910
ARYCSGG

p1369

MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV

SCHPPGQ

KGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA

WLSDAF

RYCSGGSCHPPGQWLSDAFDIWGQGTMVTVS

DI

S

COVD21_P1_HC_F1-
913
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
914
ARLRWLR

p1369

MSWVRQAPGKGLEWVTNIKLDGSEKYYVDSVK

ADFDY

GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR

LRWLRADFDYWGQGTLVTVSS

COVD21_P1_HC_C10-
917
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
918
ARYYDILT

p1369

MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV

GYYVDYY

KGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA

YMDV

RYYDILTGYYVDYYYMDVWGXGTTVTVSS

COVD21_P3_HC_H10-
921
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTH
922
TRDDSS

p1369

WMHWVRQAPGKGLVWVSRINSDGSRRAYAT

WPHFFD

SVKGRFTISRDNAKNTLYLQMDSLRDEDTAVYY

N

CTRDDSSWPHFFDNWGQGTLVTVSS

COVD21_P2_HC_D8-
925
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
926
ARAWAM

p1369

MHWVRQAPGKGLVWVSRINSDGSSTSYADSV

RQTTLTP

KGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA

EWIDY

RAWAMRQTTLTPEWIDYWGQGTLVTVSS

COVD21_P2_HC_D9-
929
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
930
ARAWAM

p1369

MHWVRQAPGKGLVWVSRINSDGSSTSYADSV

RQTTLTP

KGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA

EWIDY

RAWAMRQTTLTPEWIDYWGQGTLVTVSS

COVD21_P3_HC_G3-
933
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
934
AKGGEGF

p1369

MHWVRQAPGKGLEWVSGVTWNSGSIGYADS

RNWNDG

VKGRFIISRDNAKNSLYLQMNSLRAEDTALYYCA

LDYFDY

KGGEGFRNWNDGLDYFDYWGQGTLVTVSS

COVD21_P1_HC_A5-
937
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
938
AKDGRSG

p1369

MHWVRQAPGKGLEWVSGISWNSGTIGYADSV

DQWPEL

KGRFTISRDNAKNSLHLHMRSLRAEDTALYYCA

YYFDY

KDGRSGDQWPELYYFDYWGQGTLVTVSS

COVD21_P2_HC_E10-
941
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
942
AKAGVR

p1369

MHWVRQAPGKGLEWVSGISWNSGTIGYADSV

GIAAAGP

KGRFTISRDNAKNSLYLQMNSLRAEDTAFYYCA

DLNFDH

KAGVRGIAAAGPDLNFDHWGQGTLVTVSS

COVD21_P3_HC_F9-
945
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
946
AKGSSSS

p1369

MHWVRQAPGKGLEWVSGITWNSGSIAYADSV

YHNWFD

KGRFTISRDNAKNSLYLQMNSLRAEDTALYYCA

P

KGSSSSYHNWFDPWGQGTLVTVSS

COVD21_P1_HC_D6-
949
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
950
AKDGAG

p1369

MHWVRQAPGKGLEWVSGISWNSVSIDYADSV

TENWFD

KGRFTISRDNAKNSLYLQMNSLRAEDTALYYCA

P

KDGAGTENWFDPWGQGTLVTVSS

COVD21_P2_HC_G3-
953
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
954
AKDMLG

p1369

MHWVRQAPGKGLEWVSGISWNSGSIGYAHSV

NYYYYAM

KGRFTISRDNAKNSLYLHMNSLRAEDTALYYCA

VV

KDMLGNYYYYAMVVWGQGTTVTVSS

COVD21_P1_HC_E6-
957
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY
958
ARTMYYY

p1369

YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS

DSSGSFD

RVTISVDTSKNQFSLKLSSVTAADTAVYYCARTM

Y

YYYDSSGSFDYWGQGTLVTVSS

COVD21_P1_HC_G1-
961
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY
962
ASGELSA

p1369

YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLES

FGELFPH

RVTISVDTSKNQFSLKLSSVTAADTAVYYCASGE

DY

LSAFGELFPHDYWGXGTLVTVSS

COVD21_P3_HC_G7-
965
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY
966
ARVHVVR

p1369

YWSWIRQHPGKGLEWIGYIYYSGSPYYNPSLKS

GVANYPY

RVTISIDTSKNQFSLKLSSVTAADTAVYYCARVH

FDY

VVRGVANYPYFDYWGQGTLVTVSS

COVD21_P1_HC_D5-
969
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY
970
ARGSYSN

p1369

YWGWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS

YNGGLDY

RVTISVDTSKNQFSLKLSSVTAADTAVYYCARGS

YSNYNGGLDYWGQGTLVTVSS

COVD21_P2_HC_A9-
973
QVQLQESGPGLVKPSQTLSLTCTVSGGSFSSGG
974
ARVATDY

p1369

YYWHWIRQHPGKGLEWIGYIYYSGSTYYNPSLK

GDSFDY

SRVTISVDTSKNQFSLKLSSVTAADTAVYYCARV

ATDYGDSFDYWGQGTLVTVSS

COVD21_P3_HC_A8-
977
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
978
ARAPPGD

p1369

SWIRQPAGKGLEWIGRIYTSGSTKYNPSLKSRVT

FYDSSGY

MSVDTSKNQFSLKLSSVTAADTAVYYCARAPPG

FSAFDI

DFYDSSGYFSAFDIWGQGTMVTVSS

COVD21_P1_HC_B6-
981
QVQLQESGPGLVKPSETLSLTCTVSGGSISAYYW
982
ARDNGY

p1369

SWIRQPAGKGLEWIGRIYTSGSTIYNPSLKSRVT

VWGSYR

MSVDTSKNQFSLKLSSVTAADTAVYYCARDNGY

PDAFDI

VWGSYRPDAFDIWGQGTMVTVSS

COVD21_P1_HC_B6-
985
QVQLQESGPGLVKPSETLSLTCTVSGGSISAYYW
986
ARDNGY

p1369

SWIRQPAGKGLEWIGRIYTSGSTIYNPSLKSRVT

VWGSYR

MSVDTSKNQFSLKLSSVTAADTAVYYCARDNGY

PDAFDI

VWGSYRPDAFDIWGQGTMVTVSS

COVD21_P2_HC_D4-
989
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
990
ARVVGYS

p1369

SWIRQPAGKGLEWIGRIYTSGSTNYNPSLESRVT

SRGANYY

MSVDTSKNQFSLKLSSVTAADTAVYYCARVVGY

MDV

SSRGANYYMDVWGKGTTVTVSS

COVD21_P1_HC_H5-
993
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
994
ARVPSVG

p1369

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

DCSSTSCL

ISVDTSKNQFSLKLSSVTAADTAVYYCARVPSVG

YWYFDL

DCSSTSCLYWYFDLWGRGTLVTVSS

COVD21_P2_HC_F4-
997
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
998
ARYGMG

p1369

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

ELLTLRSE

ISVDTSKNQFSLKLSSVTAADTAVYYCARYGMG

YYFDY

ELLTLRSEYYFDYWGQGTLVTVSS

COVD21_P3_HC_C4-
1001
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
1002
ARSYDSS

p1369

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

GLSYNWF

ISVDTSKNQFSLKLSSVTAADTAVYYCARSYDSS

DP

GLSYNWFDPWGQGTLVTVSS

COVD21_P2_HC_E2-
1005
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
1006
ARGGYYY

p1369

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

DSSGYEY

ISVDTSKNQFSLKLSSVTAADTAVYYCARGGYYY

YYYYGM

DSSGYEYYYYYGMDVWGQGTTVTVSS

DV

COVD21_P1_HC_C5-
1009
QVQLQESGPGLVKPSETLSLTCAVSGGSVSSGN
1010
ARETYYY

p1369

YYWNWIRQPPGKGLEWIGYIYYSGSTNYNPSLK

DSSGYYIS

SRVTISVDTSKNQFSLKLNSVTAADTAVYHCARE

DAFDI

TYYYDSSGYYISDAFDIWGQGTMVTVSS

COVD21_P2_HC_H4-
1013
EVQLVQSGAEVKKPGESLKISCKGSGYSFSSYCIG
1014
ARQWRG

p1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG

YYDRSGY

QVTISVDKSISTAYLQWSSLKASDTAMYYCARQ

YHFDAFD

WRGYYDRSGYYHFDAFDIWGQGTMVTVSS

I

COVD21_P1_HC_C6-
1017
EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYCIG
1018
ARHWYY

p1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG

GDYGNYS

QVTISADKSISTAYLQWSSLKASDTAMYYCARH

YYYLDV

WYYGDYGNYSYYYLDVWGKGTTVTVSS

SEQ

SEQ

ID

ID

SEQUENCE_ID
NOS
aa
NOS
cdr3_aa

KAPPA

COVD21_P1_K_A4-
503
DIQMTQSPSSLSASVGDRVTITCRASQSI
504
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P1_K_B5-
507
DIQMTQSPSSLSASVGDRVTITCRASQSI
508
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P1_K_C12-
511
DIQMTQSPSSLSASVGDRVTITCRASQSI
512
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P1_K_E4-
515
DIQMTQSPSSLSASVGDRVTITCRASQSI
516
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P1_K_F1-
519
DIQMTQSPSSLSASVGDRVTITCRASQSI
520
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P2_K_B7-
523
DIQMTQSPSSLSASVGDRVTITCRASQSI
524
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P2_K_B9-
527
DIQMTQSPXSLSASVGDRVTITCRASQS
528
QQS

p1389

ISSYLNWYQQKPGKAPKLLIYAASSLQS

YST

GVPSRFSGSGSGTDFTLTISSLQPEDFAT

PRT

YYCQQSYSTPRTFGQGTKVEIK

COVD21_P2_K_E1-
531
DIQMTQSPSSLSASVGDRVTITCRASQSI
532
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P2_K_E11-
535
DIQMTQSPSSLSASVGDRVTITCRASQSI
536
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P2_K_F6-
539
DIQMTQSPSSLSASVGDRVTITCRASQSI
540
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P3_K_A6-
543
DIQMTQSPSSLSASVGDRVTITCRASQSI
544
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P3_K_B12-
547
DIQMTQSPSSLSASVGDRVTITCRASQSI
548
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P3_K_B12-
551
DIQMTQSPSSLSASVGDRVTITCRASQSI
552
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PRT

YCQQSYSTPRTFGQGTKVEIK

COVD21_P1_K_C8-
555
DIQMTQSPSSLSASVGDRVTITCQASQD
556
QQY

p1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

DNL

GVPSRFSGSGSGTDFTFTISSLQPEDIAT

PIT

YYCQQYDNLPITFGQGTRLEIK

COVD21_P1_K_F12-
559
DIQMTQSPSSLSASVGDRVTITCQASQD
560
QQY

p1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

DNL

GVPSRFSGSGSGTDFTFTISSLQPEDIAT

PIT

YYCQQYDNLPITFGQGTRLEIK

COVD21_P2_K_H9-
563
DIQMTQSPSSLSASVGDRVTITCQASQD
564
QQY

p1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

DNL

GVPSRFSGSGSGTDFTFTISSLQPEDIAT

PIT

YYCQQYDNLPITFGQGTRLEIK

LAMBDA

COVD21_P2_L_E5-
567
QSVLTQPPSASGTPGQRVTVSCSGSSSN
568
AA

p1409

IGSNTVNWYQQLPGTAPKLLIYSNNQR

WD

PSGVPDRFSGSKSGTSASLAISGLQSEDE

DSL

ADYFCAAWDDSLNGPVFGGGTKLTVX

NGP

V

COVD21_P2_L_F8-
571
QSVLTQPPSASGTPGQRVTVSCSGSSSN
572
AA

p1409

IGSNTVNWYQQLPGTAPKLLIHSNNQR

WD

PSGVPDRFSGSKSGTSASLAISGLQSEDE

DSL

ADYYCAAWDDSLNGPVFGGGTKLTVL

NGP

V

COVD21_P2_L_G5-
575
QSVLTQPPSASGTPGQRVTVSCSGSSSN
576
AA

p1409

IGSNTINWYQQLPGTAPKLLIYSNNQRP

WD

SGVPDRFSGSKSGTSASLAISGLQSEDEA

DSL

NYYCAAWDDSLNGPVFGGGTKLTVL

NGP

V

KAPPA

COVD21_P1_K_A11-
579
DIQMTQSPSSLSASVGDRVTITCRASQSI
580
QQS

p1389

SSYLNWYHQKPGKAPKLLIYTASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PP

YCQQSYSTPPWTFGQGTKVEIK

WT

COVD21_P1_K_D1-
583
DIQMTQSPSSLSASVGDRVTITCRASQSI
584
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YNT

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PP

FCQQSYNTPPWTFGQGTKVEIK

WT

COVD21_P1_K_H7-
587
DIQMTQSPSSLSASVGDRVTITCRASQSI
588
QQS

p1389

STYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PP

YCQQSYSTPPWTFGQGTKVEIK

WT

LAMBDA

COVD21_P2_L_B5-
591
QSVLTQPPSASGSPGQSVTISCTGTSSD
592
SSD

p1409

VGGYNYVSWYQQHPGKAPKLMIYEVS

AGS

KRPSGVPDRFSGSKSGNTASLTVSGLQA

NNV

EDEADYYCSSDAGSNNVVFGGGTKLTV

V

L

COVD21_P3_L_B5-
595
QSALTQPPSASGSPGQSVTISCTGTSSD
596
SSD

p1409

VGGYNYVSWYQQHPGKAPKLMIYEVS

AGS

KRPSGVPDRFSGSKSGNTASLTVSGLQA

NNV

EDEAEYYCSSDAGSNNVVFGGGTKLTVL

V

KAPPA

COVD21_P1_K_F9-
599
EIVLTQSPGTLSLSPGERATLSCRASQSV
600
QQY

p1389

RSSYLAWYQQKPGQAPRLLIYGASSRAT

GSS

GIPDRFSGSGSGTDFTLTISRLEPEDFAV

PW

YYCQQYGSSPWTFGQGTKVEIK

T

COVD21_P2_K_F10-
603
EIVLTQSPXSLSLSPGERATLSCRASQSVS
604
QQY

p1389

SSYLAWYQQKPGQAPRLLIYGASSRATG

GSS

IPDRFSGSGSGTDFTLTISRLEPEDFAVYY

PW

CQQYGSSPWTFGQGTKVEIK

T

COVD21_P1_K_E9-
607
DIVMTQSPLSLPVXPGEPASISCRSSQSL
608
MQ

p1389

LHSNGFHFLEWYLQKPGQSPQLLIYSGS

GLQ

NRASGVPDRFSGSGSGTHFTLKISRVEA

TPL

EDVGVYYCMQGLQTPLTFGGGTKVEIK

T

COVD21_P1_K_G2-
611
DIVMTQSPLSLPVTPGEPASISCRSSQSL
612
MQ

p1389

LHSNGFHFLDWYLQKPGQTPQLLIYVG

ALQ

SNRASGVPDRFSGSGSGTDFTLKISRVE

TPL

AEDVGVYYCMQALQTPLTFGGGTKVEI

T

K

COVD21_P1_K_G4-
615
DIQMTQSPSTLSASVGDRVTITCRASQSI
616
QQY

p1389

SSWLAWYQQKPGKAPKLLIYKASSLESG

NSY

VPSRFSGSGSGTEFTLTISSLQPDDFATY

ST

YCQQYNSYSTFGQGTKVEIK

COVD21_P2_K_B2-
619
DIQMTQSPSTLSASVGDRVTITCRASQSI
620
QQY

p1389

SSWLAWYQQKPGKAPKLLIYKASSLESG

NSY

VPSRFSGSGSGTEFTLTISSLQPDDFATY

ST

YCQQYNSYSTFGQGTKVEIK

LAMBDA

COVD21_P1_L_F2-
623
QSVLTQPASVSGSPGQSITISCTGTSSGV
624
SSY

p1409

GGYNFVSWYQQHPGKAPKLMIYDVSN

TSR

RPSGVSNRFSGSKSGNTASLTISGLQAE

STL

DEADYHCSSYTSRSTLGVFGGGTKLTVL

GV

COVD21_P2_L_E2-
627
QSVLTQPASVSGSPGQSITISCTGTSSDV
628
SSY

p1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSSS

RPSGVSNRFSGSKSGNTASLTISGLQAE

TVV

DEADYYCSSYTSSSTVVFGGGTKLTVL

KAPPA

COVD21_P1_K_B10-
631
DIQMTQSPSTLSASVGDSVTITCRASQSI
632
QQY

p1389

SSWLAWYQQKPGKAPKLLIYKASSLESG

NNY

VPSRFSGSGSGTEFTLTISSLQPDDFATY

RYT

YCQQYNNYRYTFGQGTKLEIK

COVD21_P1_K_H11-
635
DIQMTQSPSTLSASVGDRVTITCRASQSI
636
QKY

p1389

SSWLAWYQQKPGKAPKLLIYKASSLESG

NSY

VPSRFSGSGSGTEFTLTISSLQPDDFATY

RYT

YCQKYNSYRYTFGQGTKLEIK

LAMBDA

COVD21_P3_L_E4-
639
QSVLTQPASVSGSPGQSITISCTGTSSDI
640
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

COVD21_P1_L_G7-
643
SYVLTQPPSVSVAPGKTARITCGGNSIGS
644
QV

p1409

KSVHWYQQKPGQAPVLVIYYDSDRPSG

WD

IPERFSGSNSGNTATLTISRVEAGDEADF

SG

HCQVWDSGWVFGGGTKLTVL

WV

COVD21_P2_L_D10-
647
QSVLTQPASESGSPGQSITISCTGTSSDV
648
CSY

p1409

GTYNLVSWYQQHPGKAPKLMIYEGSKR

AAS

PSGVSNRFSGSKSGNTASLTISGLQAED

STY

EADYYCCSYAASSTYVFGTGTKVTVL

V

COVD21_P2_L_C7-
651
QSALTQPASESGSPGQSITISCTGTSSDV
652
CSY

p1409

GSYNLVSWYQQHPGKAPKLMIYEGSKR

AGS

PSGVSNRFSGSKSGNTASLTISGLQAED

NT

EADYYCCSYAGSNTWVFGGGTKLTVL

WV

COVD21_P1_L_B12-
655
QSVLTQPASVSGSPGQSITISCTGTSSDV
656
CSY

p1409

GSYNLVSWYQQHPGKAPKLMIYEVSKR

AGS

PSGVSNRFSGSKSGNTASLTISGLQAED

SIVV

EADYYCCSYAGSSIVVFGGGTKLTVL

COVD21_P2_L_F4-
659
QSALTQPASVSGSPGQSITISCTGTSSDV
660
SSY

p1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSSS

RPSGVSNRFSGSKSGNTASLTISGLQAE

TV

DEADYYCSSYTSSSTVFGTGTKVTVL

COVD21_P2_L_D7-
663
QSVLTQPASVSGSPGQSITISCTGTNSD
664
SSY

p1409

VGGYNYVSWYQQHPGKAPKLMIYDVG

TSSS

NRPSGVSNRFSGSKSGNTASLTISGLQA

TLV

EDEADYYCSSYTSSSTLVFGGGTKLTVL

COVD21_P2_L_C1-
667
QSVLTQPASVSGSPGQSITISCTGTSSDV
668
SSY

p1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSSS

RPSGVSNRFSGSKSGNTASLTISGLQAE

TYV

DEADYYCSSYTSSSTYVFGTGTKVTVL

KAPPA

COVD21_P1_K_G5-
671
DIQMTQSPSSLSASVGDRVTITCRASQSI
672
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PPS

YCQQSYSTPPSFGQGTKVEIK

LAMBDA

COVD21_P2_L_D3-
675
SYVLTQPPSVSVAPGKTARITCGGNNIG
676
QV

p1409

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WD

GIPERFSGSNSGNTAILTISRVEAGDEAD

SSS

YYCQVWDSSSDHVVFGGGTKLTVL

DHV

V

COVD21_P1_L_G8-
679
SYVLTQPPSVSVAPGKTARITCGENNIGS
680
QV

p1409

KSVHWYQQKPGQAPVLVIYYDSDRPSG

WD

IPERFSGSNSGNTATLTINRVEAGDEAD

SSS

YYCQVWDSSSDHVVFGGGTKLTVL

DHV

V

COVD21_P2_L_E4-
683
QSVLTQPSSHSASSGASVRLTCMLSSGF
684
GT

p1409

SVGDFWIRWYQQKPGNPPRYLLYYHSD

WH

SNKGQGSGVPSRFSGSNDASANAGILRI

SNS

SGLQPEDEADYYCGTWHSNSRVFGGG

RV

TKLTVL

KAPPA

COVD21_P2_K_F12-
687
DIQMTQSPSSLSASVGDRVTITCQASQD
688
QQY

p1389

ISNYLNWYQQKPGKAPKLLIYDASNLEA

DNL

GVPSRFSGSGSGTDFTFTISSLQPEDIAT

PSF

YYCQQYDNLPSFTFGPGTXVDIK

T

COVD21_P1_L_B3-
691
QSVLTQPPSASGTPGQRVTISCSGSSSNI
692
AS

p1409

GSNSVNWFQQLPGTAPKLLIYSNNQRP

WD

SGVPDRFSGSKSGASASLAISGLQSEDE

DSL

ADYYCASWDDSLNGPLFGGGTKLTVL

NGP

L

COVD21_P1_L_B3-
695
QSVLTQPPSASGTPGQRVTISCSGSSSNI
696
AS

p1409

GSNSVNWFQQLPGTAPKLLIYSNNQRP

WD

SGVPDRFSGSKSGASASLAISGLQSEDE

DSL

ADYYCASWDDSLNGPLFGGGTKLTVL

NGP

L

COVD21_P3_L_C11-
699
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
700
QSY

p1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAED

LSG

EADYYCQSYDSSLSGVVFGGGTKLTVL

VV

COVD21_P2_K_G6-
703
DIQMTQSPSSLSASVGDRVTITCQASQD
704
QQY

p1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

DNL

GVPSRFSGSGSGTDFTFTISSLQPEDIAT

PMY

YYCQQYDNLPMYTFGQGTKLEIK

T

COVD21_P1_K_B2-
707
EIVLTQSPATLSLSPGERATLSCRASQSV
708
QQ

p1389

SSYLAWYQQKPGQAPRLLIYDASNRAT

RSN

GIPARFSGSGSGTDFTLTISSLEPEDFAVY

WPL

YCQQRSNWPLTFGGGTKVEIK

T

COVD21_P2_K_D2-
711
DIQMTQSPSSLSASVGDRVTITCQASQD
712
QQ

p1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

HD

GVPSRFSGSGSGTDFTFTISSLQPEDIAT

NVV

YYCQQHDNVVTFGPGTKVEIK

T

LAMBDA

COVD21_P3_L_B4-
715
QSVLTQPASVSGSPGQSITISCTGTSSDI
716
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

COVD21_P2_L_A12-
719
NFMLTQPHSVSESPGKTVTISCTGSSGSI
720
QSY

p1409

ASNYVQWYQQRPGSAPTTVIYEDNQR

DSS

PSGVPDRFSGSIDSSSNSASLTISGLKTED

NH

EADYYCQSYDSSNHWVFGGGTKLTVL

WV

KAPPA

COVD21_P1_K_A10-
723
DIQMTQSPSSLSASVGDRVTITCRASQSI
724
QQS

p1389

SSYLNWYQQKPGKAPKVLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PPL

YCQQSYSTPPLTFGGGTKVEIK

T

LAMBDA

COVD21_P3_L_A2-
727
QSVLTQPASVSGSPGQSITISCTGTSSDI
728
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

KAPPA

COVD21_P1_K_D3-
731
DIQMTQSPSSLSASVGDRVTITCRASQSI
732
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PGL

YCQQSYSTPGLTFGGGTKVEIK

T

LAMBDA

COVD21_P1_L_D10-
735
QSVLTQPPSASGTPGQRVTISCSGSSSNI
736
AT

p1409

GSNYVYWYQQLPGTAPKLLIYRNNQRP

WD

SGVPDRFSGSKSGTSASLAISGLRSEDEA

DSL

DYYCATWDDSLSGPVFGGGTKLTVL

SGP

V

COVD21_P3_L_H6-
739
QSALTQPASVSGSPGQSITISCTGTSSDI
740
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

COVD21_P3_L_D12-
743
QSVLTQPPSASGTPGQRVTISCSGISSNL
744
AE

p1409

GSNTVNWFQQLPGTAPKLLIYNSNRRP

WD

SGVPDRFSGSKSGTSASLAISGLQSEDEG

DSL

DYYCAEWDDSLSTWVFGGGTHLTVL

STW

V

COVD21_P3_L_D11-
747
QSVLTQPASVSGSPGQSITISCTGTSSDI
748
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

COVD21_P1_L_C3-
751
QSVLTQPPSASGSPGQSVTISCTGTSSD
752
SSY

p1409

VGGYKYVSWYQQHPGKAPKLMIYEVSK

AGS

RPSGVPDRFSGSKSGNTASLTVSGLQAE

NN

DEADYYCSSYAGSNNHVFGGGTKLTVL

HV

COVD21_P2_L_F11-
755
SYVLTQPPSVSVAPGKTARITCGGNNIG
756
QV

p1409

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDLFGGGTKLTVL

DL

KAPPA

COVD21_P1_K_C4-
759
DIQMTQSPSSLSASVGDRVTITCRASQSI
760
QQS

p1389

ASYLNWFQQKPGKAPKLLIYAASSLQSG

YSS

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PPT

CCQQSYSSPPTFGQGTKLEIK

COVD21_P1_K_G9-
763
DIQMTQSPXXLSASVGDRVTITCQASQ
764
QQY

p1389

DISNYLNWYQQKPGKAPKLLIYDASNLE

DNR

TGVPSRFSGSGSGTDFTFTISSLQPEDIA

LFT

TYYCQQYDNRLFTFGPGTKVDIK

COVD21_P2_K_F7-
767
DIQMTQSPSSLSASVGDRVTITCRASQSI
768
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YNT

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PPIT

YCQQSYNTPPITFGPGTKVDIK

COVD21_P2_K_D1-
771
DIQMTQSPXSLSASVGDRVTITCRASQS
772
QQS

p1389

ISSYLNWYQQKPGKAPKLLIYAASSLQS

YSS

GVPSRFSGSGSGTDFTLTISSLQPEDFAT

TLT

YFCQQSYSSTLTFGGGTKVEIK

LAMBDA

COVD21_P3_L_E1-
775
QSALTQPASVSGSPGQSITISCTGTSSDV
776
SSY

p1409

GGYNYVSWYRQHPGKAPKLMIYDVSN

TSSS

RPSGVSNRFSGSKSGNTASLTISGLQAE

TPD

DEADYYCSSYTSSSTPDVFGSGTKVTVL

V

COVD21_P1_L_F8-
779
NFMLTQPHSVSESPGKTVTISCTGSSGSI
780
QSY

p1409

ASNYVQWYQQRPGSAPTTVIYEDNQR

DSS

PSGVPDRFSGSIDSSSNSASLTISGLKTED

NR

EADYYCQSYDSSNRWVFGGGTKLTVL

WV

COVD21_P3_L_D4-
783
QSALTQPASVSGSPGQSITISCTGTSSDI
784
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

KAPPA

COVD21_P2_K_D4-
787
DVVMTQSPLSLPVTLGQPASISCRSSQS
788
MQ

p1389

LVYSDGNTYLNWFQQRPGQSPRRLIYK

GTH

VSNRDSGVPDRFSGSGSGTDFTLKISRV

WP

EAEDVGVYYCMQGTHWPPYTFGQGTK

PYT

LEIK

COVD21_P2_K_G9-
791
DIQMTQSPSSLSASVGDRVTITCRASQSI
792
QQS

p1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSRSGTDFTLTISSLQPEDFATY

PPL

YCQQSYSTPPLTFGGGTKVEIK

T

COVD21_P1_K_H9-
795
DIQMTQSPSTLSASVGDRVTITCRANQS
796
QQY

p1389

ISSWLAWYQQKPGKAPKLLIYKASSLES

NSY

GVPSRFSGSGSGTEFTLTISSLQPDDFAT

WT

YYCQQYNSYWTFGQGTKVEIK

COVD21_P2_K_G8-
799
DIQMTQSPSSLSASVGDRVTITCQASQD
800
QQY

p1389

INNYLNWYQQKPGKAPKLLIYDASNLET

DNL

GVPSRFSGSGSGTDFAFTISSLQPEDIAT

PRT

YYCQQYDNLPRTFGQGTKVEIK

COVD21_P2_K_E12-
803
DIQMTQSPSSLSASVGDRVTITCQASQD
804
QQY

p1389

ISNYLNWYQQKPGKAPELLIYDASNLET

DNL

GVPSRFSGSGSGTDFTFTISSLQPEDIAT

PLT

YYCQQYDNLPLTFGGGTKVEI

COVD21_P3_K_H4-
807
EIVLTQSPATLSLSPGERATLSCRASQSV
808
QQ

p1389

SSYLAWYQQKPGQAPRLLIYDASNRAT

RSN

GIPARFSGSGSGTDFTLTISSLEPEDFAVY

WPL

YCQQRSNWPLTFGGGTKVEIK

T

COVD21_P2_K_C4-
811
EIVLTQSPXXLSLSPGERATLSCRASQSVS
812
QQY

p1389

SRNLAWYQQKPGQAPRLLIDGASSRAT

GSS

GIPDRFSGSGSGTDFTLTISRLEPEDFAV

PAIT

YYCQQYGSSPAITFGQGTRLEIK

COVD21_P2_K_G2-
815
DIQMTQSPSSLSASVGDRVTITCRASQSI
816
QQS

p1389

SSYLNWYQQKPGIAPKLLIYAASSLQSG

YST

VPSRFSGIGSGTDFTLTISSLQPEDFATYY

PW

CQQSYSTPWTFGQGTKVEIK

T

COVD21_P1_K_H10-
819
DIQMTQSPSSLSASVGDRVTITCRASQSI
820
QQS

p1389

SSYLNWYQQRPGKAPKLLIYAASSLQSG

YSTL

FPSRFSGSGSGTDFTLTISSLQPEDFATYY

MYT

CQQSYSTLMYTFGQGTKLEI

COVD21_P2_K_B1-
823
DIVMTQSPXSLAVSLGERATINCKSSQS
824
QQY

p1389

VLYSSNNKNYLAWYQQKPGQPPKLLIY

YST

WASTRESGVPDRFSGSGSGTDFTLTISSL

PFT

QAEDVAVYYCQQYYSTPFTFGPGTKVDI

K

COVD21_P3_L_E6-
827
QSVLTQPPSASGTPGQRVTISCSGSSSNI
828
AA

p1409

GSNTVNWYQQLPGTGPKLLIYSNNERP

WD

SGVPDRFSGSKSGTSASLAISGLQPEDEA

DSL

DYYCAAWDDSLNGPVFGTGTKVTVL

NGP

V

COVD21_P3_L_A5-
831
QSVLTQPRSVSGSPGQSVTISCTGTSSD
832
CSY

p1409

VGGYNYVSWYQQHPGKAPKLMIYDVS

AGS

KRPSGVPDRFSGSKSGNTASLTISGLQA

FW

EDEADYYCCSYAGSFWVFGGGTKLTVL

V

COVD21_P3_L_C12-
835
QSVLTQPASVSGSPGQSITISCAGTSSDV
836
SSY

p1409

GAYNYVSWYQQHPGKAPKLMIYDVSN

TSSS

RPSGVSNRFSGSKSGNTASLTISGLQAE

TW

DEADYYCSSYTSSSTWVFGGGTKLTVL

V

COVD21_P2_K_D8-
839
DIQMTQSPSSVSASVGDRVTITCRASQ
840
QQ

p1389

GISSWLAWYQQKPGKAPKLLIYAASSLQ

ANS

SGVPSRFSGSGSGTDFTLTISSLQPEDFA

LPLT

TYYCQQANSLPLTFGGGTKVEIK

COVD21_P1_K_B11-
843
DVVMTQSPLSLPVTLGQPASISCRSSQS
844
MQ

p1389

LVFSDGNTYLNWFQQRPGQSPRRLIYK

GTH

VSNRDSGVPDRFSGSGSGTDFTLKISRV

WP

EAEDVGVYFCMQGTHWPWTFGQGTK

WT

VEIK

COVD21_P1_K_C9-
847
DVVMTQSPLSLPVTLGQPASISCRSSQS
848
MQ

p1389

LVYIDGNTYLNWFQQRPGQSPRRLIYKV

GTH

SNRDSGVPDRFSGSGSGTDFTLKISRVE

WP

AEDVGVYYCMQGTHWPYTFGQGTKLE

YT

IK

LAMBDA

COVD21_P3_L_H8-
851
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
852
QSY

p1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAED

LSG

EADYYCQSYDSSLSGPYVFGTGTKVTVL

PYV

COVD21_P2_L_E10-
855
QSVLTQPRSVSGSPGQSVTISCTGTSSD
856
CSY

p1409

VGGYNYVSWYQQHPGKAPKLMIYDVS

AGS

KRPSGVPDRFSGSKSGNTASLTISGLQA

YTY

EDEADYYCCSYAGSYTYVFGTGTKVTVL

V

KAPPA

COVD21_P2_K_A4-
859
AIQLTQSPSSLSASVGDRVTITCRASQGI
860
QQF

p1389

SSALAWYQQKPGKAPKFLIYDASSLESG

NNY

VPSRFSGSGSGTDFTLTISSLQPEDFATY

PLT

YCQQFNNYPLTFGGGTKVEIK

COVD21_P2_K_G11-
863
DIVMTQSPLSLPVTPGEPASISCRSSQSL
864
MQ

p1389

LHSNGYNYLDWYLQKPGQSPQLLIYLGS

ALQ

NRASGVPDRFSGSGSGTDFTLKISRVEA

TPIT

EDVGVYYCMQALQTPITFGQGTRLEIK

LAMBDA

COVD21_P3_L_G10-
867
QSVLTQPASVSGSPGQSITISCTGTSSDV
868
SSYI

p1409

GGYNYVSWYQQHPGKAPKLIIYNVSNR

SSN

PSGVSNRFSGSKSGNTASLTISGLQAED

TV

EADYYCSSYISSNTVFGGGTKLTVL

COVD21_P1_L_H2-
871
SYVLTQPPSVSVSPGQTARITCSGDALP
872
QSA

p1409

NQYAYWYQQKPGQAPVLVIYKDSERPS

DSR

GIPERFSGSSSGTTVTLTISGVQAEDEAD

GV

YYCQSADSRGVFGGGTKLTVL

COVD21_P1_L_A8-
875
SYVLTQPPSVSVAPGKTARITCGGNNIG
876
QV

p1409

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDHLYWVFGGGTKLTV

DHL

L

YW

V

KAPPA

COVD21_P2_K_A3-
879
EIVLTQSPVSLSLSPGERATLSCRASQSVS
880
QQY

p1389

SSYLAWYQQKPGQAPRLLIYGASSRATG

GSS

IPDRFSGSGSGTDFTLTISRLEPEDFAVYY

PGT

CQQYGSSPGTFGQGTKVEIK

LAMBDA

COVD21_P3_L_G1-
883
QSVLTQPASVSGSPGQSITISCTGTSSDI
884
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

KAPPA

COVD21_P2_K_A2-
887
DIQLTQSPSFLSASVGDRVTITCRASQGI
888
QHL

p1389

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NG

VPSRFSGSGSGTEFTLTISSLQPEDSATYY

CQHLNGFGPGTKVDIK

COVD21_P1_K_F7-
891
DIQMTQSPSSLSASVGDRVTITCRASQG
892
QQY

p1389

ISNSLAWYQQKPGKAPKLLLYAASRLES

YST

GVPSRFSGSGSGTDYTLTINSLQPEDFAT

PRT

FYCQQYYSTPRTFGQGTKVEIK

COVD21_P2_K_C8-
895
EIVLTQSPGTLSLSPGERATLSCRASQSV
896
QQY

p1389

SSSYLAWYQQKPGQAPRLLIYGASSRAT

GSS

GIPDRFSGSGSGTDFTLTISRLEPEDFAV

PRT

YYCQQYGSSPRTFGQGTKVEIK

COVD21_P2_K_A10-
899
EIVLTQSPGTLSLSPGERATLSCRASQSV
900
QQY

p1389

SSTYLAWYQQKPGQAPRLLIYGASSRAT

GSS

GIPDRFSGSGSGTDFTLTISRLEPEDFAV

PRT

YYCQQYGSSPRTFGQGTKLEIK

COVD21_P2_K_B12-
903
DIQLTQSPSFLSASVGDRVTVTCRASQG
904
QQ

p1389

ISSYLAWYQQKPGKAPKLLIYAASTLQSG

VNS

VPSRFSGSGSGTEFTLTISSLQPEDFATXY

YSH

CQQVNSYSHFGGGSKAEI

LAMBDA

COVD21_P3_L_C9-
907
QSVLTQPASVSGSPGQSITISCTGTSSDI
908
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

KAPPA

COVD21_P2_K_H7-
911
DIQMTQSPXSLSASVGDRVTITCRASQS
912
QQS

p1389

ISSYLNWYQQKPGKAPKLLIYAASSLQS

YST

GVPSRFSGSGSGTDFTLTISSLQPEDFAT

WT

YYCQQSYSTWTFGQGTKVEIK

LAMBDA

COVD21_P2_L_F1-
915
NFMLTQPHSVSESPGKTVTISCTGSSGSI
916
QSY

p1409

ASNYVQWYQQRPGSAPTTVIYEDNQR

DSG

PSGVPDRFSGSIDSSSNSASLTISGLKTED

NVV

EADYYCQSYDSGNVVFGGGTKLTVL

COVD21_P2_L_C10-
919
SYVLTQPPSVSVSPGQTARITCSGDALP
920
QSA

p1409

KQYAFWYQQKPGQAPVLVIYKDSERPS

DSS

GIPERFSGSSSGTTVTLTISGVQAEDEAD

GTY

YYCQSADSSGTYVVFGGGTRLTVL

VV

KAPPA

COVD21_P3_K_H10-
923
DIQMTQSPSSLSASVGDRVTITCRASQSI
924
QQS

p1389

SSYLNWYQQKPGKAPKLLIYVASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATY

RT

YCQQSYSTRTFGQGTKVEIK

COVD21_P1_K_D8-
927
EIVLTQSPGTLSLSPGERATLSCRASQSV
928
QQY

p1389

SSSYLAWYQQKPGQAPRLLIYGASSRAT

GSS

GIPDRFSGSGSGTDFTLTISRLEPEDFAV

PYT

YYCQQYGSSPYTFGQGTKLEIK

LAMBDA

COVD21_P1_L_D9-
931
SYVLTQPPSVSVSPGQTARITCSGDALP
932
QSA

p1409

KQYAYWYQQKPGQAPVLVIYKDSERPS

DSR

GIPERFSGSSSGTTVTLTISGVQAEDEAD

KVV

YYCQSADSRKVVFGGGTKLTVL

COVD21_P3_L_G3-
935
QSVLTQPPSASGTPGQRVTISCSGSSSNI
936
AA

p1409

GSNTVNWYQQLPGTAPKLLIYSNNQRP

WD

SGVPDRFSGSKSGTSASLAISGLQSEDEA

DSL

DYYCAAWDDSLNGYVFGTGTKVTVL

NGY

V

COVD21_P2_L_A5-
939
SYVLTQPPSVSVAPGKTARITCGGNDIG
940
QV

p1409

SNGVYWYQQKPGQAPVLVIYYDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDHVVFGGGTKLTVL

DHV

V

KAPPA

COVD21_P1_K_E10-
943
EIVLTQSPATLSLSPGERATLSCRASQSV
944
QQ

p1389

SSYLAWYQQKPGQAPRLLIYDASNRAT

RIT

GIPARFSGSGSGTDFTLTISSLEPEDFAVY

YCQQRITFGQGTRLEIK

LAMBDA

COVD21_P3_L_F9-
947
QSALTQPASVSGSPGQSITISCTGTSSDI
948
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVXNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

COVD21_P2_L_D6-
951
SYVLTQPPSVSVAPGKTARITCGGNNIG
952
QV

p1409

SKSVHWYQQKPGQAPLLVIYYDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDETD

SSS

YYCQVWDSSSDPHVVFGGGTKLTV

DPH

VV

COVD21_P1_L_G3-
955
QSALTQPASVSGSPGQSITISCTGTSSDV
956
SSY

p1409

GGYNYVSWYQHHPGKAPKLMIYDVSN

TSSS

RPSGVSNRFSGSKSGNTASLTISGLQAE

TLE

DEADYYCSSYTSSSTLEGVFGGGTKLTVL

GV

KAPPA

COVD21_P2_K_E6-
959
DIVMTQSPLSLPVTPGEPASISCRSSQSL
960
MQ

p1389

LHSNGYNYLDWYLQKPGQSPQLLIYLGS

ALQ

NRASGVPDRFSGSGSGTDFTLKISRVEA

TPH

EDVGVYYCMQALQTPHTFGGGTKVEIK

T

COVD21_P2_K_G1-
963
EIVLTQSPATLSLSPGERATLSCRASQSV
964
QQ

p1389

STYLAWYQQKPGQAPRLLIYDASNRAT

RSN

GIPARFSGSGSGTDFTLTISSLEPEDFAVY

WLF

YCQQRSNWLFTFGPGTKVDIK

T

COVD21_P3_L_G7-
967
QSXXTQPRSVSGSPGQSVTISCTGTSSD
968
CSY

p1409

VGGYNCVSWYQQHPGKAPKLMIYDVS

AGS

KRPSGVPDRFSGSKSGNTASLTISGLQA

YTP

EDEADYYCCSYAGSYTPWVFGGGTKLT

WV

VL

COVD21_P2_L_D5-
971
QSVLTQPPSASGSPGQSVTISCTGTSSD
972
SSY

p1409

VGGYNYVSWYQQHPGKAPKLMIYEVS

AGS

KRPSGVPDRFSGSKSGNTASLTVSGLQA

NN

EDEADYYCSSYAGSNNWVFGGGTKLTV

WV

L

COVD21_P1_L_A9-
975
QSVLTQEPSLTVSPGGTVTLTCASSTGA
976
LLYY

p1409

VTSGYYPSWFQQKPGQAPRALIYSTSN

GGA

KHSWTPARFSGSLLGGKAALTLSGVQP

WV

EDEADYYCLLYYGGAWVFGGGTKLTVL

COVD21_P3_L_A8-
979
QSALTQPASVSGSPGQSITISCTGTSSDI
980
SSY

p1409

GVYNYISWSQQHPGKAPKVMIYDVTN

RGS

RPSGVSNRFSGSKSGNTASLTISGLQAE

STP

DEADYYCSSYRGSSTPYVFGTGTKVTVL

YV

COVD21_P2_L_B6-
983
NFMLTQPHSVSESPGKTVTISCTGSSGSI
984
QSY

p1409

ASNYVQWYQQRPGSAPTTVIYEDNQR

DSR

PSGVPDRISGSIDSSSNSASLTISGLKTED

NVV

EADYYCQSYDSRNVVFGGGTRLTVL

COVD21_P2_L_B6-
987
NFMLTQPHSVSESPGKTVTISCTGSSGSI
988
QSY

p1409

ASNYVQWYQQRPGSAPTTVIYEDNQR

DSR

PSGVPDRISGSIDSSSNSASLTISGLKTED

NVV

EADYYCQSYDSRNVVFGGGTRLTVL

COVD21_P1_L_D4-
991
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
992
QSY

p1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAED

LSD

EADYYCQSYDSSLSDSLFGGGTKLTVL

SL

COVD21_P2_K_H5-
995
DIQMTQSPVSLSASVGDRVTITCRASQS
996
QQY

p1389

ISSWLAWYQQKPGKAPKLLIYKASSLES

NSY

GVPSRFSGSGSGTEFTLTISSLQPDDFAT

ST

YYCQQYNSYSTFGQGTKVEIK

LAMBDA

COVD21_P1_L_F4-
999
QSVLTQPRSVSGSPGQSVTISCTGTSSD
1000
YSY

p1409

VGGYNYVSWYQQHPGKAPKLMIYDVS

AGS

KRPSGVPDRFSGSKSGNTASLTISGLQA

YTF

EDEADYYCYSYAGSYTFVFGGGTKLTVL

V

COVD21_P3_L_C4-
1003
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1004
QSY

p1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAED

LSG

EADYYCQSYDSSLSGYVVFGGGTKLTVL

YVV

COVD21_P1_L_E2-
1007
QSVLTQPPSASGTPGQRVTISCSGSSSNI
1008
AA

p1409

GSNYVYWYQQLPGTAPKLLIYRNNQRP

WD

SGVPDRFSGSKSGTSASLAISGLRSEDEA

DSL

DYYCAAWDDSLSGYWVFGGGTKLTVL

SGY

WV

KAPPA

COVD21_P2_K_C5-
1011
DIQMTQSPSTLSASVGDRVTITCRASQSI
1012
QQY

p1389

SSWLAWYQQKPGKAPKLLIYKASSLESG

NSF

VPSRFSGSGSGTEFTLTISSLQPDDFATY

SYT

YCQQYNSFSYTFGQGTKLEIK

COVD21_P1_K_H4-
1015
EIVMTQSPATLSVSPGERATLSCRASQS
1016
QQY

p1389

VSSNLAWYQQKSGQAPRLLIYGASTRA

NN

TGIPARFSGSGSGTEFTLTISSLQSEDFAV

WL

YYCQQYNNWLGTFGQGTKVEFK

GT

COVD21_P2_K_C6-
1019
EIVMTQSPATLSVSPGERATLSCRASQS
1020
QQY

p1389

VSSNLAWYQQKPGQAPRLLIYGASTRA

NN

TGIPARFSGSGSGTEFTLTISSLQSEDFAV

WPL

YYCQQYNNWPLTFGGGTKVEIK

T

TABLE 9

Anti-SARS-CoV-2 IgG antibodies from COV47

SEQ

SEQ

ID

ID

SEQUENCE_ID
NO
aa
NO
cdr3_aa

HEAVY

COV047_P3_IgG_43-
1021
EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNY
1022
AREGEV

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG

EGYNDF

RFTISRDKSKNTLYLQMNRLRAEDTAVYYCAREG

WSGYSR

EVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS

DRYYFDY

COV047_P4_IgG_57-
1025
EVQLVESGGGLIQPGGSLRLSCAASGFSVSSNY
1026
AREGEV

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG

EGYYDF

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG

WSGYSR

EVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS

DRYYFDY

COV047_P4_IgG_58-
1029
EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNY
1030
AREGEV

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSLKG

EGYYDF

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG

WSGYSR

EVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS

DRYYFDY

COV047_P5_IgG_26-
1033
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
1034
AREGDV

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG

EGYYDF

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG

WSGYSR

DVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS

DRYYFDY

COV047_P5_IgG_41-
1037
EVQLVESGGGLIQPGGSLRLSCAASGFTVRNNY
1038
AREGEV

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG

EGYYDF

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG

WSGYSR

EVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS

DRYYFDY

COV047_P5_IgG_49-
1041
EVQLVESGGGLIQPGGSLRLSCAASGFSVSSNY
1042
AREGEV

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG

EGYYDF

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREG

WSGYSR

EVEGYYDFWSGYSRDRYYFDYWGQGTLVTVSS

DRYYFDY

COV047_P3_IgG_16-
1045
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY
1046
ARDSSEV

P1369

MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK

RDHPGH

GRFTISRDNSKNALYLQMNSLRVEDTGVYYCAR

PGRSVG

DSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS

AFDI

COV047_P4_IgG_12-
1049
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY
1050
ARDSSEV

P1369

MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK

RDHPGH

GRFTISRDNSKNALYLQMSSLRVEDTGIYYCARD

PGRSVG

SSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS

AFDI

COV047_P4_IgG_65-
1053
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY
1054
ARDSSEV

P1369

MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK

RDHPGH

GRFTISRDNSKNALYLQMSSLRVEDTGIYYCARD

PGRSVG

SSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS

AFDI

COV047_P5_IgG_57-
1057
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY
1058
ARDSSEV

P1369

MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK

RDHPGH

GRFTISRDNSKNALYLQMNSLRVEDTGVYYCAR

PGRSVG

DSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS

AFDI

COV047_P3_IgG_10-
1061
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGI
1062
ARDRGG

P1369

SWVRQAPGQGLEWMGWISAYNGNTNYAQKL

HDFWSG

QGRVTMTTDTSTSTAYMELRSLRSDDTAVFYCA

YGFYYYY

RDRGGHDFWSGYGFYYYYGMDVWGQGTTVT

GMDV

VSS

COV047_P5_IgG_95-
1065
QVQLVQSGAEVKKPGASVKVSCKASGYNFTSYG
1066
ARDRGG

P1369

ISWVRQAPGQGLEWMGWISGYNGNTNYGQK

HNFWSG

FQGGVTMTTDTSTSTAYMELRSLRSDDTAVYYC

YGYYYYY

ARDRGGHNFWSGYGYYYYYGMDVWGQGTTV

GMDV

TVSS

COV047_P4_IgG_34-
1069
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM
1070
ARERGY

P1369

NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

YGGKTP

TISRDNAKNSLYLQMNSLRAEDTAVYYCARERG

PFL

YYGGKTPPFLGGQGTLVTVSS

COV047_P5_IgG_24-
1073
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYN
1074
ARERGY

P1369

MNWVRQAPGKGLEWVSCISSSSSYIYYADSVKG

DGGKTP

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARER

PFL

GYDGGKTPPFLGGQGTLVTVSS

COV047_P4_IgG_91-
1077
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
1078
AKNVGT

P1369

MHWVRQAPGKGLEWVAVTSYDGTNKYYADSV

GYNVMY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAK

YFDY

NVGTGYNVMYYFDYWGQGTLVTVSS

COV047_P5_IgG_87-
1081
QVQLVESGGGVVQPGRSLRLSCAASGFTFSRYG
1082
AKQAGP

P1369

MHWVRQAPGKGLEWVAVMSYDGSSKYYADS

YCSGGSC

VKGRFTISRDNSKNTLCLQMNSLRAEDTAVYYC

YSAPFDY

AKQAGPYCSGGSCYSAPFDYWGQGTLVTVSS

COV047_P4_IgG_69-
1085
QVQLVESGGGVVQPGRSLRLSCTASGFTFSSYG
1086
AKVGLG

P1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YSSGWY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK

GEEIDY

VGLGYSSGWYGEEIDYWGQGTLVTVSS

COV047_P5_IgG_68-
1089
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYG
1090
AKVGME

P1369

MHWVRQAPGKGLEWVAVISYDGSNKYFADSV

YSSGWY

KGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCAK

GEEIDF

VGMEYSSGWYGEEIDFWGQGTLVTVSS

COV047_P3_IgG_64-
1093
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG
1094
AKDPFPL

P1369

MHWVRQAPGKGLEWVAVISYDGNNKYYADSV

AVAGTG

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK

YFDY

DPFPLAVAGTGYFDYWGQGTLVTVSS

COV047_P5_IgG_77-
1097
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
1098
AKDPWE

P1369

MHWVRQAPGKGLEWVAVISYDGSNKHYADSV

LRQGNY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK

FDY

DPWELRQGNYFDYWGQGTLVTVSS

COV047_P3_IgG_65-
1101
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
1102
ARDYGD

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG

YYFDY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDY

GDYYFDYWGQGTLVTVSS

COV047_P5_IgG_27-
1105
EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM
1106
ARDFGE

P1369

SWVRQAPGKGLEWVSVIYSGGSTFYADSVKGR

FYFDY

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARDF

GEFYFDYWGQGTLVTVSS

COV047_P4_IgG_3-
1109
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY
1110
ARDSSEV

P1369

MTWVRQAPGKGLEWVSVLYSGGSDYYADSVK

RDHPGH

GRFTISRDNSKNALYLQMNSLRVEDTGVYYCAR

PGRSVG

DSSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS

AFDI

COV047_P5_IgG_90-
1113
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY
1114
ARDSSEV

P1369

MTWVRQAPGKGLEWVSALYSGGSDYYADSVK

RDHPGH

GRFTISRDNSKNTLYLQMSSLRVEDTGVYYCARD

PGRSVG

SSEVRDHPGHPGRSVGAFDIWGQGTMVTVSS

AFDI

COV047_P3_IgG_24-
1117
EVQLVESGGGLVQPGGSQRLSCAASGFTVSSNY
1118
ARIANY

P1369

MSWIRQAPGKGLEWVSVIYSGGSAYYVDSVKG

MDV

RFTISRDNSKNTLYLQMNSLRPEDTAVYYCARIA

NYMDVWGKGTTVTVSS

COV047_P5_IgG_94-
1121
EVQLVESGGGLVQPGGSQRLSCAASGFTVSSNY
1122
ARIANY

P1369

MSWIRQAPGKGLEWVSVIYSGGSAYYVDSVKG

MDV

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIA

NYMDVWGKGTTVTVSS

COV047_P3_IgG_8-
1125
EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWI
1126
ARLSDR

P1369

GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ

WYSPFD

GQVTISADKSITTAYLQWSSLKASDTAMYYCARL

P

SDRWYSPFDPWGQGTLVTVSS

COV047_P3_IgG_91-
1129
EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWI
1130
ARLSDR

P1369

GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ

WYSPFD

GQVTISADKSITTAYLQWSSLKASDTAMYYCARL

P

SDRWYSPFDPWGQGTLVTVSS

COV047_P3_IgG_77-
1133
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYN
1134
ARVPRG

P1369

ITWVRQAPGQGLEWVGWISAYNGNTNYAQKF

YYDRSGY

QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

YYLPHYL

RVPRGYYDRSGYYYLPHYLDYWGQGTLVTVSS

DY

COV047_P5_IgG_78-
1137
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGI
1138
ARDSAYS

P1369

SWVRQAPGQGLEWMGWISAYNGNTNYAQKL

GYDFFEA

QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

PRDY

RDSAYSGYDFFEAPRDYWGQGTLVTVSS

COV047_P5_IgG_21-
1141
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDI
1142
ARPSSSL

P1369

SWVRQAPGQGLEWMGWINAYNGNTNYAQKL

TSYFDY

QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

ARVPASY

RPSSSLTSYFDYWGQGTLVTVSS

COV047_P3_IgG_53-
1145
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGI
1146
GDDDYY

P1369

SWVRQAPGQGLEWMGWISAYNGNTNYAQKL

YYYGMD

QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

V

RVPASYGDDDYYYYYGMDVWGQGTTVTVSS

COV047_P4_IgG_27-
1149
QVQLVQSGAEVKKPGASVKVSCKASGYIFTDYS
1150
ARGPLF

P1369

MHWVRQAPGQGLEWIGWVNPNSGGTNYAQ

HRLVYDF

KFQGWVTMARDTSITTVYMELSRLKSDDTAVYF

WSGYHD

CARGPLFHRLVYDFWSGYHDGFDMWGQGTM

GFDM

VTVSS

COV047_P5_IgG_10-
1153
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
1154
ARTPRVY

P1369

LHWVRQAPGQGLEWMGWINPNSGGTNYAQK

DPTLPN

FQGWVTMTRDTSISTAYMELSRLRSDDTAVYYC

QWLVGE

ARTPRVYDPTLPNQWLVGEYYCDYWGQGTLVT

YYCDY

VSS

COV047_P4_IgG_60-
1157
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
1158
ARGTEY

P1369

IHWVRQAPGQGLEWMGWINPNSGGTKYAQK

NWNSA

FQGWVTMTRDTSITTVYMELSRLRSDDTAVYYC

HFDP

ARGTEYNWNSAHFDPWGQGTLVTVSS

COV047_P5_IgG_29-
1161
QVQLVQSGAEVKKPGASVKVSCMASGYTLTAY
1162
VRGGTW

P1369

YIHWVRQAPGQGLESLGWINPRTGGTTILQKFQ

NYVGGE

GWVTMTRDTSINTVYLELPRVTLADTAVYYCVR

V

GGTWNYVGGEVWGQGTAVTVSS

COV047_P3_IgG_61-
1165
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHY
1166
ASSSSTP

P1369

MHWVRQAPGQGLEWMGIINPSGGGTSYAQK

DYYGMD

FQGRVTMTRDTSMSTVYMELSSLRSEDTAVYYC

V

ASSSSTPDYYGMDVWGQGTTVTVSS

COV047_P4_IgG_48-
1169
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYI
1170
ARASTST

P1369

HWVRQAPGQGLEWMGIINPSDGGTSYAQKFQ

TNWND

GRVTMTRDTSTSTVYMELSSLRSEDTAVYSCAR

ALSLGC

ASTSTTNWNDALSLGCWGQGTLVTVSS

COV047_P3_IgG_78-
1173
QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYY
1174
ARGGSS

P1369

MHWVRQAPGQGLEWMGIINPSGGSTSYAQKF

RYCSSTS

QGRVTMTRDTSTSTVYMELNSLRSEDTAVYYCA

CYSFGVD

RGGSSRYCSSTSCYSFGVDNFDYWGQGTLVTVS

NFDY

S

COV047_P4_IgG_43-
1177
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAI
1178
ARVGYG

P1369

SWVRQAPGQGLEWMGGIIPIFGTANYAQKFQ

YYFDY

GRVTITADESTSTAYMELSSLRSEDTAVYYCARV

GYGYYFDYWGQGTLVTVSS

COV047_P4_IgG_89-
1181
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSDA
1182
ARDLRYC

P1369

ISWVRQAPGQGLEWMGGIMPIFGTANYAQKF

SGGRCL

QGRVTITADESTSTAYMELSSLRSEDTAVYYCAR

WWFDP

DLRYCSGGRCLWWFDPWGQGTLVTVSS

COV047_P5_IgG_15-
1185
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNY
1186
ARYTYYY

P1369

AISWVRQAPGQGLEWMGGIIPIFGTANYAQKL

DRSGYY

QGRVTITTDESTSTAYMELSSLRSEDTAVYYCAR

RPDYFDY

YTYYYDRSGYYRPDYFDYWGQGTLVTVSS

COV047_P3_IgG_54-
1189
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSAW
1190
TTTNDY

P1369

MSWVRQAPGKGLEWVGRIKTKTDGGTKDYAA

GDYSPA

PVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYC

Y

TTTNDYGDYSPAYWGQGTLVTVSS

COV047_P5_IgG_72-
1193
EVQLVESGGGLVKPGGSLRLSCAVSGFTFSNVW
1194
TSQVWL

P1369

MRWVRQAPGKGXEWVGRIKSKTDGGTTXYAA

RGPGDY

PVKGRFTXSRDDSKNTLYLQMNSLKTEDTAVYY

CTSQVWLRGPGDYWGQGTLVTVSS

COV047_P4_IgG_17-
1197
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYIM
1198
AREAEW

P1369

NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

EAFDI

TISRDNAKNSLYLQMNSLRAEDTAVYYCAREAE

WEAFDIWGQGTMVTVSS

COV047_P5_IgG_84-
1201
EVQLVESGGGLVKPGGSLRLSCAASGLTFTAYR
1202
ARDVAS

P1369

MNWVRQAPGKGLEWLSSISNTNGDIYYADSVK

NYAYFDL

GRFTISRDNAKNSLYLQMNSLRADDTAVYYCAR

DVASNYAYFDLWGQGTLVTVSS

COV047_P4_IgG_67-
1205
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM
1206
ARERYG

P1369

NWVRQAPGKGLEWVSSISSSTSYIYYADSVKGR

DN

FTISRDNAKNSLYLQMNSLRAEDTAVYYCARERY

GDNWGQGTLVTVSS

COV047_P3_IgG_84-
1209
EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYSM
1210
ARVVAN

P1369

NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

WFDP

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVVA

NWFDPWGQGTLVTVSS

COV047_P3_IgG_40-
1213
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM
1214
AREAAR

P1369

NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

RYDFWS

TISRDNAKNSLYLQMNSLRAEDTAVYYCAREAA

GLNWFD

RRYDFWSGLNWFDPWGQGTLVTVSS

P

COV047_P4_IgG_36-
1217
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
1218
AKSGGR

P1369

MSWVRQAPGKGLEWVSAISGSGGSTYYADSVK

HYYDSS

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKS

GYYRLPL

GGRHYYDSSGYYRLPLDDAFDIWGQGTMVTVS

DDAFDI

S

COV047_P4_IgG_52-
1221
QVQLVESGGGVVQPGRSLRLSCADSGFTFSTYG
1222
ARAEWL

P1369

MHWVRQAPGKGLEWVALISYDGSNKYYADSV

RGAFDI

KGRFTISGDNSKNTLYLQMNSLRAEDTAVYYCA

RAEWLRGAFDIWGQGTMVTVSS

COV047_P3_IgG_70-
1225
QVQLVESGGGVVQPGRSLRLSCAASGFTFNNY
1226
ARAGWE

P1369

GMHWVRQAPGKGLEWVAVISYDGNNKYYADS

LLRIRYYF

VKDRFTISRDNSKNTLYLQMNNLRAEDTAMYYC

DF

ARAGWELLRIRYYFDFWGQGTLVTVSS

COV047_P4_IgG_31-
1229
QVQLVESGGGVVQPGRSLRLSCAASGLTFSFYAI
1230
YALFERG

P1369

HWVRQAPGKGLEWVAYISYEGSDKYYADSVKG

NWNDA

RFTISRANSKSTLYLQMNSLRAEDTAVYYCYALFE

EY

RGNWNDAEYWGQGTLVTVSS

COV047_P5_IgG_30-
1233
QVQLVESGGGVVQPGRSLRLSCAASGFTFSGYD
1234
AKDLGSS

P1369

IHWVRQAPGKGLEWVAVISYDGSSKFYADSVK

LYYDAFD

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK

I

DLGSSLYYDAFDIWGQGTMVTVSS

COV047_P4_IgG_20-
1237
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
1238
AKVDGS

P1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YYYYYYG

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK

MDV

VDGSYYYYYYGMDVWGQGTTVTVSS

COV047_P4_IgG_22-
1241
QVQLVESGGGVVQPGRSLRLSCAASGFTFRTYA
1242
AREQEA

P1369

MHWVRQAPGKGLEWVAVILSDGNNKYYADSV

NYYDISG

KGRFTISRDNSKNTLYLQMNSLRAEDTAIFYCAR

YYHWGE

EQEANYYDISGYYHWGESLGYWGQGTLVTVPS

SLGY

COV047_P4_IgG_70-
1245
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
1246
ARGGRY

P1369

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

YDSSGY

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

NGTYEF

ARGGRYYDSSGYNGTYEFDYWGQGTLVTVSS

DY

COV047_P4_IgG_50-
1249
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
1250
ARDRKYS

P1369

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

SGWSVV

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

NFDY

ARDRKYSSGWSVVNFDYWGQGTLVTVSS

COV047_P5_IgG_59-
1253
QVQLVESGGGVVQPGRSLRLSCAASGFMFSSY
1254
ARDGLN

P1369

GMHWVRQAPGKGLEWVAVIWYDGSNKYYAD

WNVPHY

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

GMDV

ARDGLNWNVPHYGMDVWGQGTTVTVSS

COV047_P5_IgG_58-
1257
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
1258
ARVGGA

P1369

MSWVRQAPGKGLEWVSVIYSGYSTYYVDSVKG

HSGYDG

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARV

SFDY

GGAHSGYDGSFDYWGQGTLVTVSS

COV047_P5_IgG_8-
1261
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
1262
ARDRVIY

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVKG

GMDV

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD

RVIYGMDVWGQGTTVTVSS

COV047_P4_IgG_11-
1265
EVQLVETGGGLIQPGGSLRLSCAASGFTVSSNY
1266
ARAISES

P1369

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG

PRYGVY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAI

SESPRYGVYWGQGTLVTVSS

COV047_P3_IgG_14-
1269
EVQLVETGGGLIQPGGSLRLSCAASEFTVSSNYM
1270
ARVLPFG

P1369

SWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRF

DYFDY

TISRDNSKNTLYLQMNSLRAEDTAVYYCARVLPF

GDYFDYWGQGTLVTVSS

COV047_P5_IgG_91-
1273
EVQLVESGGGLVQPGGSLRLSCAASGFSVSTKY
1274
ARDSSEV

P1369

MTWVRQAPGKGLEWVSALYSGGSDYYADSVK

RDHPGH

GRFTISRDNSKNTLYLQMSSLRVEDTGVYYCARD

PGRSVG

SSEVRDHPGHPGRSVGAFDIWGQGTMV

AFDI

COV047_P4_IgG_51-
1277
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNY
1278

P1369

MSWVRQAPGKGLEWVSVIYSGGSAYYADSVKG

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDS

TPGYGDYISGQGTLVTVSS

COV047_P3_IgG_47-
1281
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNY
1282
ARDYGD

P1369

MSWVRQAPGKGLEWVSVIYSGGSAYYADSVKG

FYFDY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDY

GDFYFDYWGQGTLVTVSS

COV047_P5_IgG_71-
1285
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNY
1286
ARDLRD

P1369

MSWVRQAPGKGLEWVSVIYSGGSAYYADSVKG

QDGYSY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDL

GAFDY

RDQDGYSYGAFDYWGQGTLVTVSS

COV047_P5_IgG_16-
1289
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
1290
ASAFWQ

P1369

MHWVRQAPGKGLVWVSHINGDGSSTSYADSV

RGNFDY

KGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCA

SAFWQRGNFDYWGQGTLVTVSS

COV047_P3_IgG_25-
1293
EVQLVESGGGLVQPGGSLRLSCVASGFTFSSYW
1294
ARPTAV

P1369

MHWVRQVPGKGPVWVSHINSEGSSTNYADSV

AAAGNY

RGRFTISRDNAKDTLYLQMNNLRAEDTAVYYCA

FYYYGM

RPTAVAAAGNYFYYYGMDVWGQGTTVTVSS

DV

COV047_P4_IgG_86-
1297
QLQLQESGSRLVKPSQTLSLTCAVSGGSISSGGYS
1298
ARFTNP

P1369

WSWIRQPPGKGLQWIGYIYHSGSTYYNPSLKSR

NYYDSS

VTISVDRSKNQFSLKLSSVTAADTAVYYCARFTN

GYYGFD

PNYYDSSGYYGFDYWGQGTLVTVSS

Y

COV047_P4_IgG_39-
1301
QVQLQESGPGLVKPSQTLSLTCAVSGDSIRSGGY
1302
ARVKGW

P1369

YWSWVRQHPGRGLEWIGYIYFSGTTYYNPSLKS

LRGYFDY

RVTISVDTSEKQFSLKLTSVTDADTAVYFCARVK

GWLRGYFDYWGQGAPVTVSA

COV047_P4_IgG_83-
1305
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSN
1306
ARVAAFL

P1369

WWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLK

DY

SRVTISVDKSKNQFSLKLSSVTAADTAVYYCARV

AAFLDYWGQGTLVTVSS

COV047_P3_IgG_38-
1309
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSN
1310
ARTWIQ

P1369

WWSWVRQPPGKGLEWIGEIYHSGTTNYNPSLK

PHNWFD

SRVTISVDKSKNQFSLKLSSVTAADTAVYYCART

P

WIQPHNWFDPWGQGTLVTVSS

COV047_P4_IgG_72-
1313
QVQLQESGPGLVKPSETLSLTCTVSGGSISNYYW
1314
ARGPPRL

P1369

SWIRQPPGKGLEWIGYIYTSGSTNYNPSLKSRVTI

LWFGES

SVDTSKNQFSLKLSSVTAADTAVYYCARGPPRLL

PPTYWY

WFGESPPTYWYFNLWGRGTLVTVSS

FNL

COV047_P4_IgG_38-
1317
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
1318
ARYQLA

P1369

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTI

PGSGSYY

SVDTSKNQFSLKLSSVTAADTAVYYCARYQLAPG

NWGGY

SGSYYNWGGYPRESEYYFDYWGQGTLVTVSS

PRESEYY

FDY

COV047_P3_IgG_5-
1321
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
1322
ARHDTIF

P1369

SWIRQPPGKGLEWIGYIYYSRSTNYNPSLKSRVTI

GVGQYY

SVDTSKNQFSLKLSSVTAADTAVYYCARHDTIFG

FDY

VGQYYFDYWGQGTLVTVSS

COV047_P3_IgG_35-
1325
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
1326
ARHSWL

P1369

SWIRQPPGKGLEWIGYIYTSGSTNYNPSLKSRVTI

RGMADY

SVDTSKNQFSLKLSSVTAADTAVYYCARHSWLR

GMADYWGQGTLVTVSS

COV047_P3_IgG_49-
1329
QVQLQESGPGLVKPSETLSLTCTVSGDSMSSYF
1330
ARLKQQ

P1369

WTWIRQPPGKGLECIGYFYPSGSTNYNPSLKSR

LVGFGW

VTISIDTSKNQFSLKLSSVTAADTAVYYCARLKQQ

FDP

LVGFGWFDPWGQGTLVTVSS

COV047_P4_IgG_23-
1333
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNTA
1334
ARDILRD

P1369

AWNWIRQSPSRGLEWLGRTYYRSKWYNDYAV

TSWPHD

SVISRIIINPDTSKNQFSLQLKSVTPEDTAVYYCAR

AFDI

DILRDTSWPHDAFDIWGQGTMVTVSS

SEQ

SEQ

ID

ID

SEQUENCE_ID
NO
aa
NO
cdr3_aa

LAMBDA

COV047_P3_Lambda_43-
1023
QSVLTQPASVSGSPGQSITISCTGTSSDV
1024
SSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSS

RPSGVSNRFSGSKSGNTASLTISGLQAED

STR

EADYYCSSYTSSSTRVFGTGTKVTVL

V

COV047_P4_Lambda_57-
1027
QSVLTQPASVSGSPGQSITISCTGTSSDV
1028
SSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSS

RPSGVSNRFSGSKSGNTASLTISGLQAED

TTR

EADYYCSSYTSSTTRVFGTGTRVTVL

V

COV047_P4_Lambda_58-
1031
QSALTQPASVSGSPGQSITISCTGTSSDV
1032
SSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSIS

RPSGVSNRFSGSKSGNTASLTISGLQAED

TRV

EADYYCSSYTSISTRVFGTGTKVTVL

COV047_P5_Lambda_26-
1035
QSALTQPASVSGSPGQSITISCTGTSSDV
1036
SSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSS

RPSGVSNRFSGSKSGNTASLTISGLQAED

STR

EADYYCSSYTSSSTRVFGTGTKVTVL

V

COV047_P5_Lambda_41-
1039
QSALTQPASVSGSPGQSITISCTGTSSDV
1040
SSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSS

RPSGVSNRFSGSKSGNTASLTISGLQAED

STR

EADYYCSSYTSSSTRVFGTGTKVTVL

V

COV047_P5_Lambda_49-
1043
QSVLTQPASVSGSPGQSITISCTGTSSDV
1044
SSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSS

RPSGVSNRFSGSKSGNTASLTISGLQAED

TTR

EADYYCSSYTSSTTRVFGTGTRVTVL

V

COV047_P3_Lambda_16-
1047
QSVLTQPASVSGSPGQSITISCTGTSNDV
1048
CSY

P1409

GSYTLVSWYQQYPGKAPKLLIFEGTKRSS

AGA

GISNRFSGSKSGNTASLTISGLQGEDEAD

STF

YYCCSYAGASTFVFGGGTKLTVL

V

COV047_P4_Lambda_12-
1051
QSVLTQPASVSGSPGQSITISCTGTSNDV
1052
CSY

P1409

GSYTLVSWYQQYPGKAPKLLIFEGTKRSS

AGA

GISNRFSGSKSGNTASLTISGLQGEDEAD

STF

YYCCSYAGASTFVFGGGTKLTVL

V

COV047_P4_Lambda_65-
1055
QSALTQPASVSGSPGQSITISCTGTSNDV
1056
CSY

P1409

GSYTLVSWYQQYPGKAPKLLIFEGTKRSS

AGA

GISNRFSGSKSGNTASLTISGLQGEDEAD

STF

YYCCSYAGASTFVFGGGTKLTVL

V

COV047_P5_Lambda_57-
1059
QSVLTQPASVSGSPGQSITISCTGTSNDV
1060
CSY

P1409

GSYTLVSWYQQYPGKAPKLLIFEGTKRSS

AGA

GISNRFSGSKSGNTASLTISGLQGEDEAD

STF

YYCCSYAGASTFVFGGGTKLTVL

V

KAPPA

COV047_P3_Kappa_10-
1063
DIQMTQSPSSLSASVGDRVTITCRASQGI
1064
QKY

P1389

SNYLAWYQQRPGKVPKLLIFAASTLQSG

NSA

VPSRFSGSGSGTDFTLTISSLQPEDVATY

PRT

YCQKYNSAPRTFGQGTKVEIK

COV047_P5_Kappa_95-
1067
DIQMTQSPSSLXASVGDRVTITCRASQG
1068
QKY

P1389

ISNYLAWYQQKPGKVPKLLIYAASTLQSG

NSA

VPSRFSGSESGTDFTLTISSLQPEDVATYY

PRT

CQKYNSAPRTFGQGTKVEIK

LAMBDA

COV047_P4_Lambda_34-
1071
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1072
QSY

P1409

ASNYVQWYQQRPGSAPTTVIYEDNQRP

DSS

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

NY

ADYYCQSYDSSNYWVFGGGTKLTVL

WV

COV047_P5_Lambda_24-
1075
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1076
QSY

P1409

ASNYVQWYQQRPGSAPTTVIYEDNQRP

DSS

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

NY

ADYYCQSYDSSNYWVFGGGTKLTVL

WV

KAPPA

COV047_P4_Kappa_91-
1079
DIQMTQSPSSLSASVGDRVTITCQASQD
1080
QQ

P1389

ISNYLNWYQQKPGKAPKLLIYDTSNLER

YDN

GVPSRFSGSGSGSDFTFTISSLQPEDIATY

LPIT

YCQQYDNLPITFGQGTRLEIK

COV047_P5_Kappa_87-
1083
DIQMTQSPSSLSASVGDRVTITCQASQG
1084
QQ

P1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

YDN

GVPSRFSGSGSGTDFTFTISSLQPEDIATY

LPIT

YCQQYDNLPITFGQGTRLEIK

COV047_P4_Kappa_69-
1087
DIQMTQSPSSLSASVGDRVTITCRASQSI
1088
QQS

P1389

SSFLNWYQQKPGKAPNLLIYAASSLQSG

YRT

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PLT

CQQSYRTPLTFGGGTKVEIK

COV047_P5_Kappa_68-
1091
DIQMTQSPSSLSASVGDRVTITCRASQSI
1092
QQS

P1389

SSYLNWYQQKPGKVPKLLIYAASSLQSG

YRT

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PLT

CQQSYRTPLTFGGGTKVEIK

LAMBDA

COV047_P3_Lambda_64-
1095
SYVLTQPPSVSVAPGQTARISCGGNNIG
1096
QV

P1409

SKNVHWYQQKPGQAPVLVVYDDSDRP

WD

SGIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDPWVFGGGTKLTVL

DP

WV

COV047_P5_Lambda_77-
1099
SYVLTQPPSVSVAPGQTARITCGGNNIG
1100
QV

P1409

SKNVHWYQQKPGQAPVLVVYDDSDRP

WD

SGIPERFSGSNSGTTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDPWVFGGGTKLTVL

DP

WV

KAPPA

COV047_P3_Kappa_65-
1103
EIVMTQSPATLSVSPGERATLSCRASQSV
1104
QQ

P1389

SSNLAWYQQKPGQAPRLLIYGASTRAT

YNN

GIPARFSGSGSGTEFTLTISSLQSEDFAVY

WP

YCQQYNNWPRTFGQGTKVEIK

RT

COV047_P5_Kappa_27-
1107
EIVMTQSPATLSVSPGERATLSCRASQSV
1108
QQ

P1389

SSNLAWYQQKPGQAPRLLIYGASTRATA

YNN

IPARFSGSGSGTEFTLTISSLQSEDFAVYY

WP

CQQYNNWPRTFGQGTKVEIK

RT

LAMBDA

COV047_P4_Lambda_3-
1111
QSVLTQPASVSGSPGQSITISCTGTSNDV
1112
CSY

P1409

GSYTLVSWYQQYPGKAPKLLIFEVTKRSS

AGA

GISNRFSGSKSGNTASLTISGLQGEDEAD

STF

YYCCSYAGASTFVFGGGTKLTVL

V

COV047_P5_Lambda_90-
1115
QSALTQPASVSGSPGQSITISCTGTSNDV
1116
CSY

P1409

GSYTLVSWYQQYPGKAPKLLIFEDTKRSS

AGT

GISNRFSGSKSGNTASLTISGLQGEDEAD

STF

YYCCSYAGTSTFVFGGGTKLTVL

V

KAPPA

COV047_P3_Kappa_24-
1119
EIVMTQSPATLSVSPGERATLSCRASQSV
1120
QQ

P1389

SSHLAWYQQKPGQAPRLLIYGASTRATG

YNN

IPTRFSGSGSGTEFTLTISSLQSEDFAVYY

WP

CQQYNNWPPLTFGGGTKVEIK

PLT

COV047_P5_Kappa_94-
1123
EIVMTQSPATLSVSPGERATLSCRASQSV
1124
QQ

P1389

SSHLAWYQQKPGQAPRLLIYGASTRATG

YNN

IPTRFSGSGSGTEFTLTISSLQSEDFAVYY

WP

CQQYNNWPPLTFGGGTKVEIK

PLT

LAMBDA

COV047_P3_Lambda_8-
1127
QSVLTQEPSLTVSPGGTVTLTCGSSTGA
1128
LLSY

P1409

VTSGHYPYWFQQKSGQAPRTLIYETSIK

SGA

HSWTPARFSGSLLGGKAALTLSGAQPED

RPV

EADYYCLLSYSGARPVFGGGTKLTVL

COV047_P3_Lambda_91-
1131
QSVLTQEPSLTVSPGGTVTLTCGSSTGA
1132
LLSY

P1409

VTSGHYPYWFQQKSGQAPRTLIYETSIK

SGA

HSWTPARFSGSLLGGKAALTLSGAQPED

RPV

EADYYCLLSYSGARPVFGGGTKLTVL

KAPPA

COV047_P3_Kappa_77-
1135
DIQMTQSPSSLSASVGDRVTITCQASQD
1136
QQ

P1389

ISNYLNWYQQKPGKPPKLLIYDASNLET

YDS

GVPSRFSGSGSGTDFIFSISSLQPEDIATY

LPG

YCQQYDSLPGCSFGQGTKLEIK

CS

COV047_P5_Kappa_78-
1139
DIQMTQSPSSLSASVGDRVTITCRASQSI
1140
QQS

P1389

SSFLNWYQQKPGKAPKLLIYAASSLHSG

YRT

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPL

CQQSYRTPPLFGGGTKVEI

LAMBDA

COV047_P5_Lambda_21-
1143
SYVLTQPPSVSVAPGQTARITCGGNNIG
1144
QV

P1409

SKNVHWYQQKPGQAPVLVVYDDSDRP

WD

SGIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDRHWVFGGGTKLTVL

DRH

WV

COV047_P3_Lambda_53-
1147
SYVLTQPPSVSVSPGQTARITCSGDALPK
1148
QSA

P1409

QYAYWYQQKPGQAPVLVIYKDSERPSGI

DSS

PERFSGSSSGTTVTLTISGVQAEDEADYY

GTL

CQSADSSGTLWVFGGGTKLTVL

WV

COV047_P4_Lambda_27-
1151
QSVLTQPASVSGSPGQSITISCTGTSSDV
1152
NSY

P1409

GGYKFVSWYQQHPGKAPKLMIYEVSNR

TSS

PSGVSNRFSGSKSGNTASLTISGLQAEDE

ST

ADYYCNSYTSSSTWVFGGGTKLTVL

WV

COV047_P5_Lambda_10-
1155
QSALTQPRSVSGSPGQSVTISCTGTSSDV
1156
CSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSK

AGS

RPSGVPDRFSGSKSGNTASLTISGLQAED

YT

EADYYCCSYAGSYTWVFGGGTKLTVL

WV

COV047_P4_Lambda_60-
1159
QSALTQPASVSGSPGQSITISCTGTSSDV
1160
SSY

P1409

GGYNYVSWYQQHPGKAPKLMIYEVSN

TSS

RPSGVSNRFSGSKSGNTASLTISGLQAED

STS

EADYYCSSYTSSSTSWVFGGGTKLTVL

WV

COV047_P5_Lambda_29-
1163
QSALTQPASVSGSPGQSITVSCAGSSTD
1164
TSF

P1409

VGGYNFVSWYQHHPGRVPKLIIYEVNN

TSS

RPSGVSVRFSGSKSGNTASLTISGLQAED

SDS

EADYYCTSFTSSSDSWIFGGGTKLTVL

WI

KAPPA

COV047_P3_Kappa_61-
1167
DIQLTQSPSFLSASVGDRVTITCRASQGIS
1168
QQL

P1389

SYLAWYQQKPGKAPKLLIYGASTLQSGV

NSY

PSRFSGSGSGTEFTLTISSLQPEDFATYYC

PLC

QQLNSYPLCSFGQGTKLEIK

S

LAMBDA

COV047_P4_Lambda_48-
1171
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1172
QSY

P1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSG

PSGVPDRFSGSKSGTSASLAITGLOAEDE

LSG

ADYYCQSYDSGLSGSGVVFGGGTKLTVL

SGV

V

COV047_P3_Lambda_78-
1175
SYVLTQPPSVSVAPGQTARITCGGNNIG
1176
QV

P1409

SKSVHWYQQKPGQAPVLVVYDDGDRP

WD

SGIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDHYYVFGTGTKVTVL

DHY

YV

KAPPA

COV047_P4_Kappa_43-
1179
EIVLTQSPATLSLSPGERATLSCRASQSVS
1180
QQ

P1389

SYLAWYQQKPGQAPRLLIYDASNRATGI

RSN

PARFSGSGSGTDFTLTISSLEPEDFAVYYC

WP

QQRSNWPSFGQGTKLEIK

S

COV047_P4_Kappa_89-
1183
DIQMTQSPSSLSASVGDRVTITCRASQSI
1184
QQS

P1389

NNYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PRT

CQQSYSTPRTFGPGTKVDIK

COV047_P5_Kappa_15-
1187
AIQLTQSPSSLSASVGDRVTITCRASQGIS
1188
QQF

P1389

TVLAWYQQKPGKTPKLLIYDASSLESGA

NSY

PSRFSGSGSGTDFTLTISSLQPEDFATYYC

QLT

QQFNSYQLTFGGGTKVEIK

COV047_P3_Kappa_54-
1191
DIQMTQSPSSLSASVGDRVTITCRASQSI
1192
QQS

P1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTAFTLTISSLQPEDFATYY

PLT

CQQSYSTPLTFGGGTKVEIK

LAMBDA

COV047_P5_Lambda_72-
1195
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1196
QSY

P1409

ASNYVQWYQQRPGSAPTTVIYEDNQRP

DSS

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

LN

ADYYCQSYDSSLNWVFGGGTKLTVL

WV

COV047_P4_Lambda_17-
1199
QSVLTQPRSVSGSPGQSVTISCTGTSSDV
1200
CSY

P1409

GGYNYVSWYQQHPGKAPKLMICDVSK

AGS

RPSGVPDRFSGSKSGNTASLTISGLOAED

YT

EADYYCCSYAGSYTWVFGGGTKLTVL

WV

KAPPA

COV047_P5_Kappa_84-
1203
DIQMTQSPSSLSASVGDRVTITCRASQSI
1204
QQS

P1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPL

CQQSYSTPPLTFGGGTKVEIK

T

LAMBDA

COV047_P4_Lambda_67-
1207
QLVLTQSPSASASLGASVKLTCTLSSGHS
1208
QT

P1409

SYAIAWHQQQPEKGPRYLMSLNSDGSH

WG

SKGDGIPDRFSGSSSGAERYLTISSLQSED

PW

EADYYCQTWGPWVFGGGTKLTVL

V

KAPPA

COV047_P3_Kappa_84-
1211
DIVMTQSPDSLAVSXGERATINCKSSQS
1212
QQ

P1389

VLYSSNNKNYLAWYQQKPGQPPKLLIY

YYS

WASTRESGVPDRFSGSGSGTDFTLTISSL

TPQ

QAEDVAVYYCQQYYSTPQPSWTFGQG

PS

TKVEIK

WT

COV047_P3_Kappa_40-
1215
DIVMTQSPDSLAVSXGERATINCKSSQS
1216
QQ

P1389

VLYSSNNKNYLAWYQQKPGQPPKLLIY

YYS

WASTRESGVPDRFSGSGSGTDFTLTISSL

TML

QAEDVAVYYCQQYYSTMLTFGGGTKVE

T

IK

LAMBDA

COV047_P4_Lambda_36-
1219
QSVLTQPPSVSGAPGQRVTISCTGSSSSI
1220
QSY

P1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSG

ADYYCQSYDSSLSGSWVFGGGTKLTVL

SW

V

COV047_P4_Lambda_52-
1223
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1224
QSY

P1409

ASNYVQWYQQRPGSAPTTVIYEDNQRP

DST

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

NH

ADYYCQSYDSTNHWVFGGGTKLTVL

WV

KAPPA

COV047_P3_Kappa_70-
1227
DIQMTQSPSSLSASVGDRVTITCQASQD
1228
QQ

P1389

ISNYLNWYQQKPGKAPKFLIYGASNLET

YDN

GVPPRFSGSGSGTDFTFIISSLQPEDIATY

LPP

YCQQYDNLPPTFGGGTKVEIK

T

COV047_P4_Kappa_31-
1231
DVVMTQSPLSLPVTLGQPASISCRSSQSL
1232
MQ

P1389

VHSDGNIYLSWYQQRPGQSPRRLIYKVS

GTH

NRDSGVPDRFSASGSGTDFTLRISRVEAE

WP

DVGVYYCMQGTHWPRTFGQGTKLEIK

RT

COV047_P5_Kappa_30-
1235
DIQMTQSPSSLSASVGDRLTITCRASQSI
1236
QQS

P1389

TSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PP

CQQSYSTPPWTFGQGTKVEIK

WT

LAMBDA

COV047_P4_Lambda_20-
1239
QSVLTQPASVSGSPGQSITISCTGTSSDV
1240
SSY

P1409

GAYNYVSWYQQHPGKAPKLMIYEVSNR

TSS

PSGVSNRFSGSKSGNTASLTISGLQAEDE

STA

ADYYCSSYTSSSTAWVFGGGTKLTVL

WV

KAPPA

COV047_P4_Kappa_22-
1243
DIQLTQSPSFLSASVGDRVTITCRASQGIS
1244
QKV

P1389

SYLAWYQQKPGKAPKLLIYGASTLQSGV

NSH

PSRFSGSGSGTEFTLTISSLQPEDFASYYC

PPG

QKVNSHPPGLTFGGGTKVEI

LT

COV047_P4_Kappa_70-
1247
EIVMTQSPATLSVSPGERATLSCRASQSV
1248
QQ

P1389

SSNLAWYQQKPGQAPRLLIYGASTRAT

YNN

GIPARFSGSGSGTEFTLTISSLQSEDFAVY

WP

YCQQYNNWPPVTFGPGTKVDIK

PVT

LAMBDA

COV047_P4_Lambda_50-
1251
QSVLTQPPSVSEAPRQRVTISCSGSSSNI
1252
AA

P1409

GNNAVNWYQQLPGKAPKLLIYYDDLLP

WD

SGVSDRFSGSKSGTSASLAISGLQSEDEA

DSL

DYYCAAWDDSLNGWVFGGGTKLTVL

NG

WV

KAPPA

COV047_P5_Kappa_59-
1255
DIQMTQSPSSVSASVGDRVTITCRASQG
1256
QQ

P1389

ISSWLAWYQQKPGKAPKLLIYAASSLQS

ANS

GVPSRFSGSGSGTDFTLTISSLQPEDFAT

FPP

YYCQQANSFPPLTFGGGTKVEIK

LT

LAMBDA

COV047_P5_Lambda_58-
1259
QSALTQPASVSGSPGQSITISCTGTSSDV
1260
CSY

P1409

GSYNLVSWYQQHPGKAPKLMIYEGSKR

AGS

PSGVSNRFSGSKSGNTASLTISGLQAEDE

ST

ADYYCCSYAGSSTWVFGGGTKLTVL

WV

KAPPA

COV047_P5_Kappa_8-
1263
DIQMTQSPSSLSASVGDRVTITCQASQD
1264
QQ

P1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

YDN

GVPSRFSGSGSGTDFTFTISSLQPEDIATY

LPQ

YCQQYDNLPQTFGGGTKVEIK

T

COV047_P4_Kappa_11-
1267
DIQMTQSPSSLSASVGDRVTITCQASQD
1268
QQ

P1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

YDN

GVPSRFSGSGSGTDFTFTISSLQPEDIATY

LPL

YCQQYDNLPLTFGQGTRLEIK

T

LAMBDA

COV047_P3_Lambda_14-
1271
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1272
QSY

P1409

GAGYDVHWCQQLPGTAPKLLIYGYSNR

DIN

PSGVPDRFSGSKSGTSASLAITGLOAEDE

LSA

ADYYCQSYDINLSAWVFGGGTRLTXL

WV

KAPPA

COV047_P5_Kappa_91-
1275
DIVMTQSPDSLAVSXGERATINCKSSQS
1276
QQ

P1389

VLYSSNNKNYLAWYQQKPGQPPKLLIY

YYS

WASTRESGVPDRFSGSGSGTDFTLTISSL

TPL

QAEDVAVYYCQQYYSTPLTFGGGTKVEI

T

K

COV047_P4_Kappa_51-
1279
DIQMTQSPSSLSASVGDRVTITCQASQD
1280
QQ

P1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

YDN

GVPSRFSGSGSGTDFTFTISSLQPEDIATY

LPIT

YCQQYDNLPITFGQGTRLEIK

COV047_P3_Kappa_47-
1283
EIVMTQSPATLSVSPGERATLSCRASQSV
1284
QQ

P1389

SSNLAWYQQKPGQAPRLLIYGASTRAT

YNN

GIPARFSGSGSGTEFTLTISSLQSEDFAVY

WP

YCQQYNNWPRTFGQGTKVEIK

RT

LAMBDA

COV047_P5_Lambda_71-
1287
QSALTQPASVSGSPGQSITISCTGTSSDV
1288
SSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TSS

RPSGVSNRFSGSKSGNTASLTISGLQAED

SSW

EADYYCSSYTSSSSWVFGGGTKLTVL

V

COV047_P5_Lambda_16-
1291
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1292
QSY

P1409

ASNYVQWYQQRPGSAPTTVIYEDNQRP

DSSI

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

LW

ADYYCQSYDSSILWVFGGGTKLTVL

V

COV047_P3_Lambda_25-
1295
QSVLTQPASVSGSPGQSITISCTGTSSDV
1296
SSY

P1409

GYYNFVSWYQQHPGKAPKLMIYEVSNR

RSS

PSGVSNRFSGSKSGNTASLIISGLQAEDE

STL

ADYYCSSYRSSSTLVFGGGTKLTVL

V

COV047_P4_Lambda_86-
1299
QSVLTQPPSASGSPGQSVTISCTGTSSDV
1300
TSY

P1409

GGYNYVSWYQQHPGKAPKLMIYEVSKR

AGS

PSGVPDRLSGSKSGNTASLTVSGLQAED

NN

EADYYCTSYAGSNNWVFGGGTKLTVL

WV

COV047_P4_Lambda_39-
1303
NFMLTQSHSVSESPGKTVTISCTGSSGNI
1304
QSY

P1409

VNNYVQWYQQRPGSAPIIVIYEDTQRPS

DSG

GVPDRFSGSIDTSSNSASLTISGLKTEDEA

SHV

DYYCQSYDSGSHVVFGGGTKLTV

V

KAPPA

COV047_P4_Kappa_83-
1307
DIQMTQSPSSLSASVGDRVTITCRASQGI
1308
QQ

P1389

SNSLAWYQQKPGKAPKLLLYAASRLESG

YYS

VPSRFSGSGSGTDYTLTISSLQPEDFATYY

TRT

CQQYYSTRTFGQGTKVEIK

COV047_P3_Kappa_38-
1311
DIQMTQSPSSLSASVGDRVTITCRASQGI
1312
QQ

P1389

SNYLAWFQQKPGKAPKSLIYAASSLQSG

YNS

VPSKFSGSGSGTDFTLTISSLQPEDFATYY

YPL

CQQYNSYPLFTFGPGTKVDIK

FT

COV047_P4_Kappa_72-
1315
DIVMTQSPDSLAVSXGERATINCKSSQS
1316
QQ

P1389

VLYSSNNKNYLAWYQQKPRQPPKLLIY

YYS

WASTRESGVPDRISGSGSGTDFTLTISSL

TPL

QAEDVAVYYCQQYYSTPLTFGGGTKVEI

T

K

LAMBDA

COV047_P4_Lambda_38-
1319
QSVLTQPRSVSGSPGQSVTISCTGTSSDV
1320
CSY

P1409

GGYNYVSWYQQHPGKAPKLMIYDVSK

AGS

RPSGVPDRFSGSKSGNTASLTISGLQAED

YT

EADYYCCSYAGSYTWVFGGGTKLTVL

WV

COV047_P3_Lambda_5-
1323
QSVLTQPASVSGSPGQSVTISCTGTSSD
1324
CSY

P1409

VGSYNLVSWYQQHPGKAPKVMIYEDSK

AGS

RPSGVSNRFSGSKSGNTASLTISGLQAED

ST

EADYYCCSYAGSSTWVFGGGTKLTVL

WV

COV047_P3_Lambda_35-
1327
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1328
QSY

P1409

ASNYVQWYQQRPGSAPTTVIYEDNQRP

DSSI

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

WV

ADYYCQSYDSSIWVFGGGTKLTVL

COV047_P3_Lambda_49-
1331
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1332
QSY

P1409

GADYDVHWYQQFPGTAPKVLIYANTNR

DHS

PSGVPERFSGSKSGTSASLAITGLQAEDE

LN

ADYYCQSYDHSLNWVFGGGTKLTVL

WV

COV047_P4_Lambda_23-
1335
QSVLTQPASVSGSPGQSITISCTGTSSDV
1336
SSY

P1409

GGYNYLSWYQQHPGKAPKLMIYEVSNR

TSS

PSGVSNRFSGSKSGNTASLTISGLQAEDE

STP

ADYYCSSYTSSSTPFYVFGTGTKVTVL

FYV

TABLE 10

Anti-SARS-CoV-2 IgG antibodies from COV57

SEQ

SEQ

ID

ID

SEQUENCE_ID
NO
aa
NO
cdr3_aa

HEAVY

COVD57_P1_HC_B4-
1337
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
1338
ARGVA

1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

VDWYF

VTISADKSISTAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P1_HC_F6-
1341
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
1342
ARGVA

1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

VDWYF

VTISADKSISTAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P1_HC_G8-
1345
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
1346
ARGVA

1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

VDWYF

VTISADKSISTAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P2_HC_A2-
1349
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
1350
ARGVA

1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

VDWYF

VTISADKSISTAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P2_HC_B2-
1353
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWTG
1354
ARGVA

1369

WVRQMPGKGLEWMGIIYPGDSDTRYRPAFQGQ

VDWYF

VTISADKSISTAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P2_HC_B12-
1357
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
1358
ARGVA

1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

VDWYF

VTISADKSISTAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P2_HC_C10-
1361
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
1362
ARGVA

1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

VDWYF

VTISADKSISSAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P2_HC_D10-
1365
EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWIG
1366
ARGVA

1369

WVRQMPGKGLEWMGIIYPADSDTRYSPSFQGQ

VDWYF

VTISADKSISTAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P2_HC_E1-
1369
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
1370
ARGVA

1369

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

VDWYF

VTISADKSISTAYLQWSSLKASDTAMYYCARGVAV

DL

DWYFDLWGRGTLVTVSS

COVD57_P1_HC_F3-
1373
QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWT
1374
AREVV

1369

WIRQPPGKGLEWIGYIHDSGNTNYNPALRSRVTI

VQSAK

SLDTSKNQFSLKVRSVTAADTAVYYCAREVVVQS

DWSHY

AKDWSHYYYYMDVWGKGTTVSVSS

YYYMD

V

COVD57_P2_HC_A6-
1377
QVQLQESGPGLVKPSETLSLTCTVSGGSMTSYYW
1378
AREVV

1369

NWIRHTPGKDLEWIGYIDYSGNTNYNPSLRSRGTI

VSSPKD

SVDTSKNQFSLRVTSVTAADTAVYYCAREVVVSSP

WSHYY

KDWSHYYYYMDVWGKGTTVTVSS

YYMDV

COVD57_P2_HC_B11-
1381
QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWT
1382
AREVV

1369

WIRQPPGKGLEWIGYIHDSGNTNYNPALRSRVTI

VQSAK

SLDTSKNQFSLKVRSVTAADTAVYYCAREVVVQS

DWSHY

AKDWSHYYYYMDVWGKGTTVSVSS

YYYMD

V

COVD57_P2_HC_D11-
1385
QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWT
1386
AREVV

1369

WIRQPPGKGLEWIGYIHDSGNTNYNPALRSRVTI

VQSAK

SLDTSKNQFSLKVRSVTAADTAVYYCAREVVVQS

DWSHY

AKDWSHYYYYMDVWGKGTTVSVSS

YYYMD

V

COVD57_P2_HC_F10-
1389
QVQLQESGPGLVKPSETLSLTCTVSGASINSYYWT
1390
AREVV

1369

WIRQPPGKGLEWIGYIHDSGNTNYNPALRSRVTI

VQSAK

SLDTSKNQFSLKVRSVTAADTAVYYCAREVVVQS

DWSHY

AKDWSHYYYYMDVWGKGTTVSVSS

YYYMD

V

COVD57_P1_HC_B11-
1393
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
1394
ARDSEY

1369

WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV

SSSWYS

TITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS

RGYYG

SWYSRGYYGMDVWGQGTTVTVSS

MDV

COVD57_P2_HC_A11-
1397
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
1398
ARDSEY

1369

WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV

SSSWYS

TITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS

RGYYG

SWYSRGYYGMDVWGQGTTVTVSS

MDV

COVD57_P2_HC_E2-
1401
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
1402
ARDSEY

1369

WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV

SSSWYS

TITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS

RGYYG

SWYSRGYYGMDVWGQGTTVTVSS

MDV

COVD57_P1_HC_B7-
1405
EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYWM
1406
ARQPES

1369

TWVRQAPGKGLEWVASIKYNGNERNYVDSVKG

TIWYYF

RFTISRDNARNSLFLQLNNLGAEDTAVYYCARQPE

DY

STIWYYFDYWGQGTLVTVSS

COVD57_P1_HC_F5-
1409
EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYWM
1410
ARQPES

1369

TWVRQAPGKGLEWVASIKYNGNERNYVDSVKG

TIWYYF

RFTISRDNARNSLFLQLNNLGAEDTAVYYCARQPE

DY

STIWYYFDYWGQGTLVTVSS

COVD57_P1_HC_H2-
1413
EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYWM
1414
ARQPES

1369

TWVRQAPGKGLEWVASIKYNGNERNYVDSVKG

TIWYYF

RFTISRDNARNSLFLQLNNLGAEDTAVYYCARQPE

DY

STIWYYFDYWGQGTLVTVSS

COVD57_P1_HC_D12-
1417
QVQLQQWGAGLLKPSETLSRTCAVFGGSFTNYY
1418
ARRRSF

1369

WSWIRQSPGKGLEWIGEINDSGITNYNPSLKSRV

SRPSSI

TISVDTSKNQFSLSLRSVTAADTAVYYCARRRSFSR

DY

PSSIDYWGQGTLVTVSS

COVD57_P2_HC_B6-
1421
QVQLQQWGAGLLKPSETLSRTCAVFGGSFTNYY
1422
ARRRSF

1369

WSWIRQSPGKGLEWIGEINDSGITNYNPSLKSRV

SRPSSI

TISVDTSKNQFSLSLRSVTAADTAVYYCARRRSFSR

DY

PSSIDYWGQGTLVTVSS

COVD57_P2_HC_H7-
1425
QVQLQQWGAGLLKPSETLSRTCAVFGGSFTNYY
1426
ARRRSF

1369

WSWIRQSPGKGLEWIGEINDSGITNYNPSLKSRV

SRPSSI

TISVDTSKNQFSLSLRSVTAADTAVYYCARRRSFSR

DY

PSSIDYWGQGTLVTVSS

COVD57_P2_HC_H7-
1429
QVQLQQWGAGLLKPSETLSRTCAVFGGSFTNYY
1430
ARRRSF

1369

WSWIRQSPGKGLEWIGEINDSGITNYNPSLKSRV

SRPSSI

TISVDTSKNQFSLSLRSVTAADTAVYYCARRRSFSR

DY

PSSIDYWGQGTLVTVSS

COVD57_P1_HC_E6-
1433
QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA
1434
AANHC

1369

MQWVRQARGQRLEWIGWIVVGSGNTNYAQKF

SGGSCY

QERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAN

DGFDI

HCSGGSCYDGFDIWGQGTMVTVSS

COVD57_P2_HC_H6-
1437
QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA
1438
AAPYCS

1369

MQWVRQARGQRLEWIGWIVVGSGNTNYAQKF

GGSCN

QERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAP

DAFDI

YCSGGSCNDAFDIWGQGTMVTVSS

COVD57_P2_HC_A10-
1441
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW
1442
TTDPH

1369

MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP

CSSTSC

VKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT

PIFYYYY

DPHCSSTSCPIFYYYYMDVWGKGTTVTVSS

MDV

COVD57_P2_HC_C4-
1445
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW
1446
TTDPH

1369

MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP

CSSTSC

VKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT

PIFYYYY

DPHCSSTSCPIFYYYYMDVWGKGTTVTVSS

MDV

COVD57_P2_HC_C4-
1449
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW
1450
TTDPH

1369

MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP

CSSTSC

VKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT

PIFYYYY

DPHCSSTSCPIFYYYYMDVWGKGTTVTVSS

MDV

COVD57_P1_HC_E9-
1453
QVQLVESGGGVVOPGRSLRLSCAASGFTFNRIAM
1454
AKSPM

1369

YWVRQAPGKGLEWVAVISFDGSYEYYAESVKGRF

GYCTN

AISRDNSKNTLYLQMNSLRAEDTAVYYCAKSPMG

GVCYP

YCTNGVCYPDSWGQGTLVTVSS

DS

COVD57_P2_HC_G5-
1457
QVQLVESGGGVVQPGRSLRLSCAASGFTFNRIAM
1458
AKSPM

1369

YWVRQAPGKGLEWVAVISFDGSYEYYAESVKGRF

GYCTN

AISRDNSKNTLYLQMNSLRAEDTAVYYCAKSPMG

GVCYP

YCTNGVCYPDSWGQGTLVTVSS

DS

COVD57_P2_HC_G5-
1461
QVQLVESGGGVVQPGRSLRLSCAASGFTFNRIAM
1462
AKSPM

1369

YWVRQAPGKGLEWVAVISFDGSYEYYAESVKGRF

GYCTN

AISRDNSKNTLYLQMNSLRAEDTAVYYCAKSPMG

GVCYP

YCTNGVCYPDSWGQGTLVTVSS

DS

COVD57_P1_HC_F10-
1465
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYY
1466
ARAGF

1369

WSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRV

GVVITY

TISVDTSKNQFSLKLSSVTAADTAVYYCARAGFGV

GSGTD

VITYGSGTDPLFDYWGQGTLVTVSS

PLFDY

COVD57_P1_HC_H3-
1469
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYY
1470
ARAGF

1369

WSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRV

GVVITY

TISVDTSKNQFSLKLSSVTAADTAVYYCARAGFGV

GSGTD

VITYGSGTDPLFDYWGQGTLVTVSS

PLFDY

COVD57_P1_HC_A5-
1473
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
1474
AREYLE

1369

MHWVRQAPGQGLEWMGRINPNSGGTNYAQKF

RYFDG

QGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAR

GQRWI

EYLERYFDGGQRWISYYYMDVWGKGTAVTVSS

SYYYM

DV

COVD57_P1_HC_A9-
1477
QVQLVQSGAEVKKPGASVKVSCKASGYTFSNYYI
1478
AREIPDI

1369

HWVRQAPGKGLEWMGMINPNGGTTRYPLKFQ

LEVVAA

GRVTMTRDTSTRTVYMELNSLRSEDTALYFCAREI

TGSLDD

PDILEVVAATGSLDDWGQGSLVTVS

COVD57_P1_HC_A11-
1481
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
1482
ARDSEY

1369

WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV

SSSWYS

TITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS

RGYYG

SWYSRGYYGMDVWGQGTTVTVSS

MDV

COVD57_P2_HC_B1-
1485
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTIS
1486
ARDSG

1369

WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV

YSGYGS

TITADKSTSTAYMELSSLRSEDTAVYYCARDSGYSG

TYYMD

YGSTYYMDVWGKGTTVTVSS

V

COVD57_P1_HC_F11-
1489
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
1490
ARDSEY

1369

WVRQAPGQGLEWMGRIIPILGIANYAQKFQGRV

SSSWYS

TITADKSTSTAYMELSSLRSEDTAVYYCARDSEYSS

RGYYG

SWYSRGYYGMDVWGQGTTVTVSS

MDV

COVD57_P2_HC_G11-
1493
EVQLVQSGPVLVKPGPSVKISCKASGFTFTDYYM
1494
ARSGP

1369

HWVKQSHGKSLEWIGLVYPYNGGTSYNQKFKGK

DYFDY

ATLTVDTSSSTAYMELNSLTSEDSAVYYCARSGPD

YFDYWGQGTTLTVSS

COVD57_P2_HC_C12-
1497
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM
1498
ARGTTF

1369

HWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRF

NHYYY

TISRENAKNSLYLQMNSLRAGDTAVYYCARGTTF

MDV

NHYYYMDVWGKGTTVTVSS

COVD57_P2_HC_C3-
1501
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW
1502
TTDVG

1369

MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP

ADSSSA

VKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT

YYYYY

DVGADSSSAYYYYYMDVWGKGTTVTVSS

MDV

COVD57_P2_HC_E11-
1505
EVQLVESGGGLVKPGGSLRLSCAASGLTFTAYRM
1506
ARDVA

1369

NWVRQAPGKGLEWLSSISNTNGDIYYADSVKGR

SNYAYF

FTISRDNAKNSLYLQMNSLRADDTAVYYCARDVA

DL

SNYAYFDLWGQGTLVTVSS

COVD57_P2_HC_H12-
1509
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMS
1510
AKDTG

1369

WVRQAPGKGLEWVSGMSGSGGITYYADSVKGR

SMIVEL

FTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDTGS

LGY

MIVELLGYWGQGTLVTVSS

COVD57_P2_HC_H12-
1513
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMS
1514
AKDTG

1369

WVRQAPGKGLEWVSGMSGSGGITYYADSVKGR

SMIVEL

FTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDTGS

LGY

MIVELLGYWGQGTLVTVSS

COVD57_P1_HC_B8-
1517
EVQLVESGGGLVKPGRSLRLSCTASGFTFGDYAM
1518
TRARSV

1369

SWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVK

TMVW

GRFTISRDDSKSIAYLQMNSLKTEDTAVYYCTRAR

YRYYM

SVTMVWYRYYMDVWGKGTTVTVSS

DV

COVD57_P2_HC_C2-
1521
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAM
1522
AREGPF

1369

HWVRQAPGKGLEYVSVISSNGGSTYYANSVKGRF

LPSLYSS

TISRDNSKNTLYLQMGSLRAEDMAVYYCAREGPF

SRDAF

LPSLYSSSRDAFDIWGQGTMVTVSS

DI

COVD57_P1_HC_C8-
1525
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAM
1526
ARGPIA

1369

HWVRQAPGKGLEYVSGISSNGGSPYYANSVKGR

AAGSYF

FTISRDNSKNTLYLQMGSLRAEDMAVYYCARGPI

DY

AAAGSYFDYWGQGTLVTVSS

COVD57_P1_HC_F9-
1529
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM
1530
ARDLA

1369

SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFT

VYGMD

ISRDNSKNTLYLQMNSLRAEDTAVYHCARDLAVY

V

GMDVWGQGTTVTVSS

COVD57_P1_HC_C3-
1533
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM
1534
ARDGE

1369

SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFT

GQRET

ISRDNSKNTLYLQMNSLRAEDTAVYYCARDGEGQ

DY

RETDYWGQGTLVTVSS

COVD57_P1_HC_G3-
1537
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTHW
1538
TRDDSS

1369

MHWVRQAPGKGLVWVSRINSDGSRRAYATSVK

WPHFF

GRFTISRDNAKNTLYLQMDSLRDEDTAVYYCTRD

DN

DSSWPHFFDNWGQGTLVTVSS

COVD57_P2_HC_B7-
1541
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTHW
1542
TRDDSS

1369

MHWVRQAPGKGLVWVSRINSDGSRRAYATSVK

WPHFF

GRFTISRDNAKNTLYLQMDSLRDEDTAVYYCTRD

DN

DSSWPHFFDNWGQGTLVTVSS

COVD57_P1_HC_H10-
1545
QVQLQQWGAGLLKPSETLSRTCGVYGGSFRDYY
1546
ARAYVS

1369

WSWIRQSPGKGLEWIGEINHSGSTNYNPSLLGRV

SVSEDY

TISVDTSKNQFSLRLTSVTAADTAVYYCARAYVSSV

FDY

SEDYFDYWGQGTLVTVSS

COVD57_P1_HC_B9-
1549
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYY
1550
ARHW

1369

WSWIRQPPGKGLEWIGEVNHSGSTNYNPSLKSR

MPRDY

VTISVDTSKNQFFLKLSSVTAADTAVYYCARHWM

YYYGM

PRDYYYYGMDVWGQGTTVTVSS

DV

COVD57_P2_HC_E3-
1553
QVQLQQWGAGLLKPSETLSRTCAVYGGSFTDYY
1554
ARGAK

1369

WSWIRQSPGKGLEWIGEINHSGSTNYNPFLKSRV

GDSDW

TLSVDTSKNQFSLKLDSLTVADTAIYYCARGAKGD

YFDL

SDWYFDLWGRGTLVTVSS

COVD57_P2_HC_F8-
1557
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWS
1558
ARHYDI

1369

WIRQPPGKGLEWIGYIHYSGSTNYNPSLKSRVTIS

LTALSW

VDTSKNQFSLKLSSVTAADTAVYYCARHYDILTALS

FDP

WFDPWGQGTLVTVSS

COVD57_P2_HC_H11-
1561
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWS
1562
ARLLST

1369

WIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISV

EWLFN

DTSKNQFSLKLSSVTAADTAVYYCARLLSTEWLFN

WFDP

WFDPWGQGTLVTVSS

COVD57_P2_HC_A9-
1565
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
1566
ARGIAV

1369

WVRQMPGKGLEWVGIIYPGDSDTRYSPSFQGQV

DWYFD

TISADKSISTAYLQWSSLKASDTAMYYCARGIAVD

L

WYFDLWGRGTLVTVSS

SEQ

SEQ

ID

ID

SEQUENCE_ID
NO
aa
NO
cdr3_aa

LAMBDA

COVD57_P1L_B4-
1339
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1340
QSY

_1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSAL

ADYYCQSYDSSLSALYVFGTGTKVTVL

YV

COVD57_P1_L_F6-
1343
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1344
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSAL

ADYYCQSYDSSLSALYVFGTGTKVTVL

YV

COVD57_P1_L_G8-
1347
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1348
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSAL

ADYYCQSYDSSLSALYVFGTGTKVTVL

YV

COVD57_P2_L_A2-
1351
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1352
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSAL

ADYYCQSYDSSLSALYVFGTGTKVTVL

YV

COVD57_P2_L_B2-
1355
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1356
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSAL

ADYYCQSYDSSLSALYVFGTGTKVTVL

YV

COVD57_P2_L_B12-
1359
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1360
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSAL

ADYYCQSYDSSLSALYVFGTGTKVTVL

YV

COVD57_P2_L_C10-
1363
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1364
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSVL

ADYYCQSYDSSLSVLYVFGTGTKVTVL

YV

COVD57_P2_L_D10-
1367
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1368
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGYTNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSAL

ADYYCQSYDSSLSALYVFGTGTKVTVL

YV

COVD57_P2_L_E1-
1371
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1372
QSY

1409

GAGSDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSAL

ADYYCQSYDSSLSALYVFGTGTKVTVL

YV

KAPPA

COVD57_P1_K_F3-
1375
EIVLTQSPATLSLSPGERASLSCRASQSVG
1376
QQ

1389

TYLAWYQQKVGQPPRLLIYDASNRATGI

RSS

PARFSGSGSGTDFTLTISSLDPEDFAVYYC

WF

QQRSSWFVTFGQGTRLEIK

VT

COVD57_P2_K_A6-
1379
EIVLTQSPATLSLSPGERATLSCRASQSVS
1380
QQ

1389

TYLTWYQQKPGQAPRLLIYDASNRATGI

RST

PARFSGSGSGTDFTLTITSLEPEDFALYYC

WF

QQRSTWFVTFGQGTRLEIK

VT

COVD57_P2_K_Bl1-
1383
EIVLTQSPATLSLSPGERASLSCRASQSVG
1384
QQ

1389

TYLAWYQQKVGQPPRLLIYDASNRATGI

RSS

PARFSGSGSGTDFTLTISSLDPEDFAVYYC

WF

QQRSSWFVTFGQGTRLEIK

VT

COVD57_P2_K_D11-
1387
EIVLTQSPATLSLSPGERASLSCRASQSVG
1388
QQ

1389

TYLAWYQQKVGQPPRLLIYDASNRATGI

RSS

PARFSGSGSGTDFTLTISSLDPEDFAVYYC

WF

QQRSSWFVTFGQGTRLEIK

VT

COVD_K_F10-
1391
EIVLTQSPATLSLSPGERASLSCRASQSVG
1392
QQ

1389

TYLAWYQQKVGQPPRLLIYDASNRATGI

RSS

PARFSGSGSGTDFTLTISSLDPEDFAVYYC

WF

QQRSSWFVTFGQGTRLEIK

VT

COVD57_P1_K_B11-
1395
DIVMTQSPLSLPVTPGEPASISCRSSQSLL
1396
MQ

1389

HSNGYNYLDWYLQKPGQSPQLLIYLGSN

ALQ

RASGVPDRFSGSGSGTDFTLKISRVEAED

TPP

VGVYYCMQALQTPPTFGGGTKVEIK

T

COVD57_P2_K_A11-
1399
DIVMTQSPLSLPVTPGEPASISCRSSQSLL
1400
MQ

1389

HSNGYNYLDWYLQKPGQSPQLLIYLGSN

ALQ

RASGVPDRFSGSGSGTDFTLKISRVEAED

TPP

VGVYYCMQALQTPPTFGGGTKVEIK

T

COVD57_P2_K_E2-
1403
DIVMTQSPLSLPVTPGEPASISCRSSQSLL
1404
MQ

1389

HSNGYNYLDWYLQKPGQSPQLLIYLGSN

ALQ

RASGVPDRFSGSGSGTDFTLKISRVEAED

TPP

VGVYYCMQALQTPPTFGGGTKVEIK

T

LAMBDA

COVD57_P1_LB7-
1407
SYELTQPPSVSVSPGQTARVTCSGHALP
1408
QSA

1409

DQYTYWYQQRPGRAPVLVIYVNNQRPS

DSS

GIPDRFSATTSGTTVTLTISGVQAEDEAD

GSY

YYCQSADSSGSYVVFGGGTKLTVL

VV

COVD57_P1_LF5-
1411
SYVLTQPPSVSVSPGQTARVTCSGHALP
1412
QSA

1409

DQYTYWYQQRPGRAPVLVIYVNNQRPS

DSS

GIPDRFSATTSGTTVTLTISGVQAEDEAD

GSY

YYCQSADSSGSYVVFGGGTKLTVL

VV

COVD57_P1_L_H2-
1415
SYELTQPPSVSVSPGQTARVTCSGHALP
1416
QSA

1409

DQYTYWYQQRPGRAPVLVIYVNNQRPS

DSS

GIPDRFSATTSGTTVTLTISGVQAEDEAD

GSY

YYCQSADSSGSYVVFGGGTKLTVL

VV

KAPPA

COVD57_P1_K_D12-
1419
DIVMTQSPLSLPVTPGEPASISCRSSQSLL
1420
MQ

1389

HRNGYNYLDWYLQKPGQSPQLLIYLGS

ALQ

NRASGVPDRFRGSGSGTDFTLKISRVEAE

TLT

DVGVYYCMQALQTLTFGQGTRLEIK

COVD57_P2_K_B6-
1423
DIVMTQSPLSLPVTPGEPASISCRSSQSLL
1424
MQ

1389

HRNGYNYLDWYLQKPGQSPQLLIYLGS

ALQ

NRASGVPDRFRGSGSGTDFTLKISRVEAE

TLT

DVGVYYCMQALQTLTFGQGTRLEIK

COVD57_P2_K_H7-
1427
DIVMTQSPLSLPVTPGEPASISCRSSQSLX
1428
MQ

1389

HRNGYNYLDWYLQKPGQSPQLLIYLGS

ALQ

NRASGVPDRFRGSGSGTDFTLKISRVEAE

TLT

DVGVYYCMQALQTLTFGQGTRLEIK

COVD57_P2_K_H7-
1431
DIVMTQSPLSLPVTPGEPASISCRSSQSLX
1432
MQ

1389

HRNGYNYLDWYLQKPGQSPQLLIYLGS

ALQ

NRASGVPDRFRGSGSGTDFTLKISRVEAE

TLT

DVGVYYCMQALQTLTFGQGTRLEIK

COVD57_P1_K_E6-
1435
EIVLTQSPGTLSLSPGERATLSCRASQSVS
1436
QQY

1389

SSYLAWYQQRPGQAPRLLIYGASSRATG

GSS

IPDRFSGSGSGTDFTLTISRLEPEDFAVYY

PW

CQQYGSSPWMFGQGTKVEIK

M

COVD57_P2_K_H6-
1439
EIVLTQSPGTLSLSPGERATLSCRASQSVS
1440
QQY

1389

SSYLAWYQQKPGQAPRLLIYGASSRATG

GSS

IPDRFSGSGSGTDFTLTISRLEPEDFAVYY

PW

CQQYGSSPWTFGQGTKVEIK

T

LAMBDA

COVD57_P2_L_A10-
1443
SYVLTQPPSVSVAPGQTARITCGGNNIG
1444
QV

1409

SKSVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEAD

SSS

YYCQVWDSSSDQGVFGGGTKLTVL

DQ

GV

COVD57_P2_L_C4-
1447
SYVLTQPPSVSVAPGQTARITCGGNNIG
1448
QV

1409

SKSVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEAD

SSS

YYCQVWDSSSDQGVFGGGTKLTVL

DQ

GV

COVD57_P2_L_C4-
1451
SYVLTQPPSVSVAPGQTARITCGGNNIG
14
QV

1409

SKSVHWYQQKPGQAPVLVVYDDSDRPS
52
WD

GIPERFSGSNSGNTATLTISRVEAGDEAD

SSS

YYCQVWDSSSDQGVFGGGTKLTVL

DQ

GV

COVD57_P1_L_E9-
1455
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1456
QSY

1409

ASNYVQWYQQRPGSAPTTVIYEDTQRP

DIN

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

SR

ADYYCQSYDINSRWVFGGGTKLTVL

WV

COVD57_P2_L_G5-
1459
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1460
QSY

1409

ASNYVQWYQQRPGSAPTTVIYEDTQRP

DIN

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

SR

ADYYCQSYDINSRWVFGGGTKLTVL

WV

COVD57_P2_L_G5-
1463
NFMLTQPHSVSESPGKTVTISCTGSSGSI
1464
QSY

1409

ASNYVQWYQQRPGSAPTTVIYEDTQRP

DIN

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

SR

ADYYCQSYDINSRWVFGGGTKLTVL

WV

COVD57_P1_L_F10-
1467
QSVLTQPPSVSGAPGQRVTISCTGSNSNI
1468
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSG

ADYYCQSYDSSLSGSRVFGGGTKLTVL

SRV

COVD57_P1_L_H3-
1471
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1472
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSG

ADYYCQSYDSSLSGSRVFGGGTKLTVL

SRV

COVD57_P1_L_A5-
1475
QSVLTQPASVSGSPGQSITISCTGTSSDV
1476
SSY

1409

GGYNYVSWYQQHPGKAPKLMIYDVSN

TPN

RPSGVSNRFSGSKSGNTASLTISGLQAED

STL

EADYYCSSYTPNSTLVVFGGGTKLTVL

W

COVD57_P1_L_A9-
1479
QSVLTQPPSASGSPGQSVTISCTGTRSDV
1480
SSY

1409

GGYNYVSWYQQHPGKAPKLIIYEVTKRP

AGI

SGVPDRFSGSKSGDTASLTVSGLQADDE

TNL

ADYFCSSYAGITNLVFGGGTKLTV

V

COVD57_P1_L_A11-
1483
QSVLTQPPSASGSPGQSVTISCTGTSSDV
1484
YSY

1409

GGYNYVSWYQHHPGKAPKLMIFEVTKR

GG

PSGVPDRFSGSKSGNTASLTVSGLQAED

NN

EADYYCYSYGGNNNAVFGGGTKLTVL

NAV

COVD57_P2_L_B1-
1487
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1488
QSY

1409

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSG

ADYYCQSYDSSLSGSVFGTVTKVTVL

SV

KAPPA

COVD57_P1_K_F11-
1491
DIVMTQSPLSLPVTPGEPASISCRSSQSLL
1492
MQ

1389

HSNGYNYLDWYLQKPGQSPQLLIYLGSN

ALQ

RASGVPDRFSGSGSGTDFTLKISRVEAED

TPP

VGVYYCMQALQTPPTFGGGTKVEIK

T

COVD57_P2_K_G11-
1495
EIVMTQSPATLSVSPGERATLSCRASQSV
1496
QQY

1389

SSNLAWYQQKPGQAPRLLIYGASTRATG

NN

IPARFSGSGSGTEFTLTISSLQSEDFAVYY

WP

CQQYNNWPRTFGGGTKVEIK

RT

COVD57_P2_K_C12-
1499
DIQMTQSPSSLSASVGDRVXITCRASQSI
1500
QQS

1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PP

CQQSYSTPPWTFGQGTKVEIK

WT

COVD57_P2_K_C3-
1503
EIVLTQSPXSLSLSPGERATLSCGASQSVS
1504
QQY

1389

SSYLAWYQQKPGLAPRLLIYDASSRATGI

GSS

PDRFSGSGSGTDFTLTISRLEPEDFAVYYC

PYT

QQYGSSPYTFGQGTKLEIK

COVD57_P2_K_E11-
1507
EIVMTQSPATLSLSPGERATLSCRASQSV
1508
QQY

1389

SSNLAWYHQKPGQAPRLLIYGASTRATG

DN

IPARFSGSGSGTEFTLTISSLQSEDFAVYY

WPL

CQQYDNWPLFGQGTRLEIK

LAMBDA

COVD57_P2_L_H12-
1511
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1512
QSY

1409

GAGSDVHWYQKLPGTAPKVFIYGYNNR

DTS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LRV

ADYYCQSYDTSLRVVFGGGTKLTV

V

COVD57_P2_L_H12-
1515
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
1516
QSY

1409

GAGSDVHWYQKLPGTAPKVFIYGYNNR

DTS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LRV

ADYYCQSYDTSLRVVFGGGTKLTV

V

KAPPA

COVD57_P1_K_B8-
1519
DIVMTQTPLSLSVTPGQPASISCKSSQSL
1520
MQ

1389

LHSDGKTYLYWYLQKPGQPPQLLIYEVS

SIQL

NRFSGVPDRFSGSGSGTDFTLKISRVEAE

PYT

DVGVYYCMQSIQLPYTFGQGTKLEIK

LAMBDA

COVD57_P2_L_C2-
1523
SYVLTQPPSVSVAPGQTARITCGGNNIG
1524
QV

1409

SKSVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGDTATLTISRVEAGDEAD

SSS

YYCQVWDSSSDPHYVFGTGTKVTV

DPH

YV

COVD57_P1_L_C8-
1527
SYVLTQPPSVSVAPGQTARITCGGNNIG
1528
QV

1409

SKNVHWYQQKPGQAPVLVVYDDSDRP

WD

SGIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDPHWVFGGGTKLTVL

DPH

WV

KAPPA

COVD57_P1_K_F9-
1531
DIQLTQSPSFLSASVGDRVTITCRASQGIS
1532
QQL

1389

SYLAWYQQKPGKAPKLLIYAASTLQSGV

NSY

PSRFSGSGSGTEFTLTISSLQPEDFATYYC

PPV

QQLNSYPPVTFGQGTRLEIK

T

COVD57_P1_K_C3-
1535
DIQMTQSPSSLSASVGDRVTITCQASQD
1536
QQY

1389

ISNYLNWYQQKPGKAPKLLIYDASNLET

DNL

GVPSRFSGSGSGTDFTFTISSLQPEDIATY

PRT

YCQQYDNLPRTFGQGTKVEIK

COVD57_P1_K_G3-
1539
DIQMTQSPSSLSASVGDRVTITCRASQSII
1540
QQS

1389

NYLNWYQQKPGKAPKLLIYTASSLQSGV

YSS

PSRFSGSGSGTDFTLTISSLQPEDFATYFC

PLW

QQSYSSPLWTFGQGTKVEIK

T

COVD57_P2_K_B7-
1543
EIVMTQSPATLSVSPGERATLSCRASQSV
1544
QQY

1389

SSNLAWYHQKPGQAPRLLIYGASTRATG

DN

IPARFSGSGSGTEFTLTISSLQSEDFAVYY

WPL

CQQYDNWPLFGQGTRLEIK

COVD57_P1_K_H10-
1547
DIQMTQSPSSLSASVGDRVTITCRASQSI
1548
QQS

1389

STYLNWYQQKPGKAPELLIYAASSFQSG

YTT

VPSRFSGSGSGTDFTLTIRSLEPEDSATYY

PYT

CQQSYTTPYTFGQGTKLEIK

COVD57_P1_K_B9-
1551
DIQMTQSPSSLSASVGDRVTITCRASQSI
1552
QQS

1389

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PRT

CQQSYSTPRTFGQGTKVEIK

COVD57_P2_K_E3-
1555
EIVLTQSPATLSLSPGERATLSCRASQSVS
1556
GD

1389

NYLAWYQQKPGQAPRLLISDASNRATG

NW

VPDRFSGSGSGTDFTLTINSLEPEDFAVY

PR

YCQQGDNWPRMYTFGQGTKLQIK

MYT

LAMBDA

COVD57_P2_L_F8-
1559
QSVLTQPPSVSAAPGQKVTISCSGSSSNI
1560
WD

1409

GNNYVSWYQQLPGTAPKLLIYDNNKRP

SSLS

SGIPDRFSGSKSGTSATLGITGLQTGDEA

AY

DYYCGTWDSSLSAYWVFGGGTKLTVL

WV

COVD57_P2_L_H11-
1563
SYVLTQPPSVSVSPGQTASITCSGDKLGD
1564
QA

1409

KYACWYQQKPGQSPVLVIYQDSKRPSGI

WD

PERFSGSNSGNTATLTISGTQAMDEADY

SST

YCQAWDSSTAYVFGTGTKVTVL

AYV

COVD57_P2_L_A9-
1567
QSVLTQPASVSGSPGQSITISCTGTSSDIG
1568
SSY

1409

VYNYISWSQQHPGKAPKVMIYDVTNRP

RGS

SGVSNRFSGSKSGNTASLTISGLQAEDEA

STP

DYYCSSYRGSSTPYVFGTGTKVTVL

YV

TABLE 11

Anti-SARS-CoV-2 IgG antibodies from COV72

SEQ

SEQ

ID

ID

SEQUENCE_ID
NO
aa
NO
cdr3_aa

HEAVY

COV072_P3_HC_50-
1733
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYA
1734
ANHPLA

P1369

MSWVRQAPGKGLEWVSTITGSGGFTYYADSV

SGDEYY

KGRFTISRDNSKNTLFLQMNSLRAEDAAVYYCA

YYYMDV

NHPLASGDEYYYYYMDVWGKGTTVTVSS

COV072_Plate2_HC_24-
1737
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYA
1738
ANHPLA

P1369

MSWVRQAPGKGLEWVSTITGSGRDTYYADSV

SGDDYY

KGRFTISRDNSKNTLFLQLNSLRAEDAAVYSCAN

HYYMD

HPLASGDDYYHYYMDVWGKGTTVTVSS

V

COV072_Plate2_HC_66-
1741
EVQLLESGGGLVQPGGSLRLSCVASRFTFSNYA
1742
ANSPCS

P1369

MSWVRQAPGKGLEWVSTITGTGDHTYYADSV

SASCKS

KGRFTISRDNSKNTLYLQMNSLRAEDTAIFYCA

GYYYYY

NSPCSSASCKSGYYYYYMDVWGKGTTVTVSS

MDV

COV072_P3_HC_17-
1745
QVQLVQSGSEVKKPGSSVKVSCKASGGTFSSYA
1746
ARVNQ

P1369

FSWVRQAPGQGLEWIVIGRIIPILALANYAQKFQ

AVTTPF

GRVTITADKSTSTAYMELSSLRSEDTAVYYCARV

SMDV

NQAVTTPFSMDVWGQGTTVTVSS

COV072_P3_HC_21-
1749
QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSSA
1750
ARANQ

P1369

LSWVRQAPGQGLEWIVIGRIIPILGITNYAQKFQ

PVTTPFS

GRVTITADKSTSTAYMELNSLRSEDTAVYYCARA

MDV

NQPVTTPFSMDVWGQGTTVTVSS

COV072_P3_HC_53-
1753
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1754
ARDSDV

P1369

MHWVRQAPGKGLEWVAVILYDGSNKYYADSV

DTSMVT

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

WFDY

RDSDVDTSMVTWFDYWGQGTLVTVSS

COV072_Plate2_HC_83-
1757
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYA
1758
ARDSDV

P1369

MHWVRQAPGKGLEWVAVISYDGTNKFYADSV

DTAMV

KGRFTISRDNSKNTLYLQMNSLRAEDTAVFYCA

TWFDY

RDSDVDTAMVTWFDYWGQGTLVTVSS

COV072_P3_HC_80-
1761
EVQLVESGGGLVQPGGSLRLSCAASGITVSSNY
1762
ARDLGD

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

YGMDV

GRVTISRDNSKNTLYLQMNSLRVEDTAVYYCAR

DLGDYGMDVWGQGTTVTVSS

COV072_Plate2_HC_36-
1765
EVQLVESGGGLVQPGGSLRLSCAASGVTVSSNY
1766
ARDLYY

P1369

MSWVRQAPGKGLEWVSLIYSGGSTFYADSVKG

YGMDV

RFTISRDNSENTLYLQMNTLRAEDTAVYYCARD

LYYYGMDVWGQGTTVTVSS

COV072_P3_HC_49-
1769
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNY
1770
ARSRPT

P1369

YMHWVRQAPGQGLEWMGIINPSGGSTGYAQ

PDWYF

KFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYY

DL

CARSRPTPDWYFDLWGRGTLVTVSS

COV072_Plate2_HC_81-
1773
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHY
1774
AKSRPT

P1369

IHWVRQAPGQGLEWMGIINPSGGSTSYAQKF

PDWYF

QGRVTMTRDTSTTTLYMDLSSLRSEDTAVYYCA

DL

KSRPTPDWYFDLWGRGTLVTVSS

COV072_P3_HC_51-
1777
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYA
1778
AKDPLIT

P1369

MSWVRQAPGKGLEWVSAISGSDGSTYYAGSV

GPTYQY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FHY

KDPLITGPTYQYFHYWGQGTLVTVSS

COV072_Plate2_HC_93-
1781
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYA
1782
AKDPLIT

P1369

MSWVRQAPGKGLEWVSAISGSDGSTYYAGSV

GPTYQY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FHY

KDPLITGPTYQYFHYWGQGTLVTVSS

COV072_P3_HC_12-
1785
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
1786
ARALQG

P1369

MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV

PWLGA

KGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA

DY

RALQGPWLGADYWGQGTLVTVSS

COV072_Plate2_HC_33-
1789
EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYW
1790
AGGTW

P1369

MSWVRQPPGKGLEWVANIKQDGSEKYYVDSV

LRSSFDY

KGRFTISRDNAKNSLYLQMNSLRADDTAVYYCA

GGTWLRSSFDYWGQGTLVTVSS

COV072_P3_HC_25-
1793
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSNN
1794
ARGGDT

P1369

WWSCVRQPPGKGLEWIGEIYHSGSTNYNPSLK

AMGPE

SRVTISVDKSKNQFSLKLSSVTAADTAVYYCARG

YFDY

GDTAMGPEYFDYWGQGTLVTVSS

COV072_Plate2_HC_53-
1797
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSNN
1798
AKGGDR

P1369

WWSWVRQPPGKGLEWIGEIYHSGSTNYNPSL

AMGPE

KSRVTISVDKSKNQFSLKLSSVTAADTAVYYCAK

YFDY

GGDRAMGPEYFDYWGQGTLVTVSS

COV072_P3_HC_44-
1801
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG
1802
ARVLGII

P1369

ISWVRQAPGQGLEWMGWISAYNGNTKYAQK

VAGSLN

LQGRVTMTTDTSTSTAYMELRSLRSDDTAVYFC

ARVLGIIVAGSLNWGQGTLVTVSS

COV072_P3_HC_40-
1805
QVQLVQSGAEVKKPGASVKVSCKASGYTFSSNY
1806
ARDLGY

P1369

MHWVRQAPGQGLEWMGIINPSGGSTTYAQK

IPASDAF

FQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC

DI

ARDLGYIPASDAFDIWGQGTMVTVS

COV072_P3_HC_77-
1809
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYT
1810
ARFSNY

P1369

1SWVRQAPGHGLEWMGRIIPILGIANYAQKFQ

CTSTSCY

GRVTITADKSTSTAYMELSSLRSEDTAVYYCARF

DY

SNYCTSTSCYDYWGQGTLVTVSS

COV072_Plate2_HC_9-
1813
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG
1814
ARDGIT

P1369

ISWVRQAPGQGLEWMGWISAYNGNTNYAQK

GTIEYYF

LQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYC

DY

ARDGITGTIEYYFDYWGQGTLVTVSS

COV072_P3_HC_34-
1817
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELS
1818
ATNAEI

P1369

MHWVRQAPGKGLEWIVIGGFDPEDGETIYVQK

AARKGG

FQGRATMTEHTSTETAYMELSSLRSEDTAVYYC

MDV

ATNAEIAARKGGMDVWGQGTTVTVSS

COV072_P3_HC_10-
1821
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY
1822
ARDIAL

P1369

IHWVRQAPGQGLEWMGIINPSAGSTSYAQKF

VPAAM

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA

GLDY

RDIALVPAAMGLDYWGQGTLVTVSS

COV072_P3_HC_42-
1825
QMQLVQSGPEVKKPGTSVKVSCKASGFTFTNS
1826
AAVDC

P1369

AVQWVRQSRRQRLEWIGWIVVGSGNTNYAQ

NSTSCY

KFQERVTITRDMSTSTAYMELSSLRSEDTAVYYC

DAFDI

AAVDCNSTSCYDAFDIWGQGTMVTVSS

COV072_P3_HC_31-
1829
QVQLVQSGAEVKKPGSSVKVSCKASGGTVNNY
1830
AKVSLTL

P1369

AINWVRQAPGQGLEWMGGIVPIFGTPNYAQK

PIAAAP

FQGRVTITADESTSTAYMELSSLRSEDTAVYYCA

RFWFDS

KVSLTLPIAAAPRFWFDSWGQGTLVTVSS

COV072_P3_HC_30-
1833
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
1834
ARGWA

P1369

ISWVRQAPGQGLEWMGRIIPMLVIATYARKFQ

ATPGNF

GRVTITADKSTSTAYMELSSLRSEDTAVYYCARG

DI

VVAATPGNFDIWGQGTMVTVSS

COV072_P3_HC_48-
1837
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
1838
ARDLLD

P1369

INWVRQAPGQGLEWMGRIIPIVGIANYAQKFQ

PQLDDA

GRVTITADKSSSTAYMELSSLRSEDTAVYYCARD

FDI

LLDPQLDDAFDIWGQGTMVTVSS

COV072_Plate2_HC_40-
1841
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYA
1842
ARGGYS

P1369

INWVRQAPGQGLEWMGRIIPILDISNYAQKFQ

YGQLYY

GRVTITADKSTSIAYMELSSLRSEDTAVYYCARG

FDY

GYSYGQLYYFDYWGQGTLVTVSS

COV072_P3_HC_58-
1845
QVQLVESGGGLVKPGGSLRLSCAASGFTFSHYN
1846
ARDRGY

P1369

MIWIRQAPGKGLEWVSYISSSSSYTNCSDSVRG

SGYGLD

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARD

RFDY

RGYSGYGLDRFDYWGQGTLVTVSS

COV072_P3_HC_64-
1849
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYY
1850
ARDNIT

P1369

MTWIRQAPGKGLEWVSYITTSSSYTNYADSVK

MVRGVI

GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR

VRPND

DNITMVRGVIVRPNDGGYYYALDVWGQGTTV

GGYYYA

TVSS

LDV

COV072_P3_HC_5-
1853
EVQLLESGGGLVQPGGSLRLSCTASGFTFSTYA
1854
AKSKTV

P1369

MSWVRQAPGKGLEWVSAISDSGGSTYYADSV

ERLPYC

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

GGDCFS

KSKTVERLPYCGGDCFSAIDYWGQGTLVTVSS

AIDY

COV072_Plate2_HC_92-
1857
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
1858
AKAGPA

P1369

MSWVRQAPGKGLEWISAISGSGGRTYNADSV

AAYGW

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

YYYYMD

KAGPAAAYGWYYYYMDVWGKGTTVTASS

V

COV072_Plate2_HC_15-
1861
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1862
AKGPRF

P1369

MHWVRQAPGKGLEWVAVISYDGTDSVKGRFT

GWSYR

ISRDTSKNMLYLQMNSLRAEDTAVYYCAKGPRF

GGPGFD

GWSYRGGPGFDIWGQGTMVTVSS

I

COV072_P3_HC_45-
1865
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1866
ASSSGYL

P1369

MHWVRQAPGKGLEWVAVIPFDGRNKYYADS

FHSDY

VTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

AKGPRF

ASSSGYLFHSDYWGQGTLVTVSS

COV072_Plate2_HC_31-
1869
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
1870
GWSYR

P1369

MNWVRQAPGKGLEWVAVISYDGSNTYYTDSV

GGSGFD

KGRFTISRDNSKNTLYLQMNSLRVDDTATYYCA

I

KGPRFGWSYRGGSGFDIWGQGTMVTVSS

COV072_P3_HC_3-
1873
QVQLVESGGGVVQPGRSLRLSCAVSGFTFSSYG
1874
AKQLGL

P1369

MHWVRQAPGKGLEWVAVISYDGSNKHYADS

YCSGGN

VKGRFTISRDNSKNTLYVQMNSLRAEDTAMYY

CYSGAL

CAKQLGLYCSGGNCYSGALDYWGQGTLVTVSS

DY

COV072_P3_HC_37-
1877
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
1878
AKQNGL

P1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YCSGGS

KGRFTISRDNSKNMLYLQMNSLRAEDTAVYYC

CYLGYF

AKQNGLYCSGGSCYLGYFDYWGQGTLVTVSS

DY

COV072_Plate2_HC_63-
1881
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1882
AKGGAY

P1369

MHWVRQAPGKGLEWVAVISYDGSNKYSADSV

SYYYYM

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

DV

KGGAYSYYYYMDVWGKGTTVTVSS

COV072_P3_HC_69-
1885
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYT
1886
ARDSDT

P1369

MHWVRQAPGKGLEWVAVISYDGSIKYYADSV

AMVDY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

RDSDTAMVDYFDYWGQGTLVTVSS

COV072_P3_HC_74-
1889
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1890
AKVDLK

P1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YSYGLYY

KGRCTISRDNSKNTLFLQMNSLRPEDTAVYYCA

FDY

KVDLKYSYGLYYFDYWGQGTLVTVSS

COV072_Plate2_HC_12-
1893
QVQLVESGGGVVQPGRSLRLSCAASGFTFSHYA
1894
ASSSGYL

P1369

MHWVRQAPGKGLEWVAVIPFDGSNKYYADSV

FHFDY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

SSSGYLFHFDYWGQGTLVTVSS

COV072_Plate2_HC_23-
1897
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNY
1898
ARVRLG

P1369

AMHWVRQAPGKGLEWVAVISYDGSKKYSADS

AYYNYF

VKGRFTISRDNSKNTLYLQMNSLRPVDTAVYYC

GMDV

ARVRLGAYYNYFGMDVWGQGTTVTVSS

COV072_P3_HC_68-
1901
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1902
AKKGQP

P1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YCGGDC

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

YFYYFDY

KKGQPYCGGDCYFYYFDYWGQGTLVTVSS

COV072_Plate2_HC_72-
1905
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
1906
ARDGTG

P1369

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

IAAAGT

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

ANPPFD

ARDGTGIAAAGTANPPFDYWGQGTLVTVSS

Y

COV072_Plate2_HC_25-
1909
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYG
1910
ATSLFGI

P1369

MHWVRQAPGKGLEWVAVIWYDGNNKYYADS

ISLDY

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

ATSLFGIISLDYWGQGTLVTVSS

COV072_Plate2_HC_54-
1913
QVQLVESGGGVVQPGRSLRLSCAASGFTFNNY
1914
ARDWEI

P1369

GMHWVRQAPGKGLEWVAVIWYDGSNKYYAD

WAGM

SVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYY

DV

CARDWEIVVAGMDVWGQGTTVTVSS

COV072_Plate2_HC_78-
1917
EVQLVESGGVVVQPGGSLRLSCAASGFTFDDH
1918
AKGLNY

P1369

TMHWVRQAPGKGLEWVSLISWDAGSTYYADS

RPQYYY

VKGRFTISRDNRKNFLYLQMNSLRTEDTALYYC

YYGMD

AKGLNYRPQYYYYYGMDVWGQGTTVTVSS

V

COV072_P3_HC_26-
1921
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
1922
ARSFYF

P1369

MSWVRQAPGKGLEWISVIYSGGSTFYADSVKG

DAFDI

RFTISRDNSKDTLYLQMNRLRAEDTAVYYCARS

FYFDAFDIWGQGTMVTVSS

COV072_P3_HC_67-
1925
EVQLVESGGGLIQPGGSLRLSCAASGFIVSRNY
1926
TRDPVP

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

GRGDAY

GRFTISRDNSKNTLYLQMNSLRADDTAVYYCTR

DPVPGRGDAYWGQGTLVTVSS

COV072_Plate2_HC_89-
1929
EVQLVETGGGLIQPGGSLRLSCAASGITVSSNY
1930
ARDLYY

P1369

MSWVRQAPGKGLEWVSIIYSGGSTFYADSVKG

YGMDV

RFTISRDNPKNTLYLQMNSLRAEDTAVYYCARD

LYYYGMDVWGQGTTVTVS

COV072_P3_HC_22-
1933
EVQLVESGGGLVQPGGSLRLSCSASGFTFSSYA
1934
VKDITM

P1369

MHWVRQAPGKGLEYVSAISSNGGSTYYADSVK

IVDVFEY

GRFTISRDNSKNTLYLQMSSLRAEDTAVYYCVK

DITMIVDVFEYWGQGTLVTVSS

COV072_P3_HC_47-
1937
EVQLVESGGGLVQPGGSLRLSCAASEFIVSRNY
1938
ARDIAG

P1369

MSWVRQAPGKGLEWVSLIYSGGSTYYADSVKG

RLDY

RFTISRDNSKNTLYLQMNSLRAEDTAMYYCARD

IAGRLDYWGQGTLVTVSS

COV072_P3_HC_59-
1941
EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNY
1942
ARDLW

P1369

MSWVRQAPGKGLEWVSILYSGGSTYYADSVKG

YGADY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD

LVVYGADYWGQGTLVTVSS

COV072_Plate2_HC_16-
1945
EVQLVESGGDLVQPGGSLRLSCAASGLTVSSNY
1946
ARDLOY

P1369

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVK

YGMDV

GRFTISRDNSQNTLYLQMNSLRAEDTAVYYCAR

DLQYYGMDVWGQGTTVTVSS

COV072_Plate2_HC_37-
1949
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
1950
ARDQVS

P1369

MSWVRQAPGKGLEWVANIKQDGSVKYYVDSV

WYNLD

KGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCA

AFDI

RDQVSWYNLDAFDIWGQGTMVTVSS

COV072_Plate2_HC_86-
1953
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDY
1954
VRWM

P1369

SWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKS

SGIAAA

RVTISVDTSKNQFSLKLSSVTAADTAVYYCVRVV

GQNDY

MSGIAAAGQNDYWGQGTLVTVSS

COV072_Plate2_HC_32-
1957
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDY
1958
ARTYYY

P1369

YWSWIRQPPGKGLEWIGYIYYSGSTYYNPSLKS

DSSGYY

RVTISVDTSKNQFSLKLSSVTAADTAVYYCARTY

FQYYFD

YYDSSGYYFQYYFDCWGQGTLVTVSS

C

COV072_Plate2_HC_67-
1961
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY
1962
ATNYDD

P1369

YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS

YVPAEY

RVTISVDTSKKQFSLKLSSVTAADTAVYYCATNY

FQD

DDYVPAEYFQDWGQGTLVTVSS

COV072_Plate2_HC_88-
1965
QVQLQESGPGLVKPSQTLSLTCTFSGGSISSGGH
1966
ARSCSS

P1369

YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS

TSCPFD

RVIISVDTSKNQFSLRLSSVTAADTAVYYCARSCS

Y

STSCPFDYWGQGTLVTVSS

COV072_Plate2_HC_74-
1969
QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYY
1970
ARRPPG

P1369

WGWIRQSPGKGLEWIGSIYYSGSTYYNPSLKSR

DYYYM

VTISVDTSKNQFSLKLSSVTAADTAVYYCARRPP

DV

GDYYYMDVWGKGTTVTVSS

COV072_P3_HC_4-
1973
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNS
1974
ARSGSY

P1369

TAWNWIRQSPSRGLEWLGRTYYRSKWYNHYA

YISHGM

LSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYC

DV

ARSGSYYISHGMDVWGQGTTVTVSS

COV072_P3_HC_54-
1977
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1978
ARNDGS

P1369

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

SGWYPE

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

RGGGFD

RNDGSSGWYPERGGGFDYWGQGTLVTVSS

Y

COV072_P3_HC_94-
1981
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1982
ARALSFI

P1369

IHWVRQAPGKGLEWVAVISNDGSNKYYEDSVK

AVAGID

GRFTFSRDNSKNTLYLQMNSLRAEDTAVYYCAR

Y

ALSFIAVAGIDYWGRGTLVTVSS

COV072_P3_HC_91-
1985
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
1986
ARADLG

P1369

MFWVRQAPGKGLEWVAVISYDGSNKYYADSV

YCTNGV

KGRFTISRDNSKNTLYLQI\/INSLRAEDTAVYYCA

CYVDY

RADLGYCTNGVCYVDYWGQGTLVTVSS

COV072_Plate2_HC_14-
1989
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNY
1990
ASHLMP

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

DAFDI

GRFTISRDNSKNTLYLHMNSLRAEDTAVFYCAS

HLMPDAFDIWGQGTMVTVSS

COV072_P3_HC_1-
1993
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
1994
ARWGY

P1369

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

DFWSG

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

YDGGYF

VVGYDFWSGYDGGYFDYWGQGTLVTVSS

DY

COV072_P3_HC_71-
1997
QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYG
1998
ARGEW

P1369

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

DSGSYQ

VKGRFTISRDNSKNTLYLKMNSLRAEDTAVYYC

YYDYYM

ARGEWDSGSYQYYDYYMDVWGKGTTVTVSS

DV

COV072_Plate2_HC_5-
2001
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
2002
ARDTGR

P1369

MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV

ITFGGG

KGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA

DDAFDI

RDTGRITFGGGDDAFDIWGQGTMVTVSS

COV072_Plate2_HC_71-
2005
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY
2006
ARGVVL

P1369

YWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS

ITDYYFD

RVTISVDTSQNQFSLRLSSVTAADTAVYYCARG

Y

VVLITDYYFDYWGQGTLVTVSS

COV072_P3_HC_73-
2009
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYS
2010
AREGAV

P1369

WSWIRQPPGKGLEWIGEINHGGSTNYNASLKS

AGGDF

RVTISADTSKNLFSLKLSSVTAADTAVYYCAREG

DY

AVAGGDFDYWGQGTLVTVSS

COV072_Plate2_HC_76-
2013
QVQLQESG PG LVKPS ETLS LTCTVSGGS1SSYYW
2014
ARGRGL

P1369

SWIRQPPGKGLEWIGYIYYSGSTRYNPSLKSRVT

PPWFDP

ISVDTSKNQFSLKLSSVTAADTAVFYCARGRGLP

PWFDPWGQGTLVTVSS

COV072_P3_HC_18-
2017
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
2018
ARPDM

P1369

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

SSSSSPH

ISVDTSKNQFSLKLSSVTAADTAVYYCARPDMSS

YWYFDL

SSSPHYWYFDLWGRGTLVTVSS

COV072_P3_HC_84-
2021
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI
2022
ARRGGS

P1369

VWVRQMPGKGLERMGIIYPGDSDTRYSPSFQG

YYNNGD

QVTISADKSISTAYLQWSSLKASDTAMYYCARR

GMDV

GGSYYNNGDGMDVWGQGTTVTVSS

COV072_P3_HC_55-
2025
EVQLVESGGGLVKPGGSLRLSCAAASGFTISNA
2026
TTDYSIR

P1369

WMSWVRQAPGKGLEWVGRIKSKTDGGTTDY

YYYGM

AAPVKGRFTISRDNSKNTLYLQMNSLKTEDTAV

DV

YYCTTDYSIRYYYGMDVWGQGTTVTVSS

COV072_P3_HC_38-
2029
EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYS
2030
ARAKLEI

P1369

MNWVRQAPGKGLEWVSSISSSSNYIYYADSVK

AHYGGS

GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR

PGFDY

AKLEIAHYGGSPGFDYWGQGTLVTVSS

COV072_P3_HC_36-
2033
EVQLVESGGGLVKPGGSLRLSCAASGFSFRSYS
2034
ARMGLE

P1369

MNWVRQAPGKGLEWVSSISSSSSYIYYADSVK

LPGLDY

GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR

GMDV

MGLELPGLDYGMDVWGQGTTVTVSS

COV072_Plate2_HC_94-
2037
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYA
2038
AKVDYG

P1369

MTWVRQAPGKGLEWVSAISGSGGRTYYADSV

EYVFSN

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

AFDI

KVDYGEYVFSNAFDIWGQGTMVSVSS

COV072_P3_HC_56-
2041
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNY
2042
AKAGGR

P1369

GMHWVRQAPGKGLEWVAVLSYEGSSTYYADS

DYYDSS

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

GYYLLD

AKAGGRDYYDSSGYYLLDHYYGMDVWGQGTT

HYYGM

VTVSS

DV

SEQ

SEQ

ID

ID

SEQUENCE_ID
NO
aa
NO
cdr3_aa

KAPPA

COV072_Plate3_Kappa_50-
1735
EIVLTQSPGTLSLSPGERATLSCRASQSV
1736
QQY

P1389

NSRQLAWYQQKPGQGPRLLIYGASSR

GSS

ATGIPDRFSGSGSGTDFTLTISRLEPEDF

RAL

AVYYCQQYGSSRALTFGGGTKVEIK

T

COV072_Plate2_Kappa_24-
1739
EIVLTQSPGTLSLSPGERATLSCRASQSV
1740
QQY

P1389

NSRQLAWYQQKPGQAPRLLIYGASSR

GSS

ATGIPERFSGSGSGTDFTLTISRLESEDF

RAL

AVYHCQQYGSSRALTFGGGTKVEIK

T

COV072_Plate2_Kappa_66-
1743
EIVLTQSPGTLSLSPGERATLFCRASQSV
1744
QQY

P1389

TSSHLAWYQQKAGQAPRLLIYGASSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

RSLT

VYYCQQYGSSRSLTFGGGTKVEIK

COV072_Plate3_Kappa_17-
1747
EIVMTQSPATLSVSPGERATLSCRASQS
1748
QQY

P1389

VSSNLAWYQQKPGQAPRLLIYGASTRA

NN

TGIPARFSGSGSGTEFTLTISSLQSEDFA

WPI

VYYCQQYNNWPITFGQGTRLEIK

T

COV072_Plate3_Kappa_21-
1751
EIVMTQSPATLSVSPGERATLSCRASQS
1752
QQY

P1389

VSSNLAWYQQKPGQAPRLLIYAASTRA

NN

TGIPARFSGSGSGTEFTLTISSLQSEDFA

WPI

VYYCQQYNNWPITFGQGTRLEIK

T

COV072_Plate3_Kappa_53-
1755
DIQMTQSPSSLSASVGDRVTITCRASQS
1756
QQS

P1389

ISSYLNWYQQKPGKAPKLLIYAASSLQS

YSTP

GVPSRFSGSGSGTDFTLTISSLQPEDFA

PWT

TYYCQQSYSTPPWTFGQGTKVEIK

COV072_Plate2_Kappa_83-
1759
DIQMTQSPSSLSASVGDRVTITCRASQS
1760
QQS

P1389

ISSYLNWYQHKPGKAPKLLIYASSSLQS

YSTP

GVPSRFSGSGSGTDFTLTISSLQPEDFA

PWT

TYYCQQSYSTPPWTFGQGTKVEIK

COV072_Plate3_Kappa_80-
1763
DIQLTQSPSFLSASVGDRVTITCRASQGI
1764
QQL

P1389

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PPY

YCQQLNSYPPYTFGQGTKLEIK

T

COV072_Plate2_Kappa_36-
1767
DIQLTQSPSFLSASVGDRVTITCRASQGI
1768
QQL

P1389

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

SYT

YCQQLNSYSYTFGQGTKLEIK

LAMBDA

COV072_Plate3_Lambda_49-
1771
SYVLTQPPSVSVAPGKTARITCGGNNIG
1772
QV

P1409

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WDS

GIPERFSGSNSGNTATLTISRVEAGDEA

SSD

DYYCQVWDSSSDHPGVVFGGGTKLTV

HPG

L

W

COV072_Plate2_Lambda_81-
1775
SYVLTQPPSVSVAPGKTARITCGGNNIG
1776
QV

P1409

SKSVHWYQQKPGQAPVLVIYYDNDRP

WD

SGIPERFSGSNSGNTATLTISRVEAGDE

GGS

ADYYCQVWDGGSDHPGVVFGGGTKL

DHP

TVL

GW

COV072_Plate3_Lambda_51-
1779
SYVLTQPPSVSVAPGKTARITCGGNNIG
1780
QV

P1409

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WDS

GIPERFSGSNSGNTATLTISRVEAGDEA

SSD

EYHCQVWDSSSDRPGVVFGGGTKLTV

RPG

L

W

COV072_Plate2_Lambda_93-
1783
SYVLTQPPSVSVAPGKTARITCGGNNIG
1784
QV

P1409

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WDS

GIPERFSGSNSGNTATLTISRVEAGDEA

SSD

EYHCQVWDSSSDRPGVVFGGGTKLTV

RPG

L

W

COV072_Plate3_Lambda_12-
1787
NFMLNQPPCEXESPGKTVTISCTGSSG
1788
QSY

P1409

SIASNYDQWYQQRPGSAPTTVIYEDKQ

DSS

RTSGVLDWFSGSXARSSNSPSLTIXGRK

KGV

REDEADXYCQSYDSSKGVFGGGTKLTV

L

COV072_Plate2_Lambda_33-
1791
NFMLTQPHSVSESPGKTVTISCTGSSGS
1792
QSY

P1409

IASNYVQWYQQRPGSAPTTVIYEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

NW

EDEADYYCQSYDSSNWVFGGGTKLTV

V

L

COV072_Plate3_Lambda_25-
1795
QSVLTQPASVSGSPGQSITISCTGTSSD
1796
SSYT

P1409

VGGYNYVSWYQQH PGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLQA

LL

EDEADYYCSSYTSSSTLLFGGGTKLTVL

COV072_Plate2_Lambda_53-
1799
QSVLTQPASVSGSPGQSITISCTGTSSD
1800
SSFT

P1409

VGGYNYVSWYQQH PGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLQA

LL

EDEADYYCSSFTSSSTLLFGGGTRLTVL

COV072_Plate3_Lambda_44-
1803
NFVLTQPHSVSESPGKTVTISCTGSSGSI
1804
QSY

P1409

ASNYVQWYQQRPGSAPTTVIYEDNQR

DSS

PSGVPDRFSGSIDSSSNSASLTISGLKTE

TWV

DEADYYCQSYDSSTWVFGGGTKLTVL

COV072_Plate3_Lambda_40-
1807
QSVLTQPRSVSGSPGQSVTISCTGTSSD
1808
CSY

P1409

FGGYNYVSWYQQHPGKAPKLIVIIYDVS

KRPSGVPDRFSGSKSGNTASLTISGLQA

AGS

EDEADYYCCSYAGSYTRYVFGTGTKVT

YTR

VL

YV

COV072_Plate3_Lambda_77-
1811
QSVLTQPPSVSGAPGQRVTISCTGSNS
1812
QSY

P1409

NIGAGYDVHWYQQLPGTAPKLLIYVNS

DSSL

NRPSGVPDRFSGSKSGTSASLAITGLQA

SGS

EDEADYSCQSYDSSLSGSVFGTGTKVTV

V

L

KAPPA

COV072_Plate2_Kappa_9-
1815
EIVLTQSPATLSLSPGERATLSCRASQSV
1816
QQR

P1389

SSYLAWYQQKPGQAPRLLIYDASNRAT

SNW

GIPARFSGSGSGTDFTLTISSLEPEDFAV

PPG

YYCQQRSNWPPGVTFGQGTRLEIK

VT

COV072_Plate3_Kappa_34-
1819
DIVMTQSPLSLPVTPGEPASISCRSSQSL
1820
MQ

P1389

LYSNGYNYLDWYLQKPGQSPQLLIYLG

ALQ

SNRASGVPDRFSGSGSGTDFTLKISRVE

TPW

AEDVGVYYCMQALQTPWTFGQGTKV

T

EIK

COV072_Plate3_Kappa_10-
1823
DIQMTQSPSSLSASVGDRVTITCRASQS
1824
QQS

P1389

SSRYLNWYQQKPGKAPKLLIYAASSLQS

YRT

GVPSRFSGSGSGTDFTLTISSLQPEDFA

RLT

TYYCQQSYRTRLTFGGGTKVEIK

COV072_Plate3_Kappa_42-
1827
EIVLTQSPGTLSLSPGERATLSCRASQSF
1828
QQY

P1389

RSSYLAWYQQKPGQAPRLLIYGASSRA

DISP

TGIPDRFSGSGSGSDFTLTISRLEPEDFA

WT

VYYCQQYDISPWTFGQGTKVEIK

COV072_Plate3_Kappa_31-
1831
EIVMTQSPATLSVSPGERATLSCRASQS
1832
QQY

P1389

VSSHLAWYQQKPGQAPRLLIYGASTRA

HN

TGIPARFSGSGSGTEFTLTISSLQSEDFA

WPP

VYYCQQYHNWPPALTFGGGTKVEIK

ALT

COV072_Plate3_Kappa_30-
1835
EIVMTQSPATLSVSPGERATLSCRASQS
1836
QQY

P1389

VSSNLAWYQQKPGQAPRLLIYGASTRA

NNG

TGIPARFSGSGSGTEFTLTISSLQSEDFA

LT

VYYCQQYNNGLTFGGGTKVEIK

COV072_Plate3_Kappa_48-
1839
EIVLTQSPGTLSLSPGERATLSCRASQSV
1840
QQY

P1389

SSTYLAWYQQKPGQAPRLLIYGASSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

PWT

VYYCQQYGSSPWTFGQGTKVEIK

COV072_Plate2_Kappa_40-
1843
EIVLTQSPGTLSLPPGERATLSCRASQSV
1844
QQY

P1389

SSSYLAWYQQKPGQAPRLLIYGASSRA

ANS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

RT

VYYCQQYANSRTFGQGTKVEIK

COV072_Plate3_Kappa_58-
1847
DIQMTQSPSSLSASVGDRVTITCQASQ
1848
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASHL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PLT

ATYYCQQYDNLPLTFGGGTKVEIK

COV072_Plate3_Kappa_64-
1851
DIQMTQSPSSLSASVGDRVTITCRASQS
1852
QQS

P1389

ISSYLNWYQEKPGKAPKLLIYAASSLQS

YSTR

GVPSRFSGSGSGTDFTLTISSLQPEDFA

ALT

TYYCQQSYSTRALTFGGGTKVEIK

COV072_Plate3_Kappa_5-
1855
DIQMTQSPSSLSASVGDRVTITCQASQ
1856
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PPFT

ATYYCQQYDNLPPFTFGPGTKVHIK

COV072_Plate2_Kappa_92-
1859
DIQMTQSPSSLSASVGDRVTITCRASQ
1860
QKY

P1389

GISNYLAWYQQKPGKVPKLLIYAASTLQ

NSA

SGVPSRFSGSGSGTDFTLTISSLQPEDVS

LGFT

TYYCQKYNSALGFTFGPGTKVDIK

COV072_Plate2_Kappa_15-
1863
DIQMTQSPSSLSASVGDRVTITCQASQ
1864
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PIT

ATYYCQQYDNLPITFGQGTRLEIK

COV072_Plate3_Kappa_45-
1867
DIQMTQSPSTLSASVGDRVTITCRASQS
1868
QQY

P1389

ISNWLAWFQQKPGKAPKLLIYEAXSLES

NSY

GVPSRFSGSGSGTEFTLTISSLQPDDFA

PWT

TYYCQQYNSYPWTFGQGTKVEIK

COV072_Plate2_Kappa_31-
1871
DIQMTQSPSSLSASVGDRVTITCQASQ
1872
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSESGTDFTFTISSLQPEDI

PIT

ATYYCQQYDNLPITFGQGTRLEIK

COV072_Plate3_Kappa_3-
1875
DIQMTQSPSSLSASVGDRVTITCQASQ
1876
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PFT

ATYYCQQYDNLPFTFGPGTKVDIK

COV072_Plate3_Kappa_37-
1879
DIQMTQSPSSLSASVGDRVTITCQASQ
1880
LOY

P1389

DISNYLNWFQQKPGKAPKLLIYAASDLE

DNL

TGVPSRFSGSGSGTDFTFTISSLQPEDIA

PLT

SYYCLQYDNLPLTFGGGTKVEIK

COV072_Plate2_Kappa_63-
1883
DIQMTQSPSSLSASVGDRVTITCQASQ
1884
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PLT

ATYYCQQYDNLPLTFGGGTKVEIK

COV072_Plate3_Kappa_69-
1887
DIQMTQSPSSLSASVGDRVTITCRASQS
1888
QQS

P1389

ISSYLNWYQQKAGKAPKLLIYAASSLQS

YSTF

GVPSRFSGSGSGTDFTLTISSLQPEDFA

MYT

TYYCQQSYSTFMYTFGQGTKLEIK

COV072_Plate3_Kappa_74-
1891
DIQMTQSPSSLSASVGDRVTITCRASQS
1892
QQT

P1389

ISSYLNWYQQKPGKAPKLLIYAASSLQS

YITP

GVPSRFSGSGSGTDFTLTISSLQPEDFA

PS

TYYCQQTYITPPSFGPGTKVDIK

COV072_Plate2_Kappa_12-
1895
DIQMTQSPSTLSASVGDRVTITCRASQS
1896
QQY

P1389

ISSWLAWYQQKPGKAPKLLIYKASSLES

NSY

GVPSRFSGSGSGTEFTLTISSLQPDDFA

PWT

TYYCQQYNSYPWTFGQGTKVEIK

COV072_Plate2_Kappa_23-
1899
DIVMTQSPLSLPVTPGEPASISCRSSQSL
1900
MQ

P1389

LHSNGYNYLDWYLQKPGQSPQLLIYLG

ALQ

SNRASGVPDRFSGSGSGTDFTLKISRVE

TFT

AEDVGVYYCMQALQTFTFGPGTKVDIK

COV072_Plate3_Kappa_68-
1903
DIQMTQSPSSLSASLGDRVTITCQASQ
1904
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PPIT

ATYYCQQYDNLPPITFGQGTRLEIK

COV072_Plate2_Kappa_72-
1907
DIQMTQSPSSLSASVGDRVTITCQASQ
1908
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PYT

ATYYCQQYDNLPYTFGQGTKLEIK

COV072_Plate2_Kappa_25-
1911
AIQMTQSPSSLSASVGDRVTITCRAGQ
1912
LOD

P1389

GIRNDLGWYQQKPGKAPKLLIYAASSL

YNY

QSGVPSRFSGSGSGTDFTLTISSLQPED

PYT

FATYYCLQDYNYPYTFGQGTKLEIK

COV072_Plate2_Kappa_54-
1915
DVVMTQSPLSLPVTLGQPASISCRSSQS
1916
MQ

P1389

LVYNDGNTYLNWFQQRPGQSPRRLIY

GTH

KVSNRDSGVPDRFSGSGSGTDFTLKISR

CPFT

VEAEDVGVYYCMQGTHCPFTFGPGTK

VDIK

COV072_Plate2_Kappa_78-
1919
DIVMTQSPLSLPVTPGEPASISCRSSQSL
1920
MQ

P1389

LHSNGYNYLDWYLQKPGQSPQLLIYLG

ALQ

SNRASGVPDRFSGSGSGTDFTLKISRVE

TPW

AEDVGVYYCMQALQTPWTFGQGTKV

T

EIK

COV072_Plate3_Kappa_26-
1923
DIQLTQSPSFLSASVGDRVTITCRASQGI
1924
QQL

P1389

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PLLT

YCQQLNSYPLLTFGGGTKVEIK

COV072_Plate3_Kappa_67-
1927
DIQMTQSPSSLSASVGDRVTITCQASQ
1928
QQY

P1389

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISTLQPEDI

PIT

ATYYCQQYDNLPITFGGGTKVEIK

COV072_Plate2_Kappa_89-
1931
DIQLTQSPSFLSASVGDRVTITCRASQGI
1932
QQL

P1389

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PT

YCQQLNSYPTFGQGTKLEIK

COV072_Plate3_Kappa_22-
1935
DIQMTQSPSSLSASVGDRVTITCRASQS
1936
QQS

P1389

ISNYLNWYQQKPGKAPKLLIYAASSLQS

YTTP

AVPSRFSGSGSGTDFTLTISSLQPEDFAT

YT

YFCQQSYTTPYTFGQGTKLEIK

COV072_Plate3_Kappa_47-
1939
DIQMTQSPSSLSASVGDRVTITCQASQ
1940
QHY

P1389

DISKYLNWYQQKPGKAPKLLIYDASNLE

DSLS

TGVPSRFSGSGSGTDFTFTISSLQPEDF

RLT

ATYYCQHYDSLSRLTFGGGTKVEIK

COV072_Plate3_Kappa_59-
1943
DIQLTQSPSFLSASVGDRVTITCRASQGI
1944
QQL

P1389

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PPP

YCQQLNSYPPPFGGGTKVEIK

COV072_Plate2_Kappa_16-
1947
DIQLTQSPSFLSASVGDRVTITCRASQGI
1948
QQP

P1389

SSYLAWYQQKPGKAPKLLIYAASTLQSG

DSF

VPSRFSGSGSGTEFTLTISSLQPEDFATY

T

YCQQPDSFTFGPGTKVDIK

COV072_Plate2_Kappa_37-
1951
DVVMTQSPLSLPVTLGQPASISCRSSQS
1952
MQ

P1389

LVYSDGDTYLNWFQQRPGQSPRRLIYK

GTH

VSNRDSGVPDRFSGSGSGTDFTLKISRV

WPK

EAEDVGVYYCMQGTHWPKTFGQGTK

T

LEIK

COV072_Plate2_Kappa_86-
1955
DIQMTQSPSSLSASVGDRVTITCQASQ
1956
QQY

P1389

DISSYLNWYQQKPGKAPKLLIYDASNLE

DILP

TGVPSRFSGSGSGTDFTFTISSLQPEDIA

PMY

TYYCQQYDILPPMYTFGQGTKLEIK

T

COV072_Plate2_Kappa_32-
1959
EIVLTQSPGTLSLSPGERATLSCRASLSV
1960
QQY

P1389

SSSYLAWYQQKPGQAPRLLIYGASSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

PLT

VYYCQQYGSSPLTFGGGTKVEIK

COV072_Plate2_Kappa_67-
1963
EIVLTQSPATLSLSPGERATLSCRASQSV
1964
QQR

P1389

SSYLAWYQQKPGQAPRLLIYDASNRAT

SNW

GIPARFSGSGSGTDFTLTISSLEPEDFAV

PPLT

YYCQQRSNWPPLTFGGGTKVEIK

COV072_Plate2_Kappa_88-
1967
DIQMTQSPSSLSASVGDRVTITCQASQ
1968
QQY

P1389

DISNSLNWYQQKPGKAPKVLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDF

PFT

ATYYCQQYDNLPFTFGPGTKVDIK

COV072_Plate2_Kappa_74-
1971
DIQMTQSPSSLSASVGDRVTITCRASQS
1972
QQS

P1389

ISSYLNWYQQKPGKAPKLLIYAASSLQS

YSIP

GVPSRFSGSGSGTDFTLTISSLQPEDFA

QIT

TYYCQQSYSIPQITFGQGTRLEIK

COV072_Plate3_Kappa_4-
1975
EIVMTQSPATLSVSPGERATLSCRASQS
1976
QQY

P1389

VSSNLAWYQQRPGQAPRLLIYGASTRA

NN

TGIPARFSGSGSGTEFTLTISSLQSEDFA

WPP

VYYCQQYNNWPPWTFGQGTKVEIK

WT

LAMBDA

COV072_Plate3_Lambda_54-
1979
QSVLTQPPSVSGAPGQRVTISCTGSSS
1980
QSY

P1409

NIGAGYDVKWYQQLPGTAPKLLIYGNS

DSSL

NRPSGVPDRFSGSKSGTSASLAITGLQA

SGL

EDEADYYCQSYDSSLSGLWVFGGGTKL

WV

TVL

COV072_Plate3_Lambda_94-
1983
NFMLTQPHSVSESPGKTVTISCTGSSGS
1984
QSY

P1409

IASNYVQWYQQRPGSAPTIVIYEDNQR

DST

PSGVPDRFSGSIDSSSNSASLTISGLKTE

THV

DEADYYCQSYDSTTHVVFGGGTKLIVL

V

COV072_Plate3_Lambda_91-
1987
NFMLTQPHSVSESPGKTVTISCTGSSGS
1988
QSY

P1409

IASNYVQWYQQRPGSAPTTVIYEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

NW

EDEADYYCQSYDSSNWVFGGGTKLTV

V

L

COV072_Plate2_Lambda_14-
1991
QSVLTQPASVSGSPGQSITISCTGTSSD
1992
CSY

P1409

VGSYNLVSWYQQHPGKAPKLMIYEVS

GGS

KRPSGVSNRFSGSKSGNTASLTISGLQA

STSF

EDEADYYCCSYGGSSTSFYVFGTGTKVT

YV

VL

COV072_Plate3_Lambda_1-
1995
QSALTQPASVSGSPGQSITISCTGTSSD
1996
CSY

P1409

VGSYNLVSWYQQHPGKAPKLMIYEVS

AGS

KRPSGVSNRFSGSKSGNTASLTISGLQA

STW

EDEADYYCCSYAGSSTWVFGGGTKLTV

V

L

COV072_Plate3_Lambda_71-
1999
QSVLTQEPSFSVSPGGTVTLTCGLSSGS
2000
VLY

P1409

VSTSYYPSWYQQTPGQPPRTLIYITNTR

MGS

SSGVPDRFSGSILGNKAALTITGAQADD

SNW

ESDYYCVLYMGSSNWVFGGGTKLTVL

V

COV072_Plate2_Lambda_5-
2003
SYVLTQPPSVSVAPGKTARITCGGNNIG
2004
QV

P1409

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WDS

GIPERFSGSKSGNTATLTISRVEAGDEA

SSD

DYYCQVWDSSSDHRVFGGGTKLTVL

HRV

COV072_Plate2_Lambda_71-
2007
SYVLTQPPSVSVSPGQTARITCSGDTLP
2008
QSA

P1409

KQYVYWYQQKPGQAPALVIYKDSERPS

DSS

GIPERLSGSSSGTTATLTISGVQAEDEA

GTR

DYYCQSADSSGTRFGGGTKLTVL

COV072_Plate3_Lambda_73-
2011
SYVLTQPPSVSVAPGKTARITCGGNNIG
2012
QV

P1409

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

GTS

DYYCQVWDGTSDHPGWVFGGGTKLT

DHP

VL

GW

V

COV072_Plate2_Lambda_76-
2015
NFMLTQPHSVSESPGKTVTISCTGSSGS
2016
QSY

P1409

IASNYVQWYQQRPGSAPTTVIYEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

NVV

EDEADYYCQSYDSSNVVFGGGTKLTVL

COV072_Plate3_Lambda_18-
2019
SYVLTQPPSVSVAPGKTARITCGGNNIG
2020
QV

P1409

SKNVHWYQQKPGQAPVLVVYYDSDR

WDS

PSGIPERFSGSNSGNTATLTISRVEAGD

SSG

EADYYCQVWDSSSGHFHVVFGGGTKL

HFH

TVL

W

COV072_Plate3_Lambda_84-
2023
SYVLTQPPSVSVSPGQTASITCFGDKLG
2024
QA

P1409

DKYACWYQQKPGQSPVLVIYQDSKRP

WDS

SGIPERFSGSNSGNTATLTISGTQAMDE

STP

ADYYCQAWDSSTPHVVFGGGTKLTVL

HVV

COV072_Plate3_Lambda_55-
2027
SYVLTQPPSVAVSPGQTARITCSGDALP
2028
QSA

P1409

KQYAYWYQQKPGQAPVLVIYKDSERPS

DSS

GIPERFSGSSSGTTVTLTISGVQAEDEA

GTY

DYYCQSADSSGTYEVFGGGTKVTVL

EV

COV072_Plate3_Lambda_38-
2031
SYELTQPPSVSVSPGQTASITCSGDKLG
2032
QA

P1409

DKYTCWYQQKPGQSPVLVIYQDTQRP

WDS

SGIPERFSGSNSGNTATLTISGTQAMDE

STG

ADYYCQAWDSSTGVVFGGGTKVTVL

W

COV072_Plate3_Lambda_36-
2035
QSVLTQPPSVSEAPRQRVTISCSGSSSN
2036
AA

P1409

IGNNAVNWYQQLPGKAPKLLIYYDDLL

WD

PSGVSDRFSGSKSGTSASLAISGLQSED

DSF

EADYYCAAWDDSFNGPVFGGGTKLTV

NGP

L

V

COV072_Plate2_Lambda_94-
2039
QSVLTQPASVSGSPGQSITISCTGTSSD
2040
CSY

P1409

VGSYNLVSWYQQHPDKAPKLMIYEVS

AGT

KRPSGVSNRFSGSKSGNTASLTISGLQA

STYV

EDEADYYCCSYAGTSTYVFGTGTKLTVL

COV072_Plate3_Lambda_56-
2043
QSVLTQPPSVSGAPGQRVTISCTGSSS
2044
QSY

P1409

NIGAGYDVHWYQQLPGTAPKLLIYGNS

DSSL

NRPSGVPDRFSGSKSGTSASLAITGLQA

SGF

EDEADYYCQSYDSSLSGFYVFGTGTKVT

YV

VL

TABLE 12

Anti-SARS-CoV-2 IgG antibodies from COV96

SEQ

SEQ

ID

ID

SEQUENCE_ID
NO
aa
NO
cdr3_aa

HEAVY

COV096_HC_100-pl369
2045
EVQLLESGGGLEQPGGSLRLSCAASGFTFSTYAM
2046
ARESDCG

SWVRQAPGKGLEWVSAISGSGAGTFYADSVKGR

STSCYQV

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARESD

GWFDP

CGSTSCYQVGWFDPWGQGTLVTVSS

COV096_HC_164-pl369
2049
EVQLLESGGGLVQPGTSLRLSCAASGFTFSSYAMS
2050
ATERIAVA

WVRQAPGKGLEWVSAISSSGGSTYYADSVKGRF

GTRMYN

TISRDNSKNTLYLHMNSLRAEDTAVYYCATERIAV

WFDP

AGTRMYNWFDPWGQGTLVTVSS

COV096_HC_25-pl369
2053
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAM
2054
ASEEDYS

SWVRQAPGKGLEWVSAITDSGDGTFYADSVKGR

NYVGWF

FTISRDNSKNTLYLQMNSLRAEDTAVYYCASEEDY

DP

SNYVGWFDPWGQGTLVTVSS

COV096_HC_91-pl369
2057
EVQLLESGGGLEQPGGSLRLSCAASGFTFSTYAM
2058
ARESDCG

SWVRQAPGKGLEWVSAISGSGAGTFYADSVKGR

STSCYQV

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARESD

GWFDP

CGSTSCYQVGWFDPWGQGTLVTVSS

COV096_HC_91-pl369
2061
EVQLLESGGGLEQPGGSLRLSCAASGFTFSTYAM
2062
ARESDCG

SWVRQAPGKGLEWVSAISGSGAGTFYADSVKGR

STSCYQV

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARESD

GWFDP

CGSTSCYQVGWFDPWGQGTLVTVSS

COV096_HC_115-pl369
2065
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM
2066
ARDTLGR

SWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFT

GGDY

ISRDNSKNTLYLQMNSLRAEDTAVYYCARDTLGR

GGDYWGQGTLVTVSS

COV096_HC_133-pl369
2069
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM
2070
ARDTFGR

SWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFT

GGDY

ISRDNSKNTLYLQMNSLRAEDTAVYYCARDTFGR

GGDYWGQGTLVTVSS

COV096_HC_34-pl369
2073
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM
2074
ARDTLGR

SWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFT

GGDY

ISRDNSKNTLYLQMNTLRAEDTAVYYCARDTLGR

GGDYWGQGTLVTVSS

COV096_HC_34-pl369
2077
EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYM
2078
ARDTLGR

SWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFT

GGDY

ISRDNSKNTLYLQMNTLRAEDTAVYYCARDTLGR

GGDYWGQGTLVTVSS

COV096_HC_106-pl369
2081
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2082
AKGVEYS

MHWVRQAPGKGLEWVSGISWNSDSIGYADSVK

SSSNFDY

GRFTISRDNAKNSLYLQMNSLTAEDTALYYCAKG

VEYSSSSNFDYWGQGTLVTVSS

COV096_HC_132-pl369
2085
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2086
VKGVEYS

MHWVRQAPGKGLEWVSGISWNSGSIGYADSVK

SSSNFDY

GRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKG

VEYSSSSNFDYWGQGTLVTVSS

COV096_HC_6-pl369
2089
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2090
VKGVEYS

MHWVRQAPGKGLEWVSGISWNSGSIGYADSVK

SSSNFDY

GRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKG

VEYSSSSNFDYWGQGTLVTVSS

HEAVY

COV096_HC_116-pl369
2093
QVQLVQSGAEVKKPGASVKVSCKASGYTVTGYYI
2094
ARERYFDL

HWVRQAPGQGLEWMGWISPNSGGTNYAQKF

GGMDV

QGWVTMTRDMSITTAYMELSRLRSDDTAVYYCA

RERYFDLGGMDVWGQGTTVTVSS

COV096_HC_77-pl369
2097
QVQLVQSGAEVKKPGASVKVSCKASGYTVTGYYI
2098
AREPYFDL

HWVRQAPGQGLEWMGWISPNSGGTNYAQKF

GGMDV

QGWVTMTRDMSITTAYMELSRLRSDDTAVYYCA

REPYFDLGGMDVWGQGTTVTVSS

COV096_HC_138-pl369
2101
QVQLVQSGAEVKKSGASVKVSCKASGYTFTSYDI
2102
ARGFSLT

NWVRQATGQGLEWMGWMNPNSGNTGYAQK

WYFDL

FQGRVTMTRNTSISTAYMDLSSLRSEDTAVYYCA

RGFSLTWYFDLWGRGTLVTVSS

COV096_HC_176-pl369
2105
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDV
2106
ARGFSLT

NWVRQATGQGLEWMGWMNPNSGSAGYAQK

WYFDL

FQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCA

RGFSLTWYFDLWGRGTLVTVSS

COV096_HC_104-pl369
2109
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM
2110
ARVQVGA

NWVRQAPGKGLEWVSFISSRSSYIYYADSVKGRF

RGWVDY

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVQVG

ARGWVDYWGQGTLVTVSS

COV096_HC_111-pl369
2113
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSM
2114
ARVQVGA

NWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRF

RGWVDY

TISRDNAKNSLYLQMNSLRAEDTAVYYCARVQVG

ARGWVDYWGQGTLVTVSS

HEAVY

COV096_HC_158-pl369
2117
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAM
2118
AKEPIGQ

SWVRQAPGKGLEWVSAISGSGGSTYYADSVKGR

PLLWWD

FTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEPIG

Y

QPLLWWDYWGQGTLVTVSS

COV096_HC_78-pl369
2121
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAM
2122
AKEPIGQ

SWVRQAPGKGLEWVSAISGSGGSTYYADSVKGR

PLLWWD

FTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEPIG

Y

QPLLWWDYWGQGTLVTVSS

COV096_HC_130-pl369
2125
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2126
AKGSSSG

MHWVRQVPGKGLEWVSGISWNSASIGYADSVK

WTRPLDY

GRFTISRDNAKNSLYLQMNSLRPEDMAFYYCAKG

SSSGWTRPLDYWGQGTLVTVSS

COV096_HC_44-pl369
2129
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2130
AKGSSSG

MHWVRQVPGKGLEWVSGISWNSASIGYADSVK

WTRPLDY

GRFTISRDNAKNSLYLQMNSLRPEDMAFYYCAKG

SSSGWTRPLDYWGQGTLVTVSS

HEAVY

COV096_HC72-pl369
2133
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGI
2134
ARRPRDY

SWVRQAPGQGLEWMGWISAYNGNTNYAQKL

YDRSGYY

QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR

YVPGYFD

RPRDYYDRSGYYYVPGYFDYWGQGTLVTVSS

Y

COV096_HC_4-pl369
2137
QVQLVQSGAEVKKPGASVKVSCKASGSTFTGYY
2138
AREKVAT

MHWVRQAPGQGLEWMGWINPNSGGTNYAQ

MFALPPY

KFQGWVTMTRDTSISTAYMELSRLRSDDTAVYYC

GMDV

AREKVATMFALPPYGMDVWGQGTTVTVSS

COV096_HC_127-pl369
2141
QVQLVQSGAEVKKPGASVKVSCKASGYTFTYYY
2142
ARPLLPGE

MHWVRQAPGQGLEWMGIINPSGGSTSYAQKF

TGSLNRL

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR

DY

PLLPGETGSLNRLDYWGQGTLVTVSS

COV096_HC_113-pl369
2145
QVQLVQSGAEVKKPGASVKVSCKASGHTFTSYY
2146
ARGPERG

MHWVRQAPGQGLEWMGIINPSGGSTSYAQKF

IVGATDYF

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR

DY

GPERGIVGATDYFDYWGQGTLVTVSS

COV096_HC_153-pl369
2149
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNAI
2150
ASEWEIF

SWVRQAPGQGLEWMGGITPIFGTVNYAQKFQG

GFDY

RVTITADESTSTAYMELSSLRSEDTAVYYCASEWEI

FGFDYWGQGTLVTVSS

COV096_HC_55-pl369
2153
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
2154
TSGQGAG

WVRQAPGQGLEWMGGIIPIFGTTNHAQKFQGR

VNRGVVI

VTITADESTSTAYMELSSLRSEDTAVYYCTSGQGA

TTLGY

GVNRGVVITTLGYWGQGTLVTVSS

COV096_HC_42-pl369
2157
QVQLVQSGAEVKKPGSSVKVSCKASGGTISSYAIS
2158
ARDDGQ

WVRQAPGQGLEWMGGIIPIFGTTNYAQKFQGR

QLWSYFD

VTITADESTSTAYMELSSLRSEDTALYYCARDDGQ

Y

QLWSYFDYWGQGTLVTVSS

COV096_HC_156-pl369
2161
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYM
2162
ARDLPPR

SWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFT

RFDI

ISRDNAKNSLYLQMNSLRAEDTAVYYCARDLPPR

RFDIWGQGTMVTVSS

COV096_HC_137-pl369
2165
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM
2166
ARGDSGS

HWVRQATGKGLEWVSAIGTAGDTYYPGSVKGR

YLGVWYF

FTISRENAKNSLYLQMNSLRAGDTAVYYCARGDS

DL

GSYLGVWYFDLWGRGTLVTVSS

COV096_HC_75-pl369
2169
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM
2170
ARDRGSS

HWVRQATGKGLEWVSAIGTAGDTYYPDSVKGR

GWYGWY

FTISRENAKNSLYLQMNSLRAGDTAVYYCARDRG

FDL

SSGWYGWYFDLWGRGTLVTVSS

COV096_HC_123-pl369
2173
EVQLVESGGGLVQPGGSLRLSCAASGFIFSSYDM
2174
ARGDYNI

HWVRQATGKGLEWVSTIGTAGDTYYPDSVKGRF

LTGYYFDY

TISRENAKNSLYLQMNSLRAGDTAVYYCARGDYN

ILTGYYFDYWGQGTLVTVSS

COV096_HC_65-pl369
2177
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM
2178
ARDRDSS

HWVRQATGKGLQWVSAIGTAGDTYYPDSVKGR

WSFDY

FTISRENAKNSLYLQMNSLRAGDTAVYYCARDRD

SSWSFDYWGQGTLVTVSS

COV096_HC_81-pl369
2181
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDM
2182
ARGTFFY

HWVRQASGKGLEWVSAIGTSGDTYYPGSVKGRF

GSGSYN

TISRENAKNSLYLQMNSLRAGDTAVYYCARGTFF

WFDP

YGSGSYNWFDPWGQGTLVTVSS

COV096_HC_166-pl369
2185
EVQLVESGGGLVKPGGSLRVSCAASGFSFSYAW
2186
TTLSDYG

MSWVRQAPGKGLEWVGRIKSKTDGGTTDCAAP

DLSSVY

VKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT

LSDYGDLSSVYWGQGTLVTVSS

COV096_HC_140-pl369
2189
EVQLVESGGGLVKPGGSLRLSCAASGFTVRSYSM
2190
AKEEYYG

NWVRQAPGKGLEWVSCMTSSGSYLYYADSVKG

MDV

RFTISRDNAKNSLYLQMNSLRDEDTAVYYCAKEE

YYGMDVWGQGATVTVSS

COV096_HC_43-pl369
2193
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
2194
AKQLYYY

MHWVRQAPGKGLEWVAVISYDGSNKYYADSVK

GSGSYVF

GRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKQ

DY

LYYYGSGSYVFDYWGQGTLVTVSS

COV096_HC_21-pl369
2197
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
2198
AKDTPGG

MHWVRQAPGKGLEWVAVISYDGSNKYYADSVK

DDILTGW

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKD

GLYGMD

TPGGDDILTGWGLYGMDVWGQGTTVTVSS

V

COV096_HC_122-pl369
2201
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYG
2202
ARDMGTL

MHWVRQAPGKGLEWVAVIWYDGSNKHYADSV

VTHFDY

KGRFTISRDNSKNTLYLQMNSLRAEDTAEYYCAR

DMGTLVTHFDYWGQGTLVTVSS

COV096_HC_98-pl369
2205
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
2206
ARDVGRV

MHWVRQAPGKGLEWVAAIWYDGSNKHYADSV

TTWFDP

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

DVGRVTTWFDPWGQGTLVTVSS

COV096_HC_48-pl369
2209
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSM
2210
ARASGLR

NWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRF

SYYYYGM

TISRDNAKNSLYLQMNSLRDEDTAVYYCARASGL

DV

RSYYYYGMDVWGQGTTVTVSS

COV096_HC_79-pl369
2213
EVQLVESGGGLVQPGGSLRLSCAASGFTFTNYN
2214
ARVVGSG

MNWVRQAPGKGLEWVSYISSSSSTIYYADSVKG

SYYYYGM

RFTISRDNAKNSLYLQMNSLRDEDTAVYYCARVV

DV

GSGSYYYYGMDVWGQGTTVTVSS

COV096_HC_3-pl369
2217
EVQLVESGGGLVQPGRSLRLSCTASGFTFGDYAM
2218
TRDLSYYY

NWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVR

DSSGRGS

GRFTISRDDSESIAYLQMNSLKTEDTAVYYCTRDL

HLFDY

SYYYDSSGRGSHLFDYWGQGTLVTVSS

COV096_HC_3-pl369
2221
EVQLVESGGGLVQPGRSLRLSCTASGFTFGDYAM
2222
TRDLSYYY

NWFRQAPGKGLEWVGFIRSKAYGGTTEYAASVR

DSSGRGS

GRFTISRDDSESIAYLQMNSLKTEDTAVYYCTRDL

HLFDY

SYYYDSSGRGSHLFDYWGQGTLVTVSS

COV096_HC_134-pl369
2225
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYM
2226
ARDLMAY

SWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRF

GMDV

TFSRDNSKNTLYLQMNSLRAEDTAVYYCARDLM

AYGMDVWGQGTTVTVSS

COV096_HC_68-pl369
2229
EVQLVESGGGLIQPGGSLRLSCAASGVIVSSNYM
2230
ARDGGHY

SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRF

GMDV

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGH

YGMDVWGQGTTVTVSS

COV096_HC_183-pl369
2233
EVQLVESGGGLIQPGGSLRLSCAASGLTVSRNYM
2234
ARESYGM

NWVRQAPGKGLEWVSVMYSGGSTFYADSVKGR

DV

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARESYG

MDVWGQGTTVTVSS

COV096_HC_74-pl369
2237
EVQLVESGGGLVQPGGSLRLSCAASGFIVSSNYM
2238
ARDYGDF

SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRF

YFDY

TISRDNSKNTLYLQMNSLRAEDTAVYYCARDYGD

FYFDYWGQGTLVTVSS

COV096_HC_45-pl369
2241
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTHW
2242
TRDDSSW

MHWVRQAPGKGLVWVSRINSDGSRRAYATSVK

PHFFDN

GRFTISRDNAKNTLYLQMDSLRDEDTAVYYCTRD

DSSWPHFFDNWGQGTLVAVSS

COV096_HC_126-pl369
2245
EVQLVESGGGLVQPGGSLRLSCAASGFNFSTHW
2246
TRDDSSW

MHWVRQAPGKGLVWVSRINSDGSRRAYATSVK

PHFFDN

GRFTISRDNAKNTLYLQMDSLRDEDTAVYYCTRD

DSSWPHFFDNWGQGTLVTVSS

COV096_HC_8-pl369
2249
EVQLVQSGAEVKKPGESLKISCKGSGYTFTSYWIG
2250
ARPVTYD

WVRQMPGKGLEWMGFIYPGDSDTRYSPSFQG

WYFDL

QVTISADKSISTAYLQWSSLKASDTAMYYCARPVT

YDWYFDLWGRGTLVTVSS

COV096_HC_124-pl369
2253
EVQLVQSGAEVKKPGESLKISCKVSGYTFTNYWIG
2254
ARVPSSS

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

DYGDYGG

VTISADKSIITAYLQWSSLKASDTAMYYCARVPSSS

FEY

DYGDYGGFEYWGQGTLVTVSS

COV096_HC_28-pl369
2257
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
2258
ARMVTSG

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

TYYYDNS

VTISADKSISTAYLQWSSLKASDTAMYYCARMVT

GYSSSGPF

SGTYYYDNSGYSSSGPFDYWGQGTLVTVSS

DY

COV096_HC_12-pl369
2261
EVQLVQSGAEVKKPGESLKISCKGSGYRFTNYWI
2262
ARLSDRW

GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQG

YSPFDP

QVTISADKSITTAYLQWSSLKASDTAMYYCARLSD

RWYSPFDPWGQGTLVTVSS

HEAVY

COV096_HC_90-pl369
2265
QVQLVQSGAELKKPGASVKVSCKASGYTFNSYGI
2266
ARRVEDN

SWVRQAPGQGLEWMGGISAYNGNTNYAQKLO

GDDGGD

GRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARR

YYYYYGM

VEDNGDDGGDYYYYYGMDVWGQGTTVTVSS

DV

COV096_HC_71-pl369
2269
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYS
2270
ARDLEYCS

MHWVRQAPGQGLEWMGWINPNSGGTNYAQ

STSCYTST

KFQGRVTMTRDTSISTAYMELSRLGSDDTAVYYC

TFDY

ARDLEYCSSTSCYTSTTFDYWGQGTLVTVSS

COV096_HC52-pl369
2273
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYY
2274
ASGIGHN

MHWVRQAPGQGLEWMGWINPNSGGTNYAQ

WNYVSTP

KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYC

NGMDV

ASGIGHNWNYVSTPNGMDVWGQGTTVTVSS

COV096_HC_10-pl369
2277
QVQLVQSGAEVKKPGASVRVSCKASGYTFTGYYI
2278
ARDFAM

HWVRQAPGQGLEWMGWINPMSGGTNYTQKF

GTVTGTF

QGWVTMTRDTSINTAYMELSRLRSDDTAVYYCA

VY

RDFAMGTVTGTFVYWGQGTLVTVSS

COV096_HC_2-pl369
2281
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY
2282
AREGVGG

MHWVRQAPGQGLEWMGIINPSGGSTRYAQKF

TSYFDY

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAR

EGVGGTSYFDYWGQGTLVTVSS

COV096_HC_30-pl369
2285
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
2286
ARDGLSG

WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGR

HFPHNW

VTITADESTSTAYMELSSLRSEDTAVYYCARDGLS

FDP

GHFPHNWFDPWGQGTLVTVSS

COV096_HC_136-pl369
2289
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
2290
ARREAYG

WVRQAPGQGLEWMGGIIPIFGTANYAQKFQGR

PRDYYYYY

VTITADESTSTAYMELSSLRSEDTAVYYCARREAY

GMDV

GPRDYYYYYGMDVWGQGTTVTVSS

COV096_HC_99-pl369
2293
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAIS
2294
ARVLGYY

WGRQAPGQGLEWMGGIIPILGTVNYAQKFQGR

DSSGSND

VTITADKSTSTAYMELSSLRSEDTAVYYCARVLGY

AFDI

YDSSGSNDAFDIWGQGTMVTVSS

COV096_HC_152-pl369
2297
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDI
2298
ARGGRYC

NWVRQATGQGLEWMGWMNPNSGNTGYAQK

SDVSCYS

FQGRVTITRDTSISTAYMELSSLRXEDTAVYYCAR

GTGFDY

GGRYCSDVSCYSGTGFDYWGQGTLVTVSS

COV096_HC_50-pl369
2301
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW
2302
TTDLGYCS

MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP

STNCYYYY

VKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT

DLGYCSSTNCYYYYWGQGTLVTVSS

COV096_HC_92-pl369
2305
EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAW
2306
TTDDPGS

MSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAP

YYYGMDV

VKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT

DDPGSYYYGMDVWGQGTTVTVSS

COV096_HC_40-pl369
2309
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
2310
ARAGTTN

MHWVRQAPGKGLEWVALISYDGSNKHYADSVK

SDYFDY

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARA

GTTNSDYFDYWGQGTLVTVSS

COV096_HC_149-pl369
2313
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
2314
AKGGYSY

MHWVRQAPGKGLEWVAVISYDGSNKYYADSVK

GYSLYYFD

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKG

Y

GYSYGYSLYYFDYWGQGTLVTVSS

COV096_HC_157-pl369
2317
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
2318
AKAQYSY

MHWVRQAPGKGLEWVAVISYDGSNKYYADSVK

GYVVYYF

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKA

DY

QYSYGYWYYFDYWGQGALVTVSS

COV096_HC_121-pl369
2321
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYM
2322
ARSLWLR

SWVRQAPGKGLEWVSVISSGGGTFYADSVKGRF

GSFQH

TISRDNSKNTLYLQMNSLRAEDTAVYYCARSLWL

RGSFQHWGQGTLVTVSS

COV096_HC_27-pl369
2325
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
2326
ARGDYDF

MSWVRQAPGKGLEWVATIKQDGSEKYYVDSVK

WSGYYDY

GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG

DYDFWSGYYDYWGQGTLVTVSS

COV096_HC_142-pl369
2329
EVQLVESGGGLVQPGGSLRLSCAASRFTFSSYW
2330
ATAPWLR

MSWVRQAPGKGLEWVANIKQDGSEKYYVDSVK

GGFDY

GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCATA

PWLRGGFDYWGQGTLVTVSS

COV096_Hc_1-pl369
2333
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2334
AKIADIVR

MHWVRQAPGKGLEWVSGVSWNSGTIGYADSV

AYDFWSG

KGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKI

QHFDAFD

ADIVRAYDFWSGQHFDAFDIWGQGTMVTVSS

I

COV096_HC_15-pl369
2337
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2338
AKDGGSG

MHWVRQAPGKGLEWVSGISWNSGIIGYADSV

TTEYEAYY

MGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAK

FDY

DGGSGTTEYEAYYFDYWGQGTLVTVSS

COV096_HC_20-pl369
2341
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2342
AKDMGR

MHWVRQAPGKGLEWVSGISWNSGTIGYADSV

DDSSGSLL

QGRFIISRDNAKNSLYLQMNSLRAEDTALYYCAK

FDY

DMGRDDSSGSLLFDYWGQGTLVTVSS

COV096_HC_159-pl369
2345
EVQLVESGGGLIQPGRSLRLSCAASGFTFDDYAM
2346
AKDIGSKR

HWVRQAPGKGLEWVSGTSWNSGTIGYADSVKG

STSENYG

RFTISRDNAKNSLYLQMNRLRAEDTALYHCAKDI

MDV

GSKRSTSENYGMDVWGQGTTVTVSS

COV096_HC_103-pl369
2349
QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYY
2350
ASLRGAY

WGWIRQPPGKGLEWIGTIYYGGSTYYNPSLKSRV

YDFWSGP

TISVDTSKNQISLKLSSVTAADTAVYYCASLRGAYY

RDGGWF

DFWSGPRDGGWFDPWGQGTLVTVSS

DP

COV096_HC_23-pl369
2353
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGSYY
2354
AREIPST

WSWIRQPAGKGLEWIGHIYTSGSTNYNPSLKSRV

WYFDL

TISVDTSKNQFSLKLSSVTAADTAVYYCAREIPST

WYFDLWGRGTLVTVSS

COV096_HC_101-pl369
2357
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGNYY
2358
ARDIPPT

LTWIRQPAGKGLEWIGHIYTSGSTNYNPSLKSRVT

WYFDL

ISVDTSMNQFSLKLSSVTAADTAVYYCARDIPPT

WYFDLWGRGTLVTVSS

COV096_HC_174-pl369
2361
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSHWIG
2362
ARLPSGR

WVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQ

YNWFDP

VTISADKSISTAYLQWSSLKASDTAMYYCARLPSG

RYNWFDPWGQGTLVTVSS

COV096_HC_189-pl369
2365
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIG
2366
ARLPQEE

WVRQMPGKGLEWMGIIYPGDSDTTYSPSFQGQ
66
KRFLEWL

VTISADKSVTTAYLQWSSLKASDTAMYYCARLPQ

PPANVRK

EEKRFLEWLPPANVRKQIPYYYGMDVWGQGTT

QIPYYYG

VTVSS

MDV

KAPPA

COV096_KC_100-pl389
2047
DIQMTQSPSSLSASVGDRVTITCRASQSI
2048
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPW

CQQSYSTPPWTFGQGTKVEIK

T

COV096_KC_164-pl389
2051
DIQMTQSPSSLSASVGDRVTLTCRASQSI
2052
QQS

SSYLNWYQQKPGKAPNLLIYAASSLQSG

YSA

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPW

CQQSYSAPPWTFGQGTKVEIK

T

COV096_KC_25-pl389
2055
DIQMTQSPSSLSASVGDRVTITCRASQSI
2056
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPW

CQQSYSTPPWTFGQGTKVEIK

T

COV096_KC_91-pl389
2059
DIQMTQSPSSLSASVGDRVTITCRASQSI
2060
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPW

CQQSYSTPPWTFGQGTKVEIK

T

COV096_KC_91-pl389
2063
DIQMTQSPSSLSASVGDRVTITCRASQSI
2064
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPW

CQQSYSTPPWTFGQGTKVEIK

T

COV096_KC_115-pl389
2067
DIQMTQSPSSLSASVGDRVTITCQASQDI
2068
QQY

SNYLNWYQQKPGKAPKLLIYDASNLETG

DNL

VPSRFSGSGSGTDFTFTISSLQPEDIATYY

PRS

CQQYDNLPRSFGQGTKLEIK

COV096_KC_133-pl389
2071
DIQMTQSPSSLSASVGDRVTITCQASQDI
2072
QQY

SNYLNWYQQKPGKAPKLLIYDASNLETG

DNL

VPSRFSGSGSGTDFTFTISSLQPEDIATYY

PRS

CQQYDNLPRSFGQGTKLEIK

COV096_KC_34-pl389
2075
DIQMTQSPSSLSASVGDRVTITCQASQDI
2076
QQY

SNYLNWYQQKPGKAPKVLIYDASNLETG

DNL

VPSRFSGSGSGTDFTFTISSLQPEDIATYF

PRS

CQQYDNLPRSFGQGTKLEIK

COV096_KC_34-pl389
2079
DIQMTQSPSSLSASVGDRVTITCQASQDI
2080
QQY

SNYLNWYQQKPGKAPKVLIYDASNLETG

DNL

VPSRFSGSGSGTDFTFTISSLQPEDIATYF

PRS

CQQYDNLPRSFGQGTKLEIK

COV096_KC_106-pl389
2083
DIQMTQSPSSVSASVGDRVTITCRASQGI
2084
QQT

SSWLAWYQQKPGKAPKLLIYTASGLQSG

NSF

VPSRFSGSGSETDFTLTISSLQPEDFATYY

PLT

CQQTNSFPLTFGGGTKVEI

COV096_KC_132-pl389
2087
DIQMTQSPSSVSASVGDRVTITCRASQGI
2088
QQT

SSWLAWYQQKPGKAPKLLIYTASGLQSG

NSF

VPSRFSGSGSETDFTLTISSLQPEDFATYY

PLT

CQQTNSFPLTFGGGTKVEI

COV096_KC_6-pl389
2091
DIQMTQSPSSVSASVGDRVTITCRASQGI
2092
QQA

SSWLAWYQQKPGKAPKLLIYVESSLQSG

NSF

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PLT

CQQANSFPLTFGGGTKVEIK

LAMBDA

COV096_LC_116-pl409
2095
QSALTQPASVSGSPGQSITISCTGTSSDV
2096
CSY

GSYNLVSWYQQHPGKAPKLMIYEDSKR

AGS

PSGVSNRFSGSKSGNTASLTISGLQAEDE

STRL

ADYYCCSYAGSSTRLFGGGTKLTVL

COV096_LC_77-pl409
2099
QSXLTQPASVSGSPGQSITISCTGTSSDV
2100
CSY

GSYNLVSWYQQHPGKAPKLMIYEGSKR

AGS

PSGVSNRFSGSKSGNTASLTISGLQAEDE

STR

ADYYCCSYAGSSTRVFGGGTKLTVL

V

COV096_LC_138-pl409
2103
SYXLTQPPSVSVAPGKTARITCGGNNIGS
2104
QV

KSVHWYQQKPGHAPVLVVYDDSDRPSG

WD

IPERFSGSNSGNTATLTISRVEAGDEADY

STG

YCQVWDSTGGHPDVVFGGGTKLTVL

GHP

DVV

COV096_LC_176-pl409
2107
SYXLTQPPSVSVAPGKTARITCGGNNIGS
2108

KSVHWYQQKPGQAPVLVVYDDSDRPS

QV

GIPERFSGSNSGNTATLTISRVEAGDEAD

WD

YYCQVWDSTSDHPDVVFGGGTKLTVL

STS

DHP

DVV

COV096_LC_104-pl409
2111
NFMLTQPHSVSESPGKTVTISCTRSSGSI
2112
QSY

ASNYVQWYQQRPGSAPTTVIYEDNQRP

DSI

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

NW

ADYYCQSYDSINWVFGGGTKLTVL

V

COV096_LC_111-pl409
2115
NFMLTQPHSVSESPGKTVTISCTRSSGSI
2116
QSY

ASNYVQWYQQRPGSAPTTVIYEDNERP

DRI

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

NW

ADYYCQSYDRINWVFGGGTKLTVL

V

KAPPA

COV096_KC_158-pl389
2119
EIVLTQSPATLSLSPGERATLSCRASQSVS
2120
QQR

SYLAWYQQKPGQAPRLLIYDASNRATGI

SN

PARFSGSGSGTDFTLTISSLEPEDFAVYYC

WP

QQRSNWPRGFGQGTKVEIK

RG

COV096_KC_78-pl389
2123
EIVLTQSPATLSLSPGERATLSCRASQSVS
2124
QQR

SYLAWYQQKPGQAPRLLIYDASNRATGI

SN

PARFSGSGSGTDFTLTISSLEPEDFAVYYC

WP

QQRSNWPRGFGQGTKVEIK

RG

COV096_LC_130-pl409
2127
SYXLTQPPSVSVAPGKTARITCGGNNIGS
2128
QV

KSVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEAD

SSS

YYCQVWDSSSDPVVFGGGTKLTVL

DPV

V

COV096_LC_44-pl409
2131
SYVLTQPPSVSVAPGKTARITCGGNNIGS
2132
QV

KSVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEAD

SSS

YYCQVWDSSSDPVVFGGGTKLTVL

DPV

V

KAPPA

COV096_KC_72-pl389
2135
DIQMTQSPSSLSASVGDRVTITCQASQDI
2136
QQY

SNYLNWYQQKPGKAPKLLIYDASNLETG

DNL

VPSRFSGSGSGTDFTFTISSLQPEDIATYY

PLT

CQQYDNLPLTFGGGTKVEIK

COV096_KC_4-pl389
2139
EIVLTQSPATLSLSPGERATLSCRASQSVS
2140
QQR

SYLAWYQQKPGQTPRLLIYDASNRATGI

SN

PARFSGSGSGTDFTLTISSLEPEDFAVYYC

WPP

QQRSNWPPIAFGQGTRLEIK

IA

COV096_KC_127-pl389
2143
DIQMTQSPSSLSASVGDRVTITCRASQSI
2144
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YSTL

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

WT

CQQSYSTLWTFGQGTKVEIK

COV096_KC_113-pl389
2147
EIVLTQSPGTLSLSPGERATLSCRASQSVS
2148
QQY

SSYLAWYQQKPGQAPRLLIYGASSRATGI

VSS

PDRFSGSGSGTDFTLTISRLEPEDFAVYYC

PWT

QQYVSSPWTFGQGTKVEIK

COV096_KC_153-pl389
2151
DIQMTQSPSSLSASVGDRVTITCRASQSI
2152
QQS

SRYLNWYQQKSGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PWT

CQQSYSTPWTFGQGTKVEIK

COV096_KC_55-pl389
2155
DIVMTQSPDSLAVSLGERATINCKSSQSV
2156
QQY

LYSSNNKNYLAWYQQKPGQPPKLLIYW

YST

ASTRESGVPDRFSGSGSGTDFTLTISSLQ

PCS

AEDVAVYYCQQYYSTPCSFGQGTKLEIK

COV096_KC_42-pl389
2159
DIVMTQSPDSLAVSLGERATINCKSSQSV
2160
QQY

LYSSNNKSYLAWYQQKPGQPPKLLIYWA

YSTL

STRESGVPDRFSGSGSGTDFTLTISSLQAE

PLT

DVAVYYCQQYYSTLPLTFGGGTKVEIK

COV096_KC_156-pl389
2163
DIQMTQSPSSLSASVGDRVTITCQASQDI
2164
QQF

SNYLNWYQQKPGKAPKLLIYDASNLETG

DNL

VPSRFSGSGSGTDFTFTISSLQPEDIATYY

PIT

CQQFDNLPITFGQGTRLEIK

COV096_KC_137-pl389
2167
DIQMTQSPSSLSASVGDRVTITCRASQSI
2168
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YSSP

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PIT

CQQSYSSPPITFGPGTKVDIK

COV096_KC_75-pl389
2171
DIQMTQSPSSLSASVGDRVTITCRASQSI
2172
QQS

SSYLNWYQQKPGKAPKLLIYVASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPIT

CQQSYSTPPITFGQGTRLEIK

COV096_KC_123-pl389
2175
DIQMTQSPSSLSASVGDRVTITCRASQSI
2176
QQS

SSYLNWYQQKPGKAPNLLIYAASSLQSG

YNT

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PQV

CQQSYNTPQVTFGGGTKVESK

T

COV096_KC_65-pl389
2179
DIQMTQSPSSLSASVGDRVTITCRASQSI
2180
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGGGSGADFTLTISSLQPEDFATY

PPIT

YCQQSYSTPPITFGQGTRLEIK

COV096_KC_81-pl389
2183
DIQMTQSPSSLSASVGDRVTITCRASQSI
2184
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PPW

CQQSYSTPPWTFGQGTKVEIK

T

COV096_KC_166-pl389
2187
DIQMTQSPSSLSASVGDRVTITCRASQSI
2188
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PLT

CQQSYSTPLTFGGGTKVEIK

COV096_KC_140-pl389
2191
DIQMTQSPSSLSASVGDRVTITCRASQDI
2192
QQA

SSWLAWYQQKPGKAPKLLIYAASNLQSG

NRF

VPSRFSGSGSGTHFTLTISSLQPEDFVTYY

PIT

CQQANRFPITFGQGTRLEIK

COV096_KC_43-pl389
2195
DIQMTQSPSSLSASVGDRVTITCQASQDI
2196
QQY

RNFLNWYQQKPGKAPKLLIYDASNLETG

DNL

VPSRFSGSGSGTDFTFTISSLQPEDIATYY

PLT

CQQYDNLPLTFGGGTKVEIK

COV096_KC_21-pl389
2199
DIQMTQSPSSLSASVGDRVTITCRASQSI
2200
QQS

SSYLNWYQQKPGKAPKLLIYAAFSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PWT

CQQSYSTPWTFGQGTKVEIK

COV096_KC_122-pl389
2203
DIQMTQSPSSLSASVGDRVTITCRASQSI
2204
QQS

SSYLNWYQQKPGKAPKLLIYAASNLQSG

YSSP

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PWT

CQQSYSSPPWTFGQGTKVEIK

COV096_KC_98-pl389
2207
DIQMTQSPSSLSASVGDRVTITCRASQSI
2208
QQS

SSYLTWYQQKPGKAPKLLIYAASSLQSGV

YST

PSRFSGSGSGTDFTLTISSLQPEDFATYYC

PPW

QQSYSTPPWTFGQGTKVEIK

T

COV096_KC_48-pl389
2211
DIQMTQSPSSLSASVGDRVTITCRASQSI
2212
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PAT

CQQSYSTPATFGQGTKVEIK

COV096_KC_79-pl389
2215
DIQMTQSPSSLSASVGDRVTITCRASQSI
2216
QQS

SSYLNWYQQKPGKAPKLLIYGASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PAT

CQQSYSTPATFGQGTKLEIK

COV096_KC_3-pl389
2219
EIVMTQSPATLSVSPGERATLSCRASQSV
2220
QQY

SSNLAWYQQKPGQAPRLLIYGASTRATG

NN

IPARFSGSGSGTEFTLTISSLQSEDFAVYY

WW

CQQYNNWWTFGQGTKVEIK

T

COV096_KC_3-pl389
2223
EIVMTQSPATLSVSPGERATLSCRASQSV
2224
QQY

SSNLAWYQQKPGQAPRLLIYGASTRATG

NN

IPARFSGSGSGTEFTLTISSLQSEDFAVYY

WW

CQQYNNWWTFGQGTKVEIK

T

COV096_KC_134-pl389
2227
DIQLTQSPSFLSASVGDRVTITCRASQGIS
2228
QQL

SYLAWYQQKPGKAPKLLIYAASTLQSGV

NSY

PSRFSGSGSGTEFTLTISSLQPEDFATYYC

PQG

QQLNSYPQGTFGGGTKVEIK

T

COV096_KC_68-pl389
2231
DIQLTQSPSFLSASVGDRVTITCRASQGIS
2232
QQL

SYLAWYQQKPGKAPKLLIYAASTLQSGV

NSY

PSRFSGSGSGTEFTLTISSLQPEDFATYYC

PPA

QQLNSYPPAFGQGTRLEIK

COV096_KC_183-pl389
2235
EIVLTQSPGTLSLSPGERATLSCRASQSFS
2236
QQY

STYLAWYQQKPGQAPRLLIYGASSRATGI

VTS

PDRFSGSGSGTDFTLTISRLEPEDFAVYYC

PWT

QQYVTSPWTFGQGTKVEIK

COV096_KC_74-pl389
2239
EIVMTQSPATLSVSPGERATLSCRASQSV
2240
QQY

SSNLAWYQQKPGQAPRLLIYGASTRATG

NN

IPARFSGSGSGTEFTLTISSLQSEDFAVYY

WP

CQQYNNWPRTFGQGTKVEIK

RT

COV096_KC_45-pl389
2243
DIQMTQSPSSLSASVGDRVTITCQASQDI
2244
QQY

SNYLNWYQQKPGKAPKLLIYDASNLETG

DNL

VPSRFSGSGSGTDFTFTISSLQPEDIATYY

PPK

CQQYDNLPPKLTFGGGTKVEIK

LT

COV096_KC_126-pl389
2247
DIQMTQSPSSLSASVGDRVTIPCRASQNI
2248
QQS

DNYLNWYQQKPGKAPKLLIFAASGLQDE

YISP

APSRFSGVGSGTDFTLTISSLQPEDSATYY

YT

CQQSYISPYTFGRGTKLEIK

COV096_KC_8-pl389
2251
DIQMTQSPSSVSASLGDRVTITCRASQGI
2252
QQA

SSWLAWYQQKPGKAPKVLIYAASSLQSG

NSF

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PIT

CQQANSFPITFGQGTRLEIK

COV096_KC_124-pl389
2255
DIQMTQSPSSLSASVGDRVTITCRASQSI
2256
QQS

SSYLNWYQQKPGKAPKLLIYAASSLQSG

YST

VPSRFSGSGSGTDFTLTISSLQPEDFATYY

PCS

CQQSYSTPCSFGQGTKLEIK

COV096_KC_28-pl389
2259
AIQLTQSPSSLSASVGDRVTITCRASQGIS
2260
QQF

SALAWYQQKPGKAPKLLIYDASSLESGVP

NN

SRFSGSGSGTDFTLTISSLQPEDFATYYCQ

QFNNFGPGTKVDIK

COV096_KC_12-pl389
2263
EIVMTQSPATLSVSPGERATLSCRASQSV
2264
QQY

SSNLAWYQQKPGQAPRLLIYGASTRATG

NN

IPARFSGSGSGTEFTLTISSLQSEDFAVYY

WPP

CQQYNNWPPGGFTFGPGTKVDIK

GGF

T

LAMBDA

COV096_LC_90-pl409
2267
SYVLTQPPSVSVSPGQTARITCSGEALPK
2268
QSA

QYAYWYQQKPGQAPVMVIYKDSERPSG

DSS

IPERFSGSSSGTTVTLTISGVQAEDDADYY

GTL

CQSADSSGTLVVFGGGTKLTVL

VV

COV096_LC_71-pl409
2271
SYVLTQPPSVSVAPGKTARITCGGNNIGS
2272
QV

KSVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEAD

YGV

YYCQVWDYGVVFAGGTKLTVL

V

COV096_LC_52-pl409
2275
NFMLTQPHSVSESPGKTVTISCTRSSGSI
2276
QSY

ASNYVQWYQQRPGSAPTTVIYEDYQRP

DSG

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

VV

ADYYCQSYDSGVVFGGGTKLTVL

COV096_LC_10-pl409
2279
QXXLTQPPSASGSPGQSVTISCTGTSSDV
2280
SSY

GGYNYVSWYQQHPGKAPKLMIYEVSKR

AGS

PSGVPDRFSGSKSGNTASLTVSGLQAED

NN

EADYYCSSYAGSNNWVFGTGTKVTVL

WV

COV096_LC_2-pl409
2283
SYVLTQPPSVSVAPGKTARITCGGNNIGS
2284
QV

KSVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEAD

SSS

YYCQVWDSSSDPYVFGTGTKVTVL

DPY

V

COV096_LC_30-pl409
2287
QSVLTQPPSVSGAPGQRVTISCTGSSSNI
2288
QSY

GAGYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LRG

ADYYCQSYDSSLRGVFGGGTKLTVL

V

COV096_LC_136-pl409
2291
QSXXTQPPSASASLGASVTLTCTLSSGYS
2292
GAD

NYKVDWYQQRPGKGPRFVMRVGTGGI

QGS

VGSKGDGIPDRFSVLGSGLNRYLTIKNIQ

GSN

EEDESDYHCGADQGSGSNFVGVFGGGT

FVG

KLTVL

V

COV096_LC_99-pl409
2295
QSXXTQPPSVSGAPGQRVTISCTGSSSNI
2296
QSY

GAGYDVHWYQQLPGTAPKLLIYANINRP

DSS

SGVPDRFSGSKSGTSASLAITGLQAEDEA

LSG

DYYCQSYDSSLSGSVFGGGTKLTVL

SV

COV096_LC_152-pl409
2299
QSVLTQPPSASGTPGQRVTISCSGSSSNI
2300
AA

GSNYVYWYQQLPGTAPKLLIYRNNQRPS

WD

GVPDRFSGSKSGTSASLAISGLRSEDEAD

DSL

YYCAAWDDSLSGYWVFGGGTKLTVL

SGY

WV

COV096_LC_50-pl409
2303
SYVLTQPPSVSVAPGKTARITCGGNNIGS
2304
QV

KSVHWYQQKPGQAPVLVIYYDSDRPSGI

WD

PERFSGSNSGNTATLTISRVEAGDEADYY

SSS

CQVWDSSSDHPVFGGGTKLTVL

DHP

V

COV096_LC_92-pl409
2307
QSVLTQEPSLTVSPGGTVTLTCGSSTGAV
2308
LLSY

TSGHYPYWFQQKPGQAPRTLIYDTSNKH

SGA

SWTPARFSGSLLGGKGALTLSGAQPEDE

RV

AEYYCLLSYSGARVFGGGTKLTVL

COV096_LC_40-pl409
2311
SYVLTQPPSVSVAPGKTARITCGGNNIGS
2312
QV

KSVHWYQQKPGQAPVLVIYYDTDRPSGI

WD

PERFSGSNSGNTATLTISRVEAGDEADYY

SSS

CQVWDSSSALWVFGGGTKLTVL

ALW

V

COV096_LC_149-pl409
2315
QXXXTQPASVSGSPGQSITISCTGTSSDV
2316
SSYT

GGYNYVSWHQQHPGKAPKLMIYDVSN

SSST

RPSGVSNRFSGSKSGNTASLTISGLQAED

LV

EADYYCSSYTSSSTLVFGGGTKLTVL

COV096_LC_157-pl409
2319
NFMLTQPHSVSESPGKTVTISCTRSSGSI
2320
QSY

ASNYVQWYQQRPGSSPTMYEDNQRPS

DSS

GVPDRFSGSIDSSSNSASLTISGLKTEDEA

NVV

DYYCQSYDSSNVVFGGGTKLTVL

COV096_LC_121-pl409
2323
NFMLTQPHSVSESPGKTVTISCTRSSGSI
2324
QSY

ASNYVQWYQQRPGSSPTTVIYEDNQRP

DSS

SGVPDRFSGSIDSSSNSASLTISGLKTEDE

SWV

ADYYCQSYDSSSWVFGGGTKLTVL

COV096_LC_27-pl409
2327
SYXLTQPPSVSVSPGQTARITCSGDAFPN
2328
QSA

QYAYWYQQKPGQAPVLVIYKDSERPSGI

DSS

PERFSGSSSGTTVTLTISGVQAEDEADYY

SWV

CQSADSSSWVFGGGTKLTVL

COV096_LC_142-pl409
2331
NFMLTQPHSVSESPGKTVTISCTRSSGSI
2332
QSF

ASNYVQWYQQRPGSSPTTVIYEDSQRPS

DST

GVPDRFSGSIDSSSNSASLTISGLKTEDEA

NL

DYYCQSFDSTNLWVFGGGTKLTVL

WV

COV096_LC_1-pl409
2335
QSALTQPPSASGTPGQRVTISCSGSSSNI
2336
AA

GSNTVNWYQQLPGTAPKLLIYSNNQRPS

WD

GVPDRFSGSKSGTSASLAISGLQSEDEAD

DSL

YYCAAWDDSLVVFGGGTKLTVL

VV

COV096_LC_15-pl409
2339
QSVLTQPPSASGTPGQRVTISCSGSSSNI
2340
AA

GSNTVNWYQQLPGTAPKLLIYSNNQRPS

WD

GVPDRFSGSKSGTSASLAISGLQSEDEAD

DSL

YYCAAWDDSLNGVVFGGGTKLTVL

NGV

V

COV096_LC_20-pl409
2343
SYVLTQPPSVSVAPGKTARITCGGNNIGS
2344
QV

KSVHWFQQKPGQAPVLVVYDDSDRPSG

WD

IPERFSGSNSGNTATLTISRVEAGDEADY

SSS

YCQVWDSSSDHVVFGGGTKLTVL

DHV

V

COV096_LC_159-pl409
2347
SYVLTQPPSVSVAPGKTARITCGGNNIGS
2348
QV

KSVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGNTATLTISKVEAGDEAD

SSS

YYCQVWDSSSDSVVFGGGTKLTVL

DSV

V

COV096_LC_103-pl409
2351
QXXXTQPASVSGSPGQSITISCTGTSSDV
2352
CSY

GSYNLVSWYQQHPGKAPKLMIYEDSKR

AGS

PSGVSNRFSGSKSGNTASLTISGLQAEDE

SLW

ADYYCCSYAGSSLWVFGGGTKLTVL

V

COV096_LC_23-pl409
2355
QSVLTQPPSASGTPGQRVTISCSGSSSNI
2356
AA

GSNYVYWYQQLPGTAPKLLIYRNNQRPS

WD

GVPDRFSGSKSGTSASLAISGLRSEDEAD

DSL

YYCAAWDDSLSGYWVFGGGTKLTVL

SGY

WV

COV096_LC_101-pl409
2359
SYVLTQPPSVSVAPGKTARITCGGNNIGS
2360
QV

KNVHWYQQKPGQAPVLVVYDDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEAG

STS

YYCQVWDSTSDHLFWVFGGGTKLTVL

DHL

FWV

COV096_LC_174-pl409
2363
QSXXTQPPSASGTPGQRVTISCSGSSSNI
2364
AA

GSNTVNWYQQLPGTAPKLLIYSNNQRPS

WD

GVPDRFSGSKSGTSASLAISGLQSEDEAD

DSL

YYCAAWDDSLNGHVVFGGGTKLTVL

NGH

VV

COV096_LC_189-pl409
2367
QSXLTQPPSVSGAPGQRVTISCTGSSSNI
2368
QSY

GADYDVHWYQQLPGTAPKLLIYGNSNR

DSS

PSGVPDRFSGSKSGTSASLAITGLQAEDE

LSG

ADYYCQSYDSSLSGPYWVFGGGTKLTVL

PYW

V

TABLE 13

Anti-SARS-CoV-2 IgG antibodies from COV107

SEQ

SEQ

ID

ID

SEQUENCE_ID
NO
aa
NO
cdr3_aa

HEAVY

COV107_Plate1_HC_9-P1369
2721
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
2369
ARDWG

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG

EYYFDY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD

WGEYYFDYWGQGTLVTVSS

COV107_Plate1_HC_36-P1369
2725
EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM
2373
ARDYGD

SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGR

YYFDY

FTISRDNSKNTLYLQMNSLRVEDTAVYYCARDY

GDYYFDYWGQGTLVTVSS

COV107_Plate1_HC_40-P1369
2729
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
2377
ARDWG

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG

EYYFDY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD

WGEYYFDYWGQGTLVTVSS

COV107_Plate2_HC_13-P1369
2733
EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM
2381
ARDYGD

SWVRQAPGKGLEWVSVIYSGGSTFYADSVKGR

YYFDY

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARDY

GDYYFDYWGQGTLVTVSS

COV107_Plate2_HC_93-P1369
2737
EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM
2385
VRDYGD

SWVRQAPGKGLEWVSVIYSGGSTFYTDSVKGR

FYFDY

FTISRDNSKNTLYLQMNSLRAEDTAVYYCVRDY

GDFYFDYWGQGTLVTVSS

COV107_Plate1_HC_11-P1369
2741
QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFY
2389
ARKPLLY

WTWIRQPPGKGLEWIGETNHFGSTDYKASLKS

SDFSPG

RVTISVGMSRNQFSLKVTSLTAADTAVYYCARK

AFDI

PLLYSDFSPGAFDIWGQGTMIVVSS

COV107_Plate1_HC_42-P1369
2745
QVQLQQWGAGLLKPSETLSLSCAVYGGSLSGYY
2393
ARKPLLY

WSWIRQPPGKGLEWIGEINHFGSTGYNPSLKSR

SNLSPG

VTISVDTSKSQFSVKLSSVTAADTAVYYCARKPLL

AFDI

YSNLSPGAFDIWGQGTMVTVSS

COV107_Plate1_HC_84-P1369
2749
QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFY
2397
ARKTLLF

WTWIRQPPGKGLEWIGETNHFGSTDYKPSLKS

SDFSPG

RVTISVDMSRNQFSLIMTSVTAADTAVYYCARK

AFDI

TLLFSDFSPGAFDIWGQGTMVVVSS

COV107_Plate2_HC_31-P1369
2753
QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFY
2401
ARKPLL

WTWIRQPPGKGLEWIGETNHFGSTDYKPSLKS

HSDLSP

RVTISVDMSRNQFSLKVTSVTAADTAVYYCARK

GAFDI

PLLHSDLSPGAFDIWGQGTMVAVSS

COV107_Plate2_HC_53-P1369
2757
QVQLQQWGAGLLKPSETLSLTCAVSGGSLSGFY
2405
ARKPLLY

WTWIRQPPGKGLEWIGETNHFGSTGYKPSLKS

SDFSPG

RVTISVDMSRNQFSLKVTSVTAADTAVYYCARK

AFDI

PLLYSDFSPGAFDIWGQGTMVAVSS

HEAVY

COV107_Plate1_HC_29-P1369
2761
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
2409
ARGEG

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

WDLPY

GRFTISRDNSKNTLYLQMHSLRAEDTAVYYCAR

DY

GEGWDLPYDYWGQGTLVTVSS

COV107_Plate1_HC_35-P1369
2765
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
2413
ARGEG

MSWVRQAPGKGLEWVSVIYTGGSTFYADSVK

WDLPY

GRFTISRDNSKNTLYLQMNSLRAEDTAMYYCAR

DY

GEGWDLPYDYWGQGTLVTVSS

COV107_Plate2_HC_4-P1369
2769
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
2417
ARGEG

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

WELPYD

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

Y

GEGWELPYDYWGQGTLVTVSS

COV107_Plate1_HC_63-P1369
2773
QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYG
2421
ARGEAV

FSWVRQAPGQGLEWMGWISAYNGNTNFAQK

AGTTGF

LQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYC

FDY

ARGEAVAGTTGFFDYWGQGTLVTVSS

COV107_Plate1_HC_68-P1369
2777
QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYG
2425
ARGEAV

FSWVRQAPGQGLEWMGWISAYNGNTNFAQK

AGTTGF

LQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYC

FDY

ARGEAVAGTTGFFDYWGQGTLVTVSS

COV107_Plate1_HC_13-P1369
2781
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYY
2429
ARDVIV

IHWVRQAPGQGLEWMGWINPNSGGTNYAQK

SMVRG

FQGRVTMTRDTSISTAYMELSRLRSDDTAVYYC

VIFRMD

ARDVIVSMVRGVIFRMDVWGQGTTVTVSS

V

COV107_Plate1_HC_27-P1369
2785
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
2433
ATAHPR

MHWVRQAPGQGLEWMGWINPNSGGTNYA

RIQGVF

QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY

FLGPGV

YCATAHPRRIQGVFFLGPGVWGQGTTVTVSS

COV107_Plate1_HC_79-P1369
2789
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY
2437
ARANHE

MHWVRQAPGQGLEWMGIINPSGGSTSYAQKL

TTMDTY

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA

YYYYYM

RANHETTMDTYYYYYYMDVWGKGTTVTVSS

DV

COV107_Plate1_HC_91-P1369
2793
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYY
2441
ARANHE

MHWVRQAPGQGLEWMGIINPSGGSTSYAQKL

TTMDTY

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA

YYYYYM

RANHETTMDTYYYYYYMDVWGKGTTVTVSS

DV

HEAVY

COV107_Plate1_HC_53-P1369
2797
QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA
2445
AAPHCS

VQWVRQARGQRLEWIGWIVVGSGNTNYVQK

STSCFD

FQERVTITRDMSTSTAYMELSSLRSEDTAVYYCA

AFDI

APHCSSTSCFDAFDIWGQGTMVTVSS

COV107_Plate2_HC_81-P1369
2801
QMQLVQSGPEVKKPGTSVKVSCKASGFTFTSSA
2449
AAPYCS

VQWVRQARGQRLEWIGWIVVGSGNTNYAQK

GGSCSD

FQERVTITRDMSTSTAYMELSSLRSEDTAVYYCA

AFDI

APYCSGGSCSDAFDIWGQGTMVTVSS

HEAVY

COV107_Plate2_HC_42-P1369
2805
QVQLVESGGGLVQPGRSLRLSCAASGFTFSTYA
2453
ARDPIW

MHWVRQAPGKGLKWVAVISYDGGNKYYADS

FGELLSP

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

PFVHFD

ARDPIWFGELLSPPFVHFDYWGQGTLVTVSS

Y

COV107_Plate2_HC_89-P1369
2809
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYA
2457
ARDPIW

MHWVRQAPGEGLEWVAVISYDGSNTYYADSV

FGELLSP

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

PFVHFD

RDPIWFGELLSPPFVHFDYWGQGTLVTVSS

Y

COV107_Plate1_HC_22-P1369
2813
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSHA
2461
AREDYY

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DSSGSF

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

DY

REDYYDSSGSFDYWGQGTLVTVSS

COV107_Plate2_HC_88-P1369
2817
QVQLVESGGGVVQPGRSLRLSCAASGFTFSRHA
2465
AREDYY

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DSSGSF

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

DY

REDYYDSSGSFDYWGQGTLVTVSS

COV107_Plate2_HC_49-P1369
2821
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYA
2469
ASGYTG

MHWVRQAPGKGLEWVAVISYDGSNXYYADSV

YDYFVR

KGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAS

GDYYGL

GYTGYDYFVRGDYYGLDVWGQGTTVTVSS

DV

COV107_Plate2_HC_84-P1369
2825
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
2473
ASGYTG

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YDYFVG

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

GDYYG

SGYTGYDYFVGGDYYGMDVWGQGTTVTVSS

MDV

HEAVY

COV107_Plate1_HC_19-P1369
2829
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFG
2477
ARGVNP

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

DDILTG

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

VDAFDI

ARGVNPDDILTGVDAFDIWGQGTMVTVSS

COV107_Plate1_HC_38-P1369
2833
QVQLVESGGGVVQPGRSLRLSCAASGFTFSNFG
2481
ARGVNP

MHWVRQAPGKGLEWVAVIWYDGSNKYYADS

DDILTG

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

VDAFDI

ARGVNPDDILTGVDAFDIWGQGTMVTVSS

COV107_Plate2_HC_15-P1369
2837
EVQLVESGGGLIKPGRSLRLSCTASGFTFGDYA
2485
TRWDG

MTWFRQAPGKGLEWVGFIRSKAYGGTTGYAA

WSQHD

SVKYRFTISRDDSKSIAYLQMDSLKTEDTAVYYCT

Y

RWDGWSQHDYWGQGTLVTVSS

COV107_Plate2_HC_69-P1369
2841
EVQLVESGGGLIKPGRSLRLSCTASGFTFGDYA
2489
TRWDG

MTWFRQAPGKGLEWVGFIRSKAYGGTTGYAA

WSQHD

SVRYRFTISRDDSSGIAYLQMDSLKTEDTAVYYC

Y

TRWDGWSQHDYWGQGTLVTVSS

COV107_Plate2_HC_32-P1369
2845
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
2493
AREGM

MTWVRQAPGKGLEWVSLIYPGGSTYYADSVKG

GMAAA

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARE

GT

GMGMAAAGTWGQGTLVTVSS

COV107_Plate2_HC_73-P1369
2849
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
2497
AREGM

MSWVRQAPGKGLEWVSLIYPGGSTYFADSVKG

GIAAAG

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARE

T

GMGIAAAGTWGQGTLVTVSS

HEAVY

COV107_Plate1_HC_62-P1369
2853
EVQLVESGGGLIQPGGSLKLSCVVSGFTVSKNYI
2501
ARGDGE

SWVRQAPGKGLEWVSVIFAGGSTFYADSVKGR

LFFDH

FAISRDNSNNTLFLQMNSLRVEDTAIYYCARGD

GELFFDHWGQGTLVTVSS

COV107_Plate1_HC_73-P1369
2857
EVQLVESGGGLIQPGGSLKLSCVVSGFTVSKNYI
2505
ARGDGE

SWVRQAPGKGLEWVSVIFAGGSTFYADSVKGR

LFFDQ

FAISRDNSNNTLFLQMNSLRVEDTAIYYCARGD

GELFFDQWGQGTLVTVSS

COV107_Plate1_HC_46-P1369
2861
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSTN
2509
VRDGGR

WWSWVRQPPGKGLEWIGEIYHTGSTNYNPSL

PGDAFD

KSRVTISVDKSKNQFSLKLSSVTAADTAVYYCVR

I

DGGRPGDAFDIWGQGTMVTVSS

COV107_Plate2_HC57-P1369
2865
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSTN
2513
VRDGGR

WWSWVRQPPGKGLEWIGEIYHTGSTNYNPSL

PGDAFD

KSRVTISVDKSKNQFSLKLSSVTAADTAVYYCVR

I

DGGRPGDAFDIWGQGTMVTVSS

COV107_Plate2_HC_36-P1369
2869
QVQLQESGPGLVKPSETLSLTCTVSGGSISNYYW
2517
ARVED

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

WGYCSS

ISVDTSKNQFSLKLSSVTAADTAVYYCARVEDW

TNCYSG

GYCSSTNCYSGAFDIWGQGTMVTVSS

AFDI

COV107_Plate2_HC71-P1369
2873
QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYW
2521
ARVED

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

WGYCSS

ISVDTSKNQFSLKLSSVTAADTAVYYCARVEDW

TNCYSG

GYCSSTNCYSGAFDIWGQGTMVTVSS

AFDI

COV107_Plate1_HC_77-P1369
3220
QVQLQESGPGLVKPSETLSLTCTVSGASVSSGSY
2525
ARERPG

YWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKS

GTYSNT

RVTISVDTSKNQFSLKLSSVTAADTAVYYCARER

WYTPTD

PGGTYSNTWYTPTDTNWFDTWGQGTLVTVSS

TNWFD

T

COV107_Plate2_HC_72-P1369
3221
QVQLQESGPGLVKPSETLSLTCTVSGASVSSGSY
2529
ARERPG

YWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKS

GTYSNT

RVTISVDTSKNQFSLKLSSVTAADTAVYYCARER

WYTPTD

PGGTYSNTWYTPTDTNWFDTWGQGTLVTVSS

TNWFD

T

HEAVY

COV107_Plate1_HC_75-P1369
3222
EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWI
2533
ARSFRD

GWVRQMPGKGLEWMGIIYPGDSDATYSPSFQ

DPRIAV

GQVTISADRSISTAYLQWSSLKASDTAMYYCAR

AGPADA

SFRDDPRIAVAGPADAFDIWGQGTMVTVSS

FDI

COV107_Plate2_HC_90-P1369
3223
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI
2537
ARSFRD

GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ

DPRIAV

GQVTISADKSISTAYMQWSSLKASDTAMYYCA

AGPADA

RSFRDDPRIAVAGPADAFDIWGQGTMVTVSS

FDI

HEAVY

COV107_Plate1_HC_52-P1369
3224
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG
2541
ARAIAV

FSWVRQAPGQGLEWLGWISAYNGNTNYAQKL

AGTSGE

QGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCA

FDY

RAIAVAGTSGEFDYWGQGTLVTVSS

COV107_Plate1_HC_58-P1369
3225
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG
2545
ARSQG

ISWVRQAPGQGLEWMGWISAYNGNTNYAQK

WLQLN

LQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYC

DY

ARSQGWLQLNDYWGQGTLVTVSS

COV107_Plate2_HC_45-P1369
3226
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
2549
ARGHDY

MHWVRQAPGQGLEWMGWINPNSGGTKYAQ

VWGSY

KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY

RYHNV

CARGHDYVWGSYRYHNVWGQGTLVTVSS

COV107_Plate1_HC_60-P1369
3227
QVQLVQSGAEVKKPGASVMLSCKASGYTFTGY
2553
ARDLAF

YMHWVRQAPGQGLEWMGWINPNSGGTNYA

SMVRAP

QKFQGRVTMTRDTSITTTYMELSRLRSDDTAVY

GDY

YCARDLAFSMVRAPGDYWGQGTLVTVSS

COV107_Plate1_HC_5-P1369
3228
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYS
2557
ARELIAV

MHWVRQAPGQGLEWMGWINPNSGGTNYA

AGIFDY

QKFQGRVTMTRDTSISTAYMELNRLRSDDTAV

YYCARELIAVAGIFDYWGQGTLVTVSS

COV107_Plate2_HC_94-P1369
3229
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
2561
ARAPLF

MHWVRQAPGQGLEWMGWISPVSGGTNYAQ

PTGVLA

KFQGRVTMTRDTSISTAYMELSRLRSDDTAVYY

GDYYYY

CARAPLFPTGVLAGDYYYYGMDVWGQGTTVT

GMDV

VSS

COV107_Plate1_HC_83-P1369
3230
QVQLVQSGAEVKKPGASVKVSCKASGYILTDYFI
2565
ARYKGT

HWVRQAPGQGLEWMGWINPNSGGTNYAQK

TVNTNY

FQGRVTMTRDTSISTAYMELSRLRSDDTAVYHC

YYGMD

ARYKGTTVNTNYYYGMDVWGQGTTVTVSS

V

COV107_Plate2_HC_40-P1369
3231
QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYY
2569
ARDPSPI

MHWVRQAPGQGLEWMGIINPSGGSTSYAQKF

IARPGM

QGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCA

GYWFD

RDPSPIIARPGMGYWFDPWGQGTLVTVSS

P

COV107_Plate1_HC_28-P1369
3232
QVQLVQSGAEVKKPGSSVKVSCKASGGTFRSYA
2573
ARDSSG

ISWVRQAPGQGLEWMGGIIPIFGTTNYAQKFQ

YYYVSN

GRVTITADESTSRAYMELSSLRSEDTAVYYCARD

WFDP

SSGYYYVSNWFDPWGQGTLVTVSS

COV107_Plate2_HC_92-P1369
2929
QVQLLESGGGLVKPGGSLRLSCAASGFTFSDYY
2577
ATYRSYL

MSWIRQAPGKGLEWVSYISSRSSYTNYADSVKG

PLVQVD

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCATY

Y

RSYLPLVQVDYWGQGTLVTVSS

COV107_Plate2_HC_55-P1369
2933
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYS
2581
ARGQLL

MNWVRQAPGKGLEWVSSISSSSSYIYYADSVKG

PFADY

RFTISRDNAKNSLYLQMNSLRAEDTAVYYCARG

QLLPFADYWGQGTLVTVSS

COV107_Plate2_HC_47-P1369
2937
EVQLVESGGGLVKPGGSLRVSCAASGFTFSSYS
2585
TRGSRG

MNWVRQAPGKGLEWVSSISSSKNYIYYADSVK

YYDRSG

GRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTR

YYTPLDP

GSRGYYDRSGYYTPLDPYYGMDVWGQGTTVT

YYGMD

VSS

V

COV107_Plate1_HC_49-P1369
2941
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYA
2589
AKEEVL

MSWVRQAPGKGLEWVSGISDSGGSTYYADSV

PAVEYF

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

QH

KEEVLPAVEYFQHWGQGTLVTVSS

COV107_Plate2_HC_22-P1369
2945
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
2593
AKGGYY

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YYNSDS

KGRFTISRDNSKNTLDLQMNSLRAEDTAVYYCA

YQAEID

KGGYYYYNSDSYQAEIDYWGQGTLVTVSS

Y

COV107_Plate2_HC_91-P1369
2949
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSSG
2597
AKDPLP

MHWVRQAPGKGLEWVAIISYDGSNKYYADSV

FRDFFYY

KGRFTISRDNSKNTLSLQMNSLRAEDTAVYYCA

YMDV

KDPLPFRDFFYYYMDVWGKGTTVTVSS

COV107_Plate2_HC_35-P1369
2953
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
2601
ARETQG

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

GYYGSG

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

SYYASPF

RETQGGYYGSGSYYASPFDPWGQGTLVTVSS

DP

COV107_Plate2_HC_24-P1369
2957
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
2605
ARDFYH

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

NWFDP

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

RDFYHNWFDPWGQGTLVTVSS

COV107_Plate2_HC_34-P1369
2961
QVQLVESGGGVVQPGRSLRLSCAASGLTFSSYG
2609
ARDRGL

MHWVRQAPGKGLEWVAVIWYDGINKYYADS

RLGGPK

VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC

YYFDY

ARDRGLRLGGPKYYFDYWGQGTLVTVSS

COV107_Plate1_HC_41-P1369
2965
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYY
2613
ARDPQR

MNWVRQAPGKGLEWVSYISSSSSTIYYADSVK

DPADYF

GRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR

DY

DPQRDPADYFDYWGQGTLVTVSS

COV107_Plate2_HC_46-P1369
2969
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYW
2617
AIQLWL

MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV

RGGYDY

KGRFTISGDNAKNSLYLHMNSLRAEDTAVYYCAI

QLWLRGGYDYWGQGTLVTVSS

COV107_Plate1_HC_32-P1369
2973
EVQLVESGGGLVQPGGSLRLSCADSGFTFSSYW
2621
AVQLW

MSWVRQAPGKGLEWVANIKQDGSEKYYVDSV

LRGNFD

KGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCA

Y

VQLWLRGNFDYWGQGTLVTVSS

COV107_Plate2_HC_25-P1369
2977
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2625
AKDDRE

MHWVRQAPGKGLEWVSGISWNSGSRGYADS

GFGDYF

VKGRFTISRDNAKNSLYLLMNSLRAEDTAFYYCA

DY

KDDREGFGDYFDYWGQGTLVTVSS

COV107_Plate2_HC_54-P1369
2981
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
2629
AKDSLV

MHWVRQAPGKGLEWVSGISWNSGSIGYADSV

RRNFYY

KGRFTISRDNAKSSLYLQMKSLRVEDTALYYCAK

YYMDV

DSLVRRNFYYYYMDVWGKGTTVTVSS

COV107_Plate2_HC_20-P1369
2985
QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYY
2633
AGMYY

WGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR

DILTGYS

VTISVDTSKNQFSLKLSSVTAADTAVYYCAGMYY

EGAFDI

DILTGYSEGAFDIWGQGTMVTVSS

COV107_Plate1_HC_25-P1369
2989
QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYY
2673
AGGTNP

WGWIRQPPGKGLEWIGSIYYSGSTYYNPSLKSR

QWLDS

VTISVDTSKNQFSLKLSSVTAADTAVYYCAGGTN

TFDY

PQWLDSTFDYWGQGTLVTVSS

COV107_Plate1_HC_64-P1369
2993
QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSHY
2641
ASAPYL

WGWIRQPPGKGLEWIGTIYYSGSTYYNPSLKSR

NWND

VTISVDTSKNQFSLRLSSVTAADTAVYYCASAPYL

WIFDY

NWNDWIFDYWGQGTLVTVSS

COV107_Plate2_HC_28-P1369
2997
QVQLQESGPGLVKPSETLSLSCAVSGGSIGSYF
2645
ARLQWL

WSWIRQPPGKGLEWIGYLHYSGSTNYNPSLKSR

RGAFDI

VTISVDTSKNQFSLKLSSVTAADTAVYYCARLQ

WLRGAFDIWGQGTMVTVSS

COV107_Plate2_HC_58-P1369
3001
QVQLQESGPGLVKPSETLSLTCTVSGGSISGYYW
2649
ARYGW

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

GYDSSG

ISVDTSKNQFSLKLSSVTAADTAVYYCARYGWG

YYFDY

YDSSGYYFDYWGQGTLVTVSS

COV107_Plate2_HC_2-P1369
3005
QVQLQESGPRLVKPSENLSLTCTVSGGSISSYYW
2653
ARATTP

SWIRQPPGKGLEWIGYIYYTGSTKYNPSLKSRVTI

FSGVDY

SVDTSKNQFSLKLSSVTAADTAVFYCARATTPFS

GVDYWGQGTLVTVSS

COV107_Plate2_HC_10-P1369
3009
QVQLQESGPGLVKPSETLSLTCTVSGGSISNYYW
2657
ARILRGV

SWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVT

AENWF

ISVDTSKNQFSLKLTSVTAADTAVYYCARILRGV

DP

AENWFDPWGQGTLVTVSS

COV107_Plate1_HC_48-P1369
3013
QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGSY
2661
ATRGGY

YWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKS

YDSSGY

RVTISVDTSKNQFSLKLSSVTAADTAVYYCATRG

YALAFDI

GYYDSSGYYALAFDIWGQGTMVTVSS

COV107_Plate2_HC_87-P1369
3017
EVQLVQSGAEVKQPGESLKISCKALGYTFTTSWI
2665
ATETNS

SWVRQMPGKGLEWMGRIDPSDSYTKYSPSFQ

ETTDMF

GHVTISVDKSITTAYLQWSSLKASDSAVYYCATE

TGYSFD

TNSETTDMFTGYSFDPWGQGTLVTVSS

P

COV107_Plate2_HC_1-P1369
3021
EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWI
2669
ARGGPP

AWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ

GGVKLE

GQVTISADQSISTAYLQWSSLKASDTAMYYCAR

LTDY

GGPPGGVKLELTDYWGQGALVTVSS

COV107_Plate1_HC_92-P1369
3025
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI
2673
ARLHPT

GWVRQMPGKGLEWMGILYPGDSDTTYSPSFQ

YYDILTG

GQVTISADKSISTAYLQWSSLKASDTAMYYCARL

YYIDY

HPTYYDILTGYYIDYWGQGTLVTVSS

COV107_Plate1_HC_26-P1369
3029
EVQLVQSGAEVKKPGESLKISCKGSGYSFISYWI
2677
ARRPSS

GWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQ

YSGWF

GQVTISADKSISTAYLQWSSLKASDTAMYYCAR

DP

RPSSYSGWFDPWGQGTLVTVSS

HEAVY

COV107_Plate2_HC_18-P1369
3033
QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYY
2681
AREPQI

MHWVRQAPGQGLEWMGWINPNSGGTNYA

NPYYDIL

QKFQGRVTMTRDTSISTAYMELSRLRSDDTAVY

TGYRAF

YCAREPQINPYYDILTGYRAFDYWGQGTLVTVS

DY

S

COV107_Plate1_HC_21-P1369
3037
QVQLVQSGAEVVRPGASVKVSCKASGYTFTTHY
2685
ARGPRS

MHWVRQAPGQGLEWMGIINPSVGSTSYAQKF

PSDWCS

QGRVTMTRDTSTSTVYMELSSLISEDTAMYYCA

GGSCYD

RGPRSPSDWCSGGSCYDDQNWFDPWGQGTL

DQNWF

VTVSS

DP

COV107_Plate1_HC_24-P1369
3041
QVQLVQSGAEVMKPGASVKVSCKASGYTFTSY
2689
ARDFEL

YMHWVRQAPGQGLEWMGIINPTAGSTSYAQK

WFGELR

FQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC

GWFDP

ARDFELWFGELRGWFDPWGQGTLVTVSS

COV107_Plate2_HC_17-P1369
3045
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSIYAI
2693
ASFHVA

SWVRQAPGQGLEWMGGIIPILGTANYAQKFQ

YGDYIPF

GRVTITADESTSTAYMELSSLRSEDTAVYYCASF

DY

HVAYGDYIPFDYWGQGTLVTVSS

COV107_Plate1_HC_78-P1369
3049
QVQLVQSGAEVKKSGSSVKVSCKASGGTFSSYG
2697
ARAGLL

ISWVRQAPGQGLEWMGGIIPIIGTANYAQKFQ

TKNIVA

GRVTITADESMSTAYMELSSLRSEDTAVYYCAR

TIGCFDP

AGLLTKNIVATIGCFDPWGQGTLVTVSS

COV107_Plate1_HC_95-P1369
3053
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYD
2701
ARGGRY

INWVRQATGQGLEWMGWMNPNSGNTGYA

CSSTSCY

QKFQGRVTMTRNTSISTAYMELSSLRSEDTAVY

SHVGFD

YCARGGRYCSSTSCYSHVGFDPWGQGTLVTVS

P

S

COV107_Plate2_HC_38-P1369
3057
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYD
2705
ARVRYD

MHWVRQATGRGLEWVSTIGTAGDTYYPGSVK

SSGYFW

GRFTISRENAKNSLYLQMNSLRAGDTALYYCAR

SLDY

VRYDSSGYFWSLDYWGQGTLVTVSS

COV107_Plate2_HC_61-P1369
3061
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYD
2709
ARGVSG

MHWVRQATGKGLEWVSTIGTAGDTYYPGSVK

VVRGVI

GRFTISRENAKNSLYLQMNSLRAGDTAVYFCAR

RSFYYY

GVSGVVRGVIRSFYYYGLDVWGQGTTVTVSS

GLDV

COV107_Plate1_HC_80-P1369
3065
EVQLLESGGGLVQPGGSLRLSCAASGITFSSYAM
2713
VETNLW

TWVRQAPGKGLEWVSTISGSGGGTYYADSVKG

FGEDNY

RFTISRDNSKNTLYLOMNSLRAEDTAVYYCVET

YYYYGM

NLWFGEDNYYYYYGMDVWGQGTTVTVSS

DV

COV107_Plate2_HC_68-P1369
3069
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
2717
ATGGGS

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YFSPRIY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

FDY

TGGGSYFSPRIYFDYWGQGTLVTVSS

COV107_Plate2_HC_51-P1369
3073
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
3191
AKQAGP

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YCSGGT

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

CYPGTL

KQAGPYCSGGTCYPGTLDYWGQGTLVTVSS

DY

COV107_Plate1_HC_43-P1369
3077
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
3192
AKAGYS

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

YGYPQQ

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

YFDY

KAGYSYGYPQQYFDYWGQGTLVTVSS

COV107_Plate2_HC_3-P1369
3081
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
3193
AKSLGP

MHWVRQAPGKGLEWVAVILYDGSNKYYADSV

YCSGGN

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

CYSSYFD

KSLGPYCSGGNCYSSYFDYWGQGTLVTVSS

Y

COV107_Plate2_HC_44-P1369
3085
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
3194
AKKGGG

MHWVRQAPGKGLEWVAVISYDGSNKYYGDSV

AYCGGD

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

CYLGEF

KKGGGAYCGGDCYLGEFDYWGQGTLVTVSS

DY

COV107_Plate2_HC_76-P1369
3089
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYG
3195
AKSWW

MHWVRQAPGKGLEWVAVISDDGSNKYYADSV

LSENWF

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

DP

KSWWLSENWFDPWGQGTLVTVSS

COV107_Plate1_HC_16-P1369
3093
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYG
3196
AKGGLY

MHWVRQAPGKGLEWVAVISYDGSNKYYADSV

DSSGYY

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

PHYGM

KGGLYDSSGYYPHYGMDVWGQGTTVTVSS

DV

COV107_Plate1_HC_10-P1369
3097
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYA
3197
ARDQDL

MHWVRQAPGKGLEWVAVILYDGSNKYYADSV

DTAMV

KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA

TLFDY

RDQDLDTAMVTLFDYWGQGTLVTVSS

COV107_Plate1_HC_65-P1369
3101
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAI
3198
ARDSPS

HWVRQAPGKGLEWVAVISYDGSNKYYADSVK

QIVVVP

GRFTISRDNSKNTLYLQMNSLRADDTAVYYCAR

VFDY

DSPSQIVVVPVFDYWGQGTLVTVSS

COV107_Plate1_HC_2-P1369
3105
EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYS
3199
AREGAR

MNWVRQAPGKGPEWVSYISRSSSTIYYADSVK

VGATYD

GRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR

TYYFDY

EGARVGATYDTYYFDYWGQGTLVTVSS

COV107_Plate2_HC_64-P1369
3109
EVQLVESGGDLVQPGGSLRLSCAASGFTFSSYS
3200
ARVAIR

MNWVRQAPGKGLEWVSYISISSSTIYYADSVKG

WVPSA

RFTISRDNAKNSLYLQMNSLRDEDTAVYYCARV

TYYFDY

AIRVVVPSATYYFDYWGQGTLVTVSS

COV107_Plate2_HC_11-P1369
3113
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYS
3201
ARDQGY

MNWVRQAPGKGLEWVSYISTSSSTIYYADSVQ

CSSTSCY

GRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAR

DGYYYY

DQGYCSSTSCYDGYYYYMDVWGKGTTVTVSS

MDV

COV107_Plate1_HC_44-P1369
3117
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
3202
ARDLRG

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG

PGTFDI

RFTISSDNSKNTLYLQMNSLRAEDTAVYYCARDL

RGPGTFDIWGQGTMVTVSS

COV107_Plate1_HC_88-P1369
3121
EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNY
3203
AREVAA

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG

FDI

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARE

VAAFDIWGQGTMVTVSS

COV107_Plate1_HC_18-P1369
3125
EVQLVESGGGLIQPGGSLRLSCAASGVTVSRNY
3204
ARDLSA

MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK

AFDI

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

DLSAAFDIWGQGTMVTVSS

COV107_Plate1_HC_59-P1369
3129
EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM
3205
ARTMD

SWVRQAPGKGLEWVSIIYSGGSTFYADSVKGRF

GDYFDY

TISRDNSKNTLYLOMNSLRAEDTAVYYCARTMD

GDYFDYWGQGTLVTVSS

COV107_Plate1_HC_30-P1369
3133
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
3206
ARTDIV

MSWVRQAPGKGLEWVSLIYSGGSTYYADSVKG

WPAAR

RFTISRDNSKNTLYLOMNSLRAEDTAVYYCART

GFYFDY

DIVVVPAARGFYFDYWGQGTLVTVSS

COV107_Plate1_HC_15-P1369
3137
EVQLVESGGGLIQPGGSLRLSCAASGLTVSSNY
3207
ARESGD

MSWVRQAPGKGLEWVSVLYSGGSSFYADSVK

TTMAFD

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

Y

ESGDTTMAFDYWGQGTLVTVSS

COV107_Plate2_HC_23-P1369
3141
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
3208
ARDLGT

MSWVRQAPGKGLEWVSVIYSGGSTFYADSVKG

GLFDY

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD

LGTGLFDYWGQGTLVTVSS

COV107_Plate1_HC_82-P1369
3145
EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYM
3209
ARDYGD

SWVRQAPGKGLEWVSVIYSGGSTYYADSVKGR

FYFDY

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARDY

GDFYFDYWGQGTLVTVSS

COV107_Plate2_HC_95-P1369
3149
EVQLVESGGGLIQPGGSLRLSCAASGFTVSYNY
3210
ARDYGD

MSWVRQAPGKGLEWVSIIYSGGSTYYADSVKG

LYFDY

RFTISRDNSKNTLYLQMNSLRAEDTAIYYCARDY

GDLYFDYWGQGTLVTVSS

COV107_Plate1_HC_86-P1369
3153
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
3211
ATDLTS

53
MSWVRQAPGKGLEWVSVIYSGGSTYYADSVK
11
GRGP

GRFTISRDNSKNTLYLQMNSLRADDTAVYYCAT

DLTSGRGPWGQGTLVTVSS

COV107_Plate2_HC_78-P1369
3157
EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNY
3212
ARDLW

MTWVRQAPGKGLEWVSVIYSGGTTYYADSVK

WGMD

GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

V

DLVVWGMDVWGQGTTVTVSS

COV107_Plate2_HC_9-P1369
3161
EVQLVESGGGLVQPGGSLKLSCAASGFTFSGSA
3213
TKPHAH

MHWVRQASGKGLEWVGRIRSKANSYATTYAA

CGGDCY

SVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYY

SRDWF

CTKPHAHCGGDCYSRDWFDPWGQGTLVTVSS

DP

COV107_Plate2_HC_50-P1369
3165
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAI
3214
AKGLIAE

HWVRQAPEKGLEWVSGINWSSGSIVYADSVKG

LVGGG

RFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGL

WYFDY

IAELVGGGWYFDYWGQGTLVTVSS

COV107_Plate1_HC_74-P1369
3169
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYA
3215
AKALSST

MHWVRQAPGKGLEWVSGVSWNSGSIGYADS

GFLVVY

VRGRFTISRDNAKNSLYLQMNSLRAEDTALYYC

FDY

AKALSSTGFLVVYFDYWGRGTLVTVSS

COV107_Plate1_HC_93-P1369
3173
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGY
3216
AWRYSS

YWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKS

SWYTVD

RVTISVDTXKNQFSLKLSSVTAADTAVYYCAWR

NKKGDY

YSSSWYTVDNKKGDYYFDYWGQGTLVTVSS

YFDY

COV107_Plate1_HC_45-P1369
3177
EVQLVQSGAEVKKPGESLRISCKGSAYIFTTYWIS
3217
ARHISS

WVRQMPGKGLEWMGRIDPSDSYTNYSPSFQG

GWYDY

HVTISADKSISTAYLQWSSLKASDTAMYYCARHI

SSGWYDYWGQGTLVTVSS

COV107_Plate1_HC_39-P1369
3181
EVQLVQSGAEVKKPGESLRISCKGSGYSFTSYYIS
3218
ARHRHP

WVRQMPGKGLEWMGRIDPSDSYTNYSPSFQG

GITMIV

HVTISADKSISAAYLQWSSLKASDTAMYYCARH

ALDY

RHPGITMIVALDYWGQGTLVTVSS

COV107_Plate1_HC_37-P1369
3185
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWI
3219
ALTTVTT

GWVRQMPGKDLEWMGIIYPGDSDTRYSPSFO

GRWFD

GQVTISADKSISTAYLQWSSLKASDTAMYYCALT

P

TVTTGRWFDPWGQGTLVTVSS

KAPPA

COV107_Plate1_Kappa_9-P1389
2370
EIVLTQSPGTLSLSPGERATLSCRASQSV
2411
QQY

TSYLAWYQQKPGQAPRLLIYGASSRAT

GSS

GIPDRFSGSGSGTDFTLTISRLDPEDFAV

PRT

YYCQQYGSSPRTFGQGTKVEIK

COV107_Plate1_Kappa_36-P1389
2374
EIVLTQSPGTLSLSPGERATLSCRASQSV
2415
QQY

SSSYLAWYQQKPGQAPRLLIYGAFSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

PRT

VYYCQQYGSSPRTFGQGTKVEIK

COV107_Plate1_Kappa_40-P1389
2378
EIVLTQSPGTLSLSPGERATLSCRASQSV
2419
QQY

TSYLAWYQQKPGQAPRLLIYGASSRAT

GSS

GIPDRFSGSGSGTDFTLTISRLDPEDFAV

PRT

YYCQQYGSSPRTFGQGTKVEIK

COV107_Plate2_kappa_13-P1389
2382
EIVLTQSPGTLSLSPGERATLSCRASQSV
2423
QQY

SSSYLAWYQQKPGQAPRLLIYGASSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

PRT

VYYCQQYGSSPRTFGQGTKVEIK

COV107_Plate2_kappa_93-P1389
2386
EIVLTQSPGTLSLSPGERATLSCRASQSV
2427
QQY

SSSYLAWYQQKPGQAPRLLIYGASSRA

GSS

TGIPDRFSGGGSETDFTLTISRLEPEDCA

PRT

VYYCQQYGSSPRTFGQGTKVEIK

COV107_Plate1_Kappa_11-P1389
2390
EIVLTQSPGTLSLSPGERATLSCRASQTL
2431
QQY

TANYLAWYQQKPGQAPRLLIYGASKRA

HTT

AGIPDRFSGSGSGTDFTLSITRLEPEDFA

PRT

VYYCQQYHTTPRTFGGGTKVEI

COV107_Plate1_Kappa_42-P1389
2394
EIVLTQSPGTLSLSPGERATLSCWASQS
2435
QQY

VSASYLAWYQQKPGQAPRLLIYGASSR

GTT

ATGIPDRFSGSGSGTDFTLTISRLEPEDF

PRT

AVYYCQQYGTTPRTFGGGTKVEIK

COV107_Plate1_Kappa_84-P1389
2398
EIVLTQSPGTLSLSPGERATLSCRASQTL
2439
QQY

TANYLAWYQQKPGQAPRLLIYGASKRA

GTT

TGIPDRFSGSGSGTDFTLSISRLEPEDFA

PRT

VYYCQQYGTTPRTFGGGTKVEI

COV107_Plate2_kappa_31-P1389
2402
EIVLTQSPGTLSLSPGERATLSCRASQTV
2443
QQY

SANYLAWYQQKAGQAPRLLIYGASKRA

VTT

TGIPDRFSGSGSGTDFTLSISRLEPEDFA

PRT

VYYCQQYVTTPRTFGGGTKVEI

COV107_Plate2_kappa_53-P1389
2406
EIVLTQSPGTLSLSPGERATLSCRASQTV
2447
QQY

TANYLAWYQQKPGQAPRLLIYGASKRA

TTT

TGIPDRFSGSGSGTDFTLSISRLEPEDFA

PRT

VYYCQQYTTTPRTFGGGTKVEI

LAMBDA

COV107_Plate1_Lambda_29-P1409
2410
QSALTQPPSASGSPGQSVTISCTGTSSD
2451
SSY

VGGYNYVSWYQQHPGKAPKLMIYEVS

AGS

KRPSGVPDRFSGSKSGNTASLTVSGLQ

NNF

AEDEADYYCSSYAGSNNFVVFGGGTKL

VV

TVL

COV107_Plate1_Lambda_35-P1409
2414
QSVLTQPPSASGSPGQSVTISCTGTSSD
2455
SSY

VGGYNYVSWYQQHPGKAPKLMIYEVR

AGS

KRPSGVPDRFSGSKSGNTASLTVSGLQ

NNF

AEDEADYYCSSYAGSNNFVLFGGGTKL

VL

TVL

COV107_Plate2_lambda_4-P1409
2418
QSVLTQPPSASGSPGQSVTISCTGTSSD
2459
SSYE

VGGYKYVSWYQQHPGKAPKLMIYEVS

GSN

KRPSGVPDRFSGSKSGNTASLTVSGLQ

NFV

AEDEADYYCSSYEGSNNFVVFGGGTKL

V

TVL

COV107_Plate1_Lambda_63-P1409
2422
QSVLTQPPSASGTPGQRVTISCSGSSSN
2463
AA

IGSNYVYWYQQLPGTAPKLLIYRNNQR

WD

PSGVPDRFSGSKSGTSASLAISGLRSEDE

DSL

ADYYCAAWDDSLSGFVVFGGGTKLTVL

SGF

VV

COV107_Plate1_Lambda_68-P1409
2426
QSVLTQPPSASGTPGQRVTISCSGSSSN
2467
AA

IGSNYVYWYQQLPGTAPKLLIYRNNQR

WD

PSGVPDRFSGSKSGTSASLAISGLRSEDE

DSL

ADYYCAAWDDSLSGFVVFGGGTKLTVL

SGF

VV

COV107_Plate1_Lambda_13-P1409
2430
QSVLTQPPSASGTPGQRVTISCSGSSSN
2471
AA

IGSNTVNWYQQLPGTAPKLLIYSNNQR

WD

PSGVPDRFSVSKSGTSASLAISGLQSED

DSL

EADYYCAAWDDSLNGVVFGGGTKLTV

NGV

L

V

COV107_Plate1_Lambda_27-P1409
2434
QSVLTQPPSASGTPGQRVTISCSGSSSN
2475
AA

IGSNTVNWYQQLPGTAPKLLIYSNNQR

WD

PSGVPDRFSGSKSGTSASLAISGLQSED

DSL

EADYYCAAWDDSLNGVVFGGGTKLTV

NGV

L

V

COV107_Plate1_Lambda_79-P1409
2438
QSVLTQPASVSGSPGQSITISCTGTSSD
2479
SSYT

VGGYKYVSWYQRHPGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLQA

SVV

EDEADYYCSSYTSSSTSVVFGGGTQLTV

L

COV107_Plate1_Lambda_91-P1409
2442
QSALTQPASVSGSPGQSITISCTGTSSD
2483
SSYT

VGGYKYVSWYQRHPGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLQA

SVV

EDEADYYCSSYTSSSTSVVFGGGTQLTV

L

KAPPA

COV107_Plate1_Kappa_53-P1389
2446
EIVLTQSPGTLSLSPGERATLSCRASQSV
2487
QQY

SSSYLAWYQQKPGQAPRLLIYGASSRA

GNS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

PWT

VYYCQQYGNSPWTFGQGTKVEIK

COV107_Plate2_kappa_81-P1389
2450
EIVLTQSPGTLSLSPGERATLSCRASQSV
2491
QQY

SSSYLAWYQQKPGQAPRLLIYGASSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA
24
PWT

VYYCQQYGSSPWTFGQGTKVEIK
91

LAMBDA

COV107_Plate2_lambda_42-P1409
2454
QSVLTQPPSVSAAPGQKVTISCSGSSSN
2495
GT

IGNNYVSWYQQLPGTAPKLLIYENNKR

WD

PSGIPDRFSGSKSGTSATLGITGLQTGD

SSLS

EADYYCGTWDSSLSAGGVYVFGTGTTV

AGG

TVL

VYV

COV107_Plate2_lambda_89-P1409
2458
QSVLTQPPSVSAAPGQKVTISCSGSSSN
2499
GA

IGNNLVSWYQQLPGTAPKLLIYENNKR

WD

PSGIPDRFSGSKSGTSATLGITGLQTGD

SSLS

EADYYCGAWDSSLSAGGVYVFGTGTK

AGG

VTVL

VYV

COV107_Plate1_Lambda_22-P1409
2462
QSALTQPASVSGSPGQSITISCTGTSSD
2503
SSYT

VGGYNYVSWYQQHPGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLQA

WV

EDEADYYCSSYTSSSTWVFGGGTKLTVL

COV107_Plate2_lambda_88-P1409
2466
QSVLTQPASVSGSPGQSITISCTGTSSD
2507
SSYT

VGGYNYVSWYQQHPGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLQA

WV

EDEADYYCSSYTSSSTWVFGGGTKLTVL

COV107_Plate2_lambda_49-P1409
2470
QSVLTQSPSASASLGASVKLTCTLSSGH
2511
QT

SSYAIAWHQQQPEKGPRYLMKLNTDG

WG

SHSKGDGIPDRFSGSSSGAERYLTISSLQ

TGIL

SEDEADYYCQTWGTGILVFGGGTKLTV

V

L

COV107_Plate2_lambda_84-P1409
2474
QSVLTQSPSASASLGASVKLTCTLSSGH
2515
QT

SSYAIAWHQQQPEKGPRYLMKLNSDG

WG

SHSKGDGIPDRFSGSSSGAERYLTISSLQ

TGIL

SEDEADYYCQTWGTGILVFGGGTKLTV

V

L

KAPPA

COV107_Plate1_Kappa_19-P1389
2478
DIQMTQSPSTLSASVGDRVTITCRASQS
2519
QQ

MSSWLAWYQQKPGNAPKLLIYKASSLE

HNS

SGVPSRFSGSGSGTEFTLTISSLQPDDFA

SPLT

TYYCQQHNSSPLTFGGGTKVEIK

COV107_Plate1_Kappa_38-P1389
2482
DIQMTQSPSTLSASVGDRVTITCRASQS
2523
QQ

MSSWLAWYQQKPGNAPKLLIYKASSLE

HNS

SGVPSRFSGSGSGTEFTLTISSLQPDDFA

SPLT

TYYCQQHNSSPLTFGGGTKVEIK

COV107_Plate2_kappa_15-P1389
2486
DIVMTQSPLSLSVTPGEPASISCRSSQSL
2527
MQ

LHSNGNNYFDWYLQKPGQSPQLLIYLG

VLQI

SNRASGVPDRFSGSGSGTDFTLKISRVE

PYT

AEDVGVYYCMQVLQIPYTFGQGTKLEI

COV107_Plate2_kappa_69-P1389
2490
DIVMTQSPLSLPVTPGEPASISCRSSQSL
2531
MQ

LQSNGNNYFDWYLQKPGQSPQLLIYLG

VLQ

SNRASGVPDRFSGSGSGTDFTLKISRVE

VPY

AEDVGVYYCMQVLQVPYTFGQGTNLE

T

I

COV107_Plate2_kappa_32-P1389
2494
DIQMTQSPSSLSASVGDTVTITCQASQ
2535
QQY

DISKYLNWYQQKPGKAPKLLIYDASNLE

DNL

TGVPSRFSGSGSGTDFTFTISSLQPEDIA

PQT

TYYCQQYDNLPQTFGGGTKVEIK

COV107_Plate2_kappa_73-P1389
2498
DIQMTQSPSSLSASVGDTVTITCQASQ
2539
QQY

DISKYLNWYQQKPGKAPKLLIYDASNLE

DNL

TGVPSRFSGSGSGTDFTFTISSLQPEDIA

PQT

TYYCQQYDNLPQTFGGGTKVEIK

LAMBDA

COV107_Plate1_Lambda_62-P1409
2502
QSVLTQPPSVSGAPGQRVTISCTGTSS
2543
QSY

NIGAGYDVHWYQQLPGRAPKVLISGN

DSS

NIRPSEVPDRFSGSRSGTSASLAITSLQP

LYA

EDEAQYYCQSYDSSLYAVFGGGTKLTVL

V

COV107_Plate1_Lambda_73-P1409
2506
QSVLTQPPSVSGAPGQRVTISCTGTSS
2547
QSY

NIGAGYDVHWYQQLPGRAPKVLISGN

DSS

NIRPSEVPDRFSGSRSGTSASLAITSLQP

LYA

EDEAQYYCQSYDSSLYAVFGGGTKLTVL

V

COV107_Plate1_Lambda_46-P1409
2510
QSALTQPASVSGSPGQSITISCTGTSSD
2551
NSY

VGGYNFVSWYQQHPGKAPKLMIYDVS

TSSS

NRPSGVSNRFSGSKSGNTASLTISGLQA

TRV

EDEADYYCNSYTSSSTRVFGTGTKVTVL

COV107_Plate2_lambda57-P1409
2514
QSVLTQPASVSGSPGQSITISCTGTSSD
2555
NSY

VGGYNYVSWYQQHPGKAPKLMIYDVS

TSSS

NRPSGVSNRFSGSKSGNTASLTISGLQA

TRV

EDEADYYCNSYTSSSTRVFGTGTKVTVL

COV107_Plate2_lambda_36-P1409
2518
QSVLTQPPSVSEAPRQRVTISCSGSSSNI
2559
AA

GNNAVNWYQQLPGKAPKLLIYYDDLLP

WD

SGVSDRFSGSKSGTSASLAISGLQSEDE

DSL

ADYYFAAWDDSLNGAWVFGGGTKLT

NGA

VL

WV

COV107_Plate2_lambda71-P1409
2522
QSVLTQPPSVSEAPRQRVTISCSGSSSNI
2563
AA

GNNAVNWYQQVPGKAPKLLIYYDDLL

WD

PSGVSDRFSGSKSGTSASLAISGLQSED

DSL

EADYYCAAWDDSLNGAWVFGGGTKL

NGA

TVL

WV

COV107_Plate1_Lambda_77-P1409
2526
SYVLTQPPSVSVAPGKTARITCGGNNIG
2567
QV

SKSVHWYQQKPGQAPVLVIYFDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

SSR

DYYCQVWDSSRDHVVFGGGTKLTVL

DHV

V

COV107_Plate2_lambda_72-P1409
2530
SYVLTQPPSVSVAPGKTARITCGGNNIG
2571
QV

SKSVHWYQQKPGQAPVLVIYFDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

SSR

DYYCQVWDSSRDHVVFGGGTKLTVL

DHV

V

KAPPA

COV107_Plate1_Kappa_75-P1389
2534
DIQMTQSPSTLSASVGDRATITCRASQS
2575
QQY

ISYWLAWYQQKPGKAPKLLIYKASSLES

NSY

GVPSRFSGSGSGTEFTLTISSLQPDDSAT

PYT

YYCQQYNSYPYTFGQGTKLEIK

COV107_Plate2_kappa_90-P1389
2538
DIQMTQSPSTLSASVGDRVTITCRASQS
2579
QQY

ISYWLAWYQQKPGKAPKLLIYQASSLES

NSY

GVPSRFSGSESGTEFTLTISSLQPDDFAT

PYT

YYCQQYNSYPYTFGQGTKLEIK

LAMBDA

COV107_Plate1_Lambda_52-P1409
2542
QSVLTQPPSASGTPGQRVTISCSGSSSN
2583
AA

IGSNTVNWYQQLPGTAPKLLIYSNNQR

WD

PSGVPDRFSGSKSGTSASLAISGLQSED

DSL

EADYYCAAWDDSLNGHVVFGGGTKLT

NGH

VL

VV

COV107_Plate1_Lambda_58-P1409
2546
NFMLTQPHSVSESPGKTVTISCTGSSGS
2587
QSY

IASNYVQWYQQRPGSAPTTMIYEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

TPN

EDEADYYCQSYDSSTPNCVFGGGTKLT

CV

VL

COV107_Plate2_lambda_45-P1409
2550
QSVLTQPASVSGSPGQSITISCTGTSSD
2591
SSYT

VGGYNYVSWYQQHPGKAPKVMIYDV

SSST

SNRPSGVSNRFSGSKSGNTASLTISGLQ

LL

AEDEADYYCSSYTSSSTLLFGGGTKLTXL

COV107_Plate1_Lambda_60-P1409
2554
QSALTQPASVSGSPGQSITISCTGTSSD
2595
CSY

VGSYNLVSWYQQHPGKAPKLMIYEGS

AGS

KRPSGVSNRFSGSKSGNTASLTISGLQA

STW

EDEADYYCCSYAGSSTWVFGGGTKLTV

V

L

COV107_Plate1_Lambda_5-P1409
2558
SYVLTQPPSVSVAPGKTARITCGGNNIG
2599
QV

SKNVHWYQQKPGQAPVLVIYYDSDRP

WD

SGIPERFSGSNSGNTATLTISRVEAGDE

SSW

ADYYCQVWDSSWVFGGGTKLTVL

V

COV107_Plate2_lambda_94-P1409
2562
QSVLTQPASVSGSPGQSITISCTGTSSD
2603
CSY

VGSYNLVSWYQQHPGKAPKLMIYEGS

AGS

KRPSGVSNRFSGSKSGNTASLTISGLQA

STLV

EDEADYYCCSYAGSSTLVFGGGTKLTVL

COV107_Plate1_Lambda_83-P1409
2566
SYVLTQPPSVSVSPGQTASITCSGDKLG
2607
QA

DKYACWYQQKAGQSPVLVIYQDSKRP

WD

SGIPERFSGSKSGNTATLTISGTQAMDE

SST

ADYYCQAWDSSTVVFGGGTKLTVL

VV

COV107_Plate2_lambda_40-P1409
2570
QSVLTQPPSVSGAPGQRVTISCTGSSSN
2511
QSY

IGAGYDVHWYQHLPGTAPKLLIYGNN

DSS

NRPSGVPDRFSGSRSGTSASLAITGLQA

LSA

EDEADYYCQSYDSSLSAVVFGGGTKLT

VV

VL

COV107_Plate1_Lambda_28-P1409
2574
QSVLTQPPSVSGAPGQRVTISCTGSSSN
2615
QSY

IGAGYDVHWYQQLPGTAPNLLIYDNIN

DSS

RPSGVPDRFSGSKSGTSASLAITGLQAE

LSG

DEADYYCQSYDSSLSGVVFGGGTKLTV

VV

L

COV107_Plate2_lambda_92-P1409
2578
NFMLTQPHSVSESPGKTVTISCTGSSGS
2619
QSY

IASNYVQWYQQRPGSAPTTVIYEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

KHA

EDEADYYCQSYDSSKHAVFGGGTQLTV

V

L

COV107_Plate2_lambda_55-P1409
2582
NFMLTQPHSVSESPGKTVTISCAGSSGS
2623
QSY

IASNYVQWYQQRPGSAPTTVIYEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

KSW

EDEADYYCQSYDSSKSWVFGGGTKLTV

V

L

COV107_Plate2_lambda_47-P1409
2586
QSVLTQPPSVSGAPGQRVTISCTGSSSN
2627
QSY

IGAGYDVHWYQQLPGTAPKLLIYGNSN

DSS

RPSGVPDRFSGSKSGTSASLAITGLQAE

LSG

DEADYYCQSYDSSLSGSYVFGTGTKVTV

SYV

L

COV107_Plate1_Lambda_49-P1409
2590
SYVLTQPPSVSVAPGKTARITCGGNNIG
2631
QV

SKSVHWYQQKPGQAPVLVISYDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDAA

GSS

DYYCQVWDGSSDHHVVFGGGTKLTVL

DHH

VV

COV107_Plate2_lambda_22-P1409
2594
QSVLTQPPSVSAAPGQRVTISCSGSSSN
2635
GT

IGNNYVSWYQQLPGTAPKLLIYENNKR

WD

PSGIPDRFSGSKSGTSATLGITGLQTGD

SSLS

EADYYCGTWDSSLSAFVFGTGTKVTVL

AFV

COV107_Plate2_lambda_91-P1409
2598
QSALTQPASVSGSPGQSITISCTGTSSD
2639
SSYT

VGGYNYVSWYQQHPGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLQA

LGV

EDEADYYCSSYTSSSTLGVFGTGTKVTV

L

COV107_Plate2_lambda_35-P1409
2602
SYVLTQPPSVSVAPGKTARITCGGNNIG
2643
QV

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDHPVVFGGGTKLTVL

DHP

VV

COV107_Plate2_lambda_24-P1409
2606
NFMLTQPHSVSESPGKTVTISCTGSSGS
2647
QSY

IASNYVQWYQQRPGSAPTTVIYEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

NQ

EDEADYYCQSYDSSNQWVVFGGGTKL

WV

TVL

V

COV107_Plate2_lambda_34-P1409
2610
QSVLTQPASVSGSPGQSITISCPGTSSD
2651
SSYT

VGGYNYVSWYQQHPGKAPKLMIYDVS

SSS

TRPSGVSNRFSGSKSGNTASLTISGLQA

VV

EDEADYYCSSYTSSSVVFGGGTKLTVL

COV107_Plate1_Lambda_41-P1409
2614
SYVLTQPPSVSVAPGKTARITCGGNNIG
2655
QV

SKSVHWYQQKPGQAPVLVIYYDSDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

SSR

DYYCQVWDSSRVFGGGTKLTVL

V

COV107_Plate2_lambda_46-P1409
2618
QSVLTQPPSASGSPGQSVTISCTGTSSD
2659
SSY

VGGYNYVSWYQQHPGKAPKLMIYEVT

AGS

KRPSGVPDRFSGSKSGNTASLTVSGLQ

NNY

AEDEADYYCSSYAGSNNYVVFGGGTKL

VV

TVL

COV107_Plate1_Lambda_32-P1409
2622
NFMLTQPHSVSESPGKTVTISCTGSSGS
2663
QSY

IASNYVQWYQQRPGSAPTTVIYEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLAISGLKT

NHV

EDEADYYCQSYDSSNHVVFGGGTKLTV

V

L

COV107_Plate2_lambda_25-P1409
2626
SYVLTQPPSVSVAPGKTARITCGGNNIG
2667
QV

SKSVHWYQQKPGQAPVLVIYYDSVRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

SSS

DYYCQVWDSSSDHYVFGTGTKVTVL

DHY

V

COV107_Plate2_lambda_54-P1409
2630
QSVLTQPPSVSGAPGQRVTISCTGSSSN
2671
QSY

IGAGYDVHWYQQLPGTAPKLLIYGNSD

DSS

RPSGVPDRFSGSKSGTSASLAITGLQAE

LSG

DEADYYCQSYDSSLSGVVFGGGTKLTXL

VV

COV107_Plate2_lambda_20-P1409
2634
QSVLTQPASVSGSPGQSITISCTGTSSD
2675
CSY

VGSYNLVSWYQQHPGKAPKLMIYEGS

AGS

KRPSGVSNRFSGSKSGNTASLTISGLQA

STW

EDEADYYCCSYAGSSTWVFGGGTKLTV

V

L

COV107_Plate1_Lambda_25-P1409
2638
QSALTQPASVSGSPGQSITISCTGTSSD
2679
SSYT

VGGYNYVSWYQQHPGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLOA

YV

EDEADYYCSSYTSSSTYVFGTGTKVTVL

COV107_Plate1_Lambda_64-P1409
2642
QSVLTQPASVSGSPGQSITISCTGTSSD
2683
SSYT

VGGYNYVSWYQQHPGEAPKLMIHDV

SSST

SNRPSGVSNRFSGSKSGNTASLTISGLQ

LV

AEDEADYYCSSYTSSSTLVFGGGTKLTV

L

COV107_Plate2_lambda_28-P1409
2646
NFMLTQPHSVSESPGKTVTISCTGSSGS
2687
QSY

IASNYVQWYQQRPGSAPTTVINEDNQ

DSS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

NLV

EDEADYYCQSYDSSNLVFGGGTKLTVL

COV107_Plate2_lambda_58-P1409
2650
QSVLTQPASVSGSPGQSITISCTGTSSD
2691
CSY

VGSYNLVSWYQEHPGKAPKLMIYEGSK

AGS

RPSGVSNRFSGSKSGNTASLTISGLOAE

STW

DEADYYCCSYAGSSTWVFGGGTKLTVL

V

COV107_Plate2_lambda_2-P1409
2654
NFMLTQPHSVSESPGKTVTISCTGSSGS
2695
QSY

IASNYVQWYQQRPGSAPTTVIYEDNQ

DTS

RPSGVPDRFSGSIDSSSNSASLTISGLKT

NW

EDEADYYCQSYDTSNWVFGGGTKLTV

V

L

COV107_Plate2_lambda_10-P1409
2658
SYVLTQPPSVSVAPGKTARITCGGNNIG
2699
QV

SKSVHWYQQKPGQAPVLVIYYDTDRPS

WD

GIPERFSGSNSGNTATLTISRVEAGDEA

NNS

DYYCQVWDNNSDHRGVFGGGTRLTV

DHR

L

GV

COV107_Plate1_Lambda_48-P1409
2662
QSALTQPASVSGSPGQSITISCTGTSSD
2703
SSYT

VGGYNYVSWYQQHPGKAPKLMIYDVS

SSST

NRPSGVSNRFSGSKSGNTASLTISGLOA

VW

EDEADYYCSSYTSSSTVWVFGGGTKLT

V

VL

COV107_Plate2_lambda_87P1409-
2666
QSVLTQPPSASGTPGQRVTIACSGSSSN
2707
AA

IGSSPVKWYKQLPGTGPKLLIYSSNQRP

WD

SGVPDRFSGSKSGTSASLAISGLQSEDE

DSL

ADYYCAAWDDSLSGYVFGTGTKVTVL

SGY

V

COV107_Plate2_lambda_1-P1409
2670
QSVLTQPPSASGTPGQRVTISCSGSSSN
2711
AA

IGSNTVNWYQQLPGTAPQLLIYNNYQR

WD

PSGVPDRFSGSKSGTSASLAISGLQSED

DSL

EADYYCAAWDDSLNGPVVFGGGTKLT

NGP

VL

VV

COV107_Plate1_Lambda_92-P1409
2674
QSALTQPASVSGSPGQSITISCTGTSSD
2715
CLY

VGSYNLVSWYQQHPGKAPKLMIYEGS

AFS

KRPSGVSNRFSGSKSGNTASLTISGLQA

SIV

EDEADYYCCLYAFSSIVFGGGTKLTVL

COV107_Plate1_Lambda_26-P1409
2678
QSVLTQPPSASGTPGQRVTISCSGSSSN
2719
AA

IGSNTVNWYQQLPGTAPKLLIYNNNQR

WD

PSGVPDRFSGSKSGTSASLAISGLQSED

DSL

EADYYCAAWDDSLNGLVFGGGTKLTV

NGL

L

V

KAPPA

COV107_Plate2_kappa_18-P1389
2682
EIVLTQSPGTLSLSPGERATLSCRASQSV
2723
QQY

SSSYLAWYQQKPGQAPRLLIYGASSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

LT

VYYCQQYGSSLTFGQGTRLEIK

COV107_Plate1_Kappa_21-P1389
2686
DIQMTQSPSSLSASVGDRVTITCRASQS
2727
QQS

ISSYLNWYQQKPGKAPKLLIYSASSLQS

YSTL

GVPSRFSGSGSGTDFTLTISSLQPEDFAT

IT

YYCQQSYSTLITFGQGTRLEIK

COV107_Plate1_Kappa_24-P1389
2690
EIVMTQSPATLSVSPGERATLSCRASQS
2731
QQY

VSSNLAWYQQKPGQAPTLLIYGASTRA

NN

TGIPARFSGSGSGTEFTLTISSLQSEDFA

WPP

VYYCQQYNNWPPITFGQGTRLEIK

IT

COV107_Plate2_kappa_17-P1389
2694
EIVLTQSPGTLSLSPGERATLSCRASQSV
2735
QQY

SSSYLAWYQQKPGQAPRLLIYGASSRA

GRS

TGIPDRFSGSGSGTDFTLTISRLEREDFA

PTW

VYYCQQYGRSPTWTFGQGTKVEIK

T

COV107_Plate1_Kappa_78-P1389
2698
DIVMTQSPDSLAVSXGERATINCKSSQS
2739
QQY

VLYSSNNKNYLAWYQQKPGQPPKLLIY

YST

WASTRESGVPDRFSGSGSGTDFTLTISS

PLT

LQAEDVAVYYCQQYYSTPLTFGGGTKV

EIK

COV107_Plate1_Kappa_95-P1389
2702
DIQLTQSPSFLSASVGDRVTITCRASQGI
2743
QQL

SSYLAWFQQKPGKAPKLLIYAASTLQTG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PIT

YCQQLNSYPITFGQGTRLEIK

COV107_Plate2_kappa_38-P1389
2706
DIQMTQSPSSLSASVGDRVTITCRASQS
2747
QQS

ISRYLNWYQQKPGKAPKLLIYAASSLQS

YST

GVPSRFSGSGSGTDFTLTISGLQPEDFA

PQY

TYYCQQSYSTPQYTFGQGTKLEIK

T

COV107_Plate2_kappa_61-P1389
2710
DIQMTQSPSSLSASVGDRVTITCRASQS
2751
QQS

ISSYLNWYQQKPGKAPKLLIYAASSLQS

YITP

GVPSRFSGSGSGTDFTLTISSLQPEDFAT

GW

YYCQQSYITPGWTFGQGTKVEIK

T

COV107_Plate1_Kappa_80-P1389
2714
EIVLTQSPGTLSLSPGERATLSCRASQSV
2755
QQY

RSSYLAWYQQKPGQAPRLLIYGASSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

PPW

VYYCQQYGSSPPWTFGQGTKVEIK

T

COV107_Plate2_kappa_68-P1389
2718
DIQMTQSPSSLSASVGDRVTITCQASQ
2759
QQY

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PPY

ATYYCQQYDNLPPYTFGQGTKLEIK

T

COV107_Plate2_kappa_51-P1389
2722
DIQMTQSPSSLSASVGDRVTITCQASQ
2763
QQY

DISNYLNWYQQKPGKAPKLLIYDASNL

DNV

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PLT

ATYYCQQYDNVPLTFGPGTKVDIK

COV107_Plate1_Kappa_43-P1389
2726
DIQMTQSPSTLSASVGDRVTITCRASQS
2767
QQY

ISSWLAWYQQKPGKAPKLLISEASSLES

NSY

GVPSRFSGSGSGTEFTLTISSLQPDDFAT

SYT

YYCQQYNSYSYTFGQGTKLEIK

COV107_Plate2_kappa_3-P1389
2730
DIQMTQSPSTLSASVGDRVTITCRASQS
2771
QQY

ISSWLAWYQQKPGKAPKLLIYEASSLES

NSY

GVPSRFSGSGSGTEFTLTISSLQPDDFAT

ST

YYCQQYNSYSTFGPGTKVDIK

COV107_Plate2_kappa_44-P1389
2734
EIVLTQSPGTLSLSPGERATLSCRASQSV
2775
QQY

SSSYLAWYQQKPGQAPRLLIYGASSRA

GTS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

PST

VFYCQQYGTSPSTFGQGTKVESK

COV107_Plate2_kappa_76-P1389
2738
EIVMTQSPATLSVSPGERATLSCRASQS
2779
QQY

VSSNLAWYQQKPGQAPRLLIYGASTRA

NN

TGIPARFSGTGSGTEFTLTISSLQSEDFA

WPL

VYYCQQYNNWPLTFGGGTKVEIK

T

COV107_Plate1_Kappa_16-P1389
2742
DIQMTQSPSSLSASVGDRVTITCQASQ
2783
QQY

DINNYLNWYQQKPGKAPKVLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDF

PLA

ATYYCQQYDNLPLAFGGGTKVEIK

COV107_Plate1_Kappa_10-P1389
2746
DIQMTQSPSSLSASVRDRVTITCRASQS
2787
QQS

ISSYLNWYQQKPGKAPKLLIYAASSLQS

YST

GVPSRFSGSGSGTDFTLTISSLQPEDLAT

PPW

YYCQQSYSTPPWTFGQGTKVEIK

T

COV107_Plate1_Kappa_65-P1389
2750
DIQMTQSPSSLSASVGDRVTITCRASQS
2791
QQS

ISRYLNWYQQKPGKAPNLLIYAASSLQS

YSTL

GVPSRFSGSGSGTDFTLIISSLQPEDFAT

ALT

YYCQQSYSTLALTFGGGTKVEIK

COV107_Plate1_Kappa_2-P1389
2754
EIVLTQSPATLSLSPGERATLSCRASQSF
2795
QQR

SSYLAWYQQKPGQAPRLLIYDASNRAT

NN

GIPARFSGSGSGTDFTLTISSLEPEDFAV

WPP

YYCQQRNNWPPEWTFGQGTKVEIK

EWT

COV107_Plate2_kappa_64-P1389
2758
EIVLTQSPATLSLSPGERATLSCRASQSF
2799
QQR

SSYLAWYQQKPGQAPRLLIYDASNRAT

SN

GIPARFSGSGSGTDFTLTISSLEPEDFAF

WP

YYCQQRSNWPQGFTFGPGTKVDIK

QGF

T

COV107_Plate2_kappa_11-P1389
2762
DIQMTQSPSSLSASVGDRVTITCRASQS
2803
QQS

ISSYLNWYQQKPGKAPKLLIYAASSLHS

YSA

GVPSRFSGSGSGTDFTLTISSLQPEDFAT

PWT

YYCQQSYSAPWTFGQGTKVEIK

COV107_Plate1_Kappa_44-P1389
2766
DIQMTQSPSSLSASVGDRVTITCQASQ
2807
QQY

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSGSGTDFTFTISSLQPEDI

PRV

ATYYCQQYDNLPRVTFGPGTKVDIK

T

COV107_Plate1_Kappa_88-P1389
2770
DIQLTQSPSFLSASVGDRVTITCRASQGI
2811
QQL

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PPG

YCQQLNSYPPGFGQGTKVEIK

COV107_Plate1_Kappa_18-P1389
2774
DIQLTQSPSFLSASVGDRVTITCRASQGI
2815
QQL

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PPA

YCQQLNSYPPAFGQGTRLEIK

COV107_Plate1_Kappa_59-P1389
2778
DIQMTQSPSSLSASVGDRVTITCRASQ
2819
QKY

DINNYLAWYQQKPGKVPKLLIYAASTL

NSA

QSGVPSRFSGSGSGTDFTLTISSLQPED

PLT

VATFYCQKYNSAPLTFGGGTKVEIK

COV107_Plate1_Kappa_30-P1389
2782
DIQMTQSPSTLSASVGDRVTITCRASQS
2823
QQY

ISSWLAWYQQKPGKAPKLLIYKASSLES

NSY

GVPSRFSGSGSGTEFTLTISSLQPDDFAT

GT

YYCQQYNSYGTFGQGTKVEIK

COV107_Plate1_Kappa_15-P1389
2786
DIQLTQSPSFLSASVGDRVTITCRASQGI
2827
QQL

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSD

VPSRFSGSGSGTEFTLTISSLQPEDFATY

SYT

YCQQLNSDSYTFGQGTKLEIK

COV107_Plate2_kappa_23-P1389
2790
DIQLTQSPSFLSASVGDRVTITCRASQGI
2831
QQL

SSYLAWYQQKPGKAPKLLIYAASTLQSG

DSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PPG

YCQQLDSYPPGTFGPGTKVDIK

T

COV107_Plate1_Kappa_82-P1389
2794
EIVMTQSPATLSVSPGERATLSCRASQS
2835
QQY

VSSNLAWYQQKPGQAPRLLIYGASTRA

YN

TGIPARFSGSGSGTEFTLTISSLQSEDFA

WP

VYYCQQYYNWPRTFGQGTKVEIK

RT

COV107_Plate2_kappa_95-P1389
2798
EIVLTQSPGTLSLSPGERATLSCRASQSV
2839
QQY

SSSYLAWYQQKPGQAPRLLIYGASSRA

GSS

TGIPDRFSGSGSGTDFTLTISRLEPEDFA

PRT

VYYCQQYGSSPRTFGQGTRLEIK

COV107_Plate1_Kappa_86-P1389
2802
AIQMTQSPSSLSASVGDRVTITCRASQ
2843
LQD

GIRNDLGWYQQKPGKAPKLLIYAASSL

YNY

QSGVPSRFSGSGSGTDFTLTISSLQPED

PKT

FATYYCLQDYNYPKTFGQGTKVEIK

COV107_Plate2_kappa_78-P1389
2806
DIQLTQSPSFLSASVGDRVTITCRASQGI
2847
QLL

SSYLAWYQQKPGKAPKLLIYAASTLQSG

NSY

VPSRFSGSGSGTEFTLTISSLQPEDFATY

PYT

YCQLLNSYPYTFGQGTKLEIK

COV107_Plate2_kappa_9-P1389
2810
DIQMTQSPSSLSASVGDRVTITCRASQS
2851
QQS

ISSYLYWYQQKPGKAPKLLIYAASSLQS

YST

GVPSRFSGSGSGTDFTLTISSLQPEDFAT

PPF

YYCQQSYSTPPFTFGPGTKVDIK

T

COV107_Plate2_kappa_50-P1389
2814
EIVLTQSPATLSLSPGERATLSCRASQSV
2855
QQR

SSYLAWYQQKPGQAPRLLIYDASNRAT

SN

GIPARFSGGGSGTDFTLTISSLEPEDFAV

WPP

YYCQQRSNWPPLTFGQGTKVEIK

LT

COV107_Plate1_Kappa_74-P1389
2818
EIVMTQSPATLSVSPGERATLSCRASQS
2859
QQY

VSSNLAWYQQKPGQAPRLLIYGASTRA

NN

TGIPARFSGSGSGTEFTLTISSLQSEDFA

WLS

VYYCQQYNNWLSLTFGGGTKVEIK

LT

COV107_Plate1_Kappa_93-P1389
2822
DIVMTQSPLSLPVTPGEPASISCRSSESL
2863
MQ

LHSNGYNYLDWYLQKPGQSPQLLIYLG

ALQ

SNRASGVPDRFSGSGSGTDFTLKISRVE

TPR

AEDVGVYYCMQALQTPRTFGQGTKLEI

T

K

COV107_Plate1_Kappa_45-P1389
2826
DIQMTQSPSSLSASVGDRVTITCQASQ
2867
QQY

DISNYLNWYQQKPGKAPKLLIYDASNL

DNL

ETGVPSRFSGSKSGTDFTFTISSLQPEDI

PYT

ATYYCQQYDNLPYTFGQGTKVEI

COV107_Plate1_Kappa_39-P1389
2830
DIQMTQSPSSLSASVGDRVTITCQASQ
2871
QQY

DISNYLNWYQQKPGKAPKLLIYDASYLE

DNV

TGVPSRFTGSASGTDFTFTISSLQPEDIA

PL

TYYCQQYDNVPLFGPGTKVDI

COV107_Plate1_Kappa_37-P1389
2834
DVVMTQSPLSLPVTLGQPASISCRSSQS
2875
MQ

LVYSDGNTYLNWFQQRPGQSPRRLIYQ

GTH

VSNRDSGVPDRFSGSGSGTDFTLKISRV

WL

EAEDVGVYYCMQGTHWLWTFGQGTK

WT

VEIK

TABLE 14

Additional representative sequences of the example antibodies as disclosed

SEQ

ID
Anti-

NO
body
Sequence
Notes

2876
C135
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNS
VH

KNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS

2877

QVQLVESGGG VVQPGRSLRL SCAASGFTFS
HFW1

2878

SYAMH
HCDR1

2879

WVRQAPGKGL EWVA
HFW2

2880

VIPFDGRNKY YADSVTG
HCDR2

2881

RFTISRDNSK NTLYLQMNSL RAEDTAVYYC AS
HFW3

2882

SSGYLFHSDY
HCDR3

2883

WGQGTLVTVS S
HFW4

2884

TVSS
VH end

2885

ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT
IGHC

VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP

EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA

LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV

LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHSHYT QKSLSLSPG

2886

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNS
HC

KNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
(contain-

EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC
ing M428L

PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL
and N434S

TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWES
(LS;

NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPG
high-

lighted

in bold)

according

to EU

numbering)

2887

MRAWIFFLLCLAGRALAQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRN
HC (with

KYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSSASTKGPSVFPLAPSSK
N-terminal

STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV
Signal

DKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
sequence)

TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLT
(contain-

CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSL
ing M428L

SPG
and N434S

(LS;

high-

lighted

in bold)

according

to EU

numbering)

2888

DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQ
VL

PDDFATYYCQQYNSYPWTFGQGTKVEIK

2889

DIQMTQSPST LSASVGDRVT ITC
LFWI

2890

RASQSISNWL A
LCDRI

2891

WFQQKPGKAP KLLIY
LFW2

2892

EASSLES
LCDR2

2893

GVPSRFSGSG SGTEFTLTIS SLQPDDFATY YC
LFW3

2894

QQYNSYPWT
LCDR3

2895

FGQGTKVEIK
LFW4

2896

KVEIK
VL end

2897

RTVAAPSVFI FPPSDEQLKS GTASVVCLLN NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSS
IGLC

TLTLSKADYE KHKVYACEVT HQGLSSPVTK SFNRGEC

2898

DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQ
LC

PDDFATYYCQQYNSYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS

GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

2899

MRAWIFFLLCLAGRALADIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSR
LC (with

FSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY
N-terminal

PREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Signal

sequence)

2900
C144'
EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYIVISWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNT
VH

LYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS

2901

EVQLVESGGG LIQPGGSLRL SCAASGFTVS
HFWI

2902

NNYMS
HCDRI

2903

WVRQAPGKGL EWVS
HFW2

2904

VIYSGGSTYY ADSVKG
HCDR2

2905

RFTISRDKSK NTLYLQMNSL RAEDTAVYYC AR
HFW3

2906

EGEVEGYNDF WSGYSRDRYY FDY
HCDR3

2907

WGQGTLVTVS S
HFW4

2908

TVSS
VH end

2909

ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT
IGHC

VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP

EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA

LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV

LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHSHYT QKSLSLSPG

2910

EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYIVISWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNT
HC

LYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT
(contain-

AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP
ing M428L

KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
and N434S

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
(LS;

YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPG
high-

lighted

in bold)

according

to EU

numbering)

2911

MRAWIFFLLCLAGRALAEVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYIVISWVRQAPGKGLEWVSVIYSGGSTYY
HC (with

ADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSSASTK
N-terminal

GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC
Signal

NVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
sequence)

YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ.DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
(contain-

REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHE
ing M428L

ALHSHYTQKSLSLSPG
and N434S

(LS;

high-

lighted

in bold)

according

to EU

numbering)

2912

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTIS
VL

GLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL

2913

QSALTQPASV SGSPGQSITI SC
LFW1

2914

TGTSSDVGGY NYVS
LCDRI

2915

WYQQHPGKAP KLMIY
LFW2

2916

DVSNRPS
LCDR2

2917

GVSNRFSGSK SGNTASLTIS GLQ.AEDEADY YC
LFW3

2918

SSYTSSSTRV
LCDR3

2919

FGTGTKVTVL
LFW4

2920

GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV AWKADSSPVK AGVETTTPSK QSNNKYAASS
IGLC

YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTECS

2921

QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTIS
LC

GLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADS

SPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

2922

MRAWIFFLLCLAGRALAQSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGV
LC (with

SNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVC
N-terminal

LISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
Signal

sequence)

2923
C135
ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGAGAGCGCTCGCACAGGTGCAGCTGGTGGAGTCTG
HC (with

GGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTAT
N-terminal

GCTATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATACCATTTGATGGAAGA
Signal

AATAAGTACTACGCAGACTCCGTGACGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCT
sequence)

GCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGTAGTAGTGGTTATC1111CCACT

CTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTG

GCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACC

GGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAG

GACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTG

AATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCC

CACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCA

TGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAA

CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTA

CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC

AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGT

ACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTAT

CCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTG

CTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACG

TCTTCTCATGCTCCGTGCTGCATGAGGCTCTGCACAGCCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTT

GA

2924
C135
ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGCGCGCCTTGGCCGACATCCAGATGACCCAGTCTCCT
LC (with

TCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAACTGGTT
N-terminal

GGCCTGGTTTCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGAGGCGTCTAGTTTAGAAAGTGGG
Signal

GTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGA
sequence)

TTTTGCAACTTATTACTGCCAACAGTATAATAGTTATCCGTGGACGTTCGGCCAAGGGACCAAGGTGGAGATCA

AACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTG

TTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCG

GGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGC

TGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGT

CACAAAGAGCTTCAACAGGGGAGAGTGTTAG

2925
C144'
ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGAGAGCGCTCGCAGAGGTGCAGCTGGTGGAGTCTG
HC (with

GAGGAGGCTTGATCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAACAAC
N-terminal

TACATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATAGCGGTGGTAGCA
Signal

CATACTACGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAAATCCAAGAACACGCTGTATCTTCAA
sequence)

ATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTATTGTGCGAGAGAAGGGGAGGTAGAAGGGTATAAC

GATTTTTGGAGTGGTTATTCTAGAGACCGTTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCC

TCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGC

CCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGC

GGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC

AGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAG

TTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCA

GTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTG

GACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAG

ACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT

GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC

CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAA

CCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG

CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCT

CACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGCTGCATGAGGCTCTGCACAGC

CACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTTGA

2926
C144'
ATGAGGGCTTGGATCTTCTTTCTGCTCTGCCTGGCCGGGCGCGCCTTGGCCCAGTCTGCCCTGACTCAGCCTGCC
LC (with

TCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAA
N-terminal

CTATGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAATCGGCCCTC
Signal

AGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGA
sequence)

GGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGCAGCACCCGAGTCTTCGGAACTGGGACCAAGGTC

ACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTTACCCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAAC

AAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCA

GCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTA

TCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACC

GTGGAGAAGACAGTGGCCCCTACAGAATGTTCATAG

CDR sequences are identified based on the IMGT Kabat method.

TABLE 15

Additional sequence information for the disclosed anti-SARS-CoV-2 antibodies

HEAVY CHAIN
LIGHT CHAIN

sequence

miniprep
original nt
ID
miniprep
original nt
sequence ID

ALICE
AbsID
sequence
sequence
(plate/well)
sequence
sequence
(plate/well)

COV21_P2
A-C003
TACACATACGATTTAGGTG
GAGGTGCTCTTGGAGGAGG
COV21_P2
TACACATACGATTTAGGT
CGATTGGAGGGCGTTATCCA
COV21_P2

A10

ACACTATAGAATAACATCC
GTGCCAGGGGGAAGACCGA
A10
GACACTATAGAATAACA
CCTTCCACTGTACTTTGGCC
A10

ACTTTGCCTTTCTCTCCACA
TGGGCCCTTGGTGGAGGCT

TCCACTTTGCCTTTCTCT
TCTCTGGGATAGAAGTTATT

GGTGTCCACTCCCAGGTCC
GAGGAGACGGTGACCAGGG

CCACAGGTGTCCACTCCC
CAGCAGGCACACAACAGAG

AACTGCACCTCGGTTCTATC
TTCCCTGGCCCCAGTAGTCA

AGGTCCAACTGCACCTC
GCAGTTCCAGATTTCAACTG

GATTGAATTCCACCATGGG
AAGTAGAAGTCACCGTAAT

GGTTCTATCGATTGAATT
CTCATCAGATGGCGGGAAG

ATGGTCATGTATCATCCTTT
CCCTCGCACAGTAATACAC

CCACCATGGGATGGTCA
ATGAAGACAGATGGTGCAG

TTCTAGTAGCAACTGCAAC
GGCCGTGTCCCCGGCTCTC

TGTATCATCCTTTTTCTA
CCACAGTTCGTTTGATCTCC

CGGTGTACATTCTGAGGTG
AGGCTGTTCATTTGAAGAT

GTAGCAACTGCAACCGG
AGCTTGGTCCCCTGGCCAAA

CAGCTGGTGGAGTCTGGAG
ACAGCGTGTTCTTGGAATT

TGTACATTCAGAAATTGT
AGTCCTAGGTGAGCTACCAT

GAGGCTTGATCCAGCCTGG
GTCTCTGGAGATGGTGAAT

GTTGACGCAGTCTCCAG
ACTGCTGACAGTAATACACT

GGGGTCCCTGAGACTCTCC
CGGCCCTTCACGGAGTCTG

GCACCCTGTCTTTGTCTC
GCAAAATCTTCAGGCTCCAG

TGTGCAGCCTCTGGGTTCAC
CGTAGTATGTGCTACCACC

CAGGGGAAAGAGCCACC
TCTGCTGATGGTGAGAGTGA

CGTCAGTAGCAACTACATG
GCTATAAATAACTGAGACC

CTCTCCTGCAGGGCCAGT
AGTCTGTCCCAGACCCACTG

AGCTGGGTCCGCCAGGCTC
CACTCCAGCCCCTTCCCTGG

CAGAGTGTTAGCAGCAC
CCACTGAACCTGTCTGGGAT

CAGGGAAGGGGCTGGAGTG
AGCCTGGCGGACCCAGCTC

CTACTTAGCCTGGTACCA
GCCAGTGGCCCTGCTGGATG

GGTCTCAGTTATTTATAGCG
ATGTAGTTGCTACTGACGG

GCAGAAACCTGGCCAGG
CACCATAGATGAGGAGCCT

GTGGTAGCACATACTACGC
TGAACCCAGAGGCTGCACA

CTCCCAGGCTCCTCATCT
GGGAGCCTGGCCAGGTTTCT

AGACTCCGTGAAGGGCCGA
GGAGAGTCTCAGGGACCCC

ATGGTGCATCCAGCAGG
GCTGGTACCAGGCTAAGTA

TTCACCATCTCCAGAGACA
CCAGGCTGGATCAAGCCTC

GCCACTGGCATCCCAGA
GGTGCTGCTAACACTCTGAC

ATTCCAAGAACACGCTGTA
CTCCAGACTCCACCAGNCT

CAGGTTCAGTGGCAGTG
TGGCCCTGCAGGAGAGGGT

TCTTCAAATGAACAGCCTG
GCAC (SEQ ID NO:

GGTCTGGGACAGACTTC
GGCTCTTTCCCCTGGAGACA

AGAGCCGGGGACACGGCCG
3243)

ACTCTCACCATCAGCAG
AAGACAGGGAGACTGGA

TGTATTACTGTGCGAGGGA

ACTGGAGCCTGAAGATT
(SEQ ID NO: 3245)

TTACGGTGACTTCTACTTTG

TTGCAGTGTATTACTGTC

ACTACTGGGGCCAGGGAAC

AGCAGTATGGTAGCTCA

CCTGGTCACCGTCTCCTCAG

CCTAGGACTTTTGGCCAG

CGTCGACCAAGGGCCCATC

GGGACCAAGCTGGAGAT

GGTCTTCCCCCTGGCACCCT

CAAACGTACGGTGGCTG

CCTCCAAGAGCACCTCTGG

CACCATCTGTCTTCATCT

GGGCACAGCGGCCCTGGGC

TCCCGCCATCTGATGAGC

TGCCTGGTCAAGGACTACT

AGTTGAAATCTGGAACT

TCCCCGAACCTGTGACGGT

GCCTCTGTTGTGTGCCTG

CTCGTGGAACTCAGGCGCC

CTGAATAACTTCTATCCC

CTGACCAGCGGCGTGCACA

AGAGAGGCCAAAGTACA

CCTTCCCGGCTGTCCTACAG

GTGGAAGGTGGATAACG

TCCTCANGACTCTACTCCCT

CCCTCCAATCGGGTAACT

CAGCAGCGTGGTGACCGTG

CCCAGGAGAGTGTCACA

CCCTCCAGCAGCTTGGGCA

GAGCAGGACAGCAAGGA

CCCAGACCTACATCTGCAA

CAGCACCTACAGCCTCA

CGTGAATCACAAGCCCAGC

GCAGCACCCTGACGCTG

AACACCNANGTGGACAAGA

AGCAAAGCAGACTACGA

GAGTTGAGCCCAAATCTTG

GAAACACAAAGTCTACG

TGACAAAACTCACACATGC

CCTGCGAAGTCACCCAT

CCACCGTGCCCAGCACCTG

C (SEQ ID NO:

AACT (SEQ ID NO:

3244)

3242)

COV21_P1
A-C007
TACACATACGATTTAGGTG
NGAGGTGCTCTTGGAGGAG
COV21_P1
TACACATACGATTTAGGT
CGATTGGAGGGCGTTATCCA
COV21_P1

G2

ACACTATAGAATAACATCC
GGTGCCAGGGGGAAGACCG
G2
GACACTATAGAATAACA
CCTTCCACTGTACTTTGGCC
G2

ACTTTGCCTTTCTCTCCACA
ATGGGCCCTTGGTGGAGGC

TCCACTTTGCCTTTCTCT
TCTCTGGGATAGAAGTTATT

GGTGTCCACTCCCAGGTCC
TGAGGAGACGGTGACCAGG

CCACAGGTGTCCACTCCC
CAGCAGGCACACAACAGAG

AACTGCACCTCGGTTCTATC
GTTCCCTGGCCCCAGTAGTC

AGGTCCAACTGCACCTC
GCAGTTCCAGATTTCAACTG

GATTGAATTCCACCATGGG
AACAGTGTACGAATAACCA

GGTTCTATCGATTGAATT
CTCATCAGATGGCGGGAAG

ATGGTCATGTATCATCCTTT
GAATCATCATAGTGAGGGC

CCACCATGGGATGGTCA
ATGAAGACAGATGGTGCAG

TTCTAGTAGCAACTGCAAC
CTGTGGTACAGTAATACAC

TGTATCATCCTTTTTCTA
CCACAGTTCGTTTGATCTCC

CGGTGTACATTCTGAGGTG
GGCTGTGTCCTCGGTTTTCA

GTAGCAACTGCAACCGG
ACCTTGGTCCCTCCGCCGAA

CAGCTGGTGGAGTCTGGGG
GGCTGTTCATTTGCAGATAC

TGTACATGGGGATATTGT
AGTGAGGGGAGTTTGTAGA

GAGGCTTGGTAAAGCCTGG
AGCGTGTTTTTTGAATCATC

GATGACTCAGTCTCCACT
GCTTGCATGCAGTAATAAAC

GGGGTCCCTTAGACTCTCCT
TCTTGAGATGGTGAATCTG

CTCCCTGCCCGTCACCCC
CCCAACATCCTCAGCCTCCA

GTGCAGCCTCTGGATTCACT
CCTTGCACGGGTGCAGCGT

TGGAGAGCCGGCCTCCA
CTCTGCTGATTTTCAATGTA

TTCAGTAACGCCTGGATGA
AGTCTATTGTCCCACCATCA

TCTCCTGCAGGTCTAGTC
AAATCTGTGCCTGATCCACT

ACTGGGTCCGCCAGGCTCC
GATTTGTCTTTAATACGGCC

AGAGCCTCCTGCATAGT
GCCACTGAACCTGTCAGGG

AGGGAAGGGGCTGGAGTGG
AACCCACTCCAGCCCCTTCC

AATGGATTCCACTTTTTG
ACCCCGGAGGCCCGATTAG

GTTGGCCGTATTAAAGACA
CTGGAGCCTGGCGGACCCA

GATTGGTACCTGCAGAA
AACCCACATAGATCAGGAG

AATCTGATGGTGGGACAAT
GTTCATCCAGGCGTTACTG

GCCAGGGCAGACTCCAC
CTGTGGAGTCTGCCCTGGCT

AGACTACGCTGCACCCGTG
AAAGTGAATCCAGAGGCTG

AGCTCCTGATCTATGTGG
TCTGCAGGTACCAATCCAAA

CAAGGCAGATTCACCATCT
CACAGGAGAGTCTAAGGGA

GTTCTAATCGGGCCTCCG
AAGTGGAATCCATTACTATG

CAAGAGATGATTCAAAAAA
CCCCCCAGGCTTTACCAAG

GGGTCCCTGACAGGTTC
CAGGAGGCTCTGACTAGAC

CACGCTGTATCTGCAAATG
CCTCCCCCAGACTCCACCA

AGTGGCAGTGGATCAGG
CTGCAGGAGATGGAGGCCG

AACAGCCTGAAAACCGAGG
GCTGCACNT (SEQ ID

CACAGATTTTACATTGAA
GCTCTCCAGGGGTGACGGG

ACACAGCCGTGTATTACTG
NO: 3247)

AATCAGCAGAGTGGAGG
CAGGGAGANTGGA (SEQ

TACCACAGGCCCTCACTAT

CTGAGGATGTTGGGGTTT
ID NO: 3249)

GATGATTCTGGTTATTCGTA

ATTACTGCATGCAAGCTC

CACTGTTGACTACTGGGGC

TACAAACTCCCCTCACTT

CAGGGAACCCTGGTCACCG

TCGGCGGAGGGACCAAG

TCTCCTCAGCGGTCGACCA

GTGGAGATCAAACGTAC

AGGGCCCATCGGTCTTCCC

GGTGGCTGCACCATCTGT

CCTGGCACCCTCCTCCAAG

CTTCATCTTCCCGCCATC

AGCACCTCTGGGGGCACAG

TGATGAGCAGTTGAAAT

CGGCCCTGGGCTGCCTGGT

CTGGAACTGCCTCTGTTG

CAAGGACTACTTCCCCGAA

TGTGCCTGCTGAATAACT

CCTGTGACGGTCTCGTGGA

TCTATCCCAGAGAGGCC

ACTCANGCGCCCTGACCAG

AAAGTACAGTGGAAGGT

CGGCGTGCACACCTTCCCG

GGATAACGCCCTCCAAT

GCTGTCCTACAGTCCTCAN

CGGGTAACTCCCAGGAG

GACTCTACTCCCTCAGCAG

AGTGTCACAGAGCAGGA

CGTGGTGACCGTGCCCTCC

CAGCAAGGACAGCACCT

AGCAGCTTGGGCACCCAGA

ACAGCCTCAGCAGCACC

CCTACATCTGCAACGTGAA

CTGACGCTGAGCAAAGC

TCACAAGCCCAGCAACACC

AGACTACGAGAAACACA

AA (SEQ ID NO:

AAGTCTACGCCTGCGAA

3246)

GTCACCCAT (SEQ ID

NO: 3248)

COV21_P1
A-C008
TACACATACGATTTAGGTG
CGCTGTGCCCCNGAGGTGC
COV21_P1
TACACATACGATTTAGGT
TGGGANTACCCGATTGGAG
COV21_P1

H9

ACACTATAGAATAACATCC
TCTTGGAGGAGGGTGCCAG
H9
GACACTATAGAATAACA
GGCGTTATCCACCTTCCACT
H9

ACTTTGCCTTTCTCTCCACA
GGGGAAGACCGATGGGCCC

TCCACTTTGCCTTTCTCT
GTACTTTGGCCTCTCTGGGA

GGTGTCCACTCCCAGGTCC
TTGGTGGAGGCTGAGGAGA

CCACAGGTGTCCACTCCC
TAGAAGTTATTCAGCAGGCA

AACTGCACCTCGGTTCTATC
CGGTGACCAGGGTTCCCTG

AGGTCCAACTGCACCTC
CACAACAGAGGCAGTTCCA

GATTGAATTCCACCATGGG
GCCCCAGTAGTCAAAGTAC

GGTTCTATCGATTGAATT
GATTTCAACTGCTCATCAGA

ATGGTCATGTATCATCCTTT
CACTCGGGGTCACCGAATT

CCACCATGGGATGGTCA
TGGCGGGAAGATGAAGACA

TTCTAGTAGCAACTGCAAC
CTCTCGCACAGTAATACAC

TGTATCATCCTTTTTCTA
GATGGTGCAGCCACAGTTCG

CGGTGTACATTCTGAGGTG
AGCCGTGTCCTCAGCTCTCA

GTAGCAACTGCAACCGG
TTTGATTTCCACCTTGGTCC

CAGCTGGTGGAGTCTGGGG
GGCTGTTCATTTGCAGATAC

TGTACATTCTGACATCCA
CTTGGCCGAACGTCCAATAA

GAGGCGTGGTCCAGCCTGG
AGCGTGTTCTTGGAGTTGTC

GATGACCCAGTCTCCTTC
CTATTATACTGTTGGCAGTA

GAGGTCCCTGAGACTCTCC
TCTGGAGATGGTGAATCGG

CACCCTGTCTGCATCTGT
ATAAGTTGCAAAATCATCAG

TGTGCAGCCTCTGGATTCAC
CCCTTCACGGAGTCTGCAT

AGGAGACAGAGTCACCA
GCTGCAGGCTGCTGATGGTG

CTTCAGTAGCTATGGCATG
AGTATTTATTCCTTCCATCA

TCACTTGCCGGGCCAATC
AGAGTGAATTCTGTCCCAGA

CACTGGGTCCGCCAGGCTC
TATGAAATAACTGTCACCC

AGAGTATTAGTAGCTGG
TCCACTGCCGCTGAACCTTG

CAGGCAAGGGGCTGGAGTG
ACTCCAGCCCCTTGCCTGG

TTGGCCTGGTATCAGCA
ATGGGACCCCACTTTCTAAA

GGTGACAGTTATTTCATATG
AGCCTGGCGGACCCAGTGC

GAAACCAGGGAAAGCCC
CTAGACGCCTTATAGATCAG

ATGGAAGGAATAAATACTA
ATGCCATAGCTACTGAAGG

CTAAGCTCCTGATCTATA
GAGCTTAGGGGCTTTCCCTG

TGCAGACTCCGTGAAGGGC
TGAATCCAGAGGCTGCACA

AGGCGTCTAGTTTAGAA
GTTTCTGCTGATACCAGGCC

CGATTCACCATCTCCAGAG
GGAGAGTCTCAGGGACCTC

AGTGGGGTCCCATCAAG
AACCAGCTACTAATACTCTG

ACAACTCCAAGAACACGCT
CCAGGCTGGACCACGCCTC

GTTCAGCGGCAGTGGAT
ATTGGCCCGGCAAGTGATG

GTATCTGCAAATGAACAGC
CCCCAGACTCCACCAGCTG

CTGGGACAGAATTCACT
GTGACTCTGTCTCCTACAGA

CTGAGAGCTGAGGACACGG
CACCTANNANGNAAACC

CTCACCATCAGCAGCCT
TGCAGACAGGGNGANTGNA

CTGTGTATTACTGTGCGAG
(SEQ ID NO: 3251)

GCAGCCTGATGATTTTGC
NNNNGGGGTCAT (SEQ

AGAATTCGGTGACCCCGAG

AACTTATTACTGCCAACA
ID NO: 3253)

TGGTACTTTGACTACTGGG

GTATAATAGTTATTGGAC

GCCAGGGAACCCTGGTCAC

GTTCGGCCAAGGGACCA

CGTCTCCTCAGCGTCGACC

AGGTGGAAATCAAACGT

AAGGGCCCATCGGTCTTCC

ACGGTGGCTGCACCATC

CCCTGGCACCCTCCTCCAA

TGTCTTCATCTTCCCGCC

GAGCACCTCTGGGGGCACA

ATCTGATGAGCAGTTGA

GCGGCCCTGGGCTGCCTGG

AATCTGGAACTGCCTCTG

TCAAGGACTACTTCCCCGA

TTGTGTGCCTGCTGAATA

ACCTGTGACGGTCTCGTGG

ACTTCTATCCCAGAGAG

AACTCNGCGCCCTGACCAG

GCCAAAGTACAGTGGAA

CGGCGTGCACACCTTCCCG

GGTGGATAACGCCCTCC

GCTGTCCTACAGTCCTCNN

AATCGGGTAACTCCCAG

ACTCTACTCCCTCAGCAGC

GAGAGTGTCACAGAGCA

GTGGTGACCGTGCCCTCCA

GGACAGCAAGGACAGCA

GCAGCTTGGGCACCCAGAC

CCTACAGCCTCAGCAGC

CTACATCTGCAACGTGAAT

ACCCTGACGCTGANCAA

CACAAGCCCAGCAACACCA

AGCAGACTACGAGAAAC

AGNTGGANAGAGAGTTGAG

ACAAAGTCTACGCCTGC

CCCAAATCTTGTGAC

GAAGTCACCCATCNGGN

(SEQ ID NO: 3250)

CTGAGCTCGCCCGTCAC

AAAGAGCTTCAAC

(SEQ ID NO: 3252)

COV21_P1
A-C010
TACACATACGATTTAGGTG
GAGGTGCTCTTGGAGGAGG
COV21_P1
TACACATACGATTTAGGT
CGATTGGAGGGCGTTATCCA
COV21_P1

H7

ACACTATAGAATAACATCC
GTGCCAGGGGGAAGACCGA
H7
GACACTATAGAATAACA
CCTTCCACTGTACTTTGGCC
H7

ACTTTGCCTTTCTCTCCACA
TGGGCCCTTGGTGGAGGCT

TCCACTTTGCCTTTCTCT
TCTCTGGGATAGAAGTTATT

GGTGTCCACTCCCAGGTCC
GAGGAGACGGTGACCAGGG

CCACAGGTGTCCACTCCC
CAGCAGGCACACAACAGAG

AACTGCACCTCGGTTCTATC
TTCCCTGGCCCCAGTAGTCA

AGGTCCAACTGCACCTC
GCAGTTCCAGATTTCAACTG

GATTGAATTCCACCATGGG
AACCACGTAACCAGAGCTG

GGTTCTATCGATTGAATT
CTCATCAGATGGCGGGAAG

ATGGTCATGTATCATCCTTT
TATCCACGATCCCGTCTCTC

CCACCATGGGATGGTCA
ATGAAGACAGATGGTGCAG

TTCTAGTAGCAACTGCAAC
GCACAGTAATACACAGCCG

TGTATCATCCTTTTTCTA
CCACAGTTCGTTTGATTTCC

CGGTGTACATTCTGAGGTG
TGTCCTCAGCTCTCAGGCTG

GTAGCAACTGCAACCGG
ACCTTGGTCCCTTGGCCGAA

CAGCTGGTGGAGTCTGGGG
TTCATTTGCAGATACAACGT

TGTACATTCAGACATCCA
CGTCCACGGAGGGGTACTGT

GAGGCGTGGTCCAGCCTGG
GTTCTTGGAATTGTCTCTGG

GTTGACCCAGTCTCCATC
AACTCTGTTGACAGTAGTAA

GAGGTCCCTGAGACTCTCC
AGATGGTGAATCGGCCCTT

CTCCCTGTCTGCATCTGT
GTTGCAAAATCTTCAGGTTG

TGTGCAGCCTCTGGATTCAC
CACGGAGTCTGCGTAGTAT

AGGAGACAGAGTCACCA
CAGACTGCTGATGGTGAGA

CTTCAGTAGCTATGCTATGC
TTACCGCTTCCATCATATAA

TCACTTGCCGGGCAAGT
GTGAAATCTGTCCCAGATCC

ACTGGGTCCGCCAGGCTCC
TATAACTGCCACCCACTCC

CAGAGCATTAGCACCTA
ACTGCCACTGAACCTTGATG

AGCCAAGGGGCTGGAGTGG
AGCCCCTTGGCTGGAGCCT

TTTAAATTGGTATCAGCA
GGACCCCACTTTGCAAACTG

GTGGCAGTTATATTATATG
GGCGGACCCAGTGCATAGC

GAAACCAGGGAAAGCCC
GATGCAGCATAGATCAGGA

ATGGAAGCGGTAAATACTA
ATAGCTACTGAAGGTGAAT

CTAAGCTCCTGATCTATG
GCTTAGGGGCTTTCCCTGGT

CGCAGACTCCGTGAAGGGC
CCAGAGGCTGCACAGGAGA

CTGCATCCAGTTTGCAAA
TTCTGCTGATACCAATTTAA

CGATTCACCATCTCCAGAG
GTCTCAGGGACCTCCCAGG

GTGGGGTCCCATCAAGG
ATAGGTGCTAATGCTCTGAC

ACAATTCCAAGAACACGTT
CTGGACCACGCCTCCCCCA

TTCAGTGGCAGTGGATCT
TTGCCCGGCAAGTGATGGTG

GTATCTGCAAATGAACAGC
GACTCCACCAGGCTGCACC

GGGACAGATTTCACTCTC
ACTCTGTCTCCTACAGATGC

CTGAGAGCTGAGGACACGG
T (SEQ ID NO: 3255)

ACCATCAGCAGTCTGCA
AGACAGGGAG (SEQ ID

CTGTGTATTACTGTGCGAG

ACCTGAAGATTTTGCAA
NO: 3257)

AGACGGGATCGTGGATACA

CTTACTACTGTCAACAGA

GCTCTGGTTACGTGGTTTGA

GTTACAGTACCCCTCCGT

CTACTGGGGCCAGGGAACC

GGACGTTCGGCCAAGGG

CTGGTCACCGTCTCCTCAGC

ACCAAGGTGGAGATCAA

GTCGACCAAGGGCCCATCG

ACGTACGGTGGCTGCAC

GTCTTCCCCCTGGCACCCTC

CATCTGTCTTCATCTTCC

CTCCAAGAGCACCTCTGGG

CGCCATCTGATGAGCAG

GGCACAGCGGCCCTGGGCT

TTGAAATCTGGAACTGC

GCCTGGTCAAGGACTACTT

CTCTGTTGTGTGCCTGCT

CCCCGAACCTGTGACGGTC

GAATAACTTCTATCCCAG

TCGTGGAACTCNNCGCCCT

AGAGGCCAAAGTACAGT

GACCAGCGGCGTGCACACC

GGAAGGTGGATAACGCC

TTCCCGGCTGTCCTACAGTC

CTCCAATCGGGTAACTCC

CTCNNNCTCTACTCCCTCAG

CAGGAGAGTGTCACAGA

CAGCGTGGTGACCGTGCCC

GCAGGACAGCAAGGACA

TCCAGCAGCTTGGGCACCC

GCACCTACAGCCTCAGC

AGACCTACATCTGCAACGT

AGCACCCTGACGCTGAG

GAATCACAAGCCCAGCAAC

CAAAGCAGACTACGAGA

ACCAAG (SEQ ID NO:

AACACAAAGTCTACGCC

3254)

TGCGAAGTCACCCATCN

GGCCNTGAGCTCGCCCG

TCACAAAGAGCTTCAAC

AGGGGAGAGTGTTAGAA

GCTTGGCCGCCATGGCC

CAACTTGTTTATTGCAGC

TTAT (SEQ ID NO:

3256)

COV21_P2
A-C001
TACACATACGATTTAGGTG
CNCTGTGCCCCAGAGGTGC
COV21_P2
TACACATACGATTTAGGT
ATTGGAGGGCGTTATCCACC
COV21_P2

B7

ACACTATAGAATAACATCC
TCTTGGAGGAGGGTGCCAG
B7
GACACTATAGAATAACA
TTCCACTGTACTTTGGCCTC
B7

ACTTTGCCTTTCTCTCCACA
GGGGAAGACCGATGGGCCC

TCCACTTTGCCTTTCTCT
TCTGGGATAGAAGTTATTCA

GGTGTCCACTCCCAGGTCC
TTGGTGGAGGCTGAGGAGA

CCACAGGTGTCCACTCCC
GCAGGCACACAACAGAGGC

AACTGCACCTCGGTTCTATC
CGGTGACCAGGGTTCCCTG

AGGTCCAACTGCACCTC
AGTTCCAGATTTCAACTGCT

GATTGAATTCCACCATGGG
GCCCCAGTAGTCAAAGGCC

GGTTCTATCGATTGAATT
CATCAGATGGCGGGAAGAT

ATGGTCATGTATCATCCTTT
ACCACCACTACAATATCAG

CCACCATGGGATGGTCA
GAAGACAGATGGTGCAGCC

TTCTAGTAGCAACTGCAAC
ATGGTCTCCCCTCTTTCGCA

TGTATCATCCTTTTTCTA
ACAGTTCGTTTGATTTCCAC

CGGTGTACATTCTGAGGTG
CAGTAATACACAGCCGTGT

GTAGCAACTGCAACCGG
CTTGGTCCCTTGGCCGAACG

CAGCTGGTGGAGTCTGGGG
CCTCAGCTCTCAGGCTGTTC

TGTACATTCAGACATCCA
TCCGAGGGGTACTGTAACTC

GAGGCGTGGTCCAGCCTGG
ATTTGCAGATACAGCGTGT

GTTGACCCAGTCTCCATC
TGTTGACAGTAGTAAGTTGC

GAGGTCCCTGAGACTCTCC
TCTTGGAATTGTCTCTGGAG

CTCCCTGTCTGCATCTGT
AAAATCTTCAGGTTGCAGAC

TGTGCAGCCTCTGGATTCAC
ATGGTGAATCGGCCCTTCA

AGGAGACAGAGTCACCA
TGCTGATGGTGAGAGTGAA

CTTCAGTATCTATGGCATGC
CGGAGTCTGCATAGTATTT

TCACTTGCCGGGCAAGT
ATCTGTCCCAGATCCACTGC

ACTGGGTCCGCCAGGCTCC
ATTACTTCCATCATATGATA

CAGAGCATTAGCAGCTA
CACTGAACCTTGATGGGACC

AGGCAAGGGGCTGGAGTGG
TAACTGCCACCCACTCCAG

TTTAAATTGGTATCAGCA
CCACTTTGCAAACTGGATGC

GTGGCAGTTATATCATATG
CCCCTTGCCTGGAGCCTGG

GAAACCAGGGAAAGCCC
AGCATAGATCAGGAGCTTA

ATGGAAGTAATAAATACTA
CGGACCCAGTGCATGCCAT

CTAAGCTCCTGATCTATG
GGGGCTTTCCCTGGTTTCTG

TGCAGACTCCGTGAAGGGC
AGATACTGAAGGTGAATCC

CTGCATCCAGTTTGCAAA
CTGATACCAATTTAAATAGC

CGATTCACCATCTCCAGAG
AGAGGCTGCACAGGAGAGT

GTGGGGTCCCATCAAGG
TGCTAATGCTCTGACTTGCC

ACAATTCCAAGAACACGCT
CTCAGGGACCTCCCAGGCT

TTCAGTGGCAGTGGATCT
CGGCAAGTGATGGTGACTCT

GTATCTGCAAATGAACAGC
GGACCACGCCTCCCCCAGA

GGGACAGATTTCACTCTC
GTCTCCTACAGATGCAGACA

CTGAGAGCTGAGGACACGG
CTCCACCAGCTGCA (SEQ

ACCATCAGCAGTCTGCA
GGGAGANTGGAG (SEQ ID

CTGTGTATTACTGTGCGAA
ID NO: 3259)

ACCTGAAGATTTTGCAA
NO: 3261)

AGAGGGGAGACCATCTGAT

CTTACTACTGTCAACAGA

ATTGTAGTGGTGGTGGCCTT

GTTACAGTACCCCTCGG

TGACTACTGGGGCCAGGGA

ACGTTCGGCCAAGGGAC

ACCCTGGTCACCGTCTCCTC

CAAGGTGGAAATCAAAC

AGCGTCGACCAAGGGCCCA

GTACGGTGGCTGCACCA

TCGGTCTTCCCCCTGGCACC

TCTGTCTTCATCTTCCCG

CTCCTCCAAGAGCACCTCT

CCATCTGATGAGCAGTT

GGGGGCACAGCGGCCCTGG

GAAATCTGGAACTGCCT

GCTGCCTGGTCAAGGACTA

CTGTTGTGTGCCTGCTGA

CTTCCCCGAACCTGTGACG

ATAACTTCTATCCCAGAG

GTCTCGTGGAACTCANGCG

AGGCCAAAGTACAGTGG

CCCTGACCAGCGGCGTGCA

AAGGTGGATAACGCCCT

CACCTTCCCGGCTGTCCTAC

CCAATCGGGTAACTCCC

AGTCCTC (SEQ ID NO:

AGGAGAGTGTCACAGAG

3258)

CAGGACAGCAAGGACAG

GCACCCTGACGCTGAGC

AAAGCAGACTACGAGAA

ACACAAAGTCTACGCCT

GCGAAGTCACCCATCAG

GGCCTGAGCTCGCCCGT

CACAAAGAGCTTCAACN

GGGGAGAGTGTTAGAAG

CTTGGCCGCCATGGCCC

AACTTGTTTATTGCAGCT

TATAAT (SEQ ID NO:

3260)

COV21_P2
A-C002
TACACATACGATTTAGGTG
GCTNNGCNCCNNANGTGCT
COV21_P2
TACACATACGATTTAGGT
CNGGGANTTACCCGATTGG
COV21_P2

F6

ACACTATAGAATAACATCC
CTTGGAGGNNGGTGCCAGG
F6
GACACTATAGAATAACA
AGGGCGTTATCCACCTTCCA
F6

ACTTTGCCTTTCTCTCCACA
GGGAAGACCGATGGGCCCT

TCCACTTTGCCTTTCTCT
CTGTACTTTGGCCTCTCTGG

GGTGTCCACTCCCAGGTCC
TGGTGGAGGCTGAGGAGAC

CCACAGGTGTCCACTCCC
GATAGAAGTTATTCAGCAG

AACTGCACCTCGGTTCTATC
GGTGACCAGGGTTCCCTGG

AGGTCCAACTGCACCTC
GCACACAACAGAGGCAGTT

GATTGAATTCCACCATGGG
CCCCAGTAGTCAAAGGCCA

GGTTCTATCGATTGAATT
CCAGATTTCAACTGCTCATC

ATGGTCATGTATCATCCTTT
CCACCACTACAATATCAGA

CCACCATGGGATGGTCA
AGATGGCGGGAAGATGAAG

TTCTAGTAGCAACTGCAAC
TGGTCTCCCCTCTTTCGCAC

TGTATCATCCTTTTTCTA
ACAGATGGTGCAGCCACAG

CGGTGTACATTCTGAGGTG
AGTAATACACAGCCGTGTC

GTAGCAACTGCAACCGG
TTCGTTTGATTTCCACCTTG

CAGCTGGTGGAGTCTGGGG
CTCAGCTCTCAGGCTGTTCA

TGTACATTCAGACATCCA
GTCCCTTGGCCGAACGTCCG

GAGGCGTGGTCCAGCCTGG
TTTGCAGATACAGCGTGTTC

GTTGACCCAGTCTCCATC
AGGGGTACTGTAACTCTGTT

GAGGTCCCTGAGACTCTCC
TTGGAATTGTCTCTGGAGAT

CTCCCTGTCTGCATCTGT
GACAGTAGTAAGTTGCAAA

TGTGCAGCCTCTGGATTCAC
GGTGAATCGGCCCTTCACG

AGGAGACAGAGTCACCA
ATCTTCAGGTTGCAGACTGC

CTTCAGTATCTATGGCATGC
GAGTCTGCATAGTATTTATT

TCACTTGCCGGGCAAGT
TGATGGTGAGAGTGAAATCT

ACTGGGTCCGCCAGGCTCC
ACTTCCATCATATGATATAA

CAGAGCATTAGCAGCTA
GTCCCAGATCCACTGCCACT

AGGCAAGGGGCTGGAGTGG
CTGCCACCCACTCCAGCCC

TTTAAATTGGTATCAGCA
GAACCTTGATGGGACCCCAC

GTGGCAGTTATATCATATG
CTTGCCTGGAGCCTGGCGG

GAAACCAGGGAAAGCCC
TTTGCAAACTGGATGCAGCA

ATGGAAGTAATAAATACTA
ACCCAGTGCATGCCATAGA

CTAAGCTCCTGATCTATG
TAGATCAGGAGCTTAGGGG

TGCAGACTCCGTGAAGGGC
TACTGAAGGTGAATCCAGA

CTGCATCCAGTTTGCAAA
CTTTCCCTGGTTTCTGCTGAT

CGATTCACCATCTCCAGAG
GGCTGCACAGGAGAGTCTC

GTGGGGTCCCATCAAGG
ACCAATTTAAATAGCTGCTA

ACAATTCCAAGAACACGCT
AGGGACCTCCCAGGCTGGA

TTCAGTGGCAGTGGATCT
ATGCTCTGACTTGCCCGGCA

GTATCTGCAAATGAACAGC
CCACGCCTCCCCCAGACTC

GGGACAGATTTCACTCTC
AGTGATGGTGACTCTGTCTC

CTGAGAGCTGAGGACACGG
CACCAGCCTGCAC (SEQ

ACCATCAGCAGTCTGCA
CTACAGATGCAGACAGGGA

CTGTGTATTACTGTGCGAA
ID NO: 3263)

ACCTGAAGATTTTGCAA
GANTGGANNNTGGG (SEQ

AGAGGGGAGACCATCTGAT

CTTACTACTGTCAACAGA
ID NO: 3265)

ATTGTAGTGGTGGTGGCCTT

GTTACAGTACCCCTCGG

TGACTACTGGGGCCAGGGA

ACGTTCGGCCAAGGGAC

ACCCTGGTCACCGTCTCCTC

CAAGGTGGAAATCAAAC

AGCGTCGACCAAGGGCCCA

GTACGGTGGCTGCACCA

TCGGTCTTCCCCCTGGCACC

TCTGTCTTCATCTTCCCG

CTCCTCCAAGAGCACCTCT

CCATCTGATGAGCAGTT

GGGGGCACAGCGGCCCTGG

GAAATCTGGAACTGCCT

GCTGCCTGGTCAAGGACTA

CTGTTGTGTGCCTGCTGA

CTTCCCCGAACCTGTGACG

ATAACTTCTATCCCAGAG

GTCTCGTGGAACTCANGCG

AGGCCAAAGTACAGTGG

CCCTGACCAGCGGCGTGCA

AAGGTGGATAACGCCCT

CACCTTCCCGGCTGTCCTAC

CCAATCGGGTAACTCCC

AGTCCTCNNACTCTACTCCC

AGGAGAGTGTCACAGAG

TCAGCAGCGTGGTGACCGT

CANGACAGCAAGGACAG

GCCCTCCAGCAGCTTGGGC

CACCTACAGCCTCAGCA

ACCCAGACCTACATCTGCA

GCACCCTGACGCTGAGC

ACGTGAATCACAAGCCCAG

AAAGCAGACTACGAGAA

CAACACCNAAGGTGGACAA

ACACAAAGTCTACGCCT

GAGAGTTGAGCCCAAATCT

GCGAAGTCACCCATC

TGTGACAAACTCACACATG

(SEQ ID NO: 3264)

CCCACCGTGCCCAGCACCT

GAACTCCTGGGGGGACCGT

CAGTCTT (SEQ ID NO:

3262)

COV21_P1
A-C004
TACACATACGATTTAGGTG
GCTGTGCCCCAGAGGTGCT
COV21_P1
TACACATACGATTTAGGT
CNNGGANTTNCCCGATTGG
COV21_P1

F12

ACACTATAGAATAACATCC
CTTGGAGGANGGTGCCAGG
F12
GACACTATAGAATAACA
AGGGCGTTATCCACCTTCCA
F12

ACTTTGCCTTTCTCTCCACA
GGGAAGACCGATGGGCCCT

TCCACTTTGCCTTTCTCT
CTGTACTTTGGCCTCTCTGG

GGTGTCCACTCCCAGGTCC
TGGTGGAGGCTGAGGAGAC

CCACAGGTGTCCACTCCC
GATAGAAGTTATTCAGCAG

AACTGCACCTCGGTTCTATC
GGTGACCGTGGTCCCTTTGC

AGGTCCAACTGCACCTC
GCACACAACAGAGGCAGTT

GATTGAATTCCACCATGGG
CCCAGACGTCCATGTAGTA

GGTTCTATCGATTGAATT
CCAGATTTCAACTGCTCATC

ATGGTCATGTATCATCCTTT
GTAGTACCCATGATCGTAG

CCACCATGGGATGGTCA
AGATGGCGGGAAGATGAAG

TTCTAGTAGCAACTGCAAC
CCACTATATCCACGTGATG

TGTATCATCCTTTTTCTA
ACAGATGGTGCAGCCACAG

CGGTGTACATTCCCAGGTG
CTGGGCTCGCACAGTAATA

GTAGCAACTGCAACCGG
TTCGTTTAATCTCCAGTCGT

CAGCTGGTGCAGTCTGGGG
CACGGCCGTGTCGTCAGAT

TGTACATTGTGCCATCCG
GTCCCTTGGCCGAAGGTGAT

CTGAGGTGAAGAAGCCTGG
CTCAGCCTGCTCAGCTCCAT

GATGACCCAGTCTCCATC
AGGGAGATTATCATACTGTT

GGCCTCAGTGAAGGTCTCC
GTAGGCTGTGCTGATGGAC

CTCCCTGTCTGCATCTGT
GACAGTAATATGTTGCAATA

TGCAAGGCTTCTGGATACA
GTGTCCCTGGTCATGGTGA

AGGAGACAGAGTCACCA
TCTTCAGGCTGCAGGCTGCT

CCTTCACCGGCTACTATATG
CCCTGCCCTGAAACTTCTGT

TCACTTGCCAGGCGAGT
GATGGTGAAAGTAAAATCT

CACTGGGTGCGACAGGCCC
GCATAGTTTGTGCCACCACT

CAGGACATTAGCAACTA
GTCCCAGATCCACTTCCACT

CTGGACAAGGGCTTGAGTG
GATAGGGTTGATCCATCCC

TTTAAATTGGTATCAGCA
GAACCTTGATGGGACCCCTG

GATGGGATGGATCAACCCT
ATCCACTCAAGCCCTTGTCC

GAAACCAGGGAAAGCCC
TTTCCAAATTGGATGCATCG

ATCAGTGGTGGCACAAACT
AGGGGCCTGTCGCACCCAG

CTAAGCTCCTGATCTACG
TAGATCAGGAGCTTAGGGG

ATGCACAGAAGTTTCAGGG
TGCATATAGTAGCCGGTGA

ATGCATCCAATTTGGAA
CTTTCCCTGGTTTCTGCTGAT

CAGGGTCACCATGACCAGG
AGGTGTATCCAGAAGCCTT

ACAGGGGTCCCATCAAG
ACCAATTTAAATAGTTGCTA

GACACGTCCATCAGCACAG
GCAGGAGACCTTCACTGAG

GTTCAGTGGAAGTGGAT
ATGTCCTGACTCGCCTGGCA

CCTACATGGAGCTGAGCAG
GCCCCAGGCTTCTTCACCTC

CTGGGACAGATTTTACTT
AGTGATGGTGACTCTGTCTC

GCTGAGATCTGACGACACG
AGCCCCAGACTGCACCAGC

TCACCATCAGCAGCCTG
CTACAGATGCAGACAGGGN

GCCGTGTATTACTGTGCGA
TGCACCT (SEQ ID NO:

CAGCCTGAAGATATTGC
G (SEQ ID NO: 3269)

GCCCAGCATCACGTGGATA
3267)

AACATATTACTGTCAAC

TAGTGGCTACGATCATGGG

AGTATGATAATCTCCCTA

TACTACTACTACATGGACG

TCACCTTCGGCCAAGGG

TCTGGGGCAAAGGGACCAC

ACACGACTGGAGATTAA

GGTCACCGTCTCCTCAGCGT

ACGTACGGTGGCTGCAC

CGACCAAGGGCCCATCGGT

CATCTGTCTTCATCTTCC

CTTCCCCCTGGCACCCTCCT

CGCCATCTGATGAGCAG

CCAAGAGCACCTCTGGGGG

TTGAAATCTGGAACTGC

CACAGCGGCCCTGGGCTGC

CTCTGTTGTGTGCCTGCT

CTGGTCAAGGACTACTTCC

GAATAACTTCTATCCCAG

CCGAACCTGTGACGGTCTC

AGAGGCCAAAGTACAGT

GTGGAACTCAGGCGCCCTG

GGAAGGTGGATAACGCC

ACCAGCGGCGTGCACACCT

CTCCAATCGGGTAACTCC

TCCCGGCTGTCCTACAGTCC

CAGGAGAGTGTCACAGA

TCAGGACTCTACTCCCTCAG

GCAGGACAGCAAGGACA

CAGCGTGGTGACCGTGCCC

GCACCTACAGCCTCAGC

TCCAGCAGCTTGGGCACCC

AGCACCCTGACGCTGAG

AGACCTACATCTGCAACGT

CAAAGCAGACTACGAGA

GAATCACAAGCCCAGCAAC

AACACAAAGTCTACGCC

ACCAAGGTGGACAAGAGAG

TGCGAAGTCACCCATCA

TTGAGCCCAAATCTTGTGA

GGGCCTGAGCTCGCCCG

CAAAAC (SEQ ID NO:

TCACAAAGAGCTTCAAC

3266)

AGGGGAGAGTGTTAGAA

GCTTGGCCGCCATGGCC

CAACTTGTTTATTGCAGC

TTATAATGGTTACAAATA

AA (SEQ ID NO:

3268)

COV21_P1
A-C005
TACACATACGATTTAGGTG
NGAGGTGCTCTTGGAGGAG
COV21_P1
TACACATACGATTTAGGT
ANTTACCCGATTGGAGGGC
COV21_P1

F9

ACACTATAGAATAACATCC
GGTGCCAGGGGGAAGACCG
F9
GACACTATAGAATAACA
GTTATCCACCTTCCACTGTA
F9

ACTTTGCCTTTCTCTCCACA
ATGGGCCCTTGGTGGAGGC

TCCACTTTGCCTTTCTCT
CTTTGGCCTCTCTGGGATAG

GGTGTCCACTCCCAGGTCC
TGAAGAGACGGTGACCATT

CCACAGGTGTCCACTCCC
AAGTTATTCAGCAGGCACAC

AACTGCACCTCGGTTCTATC
GTCCCTTGGCCCCAGATATC

AGGTCCAACTGCACCTC
AACAGAGGCAGTTCCAGAT

GATTGAATTCCACCATGGG
AAAAGCATCAAGGCAGCTA

GGTTCTATCGATTGAATT
TTCAACTGCTCATCAGATGG

ATGGTCATGTATCATCCTTT
CCACCGCTACAATGGGGAG

CCACCATGGGATGGTCA
CGGGAAGATGAAGACAGAT

TTCTAGTAGCAACTGCAAC
CCGCACAGTAATACACGGC

TGTATCATCCTTTTTCTA
GGTGCAGCCACAGTTCGTTT

CGGTGTACATTCCCAGGTG
CGTGTCCTCGGATCTCAGG

GTAGCAACTGCAACCGG
GATTTCCACCTTGGTCCCTT

CAGCTGGTGCAGTCTGGGC
CTGCTCAGCTCCATGTAGG

TGTACATTCAGAAATTGT
GGCCGAACGTCCACGGTGA

CTGAGGTGAAGAAGCCTGG
CTGTGCTTGTGGACATGTCC

GTTGACGCAGTCTCCAG
GCTACCATACTGCTGACAGT

GACCTCAGTGAAGGTCTCC
CTGGTAATGGTGACTCTTTC

GCACCCTGTCTTTGTCTC
AATACACTGCAAAATCTTCA

TGCAAGGCTTCTGGATTCA
CTGGAACTTCTGTGCGTAGT

CAGGGGAAAGAGCCACC
GGCTCCAGTCTGCTGATGGT

CCTTTACTAGCTCTGCTGTG
TTGTGTTACCACTGCCAACG

CTCTCCTGCAGGGCCAGT
GAGAGTGAAGTCTGTCCCA

CAGTGGGTGCGACAGGCTC
ACGATCCATCCTATCCACTC

CAGAGTGTTAGAAGCAG
GACCCACTGCCACTGAACCT

GTGGACAACGCCTTGAGTG
AAGGCGTTGTCCACGAGCC

CTACTTAGCCTGGTACCA
GTCTGGGATGCCAGTGGCCC

GATAGGATGGATCGTCGTT
TGTCGCACCCACTGCACAG

GCAGAAACCTGGCCAGG
TGCTGGATGCACCATAGATG

GGCAGTGGTAACACAAACT
CAGAGCTAGTAAAGGTGAA

CTCCCAGGCTCCTCATCT
AGGAGCCTGGGAGCCTGGC

ACGCACAGAAGTTCCAGGA
TCCAGAAGCCTTGCAGGAG

ATGGTGCATCCAGCAGG
CAGGTTTCTGCTGGTACCAG

AAGAGTCACCATTACCAGG
ACCTTCACTGAGGTCCCAG

GCCACTGGCATCCCAGA
GCTAAGTAGCTGCTTCTAAC

GACATGTCCACAAGCACAG
GCTTCTTCACCTCAGGCCCA

CAGGTTCAGTGGCAGTG
ACTCTGACTGGCCCTGCAGG

CCTACATGGAGCTGAGCAG
GACTGCACCAGCTGCACCT

GGTCTGGGACAGACTTC
AGAGGGTGGCTCTTTCCCCT

CCTGAGATCCGAGGACACG
(SEQ ID NO: 3271)

ACTCTCACCATCAGCAG
GGAGACAAAGACAGGGAGA

GCCGTGTATTACTGTGCGG

ACTGGAGCCTGAAGATT
CTGGA (SEQ ID NO:

CTCCCCATTGTAGCGGTGGT

TTGCAGTGTATTACTGTC
3273)

AGCTGCCTTGATGCTTTTGA

AGCAGTATGGTAGCTCA

TATCTGGGGCCAAGGGACA

CCGTGGACGTTCGGCCA

ATGGTCACCGTCTCTTCAGC

AGGGACCAAGGTGGAAA

GTCGACCAAGGGCCCATCG

TCAAACGTACGGTGGCT

GTCTTCCCCCTGGCACCCTC

GCACCATCTGTCTTCATC

CTCCAAGAGCACCTCTGGG

TTCCCGCCATCTGATGAG

GGCACAGCGGCCCTGGGCT

CAGTTGAAATCTGGAAC

GCCTGGTCAAGGACTACTT

TGCCTCTGTTGTGTGCCT

CCCCGAACCTGTGACGGTC

GCTGAATAACTTCTATCC

TCGTGGAACTCANGCGCCC

CAGAGAGGCCAAAGTAC

TGACCAGCGGCGTGCACAC

AGTGGAAGGTGGATAAC

CTTCCCGGCTGTCCTACAGT

GCCCTCCAATCGGGTAA

CCTCNNNCTCTACTCCCTCA

CTCCCAGGAGAGTGTCA

GCAGCGTGGNGACCGTGCC

CAGAGCNNACAGCAAGG

CTCCAGCAGCTTGGGCACC

ACAGCACCTACAGCCTC

CAGACCTACATCTGCAACG

AGCAGCACCCTGACGCT

TGAATCACAAGCCCAGCAA

GAGCAAAGCAGACTACG

CACCA (SEQ ID NO:

AGAAACACAAAGTCTAC

3270)

GCCTGCGAAGTCACCCA

TC (SEQ ID NO:

3272)

COV21 P2
A-C006
TACACATACGATTTAGGTG
GNNGCTGTNNNNNNGAGGT
COV21 P2
TACACATACGATTTAGGT
GNNAGCCTTGGGCTGACCTA
COV21 P2

E5

ACACTATAGAATAACATCC
GCTCTTGGAGGAGGGTGCC
E5
GACACTATAGAATAACA
NGACGGTCAGCTTGGTCCCT
E5

ACTTTGCCTTTCTCTCCACA
AGGGGGAAGACCGATGGGC

TCCACTTTGCCTTTCTCT
CCGCCGAATACCGGACCATT

GGTGTCCACTCCCAGGTCC
CCTTGGTGGAGGCTGAGGA

CCACAGGTGTCCACTCCC
CAGGCTGTCATCCCATGCTG

AACTGCACCTCGGTTCTATC
GACGGTGACCGTGGTCCCT

AGGTCCAACTGCACCTC
CACAGAAATAATCAGCCTC

GATTGAATTCCACCATGGG
TTGCCCCAGACGTCCATGT

GGTTCTATCGATTGAATT
ATCCTCAGACTGGAGCCCAC

ATGGTCATGTATCATCCTTT
AGTTGTAGTAGTAGATCGA

CCACCATGGGATGGTCA
TGATGGCCAGGGAGGCTGA

TTCTAGTAGCAACTGCAAC
GCTGCTACCGTCCCCCCTTC

TGTATCATCCTTTTTCTA
GGTGCCAGACTTGGAGCCA

CGGTGTACATTCTCAGGTG
TCGCACAGTAATAAACGGC

GTAGCAACTGCAACCGG
GAGAATCGGTCAGGGACCC

CAGCTGGTGGAGTCTGGGG
CGTGTCTTCGGCGCTCAGG

TTCCTGGGCCCAGTCTGT
CTGAGGGCCGCTGATTATTA

GAGGCTTGGTCAAGCCTGG
CTGTCCATTTGCAGATACA

GCTGACTCAGCCACCCTC
CTATAGATGAGGAGTTTGGG

AGGGTCCCTGAGACTCTCC
GTGAGTTCCTGCCGTTGTCC

AGCGTCTGGGACCCCCG
GGCCGTTCCTGGGAGCTGCT

TGTGCAGCCTCTGGATTCAT
CTGGAGATGGTGAATCGGC

GACAGAGGGTCACCGTC
GGTACCAGTTTACAGTATTG

CTTCAGTGACTACTGCATG
CCTTCACAGAGTCTGCGTA

TCTTGTTCTGGAAGCAGC
CTTCCGATGTTGGAGCTGCT

AGCTGGATCCGCCGGGCTC
GTATCTGGTGGTACCACTAT

TCCAACATCGGAAGCAA
TCCAGAACAAGAGACGGTG

CAGGGAAGGGGCTGGAATG
TACTAATATATGAAAGCCA

TACTGTAAACTGGTACC
ACCCTCTGTCCGGGGGTCCC

GCTTTCATATATTAGTAATA
TTCCAGCCCCTTCCCTGGAG

AGCAGCTCCCAGGAACG
AGACGCTGAGGGTGGCTGA

GTGGTACCACCAGATACTA
CCCGGCGGATCCAGCTCAT

GCCCCCAAACTCCTCATC
GTCAGCACAGACTGGGCCC

CGCAGACTCTGTGAAGGGC
GCAGTAGTCACTGAAGATG

TATAGTAATAATCAGCG
NGGAACCGGTTGCNNNTNN

CGATTCACCATCTCCAGGG
AATCCAGAGGCTGCACAGG

GCCCTCAGGGGTCCCTG
CTTACTAGA (SEQ ID NO:

ACAACGGCAGGAACTCACT
AGAGTCTCAGGGACCCTCC

ACCGATTCTCTGGCTCCA
3277)

GTATCTGCAAATGGACAGC
AGGCTTGACCAAGCCTCCC

AGTCTGGCACCTCAGCCT

CTGAGCGCCGAAGACACGG
CCAGACTCCACCAGCCTGC

CCCTGGCCATCAGTGGG

CCGTTTATTACTGTGCGAGA
AC (SEQ ID NO: 3275)

CTCCAGTCTGAGGATGA

AGGGGGGACGGTAGCAGCT

GGCTGATTATTTCTGTGC

CGATCTACTACTACAACTA

AGCATGGGATGACAGCC

CATGGACGTCTGGGGCAAA

TGAATGGTCCGGTATTCG

GGGACCACGGTCACCGTCT

GCGGAGGGACCAAGCTG

CCTCAGCCTCCACCAAGGG

ACCGTCCTAGGTCAGCC

CCCATCGGTCTTCCCCCTGG

CAAGGCTGCCCCCTCGG

CACCCTCCTCCAAGAGCAC

TCACTCTGTTCCCACCCT

CTCTGGGGGCACAGCGGCC

CGAGTGAGGAGCTTCAA

CTGGGCTGCCTGGTCAAGG

GCCAACAAGGCCACACT

ACTACTTCCCCGAACCTGTG

GGTGTGTCTCATAAGTG

ACGGTCTCGTGGAACTCAG

ACTTCTACCCGGGAGCC

GCGCCCTGACCAGCGGCGT

GTGACAGTGGCCTGGAA

GCACACCTTCCCGGCTGTCC

GGCAGATAGCAGCCCCG

TACAGTCCTCNNNCTCTACT

TCAAGGCGGGAGTGGAG

CCCTCAGCAGCGTGGTGAC

ACCACCACACCCTCCAA

CGTGCCCTCCAGCAGCTTG

ACAAAGCAACAACAAGT

GGCACCCAGACCTACATCT

ACGCGGCCAGCAGCTAC

GCAACGTGAATCACAAGCC

CTGAGCCTGACGCCTGA

CAGCAACACCAAGNGGACN

GCAGTGGAAGTCCCACA

AGANAGTTGAGCCCAAATC

GAAGCTACAGCTGCCAG

TTGTGANAAACTCACNCAT

GTCACGCATGAAGGGAG

GCCCACCGTGCCCAG (SEQ

CACCGTGGAGAAGACAG

ID NO: 3274)

TGGCCCCTACAGAATGTT

CATAGAAGCTTGGCCGC

CATGGCCCAACTTGTTTA

TTGCAGCTTATAATGGTT

ACAAATAAAGCAA (SEQ

ID NO: 3276)

COV21_P3
A-C009
TACACATACGATTTAGGTG
CAGAGGTGCTCTTGGAGGA
COV21_P3
TACACATACGATTTAGGT
TTGGGCTGACCTAGGACGGT
COV21_P3

B5

ACACTATAGAATAACATCC
GGGTGCCAGGGGGAAGACC
B5
GACACTATAGAATAACA
CAGCTTGGTCCCTCCGCCGA
B5

ACTTTGCCTTTCTCTCCACA
GATGGGCCCTTGGTGGAGG

TCCACTTTGCCTTTCTCT
ATACCACATTGTTGCTGCCT

GGTGTCCACTCCCAGGTCC
CTGAGGAGACGGTGACCAG

CCACAGGTGTCCACTCCC
GCATCTGAGCTGCAGTAATA

AACTGCACCTCGGTTCTATC
GGTTCCCTGGCCCCAGTAG

AGGTCCAACTGCACCTC
CTCAGCCTCATCCTCAGCCT

GATTGAATTCCACCATGGG
TCATTGGAGGCCCCTAAAG

GGTTCTATCGATTGAATT
GGAGCCCAGAGACGGTCAG

ATGGTCATGTATCATCCTTT
CACTAAATGGGGAGTCTCT

CCACCATGGGATGGTCA
GGAGGCCGTGTTGCCAGACT

TTCTAGTAGCAACTGCAAC
CGCACAGTAATACACGGCC

TGTATCATCCTTTTTCTA
TGGAGCCAGAGAAGCGATC

CGGTGTACATTCCCAGGTG
GTGTCGTCAGATCTCAGCCT

GTAGCAACTGCAACCGG
AGGGACCCCTGAGGGCCGC

CAGCTGGTGCAGTCTGGGG
GCTCAGCTCCATGTAGGCT

TTCCTGGGCCCAGTCTGC
TTACTGACCTCATAAATCAT

CTGAGGTGAAGAAGCCTGG
GTGCTGATGGACGTGTCCC

CCTGACTCAGCCTCCCTC
GAGTTTGGGGGCTTTGCCTG

GGCCTCAGTGAAGGTCTCC
TGGTCATGGTGACCCTGCC

CGCGTCCGGGTCTCCTGG
GGTGCTGTTGGTACCAGGAG

TGCATGGCTTCTGGATACA
CTGAAACTTCTGTGCATAGT

ACAGTCAGTCACCATCTC
ACATAGTTATAACCACCAAC

CCTTCACCGGCTACTATATG
TTGTGCCACCACTGTTAGG

CTGCACTGGAACCAGCA
GTCACTGCTGGTTCCAGTGC

CACTGGGTGCGACAGGCCC
GTTGATCCATCCCATCCACT

GTGACGTTGGTGGTTATA
AGGAGATGGTGACTGACTG

CTGGACAAGGGCTTGAGTG
CAAGCCCTTGTCCAGGGGC

ACTATGTCTCCTGGTACC
TCCAGGAGACCCGGACGCG

GATGGGATGGATCAACCCT
CTGTCGCACCCAGTGCATA

AACAGCACCCAGGCAAA
GAGGGAGGCTGAGTCAG

AACAGTGGTGGCACAAACT
TAGTAGCCGGTGAAGGTGT

GCCCCCAAACTCATGATT
(SEQ ID NO: 3281)

ATGCACAGAAGTTTCAGGG
ATCCAGAAGCCATGCAGGA

TATGAGGTCAGTAAGCG

CAGGGTCACCATGACCAGG
GACCTTCACTGAGGCCCCA

GCCCTCAGGGGTCCCTG

GACACGTCCATCAGCACAG
GGCTTCTTCACCTCAGCCCC

ATCGCTTCTCTGGCTCCA

CCTACATGGAGCTGAGCAG
AGACTGCACCAGCTGCACC

AGTCTGGCAACACGGCC

GCTGAGATCTGACGACACG
TGNNANNGGGACNCCC

TCCCTGACCGTCTCTGGG

GCCGTGTATTACTGTGCGA
(SEQ ID NO: 3279)

CTCCAGGCTGAGGATGA

GAGACTCCCCATTTAGTGCT

GGCTGAGTATTACTGCA

TTAGGGGCCTCCAATGACT

GCTCAGATGCAGGCAGC

ACTGGGGCCAGGGAACCCT

AACAATGTGGTATTCGG

GGTCACCGTCTCCTCAGCGT

CGGAGGGACCAAGCTGA

CGACCAAGGGCCCATCGGT

CCGTCCTAGGTCAGCCC

CTTCCCCCTGGCACCCTCCT

AAGGCTGCCCCCTCGGT

CCAAGAGCACCTCTGGGGG

CACTCTGTTCCCGCCCTC

CACAGCGGCCCTGGGCTGC

GAGTGAGGAGCTTCAAG

CTGGTCAAGGACTACTTCC

CCAACAAGGCCACACTG

CCGAACCTGTGACGGTCTC

GTGTGTCTCATAAGTGAC

GTGGAACTCANGCGCCCTG

TTCTACCCGGGAGCCGT

ACCAGCGGCGTGCACACCT

GACAGTGGCCTGGAAGG

TCCCGGCTGTCCTACAGTCC

CAGATAGCAGCCCCGTC

TCNNACTCTACTCCCTCAGC

AAGGCGGGAGTGGAGAC

AGCGTGGTGACCGTGCCCT

CACCACACCCTCCAAAC

CCAGCAGCTTGGGCACCCA

AAAGCAACAACAAGTAC

GACCTACATCTGCAACGTG

GCGGCCAGCAGCTACCT

AATCACAAGCCCAGCAACA

GAGCCTGACGCCTGAGC

CCANNNGGANANAGAGTTG

AGTGGAAGTCCCACAGA

AGCCCAAATCTTGTGACAA

AGCTACAGCTGCCAGGT

AACTCACACATGCCCNCCG

CACGCATGAAGGGAGCA

TGCCCAGC (SEQ ID NO:

CCGTGGAGAAGACAGTG

3278)

GCCCCTACAGAATGTTC

ATAGAAGCTTGGCCGCC

ATGGCCCAACTTGTTTAT

TGCAGCTTATAATGGTTA

CAAA (SEQ ID NO:

3280)

COV21_P2
A-C012
TACACATACGATTTAGGTG
GNNCGCTNNGNNNNNNNN
COV21_P2
TACACATACGATTTAGGT
GNCAGCCTTGGGCTGACCTA
COV21_P2

C7

ACACTATAGAATAACATCC
GTGCTNTTGGANNNNGGTG
C7
GACACTATAGAATAACA
GGACGGTCAGCTTGGTCCCT
C7

ACTTTGCCTTTCTCTCCACA
CCAGGGGGAAGACCGATGG

TCCACTTTGCCTTTCTCT
CCGCCGAACACCCAAGTGTT

GGTGTCCACTCCCAGGTCC
GCCCTTGGTGGAGGCTGAG

CCACAGGTGTCCACTCCC
ACTACCTGCATATGAGCAGC

AACTGCACCTCGGTTCTATC
GAGACGGTGACCAGGGTTC

AGGTCCAACTGCACCTC
AGTAATAATCAGCCTCGTCC

GATTGAATTCCACCATGGG
CCNGGCCCCAGTAGTCAAA

GGTTCTATCGATTGAATT
TCAGCCTGGAGCCCAGAGA

ATGGTCATGTATCATCCTTT
GTACCCTTGGACATAGCTG

CCACCATGGGATGGTCA
TTGTCAGGGAGGCCGTGTTG

TTCTAGTAGCAACTGCCAA
TATCCGAGATCTCTCGCAC

TGTATCATCCTTTTTCTA
CCAGACTTGGAGCCAGAGA

CCGGTGTACATTCCCAGGT
AGTAATATACGGCCGTGTC

GTAGCAACTGCAACCGG
AGCGATTAGAAACCCCTGA

GCAGCTGGTGCAGTCTGGG
GTCAGATCTCAGCCTGCTC

TTCCTGGGCCCAGTCTGC
GGGCCGCTTACTGCCCTCAT

GCTGAGGTGAAGAAGCCTG
AGCTCCATGTAGGCTGTGC

CCTGACTCAGCCTGCCTC
AAATCATGAGTTTGGGGGCT

GGGCCTCAGTGAAGGTCTC
TGATGGACGTGTCCCTGGT

CGAGTCTGGGTCTCCTGG
TTGCCTGGGTGCTGTTGGTA

CTGCAAGGCTTCTGGATAC
CATGGTGACCCTGCCCTGA

ACAGTCGATCACCATCTC
CCAGGAGACAAGGTTATAA

ACCTTCACCGGCTACTATAT
AACTTCTGTGTATAGTTTCT

CTGCACTGGAACCAGCA
CTCCCAACATCACTGCTGGT

GCACTGGGTGCGACAGGCC
GCCACCACTGTTAGGGTTG

GTGATGTTGGGAGTTAT
TCCAGTGCAGGAGATGGTG

CCTGGACAAGGGCTTGAGT
ATCCATCCCATCCACTCAA

AACCTTGTCTCCTGGTAC
ATCGACTGTCCAGGAGACCC

GGATGGGATGGATCAACCC
GCCCTTGTCCAGGGGCCTG

CAACAGCACCCAGGCAA
AGACTCGGAGGCAGGCTGA

TAACAGTGGTGGCAGAAAC
TCGCACCCAGTGCATATAG

AGCCCCCAAACTCATGA
GTCAGCACAGACTGGGACC

TATACACAGAAGTTTCAGG
TAGCCGGTGAAGGTGTATC

TTTATGAGGGCAGTAAG
AGGAACCGGTTGCNNNNGN

GCAGGGTCACCATGACCAG
CAGAAGCCTTGCAGGAGAC

CGGCCCTCAGGGGTTTCT
NNAACTAGA (SEQ ID NO:

GGACACGTCCATCAGCACA
CTTCACTGAGGCCCCAGGC

AATCGCTTCTCTGGCTCC
3285)

GCCTACATGGAGCTGAGCA
TTCTTCACCTCAGCCCCAGA

AAGTCTGGCAACACGGC

GGCTGAGATCTGACGACAC
CTGCACCAGCTGCACCTG

CTCCCTGACAATCTCTGG

GGCCGTATATTACTGTGCG
(SEQ ID NO: 3283)

GCTCCAGGCTGAGGACG

AGAGATCTCGGATACAGCT

AGGCTGATTATTACTGCT

ATGTCCAAGGGTACTTTGA

GCTCATATGCAGGTAGT

CTACTGGGGCCAGGGAACC

AACACTTGGGTGTTCGG

CTGGTCACCGTCTCCTCAGC

CGGAGGGACCAAGCTGA

GTCGACCAAGGGCCCATCG

CCGTCCTAGGTCAGCCC

GTCTTCCCCCTGGCACCCTC

AAGGCTGCCCCCTCGGT

CTCCAAGAGCACCTCTGGG

CACTCTGTTCCCACCCTC

GGCACAGCGGCCCTGGGCT

GAGTGAGGAGCTTCAAG

GCCTGGTCAAGGACTACTT

CCAACAAGGCCACACTG

CCCCGAACCTGTGACGGTC

GTGTGTCTCATAAGTGAC

TCGTGGAACTCANGCGCCC

TTCTACCCGGGAGCCGT

TGACCAGCGGCGTGCACAC

GACAGTGGCCTGGAAGG

CTTCCCGGCTGTCCTACAGT

CAGATAGCAGCCCCGTC

CCTCNNNCTCTACTCCCTCA

AAGGCGGGAGTGGAGAC

GCAGCGTGGTGACCGTGCC

CACCACACCCTCCAAAC

CTCCAGCAGCTTGGGCACC

AAAGCAACAACAAGTAC

CAGACCTACATCTGCAACG

GCGGCCAGCAGCTACCT

TGAATCACAAGCCCAGCAA

GAGCCTGACGCCTGAGC

CACCAAGGTGGACAGA

AGTGGAAGTCCCACAGA

(SEQ ID NO: 3282)

AGCTACAGCTGCCAGGT

CACGCATGAAGGGAGCA

CCGTGG (SEQ ID NO:

3284)

COV21_P1
A-C013
TACACATACGATTTAGGTG
GGNCGCNGTGCCCCAGAGG
COV21_P1
TACACATACGATTTAGGT
CGATTGGAGGGCGTTATCCA
COV21_P1

B2

ACACTATAGAATAACATCC
TGCTCTTGGAGGAGGGTGC
B2
GACACTATAGAATAACA
CCTTCCACTGTACTTTGGCC
B2

ACTTTGCCTTTCTCTCCACA
CAGGGGGAAGACCGATGGG

TCCACTTTGCCTTTCTCT
TCTCTGGGATAGAAGTTATT

GGTGTCCACTCCCAGGTCC
CCCTTGGTGGAGGCTGAGG

NNNNNGNGTCCACTCCC
CAGCAGGCACACAACAGAG

AACTGCACCTCGGTTCTATC
AGACGGTGACCGTGGTCCC

AGGTCCAACTGCACCTC
GCAGTTCCAGATTTCAACTG

GATTGAATTCCACCATGGG
TTTGCCCCAGACGTCCATGT

GGTTCTATCGATTGAATT
CTCATCAGATGGCGGGAAG

ATGGTCATGTATCATCCTTT
AGTAGTAGTAGTAGTACCC

CCACCATGGGATGGTCA
ATGAAGACAGATGGTGCAG

TTCTAGTAGCAACTGCAAC
CTGCCTAACCGCATCTAGA

TGTATCATCCTTTTTCTA
CCACAGTTCGTTTGATCTCC

CGGTGTACATTCCCAGGTG
TAGCAGCTGGTACTACTAC

GTAGCAACTGCAACCGG
ACCTTGGTCCCTCCGCCGAA

CAGCTGGTGCAGTCTGGGG
AATAAAGTAGTCGATTCCC

TGTACATTCAGAAATTGT
AGTGAGGGGCCAGTTGCTA

CTGAGGTGAAGAAGCCTGG
TCTCGCACAGTAATACACG

GTTGACACAGTCTCCAG
CGCTGCTGACAGTAATAAAC

GTCCTCGGTGAAGGTCTCCT
GCCGTGTCCTCAGATCTCA

CCACCCTGTCTTTGTCTC
TGCAAAATCTTCAGGCTCTA

GCAAGGCTTCTGGAGGCAC
GGCTGCTCAGCTCCATGTA

CAGGGGAAAGAGCCACC
GGCTGCTGATGGTGAGAGT

CTTCAGCAGCTATGCTATCA
GGCTGTGCTCGTGGATTCGT

CTCTCCTGCAGGGCCAGT
GAAGTCTGTCCCAGACCCAC

GCTGGGTGCGACAGGCCCC
CCGCGGTAATCGTGACTCT

CAGAGTGTTAGCAGCTA
TGCCACTGAACCTGGCTGGG

TGGACAAGGGCTTGAGTGG
GCCCTGGAACTTCTGTGCGT

CTTAGCCTGGTACCAAC
ATGCCAGTGGCCCTGTTGGA

ATGGGAGGGATCATCCCTA
AGTTTGCTGTACCAAAGAT

AGAAACCTGGCCAGGCT
TGCATCATAGATGAGGAGC

TCTTTGGTACAGCAAACTA
AGGGATGATCCCTCCCATC

CCCAGGCTCCTCATCTAT
CTGGGAGCCTGGCCAGGTTT

CGCACAGAAGTTCCAGGGC
CACTCAAGCCCTTGTCCAG

GATGCATCCAACAGGGC
CTGTTGGTACCAGGCTAAGT

AGAGTCACGATTACCGCGG
GGGCCTGTCGCACCCAGCT

CACTGGCATCCCAGCCA
AGCTGCTAACACTCTGACTG

ACGAATCCACGAGCACAGC
GATAGCATAGCTGCTGAAG

GGTTCAGTGGCAGTGGG
GCCCTGCAGGAGAGGGTGG

CTACATGGAGCTGAGCAGC
GTGCCTCCAGAAGCCTTGC

TCTGGGACAGACTTCACT
CTCTTTCCCCTGGAGACAAA

CTGAGATCTGAGGACACGG
AGGAGACCTTCACCGAGGA

CTCACCATCAGCAGCCT
GACAGGG (SEQ ID NO:

CCGTGTATTACTGTGCGAG
CCCAGGCTTCTTCACCTCAG

AGAGCCTGAAGATTTTG
3289)

AGGGAATCGACTACTTTAT
CCCCAGACTGCACCAGCTG

CAGTTTATTACTGTCAGC

TGTAGTAGTACCAGCTGCT
GCACCT (SEQ ID NO:

AGCGTAGCAACTGGCCC

ATCTAGATGCGGTTAGGCA
3287)

CTCACTTTCGGCGGAGG

GGGGTACTACTACTACTAC

GACCAAGGTGGAGATCA

TACATGGACGTCTGGGGCA

AACGTACGGTGGCTGCA

AAGGGACCACGGTCACCGT

CCATCTGTCTTCATCTTC

CTCCTCAGCGTCGACCAAG

CCGCCATCTGATGAGCA

GGCCCATCGGTCTTCCCCCT

GTTGAAATCTGGAACTG

GGCACCCTCCTCCAAGAGC

CCTCTGTTGTGTGCCTGC

ACCTCTGGGGGCACAGCGG

TGAATAACTTCTATCCCA

CCCTGGGCTGCCTGGTCAA

GAGAGGCCAAAGTACAG

GGACTACTTCCCCGAACCT

TGGAAGGTGGATAACGC

GTGACGGTCTCGTGGAACT

CCTCCAATCGGGTAACTC

CAGGCGCCCTGACCAGCGG

CCAGGAGAGTGTCACAG

CGTGCACACCTTCCCGGCT

AGCNNACAGCAAGGACA

GTCCTACAGTCCTCAGGAC

GCACCTACAGCCTCAGC

TCTACTCCCTCAGCAGCGTG

AGCACCCTGACGCTGAN

GTGACCGTGCCCTCCAGCA

CAAAGCANACTACGAGA

GCTTGGGCACCCAGACCTA

AACACAAAGTCTACGCC

CATCTGCAACGTGAATCAC

TGCGAAGTCACCCATCN

AAGCCCAGCAACACCAA

NNNCTGAGCTCGCCCGT

(SEQ ID NO: 3286)

CACAAAGAGCTTCAACA

GGGGGANANTGTTANAA

GCTTGGCCGCCATGGCC

CAACTTGTTNATTGCAGC

TTANATGGTTA (SEQ ID

NO: 3288)

COV21_P3
A-C014
TACACATACGATTTAGGTG
GGGGCCACCGGTGTGCACA
COV21_P3
TACACATACGATTTAGGT
CTTGGGCTGACCTAGGACGG
COV21_P3

H10

ACACTATAGAATAACATCC
GCAGTGGGGGAGGCTTGGT
H10
GACACTATAGAATAACA
TCAGCTTGGTCCCTCCGCCG
H10

ACTTTGCCTTTCTCTCCACA
GCAACCTGGTGGCTCATTG

TCCACTTTGCCTTTCTCT
AATATCACATATCGAGAGTG

GGTGTCCACTCCCAGGTCC
CGCCTCAGCTGCGCGGCGT

CCACAGGTGTCCACTCCC
CTGCTGCTTGTATATGAGCT

AACTGCACCTCGGTTCTATC
CCGGCTTCAATTTTTCCACT

AGGTCCAACTGCACCTC
GCAGTAATAATCAGCCTCGT

GATTGAATTCCACCATGGG
CACTGGATGCATTGGGTCA

GGTTCTATCGATTGAATT
CCTCAGCCTGGAGCCCAGA

ATGGTCATGTATCATCCTTT
GGCAAGCACCGGGAAAGG

CCACCATGGGATGGTCA
GATGGTCAGGGAGGCCGTG

TTCTAGTAGCAACTGCAAC
GCCTCGTGTGGGTATCTCG

TGTATCATCCTTTTTCTA
TTGCCAGACTTGGAGCCAGA

CGGTGTGCACAGCAGTGGG
GATTAACTCCGATGGCAGC

GTAGCAACTGCAACCGG
GAAGCGATTAGAAACCCCT

GGAGGCTTGGTGCAACCTG
AGAAGAGCCTACGCTACCT

TTCCTGGGCCCAGTCTGT
GAGGGCCGATTACTGACATC

GTGGCTCATTGCGCCTCAG
CAGTGAAAGGGAGGTTCAC

GCTGACTCAGCCTGCCTC
ATAAATCATGAGTTTGGGGG

CTGCGCGGCGTCCGGCTTC
AATTTCACGGGATAACGCA

CGTGTCTGGGTCTCCTGG
CTTTGCCTGGGTGTTGTTGG

AATTTTTCCACTCACTGGAT
AAAAACACTCTCTATCTCC

ACAGTCGATCACCATCTC
TACCAGGAGACATAGTTATA

GCATTGGGTCAGGCAAGCA
AGATGGACTCACTCCGCGA

CTGCACTGGAACCAGCA
ACCACCAACGTCACTGCTGG

CCGGGAAAGGGCCTCGTGT
CGAAGATACAGCTGTCTAT

GTGACGTTGGTGGTTATA
TTCCAGTGCAGGAGATGGTG

GGGTATCTCGGATTAACTC
TACTGTACTAGGGATGATA

ACTATGTCTCCTGGTACC
ATCGACTGTCCAGGAGACCC

CGATGGCAGCAGAAGAGCC
GTTCTTGGCCGCATTTCTTC

AACAACACCCAGGCAAA
AGACACGGAGGCAGGCTGA

TACGCTACCTCAGTGAAAG
GACAACTGGGGTCAGGGGA

GCCCCCAAACTCATGATT
GTCAGCACAGACTGGGNCC

GGAGGTTCACAATTTCACG
CCTTGGTGACGGTCTCTAGC

TATGATGTCAGTAATCG
AGGAACCGGNT (SEQ ID

GGATAACGCAAAAAACACT
GCGTCGACGGCA (SEQ ID

GCCCTCAGGGGTTTCTAA
NO: 3293)

CTCTATCTCCAGATGGACTC
NO: 3291)

TCGCTTCTCTGGCTCCAA

ACTCCGCGACGAAGATACA

GTCTGGCAACACGGCCT

GCTGTCTATTACTGTACTAG

CCCTGACCATCTCTGGGC

GGATGATAGTTCTTGGCCG

TCCAGGCTGAGGACGAG

CATTTCTTCGACAACTGGG

GCTGATTATTACTGCAGC

GTCAGGGGACCTTGGTGAC

TCATATACAAGCAGCAG

GGTCTCTAGCGCGTCGACC

CACTCTCGATATGTGATA

AAGGGCCCATCGGTCTTCC

TTCGGCGGAGGGACCAA

CCCTGGCACCCTCCTCCAA

GCTGACCGTCCTAGGTC

GAGCACCTCTGGGGGCACA

AGCCCAAGGCTGCCCCC

GCGGCCCTGGGCTGCCTGG

TCGGTCACTCTGTTCCCG

TCAAGGACTACTTCCCCGA

CCCTCGAGTGAGGAGCT

ACCTGTGACGGTCTCGTGG

TCAAGCCAACAAGGCCA

AACTCAGGCGCCCTGACCA

CACTGGTGTGTCTCATAA

GCGGCGTGCACACCTTCCC

GTGACTTCTACCCGGGA

GGCTGTCCTACAGTCCTCA

GCCGTGACAGTGGCCTG

GGACTCTACTCCCTCAGCA

NAAGGCAGATAGCAGCC

GCGTGGTGACCGTGCCCTC

CCGTCAAGGCGGGAGTG

CAGCAGCTTGGGCACCCAG

GAGACCACCACACCCTC

ACCTACATCTGCAACGTGA

CAAACAAAGCAACAACA

ATCACAAGCCCAGCAACAC

AGTACGCGGCCAGCAGC

CAAGGTGGACAAGAGAGTT

TACCTGAGCCTGACGCCT

GAGCCCAAATCTTGTGACA

GAGCAGTGGAAGTCCCA

AAACTCACACATGCCCNNN

CAGAAGCTACAGCTGCC

CNNGNGNCCAGCACCTGAA

AGGTCACGCATGAAGGA

CTCCTGGGGGGACCGTC

GCACCGTGGANAAGACA

(SEQ ID NO: 3290)

GTGGCCCCTACAGAATG

TTCATAGAAGCTTGGCC

GCCATGGCCCAACTTGTT

TATTGCAGCTTAT (SEQ

ID NO: 3292)

COV21_P3
A-C015
TACACATACGATTTAGGTG
GGGGCCACCGGTGTGCACA
COV21_P3
TACACATACGATTTAGGT
GGGNNNNNCTTGGGCTGAC
COV21_P3

D12

ACACTATAGAATAACATCC
GCGTCTGGAGGGGGCTTGG
D12
GACACTATAGAATAACA
GTAGGACGGTCAGGTGGGT
D12

ACTTTGCCTTTCTCTCCACA
TGAAACCTGGTGGTTCTCTT

TCCACTTTGCCTTTCTCT
CCCTCCACCGAACACCCAAG

GGTGTCCACTCCCAGGTCC
AGGCTGAGTTGCGCTGCGT

CCACAGGTGTCCACTCCC
TACTCAGGCTGTCATCCCAT

AACTGCACCTCGGTTCTATC
CAGGCTTTACCTTTTCTTCT

AGGTCCAACTGCACCTC
TCTGCACAGTAATAGTCACC

GATTGAATTCCACCATGGG
TATAGCATGAACTGGGTAC

GGTTCTATCGATTGAATT
CTCATCCTCAGACTGGAGCC

ATGGTCATGTATCATCCTTT
GCCAAGCGCCGGGCAAAGG

CCACCATGGGATGGTCA
CACTGATGGCCAGGGAGGC

TTCTAGTAGCAACTGCAAC
TCTCGAGTGGGTGTCCTCTA

TGTATCATCCTTTTTCTA
TGAGGTGCCAGACTTGGAG

CGGTGTGCACAGCGTCTGG
TATCAAGTTCCAGTAGCTA

GTAGCAACTGCAACCGG
CCAGAGAATCGGTCAGGGA

AGGGGGCTTGGTGAAACCT
CATTTACTATGCTGACTCAG

TTCCTGGGCCCAGTCTGT
CCCCTGAGGGCCGCCGATTA

GGTGGTTCTCTTAGGCTGA
TCAAAGGCAGATTTACCAT

GCTGACTCAGCCACCCTC
CTATTGTAAATGAGGAGTTT

GTTGCGCTGCGTCAGGCTTT
CAGCCGCGATAATGCCAAA

AGCGTCTGGGACCCCCG
GGGGGCCGTTCCTGGGAGCT

ACCTTTTCTTCTTATAGCAT
AATTCACTCTATCTGCAAAT

GACAGAGGGTCACCATC
GCTGGAACCAGTTAACAGT

GAACTGGGTACGCCAAGCG
GAACTCTCTTCGCGCAGAG

TCTTGTTCTGGAATCAGC
ATTACTTCCGAGGTTGGAGC

CCGGGCAAAGGTCTCGAGT
GATACCGCTGTCTACTACTG

TCCAACCTCGGAAGTAA
TGATTCCAGAACAAGAGAT

GGGTGTCCTCTATATCAAGT
TGCTAGGGAGGTGAAAAGA

TACTGTTAACTGGTTCCA
GGTGACCCTCTGTCCGGGGG

TCCAGTAGCTACATTTACTA
GTAGTAGCTGCCCCAGAGT

GCAGCTCCCAGGAACGG
TCCCAGACGCTGAGGGTGG

TGCTGACTCAGTCAAAGGC
ACTACTTTGATTATTGGGGT

CCCCCAAACTCCTCATTT
CTGAGTCAGCACAGACTGG

AGATTTACCATCAGCCGCG
CAAGGGACACTTGTTACAG

ACAATAGTAATCGGCGG
GACCAGGAACCGGTTG (SEQ

ATAATGCCAAAAATTCACT
TCTCATCCGCGTCGACGGC

CCCTCAGGGGTCCCTGA
ID NO: 3297)

CTATCTGCAAATGAACTCTC
A (SEQ ID NO: 3295)

CCGATTCTCTGGCTCCAA

TTCGCGCAGAGGATACCGC

GTCTGGCACCTCAGCCTC

TGTCTACTACTGTGCTAGGG

CCTGGCCATCAGTGGGC

AGGTGAAAAGAGTAGTAGC

TCCAGTCTGAGGATGAG

TGCCCCAGAGTACTACTTTG

GGTGACTATTACTGTGCA

ATTATTGGGGTCAAGGGAC

GAATGGGATGACAGCCT

ACTTGTTACAGTCTCATCCG

GAGTACTTGGGTGTTCG

CGTCGACCAAGGGCCCATC

GTGGAGGGACCCACCTG

GGTCTTCCCCCTGGCACCCT

ACCGTCCTACGTCAGCCC

CCTCCAAGAGCACCTCTGG

AAGGCTGCCCCCTCGGT

GGGCACAGCGGCCCTGGGC

CACTCTGTTCCCACCCTC

TGCCTGGTCAAGGACTACT

GAGTGAGGAGCTTCAAG

TCCCCGAACCTGTGACGGT

CCAACAAGGCCACACTG

CTCGTGGAACTCAGGCGCC

GTGTGTCTCATAAGTGAC

CTGACCAGCGGCGTGCACA

TTCTACCCGGGAGCCGT

CCTTCCCGGCTGTCCTACAG

GACAGTGGCCTGGAAGG

TCCTCAGGACTCTACTCCCT

CAGATAGCAGCCCCGTC

CAGCAGCGTGGTGACCGTG

AAGGCGGGAGTGGAGAC

CCCTCCAGCAGCTTGGGCA

CACCACACCCTCCAAAC

CCCAGACCTACATCTGCAA

AAAGCAACAACAAGTAC

CGTGAATCACAAGCCCAGC

GCGGCCAGCAGCTACCT

AACACCAAGGTGGACAAGA

GAGCCTGACGCCTGAGC

GAGTTGAGCCCAAATCTTG

AGTGGAAGTCCCACAGA

TGACAAAACTCACACATGC

AGCTACAGCTGCCAGGT

CCACCGTGCCCAGCACC

CACGCATGAAGGGAGCA

(SEQ ID NO: 3294)

CCGTGGAGAAGACAGTG

GCCCCTACAGAATGTTC

ATAGAAGCTTGGCCGCC

ATGGCCCAACTTGTTTAT

TGCAGCTTATAATGGTTA

CAAA (SEQ ID NO: 3296)

COV21_P3
A-C016
TACACATACGATTTAGGTG
GCTGTGNNNNAGAGGTGCT
COV21_P3
TACACATACGATTTAGGT
TNCCCGATTGGAGGGCGTTA
COV21_P3

A4

ACACTATAGAATAACATCC
CTTGGAGGAGGGTGCCAGG
A4
GACACTATAGAATAACA
TCCACCTTCCACTGTACTTT
A4

ACTTTGCCTTTCTCTCCACA
GGGAAGACCGATGGGCCCT

TCCACTTTGCCTTTCTCT
GGCCTCTCTGGGATAGAAGT

GGTGTCCACTCCCAGGTCC
TGGTGGAGGCTGAGGAGAC

CCACAGGTGTCCACTCCC
TATTCAGCAGGCACACAAC

AACTGCACCTCGGTTCTATC
GGTGACCAGGGTTCCCTGG

AGGTCCAACTGCACCTC
AGAGGCAGTTCCAGATTTCA

GATTGAATTCCACCATGGG
CCCCAGTAGTCAAAGTTAC

GGTTCTATCGATTGAATT
ACTGCTCATCAGATGGCGGG

ATGGTCATGTATCATCCTTT
CTCCGTAGCAGCTACCACC

CCACCATGGGATGGTCA
AAGATGAAGACAGATGGTG

TTCTAGTAGCAACTGCAAC
ACTACAATAAGGGGCGGTC

TGTATCATCCTTTTTCTA
CAGCCACAGTTCGTTTGATC

CGGTGTACATTCTGAGGTG
ACTTTCGCACAGTAATACA

GTAGCAACTGCAACCGG
TCCACCTTGGTCCCTCCGCC

CAGCTGGTGGAGTCTGGGG
CAGCCGTGTCCTCAGCTCTC

TGTACATTGTGCCATCCG
GAAAGTAGGAGGGAGATTA

GAGGCGTGGTCCAGCCTGG
AGGCTGTTCATTTGCAGAT

GATGACCCAGTCTCCATC
TCATACTGTTGACAGTAATA

GAGGTCCCTGAGACTCTCC
ACAGCGTGTTCTTGGAATT

CTCCCTGTCTGCATCTGT
TGTTGCAATATCTTCAGGCT

TGTGCAGCCTCTGGATTCAC
GTCTCTGGAGATGGTGAAT

AGGAGACAGAGTCACCA
GCAGGCTGTTGATGGTGAA

CTTCAGTAGATATGGCATG
CGGCCCTTCACGGAGTCTG

TCACTTGCCAGGCGAGT
AGTAAAATCTGTCCCAGATC

CACTGGGTCCGCCAGGCTC
CATAGTATTTATTACTTCCA

CAGGACATTAGCAACTA
CACTTCCGCTGAACCTTGAT

CAGGCAAGGGGCTGGAGTG
TCATATGATATAACTGCCA

TTTAAATTGGTATCAGCA
GGGACCCCTGTTTCCAAATT

GGTGGCAGTTATATCATAT
CCCACTCCAGCCCCTTGCCT

GAAACCAGGGAAAGCCC
GGATGCATCGTAGATCAGG

GATGGAAGTAATAAATACT
GGAGCCTGGCGGACCCAGT

CTAAGCTCCTGATCTACG
AGCTTAGGGGCTTTCCCTGG

ATGCAGACTCCGTGAAGGG
GCATGCCATATCTACTGAA

ATGCATCCAATTTGGAA
TTTCTGCTGATACCAATTTA

CCGATTCACCATCTCCAGA
GGTGAATCCAGAGGCTGCA

ACAGGGGTCCCATCAAG
AATAGTTGCTAATGTCCTGA

GACAATTCCAAGAACACGC
CAGGAGAGTCTCAGGGACC

GTTCAGCGGAAGTGGAT
CTCGCCTGGCAAGTGATGGT

TGTATCTGCAAATGAACAG
TCCCAGGCTGGACCACGCC

CTGGGACAGATTTTACTT
GACTCTGTCTCCTACAGATG

CCTGAGAGCTGAGGACACG
TCCCCCAGACTCCACCANN

TCACCATCAACAGCCTG
CAGACAGGGNG (SEQ ID

GCTGTGTATTACTGTGCGA
CTGCAC (SEQ ID NO:

CAGCCTGAAGATATTGC
NO: 3301)

AAGTGACCGCCCCTTATTGT
3299)

AACATATTACTGTCAAC

AGTGGTGGTAGCTGCTACG

AGTATGATAATCTCCCTC

GAGGTAACTTTGACTACTG

CTACTTTCGGCGGAGGG

GGGCCAGGGAACCCTGGTC

ACCAAGGTGGAGATCAA

ACCGTCTCCTCAGCGTCGA

ACGTACGGTGGCTGCAC

CCAAGGGCCCATCGGTCTT

CATCTGTCTTCATCTTCC

CCCCCTGGCACCCTCCTCCA

CGCCATCTGATGAGCAG

AGAGCACCTCTGGGGGCAC

TTGAAATCTGGAACTGC

AGCGGCCCTGGGCTGCCTG

CTCTGTTGTGTGCCTGCT

GTCAAGGACTACTTCCCCG

GAATAACTTCTATCCCAG

AACCTGTGACGGTCTCGTG

AGAGGCCAAAGTACAGT

GAACTCANGCGCCCTGACC

GGAAGGTGGATAACGCC

AGCGGCGTGCACACCTTCC

CTCCAATCGGGTAACTCC

CGGCTGTCCTACAGTCCTCN

CAGGAGAGTGTCACAGA

NACTCTACTCCCTCAGCAG

GCAGGACAGCAAGGACA

CGTGGTGACCGTGCCCTCC

GCACCTACAGCCTCAGC

AGCAGCTTGGGCACCCAGA

AGCACCCTGACGCTGAG

CCTACATCTGCAACGTGAA

CAAAGCAGACTACGAGA

TCACAAGCCCAGCAACACC

AACACAAAGTCTACGCC

A (SEQ ID NO: 3298)

TGCGAAGTCACCCATCA

GGGCCTGAGCTCGCCCG

TCACAAAGAGCTTCAAC

AGGGGAGAGTGTTAGAA

GCTTGGCCGCCATGGCC

CAACTTGTTTATTGCAGC

TTATAATGG (SEQ ID

NO: 3300)

COV21_P1
A-C017
TACACATACGATTTAGGTG
GAGGTGCTCTTGGAGGAGG
COV21_P1
TACACATACGATTTAGGT
CCGATTGGAGGGCGTTATCC
COV21_P1

E10

ACACTATAGAATAACATCC
GTGCCAGGGGGAAGACCGA
E10
GACACTATAGAATAACA
ACCTTCCACTGTACTTTGGC
E10

ACTTTGCCTTTCTCTCCACA
TGGGCCCTTGGTGGAGGCT

TCCACTTTGCCTTTCTCT
CTCTCTGGGATAGAAGTTAT

GGTGTCCACTCCCAGGTCC
GAGGAGACGGTGACCAGGG

CCACAGGTGTCCACTCCC
TCAGCAGGCACACAACAGA

AACTGCACCTCGGTTCTATC
TTCCCTGGCCCCAGTGGTCG

AGGTCCAACTGCACCTC
GGCAGTTCCAGATTTCAACT

GATTGAATTCCACCATGGG
AAGTTGAGGTCGGGACCAG

GGTTCTATCGATTGAATT
GCTCATCAGATGGCGGGAA

ATGGTCATGTATCATCCTTT
CTGCTGCTATACCCCTTACG

CCACCATGGGATGGTCA
GATGAAGACAGATGGTGCA

TTCTAGTAGCAACTGCAAC
CCCGCTTTTGCACAGTAATA

TGTATCATCCTTTTTCTA
GCCACAGTTCGTTTAATCTC

CGGTGTACATTCTGAAGTG
AAAGGCCGTGTCCTCAGCT

GTAGCAACTGCAACCGG
CAGTCGTGTCCCTTGGCCGA

CAGCTGGTGGAGTCTGGGG
CTCAGACTGTTCATTTGCAG

TGTACATTCAGAAATTGT
AGGTGATACGCTGCTGACA

GAGGCTTGGTACAGCCTGG
ATACAGGGAGTTCTTGGCG

GTTGACACAGTCTCCAG
GTAATAAACTGCAAAATCTT

CAGGTCCCTGAGACTCTCCT
TTGTCTCTGGAGATGGTGA

CCACCCTGTCTTTGTCTC
CAGGCTCTAGGCTGCTGATG

GTGCAGCCTCTGGATTCAC
ATCGGCCCTTCACAGAGTC

CAGGGGAAAGAGCCACC
GTGAGAGTGAAGTCTGTCCC

CTTTGATGATTATGCCATGC
CGCATAGCCTATGGTACCA

CTCTCCTGCAGGGCCAGT
AGACCCACTGCCACTGAACC

ACTGGGTCCGGCAAGCTCC
CTATTCCAACTAATACCTGA

CAGAGTGTTAGCAGCTA
TGGCTGGGATGCCAGTGGCC

AGGGAAGGGCCTGGAGTGG
GACCCACTCCAGGCCCTTC

CTTAGCCTGGTACCAAC
CTGTTGGATGCATCATAGAT

GTCTCAGGTATTAGTTGGA
CCTGGAGCTTGCCGGACCC

AGAAACCTGGCCAGGCT
GAGGAGCCTGGGAGCCTGG

ATAGTGGTACCATAGGCTA
AGTGCATGGCATAATCATC

CCCAGGCTCCTCATCTAT
CCAGGTTTCTGTTGGTACCA

TGCGGACTCTGTGAAGGGC
AAAGGTGAATCCAGAGGCT

GATGCATCCAACAGGGC
GGCTAAGTAGCTGCTAACAC

CGATTCACCATCTCCAGAG
GCACAGGAGAGTCTCAGGG

CACTGGCATCCCAGCCA
TCTGACTGGCCCTGCAGGAG

ACAACGCCAAGAACTCCCT
ACCTGCCAGGCTGTACCAA

GGTTCAGTGGCAGTGGG
AGGGTGGCTCTTTCCCCTGG

GTATCTGCAAATGAACAGT
GCCTCCCCCAGACTCCACN

TCTGGGACAGACTTCACT
AGACAAAGACAGGGAGACT

CTGAGAGCTGAGGACACGG
NNNTTGCAC (SEQ ID NO:

CTCACCATCAGCAGCCT
GGA (SEQ ID NO: 3305)

CCTTTTATTACTGTGCAAAA
3303)

AGAGCCTGAAGATTTTG

GCGGGCGTAAGGGGTATAG

CAGTTTATTACTGTCAGC

CAGCAGCTGGTCCCGACCT

AGCGTATCACCTTCGGCC

CAACTTCGACCACTGGGGC

AAGGGACACGACTGGAG

CAGGGAACCCTGGTCACCG

ATTAAACGTACGGTGGC

TCTCCTCAGCGTCGACCAA

TGCACCATCTGTCTTCAT

GGGCCCATCGGTCTTCCCCC

CTTCCCGCCATCTGATGA

TGGCACCCTCCTCCAAGAG

GCAGTTGAAATCTGGAA

CACCTCTGGGGGCACAGCG

CTGCCTCTGTTGTGTGCC

GCCCTGGGCTGCCTGGTCA

TGCTGAATAACTTCTATC

AGGACTACTTCCCCGAACC

CCAGAGAGGCCAAAGTA

TGTGACGGTCTCGTGGAAC

CAGTGGAAGGTGGATAA

TCAGGCGCCCTGACCAGCG

CGCCCTCCAATCGGGTA

GCGTGCACACCTTCCCGGC

ACTCCCAGGAGAGTGTC

TGTCCTACAGTCCTCAGGA

ACAGAGCAGGACAGCAA

CTCTACTCCCTCAGCAGCGT

GGACAGCACCTACAGCC

GGTGACCGTGCCCTCCAGC

TCAGCAGCACCCTGACG

AGCTTGGGCACCCAGACCT

CTGAGCAAAGCAGACTA

ACATCTGCAACGTGAATCA

CGAGAAACACAAAGTCT

CAAGCCCAGCAACACCAA

ACGCCTGCGAAGTCACC

(SEQ ID NO: 3302)

CATCNGGCCTGAGCTCG

CCCGTCACAAAGAGCTT

CAACAGGGGAGAGTGTT

AGAAGCTTGGNCGCCAT

GGCCCAACTTGTTTATTG

CAGCTTATNATGGNTAC

AAATAAAGCAATAGCAT

CACAAATTTCAC (SEQ

ID NO: 3304)

COV21_P3
A-C028
TACACATACGATTTAGGTG
CTGTGCCCCAGAGGTGCTC
COV21_P3
TACACATACGATTTAGGT
TACCCGATTGGAGGGCGTTA
COV21_P3

E2

ACACTATAGAATAACATCC
TTGGAGGAGGGTGCCAGGG
E2
GACACTATAGAATAACA
TCCACCTTCCACTGTACTTT
E2

ACTTTGCCTTTCTCTCCACA
GGAAGACCGATGGGCCCTT

TCCACTTTGCCTTTCTCT
GGCCTCTCTGGGATAGAAGT

GGTGTCCACTCCCAGGTCC
GGTGGAGGCTGAGGAGACG

CCACAGGTGTCCACTCCC
TATTCAGCAGGCACACAAC

AACTGCACCTCGGTTCTATC
GTGACCAGGGTTCCCTGGC

AGGTCCAACTGCACCTC
AGAGGCAGTTCCAGATTTCA

GATTGAATTCCACCATGGG
CCCAGTAGTCAAAGTTGAG

GGTTCTATCGATTGAATT
ACTGCTCATCAGATGGCGGG

ATGGTCATGTATCATCCTTT
GTCGGGACCAGCTGCTGCT

CCACCATGGGATGGTCA
AAGATGAAGACAGATGGTG

TTCTAGTAGCAACTGCAAC
ATACCCCTTACGCCCGCTTT

TGTATCATCCTTTTTCTA
CAGCCACAGTTCGTTTAATC

CGGTGTACTTCTGAAGTGC
TGCACAGTAATACAAGGCC

GTAGCAACTGCAACCGG
TCCAGTCGTGTCCCTTGGCC

AGCTGGTGGAGTCTGGGGG
GTGTCCTCAGCTCTCAGACT

TGTACATTCAGAAATTGT
GAAGGTGATACGCTGCTGA

AGGCTTGGTACAGCCTGGC
GTTCATTTGCAGATACAGG

GTTGACACAGTCTCCAG
CAGTAATAAACTGCAAAAT

AGGTCCCTGAGACTCTCCT
GAGTTCTTGGCGTTGTCTCT

CCACCCTGTCTTTGTCTC
CTTCAGGCTCTAGGCTGCTG

GTGCAGCCTCTGGATTCAC
GGAGATGGTGAATCGGCCC

CAGGGGAAAGAGCCACC
ATGGTGAGAGTGAAGTCTGT

CTTTGATGATTATGCCATGC
TTCACAGAGTCCGCATAGC

CTCTCCTGCAGGGCCAGT
CCCAGACCCACTGCCACTGA

ACTGGGTCCGGCAAGCTCC
CTATGCTACCACTATTCCAA

CAGAGTGTTAGCAGCTA
ACCTGGCTGGGATGCCAGTG

AGGGAAGGGCCTGGAGTGG
CTAATACCTGAGACCCACT

CTTAGCCTGGTACCAAC
GCCCTGTTGGATGCATCATA

GTCTCAGGTATTAGTTGGA
CCAGGCCCTTCCCTGGAGC

AGAAACCTGGCCAGGCT
GATGAGGAGCCTGGGAGCC

ATAGTGGTAGCATAGGCTA
TTGCCGGACCCAGTGCATG

CCCAGGCTCCTCATCTAT
TGGCCAGGTTTCTGTTGGTA

TGCGGACTCTGTGAAGGGC
GCATAATCATCAAAGGTGA

GATGCATCCAACAGGGC
CCAGGCTAAGTAGCTGCTAA

CGATTCACCATCTCCAGAG
ATCCAGAGGCTGCACAGGA

CACTGGCATCCCAGCCA
CACTCTGACTGGCCCTGCAG

ACAACGCCAAGAACTCCCT
GAGTCTCAGGGACCTGCCA

GGTTCAGTGGCAGTGGG
GAGAGGGTGGCTCTTTCCCC

GTATCTGCAAATGAACAGT
GGCTGTACCAAGCCTCCCC

TCTGGGACAGACTTCACT
TGGAGACAAAGACAGGGNG

CTGAGAGCTGAGGACACGG
CAGACTCCACCAGCTGCAC

CTCACCATCAGCAGCCT
ACTGNNNNNGGGGGTCATA

CCTTGTATTACTGTGCAAAA
(SEQ ID NO: 3307)

AGAGCCTGAAGATTTTG
CCAATCTCGCANGT (SEQ

GCGGGCGTAAGGGGTATAG

CAGTTTATTACTGTCAGC
ID NO: 3309)

CAGCAGCTGGTCCCGACCT

AGCGTATCACCTTCGGCC

CAACTTTGACTACTGGGGC

AAGGGACACGACTGGAG

CAGGGAACCCTGGTCACCG

ATTAAACGTACGGTGGC

TCTCCTCAGCGTCGACCAA

TGCACCATCTGTCTTCAT

GGGCCCATCGGTCTTCCCCC

CTTCCCGCCATCTGATGA

TGGCACCCTCCTCCAAGAG

GCAGTTGAAATCTGGAA

CACCTCTGGGGGCACAGCG

CTGCCTCTGTTGTGTGCC

GCCCTGGGCTGCCTGGTCA

TGCTGAATAACTTCTATC

AGGACTACTTCCCCGAACC

CCAGAGAGGCCAAAGTA

TGTGACGGTCTCGTGGAAC

CAGTGGAAGGTGGATAA

TCAGGCGCCCTGACCAGCG

CGCCCTCCAATCGGGTA

GCGTGCACACCTTCCCGGC

ACTCCCAGGAGAGTGTC

TGTCCTACAGTCCTCAGGA

ACAGAGCAGGACAGCAA

CTCTACTCCCTCAGCAGCGT

GGACAGCACCTACAGCC

GGTGACCGTGCCCTCCAGC

TCAGCAGCACCCTGACG

AGCTTGGGCACCCAGACCT

CTGAGCAAAGCANACTA

ACATCTGCAACGTGAATCA

CGAGAAACACAAAGTCT

CAAGCCCAGCAACACCAAN

ACGCCTGCGAAGTCACC

GTGGACAAGAGAGTTGAGC

CATCNGNCCTGAGCTCG

CCAAATCTTGTGACAAAAC

CCCGTCACAAAGAGCTT

TCACACATGCCCACCGTGC

CAACAGGGGAGAGTGTT

CC (SEQ ID NO: 3306)

AGAAGCTTGGCCGCCAT

GGNNCAACTTGTTTATTG

CAGCTTATAATGGTTACA

AATAAAGCAATAGCATC

(SEQ ID NO: 3308)

COV21_P3
A-C018
TACACATACGATTTAGGTG
GCTGTGNNNNNGAGGTGCT
COV21_P3
TACACATACGATTTAGGT
GGNNNTNCNNGATTGGAGG
COV21_P3

B9

ACACTATAGAATAACATCC
CTTGGAGGAGGGTGCCAGG
B9
GACACTATAGAATAACA
GCGTTATCCACCTTCCACTG
B9

ACTTTGCCTTTCTCTCCACA
GGGAAGACCGATGGGCCCT

TCCACTTTGCCTTTCTCT
TACTTTGGCCTCTCTGGGAT

GGTGTCCACTCCCAGGTCC
TGGTGGAGGCTGAGGAGAC

CCACAGGTGTCCACTCCC
AGAAGTTATTCAGCAGGCA

AACTGCACCTCGGTTCTATC
GGTGACCAGGGTTCCCTGG

AGGTCCAACTGCACCTC
CACAACAGAGGCAGTTCCA

GATTGAATTCCACCATGGG
CCCCAGTAGTCAAACGCCC

GGTTCTATCGATTGAATT
GATTTCAACTGCTCATCAGA

ATGGTCATGTATCATCCTTT
AGAACGAACTATCGTCAAA

CCACCATGGGATGGTCA
TGGCGGGAAGATGAAGACA

TTCTAGTAGCAACTGCAAC
ATCTCTCGCACAGTAATAC

TGTATCATCCTTTTTCTA
GATGGTGCAGCCACAGTTCG

CGGTGTACATTCTGAGGTG
ACAGCCGTGTCCTCAGCTCT

GTAGCAACTGCAACCGG
TTTGATCTCCAGCTTGGTCC

CAGCTGGTGGAGTCTGGGG
CAGGCTGTTCATTTGCAGAT

TGTACATTCAGACATCCA
CCTGGCCAAAAGTGGCCGG

GAGGCGTGGTCCAGCCTGG
ACAGCGTGTTCTTGGAATT

GTTGACCCAGTCTCCATC
AGGGGTACTGTAACTCTGTT

GAGGTCCCTGAGACTCTCC
GTCTCTGGAGATGGTGAAT

CTCCCTGTCTGCGTCTGT
GACAGTAGTAAGTTGCAAA

TGTGCAGCCTCTGGATTCAC
CGGCCCTTCACGGAGTCTG

AGGAGACAGAGTCACCA
ATCATCAGGTTGCAGACTGC

CTTCAGTAACTATGCTATAC
CGTAGTATTTATTGCTTCCA

TCACTTGCCGGGCAAGT
TGATGGTGAGAGTGAAATCT

ACTGGGTCCGCCAGGCTCC
TCATATGATATAACTGCCA

CAGAGCATTCGCAGCTA
GTCCCAGATCCACTGCCACT

AGGCAAGGGGCTGGAGTGG
CCCACTCCAGCCCCTTGCCT

TTTAAATTGGTATCAACA
GAACCTTGAAGGGACCCCA

GTGGCAGTTATATCATATG
GGAGCCTGGCGGACCCAGT

GAAACCAGGGAAAGCCC
CTTTGCAAACTGGATGCAGC

ATGGAAGCAATAAATACTA
GTATAGCATAGTTACTGAA

CTAAGCTCCTGATCTATG
ATAGATCAGGAGCTTAGGG

CGCAGACTCCGTGAAGGGC
GGTGAATCCAGAGGCTGCA

CTGCATCCAGTTTGCAAA
GCTTTCCCTGGTTTCTGTTG

CGATTCACCATCTCCAGAG
CAGGAGAGTCTCAGGGACC

GTGGGGTCCCTTCAAGG
ATACCAATTTAAATAGCTGC

ACAATTCCAAGAACACGCT
TCCCAGGCTGGACCACGCC

TTCAGTGGCAGTGGATCT
GAATGCTCTGACTTGCCCGG

GTATCTGCAAATGAACAGC
TCCCCCAGACTCCACCAGN

GGGACAGATTTCACTCTC
CAAGTGATGGTGACTCTGTC

CTGAGAGCTGAGGACACGG
CCTGCAC (SEQ ID

ACCATCAGCAGTCTGCA
TCCTACAGACGCAGACAGG

CTGTGTATTACTGTGCGAG
NO: 3311)

ACCTGATGATTTTGCAAC
GNGG (SEQ ID NO:

AGATTTTGACGATAGTTCGT

TTACTACTGTCAACAGA
3313)

TCTGGGCGTTTGACTACTGG

GTTACAGTACCCCTCCGG

GGCCAGGGAACCCTGGTCA

CCACTTTTGGCCAGGGG

CCGTCTCCTCAGCGTCGACC

ACCAAGCTGGAGATCAA

AAGGGCCCATCGGTCTTCC

ACGTACGGTGGCTGCAC

CCCTGGCACCCTCCTCCAA

CATCTGTCTTCATCTTCC

GAGCACCTCTGGGGGCACA

CGCCATCTGATGAGCAG

GCGGCCCTGGGCTGCCTGG

TTGAAATCTGGAACTGC

TCAAGGACTACTTCCCCGA

CTCTGTTGTGTGCCTGCT

ACCTGTGACGGTCTCGTGG

GAATAACTTCTATCCCAG

AACTCAGGCGCCCTGACCA

AGAGGCCAAAGTACAGT

GCGGCGTGCACACCTTCCC

GGAAGGTGGATAACGCC

GGCTGTCCTACAGTCCTCA

CTCCAATCGGGTAACTCC

GGACTCTACTCCCTCAGCA

CAGGAGAGTGTCACAGA

GCGTGGTGACCGTGCCCTC

GCAGGACAGCAAGGACA

CAGCAGCTTGGGCACCCAG

GCACCTACAGCCTCAGC

ACCTACATCTGCAACGTGA

AGCACCCTGACGCTGAG

ATCACAAGCCCAGCAACAC

CAAAGCAGACTACGAGA

CAANGTGGACAAGAGAGTT

AACACAAAGTCTACGCC

GAGCCCAAATCTTGTGACA

TGCGAAGTCACCCATCA

AAACTCACACATGCCCACC

GGGCCTGAGCTCGCCCG

GTGCCCAGCACCT (SEQ

TCACAAAGAGCTTCAAC

ID NO: 3310)

AGGGGAGAGTGTTAGAA

GCTTGGCCGCCATGGCC

CAACTTGTTTATTGCAGC

TTATAATGGTTACAAA

(SEQ ID NO: 3312)

COV21_P1
A-C019
TACACATACGATTTAGGTG
GNCGCTGTNNNNNAGAGGT
COV21_P1
TACACATACGATTTAGGT
AGGGGGCCANCTTGGGCTG
COV21_P1

G8

ACACTATAGAATAACATCC
GCTCTTGGAGGAGGGTGCC
G8
GACACTATAGAATAACA
ACCTAGGACGGTCAGCTTGG
G8

ACTTTGCCTTTCTCTCCACA
AGGGGGAAGACCGATGGGC

TCCACTTTGCCTTTCTCT
TCCCTCCGCCGAATACCACA

GGTGTCCACTCCCAGGTCC
CCTTGGTGGAGGCTGAGGA

CCACAGGTGTCCACTCCC
TGATCACTACTACTATCCCA

AACTGCACCTCGGTTCTATC
GACGGTGACCAGGGTTCCC

AGGTCCAACTGCACCTC
CACCTGACAGTAATAGTCGG

GATTGAATTCCACCATGGG
TGGCCCCAGGGGTCGAACC

GGTTCTATCGATTGAATT
CCTCATCCCCGGCTTCGACC

ATGGTCATGTATCATCCTTT
CTGGGGTCCCCTCACGGGG

CCACCATGGGATGGTCA
CTGTTGATGGTCAGGGTGGC

TTCTAGTAGCAACTGCAAC
CACTCTAGCACAGTAATAC

TGTATCATCCTTTTTCTA
CGTGTTCCCAGAGTTGGAGC

CGGTGTACATTCCCAGGTG
ACGGCCGTGTCCTCAGATC

GTAGCAACTGCAACCGG
CAGAGAATCGCTCAGGGAT

CAGCTGGTGCAGTCTGGGG
TCAGGCTGCTCAGCTCCAT

TTCTGTGACCTCCTATGA
CCCTGAGGGCCGGTCGCTAT

CTGAGGTGAAGAAGCCTGG
GTAGACTGTGCTCGTGGAC

GCTGACACAGCCACCCT
CATAATAGATGACCAGCAC

GGCCTCAGTGAAGGTTTCC
GTGTCCCTGGTCATGGTGA

CAGTGTCAGTGGCCCCA
AGGGGCCTGGCCTGGCTTCT

TGCAAGGCATCTGGATACA
CTCTGCCCTGGAACTTCTGT

GGAAAGACGGCCAGGAT
GCTGGTACCAGTGCACACTT

CCTTCACCAGTTACTATATG
GCGTAGCTTGTGCTACCAC

TACCTGTGGGGAAAACA
TTACTTCCAATGTTGTTTTCC

CACTGGGTGCGACAGGCCC
CACTAGGGTTGATTATTCCC

ACATTGGAAGTAAAAGT
CCACAGGTAATCCTGGCCGT

CTGGACAAGGGCTTGAGTG
ATCCACTCAAGCCCTTGTCC

GTGCACTGGTACCAGCA
CTTTCCTGGGGCCACTGACA

GATGGGAATAATCAACCCT
AGGGGCCTGTCGCACCCAG

GAAGCCAGGCCAGGCCC
CTGAGGGTGGCTGAGTCAG

AGTGGTGGTAGCACAAGCT
TGCATATAGTAACTGGTGA

CTGTGCTGGTCATCTATT
CACAGACTGGGCCCAGGAA

ACGCACAGAAGTTCCAGGG
AGGTGTATCCAGATGCCTT

ATGATAGCGACCGGCCC
CCGGTTGCAGNNNNNTACT

CAGAGTCACCATGACCAGG
GCAGGAAACCTTCACTGAG

TCAGGGATCCCTGAGCG
AAAANNG (SEQ ID

GACACGTCCACGAGCACAG
GCCCCAGGCTTCTTCACCTC

ATTCTCTGGCTCCAACTC
NO: 3317)

TCTACATGGAGCTGAGCAG
AGCCCCAGACTGCACCAGC

TGGGAACACGGCCACCC

CCTGAGATCTGAGGACACG
TGCACCTGNNA (SEQ ID

TGACCATCAACAGGGTC

GCCGTGTATTACTGTGCTAG
NO: 3315)

GAAGCCGGGGATGAGGC

AGTGCCCCGTGAGGGGACC

CGACTATTACTGTCAGGT

CCAGGGTTCGACCCCTGGG

GTGGGATAGTAGTAGTG

GCCAGGGAACCCTGGTCAC

ATCATGTGGTATTCGGCG

CGTCTCCTCAGCGTCGACC

GAGGGACCAAGCTGACC

AAGGGCCCATCGGTCTTCC

GTCCTAGGTCAGCCCAA

CCCTGGCACCCTCCTCCAA

GGCTGCCCCCTCGGTCAC

GAGCACCTCTGGGGGCACA

TCTGTTCCCACCCTCGAG

GCGGCCCTGGGCTGCCTGG

TGAGGAGCTTCAAGCCA

TCAAGGACTACTTCCCCGA

ACAAGGCCACACTGGTG

ACCTGTGACGGTCTCGTGG

TGTCTCATAAGTGACTTC

AACTCAGGCGCCCTGACCA

TACCCGGGAGCCGTGAC

GCGGCGTGCACACCTTCCC

AGTGGCCTGGAAGGCAG

GGCTGTCCTACAGTCCTCA

ATAGCAGCCCCGTCAAG

NGACTCTACTCCCTCAGCA

GCGGGAGTGGAGACCAC

GCGTGGTGACCGTGCCCTC

CACACCCTCCAAACAAA

CAGCAGCTTGGGCACCCAG

GCAACAACAAGTACGCG

ACCTACATCTGCAACGTGA

GCCAGCAGCTACCTGAG

ATCACAAGCCCAGCAACAC

CCTGACGCCTGAGCAGT

C (SEQ ID NO: 3314)

GGAAGTCCCACAGAAGC

TACAGCTGCCAGGTCAC

GCATGAAAGGGAGCACC

GTGGANAAGACAGTGGC

CCCTACAGAATGTTCATA

GAAGCTTGGCCGCCATG

GCCCAACTTGTTTATTGC

AGCTTATAATGG (SEQ

ID NO: 3316)

COV21_P3
A-C020
TACACATACGATTTAGGTG
GNCGCTGTNNNNNAGAGGT
COV21_P3
TACACATACGATTTAGGT
GGGGCCACCGGTGTACATTC
COV21_P3

G5

ACACTATAGAATAACATCC
GCTCTTGGAGGAGGGTGCC
G5
GACACTTATAGAATAAC
CCTCCCTGTCTGCATCTGTA
G5

ACTTTGCCTTTCTCTCCACA
AGGGGGAAGACCGATGGGC

ATCCACTTTGCCTTTCTC
GGAGACAGAGTCACCATCA

GGTGTCCACTCCCAGGTCC
CCTTGGTGGAGGCTGAGGA

TCCACAGGTGTCCACTCC
CTTGCCGGGCAAGTCAGAG

AACTGCACCTCGGTTCTATC
GACGGTGACCAGGGTTCCC

CAGGTCCAACTGCACCT
CATTAGCAGCTATTTAAATT

GATTGAATTCCACCATGGG
TGGCCCCAGTACCCCAATA

CGGTTCTATCGATTGAAT
GGTATCAGCAGAAACCAGG

ATGGTCATGTATCATCCTTT
GGTAATAACCACTACTATC

TCCACCATGGGANGGNC
GAAAGCCCCTAAGCTCCTGA

TTCTAGTAGCAACTGCAAC
ATAGTAATACGTTTCCGATC

ATGTATCATCCTTTTTCT
TCTATGCTGCATCCAGTTTG

CGGTGTACATTCCCAGGTG
CCTCGGTCTCGGCCCGATCT

AGTAGCAACTGCAACCG
CAAAGTGGGGTCCCATCAA

CAGCTGGTGCAGTCTGGGG
CTAGCACAGTAATACACGG

GTGTACATTCCCTCCCTG
GGTTCAGTGGCAGTGGATCT

CTGAGGTGAAGAAACCTGG
CCGTGTCCTCAGATCTCAG

TCTGCATCTGTAGGAGA
GGGACAGATTTCACTCTCAC

GGCCTCAGTGAAGGTTTCC
GCTGCTCAGCTCCATGTAG

CAGAGTCACCATCACTT
CATCAGCAGTCTGCAACCTG

TGCAAGGCATCTGGATACA
ACTGTGCTCGTGGACGTGT

GCCGGGCAAGTCAGAGC
AAGATTTTGCAACTTACTAC

CCTTCACCAGCTACTATATG
CCCTGGTCATGGTGACTCTG

ATTAGCAGCTATTTAAAT
TGTCAACAGAGTTACAGTAC

CACTGGGTGCGACAGGCCC
CCCTGGAACTTCTGTGCGTA

TGGTATCAGCAGAAACC
CCCACCGTCGTTCGGCCAAG

CTGGACAAGGGCTTGAGTG
GGTTGTGCTACCACCACTA

AGGGAAAGCCCCTAAGC
GGACCAAGGTGGAAATCAA

GATGGGAATAATCAACCCT
GGGTTGATTATTCCCATCCA

TCCTGATCTATGCTGCAT
ACGGTGGAGGCACCAAGCT

AGTGGTGGTAGCACAACCT
CTCAAGCCCTTGTCCAGGG

CCAGTTTGCAAAGTGGG
GGAAATCAAACGTACGGGC

ACGCACAGAAGTTCCAGGG
GCCTGTCGCACCCAGTGCA

GTCCCATCAAGGTTCAGT
A (SEQ ID NO: 3321)

CAGAGTCACCATGACCAGG
TATAGTAGCTGGTGAAGGT

GGCAGTGGATCTGGGAC

GACACGTCCACGAGCACAG
GTATCCAGATGCCTTGCAG

AGATTTCACTCTCACCAT

TCTACATGGAGCTGAGCAG
GAAACCTTCACTGAGGCCC

CAGCAGTCTGCAACCTG

CCTGAGATCTGAGGACACG
CAGGTTTCTTCACCTCAGCC

AAGATTTTGCAACTTACT

GCCGTGTATTACTGTGCTAG
CCAGACTGCACCAGCTGCA

ACTGTCAACAGAGTTAC

AGATCGGGCCGAGACCGAG
CCNNNGACANGACCCC

AGTACCCCACCGTCGTTC

GGATCGGAAACGTATTACT
(SEQ ID NO: 3319)

GGCCAAGGGACCAAGGT

ATGATAGTAGTGGTTATTA

GGAAATCAAACGGTGGA

CCTATTGGGGTACTGGGGC

GGCACCAAGCTGGAAAT

CAGGGAACCCTGGTCACCG

CAAACGTACGGTGGCTG

TCTCCTCAGCGTCGACCAA

CACCATCTGTCTTCATCT

GGGCCCATCGGTCTTCCCCC

TCCCGCCATCTGATGAGC

TGGCACCCTCCTCCAAGAG

AGTTGAAATCTGGAACT

CACCTCTGGGGGCACAGCG

GCCTCTGTTGTGTGCCTG

GCCCTGGGCTGCCTGGTCA

CTGAATAACTTCTATCCC

AGGACTACTTCCCCGAACC

AGAGAGGCCAAAGTACA

TGTGACGGTCTCGTGGAAC

GTGGAAGGTGGATAACG

TCAGGCGCCCTGACCAGCG

CCCTCCAATCGGGTAACT

GCGTGCACACCTTCCCGGC

CCCAGGAGAGTGTCACA

TGTCCTACAGTCCTCANGA

GAGCAGGACAGCAAGGA

CTCTACTCCCTCAGCAGCGT

CAGCACCTACAGCCTCA

GGTGACCGTGCCCTCCAGC

GCAGCACCCTGACGCTG

AGCTTGGGCACCCAGACCT

AGCAAAGCAGACTACGA

ACATCTGCAACGTGAATCA

GAAACACAAAGTCTACG

CAAGCCCAGCAACACCA

CCTGCGAAGTCACCCAT

(SEQ ID NO: 3318)

CAGGGCCTGAGCTCGCC

CGTCACAAAGAGCTTCA

ACAGGGGAGAGTGTTAG

AAGCTTGGCCGCCATGG

CCCAACTTGTTTATTGCA

GCTTATAATGGTTACAA

ATAAAGCAATAG (SEQ

ID NO: 3320)

COV21_P3
A-C021
TACACATACGATTTAGGTG
GCTGTGNNNNNGAGGTGCT
COV21_P3
TACACATACGATTTAGGT
TNNCCGATTGGAGGGCGTTA
COV21_P3

E7

ACACTATAGAATAACATCC
CTTGGAGGAGGGTGCCAGG
E7
GACACTATAGAATAACA
TCCACCTTCCACTGTACTTT
E7

ACTTTGCCTTTCTCTCCACA
GGGAAGACCGATGGGCCCT

TCCACTTTGCCTTTCTCT
GGCCTCTCTGGGATAGAAGT

GGTGTCCACTCCCAGGTCC
TGGTGGAGGCTGAGGAGAC

CCACAGGTGTCCACTCCC
TATTCAGCAGGCACACAAC

AACTGCACCTCGGTTCTATC
GGTGACCAGGGTTCCCTGG

AGGTCCAACTGCACCTC
AGAGGCAGTTCCAGATTTCA

GATTGAATTCCACCATGGG
CCCCAGTAGTCAAAGGAAC

GGTTCTATCGATTGAATT
ACTGCTCATCAGATGGCGGG

ATGGTCATGTATCATCCTTT
CACTACTATCATAGTATTGC

CCACCATGGGATGGTCA
AAGATGAAGACAGATGGTG

TTCTAGTAGCAACTGCAAC
CAAACTCTCGCACAGTAAT

TGTATCATCCTTTTTCTA
CAGCCACAGTTCGTTTGATA

CGGTGTACATTCCCAGGTG
ACACGGCCGTGTCCGCGGC

GTAGCAACTGCAACCGG
TCCACTTTGGTCCCAGGGCC

CAGCTGCAGGAGTCGGGCC
AGTCACAGAGCTCAGCTTC

TGTACATGGGGATATTGT
GAAAGTGAATGGAGTTTGT

CAGGACTGGTGAAGCCTTC
AGGGAGAACTGGTTCTTAG

GATGACTCAGTCTCCACT
AGAGCTTGCATGCAGTAATA

ACAGACCCTGTCCCTCACCT
ACGTGTCTACTGATATGGT

CTCCCTGCCCGTCACCCC
AACCCCAACATCCTCAGCCT

GCACTGTCTCTGGTGGCTCC
AACTCGACTCTTGAGGGAC

TGGAGAGCCGGCCTCCA
CCACTCTGCTGATTTTCAGT

ATCAGCAGTGGTGGTTACT
GGGTTGTAGTAGGTGCTCC

TCTCCTGCAGGTCTAGTC
GTAAAATCTGTGCCTGATCC

ACTGGAGCTGGATCCGCCA
CACTGTAATAGATGTACCC

AGAGCCTCCTGCATAGT
ACTGCCACTGAACCTGTCAG

GCACCCAGGGAAGGGCCTG
AATCCACTCCAGGCCCTTCC

AATGGATACAACTATTT
GGACCCCGGAGGCCCGATT

GAGTGGATTGGGTACATCT
CTGGGTGCTGGCGGATCCA

GGATTGGTACCTGCAGA
AGAACCCAAATAGATCAGG

ATTACAGTGGGAGCACCTA
GCTCCAGTAGTAACCACCA

AGCCAGGGCAGTCTCCA
AGCTGTGGAGACTGCCCTGG

CTACAACCCGTCCCTCAAG
CTGCTGATGGAGCCACCAG

CAGCTCCTGATCTATTTG
CTTCTGCAGGTACCAATCCA

AGTCGAGTTACCATATCAG
AGACAGTGCAGGTGAGGGA

GGTTCTAATCGGGCCTCC
AATAGTTGTATCCATTACTA

TAGACACGTCTAAGAACCA
CAGGGTCTGTGAAGGCTTC

GGGGTCCCTGACAGGTT
TGCAGGAGGCTCTGACTAG

GTTCTCCCTGAAGCTGAGCT
ACCAGTCCTGGGCCCGACT

CAGTGGCAGTGGATCAG
ACCTGCAGGAGATGGAGGC

CTGTGACTGCCGCGGACAC
CCTGCAGCTGCACCT

GCACAGATTTTACACTG
CGGCTCTCCAGGGGTGACG

GGCCGTGTATTACTGTGCG
(SEQ ID NO: 3323)

AAAATCAGCAGAGTGGA
GGCAGGGAGGATGGA (SEQ

AGAGTTTGGCAATACTATG

GGCTGAGGATGTTGGGG
ID NO: 3325)

ATAGTAGTGGTTCCTTTGAC

TTTATTACTGCATGCAAG

TACTGGGGCCAGGGAACCC

CTCTACAAACTCCATTCA

TGGTCACCGTCTCCTCAGCG

CTTTCGGCCCTGGGACCA

TCGACCAAGGGCCCATCGG

AAGTGGATATCAAACGT

TCTTCCCCCTGGCACCCTCC

ACGGTGGCTGCACCATC

TCCAAGAGCACCTCTGGGG

TGTCTTCATCTTCCCGCC

GCACAGCGGCCCTGGGCTG

ATCTGATGAGCAGTTGA

CCTGGTCAAGGACTACTTC

AATCTGGAACTGCCTCTG

CCCGAACCTGTGACGGTCT

TTGTGTGCCTGCTGAATA

CGTGGAACTCANGCGCCCT

ACTTCTATCCCAGAGAG

GACCAGCGGCGTGCACACC

GCCAAAGTACAGTGGAA

TTCCCGGCTGTCCTACAGTC

GGTGGATAACGCCCTCC

CTCAGGACTCTACTCCCTCA

AATCGGGTAACTCCCAG

GCAGCGTGGTGACCGTGCC

GAGAGTGTCACAGAGCA

CTCCAGCAGCTTGGGCACC

GGACAGCAAGGACAGCA

CAGACCTACATCTGCAACG

CCTACAGCCTCAGCAGC

TGAATCACAAGCCCAGCAA

ACCCTGACGCTGANCAA

CACCAAGGTGGACAAGAGA

AGCAGACTACGAGAAAC

GTTGAGCCCAAATCTTGTG

ACAAAGTCTACGCCTGC

ACAAAACTCACACATGCCC

GAAGTCACCCATCNGGC

ACCGTGCCCAGCACC

CTGAGCTCGCCCGTCAC

(SEQ ID NO: 3322)

AAAGANCTTCAACAGGG

GANANTGTTANAAGCTT

GGNCGCCATGGCCCAAC

TTGTTTATTGCAGCTTAT

AATGG (SEQ ID NO:

3324)

COV21_P2
A-C029
TACACATACGATTTAGGTG
GCTNNGCCCCAGAGGTGCT
COV21_P2
TACACATACGATTTAGGT
TTNCCCGATTGGAGGGCGTT
COV21_P2

E6

ACACTATAGAATAACATCC
CTTGGAGGAGGGTGCCAGG
E6
GACACTATAGAATAACA
ATCCACCTTCCACTGTACTT
E6

ACTTTGCCTTTCTCTCCACA
GGGAAGACCGATGGGCCCT

TCCACTTTGCCTTTCTCT
TGGCCTCTCTGGGATAGAAG

GGTGTCCACTCCCAGGTCC
TGGTGGAGGCTGAGGAGAC

CCACAGGTGTCCACTCCC
TTATTCAGCAGGCACACAAC

AACTGCACCTCGGTTCTATC
GGTGACCAGGGTTCCCTGG

AGGTCCAACTGCACCTC
AGAGGCAGTTCCAGATTTCA

GATTGAATTCCACCATGGG
CCCCAGTAGTCAAAGGAAC

GGTTCTATCGATTGAATT
ACTGCTCATCAGATGGCGGG

ATGGTCATGTATCATCCTTT
CACTACTATCATAGTAATA

CCACCATGGGATGGTCA
AAGATGAAGACAGATGGTG

TTCTAGTAGCAACTGCAAC
CATTGTTCTCGCACAGTAAT

TGTATCATCCTTTTTCTA
CAGCCACAGTTCGTTTGATC

CGGTGTACATTCCCAGGTG
ACACGGCCGTGTCCGCGGC

GTAGCAACTGCAACCGG
TCCACCTTGGTCCCTCCGCC

CAGCTGCAGGAGTCGGGCC
AGTCACAGAGCTCAGCTTC

TGTACATGGGGATATTGT
GAAAGTGTGAGGAGTTTGT

CAGGACTGGTGAAGCCTTC
AGGGAGAACTGGTTCTTAG

GATGACTCAGTCTCCACT
AGAGCTTGCATGCAGTAATA

ACAGACCCTGTCCCTCACCT
ACGTGTCTACTGATATGGT

CTCCCTGCCCGTCACCCC
AACCCCAACATCCTCAGCCT

GCACTGTCTCTGGTGGCTCC
AACTCGACTCTTGAGGGAC

TGGAGAGCCGGCCTCCA
CCACTCTGCTGATTTTCAGT

ATCAGCAGTGGTGGTTACT
GGGTTGTAGTAGGTGCTCC

TCTCCTGCAGGTCTAGTC
GTAAAATCTGTGCCTGATCC

ACTGGAGCTGGATCCGCCA
CACTGTAATAGATGTACCC

AGAGCCTCCTGCATAGT
ACTGCCACTGAACCTGTCAG

GCACCCAGGGAAGGGCCTG
AATCCACTCCAGGCCCTTCC

AATGGATACAACTATTT
GGACCCCGGAGGCCCGATT

GAGTGGATTGGGTACATCT
CTGGGTGCTGGCGGATCCA

GGATTGGTACCTGCAGA
AGAACCCAAATAGATCAGG

ATTACAGTGGGAGCACCTA
GCTCCAGTAGTAACCACCA

AGCCAGGGCAGTCTCCA
AGCTGTGGAGACTGCCCTGG

CTACAACCCGTCCCTCAAG
CTGCTGATGGAGCCACCAG

CAGCTCCTGATCTATTTG
CTTCTGCAGGTACCAATCCA

AGTCGAGTTACCATATCAG
AGACAGTGCAGGTGAGGGA

GGTTCTAATCGGGCCTCC
AATAGTTGTATCCATTACTA

TAGACACGTCTAAGAACCA
CAGGGTCTGTGAAGGCTTC

GGGGTCCCTGACAGGTT
TGCAGGAGGCTCTGACTAG

GTTCTCCCTGAAGCTGAGCT
ACCAGTCCTGGGCCCGACT

CAGTGGCAGTGGATCAG
ACCTGCAGGAGATGGAGGC

CTGTGACTGCCGCGGACAC
CCTGCAGCTTNNACC

GCACAGATTTTACACTG
CGGCTCTCCAGGGGTGACG

GGCCGTGTATTACTGTGCG
(SEQ ID NO: 3327)

AAAATCAGCAGAGTGGA
GGCAGGGAGANTGGAGNNT

AGAACAATGTATTACTATG

GGCTGAGGATGTTGGGG
NNG (SEQ ID NO:

ATAGTAGTGGTTCCTTTGAC

TTTATTACTGCATGCAAG
3329)

TACTGGGGCCAGGGAACCC

CTCTACAAACTCCTCACA

TGGTCACCGTCTCCTCAGCG

CTTTCGGCGGAGGGACC

TCGACCAAGGGCCCATCGG

AAGGTGGAGATCAAACG

TCTTCCCCCTGGCACCCTCC

TACGGTGGCTGCACCAT

TCCAAGAGCACCTCTGGGG

CTGTCTTCATCTTCCCGC

GCACAGCGGCCCTGGGCTG

CATCTGATGAGCAGTTG

CCTGGTCAAGGACTACTTC

AAATCTGGAACTGCCTCT

CCCGAACCTGTGACGGTCT

GTTGTGTGCCTGCTGAAT

CGTGGAACTCAGGCGCCCT

AACTTCTATCCCAGAGA

GACCAGCGGCGTGCACACC

GGCCAAAGTACAGTGGA

TTCCCGGCTGTCCTACAGTC

AGGTGGATAACGCCCTC

CTCAGGACTCTACTCCCTCA

CAATCGGGTAACTCCCA

GCAGCGTGGTGACCGTGCC

GGAGAGTGTCACAGAGC

CTCCAGCAGCTTGGGCACC

AGGACAGCAAGGACAGC

CAGACCTACATCTGCAACG

ACCTACAGCCTCAGCAG

TGAATCACAAGCCCAGCAA

CACCCTGACGCTGANCA

CACCAANGTGGACAAGAGA

AAGCAGACTACGAGAAA

GTTGAGCCCAAATCTTGTG

CACAAAGTCTACGCCTG

ACAAAACTCACACATGCCC

CGAAGTCACCCATCNGG

ACCGTGCCCAGCACC

NCTGAGCTCGCCCGTCA

(SEQ ID NO: 3326)

CAAAGAGCTTCAACNGG

GGANAGTGTTAGAAGCT

TGGCCGCCATGGCCCAA

CTTGTTTATTGCAGCTTA

TAATGG (SEQ ID NO:

3328)

COV21_P1
A-C022
TACACATACGATTTAGGTG
GCTGTGCCCCAGAGGTGCT
COV21_P1
TACACATACGATTTAGGT
CTGGNNTTNCCCGATTGGAG
COV21_P1

B10

ACACTATAGAATAACATCC
CTTGGAGGAGGGTGCCAGG
B10
GACACTATAGAATAACA
GGCGTTATCCACCTTCCACT
B10

ACTTTGCCTTTCTCTCCACA
GGGAAGACCGATGGGCCCT

TCCACTTTGCCTTTCTCT
GTACTTTGGCCTCTCTGGGA

GGTGTCCACTCCCAGGTCC
TGGTGGAGGCTGAGGAGAC

CCACAGGTGTCCACTCCC
TAGAAGTTATTCAGCAGGCA

AACTGCACCTCGGTTCTATC
GGTGACCAGGGTGCCCTGG

AGGTCCAACTGCACCTC
CACAACAGAGGCAGTTCCA

GATTGAATTCCACCATGGG
CCCCAGTGCTGGAAGTATT

GGTTCTATCGATTGAATT
GATTTCAACTGCTCATCAGA

ATGGTCATGTATCATCCTTT
CGATGAAATAATAACCACT

CCACCATGGGATGGTCA
TGGCGGGAAGATGAAGACA

TTCTAGTAGCAACTGCAAC
TCTATCATAGTATGCTGCCG

TGTATCATCCTTTTTCTA
GATGGTGCAGCCACAGTTCG

CGGTGTACATTCCCAGGTG
CATGTCTCGCACAGTAATA

GTAGCAACTGCAACCGG
TTTGATCTCCAGCTTGGTCC

CAGTTGCAGGAGTCGGGCC
CACAGCCGTGTCTGCGGCG

TGTACATTCTGACATCCA
CCTGGCCAAAAGTGTACCG

CAGGACTGGTGAAGCCTTC
GTCACAGAGCTCAGCTTCA

GATGACCCAGTCTCCTTC
GTAATTATTATACTGTTGGC

GGAGACCCTGTCCGTCACT
GGGAGAACTGGTTCTTGGA

CACCCTGTCTGCATCTGT
AGTAATAAGTTGCAAAATC

TGCACTGTCTCTGGTGGCTC
CGTGTCCACGGATATGGTG

AGGAGACAGCGTCACCA
ATCAGGCTGCAGGCTGCTGA

CATCAGCAGTAGTAGGTAC
ACTCGACTCTTGAGGGACG

TCACTTGCCGGGCCAGTC
TGGTGAGAGTGAATTCTGTC

TACTGGGGCTGGATCCGCC
GGTTGTAGTAGGTGCTCCC

AGAGTATTAGTAGCTGG
CCAGATCCACTGCCGCTGAA

AGCCCCCAGGGAAGGGGCT
ACTATAATAGATACTCCCA

TTGGCCTGGTATCAGCA
CCTTGATGGGACCCCACTTT

GGAGTGGATTGGGAGTATC
ATCCACTCCAGCCCCTTCCC

GAAACCAGGGAAAGCCC
CTAAACTAGACGCCTTATAG

TATTATAGTGGGAGCACCT
TGGGGGCTGGCGGATCCAG

CTAAGCTCCTGATCTATA
ATCAGGAGCTTAGGGGCTTT

ACTACAACCCGTCCCTCAA
CCCCAGTAGTACCTACTACT

AGGCGTCTAGTTTAGAA
CCCTGGTTTCTGCTGATACC

GAGTCGAGTCACCATATCC
GCTGATGGAGCCACCAGAG

AGTGGGGTCCCATCAAG
AGGCCAACCAGCTACTAAT

GTGGACACGTCCAAGAACC
ACAGTGCAAGTGACGGACA

GTTCAGCGGCAGTGGAT
ACTCTGACTGGCCCGGCAAG

AGTTCTCCCTGAAGCTGAG
GGGTCTCCGAAGGCTTCAC

CTGGGACAGAATTCACT
TGATGGTGACGCTGTCTCCT

CTCTGTGACCGCCGCAGAC
CAGTCCTGGGCCCGACTCC

CTCACCATCAGCAGCCT
ACAGATGCAGACAGGG

ACGGCTGTGTATTACTGTGC
NG (SEQ ID NO: 3331)

GCAGCCTGATGATTTTGC
(SEQ ID NO: 3333)

GAGACATGCGGCAGCATAC

AACTTATTACTGCCAACA

TATGATAGAAGTGGTTATT

GTATAATAATTACCGGT

ATTTCATCGAATACTTCCAG

ACACTTTTGGCCAGGGG

CACTGGGGCCAGGGCACCC

ACCAAGCTGGAGATCAA

TGGTCACCGTCTCCTCAGCC

ACGTACGGTGGCTGCAC

TCCACCAAGGGCCCATCGG

CATCTGTCTTCATCTTCC

TCTTCCCCCTGGCACCCTCC

CGCCATCTGATGAGCAG

TCCAAGAGCACCTCTGGGG

TTGAAATCTGGAACTGC

GCACAGCGGCCCTGGGCTG

CTCTGTTGTGTGCCTGCT

CCTGGTCAAGGACTACTTC

GAATAACTTCTATCCCAG

CCCGAACCTGTGACGGTCT

AGAGGCCAAAGTACAGT

CGTGGAACTCANGCGCCCT

GGAAGGTGGATAACGCC

GACCAGCGGCGTGCACACC

CTCCAATCGGGTAACTCC

TTCCCGGCTGTCCTACAGTC

CAGGAGAGTGTCACAGA

CTCAGGACTCTACTCCCTCA

GCAGGACAGCAAGGACA

GCAGCGTGGTGACCGTGCC

GCACCTACAGCCTCAGC

CTCCAGCAGCTTGGGCACC

AGCACCCTGACGCTGAG

CAGACCTACATCTGCAACG

CAAAGCAGACTACGAGA

TGAATCACAAGCCCAGCAA

AACACAAAGTCTACGCC

CACCAANNGGACAAGAGA

TGCGAAGTCACCCATCA

GTTGAGCCCAAATCTTGTG

GGGCCTGAGCTCGCCCG

AC (SEQ ID NO: 3330)

TCACAAAGAGCTTCAAC

NGGGGAGAGTGTTAGAA

GCTTGGNCGCCATGGCC

CAACTTGTTTATTGCAGC

TTATAATGG (SEQ ID

NO: 3332)

COV21_P1
A-C027
TACACATACGATTTAGGTG
GCTGNGCCCCAGAGGTGCT
COV21_P1
TACACATACGATTTAGGT
CGATTGGAGGGCGTTATCCA
COV21_P1

G4

ACACTATANAATAACATCC
CTTGGAGGAGGGTGCCAGG
G4
GACACTATAGAATAACA
CCTTCCACTGTACTTTGGCC
G4

ACTTTGCCTTTCTCTCCACA
GGGAAGACCGATGGGCCCT

TCCACTTTGCCTTTCTCT
TCTCTGGGATAGAAGTTATT

GGTGTCCACTCCCAGGTCC
TGGTGGAGGCTGAGGAGAC

CCACAGGTGTCCACTCCC
CAGCAGGCACACAACAGAG

AACTGCACCTCGGTTCTATC
GGTGACCAGGGTTCCCTGG

AGGTCCAACTGCACCTC
GCAGTTCCAGATTTCAACTG

GATTGAATTCCACCATGGG
CCCCAGTAGTCAAAGTAGT

GGTTCTATCGATTGAATT
CTCATCAGATGGCGGGAAG

ATGGTCATGTATCATCCTTT
ATGAGTAGCAGTCTCCACC

CCACCATGGGATGGTCA
ATGAAGACAGATGGTGCAG

TTCTAGTAGCAACTGCAAC
ACTACAATAAATTCCACTT

TGTATCATCCTTTTTCTA
CCACAGTTCGTTTGATTTCC

CGGTGTACATTCTGAGGTG
GCTTTCGCACAGTAATACA

GTAGCAACTGCAACCGG
ACCTTGGTCCCTTGGCCGAA

CAGCTGGTGGAGTCTGGGG
CAGCCGTGTCCTCAGCTCTC

TGTACATTCTGACATCCA
CGTCGAATAACTATTATACT

GAGGCGTGGTCCAGCCTGG
AGGCTGTTCATTTGCAGAT

GATGACCCAGTCTCCTTC
GTTGGCAGTAATAAGTTGCA

GAGGTCCCTGAGACTCTCC
ACAGCGTGTTCTTGGAATT

CACCCTGTCTGCATCTGT
AAATCATCAGGCTGCAGGCT

TGTGCAGCCTCTGGATTCAC
GTCTCTGGAGATGGTGAAT

AGGAGACAGAGTCACCA
GCTGATGGTGAGAGTGAATT

CTTCAGTAGCTATGGCATG
CGGCCCTTCACGGAGTCTG

TCACTTGCCGGGCCAGTC
CTGTCCCAGATCCACTGCCG

CACTGGGTCCGCCAGGCTC
CATAGTATTTATTACTTCCA

AGAGTATTAGTAGCTGG
CTGAACCTTGATGGGACCCC

CAGGCAAGGGGCTGGAGTG
TCATATGATATAACTGCCA

TTGGCCTGGTATCAGCA
ACTTTCTAAACTAGACGCCT

GGTGGCAGTTATATCATAT
CCCACTCCAGCCCCTTGCCT

GAAACCAGGGAAAGCCC
TATAGATCAGGAGCTTAGG

GATGGAAGTAATAAATACT
GGAGCCTGGCGGACCCAGT

CTAAGCTCCTGATCTATA
GGCTTTCCCTGGTTTCTGCT

ATGCAGACTCCGTGAAGGG
GCATGCCATAGCTACTGAA

AGGCGTCTAGTTTAGAA
GATACCAGGCCAACCAGCT

CCGATTCACCATCTCCAGA
GGTGAATCCAGAGGCTGCA

AGTGGGGTCCCATCAAG
ACTAATACTCTGACTGGCCC

GACAATTCCAAGAACACGC
CAGGAGAGTCTCAGGGACC

GTTCAGCGGCAGTGGAT
GGCAAGTGATGGTGACTCTG

TGTATCTGCAAATGAACAG
TCCCAGGCTGGACCACGCC

CTGGGACAGAATTCACT
TCTCCTACAGATGCAGACAG

CCTGAGAGCTGAGGACACG
TCCCCCAGACTCCACCAGC

CTCACCATCAGCAGCCT
GGNG (SEQ ID NO:

GCTGTGTATTACTGTGCGA
TGCA (SEQ ID NO:

GCAGCCTGATGATTTTGC
3337)

AAGCAAGTGGAATTTATTG
3335)

AACTTATTACTGCCAACA

TAGTGGTGGAGACTGCTAC

GTATAATAGTTATTCGAC

TCATACTACTTTGACTACTG

GTTCGGCCAAGGGACCA

GGGCCAGGGAACCCTGGTC

AGGTGGAAATCAAACGT

ACCGTCTCCTCAGCGTCGA

ACGGTGGCTGCACCATC

CCAAGGGCCCATCGGTCTT

TGTCTTCATCTTCCCGCC

CCCCCTGGCACCCTCCTCCA

ATCTGATGAGCAGTTGA

AGAGCACCTCTGGGGGCAC

AATCTGGAACTGCCTCTG

AGCGGCCCTGGGCTGCCTG

TTGTGTGCCTGCTGAATA

GTCAAGGACTACTTCCCCG

ACTTCTATCCCAGAGAG

AACCTGTGACGGTCTCGTG

GCCAAAGTACAGTGGAA

GAACTCANGCGCCCTGACC

GGTGGATAACGCCCTCC

AGCGGCGTGCACACCTTCC

AATCGGGTAACTCCCAG

CGGCTGTCCTACAGTCCTCA

GAGAGTGTCACAGAGCA

GNACTCTACTCCCTCAGCA

GGACAGCAAGGACAGCA

GCGTGGTGACCGTGCCCTC

CCTACAGCCTCAGCAGC

CAGCAGCTTGGGCACCCAG

ACCCTGACGCTGAGCAA

ACCTACATCTGCAACGTGA

AGCANACTACGAGAAAC

ATCACAAGCCCAGCAACAC

ACAAAGTCTACGCCTGC

CAAGGTGGNANNAGAGAGT

GAAGTCACCCATCNGGN

TGAGCCCAAATCTTGTGAN

CNTGANCTCGCCCGTCA

AAAACTCACACATGCCC

CAAAGAGCTTCAACAGG

(SEQ ID NO: 3334)

GGAGAGTGTTAGAAGCT

TGGCCGCCATGGCCCAA

CTTGTTTATTGCAGCTTA

TAATGGNTACAAATAAA

GCAATAGCATCA (SEQ

ID NO: 3336)

COV21_P2
A-C030
TACACATACGATTTAGGTG
AGAGGTGCTCTTGGAGGAG
COV21_P2
TACACATACGATTTAGGT
TTACCCGATTGGAGGGCGTT
COV21_P2

B2

ACACTATAGAATAACATCC
GGTGCCAGGGGGAAGACCG
B2
GACACTATAGAATAACA
ATCCACCTTCCACTGTACTT
B2

ACTTTGCCTTTCTCTCCACA
ATGGGCCCTTGGTGGAGGC

TCCACTTTGCCTTTCTCT
TGGCCTCTCTGGGATAGAAG

GGTGTCCACTCCCAGGTCC
TGAGGAGACGGTGACCAGG

CCACAGGTGTCCACTCCC
TTATTCAGCAGGCACACAAC

AACTGCACCTCGGTTCTATC
GTTCCCTGGCCCCAGTAGTC

AGGTCCAACTGCACCTC
AGAGGCAGTTCCAGATTTCA

GATTGAATTCCACCATGGG
AAAGTAGTATGAGTAGCAG

GGTTCTATCGATTGAATT
ACTGCTCATCAGATGGCGGG

ATGGTCATGTATCATCCTTT
TTACCACCACTACAATATAT

CCACCATGGGATGGTCA
AAGATGAAGACAGATGGTG

TTCTAGTAGCAACTGCAAC
TCCACTTGCTTTCGCACAGT

TGTATCATCCTTTTTCTA
CAGCCACAGTTCGTTTGATT

CGGTGTACATTCTGAGGTG
AATACACAGCCGTGTCCTC

GTAGCAACTGCAACCGG
TCCACCTTGGTCCCTTGGCC

CAGCTGGTGGAGTCTGGGG
AGCTCTCAGGCTGTTCATTT

TGTACATTCTGACATCCA
GAACGTCGAATAACTATTAT

GAGGCGTGGTCCAGCCTGG
GCAGATACAGCGTGTTCTT

GATGACCCAGTCTCCTTC
ACTGTTGGCAGTAATAAGTT

GAGGTCCCTGAGACTCTCC
GGAATTGTCTCTGGAGATG

CACCCTGTCTGCATCTGT
GCAAAATCATCAGGCTGCA

TGTGCAGCCTCTGGATTCAC
GTGAATCGGCCCTTCACGG

AGGAGACAGAGTCACCA
GGCTGCTGATGGTGAGAGT

CTTCAGTAGCTATGGCATG
AGTCTGCATAGTATTTATTA

TCACTTGCCGGGCCAGTC
GAATTCTGTCCCAGATCCAC

CACTGGGTCCGCCAGGCTC
CTTCCATCATATGATATAAC

AGAGTATTAGTAGCTGG
TGCCGCTGAACCTTGATGGG

CAGGCAAGGGGCTGGAGTG
TGCCACCCACTCCAGCCCCT

TTGGCCTGGTATCAGCA
ACCCCACTTTCTAAACTAGA

GGTGGCAGTTATATCATAT
TGCCTGGAGCCTGGCGGAC

GAAACCAGGGAAAGCCC
CGCCTTATAGATGAGGAGCT

GATGGAAGTAATAAATACT
CCAGTGCATGCCATAGCTA

CTAAGCTCCTCATCTATA
TAGGGGCTTTCCCTGGTTTC

ATGCAGACTCCGTGAAGGG
CTGAAGGTGAATCCAGAGG

AGGCGTCTAGTTTAGAA
TGCTGATACCAGGCCAACCA

CCGATTCACCATCTCCAGA
CTGCACAGGAGAGTCTCAG

AGTGGGGTCCCATCAAG
GCTACTAATACTCTGACTGG

GACAATTCCAAGAACACGC
GGACCTCCCAGGCTGGACC

GTTCAGCGGCAGTGGAT
CCCGGCAAGTGATGGTGACT

TGTATCTGCAAATGAACAG
ACGCCTCCCCCAGACTCCA

CTGGGACAGAATTCACT
CTGTCTCCTACAGATGCAGA

CCTGAGAGCTGAGGACACG
NNNNCTGCAC (SEQ ID

CTCACCATCAGCAGCCT
CAGGGAGACTGGAGNNNNG

GCTGTGTATTACTGTGCGA
NO: 3339)

GCAGCCTGATGATTTTGC
GGTCA (SEQ ID NO:

AAGCAAGTGGAATATATTG

AACTTATTACTGCCAACA
3341)

TAGTGGTGGTAACTGCTAC

GTATAATAGTTATTCGAC

TCATACTACTTTGACTACTG

GTTCGGCCAAGGGACCA

GGGCCAGGGAACCCTGGTC

AGGTGGAAATCAAACGT

ACCGTCTCCTCAGCGTCGA

ACGGTGGCTGCACCATC

CCAAGGGCCCATCGGTCTT

TGTCTTCATCTTCCCGCC

CCCCCTGGCACCCTCCTCCA

ATCTGATGAGCAGTTGA

AGAGCACCTCTGGGGGCAC

AATCTGGAACTGCCTCTG

AGCGGCCCTGGGCTGCCTG

TTGTGTGCCTGCTGAATA

GTCAAGGACTACTTCCCCG

ACTTCTATCCCAGAGAG

AACCTGTGACGGTCTCGTG

GCCAAAGTACAGTGGAA

GAACTCANGCGCCCTGACC

GGTGGATAACGCCCTCC

AGCGGCGTGCACACCTTCC

AATCGGGTAACTCCCAG

CGGCTGTCCTACAGTCCTCN

GAGAGTGTCACAGAGCA

NNCTCTACTCCCTCAGCAG

NGACAGCAAGGACAGCA

CGTGGTGACCGTGCCCTCC

CCTACAGCCTCAGCAGC

AGCAGCTTGGGCACCCAGA

ACCCTGACGCTGAGCAA

CCTACATCTGCAACGTGAA

AGCAGACTACGAGAAAC

TCACAAGCCCAGCAACACC

ACAAAGTCTACGCCTGC

ANNNGGACAAGANAGTTGA

GAAGTCACCCATCNGNC

GCCCAAATCTTGTGACAAA

CTGAGCTCGCCCGTCAC

ACTCACACATGCCCACCG

AAAGAGCTTCAACAGGG

(SEQ ID NO: 3338)

GANAGTGTTAGAAGCTT

GGCCGCCATGGCCCAAC

TTGTTTATTGCAGCTTAT

AATGGTTACAAATAAAG

CAATAGCATCAC (SEQ

ID NO: 3340)

COV21_P1
A-C031
TACACATACGATTTAGGTG
CGCTGTGCCCCNGAGGTGC
COV21_P1
TACACATACGATTTAGGT
TACCCGATTGGAGGGCGTTA
COV21_P1

A10

ACACTATAGAATAACATCC
TCCTGGAGCAGGGCGCCAG
A10
GACACTATAGAATAACA
TCCACCTTCCACTGTACTTT
A10

ACTTTGCCTTTCTCTCCNCN
GGGGAAGACCGATGGGCCC

TCCACTTTGCCTTTCTCT
GGCCTCTCTGGGATAGAAGT

GGTGTCCACTCCCAGGTCC
TTGGTGGAAGCTGAGGAGA

CCACAGGTGTCCACTCCC
TATTCAGCAGGCACACAAC

AACTGCACCTCGGTTCTATC
CAGTGACCAGGGTGCCACG

AGGTCCAACTGCACCTC
AGAGGCAGTTCCAGATTTCA

GATTGAATTCCACCATGGG
GCCCCAGAGATCGAAGTAC

GGTTCTATCGATTGAATT
ACTGCTCATCAGATGGCGGG

ATGGTCATGTATCATCCTTT
CAGCCCGAATAACCACTAC

CCACCATGGGATGGTCA
AAGATGAAGACAGATGGTG

TTCTAGTAGCAACTGCAAC
TATCATACCCTACTCTTGCA

TGTATCATCCTTTTTCTA
CAGCCACAGTTCGTTTGATC

CGGTGTACATTCTGAGGTG
CAGTAATACACAGCCGTGT

GTAGCAACTGCAACCGG
TCCACCTTGGTCCCTCCGCC

CAGCTGGTGGAGTCTGGGG
CCCCGGCTCTCAGGCTGTTC

TGTACATTCTGACATCCA
GAAAGTGAGCGGAGGGGTA

GAGGCTTGGTACAGCCTGG
ATTTGAAGATACAAGGAGT

GATGACCCAGTCTCCATC
CTGTAACTCTGTTGACAGTA

GGGGTCCCTGAGACTCTCC
TCTTGGCATTTTCTCTGGAG

CTCCCTGTCTGCATCTGT
GTAAGTTGCAAAATCTTCAG

TGTGCAGCCTCTGGATTCAC
ATGGTGAATCGGCCCTTCA

AGGAGACAGAGTCACCA
GTTGCAGACTGCTGATGGTG

CTTCAGTAGCTACGACATG
CGGAGCCTGGATAGTATGT

TCACTTGCCGGGCAAGT
AGAGTGAAATCTGTCCCAG

CACTGGGTCCGCCAAGCTA
GTCACCAGCAGTACCAATA

CAGAGCATTAGCAGCTA
ATCCACTGCCACTGAACCTT

CAGGAAAAGGTCTGGAGTG
GCTGAGACCCACTCCAGAC

TTTAAATTGGTATCAGCA
GATGGGACCCCACTTTGCAA

GGTCTCAGCTATTGGTACTG
CTTTTCCTGTAGCTTGGCGG

GAAACCAGGGAAAGCCC
ACTGGATGCAGCATAGATC

CTGGTGACACATACTATCC
ACCCAGTGCATGTCGTAGC

CTAAGGTCCTGATCTATG
AGGACCTTAGGGGCTTTCCC

AGGCTCCGTGAAGGGCCGA
TACTGAAGGTGAATCCAGA

CTGCATCCAGTTTGCAAA
TGGTTTCTGCTGATACCAAT

TTCACCATCTCCAGAGAAA
GGCTGCACAGGAGAGTCTC

GTGGGGTCCCATCAAGG
TTAAATAGCTGCTAATGCTC

ATGCCAAGAACTCCTTGTA
AGGGACCCCCCAGGCTGTA

TTCAGTGGCAGTGGATCT
TGACTTGCCCGGCAAGTGAT

TCTTCAAATGAACAGCCTG
CCAAGCCTCCCCCAGACTC

GGGACAGATTTCACTCTC
GGTGACTCTGTCTCCTACAG

AGAGCCGGGGACACGGCTG
CACCAGCCTGCACCT

ACCATCAGCAGTCTGCA
ATGCAGACAGGGAG (SEQ

TGTATTACTGTGCAAGAGT
(SEQ ID NO: 3343)

ACCTGAAGATTTTGCAA
ID NO: 3345)

AGGGTATGATAGTAGTGGT

CTTACTACTGTCAACAGA

TATTCGGGCTGGTACTTCGA

GTTACAGTACCCCTCCGC

TCTCTGGGGCCGTGGCACC

TCACTTTCGGCGGAGGG

CTGGTCACCGTCTCCTCAGC

ACCAAGGTGGAGATCAA

GTCGACCAAGGGCCCATCG

ACGTACGGTGGCTGCAC

GTCTTCCCCCTGGCACCCTC

CATCTGTCTTCATCTTCC

CTCCAAGAGCACCTCTGGG

CGCCATCTGATGAGCAG

GGCACAGCGGCCCTGGGCT

TTGAAATCTGGAACTGC

GCCTGGTCAAGGACTACTT

CTCTGTTGTGTGCCTGCT

CCCCGAACCTGTGACGGTC

GAATAACTTCTATCCCAG

TCGTGGAACTCANGCGCCC

AGAGGCCAAAGTACAGT

TGACCAGCGGCGTGCACAC

GGAAGGTGGATAACGCC

CTTCCCGGCTGTCCTACAGT

CTCCAATCGGGTAACTCC

CCTCAGGACTCTACTCCCTC

CAGGAGAGTGTCACAGA

AGCAGCGTGGTGACCGTGC

GCANGACAGCAAGGACA

CCTCCAGCAGCTTGGGCAC

GCACCTACAGCCTCAGC

CCAGACCTACATCTGCAAC

AGCACCCTGACGCTGAG

GTGAATCACAAGCCCAGCA

CAAAGCAGACTACGAGA

CACC (SEQ ID NO:

AACACAAAGTCTACGCC

3342)

TGCGAAGTCACCCATCA

GGCCTGAGCTCGCCCGT

CACAAAGAGCTTCAACN

GGGGANANTGTTAGAAG

CTTGGCCGCCATGGCCC

AACTTGTTTATTGCAGCT

TATNATGGNTACAAATA

AAGCAATAGCA (SEQ

ID NO: 3344)

COV21_P1
A-C042
TACACATACGATTTAGGTG
CGCTGTGCNNNNGAGGTGC
COV21_P1
TACACATACGATTTAGGT
ANGGGGCNACCTTGGGCTG
COV21_P1

F2

ACACTATAGAATAACATCC
TCTTGGAGGAGGGTGCCAG
F2
GACACTATAGAATAACA
ACCTAGGACGGTCAGCTTGG
F2

ACTTTGCCTTTCTCTCCACA
GGGGAAGACCGATGGGCCC

TCCACTTTGCCTTTCTCT
TCCCTCCGCCGAATACCCCC

GGTGTCCACTCCCAGGTCC
TTGGTGGAGGCTGAGGAGA

CCACAGGTGTCCACTCCC
AGAGTGCTCCTGCTTGTATA

AACTGCACCTCGGTTCTATC
CGGTGACCAGGGTTCCCTG

AGGTCCAACTGCACCTC
TGAGCTGCAGTGATAGTCAG

GATTGAATTCCACCATGGG
GCCCCAGTAGTCAAACGGC

GGTTCTATCGATTGAATT
CCTCGTCCTCAGCCTGGAGC

ATGGTCATGTATCATCCTTT
GAGACCGAGTCCGGGTCTA

CCACCATGGGATGGTCA
CCAGAGATGGTCAGGGAGG

TTCTAGTAGCAACTGCAAC
TAGCATACACCACCCTGCC

TGTATCATCCTTTTTCTA
CCGTGTTGCCAGACTTGGAG

CGGTGTACATTCTGAAGTG
TTTTGCACAGTAATACAAG

GTAGCAACTGCAACCGG
CCAGAGAAGCGATTAGAAA

CAGCTGGTGGAGTCTGGGG
GCCGTGTCCTCAGCTCTCAG

TTCCTGGGCCCAGTCTGC
CCCCTGAGGGCCGATTACTG

GAGGCTTGGTACAGCCTGG
ACTGTTCATTTGCAGATACA

CCTGACTCAGCCTGCCTC
ACATCATAAATCATGAGTTT

CAGGTCCCTGAGACTCTCCT
GGGAGTTCTTGGCGTTGTCT

CGTGTCTGGGTCTCCTGG
GGGGGCTTTGCCTGGGTGTT

GTGCAGCCTCTGGATTCAC
CTGGAGATGGTGAATCGGC

ACAGTCGATCACCATCTC
GTTGGTACCAGGAGACAAA

CTTTGATGATTATGCCATGC
CCTTCACAGAGTCCGCATA

CTGCACTGGAACCAGCA
GTTATAACCACCAACGCCAC

ACTGGGTCCGGCAAGCTCC
GCCTATGGTGCCACTATTCC

GTGGCGTTGGTGGTTATA
TGCTGGTTCCAGTGCAGGAG

AGGGAAGGGCCTGGAGTGG
AACTAGTGCCTGAGACCCA

ACTTTGTCTCCTGGTACC
ATGGTGATCGACTGTCCAGG

GTCTCAGGCACTAGTTGGA
CTCCAGGCCCTTCCCTGGA

AACAACACCCAGGCAAA
AGACCCAGACACGGAGGCA

ATAGTGGCACCATAGGCTA
GCTTGCCGGACCCAGTGCA

GCCCCCAAACTCATGATT
GGCTGAGTCAGCACAGACT

TGCGGACTCTGTGAAGGGC
TGGCATAATCATCAAAGGT

TATGATGTCAGTAATCG
GGGACCAGGAACCGGTTGC

CGATTCACCATCTCCAGAG
GAATCCAGAGGCTGCACAG

GCCCTCAGGGGTTTCTAA
NNNTNNCCTACTAGAA

ACAACGCCAAGAACTCCCT
GAGAGTCTCAGGGACCTGC

TCGCTTCTCTGGCTCCAA
(SEQ ID NO: 3349)

GTATCTGCAAATGAACAGT
CAGGCTGTACCAAGCCTCC

GTCTGGCAACACGGCCT

CTGAGAGCTGAGGACACGG
CCCAGACTCCACCAGCCTG

CCCTGACCATCTCTGGGC

CCTTGTATTACTGTGCAAAA
CACCTANNATG (SEQ ID

TCCAGGCTGAGGACGAG

GGCAGGGTGGTGTATGCTA
NO: 3347)

GCTGACTATCACTGCAG

TAGACCCGGACTCGGTCTC

CTCATATACAAGCAGGA

GCCGTTTGACTACTGGGGC

GCACTCTGGGGGTATTC

CAGGGAACCCTGGTCACCG

GGCGGAGGGACCAAGCT

TCTCCTCAGCGTCGACCAA

GACCGTCCTAGGTCAGC

GGGCCCATCGGTCTTCCCCC

CCAAGGCTGCCCCCTCG

TGGCACCCTCCTCCAAGAG

GTCACTCTGTTCCCACCC

CACCTCTGGGGGCACAGCG

TCGAGTGAGGAGCTTCA

GCCCTGGGCTGCCTGGTCA

AGCCAACAAGGCCACAC

AGGACTACTTCCCCGAACC

TGGTGTGTCTCATAAGTG

TGTGACGGTCTCGTGGAAC

ACTTCTACCCGGGAGCC

TCANGCGCCCTGACCAGCG

GTGACAGTGGCCTGGAA

GCGTGCACACCTTCCCGGC

GGCAGATAGCAGCCCCG

TGTCCTACAGTCCTCANGA

TCAAGGCGGGAGTGGAG

CTCTACTCCCTCAGCAGCGT

ACCACCACACCCTCCAA

GGTGACCGTGCCCTCCAGC

ACAAAGCAACAACAAGT

AGCTTGGGCACCCAGACCT

ACGCGGCCAGCAGCTAC

ACATCTGCAACGTGAATCA

CTGAGCCTGACGCCTGA

CAAGCCCAGCAACACCAAN

GCAGTGGAAGTCCCACA

GTGGACAAGAGAGTTGAGC

GAAGCTACAGCTGCCAG

CCAAATCTTGTGACAAAAC

GTCACGCATGAAGGGAG

TCACACATGCCCACCG

CACCGTGGANAAGACAG

(SEQ ID NO: 3346)

TGGCCCTACAGAATGTTC

ATAGAAGCTTGGCCGCC

ATGGNCCAACTTGTTTAT

TGCAGCTTATAATGGTTA

CNAATAAAGCA (SEQ

ID NO: 3348)

COV21_P1
A-C023
TACACATACGATTTAGGTG
TGAGGAGACGGTGACCAGG
COV21_P1
TACACATACGATTTAGGT
TGGGCTGACCCAGGACGGT
COV21_P1

H8

ACACTATAGAATAACATCC
GTTCCCTGGCCCCAGGAGT
H8
GACACTATAGAATAACA
CAGCTTGGTCCCTCCGCCGA
H8

ACTTTGCCTTTCTCTCCACA
CGAACCAACTATGCAAGCA

TCCACTTTGCCTTTCTCT
ATACCACCCTCAGGCTGGTG

GGTGTCCACTCCCAGGTCC
GCTGATACTACTACAATGT

CCACAGGTGTCCACTCCC
TCATAGGACTGGCAGTAATA

AACTGCACCTCGGTTCTATC
CCCCGACCTCTTGCACAGT

AGGTCCAACTGCACCTC
ATCAGCCTCATCCTCAGCCT

GATTGAATTCCACCATGGG
AATACACAGCCGTGTCCCC

GGTTCTATCGATTGAATT
GGAGCCCTGTGATGGCCAG

ATGGTCATGTATCATCCTTT
GGCTCTCAGGCTGTTCATTT

CCACCATGGGATGGTCA
GGAGGCTGAGGTGCCAGAC

TTCTAGTAGCAACTGCAAC
GAAGAAACACGGAGTTCTT

TGTATCATCCTTTTTCTA
TTGGAGCCAGAGAATCGGT

CGGTGTACATTCTGAGGTG
GGCATTTTCTCTGGAGATG

GTAGCAACTGCAACCGG
CAGGGACCCCTGAGGGCCG

CAGCTGGTGGAGTCTGGGG
GTGAATCGGCCCCTCACGG

TTCCTGGGCCCAGTCTGT
ATTGCTGTAACCATAGATGA

GAGGCTTGGTACAGCCTGG
AGCCTGGATAGTATGTGTC

GCTGACGCAGCCGCCCT
GGACTTTGGGGGCTGTTCCT

GGGGTCCCTGAGACTCTCG
ACCACCAGTACCAATTGCT

CAGTGTCTGGGGCCCCA
GGAAGTTTCTGGTACCAGTG

TGTGCAGCCTCTGGATTCAC
GAGACCCACTCCAGACCTT

GGGCAGAGGGTCACCAT
TACATCAGAACCTGCCCCGA

CTTCAGTAACTACGACATTC
CTCCTGTAGCTTGGCGGAC

CTCCTGCACTGGGAGCA
TGTTGGAGCTGCTCCCAGTG

ACTGGGTCCGCCAAGCTAC
ACAGTGAATGTCGTAGTTA

GCTCCAACATCGGGGCA
CAGGAGATGGTGACCCTCTG

AGGAGAAGGTCTGGAGTGG
CTGAAGGTGAATCCAGAGG

GGTTCTGATGTACACTGG
CCCTGGGGCCCCAGACACTG

GTCTCAGCAATTGGTACTG
CTGCACACGAGAGTCTCAG

TACCAGAAACTTCCAGG
AGGGCGGCTGAGTCAGCAC

GTGGTGACACATACTATCC
GGACCCCCCAGGCTGTACC

AACAGCCCCCAAAGTCC
AGACTNGGCNCCNAGAANC

AGGCTCCGTGAGGGGCCGA
AAGCCTCCCCCAGACTCCA

TCATCTATGGTTACAGCA
GNNT (SEQ ID NO:

TTCACCATCTCCAGAGAAA
CCAGCTGCACCTANNATG

ATCGGCCCTCAGGGGTC
3353)

ATGCCAAGAACTCCGTGTT
(SEQ ID NO: 3351)

CCTGACCGATTCTCTGGC

TCTTCAAATGAACAGCCTG

TCCAAGTCTGGCACCTCA

AGAGCCGGGGACACGGCTG

GCCTCCCTGGCCATCACA

TGTATTACTGTGCAAGAGG

GGGCTCCAGGCTGAGGA

TCGGGGACATTGTAGTAGT

TGAGGCTGATTATTACTG

ATCAGCTGCTTGCATAGTTG

CCAGTCCTATGACACCA

GTTCGACTCCTGGGGCCAG

GCCTGAGGGTGGTATTC

GGAACCCTGGTCACCGTCT

GGCGGAGGGACCAAGCT

CCTCAGCGTCGACCAAGGG

GACCGTCCTGGGTCAGC

CCCATCGGTCTTCCCCCTGG

CCAAGGCTGCCCCCTCG

CACCCTCCTCCAAGAGCAC

GTCACTCTGTTCCCGCCC

CTCTGGGGGCACAGCGGCC

TCGAGTGAGGAGCTTCA

CTGGGCTGCCTGGTCAAGG

AGCCAACAAGGCCACAC

ACTACTTCCCCGAACCTGTG

TGGTGTGTCTCATAAGTG

ACGGTCTCGTGGAACTCAG

ACTTCTACCCGGGAGCC

GCGCCCTGACCAGCGGCGT

GTGACAGTGGCCTGGAA

GCACACCTTCCCGGCTGTCC

GGCAGATAGCAGCCCCG

TACAGTCCTCANGACTCTA

TCAAGGCGGGAGTGGAG

CTCCCTCAGCAGCGTGGTG

ACCACCACACCCTCCAA

ACCGTGCCCTCCAGCAGCT

ACAAAGCAACAACAAGT

TGGGCACCCAGACCTACAT

ACGCGGCCAGCAGCTAC

CTGCAACGTGAATCACAAG

CTGAGCCTGACGCCTGA

CCCAGCAACACCNAAGGTG

GCAGTGGAAGTCCCACA

GACNAGANAGTTGAGCCCA

GAAGCTACAGCTGCCAG

AATCTTGTGACAAAACTCA

GTCACGCATGAAGGGAG

CACATGCCCACCGT

CACCGTGGAGAAGACAG

(SEQ ID NO: 3350)

TGGCCCCTACAGAATGTT

CATAGAAGCTTGGCCGC

CATGGCCCAACTTGTTTA

TTGCAGCTTATAATGGTT

ACAAA (SEQ ID NO:

3352)

COV21_P1
A-C024
TACACATACGATTTAGGTG
CTGAGGAGACGGTGACCAG
COV21_P1
TACACATACGATTTAGGT
TTGGGCTGACCCAGGACGGT
COV21_P1

B2

ACACTATAGAATAACATCC
GGTTCCCTGGCCCCAGGAG
B2
GACACTATAGAATAACA
CAGCTTGGTCCCTCCGCCGA
B2

ACTTTGCCTTTCTCTCCACA
TCGAACCAGCTATGCAAGC

TCCACTTTGCCTTTCTCT
ATACCACCCTCAGGCTGGTG

GGTGTCCACTCCCAGGTCC
AGCTGATACTACTACAATG

CCACAGGTGTCCACTCCC
TCATAGGACTGGCAGTAATA

AACTGCACCTCGGTTCTATC
TCCCCGACCTCTTGCACAGT

AGGTCCAACTGCACCTC
ATCAGCCTCATCCTCAGCCT

GATTGAATTCCACCATGGG
AATACACAGCCGTGTCCCC

GGTTCTATCGATTGAATT
GGAGCCCTGTGATGGCCAG

ATGGTCATGTATCATCCTTT
GGCTCTCAGGCTGTTCATTT

CCACCATGGGATGGTCA
GGAGGCTGAGGTGCCAGAC

TTCTAGTAGCAACTGCAAC
GAAGAAACACGGAGTTCTT

TGTATCATCCTTTTTCTA
TTGGAGCCAGAGAATCGGT

CGGTGTACATTCTGAGGTG
GGCATTTTCTCTGGAGATG

GTAGCAACTGCAACCGG
CAGGGACCCCTGAGGGCCG

CAGCTGGTGGAGTCTGGGG
GTGAATCGGCCCTTCACGG

TTCCTGGGCCCAGTCTGT
ATTGCTGTAGCCATAGATGA

GAGGCTTGGTACAGCCTGG
AGCCTGGATAGTATGTGTC

GCTGACGCAGCCGCCCT
GGACTTTGGGGGCTATTCCT

GGGGTCCCTGAGACTCTCG
ACCAGCAGTACCAATTGCT

CAGTGTCTGGGGCCCCA
GGAAGTTTCTGGTACCAGTG

TGTGCAGCCTCTGGATTCAC
GAGACCCACTCCAGACCTT

GGGCAGAGGGTCACCAT
TACATCAGAACCTGCCCCGA

CTTCAGTAACTACGACATG
CTCCTGTAACTTGGCGGAC

CTCCTGCACTGGGAGCA
TGTTGGAGCTGCTCCCAGTG

CACTGGGTCCGCCAAGTTA
CCAGTGCATGTCGTAGTTA

GCTCCAACATCGGGGCA
CAGGAGATGGTGACCCTCTG

CAGGAGAAGGTCTGGAGTG
CTGAAGGTGAATCCAGAGG

GGTTCTGATGTACACTGG
CCCTGGGGCCCCAGACACTG

GGTCTCAGCAATTGGTACT
CTGCACACGAGAGTCTCAG

TACCAGAAACTTCCAGG
AGGGCGGCTGAGTCAGCAC

GCTGGTGACACATACTATC
GGACCCCCCAGGCTGTACC

AATAGCCCCCAAAGTCC
AGACTGGGACCNGGAACCG

CAGGCTCCGTGAAGGGCCG
AAGCCTCCCCCAGACTCCA

TCATCTATGGCTACAGCA
GNN (SEQ ID NO:

ATTCACCATCTCCAGAGAA
CCAGCTGCACNNNACACTG

ATCGGCCCTCAGGGGTC
3357)

AATGCCAAGAACTCCGTGT
NNACACC (SEQ ID

CCTGACCGATTCTCTGGC

TTCTTCAAATGAACAGCCT
NO: 3355)

TCCAAGTCTGGCACCTCA

GAGAGCCGGGGACACGGCT

GCCTCCCTGGCCATCACA

GTGTATTACTGTGCAAGAG

GGGCTCCAGGCTGAGGA

GTCGGGGACATTGTAGTAG

TGAGGCTGATTATTACTG

TATCAGCTGCTTGCATAGCT

CCAGTCCTATGACACCA

GGTTCGACTCCTGGGGCCA

GCCTGAGGGTGGTATTC

GGGAACCCTGGTCACCGTC

GGCGGAGGGACCAAGCT

TCCTCAGCGTCGACCAAGG

GACCGTCCTGGGTCAGC

GCCCATCGGTCTTCCCCCTG

CCAAGGCTGCCCCCTCG

GCACCCTCCTCCAAGAGCA

GTCACTCTGTTCCCACCC

CCTCTGGGGGCACAGCGGC

TCGAGTGAGGAGCTTCA

CCTGGGCTGCCTGGTCAAG

AGCCAACAAGGCCACAC

GACTACTTCCCCGAACCTGT

TGGTGTGTCTCATAAGTG

GACGGTCTCGTGGAACTCA

ACTTCTACCCGGGAGCC

GGCGCCCTGACCAGCGGCG

GTGACAGTGGCCTGGAA

TGCACACCTTCCCGGCTGTC

GGCAGATAGCAGCCCCG

CTACAGTCCTCAGGACTCT

TCAAGGCGGGAGTGGAG

ACTCCCTCAGCAGCGTGGT

ACCACCACACCCTCCAA

GACCGTGCCCTCCAGCAGC

ACAAAGCAACAACAAGT

TTGGGCACCCAGACCTACA

ACGCGGCCAGCAGCTAC

TCTGCAACGTGAATCACAA

CTGAGCCTGACGCCTGA

GCCCAGCAACACCAANGTG

GCAGTGGAAGTCCCACA

GACAAGAGAGTTGAGCCCA

GAAGCTACAGCTGCCAG

AATCTTGTGACAAAACTCA

GTCACGCATGAAGGGAG

CACATGCCCACCGTGCCC

CACCGTGGAGAAGACAG

(SEQ ID NO: 3354)

TGGCCCCTACAGAATGTT

CATAGAAGCTTGGCCGC

CATGGCCCAACTTGTTTA

TTGCAGCTTATAATGGTT

ACAAATAAAGCAA (SEQ

ID NO: 3356)

COV21_P1
A-C025
TACACATACGATTTAGGTG
GGTGACCAGGGTTNCCTGG
COV21_P1
TACACATACGATTTAGGT
CTTGGGCTGACCCAGGACG
COV21_P1

A12

ACACTATAGAATAACATCC
CCCCAGGAGTCGAACCAGC
A12
GACACTATAGAATAACA
GTCAGCTTGGTCCCTCCGCC
A12

ACTTTGCCTTTCTCTCCACA
TATGCAAGCAGCTGATACT

TCCACTTTGCCTTTCTCT
GAATACCACCCTCAGGCTGG

GGTGTCCACTCCCAGGTCC
ACTACAATGTCCCCGACCT

CCACAGGTGTCCACTCCC
TGTCATAGGACTGGCAGTAA

AACTGCACCTCGGTTCTATC
CTTGCACAGTAATACACAG

AGGTCCAACTGCACCTC
TAATCAGCCTCATCCTCAGC

GATTGAATTCCACCATGGG
CCGTGTCCCCGGCTCTCAG

GGTTCTATCGATTGAATT
CTGGAGCCCTGTGATGGCCA

ATGGTCATGTATCATCCTTT
GCTGTTCATTTGAAGAAAC

CCACCATGGGATGGTCA
GGGAGGCTGAGGTGCCAGA

TTCTAGTAGCAACTGCAAC
ACGGAGTTCTTGGCATTTTC

TGTATCATCCTTTTTCTA
CTTGGAGCCAGAGAATCGG

CGGTGTACATTCTGAGGTG
TCTGGAGATGGTGAATCGG

GTAGCAACTGCAACCGG
TCAGGGACCCCCGAGGGCC

CAGCTGGTGGAGTCTGGGG
CCCTTCACGGAGCCTGGAT

TTCCTGGGCCCAGTCTGT
GATTGCTGTAACCATAGATG

GAGGCTTGGTACAGCCTGG
AGTATGTGTCACCAGCAGT

GCTGACGCAGCCGCCCT
AGGACTTTGGGGGCTGTTCC

GGGGTCCCTGAGACTCTCG
ACCAATTGCTGAGACCCAC

CAGTGTCTGGGGCCCCA
TGGAAGTTTCTGGTACCAGT

TGTGCAGCCTCTGGATTCAC
TCCAGACCTTCTCCTGTAGC

GGGCAGAGGGTCACCAT
GTACATCAGAACCTGCCCCG

CTTCAGTAACTACGACATG
TTGGCGGACCCAGTGCATG

CTCCTGCACTGGGAGTA
ATGTTGGAGCTACTCCCAGT

CACTGGGTCCGCCAAGCTA
TCGTAGTTACTGAAGGTGA

GCTCCAACATCGGGGCA
GCAGGAGATGGTGACCCTCT

CAGGAGAAGGTCTGGAGTG
ATCCAGAGGCTGCACACGA

GGTTCTGATGTACACTGG
GCCCTGGGGCCCCAGACACT

GGTCTCAGCAATTGGTACT
GAGTCTCAGGGACCCCCCA

TACCAGAAACTTCCAGG
GAGGGCGGCTGAGTCAGCA

GCTGGTGACACATACTATC
GGCTGTACCAAGCCTCCCC

AACAGCCCCCAAAGTCC
CAGACTGGGNCCAGGAACC

CAGGCTCCGTGAAGGGCCG
CAGACTCCACCANCTGCAC

TCATCTATGGTTACAGCA
GGNN (SEQ ID NO:

ATTCACCATCTCCAGAGAA
CTANNATG (SEQ ID

ATCGGCCCTCGGGGGTC
3361)

AATGCCAAGAACTCCGTGT
NO: 3359)

CCTGACCGATTCTCTGGC

TTCTTCAAATGAACAGCCT

TCCAAGTCTGGCACCTCA

GAGAGCCGGGGACACGGCT

GCCTCCCTGGCCATCACA

GTGTATTACTGTGCAAGAG

GGGCTCCAGGCTGAGGA

GTCGGGGACATTGTAGTAG

TGAGGCTGATTATTACTG

TATCAGCTGCTTGCATAGCT

CCAGTCCTATGACACCA

GGTTCGACTCCTGGGGCCA

GCCTGAGGGTGGTATTC

GGGAACCCTGGTCACCGTC

GGCGGAGGGACCAAGCT

TCCTCAGCGTCGACCAAGG

GACCGTCCTGGGTCAGC

GCCCATCGGTCTTCCCCCTG

CCAAGGCTGCCCCCTCG

GCACCCTCCTCCAAGAGCA

GTCACTCTGTTCCCACCC

CCTCTGGGGGCACAGCGGC

TCGAGTGAGGAGCTTCA

CCTGGGCTGCCTGGTCAAG

AGCCAACAAGGCCACAC

GACTACTTCCCCGAACCTGT

TGGTGTGTCTCATAAGTG

GACGGTCTCGTGGAACTCA

ACTTCTACCCGGGAGCC

GGCGCCCTGACCAGCGGCG

GTGACAGTGGCCTGGAA

TGCACACCTTCCCGGCTGTC

GGCAGATAGCAGCCCCG

CTACAGTCCTCAGGACTCT

TCAAGGCGGGAGTGGAG

ACTCCCTCAGCAGCGTGGT

ACCACCACACCCTCCAA

GACCGTGCCCTCCAGCAGC

ACAAAGCAACAACAAGT

TTGGGCACCCAGACCTACA

ACGCGGCCAGCAGCTAC

TCTGCAACGTGAATCACAA

CTGAGCCTGACGCCTGA

GCCCAGCAACACCAANGTG

NCAGTGGAAGTCCCACA

GACAAGAGAGTTGAGCCCA

GAAGCTACAGCTGCCAG

AATCTTGTGACAAAACTCA

GTCACGCATGAAGGGAG

CACATGCCCACCGTGCCC

CACCGTGGAGAAGACAG

(SEQ ID NO: 3358)

TGGCCCCTACAGAATGTT

CATAGAAGCTTGGCCGC

CATGGCCCAACTTGTTTA

TTGCAGCTTATAATGGTT

ACAAATAAAGCAAT

(SEQ ID NO: 3360)

COV21_P1
A-C026
TACACATACGATTTAGGTG
CTGAGGAGANGGTGACCAG
COV21_P1
TACACATACGATTTAGGT
TTGGGCTGACCCAGGACGGT
COV21_P1

D11

ACACTATAGAATAACATCC
GGTTCCCTGGCCCCAGGAG
D11
GACACTATAGAATAACA
CAGCTTGGTCCCTCCGCCGA
D11

ACTTTGCCTTTCTCTCCACA
TCGAACCAGCTATGCAAGC

TCCACTTTGCCTTTCTCT
ATACCACCCTCAAACTGGTG

GGTGTCCACTCCCAGGTCC
AGCTGATACTACTACAATG

CCACAGGTGTCCACTCCC
TCATAGGACTGGCAGTAATA

AACTGCACCTCGGTTCTATC
TCCCCGACCTCTTGCACAGT

AGGTCCAACTGCACCTC
ATCAGCCTCATCCTCAGCCT

GATTGAATTCCACCATGGG
AATACACCGCCGTGTCCCC

GGTTCTATCGATTGAATT
GGAGCCCTGTGATGGCCAG

ATGGTCATGTATCATCCTTT
GGCTCTCAGGCTGTTCATTT

CCACCATGGGATGGTCA
GGAGGCTGAGGTGCCAGAC

TTCTAGTAGCAACTGCAAC
GAAGAAACACGGAGTTCTT

TGTATCATCCTTTTTCTA
TTGGAGCCAGAGAATCGGT

CGGTGTACATTCTGAGGTG
GGCATTTTCTCTGGAGATG

GTAGCAACTGCAACCGG
CAGGGACCCCTGAGGGCCG

CAGCTGGTGGAGTCTGGGG
GTGAATCGGCCCTTCACGG

TTCCTGGGCCCAGTCTGT
ATTGTTGTAACCATAGATGA

GAGGCTTGGTACAGCCTGG
AGCCTGGATAGTATGTGTC

GCTGACGCAGCCGCCCT
GGACTTTGGGGGCTGTTCCT

GGGGTCCCTGAGACTCTCG
ACCAGCAGTACCAATTGCT

CAGTGTCTGGGGCCCCA
GGAAGTTTCTGGTACCAGTG

TGTGCAGCCTCTGGATTCAC
GAGACCCACTCCAGACCTT

GGGCAGAGGGTCACCAT
TACATCAGAACCTGCCCCGA

CTTCAGTAACTACGACATA
CTCCTGTAGCCTGGCGGAC

CTCCTGCACTGGGAGCA
TGTTGGAGCTGCTCCCAGTG

CACTGGGTCCGCCAGGCTA
CCAGTGTATGTCGTAGTTAC

GCTCCAACATCGGGGCA
CAGGAGATGGTGACCCTCTG

CAGGAGAAGGTCTGGAGTG
TGAAGGTGAATCCAGAGGC

GGTTCTGATGTACACTGG
CCCTGGGGCCCCAGACACTG

GGTCTCAGCAATTGGTACT
TGCACACGAGAGTCTCAGG

TACCAGAAACTTCCAGG
AGGGCGGCTGAGTCAGCAC

GCTGGTGACACATACTATC
GACCCCCCAGGCTGTACCA

AACAGCCCCCAAAGTCC
AGACTGGGNNNNGGAACCG

CAGGCTCCGTGAAGGGCCG
AGCCTCCCCCAGACTCCAC

TCATCTATGGTTACAACA
GNTGNNNNTG (SEQ ID

ATTCACCATCTCCAGAGAA
CAGCTGCACCTANNATG

ATCGGCCCTCAGGGGTC
NO: 3365)

AATGCCAAGAACTCCGTGT
(SEQ ID NO: 3363)

CCTGACCGATTCTCTGGC

TTCTTCAAATGAACAGCCT

TCCAAGTCTGGCACCTCA

GAGAGCCGGGGACACGGCG

GCCTCCCTGGCCATCACA

GTGTATTACTGTGCAAGAG

GGGCTCCAGGCTGAGGA

GTCGGGGACATTGTAGTAG

TGAGGCTGATTATTACTG

TATCAGCTGCTTGCATAGCT

CCAGTCCTATGACACCA

GGTTCGACTCCTGGGGCCA

GTTTGAGGGTGGTATTCG

GGGAACCCTGGTCACCGTC

GCGGAGGGACCAAGCTG

TCCTCAGCGTCGACCAAGG

ACCGTCCTGGGTCAGCC

GCCCATCGGTCTTCCCCCTG

CAAGGCTGCCCCCTCGG

GCACCCTCCTCCAAGAGCA

TCACTCTGTTCCCGCCCT

CCTCTGGGGGCACAGCGGC

CGAGTGAGGAGCTTCAA

CCTGGGCTGCCTGGTCAAG

GCCAACAAGGCCACACT

GACTACTTCCCCGAACCTGT

GGTGTGTCTCATAAGTG

GACGGTCTCGTGGAACTCA

ACTTCTACCCGGGAGCC

NGCGCCCTGACCAGCGGCG

GTGACAGTGGCCTGGAA

TGCACACCTTCCCGGCTGTC

GGCAGATAGCAGCCCCG

CTACAGTCCTCANGACTCT

TCAAGGCGGGAGTGGAG

ACTCCCTCAGCAGCGTGGT

ACCACCACACCCTCCAA

GACCGTGCCCTCCAGCAGC

ACAAAGCAACAACAAGT

TTGGGCACCCAGACCTACA

ACGCGGCCAGCAGCTAC

TCTGCAACGTGAATCACAA

CTGAGCCTGACGCCTGA

GCCCAGCAACACCAAGGTG

GCAGTGGAAGTCCCACA

GACAGANAGTTGAGCCCAA

GAAGCTACAGCTGCCAG

ATCTTGTGACAAAACTCAC

GTCACGCATGAAGGGAG

ACATGCCCACCGTGCCC

CACCGTGGAGAAGACAG

(SEQ ID NO: 3362)

TGGCCCCTACAGAATGTT

CATAGAAGCTTGGCCGC

CATGGCCCAACTTGTTTA

TTGCAGCTTATAATGGTT

ACAAATAAAGCAAT

(SEQ ID NO: 3364)

COV57_P1
A-C032
TACACATACGATTTAGGTG
GNNGCTGTGCCCCAGAGGT
COV57_P1
TACACATACGATTTAGGT
CTTGGGCTGACCTAGGACGG
COV57_P1

F6

ACACTATAGAATAACATCC
GCTCTTGGAGGAGGGTGCC
F6
GACACTATAGAATAACA
TGACCTTGGTCCCAGTTCCG
F6

ACTTTGCCTTTCTCTCCACA
AGGGGGAAGACCGATGGGC

TCCACTTTGCCTTTCTCT
AAGACATAAAGGGCACTCA

GGTGTCCACTCCCAGGTCC
CCTTGGTGGAGGCTGAGGA

CCACAGGTGTCCACTCCC
GGCTGCTGTCATAGGACTGG

AACTGCACCTCGGTTCTATC
GACAGTGACCAGGGTGCCA

AGGTCCAACTGCACCTC
CAGTAATAATCAGCCTCATC

GATTGAATTCCACCATGGG
CGGCCCCAGAGATCGAAGT

GGTTCTATCGATTGAATT
CTCAGCCTGGAGCCCAGTGA

ATGGTCATGTATCATCCTTT
ACCAGTCCACTGCTACCCCT

CCACCATGGGATGGTCA
TGGCCAGGGAGGCTGAGGT

TTCTAGTAGCAACTGCAAC
CTCGCACAGTAATACATGG

TGTATCATCCTTTTTCTA
GCCAGACTTGGAGCCAGAG

CGGTGTACATTCCGAGGTG
CGGTGTCCGAGGCCTTCAG

GTAGCAACTGCAACCGG
AATCGGTCAGGGACCCCTG

CAGCTGGTGCAGTCTGGAG
GCTGCTCCACTGCAGGTAG

TTCCTGGGCCCAGTCTGT
AGGGCCGATTGCTGTTACCA

CAGAGGTGAAAAAGCCCGG
GCGGTGCTGATGGACTTGT

GCTGACTCAGCCGCCCTC
TAGATGAGGAGTTTGGGGG

GGAGTCTCTGAAGATCTCC
CGGCTGAGATGGTGACCTG

AGTGTCTGGGGCCCCAG
CTGTTCCTGGAAGCTGCTGG

TGTAAGGGTTCTGGATACA
GCCTTGGAAGGACGGGCTG

GGCAGAGGGTCACCATC
TACCAGTGTACATCATAACC

GCTTTACCAGCTACTGGATC
TATCTGGTATCAGAGTCAC

TCCTGCACTGGGAGCAG
TGCCCCGATGTTGGAGCTGC

GGCTGGGTGCGCCAGATGC
CAGGATAGATGATCCCCAT

CTCCAACATCGGGGCAG
TCCCAGTGCAGGAGATGGT

CCGGGAAAGGCCTGGAGTG
CCACTCCAGGCCTTTCCCGG

GTTATGATGTACACTGGT
GACCCTCTGCCCTGGGGCCC

GATGGGGATCATCTATCCT
GCATCTGGCGCACCCAGCC

ACCAGCAGCTTCCAGGA
CAGACACTGAGGGCGGCTG

GGTGACTCTGATACCAGAT
GATCCAGTAGCTGGTAAAG

ACAGCCCCCAAACTCCT
AGTCAGCACAGACTGGGAC

ACAGCCCGTCCTTCCAAGG
CTGTATCCAGAACCCTTAC

CATCTATGGTAACAGCA
CAGGAACCGGNTG (SEQ

CCAGGTCACCATCTCAGCC
AGGAGATCTTCAGAGACTC

ATCGGCCCTCAGGGGTC
ID NO: 3369)

GACAAGTCCATCAGCACCG
CCCGGGCTTTTTCACCTCTG

CCTGACCGATTCTCTGGC

CCTACCTGCAGTGGAGCAG
CTCCAGACTGCACCAGCTG

TCCAAGTCTGGCACCTCA

CCTGAAGGCCTCGGACACC
CAC (SEQ ID NO:

GCCTCCCTGGCCATCACT

GCCATGTATTACTGTGCGA
3367)

GGGCTCCAGGCTGAGGA

GAGGGGTAGCAGTGGACTG

TGAGGCTGATTATTACTG

GTACTTCGATCTCTGGGGCC

CCAGTCCTATGACAGCA

GTGGCACCCTGGTCACCGT

GCCTGAGTGCCCTTTATG

CTCCTCAGCGTCGACCAAG

TCTTCGGAACTGGGACC

GGCCCATCGGTCTTCCCCCT

AAGGTCACCGTCCTAGG

GGCACCCTCCTCCAAGAGC

TCAGCCCAAGGCCAACC

ACCTCTGGGGGCACAGCGG

CCACTGTCACTCTGTTCC

CCCTGGGCTGCCTGGTCAA

CACCCTCGAGTGAGGAG

GGACTACTTCCCCGAACCT

CTTCAAGCCAACAAGGC

GTGACGGTCTCGTGGAACT

CACACTGGTGTGTCTCAT

CAGGCGCCCTGACCAGCGG

AAGTGACTTCTACCCGG

CGTGCACACCTTCCCGGCT

GAGCCGTGACAGTGGCC

GTCCTACAGTCCTCAGGAC

TGGAAGGCAGATAGCAG

TCTACTCCCTCAGCAGCGTG

CCCCGTCAAGGCGGGAG

GTGACCGTGCCCTCCAGCA

TGGAGACCACCACACCC

GCTTNNCACCCAGACCTAC

TCCAAACAAAGCAACAA

ATCTGCAACGTGAATCACA

CAAGTACGCGGCCAGCA

AGCCCAGCAACACCAAGGT

GCTACCTGAGCCTGACG

GGACAAGAGAGTTGAGCCC

CCTGAGCAGTGGAAGTC

AAATCTTGTGACAAAACTC

CCACAGAAGCTACAGCT

ACACATGCCCACCGTGCCC

GCCAGGTCACGCATGAA

AGCACC (SEQ ID NO:

GGGAGCACCGTGGAGAA

3366)

GACAGTGGCCCCTACAG

AATGTTCATAGAAGCTT

GGCCGCCATGGCCCAAC

TTGTTTATTGCAGCTTAT

AAT (SEQ ID NO:

3368)

COV57_P2
A-C033
TACACATACGATTTAGGTG
AGAGGTGCTCTTGGAGGAG
COV57_P2
TACACATACGATTTAGGT
TACCGATTGGAGGGCGTTAT
COV57_P2

F10

ACACTATAGAATAACATCC
GGTGCCAGGGGGAAGACCG
F10
GACACTATAGAATAACA
CCACCTTCCACTGTACTTTG
F10

ACTTTGCCTTTCTCTCCACA
ATGGGCCCTTGGTGGAGGC

TCCACTTTGCCTTTCTCT
GCCTCTCTGGGATAGAAGTT

GGTGTCCACTCCCAGGTCC
TGAGGAGACGCTGACCGTG

CCACAGGTGTCCACTCCC
ATTCAGCAGGCACACAACA

AACTGCACCTCGGTTCTATC
GTCCCTTTGCCCCAGACGTC

AGGTCCAACTGCACCTC
GAGGCAGTTCCAGATTTCAA

GATTGAATTCCACCATGGG
CATGTAGTAGTAGTAGTGA

GGTTCTATCGATTGAATT
CTGCTCATCAGATGGCGGGA

ATGGTCATGTATCATCCTTT
GACCAATCTTTTGCAGATTG

CCACCATGGGATGGTCA
AGATGAAGACAGATGGTGC

TTCTAGTAGCAACTGCAAC
TACTACTACCTCTCTCGCAC

TGTATCATCCTTTTTCTA
AGCCACAGTTCGTTTAATCT

CGGTGTACATTCCCAGGTG
AGTAATAGACGGCCGTGTC

GTAGCAACTGCAACCGG
CCAGTCGAGTCCCTTGGCCG

CAGCTGCAGGAGTCGGGCC
CGCAGCGGTCACAGACCTC

TGTACATTCAGAAATTGT
AAGGTGACGAACCAGCTGC

CAGGACTAGTGAAGCCTTC
ACCTTCAGGGAGAACTGAT

GTTGACACAGTCTCCAG
TACGCTGCTGACAGTAATAA

GGAGACCCTGTCCCTCACC
TCTTCGACGTGTCTAGTGAT

CCACCCTGTCTTTGTCTC
ACTGCAAAATCTTCAGGGTC

TGCACTGTCTCTGGTGCCTC
ATGGTGACTCGACTCCTGA

CAGGGGAAAGAGCCTCC
TAGGCTGCTGATGGTGAGA

CATCAATAGTTACTACTGG
GGGCGGGGTTGTAGTTGGT

CTCTCCTGCAGGGCCAGT
GTGAAGTCTGTCCCAGACCC

ACCTGGATCCGGCAGCCCC
GTTCCCACTGTCATGGATAT

CAGAGTGTTGGTACCTA
ACTGCCACTGAACCTGGCTG

CAGGGAAGGGACTGGAATG
ATCCAATCCATTCCAGTCCC

CTTAGCCTGGTACCAAC
GGATGCCAGTGGCCCTGTTG

GATTGGATATATCCATGAC
TTCCCTGGGGGCTGCCGGA

AGAAAGTTGGCCAGCCT
GACGCATCATAGATGAGGA

AGTGGGAACACCAACTACA
TCCAGGTCCAGTAGTAACT

CCCAGGCTCCTCATCTAT
GCCTGGGAGGCTGGCCAAC

ACCCCGCCCTCAGGAGTCG
ATTGATGGAGGCACCAGAG

GATGCGTCCAACAGGGC
TTTCTGTTGGTACCAGGCTA

AGTCACCATATCACTAGAC
ACAGTGCAGGTGAGGGACA

CACTGGCATCCCAGCCA
AGTAGGTACCAACACTCTGA

ACGTCGAAGAATCAGTTCT
GGGTCTCCGAAGGCTTCAC

GGTTCAGTGGCAGTGGG
CTGGCCCTGCAGGAGAGGG

CCCTGAAGGTGAGGTCTGT
TAGTCCTGGGCCCGACTCC

TCTGGGACAGACTTCACT
AGGCTCTTTCCCCTGGAGAC

GACCGCTGCGGACACGGCC
NGCAGCCTGCACCT

CTCACCATCAGCAGCCT
AAAGACAGGG (SEQ ID

GTCTATTACTGTGCGAGAG
(SEQ ID NO: 3371)

AGACCCTGAAGATTTTG
NO: 3373)

AGGTAGTAGTACAATCTGC

CAGTTTATTACTGTCAGC

AAAAGATTGGTCTCACTAC

AGCGTAGCAGCTGGTTC

TACTACTACATGGACGTCT

GTCACCTTCGGCCAAGG

GGGGCAAAGGGACCACGGT

GACACGACTGGAGATTA

CACCGTCTCCTCAGCGTCG

AACGTACGGTGGCTGCA

ACCAAGGGCCCATCGGTCT

CCATCTGTCTTCATCTTC

TCCCCCTGGCACCCTCCTCC

CCGCCATCTGATGAGCA

AAGAGCACCTCTGGGGGCA

GTTGAAATCTGGAACTG

CAGCGGCCCTGGGCTGCCT

CCTCTGTTGTGTGCCTGC

GGTCAAGGACTACTTCCCC

TGAATAACTTCTATCCCA

GAACCTGTGACGGTCTCGT

GAGAGGCCAAAGTACAG

GGAACTCAGGCGCCCTGAC

TGGAAGGTGGATAACGC

CAGCGGCGTGCACACCTTC

CCTCCAATCGGGTAACTC

CCGGCTGTCCTACAGTCCTC

CCAGGAGAGTGTCACAG

AGGACTCTACTCCCTCAGC

AGCAGGACAGCAAGGAC

AGCGTGGTGACCGTGCCCT

AGCACCTACAGCCTCAG

CCAGCAGCTTGGGCACCCA

CAGCACCCTGACGCTGA

GACCTACATCTGCAACGTG

GCAAAGCAGACTACGAG

AATCACAAGCCCAGCAACA

AAACACAAAGTCTACGC

CCAAGGTGGACAAGAGAGT

CTGCGAAGTCACCCATC

TGAGCCCAAATCTTGTGAC

ANGGCCTGAGCTCGCCC

AAAACTCACACATGCCCA

GTCACAAAGAGCTTCAA

(SEQ ID NO: 3370)

CAGGGGAGAGTGNNNNA

AANCTTGGCCGCCATGG

CCCAACTTGTTTATTGCA

GCTTATAATGGTTACAA

ATAAA (SEQ ID

NO: 3372)

COV57_P1
A-C036
TACACATACGATTTAGGTG
GCTGTGCCNNGAGGTGCTC
COV57_P1
TACACATACGATTTAGGT
TACCCGATTGGAGGGCGTTA
COV57_P1

D12

ACACTATAGAATAACATCC
TTGGAGGAGGGTGCCAGGG
D12
GACACTATAGAATAACA
TCCACCTTCCACTGTACTTT
D12

ACTTTGCCTTTCTCTCCACA
GGAAGACCGATGGGCCCTT

TCCACTTTGCCTTTCTCT
GGCCTCTCTGGGATAGAAGT

GGTGTCCACTCCCAGGTCC
GGTGGAGGCTGAGGAGACG

CCACAGGTGTCCACTCCC
TATTCAGCAGGCACACAAC

AACTGCACCTCGGTTCTATC
GTGACCAGGGTTCCCTGGC

AGGTCCAACTGCACCTC
AGAGGCAGTTCCAGATTTCA

GATTGAATTCCACCATGGG
CCCAGTAGTCGATAGACGA

GGTTCTATCGATTGAATT
ACTGCTCATCAGATGGCGGG

ATGGTCATGTATCATCCTTT
AGGACGAGAGAAGGACCTC

CCACCATGGGATGGTCA
AAGATGAAGACAGATGGTG

TTCTAGTAGCAACTGCAAC
CTTCTGGCACAGTAATACA

TGTATCATCCTTTTTCTA
CAGCCACAGTTCGTTTAATC

CGGTGTACATTCCCAGGTG
CAGCCGTGTCCGCGGCGGT

GTAGCAACTGCAACCGG
TCCAGTCGTGTCCCTTGGCC

CAGCTACAGCAGTGGGGCG
CACAGACCTCAGGCTCAGG

TGTACATGGGGATATTGT
GAAGGTGAGAGTTTGTAGA

CAGGACTGTTGAAGCCTTC
GAGAACTGGTTCTTGGACG

GATGACTCAGTCTCCACT
GCTTGCATGCAGTAATAAAC

GGAGACCCTGTCCCGCACC
TGTCTACTGAGATGGTGAC

CTCCCTGCCCGTCACCCC
CCCAACATCCTCAGCCTCCA

TGCGCTGTCTTTGGTGGGTC
TCGACTCTTGAGGGACGGG

TGGAGAGCCGGCCTCCA
CTCTGCTGATTTTCAGTGTG

CTTCACTAATTACTACTGGA
TTGTAGTTGGTGATTCCACT

TCTCCTGCAGGTCTAGTC
AAATCTGTGCCTGATCCACT

GTTGGATCCGCCAGTCCCC
ATCATTGATTTCCCCAATCC

AGAGCCTCCTGCATAGA
GCCCCTGAACCTGTCAGGGA

AGGGAAGGGGCTGGAGTGG
ACTCCAGCCCCTTCCCTGGG

AATGGATACAACTATTT
CCCCGGAGGCCCGATTGGA

ATTGGGGAAATCAATGATA
GACTGGCGGATCCAACTCC

GGATTGGTACCTGCAGA
ACCCAAATAGATCAGGAGC

GTGGAATCACCAACTACAA
AGTAGTAATTAGTGAAGGA

AGCCAGGGCAGTCTCCA
TGTGGAGACTGCCCTGGCTT

CCCGTCCCTCAAGAGTCGA
CCCACCAAAGACAGCGCAG

CAGCTCCTGATCTATTTG
CTGCAGGTACCAATCCAAAT

GTCACCATCTCAGTAGACA
GTGCGGGACAGGGTCTCCG

GGTTCCAATCGGGCCTCC
AGTTGTATCCATTTCTATGC

CGTCCAAGAACCAGTTCTC
AAGGCTTCAACAGTCCTGC

GGGGTCCCTGACAGGTT
AGGAGGCTCTGACTAGACCT

CCTGAGCCTGAGGTCTGTG
GCCCCACTGCTGTAGCTGC

CAGGGGCAGTGGATCAG
GCAGGAGATGGAGGCCGGC

ACCGCCGCGGACACGGCTG
AC (SEQ ID NO: 3375)

GCACAGATTTCACACTG
TCTCCAGGGGTGACGGGGC

TGTATTACTGTGCCAGAAG

AAAATCAGCAGAGTGGA
AGGGAG (SEQ ID NO:

GAGGTCCTTCTCTCGTCCTT

GGCTGAGGATGTTGGGG
3377)

CGTCTATCGACTACTGGGG

TTTATTACTGCATGCAAG

CCAGGGAACCCTGGTCACC

CTCTACAAACTCTCACCT

GTCTCCTCAGCGTCGACCA

TCGGCCAAGGGACACGA

AGGGCCCATCGGTCTTCCC

CTGGAGATTAAACGTAC

CCTGGCACCCTCCTCCAAG

GGTGGCTGCACCATCTGT

AGCACCTCTGGGGGCACAG

CTTCATCTTCCCGCCATC

CGGCCCTGGGCTGCCTGGT

TGATGAGCAGTTGAAAT

CAAGGACTACTTCCCCGAA

CTGGAACTGCCTCTGTTG

CCTGTGACGGTCTCGTGGA

TGTGCCTGCTGAATAACT

ACTCAGGCGCCCTGACCAG

TCTATCCCAGAGAGGCC

CGGCGTGCACACCTTCCCG

AAAGTACAGTGGAAGGT

GCTGTCCTACAGTCCTCAG

GGATAACGCCCTCCAAT

GACTCTACTCCCTCAGCAG

CGGGTAACTCCCAGGAG

CGTGGTGACCGTGCCCTCC

AGTGTCACAGAGCAGGA

AGCAGCTTGGGGCACCCAG

CAGCAAGGACAGCACCT

ACCTACATCTGCAACGTGA

ACAGCCTCAGCAGCACC

ATCACAAGCCCAGCAACAC

CTGACGCTGAGCAAAGC

CAAGGTGGACAAGAGAGTT

AGACTACGAGAAACACA

GAGCCCAAATCTTGTGACA

AAGTCTACGCCTGCGAA

AAACTCACACATGCCCACC

GTCACCCATCAGGGCCT

GTGCCCAGCACCTGAAC

GAGCTCGCCCGTCACAA

(SEQ ID NO: 3374)

AGAGCTTCAACANGGGN

ANAGTGTTAGAAGCTTG

GCCGCCATGGCCCAACT

TGTTTATT (SEQ ID

NO: 3376)

COV57_P2
A-C037
TACACATACGATTTAGGTG
CGCTGTGCCCCNGAGGTGC
COV57_P2
TACACATACGATTTAGGT
ATTGGAGGGCGTTATCCACC
COV57_P2

H6

ACACTATAGAATAACATCC
TCCTGGAGCAGGGCGCCAG
H6
GACACTATAGAATAACA
TTCCACTGTACTTTGGCCTC
H6

ACTTTGCCTTTCTCTCCACA
GGGGAAGACCGATGGGCCC

TCCACTTTGCCTTTCTCT
TCTGGGATAGNNCNTAANN

GGTGTCCACTCCCAGGTCC
TTGGTGGAAGCTGAAGAGA

CCACAGGTGTCCACTCCC
CAGCAGGCACACAACAGAG

AACTGCACCTCGGTTCTATC
CGGTGACCATTGTCCCTTGG

AGGTCCAACTGCACCTC
GCAGTTCCAGATTTCAACTG

GATTGAATTCCACCATGGG
CCCCAGATATCAAAAGCAT

GGTTCTATCGATTGAATT
CTCATCAGATGGCGGGAAG

ATGGTCATGTATCATCCTTT
CATTGCAGCTACCACCACT

CCACCATGGGATGGTCA
ATGAAGACAGATGGTGCAG

TTCTAGTAGCAACTGCAAC
ACAATATGGGGCCGCACAG

TGTATCATCCTTTTTCTA
CCACAGTTCGTTTGATTTCC

CGGTGTACATTCCCAGGTG
TAATACACGGCCGTGTCCT

GTAGCAACTGCAACCGG
ACCTTGGTCCCTTGGCCGAA

CAGCTGGTGCAGTCTGGGC
CGGATCTCAGGCTGCTCAG

TGTACATTCAGAAATTGT
CGTCCACGGTGAGCTACCAT

CTGAGGTGAAGAAGCCTGG
CTCCATGTAGGCTGTGCTTG

GTTGACGCAGTCTCCAG
ACTGCTGACAGTAATACACT

GACCTCAGTGAAGGTCTCC
TGGACATGTCCCTGGTAAT

GCACCCTGTCTTTGTCTC
GCAAAATCTTCAGGCTCCAG

TGCAAGGCTTCTGGATTCA
GGTGACTCTTTCCTGGAACT

CAGGGGAAAGAGCCACC
TCTGCTGATGGTGAGAGTGA

CCTTTACTAGCTCTGCTATG
TCTGTGCGTAGTTTGTGTTA

CTCTCCTGCAGGGCCAGT
AGTCTGTCCCAGACCCACTG

CAGTGGGTGCGACAGGCTC
CCACTGCCAACGACGATCC

CAGAGTGTTAGCAGCAG
CCACTGAACCTGTCTGGGAT

GTGGACAACGCCTTGAGTG
ATCCTATCCACTCAAGGCG

CTACTTAGCCTGGTACCA
GCCAGTGGCCCTGCTGGATG

GATAGGATGGATCGTCGTT
TTGTCCACGAGCCTGTCGC

GCAGAAACCTGGCCAGG
CACCATAGATGAGGAGCCT

GGCAGTGGTAACACAAACT
ACCCACTGCATAGCAGAGC

CTCCCAGGCTCCTCATCT
GGGAGCCTGGCCAGGTTTCT

ACGCACAGAAGTTCCAGGA
TAGTAAAGGTGAATCCAGA

ATGGTGCATCCAGCAGG
GCTGGTACCAGGCTAAGTA

AAGAGTCACCATTACCAGG
AGCCTTGCAGGAGACCTTC

GCCACTGGCATCCCAGA
GCTGCTGCTAACACTCTGAC

GACATGTCCACAAGCACAG
ACTGAGGTCCCAGGCTTCTT

CAGGTTCAGTGGCAGTG
TGGCCCTGCAGGAGAGGGT

CCTACATGGAGCTGAGCAG
CACCTCAGGCCCAGACTGC

GGTCTGGGACAGACTTC
GGCTCTTTCCCCTGGAGACA

CCTGAGATCCGAGGACACG
NC (SEQ ID NO:

ACTCTCACCATCAGCAG
AAGACAGGGNGANTGNAGA

GCCGTGTATTACTGTGCGG
3379)

ACTGGAGCCTGAAGATT
NTGGGTC (SEQ ID NO:

CCCCATATTGTAGTGGTGGT

TTGCAGTGTATTACTGTC
3381)

AGCTGCAATGATGCTTTTG

AGCAGTATGGTAGCTCA

ATATCTGGGGCCAAGGGAC

CCGTGGACGTTCGGCCA

AATGGTCACCGTCTCTTCAG

AGGGACCAAGGTGGAAA

CGTCGACCAAGGGCCCATC

TCAAACGTACGGTGGCT

GGTCTTCCCCCTGGCACCCT

GCACCATCTGTCTTCATC

CCTCCAAGAGCACCTCTGG

TTCCCGCCATCTGATGAG

GGGCACAGCGGCCCTGGGC

CAGTTGAAATCTGGAAC

TGCCTGGTCAAGGACTACT

TGCCTCTGTTGTGTGCCT

TCCCCGAACCTGTGACGGT

GCTGAATAACTTCTATCC

CTCGTGGAACTCAGGCGCC

CAGAGAGGCCAAAGTAC

CTGACCAGCGGCGTGCACA

AGTGGAAGGTGGATAAC

CCTTCCCGGCTGTCCTACAG

GCCCTCCAATCGGGTAA

TCCTCAGGACTCTACTCCCT

CTCCCAGGAGAGTGTCA

CAGCAGCGTGGTGACCGTG

CAGAGCAGGACAGCAAG

CCCTCCAGCAGCTTGGGCA

GACAGCACCTACAGCCT

CCCAGACCTACATCTGCAA

CAGCAGCACCCTGACGC

CGTGAATCACAAGCCCAGC

TGAGCAAAGCAGACTAC

AACACCNAAGGTGGACAAG

GAGAAACACAAAGTCTA

AGAGTTGAGCCCAAATCTT

CGCCTGCGAAGTCACCC

GTGACAAAACTCACACATG

ATCANGGCCTGAGCTCG

CCCACCGTGCC (SEQ

CCCGTCACAAAGAGCTT

ID NO: 3378)

CAACAGGGGAGAGTGTT

AGAAGCTTGGCCGCCAT

GGCCCAACTTGTTTATTG

CAGCTTATAATGGTTACA

AA (SEQ ID NO:

3380)

COV57_P1
A-C038
TACACATACGATTTAGGTG
CTGTGCTCTCGGANGTGCTC
COV57_P1
TACACATACGATTTAGGT
TGGGCTGGCTTAGGACGGTC
COV57_P1

E9

ACACTATAGAATAACATCC
CTGGAGCAGGGCGCCAGGG
E9
GACACTATAGAATAACA
AGCTTGGTCCCTCCGCCGAA
E9

ACTTTGCCTTTCTCTCCACA
GGAAGACCGATGGGCCCTT

TCCACTTTGCCTTTCTCT
CACCCAACGACTGTTGATAT

GGTGTCCACTCCCAGGTCC
GGTGGAGGCTGAGGAGACG

CCACAGGTGTCCACTCCC
CATAAGACTGACAGTAGTA

AACTGCACCTCGGTTCTATC
GTGACCAGGGTTCCCTGGC

AGGTCCAACTGCACCTC
GTCAGCCTCGTCCTCAGTCT

GATTGAATTCCACCATGGG
CCCAGGAGTCAGGATAGCA

GGTTCTATCGATTGAATT
TCAGTCCAGAGATGGTGAG

ATGGTCATGTATCATCCTTT
TACACCATTAGTGCAATAA

CCACCATGGGATGGTCA
GGAGGCAGAATTGGAGGAG

TTCTAGTAGCAACTGCAAC
CCCATCGGACTTTTCGCACA

TGTATCATCCTTTTTCTA
CTGTCGATGGAGCCAGAGA

CGGTGTACATTCTGAGGTG
GTAATAGACAGCCGTGTCC

GTAGCAACTGCAACCGG
ACCGATCAGGGACCCCAGA

CAGCTGGTGGAGTCTGGGG
TCAGCTCTCAGGCTGTTCAT

TTCTTGGGCCAATTTTAT
GGGTCTTTGGGTATCTTCAT

GAGGCGTGGTCCAGCCTGG
CTGTAGATACAGCGTGTTCT

GCTGACTCAGCCCCACTC
AGATCACAGTGGTGGGGGC

GAGGTCCCTGAGACTCTCC
TGGAATTGTCTCTGGAGAT

TGTGTCGGAGTCTCCGG
ACTGCCCGGGCGCTGCTGGT

TGTGCAGCCTCTGGATTCAC
GGCGAACCGGCCCTTCACG

GGAAGACGGTTACCATC
ACCACTGCACATAGTTGCTG

CTTCAATAGAATTGCCATGT
GACTCTGCATAGTATTCATA

TCCTGCACCGGCAGCAG
GCAATGCTGCCACTGCTGCC

ACTGGGTCCGCCAGGCTCC
ACTTCCATCAAATGATATA

TGGCAGCATTGCCAGCA
GGTGCAGGAGATGGTAACC

AGGCAAGGGGCTGGAATGG
ACTGCCACCCATTCCAGCC

ACTATGTGCAGTGGTAC
GTCTTCCCCGGAGACTCCGA

GTGGCAGTTATATCATTTGA
CCTTGCCTGGAGCCTGGCG

CAGCAGCGCCCGGGCAG
CACAGAGTGGGGCTGAGTC

TGGAAGTTATGAATACTAT
GACCCAGTACATGGCAATT

TGCCCCCACCACTGTGAT
AGCACAGACTGGGACCAGG

GCAGAGTCCGTGAAGGGCC
CTATTGAAGGTGAATCCAG

CTATGAAGATACCCAAA
AACCGGNTG (SEQ ID

GGTTCGCCATCTCCAGAGA
AGGCTGCACAGGAGAGTCT

GACCCTCTGGGGTCCCTG
NO: 3385)

CAATTCCAAGAACACGCTG
CAGGGACCTCCCAGGCTGG

ATCGGTTCTCTGGCTCCA

TATCTACAGATGAACAGCC
ACCACGCCTCCCCCAGACT

TCGACAGCTCCTCCAATT

TGAGAGCTGAGGACACGGC
CCACCANNCTGCAC

CTGCCTCCCTCACCATCT

TGTCTATTACTGTGCGAAA
(SEQ ID NO: 3383)

CTGGACTGAAGACTGAG

AGTCCGATGGGTTATTGCA

GACGAGGCTGACTACTA

CTAATGGTGTATGCTATCCT

CTGTCAGTCTTATGATAT

GACTCCTGGGGCCAGGGAA

CAACAGTCGTTGGGTGTT

CCCTGGTCACCGTCTCCTCA

CGGCGGAGGGACCAAGC

GCGTCGACCAAGGGCCCAT

TGACCGTCCTAAGCCAG

CGGTCTTCCCCCTGGCACCC

CCCAAGGCTGCCCCCTC

TCCTCCAAGAGCACCTCTG

GGTCACTCTGTTCCCACC

GGGGCACAGCGGCCCTGGG

CTCGAGTGAGGAGCTTC

CTGCCTGGTCAAGGACTAC

AAGCCAACAAGGCCACA

TTCCCCGAACCTGTGACGG

CTGGTGTGTCTCATAAGT

TCTCGTGGAACTCAGGCGC

GACTTCTACCCGGGAGC

CCTGACCAGCGGCGTGCAC

CGTGACAGTGGCCTGGA

ACCTTCCCGGCTGTCCTACA

AGGCAGATAGCAGCCCC

GTCCTCAGGACTCTACTCCC

GTCAAGGCGGGAGTGGA

TCAGCAGCGTGGTGACCGT

GACCACCACACCCTCCA

GCCCTCCAGCAGCTTGGGC

AACAAAGCAACAACAAG

ACCCAGACCTACATCTGCA

TACGCGGCCAGCAGCTA

ACGTGAATCACAAGCCCAG

CCTGAGCCTGACGCCTG

CAACACCNANGTGGACAAG

AGCAGTGGAAGTCCCAC

AGAGTTGAGCCCAAATCTT

AGAAGCTACAGCTGCCA

GTGACAAAACTCACACATG

GGTCACGCATGAAGGGA

CCCACCGTGCCCA

GCACCGTGGAGAAGACA

(SEQ ID NO: 3382)

GTGGCCCCTACAGAATG

TTCATAGAAGCTTGGGC

CGCCATGGCCCAACTTGT

TTATTGCAGCTTATAATG

G (SEQ ID NO: 3384)

COV57_P1
A-C039
TACACATACGATTTAGGTG
CGCTGTGNNNNNGAGGTGC
COV57_P1
TACACATACGATTTAGGT
TTGGGCTGACCTAGGACGGT
COV57_P1

F10

ACACTATAGAATAACATCC
TCTTGGAGGAGGGTGCCAG
F10
GACACTATAGAATAACA
CAGCTTGGTCCCTCCGCCAA
F10

ACTTTGCCTTTCTCTCCACA
GGGGAAGACCGATGGGCCC

TCCACTTTGCCTTTCTCT
ACACCCTCGAACCACTCAGG

GGTGTCCACTCCCAGGTCC
TTGGTGGAGGCTGAGGAGA

CCACAGGTGTCCACTCCC
CTGCTGTCATAGGACTGGCA

AACTGCACCTCGGTTCTATC
CGGTGACCAGGGTTCCCTG

AGGTCCAACTGCACCTC
GTAATAATCAGCCTCATCCT

GATTGAATTCCACCATGGG
GCCCCAGTAGTCAAAAAGG

GGTTCTATCGATTGAATT
CAGCCTGGAGCCCAGTGAT

ATGGTCATGTATCATCCTTT
GGATCCGTTCCTGAACCAT

CCACCATGGGATGGTCA
GGCCAGGGAGGCTGAGGTG

TTCTAGTAGCAACTGCAAC
AGGTAATAACCACTCCAAA

TGTATCATCCTTTTTCTA
CCAGACTTGGAGCCAGAGA

CGGTGTACATTCCCAGGTG
ACCAGCTCTCGCACAGTAA

GTAGCAACTGCAACCGG
ATCGGTCAGGGACCCCTGA

CAGCTACAGCAGTGGGGCG
TACACAGCCGTGTCCGCGG

TTCCTGGGCCCAGTCTGT
GGGCCGATTGCTGTTACCAT

CAGGACTGTTGAAGCCTTC
CGGTCACAGAGCTCAGCTT

GCTGACTCAGCCGCCCTC
AGATGAGGAGTTTGGGGGC

GGAGACCCTGTCCCTCACC
CAGGGAGAACTGGTTCTTG

AGTGTCTGGGGCCCCAG
TGTTCCTGGAAGCTGCTGGT

TGCGCTGTCTATGGTGGGTC
GACGTGTCTACTGATATGG

GGCAGAGGGTCACCATC
ACCAGTGTACATCATAACCT

CTTCAGTGGTTACTACTGGA
TGACTCGACTCTTGAGGGA

TCCTGCACTGGGAGCAA
GCCCCGATGTTGGAGTTGCT

GCTGGATCCGCCAGCCCCC
CGGGTTGTAGTTGGTGCTTC

CTCCAACATCGGGGCAG
CCCAGTGCAGGAGATGGTG

AGGGAAGGGGCTGGAGTGG
CACTATGATTGATTTCCCCA

GTTATGATGTACACTGGT
ACCCTCTGCCCTGGGGCCCC

ATTGGGGAAATCAATCATA
ATCCACTCCAGCCCCTTCCC

ACCAGCAGCTTCCAGGA
AGACACTGAGGGCGGCTGA

GTGGAAGCACCAACTACAA
TGGGGGCTGGCGGATCCAG

ACAGCCCCCAAACTCCT
GTCAGCACAGACTGGGACC

CCCGTCCCTCAAGAGTCGA
CTCCAGTAGTAACCACTGA

CATCTATGGTAACAGCA
AGGAACCGGNTG (SEQ ID

GTCACCATATCAGTAGACA
AGGACCCACCATAGACAGC

ATCGGCCCTCAGGGGTC
NO: 3389)

CGTCCAAGAACCAGTTCTC
GCAGGTGAGGGACAGGGTC

CCTGACCGATTCTCTGGC

CCTGAAGCTGAGCTCTGTG
TCCGAAGGCTTCAACAGTC

TCCAAGTCTGGCACCTCA

ACCGCCGCGGACACGGCTG
CTGCGCCCCACTGCTGTAG

GCCTCCCTGGCCATCACT

TGTATTACTGTGCGAGAGC
CTGCACCTGGGA (SEQ ID

GGGCTCCAGGCTGAGGA

TGGTTTTGGAGTGGTTATTA
NO: 3387)

TGAGGCTGATTATTACTG

CCTATGGTTCAGGAACGGA

CCAGTCCTATGACAGCA

TCCCCTTTTTGACTACTGGG

GCCTGAGTGGTTCGAGG

GCCAGGGAACCCTGGTCAC

GTGTTTGGCGGAGGGAC

CGTCTCCTCAGCGTCGACC

CAAGCTGACCGTCCTAG

AAGGGCCCATCGGTCTTCC

GTCAGCCCAAGGCTGCC

CCCTGGCACCCTCCTCCAA

CCCTCGGTCACTCTGTTC

GAGCACCTCTGGGGGCACA

CCGCCCTCGAGTGAGGA

GCGGCCCTGGGCTGCCTGG

GCTTCAAGCCAACAAGG

TCAAGGACTACTTCCCCGA

CCACACTGGTGTGTCTCA

ACCTGTGACGGTCTCGTGG

TAAGTGACTTCTACCCGG

AACTCAGGCGCCCTGACCA

GAGCCGTGACAGTGGCC

GCGGCGTGCACACCTTCCC

TGGAAGGCAGATAGCAG

GGCTGTCCTACAGTCCTCA

CCCCGTCAAGGCGGGAG

GGACTCTACTCCCTCAGCA

TGGAGACCACCACACCC

GCGTGGTGACCGTGCCCTC

TCCAAACAAAGCAACAA

CAGCAGCTTGGGCACCCAG

CAAGTACGCGGCCAGCA

ACCTACATCTGCAACGTGA

GCTACCTGAGCCTGACG

ATCACAAGCCCAGCAACAC

CCTGAGCAGTGGAAGTC

CAAGGTGGACAAGAGAGTT

CCACAGAAGCTACAGCT

GAGCCCAAATCTTGTGACA

GCCAGGTCACGCATGAA

AAACTCACACATGCCCAC

GGGAGCACCGTGGAGAA

(SEQ ID NO: 3386)

GACAGTGGCCCCTACAG

AATGTTCATAGAAGCTT

GGCCGCCATGGCCCAAC

TTGTTTATTGCAGCTTAT

AATGGTTACAAATAAA

(SEQ ID NO: 3388)

CO57_P2
A-C040
TACACATACGATTTAGGTG
CGCTGTGNNNNNGAGGTGC
CO57_P2
TACACATACGATTTAGGT
TTGGGCTGACCTAGGACGGT
CO57_P2

A10

ACACTATAGAATAACATCC
TCTTGGAGGAGGGTGCCAG
A10
GACACTATAGAATAACA
CAGCTTGGTCCCTCCGCCGA
A10

ACTTTGCCTTTCTCTCCACA
GGGGAAGACCGATGGGCCC

TCCACTTTGCCTTTCTCT
ATACCCCCTGATCACTACTA

GGTGTCCACTCCCAGGTCC
TTGGTGGAGGCTGAGGAGA

CCACAGGTGTCCACTCCC
CTATCCCACACCTGACAGTA

AACTGCACCTCGGTTCTATC
CGGTGACCGTGGTCCCTTTG

AGGTCCAACTGCACCTC
ATAGTCGGCCTCATCCCCGG

GATTGAATTCCACCATGGG
CCCCAGACGTCCATGTAGT

GGTTCTATCGATTGAATT
CTTCGACCCTGCTGATGGTC

ATGGTCATGTATCATCCTTT
AGTAGTAAAAAATGGGGCA

CCACCATGGGATGGTCA
AGGGTGGCCGTGTTCCCAGA

TTCTAGTAGCAACTGCAAC
GCTGGTACTACTACAATGG

TGTATCATCCTTTTTCTA
GTTGGAGCCAGAGAATCGC

CGGTGTACATTCTGAGGTG
GGATCTGTGGTACAGTAAT

GTAGCAACTGCAACCGG
TCAGGGATCCCTGAGGGCC

CAGCTGGTGGAGTCTGGGG
ACACGGCTGTGTCCTCGGTT

TTCTGTGACCTCCTATGA
GGTCGCTATCATCATAGACG

GAGGCTTGGTAAAGCCTGG
TTCAGGCTGTTCATTTGCAG

GCTGACTCAGCCACCCTC
ACCAGCACAGGGGCCTGGC

GGGGTCCCTTAGACTCTCCT
ATACAGCGTGTTTTTTGAAT

GGTGTCAGTGGCCCCAG
CTGGCTTCTGCTGGTACCAG

GTGCAGCCTCTGGATTCACT
CATCTCTTGAGATGGTGAA

GACAGACGGCCAGGATT
TGCACACTTTTACTTCCAAT

TTCAGTAACGCCTGGATGA
TCTGCCTTTCACGGGTGCAG

ACCTGTGGGGGAAACAA
gttgtttcccccAcAggtAA

GCTGGGTCCGCCAGGCTCC
CGTAGTCTGTTGTCCCACCA

CATTGGAAGTAAAAGTG
TCCTGGCCGTCTGTCCTGGG

AGGGAAGGGGCTGGAGTGG
TCAGTTTTGCTTTTAATACG

TGCACTGGTACCAGCAG
GCCACTGACACCGAGGGTG

GTTGGCCGTATTAAAAGCA
GCCAACCCACTCCAGCCCC

AAGCCAGGCCAGGCCCC
GCTGAGTCAGCACATACTGG

AAACTGATGGTGGGACAAC
TTCCCTGGAGCCTGGCGGA

TGTGCTGGTCGTCTATGA
GACCAGGAACCGGTTG

AGACTACGCTGCACCCGTG
CCCAGCTCATCCAGGCGTT

TGATAGCGACCGGCCCT
(SEQ ID NO: 3393)

AAAGGCAGATTCACCATCT
ACTGAAAGTGAATCCAGAG

CAGGGATCCCTGAGCGA

CAAGAGATGATTCAAAAAA
GCTGCACAGGAGAGTCTAA

TTCTCTGGCTCCAACTCT

CACGCTGTATCTGCAAATG
GGGACCCCCCAGGCTTTAC

GGGAACACGGCCACCCT

AACAGCCTGAAAACCGAGG
CAAGCCTCCCCCAGACTCC

GACCATCAGCAGGGTCG

ACACAGCCGTGTATTACTG
NNNNCTGCACC (SEQ ID

AAGCCGGGGATGAGGCC

TACCACAGATCCCCATTGT
NO: 3391)

GACTATTACTGTCAGGTG

AGTAGTACCAGCTGCCCCA

TGGGATAGTAGTAGTGA

TTTTTTACTACTACTACATG

TCAGGGGGTATTCGGCG

GACGTCTGGGGCAAAGGGA

GAGGGACCAAGCTGACC

CCACGGTCACCGTCTCCTCA

GTCCTAGGTCAGCCCAA

GCGTCGACCAAGGGCCCAT

GGCTGCCCCCTCGGTCAC

CGGTCTTCCCCCTGGCACCC

TCTGTTCCCGCCCTCGAG

TCCTCCAAGAGCACCTCTG

TGAGGAGCTTCAAGCCA

GGGGC_AC_AGCGGCCCTGGG

ACAAGGCCACACTGGTG

CTGCCTGGTCAAGGACTAC

TGTCTCATAAGTGACTTC

TTCCCCGAACCTGTGACGG

TACCCGGGAGCCGTGAC

TCTCGTGGAACTCAGGCGC

AGTGGCCTGGAAGGCAG

CCTGACCAGCGGCGTGCAC

ATAGCAGCCCCGTCAAG

ACCTTCCCGGCTGTCCTACA

GCGGGAGTGGAGACCAC

GTCCTCANGACTCTACTCCC

CACACCCTCCAAACAAA

TCAGCAGCGTGGTGACCGT

GCAACAACAAGTACGCG

GCCCTCCAGCAGCTTGGGC

GCCAGCAGCTACCTGAG

ACCCAGACCTACATCTGCA

CCTGACGCCTGAGCAGT

ACGTGAATCACAAGCCCAG

GGAAGTCCCACAGAAGC

CAACACCNANGTGGACAAG

TACAGCTGCCAGGTCAC

AGAGTTGAGCCCAAATCTT

GCATGAAGGGAGCACCG

GTGACAAAAC (SEQ ID

TGGAGAAGACAGTGGCC

NO: 3390)

CCTACAGAATGTTCATA

GAAGCTTGGCCGCCATG

GCCCAACTTGTTTATTGC

AGCTTATAATGGTTACA

AATAAAG (SEQ ID NO:

3392)

CO57_P1
A-C041
TACACATACGATTTAGGTG
GNCGCTGTGNNNNNNAGGT
CO57_P1
TACACATACGATTTAGGT
GANTTNCCCGATTGGAGGG
CO57_P1

B9

ACACTATAGAATAACATCC
GCTCTTGGAGGAGGGTGCC
B9
GACACTATAGAATAACA
CGTTATCCACCTTCCACTGT
B9

ACTTTGCCTTTCTCTCCACA
AGGGGGAAGACCGATGGGC

TCCACTTTGCCTTTCTCT
ACTTTGGCCTCTCTGGGATA

GGTGTCCACTCCCAGGTCC
CCTTGGTGGAGGCTGAGGA

CCACAGGTGTCCACTCCC
GAAGTTATTCAGCAGGCAC

AACTGCACCTCGGTTCTATC
GACGGTGACCGTGGTCCCT

AGGTCCAACTGCACCTC
ACAACAGAGGCAGTTCCAG

GATTGAATTCCACCATGGG
TGGCCCCAGACGTCCATAC

GGTTCTATCGATTGAATT
ATTTCAACTGCTCATCAGAT

ATGGTCATGTATCATCCTTT
CGTAGTAGTAGTAGTCCCT

CCACCATGGGATGGTCA
GGCGGGAAGATGAAGACAG

TTCTAGTAGCAACTGCAAC
CGGCATCCAGTGTCTCGCA

TGTATCATCCTTTTTCTA
ATGGTGCAGCCACAGTTCGT

CGGTGTACATTCCCAGGTG
CAGTAATACACAGCCGTGT

GTAGCAACTGCAACCGG
TTGATTTCCACCTTGGTCCC

CAGCTACAGCAGTGGGGCG
CCGCGGCGGTCACAGAGCT

TGTACATTCAGACATCCA
TTGGCCGAACGTCCGAGGG

CAGGACTGTTGAAGCCTTC
CAGCTTCAGGAAGAACTGG

GTTGACCCAGTCTCCATC
GTACTGTAACTCTGTTGACA

GGAGACCCTGTCCCTCACC
TTCTTGGACGTGTCTACTGA

CTCCCTGTCTGCATCTGT
GTAGTAAGTTGCAAAATCTT

TGCGCTGTCTATGGTGGGTC
TATGGTGACTCGACTCTTGA

AGGAGACAGAGTCACCA
CAGGTTGCAGACTGCTGATG

CTTCAGTGGTTACTACTGGA
GGGACGGGTTGTAGTTGGT

TCACTTGCCGGGCAAGT
GTGAGAGTGAAATCTGTCCC

GCTGGATCCGCCAGCCCCC
GCTTCCACTATGATTGACTT

CAGAGCATTAGCAGCTA
AGATCCACTGCCACTGAACC

AGGGAAGGGGCTGGAGTGG
CCCCAATCCACTCCAGCCC

TTTAAATTGGTATCAGCA
TTGATGGGACCCCACTTTGC

ATTGGGGAAGTCAATCATA
CTTCCCTGGGGGCTGGCGG

GAAACCAGGGAAAGCCC
AAACTGGATGCAGCATAGA

GTGGAAGCACCAACTACAA
ATCCAGCTCCAGTAGTAAC

CTAAGCTCCTGATCTATG
TCAGGAGCTTAGGGGCTTTC

CCCGTCCCTCAAGAGTCGA
CACTGAAGGACCCACCATA

CTGCATCCAGTTTGCAAA
CCTGGTTTCTGCTGATACCA

GTCACCATATCAGTAGACA
GACAGCGCAGGTGAGGGAC

GTGGGGTCCCATCAAGG
ATTTAAATAGCTGCTAATGC

CGTCCAAGAACCAGTTCTT
AGGGTCTCCGAAGGCTTCA

TTCAGTGGCAGTGGATCT
TCTGACTTGCCCGGCAAGTG

CCTGAAGCTGAGCTCTGTG
ACAGTCCTGCGCCCCACTG

GGGACAGATTTCACTCTC
ATGGTGACTCTGTCTCCTAC

ACCGCCGCGGACACGGCTG
CTGTAGCTGCACCTNNNAA

ACCATCAGCAGTCTGCA
AGATGCAGACAGGGAG

TGTATTACTGTGCGAGACA
(SEQ ID NO: 3395)

ACCTGAAGATTTTGCAA
(SEQ ID NO: 3397)

CTGGATGCCGAGGGACTAC

CTTACTACTGTCAACAGA

TACTACTACGGTATGGACG

GTTACAGTACCCCTCGG

TCTGGGGCCAAGGGACCAC

ACGTTCGGCCAAGGGAC

GGTCACCGTCTCCTCAGCGT

CAAGGTGGAAATCAAAG

CGACCAAGGGCCCATCGGT

TACGGTGGCTGCACCAT

CTTCCCCCTGGCACCCTCCT

CTGTCTTCATCTTCCCGC

CCAAGAGCACCTCTGGGGG

CATCTGATGAGCAGTTG

CACAGCGGCCCTGGGCTGC

AAATCTGGAACTGCCTCT

CTGGTCAAGGACTACTTCC

GTTGTGTGCCTGCTGAAT

CCGAACCTGTGACGGTCTC

AACTTCTATCCCAGAGA

GTGGAACTCNGCGCCCTGA

GGCCAAAGTACAGTGGA

CCAGCGGCGTGCACACCTT

AGGTGGATAACGCCCTC

CCCGGCTGTCCTACAGTCCT

CAATCGGGTAACTCCCA

CANGACTCTACTCCCTCAG

GGAGAGTGTCACAGAGC

CAGCGTGGTGACCGTGCCC

AGGACAGCAAGGACAGC

TCCAGCAGCTTGGGCACCC

ACCTACAGCCTCAGCAG

AGACCTACATCTGCAACGT

CACCCTGACGCTGAGCA

GAATCACAAGCCCAGCAAC

AAGCAGACTACGAGAAA

ACCNANGTGGACAAGANAG

CACAAAGTCTACGCCTG

TTGAGCCCAAATCTTGTGA

CGAAGTCACCCATCAGG

CAAACTCACACATGCCCAC

GCCTGAGCTCGCCCGTC

CGTGCCCAG (SEQ ID

ACAAAGAGCTTCAACAG

NO: 3394)

GGGAGAGTGTTAGAAGC

TTGGNCGCCATGGCCCA

ACTTGTTTATTGCAGCTT

ATAATGGTTACAAATAA

AGCAATAGCATCAC

(SEQ ID NO: 3396)

V-C001
NNNNNNNNNNNNNGTATCA
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNCNNATGTATC
GAAATTGTGTTGACGCAGTC
COV107_

TACACATACGATTTAGGTG
CTGGAGGAGGCTTGATCCA
P2_H9
NTACACATACGATTTAG
TCCAGGCACCCTGTCTTTGT
P2_H9

ACACTATAGAATAACATCC
GCCTGGGGGGTCCCTGAGA

GTGACACTATAGAATAA
CTCCAGGGGAAAGAGCCAC

ACTTTGCCTTTCTCTCCACA
CTCTCCTGTGCAGCCTCTGG

CATCCACTTTGCCTTTCT
CCTCTCCTGCAGGGCCAGTC

GGTGTCCACTCCCAGGTCC
GTTCATCGTCAGTAGCAAC

CTCCACAGGTGTCCACTC
AGAGTGTTAGCAGCAGCTA

AACTGCACCTCGGTTCTATC
TACATGAGCTGGGTCCGCC

CCAGGTCCAACTGCACC
CTTAGCCTGGTACCAGCAGA

GATTGAATTCCACCATGGG
AGGCTCCAGGGAAGGGGCT

TCGGTTCTATCGATTGAA
AACCTGGCCAGGCTCCCAG

ATGGTCATGTATCATCCTTT
GGAGTGGGTCTCAGTTATTT

TTCCACCATGGGATGGTC
GCTCCTCATCTATGGTGCAT

TTCTAGTAGCAACTGCAAC
ATAGCGGTGGTAGCACATT

ATGTATCATCCTTTTTCT
CCAGCAGGGCCACTGGCAT

CGGTGTACATTCTCAGGTG
CTACACAGACTCCGTGAAG

AGTAGCAACTGCAACCG
CCCAGACAGGTTCAGTGGC

CAGCTGGTGGAGTCTGGAG
GGCCGATTCACCATCTCCA

GTGTACATTCAGAAATT
GGTGGGTCTGAGACAGACTT

GAGGCTTGATCCAGCCTGG
GAGACAATTCCAAGAACAC

GTGTTGACGCAGTCTCCA
CACTCTCACCATCAGCAGAC

GGGGTCCCTGAGACTCTCC
TCTGTATCTTCAAATGAACA

GGCACCCTGTCTTTGTCT
TGGAGCCTGAAGATTGTGCA

TGTGCAGCCTCTGGGTTCAT
GCCTGAGAGCCGAGGACAC

CCAGGGGAAAGAGCCAC
GTGTATTACTGTCAGCAGTA

CGTCAGTAGCAACTACATG
GGCCGTGTATTACTGTGTGC

CCTCTCCTGCAGGGCCA
TGGTAGCTCACCCCGGACGT

AGCTGGGTCCGCCAGGCTC
GGGACTACGGTGACTTCTA

GTCAGAGTGTTAGCAGC
TCGGCCAAGGGACCAAGGT

CAGGGAAGGGGCTGGAGTG
CTTTGACTACTGGGGCCAG

AGCTACTTAGCCTGGTAC
GGAAATCAAAC (SEQ

GGTCTCAGTTATTTATAGCG
GGAACCCTGGTCACCGTCT

CAGCAGAAACCTGGCCA
ID NO: 3401)

GTGGTAGCACATTCTACAC
CCTCAG (SEQ ID

GGCTCCCAGGCTCCTCAT

AGACTCCGTGAAGGGCCGA
NO: 3399)

CTATGGTGCATCCAGCA

TTCACCATCTCCAGAGACA

GGGCCACTGGCATCCCA

ATTCCAAGAACACTCTGTA

GACAGGTTCAGTGGCGG

TCTTCAAATGAACAGCCTG

TGGGTCTGAGACAGACT

AGAGCCGAGGACACGGCCG

TCACTCTCACCATCAGCA

TGTATTACTGTGTGCGGGA

GACTGGAGCCTGAAGAT

CTACGGTGACTTCTACTTTG

TGTGCAGTGTATTACTGT

ACTACTGGGGCCAGGGAAC

CAGCAGTATGGTAGCTC

CCTGGTCACCGTCTCCTCAG

ACCCCGGACGTTCGGCC

CGTCGACCAAGGGCCCATC

AAGGGACCAAGGTGGAA

GGTCTTCCCCCTGGCACCCT

ATCAAACGTACGGTGGC

CCTCCAAGAGCACCTCTGG

TGCACCATCTGTCTTCAT

GGGCACAGCGGCCCTGGGC

CTTCCCGCCATCTGATGA

TGCCTGGTCAAGGACTACT

GCAGTTGAAATCTGGAA

TCCCCGAACCTGTGACGGT

CTGCCTCTGTTGTGTGCC

CTCGTGGAACTCAGGCGCC

TGCTGAATAACTTCTATC

CTGACCAGCGGCGTGCACA

CCAGAGAGGCCAAAGTA

CCTTCCCGGCTGTCCTACAG

CAGTGGAAGGTGGATAA

TCCTCAGGACTCTACTCCCT

CGCCCTCCAATCGGGTA

CAGCAGCGTGGTGACCGTG

ACTCCCAGGAGAGTGTC

CCCTCCAGCAGCTTGGGCA

ACAGAGCAGGACAGCAA

CCCAGACCTACATCTGCAA

GGACAGCACCTACAGCC

CGTGAATCACAAGCCCAGC

TCAGCAGCACCCTGACG

AACACCNANNTGGACAAGA

CTGAGCAAAGCAGACTA

GAGTTGAGCCCAAATCTTG

CGAGAAACACAAAGTCT

TGACAAAACTCACACATGC

ACGCCTGCGAAGTCACC

CCACCGTGCCCAGCACCTG

CATCNGGNCNTGAGCTC

AACTCCTGGGGGGACCGTC

GCCCGTCACAAAGAGCT

AGTCTTCCTCTTCCCCCCAA

TCAACAGGGGAGAGTGT

AACCCNAGGACACCCTCAT

TAGAAGCTTGGCCGCCA

GATCTCCCNGACCCCNGAG

TGGCCCAACTTGTTTATT

TCACATGCGTGGNNGTGGN

GCAGCTTATAATGGTTAC

NGTGANCCACGAAGANCCT

AAATAAAGCAATAGCAT

GAGGTCAAGTTCAACTGGN

CACAAATTTCACAAATA

ACNNNGNNNNGNN

AAGCATTTTTTTCACTGC

(SEQ ID NO: 3398)

ATTCTANTTGNNGTTNGT

CCAAACTCATCANGTAT

NTNNCATGTCTGGNTCG

GGANTNNNGCGCAGCNC

NTGCTGAANNNACNTCT

GAANNAGANNNNGTTAG

GTACCTTNNGNNNGNNN

NNNN (SEQ ID

NO: 3400)

V-C002
NNNNNNNNNNNTNTGNNTC
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNCNTATGTATC
GAAATTGTGTTGACGCAGTC
COV107_

NTACNCATACGATTTAGGT
CTGGAGGAGGCTTGATCCA
P2_b1
NTACACATACGATTTAG
TCCAGGCACCCTGTCTTTGT
P2_b1

GACACTATAGAATAACATC
GCCTGGGGGGTCCCTGAGA

GTGACACTATAGAATAA
CTCCAGGGGAAAGAGCCAC

CACTTTGCCTTTCTCTCCAC
CTCTCCTGTGCAGCCTCTGG

CATCCACTTTGCCTTTCT
CCTCTCCTGCAGGGCCAGTC

AGGTGTCCACTCCCAGGTC
GTTCATCGTCAGTAGCAAC

CTCCACAGGTGTCCACTC
AGAGTGTTAGCAGCAGCTA

CAACTGCACCTCGGTTCTAT
TACATGAGCTGGGTCCGCC

CCAGGTCCAACTGCACC
CTTAGCCTGGTACCAGCAGA

CGATTGAATTCCACCATGG
AGGCTCCAGGGAAGGGGCT

TCGGTTCTATCGATTGAA
AACCTGGCCAGGCTCCCAG

GATGGTCATGTATCATCCTT
GGAGTGGGTCTCAGTTATTT

TTCCACCATGGGATGGTC
GCTCCTCATCTATGGTGCAT

TTTCTAGTAGCAACTGCAA
ATAGCGGTGGTAGCACATT

ATGTATCATCCTTTTTCT
CCAGCAGGGCCACTGGCAT

CCGGTGTACATTCTCAGGT
CTACGCAGACTCCGTGAAG

AGTAGCAACTGCAACCG
CCCAGACAGGTTCAGTGGC

GCAGCTGGTGGAGTCTGGA
GGCCGATTCACCATCTCCA

GTGTACATTCAGAAATT
AGTGGGTCTGGGACAGACTT

GGAGGCTTGATCCAGCCTG
GAGACAATTCCAAGAACAC

GTGTTGACGCAGTCTCCA
CACTCTCACCATCAGCAGAC

GGGGGTCCCTGAGACTCTC
GCTGTATCTTCAAATGAAC

GGCACCCTGTCTTTGTCT
TGGAGCCTGAAGATTTTGCA

CTGTGCAGCCTCTGGGTTCA
AGCCTGAGAGCCGAGGACA

CCAGGGGAAAGAGCCAC
GTCTATTACTGTCAGCAGTA

TCGTCAGTAGCAACTACAT
CGGCCGTGTATTACTGTGC

CCTCTCCTGCAGGGCCA
TGGTAGCTCACCTCGGACGT

GAGCTGGGTCCGCCAGGCT
GAGGGACTACGGTGACTAC

GTCAGAGTGTTAGCAGC
TCGGCCAAGGGACCAAGGT

CCAGGGAAGGGGCTGGAGT
TACTTTGACTACTGGGGCC

AGCTACTTAGCCTGGTAC
GGAAATCAAAC (SEQ

GGGTCTCAGTTATTTATAGC
AGGGAACCCTGGTCACCGT

CAGCAGAAACCTGGCCA
ID NO: 3405)

GGTGGTAGCACATTCTACG
CTCCTCAG (SEQ ID

GGCTCCCAGGCTCCTCAT

CAGACTCCGTGAAGGGCCG
NO: 3403)

CTATGGTGCATCCAGCA

ATTCACCATCTCCAGAGAC

GGGCCACTGGCATCCCA

AATTCCAAGAACACGCTGT

GACAGGTTCAGTGGCAG

ATCTTCAAATGAACAGCCT

TGGGTCTGGGACAGACT

GAGAGCCGAGGACACGGCC

TCACTCTCACCATCAGCA

GTGTATTACTGTGCGAGGG

GACTGGAGCCTGAAGAT

ACTACGGTGACTACTACTTT

TTTGCAGTCTATTACTGT

GACTACTGGGGCCAGGGAA

CAGCAGTATGGTAGCTC

CCCTGGTCACCGTCTCCTCA

ACCTCGGACGTTCGGCC

GCGTCGACCAAGGGCCCAT

AAGGGACCAAGGTGGAA

CGGTCTTCCCCCTGGCACCC

ATCAAACGTACGGTGGC

TCCTCCAAGAGCACCTCTG

TGCACCATCTGTCTTCAT

GGGGCACAGCGGCCCTGGG

CTTCCCGCCATCTGATGA

CTGCCTGGTCAAGGACTAC

GCAGTTGAAATCTGGAA

TTCCCCGAACCTGTGACGG

CTGCCTCTGTTGTGTGCC

TCTCGTGGAACTCAGGCGC

TGCTGAATAACTTCTATC

CCTGACCAGCGGCGTGCAC

CCAGAGAGGCCAAAGTA

ACCTTCCCGGCTGTCCTACA

CAGTGGAAGGTGGATAA

GTCCTCAGGACTCTACTCCC

CGCCCTCCAATCGGGTA

TCAGCAGCGTGGTGACCGT

ACTCCCAGGAGAGTGTC

GCCCTCCAGCAGCTTGGGC

ACAGAGCAGGACAGCAA

ACCCAGACCTACATCTGCA

GGACAGCACCTACAGCC

ACGTGAATCACAAGCCCAG

TCAGCAGCACCCTGACG

CAACACCAAGGTGGACAAG

CTGAGCAAAGCAGACTA

AGAGTTGAGCCCAAATCTT

CGAGAAACACAAAGTCT

GTGACAAAACTCACACATG

ACGCCTGCGAAGTCACC

CCCACCGTGCCCAGCACCT

CATCNGGNCCTGAGCTC

GAACTCCTGGGGGGACCGT

GCCCGTCACAAAGAGCT

CAGTCTTCCTCTTCCCCCCA

TCAACAGGGGAGAGTGT

AAACCCAANGACACCCTCA

TAGAAGCTTGGCCGCCA

TGATCTCCCGGACCCCTGA

TGGNCCAACTTGTTTATT

GGTCACATGCGTGGTGGTG

GCAGCTTATAATGGNTA

GACGTGAGCCACGAANANC

CAAATAAAGCAATAGCA

CTGANNCAAGTTCNACTGG

TCACAAATTTCACAAAT

NACGTGGNNGGCGTNNNGT

AAAGCATTTTTTTCACTG

GCATANGCCANANAAGCNG

CATTCTAGTTGNGGNTTG

CGGAGGAGCANTANANAGC

TCCAAACTCATCAATGN

ACGTACGNNNNGNCAGCGT

ATNTNTCATGTCTGGNTC

CCNNNNCNNCNGCNNNGAC

GGGNATNATTCNNNGCA

TNNNNANNNNNNNNANAN

GCACCNTGGNNTGAAAN

NNCAGNCTCANAANCNNNC

NACCTNNTGAANNNGNN

CNNCCCCANCNANAAAANC

CTNNGN (SEQ ID

NTNNNNNAGCNNANNNGN

NO: 3404)

NNNNCCCNNAN (SEQ

ID NO: 3402)

V-C003
NNNNNNNNNNNNTGNNTCN
CAGGTGCAGCTACAGCAGT
COV107_
NNNNNNNNNNNATGTAT
GAAATTGTGTTGACGCAGTC
COV107_

TACACATACGATTTAGGTG
GGGGCGCAGGACTGTTGAA
P2_E5
CNTACACATACGATTTA
TCCAGGCACCCTGTCTTTGT
P2_E5

ACACTATAGAATAACATCC
GCCTTCGGAGACCCTGTCC

GGTGACACTATAGAATA
CTCCAGGGGAAAGAGCCAC

ACTTTGCCTTTCTCTCCACA
CTCACCTGCGCTGTCTCTGG

ACATCCACTTTGCCTTTC
CCTCTCCTGCAGGGCCAGTC

GGTGTCCACTCCCAGGTCC
TGGGTCACTCAGTGGTTTCT

TCTCCACAGGTGTCCACT
AGACTGTTACCGCCAACTAC

AACTGCACCTCGGTTCTATC
ACTGGACCTGGATCCGCCA

CCCAGGTCCAACTGCAC
TTAGCCTGGTACCAGCAGAA

GATTGAATTCCACCATGGG
GCCCCCAGGAAAGGGGCTG

CTCGGTTCTATCGATTGA
ACCTGGCCAGGCTCCCAGAC

ATGGTCATGTATCATCCTTT
GAGTGGATTGGGGAAACCA

ATTCCACCATGGGATGG
TCCTCATCTATGGTGCATCC

TTCTAGTAGCAACTGCAAC
ATCATTTTGGAAGCACCGG

TCATGTATCATCCTTTTT
AAGAGGGCCACTGGCATCC

CGGTGTACATTCCCAGGTG
CTACAAGCCGTCCCTCAAG

CTAGTAGCAACTGCAAC
CAGACAGGTTCAGTGGCAG

CAGCTACAGCAGTGGGGCG
AGTCGAGTCACCATATCAG

CGGTGTACATTCAGAAA
TGGGTCTGGGACAGACTTCA

CAGGACTGTTGAAGCCTTC
TAGACATGTCCAGGAACCA

TTGTGTTGACGCAGTCTC
CTCTCAGCATCAGCAGACTG

GGAGACCCTGTCCCTCACC
GTTCTCCCTGAAGGTGACCT

CAGGCACCCTGTCTTTGT
GAGCCTGAAGATTTTGCAGT

TGCGCTGTCTCTGGTGGGTC
CTGTGACCGCCGCGGACAC

CTCCAGGGGAAAGAGCC
GTATTACTGTCAGCAGTATA

ACTCAGTGGTTTCTACTGGA
GGCTGTGTATTACTGTGCG

ACCCTCTCCTGCAGGGCC
CTACTACACCTCGGACTTTC

CCTGGATCCGCCAGCCCCC
AGAAAGCCCCTCCTCTACA

AGTCAGACTGTTACCGC
GGCGGAGGGACCAAGGTGG

AGGAAAGGGGCTGGAGTGG
GTGACTTCTCTCCTGGTGCT

CAACTACTTAGCCTGGTA
AGATCAA (SEQ ID

ATTGGGGAAACCAATCATT
TTTGATATCTGGGGCCAAG

CCAGCAGAAACCTGGCC
NO: 3409)

TTGGAAGCACCGGCTACAA
GGACAATGGTCGCCGTCTC

AGGCTCCCAGACTCCTC

GCCGTCCCTCAAGAGTCGA
TTCAG (SEQ ID NO:

ATCTATGGTGCATCCAA

GTCACCATATCAGTAGACA
3407)

GAGGGCCACTGGCATCC

TGTCCAGGAACCAGTTCTC

CAGACAGGTTCAGTGGC

CCTGAAGGTGACCTCTGTG

AGTGGGTCTGGGACAGA

ACCGCCGCGGACACGGCTG

CTTCACTCTCAGCATCAG

TGTATTACTGTGCGAGAAA

CAGACTGGAGCCTGAAG

GCCCCTCCTCTACAGTGACT

ATTTTGCAGTGTATTACT

TCTCTCCTGGTGCTTTTGAT

GTCAGCAGTATACTACT

ATCTGGGGCCAAGGGACAA

ACACCTCGGACTTTCGGC

TGGTCACCGTCTCTTCAGCG

GGAGGGACCAAGGTGGA

TCGACCAAGGGCCCATCGG

GATCAAACGTACGGTGG

TCTTCCCCCTGGCACCCTCC

CTGCACCATCTGTCTTCA

TCCAAGAGCACCTCTGGGG

TCTTCCCGCCATCTGATG

GCACAGCGGCCCTGGGCTG

AGCAGTTGAAATCTGGA

CCTGGTCAAGGACTACTTC

ACTGCCTCTGTTGTGTGC

CCCGAACCTGTGACGGTCT

CTGCTGAATAACTTCTAT

CGTGGAACTCAGGCGCCCT

CCCAGAGAGGCCAAAGT

GACCAGCGGCGTGCACACC

ACAGTGGAAGGTGGATA

TTCCCGGCTGTCCTACAGTC

ACGCCCTCCAATCGGGT

CTCAGGACTCTACTCCCTCA

AACTCCCAGGAGAGTGT

GCAGCGTGGTGACCGTGCC

CACAGAGCAGGACAGCA

CTCCAGCAGCTTGGGCACC

AGGACAGCACCTACAGC

CAGACCTACATCTGCAACG

CTCAGCAGCACCCTGAC

TGAATCACAAGCCCAGCAA

GCTGAGCAAAGCAGACT

CACCAAGGTGGACAAGAGA

ACGAGAAACACAAAGTC

GTTGAGCCCAAATCTTGTG

TACGCCTGCGAAGTCAC

ACAAAACTCACACATGCCC

CCATCAGGGCCTGAGCT

ACCGTGCCCAGCACCTGAA

CGCCCGTCACAAAGAGC

CTCCTGGGGGGACCGTCAG

TTCAACAGGGGANAGTG

TCTTCCTCTTCCCCCCAAAA

TTAGAAGCTTGGNCGCC

CCCAAGGACACCCTCATGA

ATGGNCCAACTTGTTTAT

TCTCCCGGACCCCTGAGGT

TGCAGCTTATAATGGNTT

CACATGCGTGGNGGTGGNC

ACNAATAAAGCAATAGC

GTGAGCCACGAANACCCTG

ATCACAAATTTCACAAA

ANNCAAGTTCAACTGGNAC

TAAAGCATTTTTTTCACT

NTGNNGGCNNNNNNGCATA

GCATTCTAGTTGTGGNTN

NGCCANGAANAAGCCNCGG

GNCCAAACTCATCAATG

NAGNANCANTANANNGCNC

NATNTNATCATGTCTGG

GTACNNNNNNNAGCNTCNN

NTCGGNAATTAATTCGG

NCNNNCNGCNCANNACTNN

NGNNGCNNNNATGGNNT

NNANNNNNNGNNNNNNNN

GAANNACNNNNNGN

NNNAGNNNCANNANNCNN

(SEQ ID NO: 3408)

NCCNNNNCCNTCNANNANN

NTNNNNAANNNNAAGGGN

NN (SEQ ID NO:

3406)

V-C004
NNNNNNCNNATGTATCNTA
CAGGTGCAGCTACAGCAGT
COV107_
NNNNNNNNNNNTATGNA
GAAATTGTGTTGACGCAGTC
COV107_

CACNTACGATTTAGGTGAC
GGGGCGCAGGACTGTTGAA
P1_D6
TCNTACACATACGATTTA
TCCAGGCACCCTGTCTTTGT
P1_D6

ACTATAGAATAACATCCAC
GCCTTCGGAGACCCTGTCC

GGTGACACTATAGAATA
CTCCAGGGGAAAGAGCCAC

TTTGCCTTTCTCTCCACAGG
CTCTCCTGCGCTGTCTATGG

ACATCCACTTTGCCTTTC
CCTCTCCTGCTGGGCCAGTC

TGTCCACTCCCAGGTCCAA
TGGGTCCCTCAGTGGTTACT

TCTCCACAGGTGTCCACT
AGAGTGTTAGCGCCAGCTAC

CTGCACCTCGGTTCTATCGA
ACTGGAGCTGGATCCGCCA

CCCAGGTCCAACTGCAC
TTAGCCTGGTACCAGCAGAA

TTGAATTCCACCATGGGAT
GCCCCCAGGGAAGGGGCTG

CTCGGTTCTATCGATTGA
ACCTGGCCAGGCTCCCAGGC

GGTCATGTATCATCCTTTTT
GAGTGGATTGGGGAGATCA

ATTCCACCATGGGATGG
TCCTCATCTATGGTGCATCC

CTAGTAGCAACTGCAACCG
ATCATTTTGGAAGCACCGG

TCATGTATCATCCTTTTT
AGCAGGGCCACTGGCATCC

GTGTACATTCCCAGGTGCA
CTACAACCCGTCCCTCAAG

CTAGTAGCAACTGCAAC
CAGACAGGTTCAGTGGCAG

GCTACAGCAGTGGGGCGCA
AGTCGAGTCACCATCTCCG

CGGTGTACATTCAGAAA
TGGGTCTGGGACAGACTTCA

GGACTGTTGAAGCCTTCGG
TGGACACGTCCAAGAGCCA

TTGTGTTGACGCAGTCTC
CTCTCACCATCAGTAGACTG

AGACCCTGTCCCTCTCCTGC
GTTCTCCGTGAAGCTGAGC

CAGGCACCGTGTCTTTGT
GAGCCTGAAGATTTTGCAGT

GCTGTCTATGGTGGGTCCCT
TCTGTGACCGCCGCGGACA

CTCCAGGGGAAAGAGCC
ATATTACTGTCAGCAGTACG

CAGTGGTTACTACTGGAGC
CGGCTGTCTATTACTGTGCG

ACCCTCTCCTGCTGGGCC
GTACTACACCTCGGACTTTC

TGGATCCGCCAGCCCCCAG
AGAAAGCCCCTCCTCTACA

AGTCAGAGTGTTAGCGC
GGCGGAGGGACCAAGGTGG

GGAAGGGGCTGGAGTGGAT
GTAACTTATCCCCTGGTGCT

CAGCTACTTAGCCTGGTA
AGATCAAAC (SEQ ID

TGGGGAGATCAATCATTTT
TTTGATATCTGGGGCCAAG

CCAGCAGAAACCTGGCC
NO: 3413)

GGAAGCACCGGCTACAACC
GGACAATGGTCACCGTCTC

AGGCTCCCAGGCTCCTC

CGTCCCTCAAGAGTCGAGT
TTCAG (SEQ ID NO:

ATCTATGGTGCATCCAGC

CACCATCTCCGTGGACACG
3411)

AGGGCCACTGGCATCCC

TCCAAGAGCCAGTTCTCCG

AGACAGGTTCAGTGGCA

TGAAGCTGAGCTCTGTGAC

GTGGGTCTGGGACAGAC

CGCCGCGGACACGGCTGTC

TTCACTCTCACCATCAGT

TATTACTGCGCGAGAAAGC

AGACTGGAGCCTGAAGA

CCCTCCTCTACAGTAACTTA

TTTTGCAGTATATTACTG

TCCCCTGGTGCTTTTGATAT

TCAGCAGTACGGTACTA

CTGGGGCCAAGGGACAATG

CACCTCGGACTTTCGGCG

GTCACCGTCTCTTCAGCGTC

GAGGGACCAAGGTGGAG

GACCAAGGGCCCATCGGTC

ATCAAACGTACGGTGGC

TTCCCCCTGGCACCCTCCTC

TGCACCATCTGTCTTCAT

CAAGAGCACCTCTGGGGGC

CTTCCCGCCATCTGATGA

ACAGCGGCCCTGGGCTGCC

GCAGTTGAAATCTGGAA

TGGTCAAGGACTACTTCCC

CTGCCTCTGTTGTGTGCC

CGAACCTGTGACGGTCTCG

TGCTGAATAACTTCTATC

TGGAACTCAGGCGCCCTGA

CCAGAGAGGCCAAAGTA

CCAGCGGCGTGCACACCTT

CAGTGGAAGGTGGATAA

CCCGGCTGTCCTACAGTCCT

CGCCCTCCAATCGGGTA

CAGGACTCTACTCCCTCAG

ACTCCCAGGAGAGTGTC

CAGCGTGGTGACCGTGCCC

ACAGAGCAGGACAGCAA

TCCAGCAGCTTGGGCACCC

GGACAGCACCTACAGCC

AGACCTACATCTGCAACGT

TCAGCAGCACCCTGACG

GAATCACAAGCCCAGCAAC

CTGAGCAAAGCAGACTA

ACCNANGTGGACAAGANAG

CGAGAAACACAAAGTCT

TTGAGCCCAAATCTTGTGA

ACGCCTGCGAAGTCACC

CAAAACTCACACATGCCCA

CATCAGGGCCTGAGCTC

CCGTGCCCAGCACCTGANT

GCCCGTCACAAAGAGCT

CCTGGGGGGACCGTCAGTC

TCAACAGGGGAGAGTGT

TTCCTCTTCCCCCCAAAACC

TAGAAGCTTGGCCGCCA

CNAGGANACCCTCATGATC

TGGCCCAACTTGTTTATT

TCCNNNCCCNTGNNNCACA

GCAGCTTATAATGGTTAC

TGCGTGGNGNNNGNNGTGA

AAATAAAGCAATAGCAT

GCCACNANACCCTGAGTCA

CACAAATTTCACAAATA

AGTTCAACTGGNACNNNGN

AAGCATTTTTTTCACTGC

NNGGCGTNNNNGNTGCANN

ATTCTAGTTGTGGTTTGT

NN (SEQ ID NO:

CCAAACTCATCAATGTAT

3410)

CTTATCATGTCTGGATCG

GGAATTAANTTCGNCGC

AGCACNTGGCNTGAAAT

NACCTCTGAAAGANGAA

CTTG (SEQ ID

NO: 3412)

V-C005
NNNNNNNNNNNATGTATCA
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNTATGTATCN
CAGTCTGTGCTGACTCAGCC
COV107_

TACACATACGATTTAGGTG
CTGGAGGAGGCTTGATCCA
P2_A4
TACACATACGATTTAGGT
TCCCTCCGCGTCCGGGTCTC
P2_A4

ACACTATAGAATAACATCC
GCCTGGGGGGTCCCTGAGA

GACACTATAGAATAACA
CTGGACAGTCAGTCACCATC

ACTTTGCCTTTCTCTCCACA
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
TCCTGCACTGGAACCAGCAG

GGTGTCCACTCCCAGGTCC
GTTCACCGTCAGTAGCAAC

CCACAGGTGTCCACTCCC
TGACGTTGGTGGTTATAAGT

AACTGCACCTCGGTTCTATC
TACATGAGCTGGGTCCGCC

AGGTCCAACTGCACCTC
ATGTCTCCTGGTACCAACAG

GATTGAATTCCACCATGGG
AGGCTCCAGGGAAGGGGCT

GGTTCTATCGATTGAATT
CACCCAGGCAAAGCCCCCA

ATGGTCATGTATCATCCTTT
GGAGTGGGTCTCAGTTATTT

CCACCATGGGATGGTCA
AACTCATGATTTATGAGGTC

TTCTAGTAGCAACTGCAAC
ATAGCGGTGGTAGTACATA

TGTATCATCCTTTTTCTA
AGTAAGCGGCCCTCAGGGG

CGGTGTACATTCTCAGGTG
CTACGCAGACTCCGTGAAG

GTAGCAACTGCAACCGG
TCCCTGATCGCTTCTCTGGC

CAGCTGGTGGAGTCTGGAG
GGCCGATTCACCATCTCCA

TTCCTGGGCCCAGTCTGC
TCCAAGTCTGGCAACACGGC

GAGGCTTGATCCAGCCTGG
GAGACAATTCCAAGAACAC

CCTGACTCAGCCTCCCTC
CTCCCTGACCGTTTCTGGGC

GGGGTCCCTGAGACTCTCC
GCTGTATCTTCAAATGAAC

CGCGTCCGGGTCTCCTGG
TCCAGGCTGAGGATGAGGC

TGTGCAGCCTCTGGGTTCAC
AGCCTGAGAGCCGAGGACA

ACAGTCAGTCACCATCTC
TGATTATTACTGCAGCTCAT

CGTCAGTAGCAACTACATG
CGGCCGTGTATTACTGTGC

CTGCACTGGAACCAGCA
ATGAAGGCAGCAACAATTTT

AGCTGGGTCCGCCAGGCTC
GAGAGGCGAGGGGTGGGA

GTGACGTTGGTGGTTATA
GTGGTATTCGGCGGAGGGA

CAGGGAAGGGGCTGGAGTG
GCTACCATACGACTACTGG

AGTATGTCTCCTGGTACC
CCAAGCTGACCGTCCTAG

GGTCTCAGTTATTTATAGCG
GGCCAGGGAACCCTGGTCA

AACAGCACCCAGGCAAA
(SEQ ID NO: 3417)

GTGGTAGTACATACTACGC

GCCCCCAAACTCATGATT

AGACTCCGTGAAGGGCCGA
CCGTCTCCTCAG (SEQ ID

TATGAGGTCAGTAAGCG

TTCACCATCTCCAGAGACA
NO: 3415)

GCCCTCAGGGGTCCCTG

ATTCCAAGAACACGCTGTA

ATCGCTTCTCTGGCTCCA

TCTTCAAATGAACAGCCTG

AGTCTGGCAACACGGCC

AGAGCCGAGGACACGGCCG

TCCCTGACCGTTTCTGGG

TGTATTACTGTGCGAGAGG

CTCCAGGCTGAGGATGA

CGAGGGGTGGGAGCTACCA

GGCTGATTATTACTGCAG

TACGACTACTGGGGCCAGG

CTCATATGAAGGCAGCA

GAACCCTGGTCACCGTCTC

ACAATTTTGTGGTATTCG

CTCAGCGTCGACCAAGGGC

GCGGAGGGACCAAGCTG

CCATCGGTCTTCCCCCTGGC

ACCGTCCTAGGTCAGCC

ACCCTCCTCCAAGAGCACC

CAAGGCTGCCCCCTCGG

TCTGGGGGCACAGCGGCCC

TCACTCTGTTCCCACCCT

TGGGCTGCCTGGTCAAGGA

CGAGTGAGGAGCTTCAA

CTACTTCCCCGAACCTGTGA

GCCAACAAGGCCACACT

CGGTCTCGTGGAACTCAGG

GGTGTGTCTCATAAGTG

CGCCCTGACCAGCGGCGTG

ACTTCTACCCGGGAGCC

CACACCTTCCCGGCTGTCCT

GTGACAGTGGCCTGGAA

ACAGTCCTCANGACTCTAC

GGCAGATAGCAGCCCCG

TCCCTCAGCAGCGTGGTGA

TCAAGGCGGGAGTGGAG

CCGTGCCCTCCAGCAGCTT

ACCACCACACCCTCCAA

GGGCACCCAGACCTACATC

ACAAAGCAACAACAAGT

TGCAACGTGAATCACAAGC

ACGCGGCCAGCAGCTAC

CCAGCAACACCANNGTGGA

CTGAGCCTGACGCCTGA

CAAGANAGTTGAGCCCAAA

GCAGTGGAAGTCCCACA

TCTTGTGACAAAACTCACA

GAAGCTACAGCTGCCAG

CATGCCCACCGTGCCCAGC

GTCACGCATGNAAGGGA

ACCTGAACTCCTGGGGGGA

GCACCGTGGNNAAGACA

CCGTCAGTCTTCCTCNTCCC

GTGGCCCCTACAGAATG

CCCAAAACCCNNNCACCCN

TTCATAGAAGCTTGGCC

CATGATCTNCCNNACCCNG

GCCATGGCCCAACTTGTT

AGTCNNNNTGNNNNGGNGG

TATTGCAGCTTATAATGG

NNGNNGTGANCNNNNANA

NTACNAATAAAGCATAG

CCCTGNNNGTCAAGTTCAA

CATCACAAATTTCACAA

NTGGNACNN (SEQ ID NO:

ATAAAGCATTTTTTTCAC

3414)

TGCATTCTANTTGTNGNT

NGTCCAAACTCATCNAT

GNNNCTTATCATGTCTGG

NTCGGGAATTAANTNNG

NNGCAGCNNCNNNGN

(SEQ ID NO: 3416)

V-C006
NNNNNNNNNTATGNATCNT
CAGGTGCAGCTGCAGGAGT
COV107_
NNNNNNNNNNATGTATC
TCCTATGTGCTGACTCAGCC
COV107_

ACACATACGATTTAGGTGA
CGGGCCCAGGACTGGTGAA
P2_F12
NTACACATACGATTTAG
ACCCTCAGTGTCAGTGGCCC
P2_F12

CACTATAGAATAACATCCA
GCCTTCGGAGACCCTGTCC

GTGACACTATAGAATAA
CAGGAAAGACGGCCAGGAT

CTTTGCCTTTCTCTCCACAG
CTCACCTGCACTGTCTCTGG

CATCCACTTTGCCTTTCT
TACCTGTGGGGGAAACAAC

GTGTCCACTCCCAGGTCCA
TGCCTCCGTCAGCAGTGGT

CTCCACAGGTGTCCACTC
ATTGGAAGTAAAAGTGTGC

ACTGCACCTCGGTTCTATCG
AGTTACTACTGGAGCTGGA

CCAGGTCCAACTGCACC
ACTGGTACCAGCAGAAGCC

ATTGAATTCCACCATGGGA
TCCGGCAGCCCCCAGGGAA

TCGGTTCTATCGATTGAA
AGGCCAGGCCCCTGTGCTGG

TGGTCATGTATCATCCTTTT
GGGACTGGAATGGATTGGG

TTCCACCATGGGATGGTC
TCATCTATTTTGATAGCGAC

TCTAGTAGCAACTGCAACC
TATATCTATTACAGTGGGA

ATGTATCATCCTTTTTCT
CGGCCCTCAGGGATCCCTGA

GGTGTACATTCCCAGCTGC
GCACCAACTACAACCCCTC

AGTAGCAACTGCAACCG
GCGATTCTCTGGCTCCAACT

AGCTGCAGGAGTCGGGCCC
CCTCAAGAGTCGAGTCACC

GTTCTGTGACCTCCTATG
CTGGGAACACGGCCACCCT

AGGACTGGTGAAGCCTTCG
ATATCAGTGGACACGTCCA

AGCTGACACAGCCACCC
GACCATCAGCAGGGTCGAA

GAGACCCTGTCCCTCACCT
AGAACCAGTTCTCCCTGAA

TCAGTGTCAGTGGCCCC
GCCGGGGATGAGGCCGACT

GCACTGTCTCTGGTGCCTCC
GCTGAGCTCTGTGACCGCT

AGGAAAGACGGCCAGGA
ATTACTGTCAGGTGTGGGAT

GTCAGCAGTGGTAGTTACT
GCGGACACGGCCGTGTATT

TTACCTGTGGGGGAAAC
AGTAGTCGTGATCATGTGGT

ACTGGAGCTGGATCCGGCA
ACTGTGCGAGAGAGCGGCC

AACATTGGAAGTAAAAG
ATTCGGCGGAGGGACCAAG

GCCCCCAGGGAAGGGACTG
CGGTGGAACGTATAGCAAC

TGTGCACTGGTACCAGC
CTGACCGTCCTAG (SEQ

GAATGGATTGGGTATATCT
ACCTGGTACACCCCAACCG

AGAAGCCAGGCCAGGCC
ID NO: 3421)

ATTACAGTGGGAGCACCAA
ATACCAACTGGTTCGACAC

CCTGTGCTGGTCATCTAT

CTACAACCCCTCCCTCAAG
CTGGGGCCAGGGAACCCTG

TTTGATAGCGACCGGCC

AGTCGAGTCACCATATCAG
GTCACCGTCTCCTCAG

CTCAGGGATCCCTGAGC

TGGACACGTCCAAGAACCA
(SEQ ID NO: 3419)

GATTCTCTGGCTCCAACT

GTTCTCCCTGAAGCTGAGCT

CTGGGAACACGGCCACC

CTGTGACCGCTGCGGACAC

CTGACCATCAGCAGGGT

GGCCGTGTATTACTGTGCG

CGAAGCCGGGGATGAGG

AGAGAGCGGCCCGGTGGAA

CCGACTATTACTGTCAGG

CGTATAGCAACACCTGGTA

TGTGGGATAGTAGTCGT

CACCCCAACCGATACCAAC

GATCATGTGGTATTCGGC

TGGTTCGACACCTGGGGCC

GGAGGGACCAAGCTGAC

AGGGAACCCTGGTCACCGT

CGTCCTAGGTCAGCCCA

CTCCTCAGCGTCGACCAAG

AGGCTGCCCCCTCGGTC

GGCCCATCGGTCTTCCCCCT

ACTCTGTTCCCGCCCTCG

GGCACCCTCCTCCAAGAGC

AGTGAGGAGCTTCAAGC

ACCTCTGGGGGCACAGCGG

CAACAAGGCCACACTGG

CCCTGGGCTGCCTGGTCAA

TGTGTCTCATAAGTGACT

GGACTACTTCCCCGAACCT

TCTACCCGGGAGCCGTG

GTGACGGTCTCGTGGAACT

ACAGTGGCCTGGAAGGC

CAGGCGCCCTGACCAGCGG

AGATAGCAGCCCCGTCA

CGTGCACACCTTCCCGGCT

AGGCGGGAGTGGAGACC

GTCCTACAGTCCTCANGAC

ACCACACCCTCCAAACA

TCTACTCCCTCAGCAGCGTG

AAGCAACAACAAGTACG

GTGACCGTGCCCTCCAGCA

CGGCCAGCAGCTACCTG

GCTTGGGCACCCAGACCTA

AGCCTGACGCCTGAGCA

CATCTGCAACGTGAATCAC

GTGGAAGTCCCACAGAA

AAGCCCAGCAACACCAAGG

GCTACAGCTGCCAGGTC

TGGACAAGAGAGTTGAGCC

ACGCATGAAGGGAGCAC

CAAATCTTGTGACAAAACT

CGTGGAGAAGACAGTGG

CACACATGCCCACCGTGCC

CCCCTACAGAATGTTCAT

CAGCACCTGAACTCCTGGG

AGAAGCTTGGCCGCCAT

GGGANCGTCAGTCTTCCTCT

GGCCCAACTTGTTTATTG

TCCCCCCAAAACCCAAGGA

CAGCTTATAATGGTTACA

CACCCTCATGATCTCCCGG

AATAAAGCAATAGCATC

ACCCCTGAGTCACATGCGT

ACAAATTTCACAAATAA

NNNNNGANGTGANCCACGA

AGCATTTTTTTCACTGCA

ANACCCTGAGNCAAGTTCA

TTCTANTTGTGGTTTGTC

CTGGNACGTNNNNNNTNNN

CAAACTCATCAATGTATC

NNCATNANNCANNAANAA

TTATCATGTCTGGATCGG

GCNNNNGGANGANCANTN

GAATTAATTCGNCGCAG

NANNNNACNNNCNNNNNN

CACCATGNNNTGAAATA

NGNNAGCNTCNTNNCGNNC

ACCTCTGAAAGAGNAAC

NNNNNCNNNNTNNNTNANN

NN (SEQ ID NO:

NNNGNNNNANNNNNNNNN

3420)

NCNNNNNCCNNNCNNNNCC

ATCNNNANCCNTNNNNNNA

NNNNNN (SEQ ID )

NO: 3418

V-C007
NNNNNNNNNATGTATCNTA
CAGGTTCAGCTGGTGCAGT
COV107_
NNNNNNNNNNNNNNNG
CAGTCTGTGCTGACTCAGCC
COV107_

CACATACGATTTAGGTGAC
CTGGAGCTGAGGTGAAGAA
P1_F3
NATCTACACNTACGATTT
ACCCTCAGCGTCTGGGACCC
P1_F3

ACTATAGAATAACATCCAC
GCCTGGGGCCTCAGTGAGG

AGGTGACACTATAGAAT
CCGGGCAGAGGGTCACCAT

TTTGCCTTTCTCTCCACAGG
GTCTCCTGCAAGGCTTCTGG

AACATCCACTTTGCCTTT
CTCTTGTTCTGGAAGCAGCT

TGTCCACTCCCAGGTCCAA
TTACACCTTTACCAGCTATG

CTCTCCACAGGTGTCCAC
CCAACATCGGAAGTAATTAT

CTGCACCTCGGTTCTATCGA
GTTTCAGCTGGGTGCGACA

TCCCAGGTCCAACTGCA
GTATACTGGTACCAGCAGCT

TTGAATTCCACCATGGGAT
GGCCCCTGGACAAGGGCTT

CCTCGGTTCTATCGATTG
CCCAGGAACGGCCCCCAAA

GGTCATGTATCATCCTTTTT
GAGTGGATGGGATGGATCA

AATTCCACCATGGGATG
CTCCTCATCTATAGGAATAA

CTAGTAGCAACTGCAACCG
GCGCTTACAATGGTAACAC

GTCATGTATCATCCTTTT
TCAGCGGCCCTCAGGGGTCC

GTGTACATTCCCAGGTTCA
AAACTTTGCACAGAAGCTC

TCTAGTAGCAACTGCAA
CTGACCGATTCTCTGGCTCC

GCTGGTGCAGTCTGGAGCT
CAGGGCAGAGTCACCATGA

CCGGTTCCTGGGCCCAGT
AAGTCTGGCACCTCAGCCTC

GAGGTGAAGAAGCCTGGGG
CCACAGACACATCCACGAG

CTGTGCTGACTCAGCCAC
CCTGGCCATCAGTGGGCTCC

CCTCAGTGAGGGTCTCCTG
CACAGCCTACATGGAGCTG

CCTCAGCGTCTGGGACC
GGTCCGAGGATGAGGCTGA

CAAGGCTTCTGGTTACACCT
AGGAGCCTGAGATCTGACG

CCCGGGCAGAGGGTCAC
TTATTACTGTGCAGCATGGG

TTACCAGCTATGGTTTCAGC
ACACGGCCGTGTATTACTG

CATCTCTTGTTCTGGAAG
ATGACAGCCTGAGTGGTTTT

TGGGTGCGACAGGCCCCTG
TGCGAGAGGGGAAGCAGTG

CAGCTCCAACATCGGAA
GTGGTATTCGGCGGAGGGA

GACAAGGGCTTGAGTGGAT
GCTGGTACAACCGGTTTTTT

GTAATTATGTATACTGGT
CCAAGCTGACCGTCCTAG

GGGATGGATCAGCGCTTAC
TGACTACTGGGGCCAGGGA

ACCAGCAGCTCCCAGGA
(SEQ ID NO: 3425)

AATGGTAACACAAACTTTG
ACCCTGGTCACCGTCTCCTC

ACGGCCCCCAAACTCCT

CACAGAAGCTCCAGGGCAG
AG (SEQ ID NO: 3423)

CATCTATAGGAATAATC

AGTCACCATGACCACAGAC

AGCGGCCCTCAGGGGTC

ACATCCACGAGCACAGCCT

CCTGACCGATTCTCTGGC

ACATGGAGCTGAGGAGCCT

TCCAAGTCTGGCACCTCA

GAGATCTGACGACACGGCC

GCCTCCCTGGCCATCAGT

GTGTATTACTGTGCGAGAG

GGGCTCCGGTCCGAGGA

GGGAAGCAGTGGCTGGTAC

TGAGGCTGATTATTACTG

AACCGGTTTTTTTGACTACT

TGCAGCATGGGATGACA

GGGGCCAGGGAACCCTGGT

GCCTGAGTGGTTTTGTGG

CACCGTCTCCTCAGCGTCG

TATTCGGCGGAGGGACC

ACCAAGGGCCCATCGGTCT

AAGCTGACCGTCCTAGG

TCCCCCTGGCACCCTCCTCC

TCAGCCCAAGGCTGCCC

AAGAGCACCTCTGGGGGCA

CCTCGGTCACTCTGTTCC

CAGCGGCCCTGGGCTGCCT

CGCCCTCGAGTGAGGAG

GGTCAAGGACTACTTCCCC

CTTCAAGCCAACAAGGC

GAACCTGTGACGGTCTCGT

CACACTGGTGTGTCTCAT

GGAACTCAGGCGCCCTGAC

AAGTGACTTCTACCCGG

CAGCGGCGTGCACACCTTC

GAGCCGTGACAGTGGCC

CCGGCTGTCCTACAGTCCTC

TGGAAGGCAGATAGCAG

AGGACTCTACTCCCTCAGC

CCCCGTCAAGGCGGGAG

AGCGTGGTGACCGTGCCCT

TGGAGACCACCACACCC

CCAGCAGCTTGGGCACCCA

TCCAAACAAAGCAACAA

GACCTACATCTGCAACGTG

CAAGTACGCGGCCAGCA

AATCACAAGCCCAGCAACA

GCTACCTGAGCCTGACG

CCNAAGGTGGACAAGANAG

CCTGAGCAGTGGAAGTC

TTGAGCCCAAATCTTGTGA

CCACAGAAGCTACAGCT

CAAAACTCACACATGCCCA

GCCAGGTCACGCATGAA

CCGTGCCCAGCACCTGAAC

GGGAGCACCGTGGAGAA

TNCTGGGGGGACCGTCAGT

GACAGTGGCCCCTACAG

CTTCCTCTTCCCCCCNAAAC

AATGTTCATAGAAGCTT

CCAAGGACANCCTCATGAT

GGCCGCCATGGCCCAAC

NTNCCNGACCCNTGAGTCA

TTGTTTATTGCAGCTTAT

CATGNNGTNGTGGNGGNCG

AATGGTTACAAATAAAG

TGNNCCACNAANNACCNNG

CAATAGCATCACAAATT

NAGGTCAAGTTCAACNGGN

TCACAAATAAAGCATTTT

ACNNNGNNN (SEQ ID NO:

TTTCACTGCATTCTAGTT

3422)

GNGGNTTGTCCAAACTC

ATCAATGTATCTNATCAT

GTCTGGNTCNGGGANTA

ATTCNGCGCAGCACCAT

GGCNTGAAANNACCTCT

GAAAGAGNNTNNNNGNN

CNNCTNNGNNNNNNNNT

CNGNGANNNGNGNTCAN

TNNNNNNGAAAGNCCCC

NGNNNCCCNNCAGNNNA

NNNTGN (SEQ ID NO:

3424)

V-C008
NNNNNNNCNTATGNATCNT
CAGGTGCAGCTGCAGGAGT
COV107_
NNNNNNNNNTTATGTAT
CAGTCTGTGCTGACTCAGCC
COV107_

ACACATACGATTTAGGTGA
CGGGCCCAGGACTGGTGAA
P2_E9
CNTACNCATACGATTTA
TGCCTCCGTGTCTGGGTCTC
P2_E9

CACTATAGAATAACATCCA
GCCTTCGGGGACCCTGTCC

GGTGACACTATAGAATA
CTGGACAGTCGATCACCATC

CTTTGCCTTTCTCTCCACAG
CTCACCTGCGCTGTCTCTGG

ACATCCACTTTGCCTTTC
TCCTGCACTGGAACCAGCAG

GTGTCCACTCCCAGGTCCA
TGGCTCCATCAGCAGTACT

TCTCCACAGGTGTCCACT
TGACGTTGGTGGTTATAACT

ACTGCACCTCGGTTCTATCG
AACTGGTGGAGTTGGGTCC

CCCAGGTCCAACTGCAC
ATGTCTCCTGGTACCAACAA

ATTGAATTCCACCATGGGA
GCCAGCCCCCAGGGAAGGG

CTCGGTTCTATCGATTGA
CACCCAGGCAAAGCCCCCA

TGGTCATGTATCATCCTTTT
GCTGGAGTGGATTGGGGAA

ATTCCACCATGGGATGG
AACTCATGATTTATGATGTC

TCTAGTAGCAACTGCAACC
ATCTATCATACTGGGAGCA

TCATGTATCATCCTTTTT
AGTAATCGGCCCTCAGGGGT

GGTGTACATTCCCAGGTGC
CCAACTACAACCCGTCCCT

CTAGTAGCAACTGCAAC
TTCTAATCGCTTCTCTGGCT

AGCTGCAGGAGTCGGGCCC
CAAGAGTCGAGTCACCATA

CGGTTCCTGGGCCCAGTC
CCAAGTCTGGCAACACGGC

AGGACTGGTGAAGCCTTCG
TCAGTAGACAAGTCCAAGA

TGCCCTGACTCAGCCTGC
CTCCCTGACCATCTCTGGGC

GGGACCCTGTCCCTCACCT
ACCAGTTCTCCCTGAAGCT

CTCCGTGTCTGGGTCTCC
TCCAGGCTGAGGACGAGGC

GCGCTGTCTCTGGTGGCTCC
GAGCTCTGTGACCGCCGCG

TGGACAGTCGATCACCA
TGATTATTACTGCAACTCAT

ATCAGCAGTACTAACTGGT
GACACGGCCGTGTATTACT

TCTCCTGCACTGGAACCA
ATACAAGCAGCAGCACTCG

GGAGTTGGGTCCGCCAGCC
GTGTGAGAGATGGAGGACG

GCAGTGACGTTGGTGGT
AGTCTTCGGAACTGGGACCA

CCCAGGGAAGGGGCTGGAG
ACCCGGGGATGCTTTTGAT

TATAACTATGTCTCCTGG
AGGTCACCGTCCTAG (SEQ

TGGATTGGGGAAATCTATC
ATCTGGGGCCAAGGGACAA

TACCAACAACACCCAGG
ID NO: 3429)

ATACTGGGAGCACCAACTA
TGGTCACCGTCTCTTCAG

CAAAGCCCCCAAACTCA

CAACCCGTCCCTCAAGAGT
(SEQ ID NO: 3427)

TGATTTATGATGTCAGTA

CGAGTCACCATATCAGTAG

ATCGGCCCTCAGGGGTTT

ACAAGTCCAAGAACCAGTT

CTAATCGCTTCTCTGGCT

CTCCCTGAAGCTGAGCTCT

CCAAGTCTGGCAACACG

GTGACCGCCGCGGACACGG

GCCTCCCTGACCATCTCT

CCGTGTATTACTGTGTGAG

GGGCTCCAGGCTGAGGA

AGATGGAGGACGACCCGGG

CGAGGCTGATTATTACTG

GATGCTTTTGATATCTGGGG

CAACTCATATACAAGCA

CCAAGGGACAATGGTCACC

GCAGCACTCGAGTCTTC

GTCTCTTCAGCGTCGACCA

GGAACTGGGACCAAGGT

AGGGCCCATCGGTCTTCCC

CACCGTCCTAGGTCAGC

CCTGGCACCCTCCTCCAAG

CCAAGGCCAACCCCACT

AGCACCTCTGGGGGCACAG

GTCACTCTGTTCCCACCC

CGGCCCTGGGCTGCCTGGT

TCGAGTGAGGAGCTTCA

CAAGGACTACTTCCCCGAA

AGCCAACAAGGCCACAC

CCTGTGACGGTCTCGTGGA

TGGTGTGTCTCATAAGTG

ACTCAGGCGCCCTGACCAG

ACTTCTACCCGGGAGCC

CGGCGTGCACACCTTCCCG

GTGACAGTGGCCTGGAA

GCTGTCCTACAGTCCTCAG

GGCAGATAGCAGCCCCG

GACTCTACTCCCTCAGCAG

TCAAGGCGGGAGTGGAG

CGTGGTGACCGTGCCCTCC

ACCACCACACCCTCCAA

AGCAGCTTGGGCACCCAGA

ACAAAGCAACAACAAGT

CCTACATCTGCAACGTGAA

ACGCGGCCAGCAGCTAC

TCACAAGCCCAGCAACACC

CTGAGCCTGACGCCTGA

AAGGTGGACAAGANAGTTG

GCAGTGGAAGTCCCACA

AGCCCAAATCTTGTGACAA

GAAGCTACAGCTGCCAG

AACTCACACATGCCCACCG

GTCACGCATGAANGGGA

TGCCCAGCACCTGAACTNC

GCACCGTGGAGAAGACA

TGGGGGGACCGTCAGTCTT

GTGGCCCCTACAGAATG

CCTCTTCCCCCAAANCCNA

TTCATAGAAGCTTGGCC

GGACACCCTCATGATCTNC

GCCATGGNCCAACTTGTT

CNGACCCTGAGTCACATGC

TATTGCAGCTTATAATGG

GTGGNNNNNNGTGAGCCAC

TTACAAATAAAGCAATA

NANANCCTGAGTCAGTTCA

GCATCACAAATTTCACA

ACTGGNACGNNGNNGGNN

AATAAAGCATTTTTTTNA

NNGGNNGNNGCATNATGNN

CTGCATTCTANTNGTGGT

(SEQ ID NO: 3426)

TNGTCCAANTCATCAAT

GTATNNNTCATGTCTGG

NTCGGGNATTAATTCGN

CGCAGCACCANGGCCTG

AANNNACCTCTNNAANN

ANN (SEQ ID

NO: 3428)

V-C009
NNNNNNNNNTTATGTATCN
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNNNNNNNTAT
CAGTCTGTGCTGACTCAGCC
COV107_

TACACATACGATTTAGGTG
CTGGGGGAGGCTTGGTCCA
P2_D10
GTATCNTACACATACGA
TCCCTCCGCGTCCGGGTCTC
P2_D10

ACACTATAGAATAACATCC
GCCTGGGGGGTCCCTGAGA

TTTAGGTGACACTATAG
CTGGACAGTCAGTCACCATC

ACTTTGCCTTTCTCTCCACA
CTCTCCTGTGCAGCCTCTGG

AATAACATCCACTTTGCC
TCCTGCACTGGAACCAGCAG

GGTGTCCACTCCCAGGTCC
ATTCACCTTTAGTAGCTATT

TTTCTCTCCACAGGTGTC
TGACGTTGGTGGTTATAACT

AACTGCACCTCGGTTCTATC
GGATGAGCTGGGTCCGCCA

CACTCCCAGGTCCAACT
ATGTCTCCTGGTACCAACAG

GATTGAATTCCACCATGGG
GGCTCCAGGGAAGGGGCTG

GCACCTCGGTTCTATCGA
CACCCAGGCAAAGCCCCCA

ATGGTCATGTATCATCCTTT
GAGTGGGTGGCCAACATAA

TTGAATTCCACCATGGG
AACTCATGATTTATGAGGTC

TTCTAGTAGCAACTGCAAC
AGCAAGATGGAAGTGAGAA

ATGGTCATGTATCATCCT
ACTAAGCGGCCCTCAGGGG

CGGTGTACATTCTGAAGTG
ATACTATGTGGACTCTGTG

TTTTCTAGTAGCAACTGC
TCCCTGATCGCTTCTCTGGC

CAGCTGGTGGAGTCTGGGG
AAGGGCCGATTCACCATCT

AACCGGTTCCTGGGCCC
TCCAAGTCTGGCAACACGGC

GAGGCTTGGTCCAGCCTGG
CCGGAGACAACGCCAAGAA

AGTCTGCCCTGACTCAGC
CTCCCTGACCGTCTCTGGGC

GGGGTCCCTGAGACTCTCC
CTCACTGTATCTGCACATGA

CTCCCTCCGCGTCCGGGT
TCCAGGCTGAGGATGAGGC

TGTGCAGCCTCTGGATTCAC
ACAGCCTGAGAGCCGAGGA

CTCCTGGACAGTCAGTC
TGATTATTACTGCAGCTCAT

CTTTAGTAGCTATTGGATGA
CACGGCTGTGTATTACTGTG

ACCATCTCCTGCACTGGA
ATGCAGGCAGCAACAATTA

GCTGGGTCCGCCAGGCTCC
CTATACAGCTATGGTTAAG

ACCAGCAGTGACGTTGG
TGTGGTATTCGGCGGAGGG

AGGGAAGGGGCTGGAGTGG
GGGGGGCTATGACTACTGG

TGGTTATAACTATGTCTC
ACCAAGCTGACCGTCCTAG

GTGGCCAACATAAAGCAAG
GGCCAGGGAACCCTGGTCA

CTGGTACCAACAGCACC
(SEQ ID NO: 3433)

ATGGAAGTGAGAAATACTA
CCGTCTCCTCAG (SEQ

CAGGCAAAGCCCCCAAA

TGTGGACTCTGTGAAGGGC
ID NO: 3431)

CTCATGATTTATGAGGTC

CGATTCACCATCTCCGGAG

ACTAAGCGGCCCTCAGG

ACAACGCCAAGAACTCACT

GGTCCCTGATCGCTTCTC

GTATCTGCACATGAACAGC

TGGCTCCAAGTCTGGCA

CTGAGAGCCGAGGACACGG

ACACGGCCTCCCTGACC

CTGTGTATTACTGTGCTATA

GTCTCTGGGCTCCAGGCT

CAGCTATGGTTAAGGGGGG

GAGGATGAGGCTGATTA

GCTATGACTACTGGGGCCA

TTACTGCAGCTCATATGC

GGGAACCCTGGTCACCGTC

AGGCAGCAACAATTATG

TCCTCAGCGTCGACCAAGG

TGGTATTCGGCGGAGGG

GCCCATCGGTCTTCCCCCTG

ACCAAGCTGACCGTCCT

GCACCCTCCTCCAAGAGCA

AGGTCAGCCCAAGGCTG

CCTCTGGGGGCACAGCGGC

CCCCCTCGGTCACTCTGT

CCTGGGCTGCCTGGTCAAG

TCCCGCCCTCGAGTGAG

GACTACTTCCCCGAACCTGT

GAGCTTCAAGCCAACAA

GACGGTCTCGTGGAACTCA

GGCCACACTGGTGTGTCT

NGCGCCCTGACCAGCGGCG

CATAAGTGACTTCTACCC

TGCACACCTTCCCGGCTGTC

GGGAGCCGTGACAGTGG

CTACAGTCCTCANGACTCT

CCTGNAAGGCAGATAGC

ACTCCCTCAGCAGCGTGGT

AGCCCCGTCAAGGCGGG

GACCGTGCCCTCCAGCAGC

AGTGGAGACCACCACAC

TTGGGCACCCAGACCTACA

CCTCCAAACAAAGCAAC

TCTGCAACGTGAATCACAA

AACAAGTACGCGGCCAG

GCCCAGCAACACCNANGTG

CAGCTACCTGAGCCTGA

GACAAGAGAGTTGAGCCCA

CGCCTGAGCAGTGGAAG

AATCTTGTGACAAAACTCA

TCCCACAGAAGCTACAG

CACATGCCCACCGTGCCCA

CTGCCAGGTCACGCATG

GCACCTGAACTCCTGGGGG

ANGGAGCACCGTGGAGA

GACCGTCAGTCTTCCTCTTC

ANACAGTGGCCCCTACA

CCCCCAAAACCCAAGNANA

GAATGTTCATAGAAGCT

NCCTCATGATCTCCCNGAC

TGGCCGCCATGGCCCAA

CCCTGAGTCACATGCGTGN

CTTGTTTATTGCAGCTTA

NNNGACGTGAGCCACGANA

TAATGGNTACNAATAAA

CCCTGAGNCAAGTTCAACT

GCAATAGCATCACAAAT

GGNACNNNGNNGNNNNNN

TTCNNAAANAAAGCATT

GNNNGCATAATGNCANNAA

tttttcactgcatnntan

NAAAGCCNN (SEQ ID

TNGNGGNTTNTCNNAAC

NO: 3430)

TCATCNATGNATCTTATC

ATGTCTGGNTNGGAATT

NATTCGGNNNNNN

(SEQ ID NO: 3432)

V-C010
NNNNNNNNNNTGNNTCNTA
GAGGTGCAGCTGGTGCAGT
COV107_
NNNNNNNNNNNATGTAT
GACATCCAGATGACCCAGTC
COV107_

CACATACGATTTAGGTGAC
CTGGAGCAGAGGTGAAAAA
P2_H6
CNTACACATACGATTTA
TCCTTCCACCCTGTCTGCAT
P2_H6

ACTATAGAATAACATCCAC
GCCCGGGGAGTCTCTGAAG

GGTGACACTATAGAATA
CTGTAGGAGACAGAGTCAC

TTTGCCTTTCTCTCCACAGG
ATCTCCTGTAAGGGTTCTGG

ACATCCACTTTGCCTTTC
CATCACTTGCCGGGCCAGTC

TGTCCACTCCCAGGTCCAA
ATACAGCTTTACCAGCTACT

TCTCCACAGGTGTCCACT
AGAGTATTAGTTACTGGTTG

CTGCACCTCGGTTCTATCGA
GGATCGGCTGGGTGCGCCA

CCCAGGTCCAACTGCAC
GCCTGGTATCAGCAGAAAC

TTGAATTCCACCATGGGAT
GATGCCCGGGAAAGGCCTG

CTCGGTTCTATCGATTGA
CAGGGAAAGCCCCTAAGCT

GGTCATGTATCATCCTTTTT
GAGTGGATGGGGATCATCT

ATTCCACCATGGGATGG
CCTGATCTATCAGGCGTCTA

CTAGTAGCAACTGCAACCG
ATCCTGGTGACTCTGATACC

TCATGTATCATCCTTTTT
GTTTAGAAAGTGGGGTCCCG

GTGTACATTCCCAGGTACA
AGATACAGCCCGTCCTTCC

CTAGTAGCAACTGCAAC
TCAAGGTTCAGCGGCAGTG

GCTGCAGCAGTCTGGAGCA
AAGGCCAGGTCACCATCTC

CGGTGTACATTCTGACAT
AGTCTGGGACAGAATTCACT

GAGGTGAAAAAGCCCGGGG
AGCCGACAAGTCCATCAGC

CCAGATGACCCAGTCTC
CTCACCATCAGCAGCCTGCA

AGTCTCTGAAGATCTCCTGT
ACCGCCTACATGCAGTGGA

CTTCCACCCTGTCTGCAT
GCCTGATGATTTTGCAACTT

AAGGGTTCTGGATACAGCT
GCAGCCTGAAGGCCTCGGA

CTGTAGGAGACAGAGTC
ATTACTGCCAACAGTATAAT

TTACCAGCTACTGGATCGG
CACCGCCATGTATTACTGTG

ACCATCACTTGCCGGGC
AGTTACCCGTACACTTTTGG

CTGGGTGCGCCAGATGCCC
CGAGATCGTTCCGGGACGA

CAGTCAGAGTATTAGTT
CCAGGGGACCAAGCTGGAG

GGGAAAGGCCTGGAGTGGA
CCCCCGTATAGCAGTGGCT

ACTGGTTGGCCTGGTATC
ATCAAAC (SEQ ID

TGGGGATCATCTATCCTGGT
GGCCCGGCTGATGCTTTTG

AGCAGAAACCAGGGAAA
NO: 3437)

GACTCTGATACCAGATACA
ATATCTGGGGCCAAGGGAC

GCCCCTAAGCTCCTGATC

GCCCGTCCTTCCAAGGCCA
AATGGTCACCGTCTCTTCAG

TATCAGGCGTCTAGTTTA

GGTCACCATCTCAGCCGAC
(SEQ ID NO: 3435)

GAAAGTGGGGTCCCGTC

AAGTCCATCAGCACCGCCT

AAGGTTCAGCGGCAGTG

ACATGCAGTGGAGCAGCCT

AGTCTGGGACAGAATTC

GAAGGCCTCGGACACCGCC

ACTCTCACCATCAGCAG

ATGTATTACTGTGCGAGAT

CCTGCAGCCTGATGATTT

CGTTCCGGGACGACCCCCG

TGCAACTTATTACTGCCA

TATAGCAGTGGCTGGCCCG

ACAGTATAATAGTTACC

GCTGATGCTTTTGATATCTG

CGTACACTTTTGGCCAGG

GGGCCAAGGGACAATGGTC

GGACCAAGCTGGAGATC

ACCGTCTCTTCAGCGTCGAC

AAACGTACGGTGGCTGC

CAAGGGCCCATCGGTCTTC

ACCATCTGTCTTCATCTT

CCCCTGGCACCCTCCTCCAA

CCCGCCATCTGATGAGC

GAGCACCTCTGGGGGCACA

AGTTGAAATCTGGAACT

GCGGCCCTGGGCTGCCTGG

GCCTCTGTTGTGTGCCTG

TCAAGGACTACTTCCCCGA

CTGAATAACTTCTATCCC

ACCTGTGACGGTCTCGTGG

AGAGAGGCCAAAGTACA

AACTCAGGCGCCCTGACCA

GTGGAAGGTGGATAACG

GCGGCGTGCACACCTTCCC

CCCTCCAATCGGGTAACT

GGCTGTCCTACAGTCCTCA

CCCAGGAGAGTGTCACA

GGACTCTACTCCCTCAGCA

GAGCANGACAGCAAGGA

GCGTGGTGACCGTGCCCTC

CAGCACCTACAGCCTCA

CAGCAGCTTGGGCACCCAG

GCAGCACCCTGACGCTG

ACCTACATCTGCAACGTGA

AGCAAAGCAGACTACGA

ATCACAAGCCCAGCAACAC

GAAACACAAAGTCTACG

CAAGGTGGANANAGAGTTG

CCTGCGAAGTCACCCAT

AGCCCAAATCTTGTGACAA

CAGGGCCTGAGCTCGCC

ACTCACACATGCCCACCGT

CGTCACAAAGAGCTTCA

GCCCAGCACCTGAACTCCT

ACAGGGGAGAGTGTTAG

GGGGGGACCGTCAGTCTTC

AAGCTTGGCCGCCATGG

CTCTTCCCCCCAAAACCCN

CCCAACTTGTTTATTGCA

NNNCACCCNCATGATCTCC

GCTTATNATGGNTACNA

CNNACCCNNGAGTCACATG

ATAAAGCAATAGCATCA

CNTGGNGNNGGNNGTGNNC

CAAATTTCACAAATAAA

CNCNANACCCNGNANGTCA

GCATTTTTTTCACTGCAT

AGTNN (SEQ ID

TCTANTNNTGGTTTNTCC

NO: 3434)

AAACTCATCANNNNTCT

TATCATGTCTGGNTCGGG

AANTAANTCGNNNNNAG

NNNNNTGGNNTGNAANN

AACNNNNNNNNN (SEQ

ID NO: 3436)

V-011
NNNNNNNNNNNNNNNTAT
CAGGTGCAGCTGCAGGAGT
COV107_
NNNNNNNNNNNATGNAT
CAGTCTGTGCTGACTCAGCC
COV107_

GTATNNTACACATACGATT
CGGGCCCAGGACTGGTGAA
P2_F11
CNTACACATACGATTTA
ACCCTCGGTGTCTGAAGCCC
P2_F11

TAGGTGACACTATAGAATA
GCCTTCGGAGACCCTGTCC

GGTGACACTATAGAATA
CCAGGCAGAGGGTCACCAT

ACATCCACTTTGCCTTTCTC
CTCACCTGCACTGTCTCTGG

ACATCCACTTTGCCTTTC
CTCCTGTTCTGGAAGCAGCT

TCCACAGGTGTCCACTCCC
TGGCTCCATCAGTAGTTACT

TCTCCACAGGTGTCCACT
CCAACATCGGAAATAATGCT

AGGTCCAACTGCACCTCGG
ACTGGAGCTGGATCCGGCA

CCCAGGTCCAACTGCAC
GTAAATTGGTACCAGCAGGT

TTCTATCGATTGAATTCCAC
GCCCCCAGGGAAGGGACTG

CTCGGTTCTATCGATTGA
CCCAGGAAAGGCTCCCAAA

CATGGGATGGTCATGTATC
GAGTGGATTGGGTATATCT

ATTCCACCATGGGATGG
CTCCTCATCTATTATGATGA

ATCCTTTTTCTAGTAGCAAC
ATTACAGTGGGAGCACCAA

TCATGTATCATCCTTTTT
TCTGCTGCCCTCAGGGGTCT

TGCAACCGGTGTACATTCC
CTACAACCCCTCCCTCAAG

CTAGTAGCAACTGCAAC
CTGACCGATTCTCTGGCTCC

CAGCTGCAGCTGCAGGAGT
AGTCGAGTCACCATATCAG

CGGTTCCTGGGCCCAGTC
AAGTCTGGCACCTCAGCCTC

CGGGCCCAGGACTGGTGAA
TAGACACGTCCAAGAACCA

TGTGCTGACGCAGCCAC
CCTGGCCATCAGTGGGCTCC

GCCTTCGGAGACCCTGTCC
GTTCTCCCTGAAGCTGAGCT

CCTCGGTGTCTGAAGCCC
AGTCTGAGGATGAGGCTGA

CTCACCTGCACTGTCTCTGG
CTGTGACCGCTGCGGACAC

CCAGGCAGAGGGTCACC
TTATTACTGTGCAGCATGGG

TGGCTCCATCAGTAGTTACT
GGCCGTGTATTACTGTGCG

ATCTCCTGTTCTGGAAGC
ATGACAGCCTGAATGGCGCT

ACTGGAGCTGGATCCGGCA
AGAGTAGAAGACTGGGGAT

AGCTCCAACATCGGAAA
TGGGTGTTCGGCGGAGGGA

GCCCCCAGGGAAGGGACTG
ATTGTAGTAGTACCAACTG

TAATGCTGTAAATTGGTA
CCAAGCTGACCGTCCTAG

GAGTGGATTGGGTATATCT
CTATTCTGGTGCTTTTGATA

CCAGCAGGTCCCAGGAA
(SEQ ID NO: 3441)

ATTACAGTGGGAGCACCAA
TCTGGGGCCAAGGGACAAT

AGGCTCCCAAACTCCTC

CTACAACCCCTCCCTCAAG
GGTCACCGTCTCTTCAG

ATCTATTATGATGATCTG

AGTCGAGTCACCATATCAG
(SEQ ID NO: 3439)

CTGCCCTCAGGGGTCTCT

TAGACACGTCCAAGAACCA

GACCGATTCTCTGGCTCC

GTTCTCCCTGAAGCTGAGCT

AAGTCTGGCACCTCAGC

CTGTGACCGCTGCGGACAC

CTCCCTGGCCATCAGTGG

GGCCGTGTATTACTGTGCG

GCTCCAGTCTGAGGATG

AGAGTAGAAGACTGGGGAT

AGGCTGATTATTACTGTG

ATTGTAGTAGTACCAACTG

CAGCATGGGATGACAGC

CTATTCTGGTGCTTTTGATA

CTGAATGGCGCTTGGGT

TCTGGGGCCAAGGGACAAT

GTTCGGCGGAGGGACCA

GGTCACCGTCTCTTCAGCGT

AGCTGACCGTCCTAGGT

CGACCAAGGGCCCATCGGT

CAGCCCAAGGCTGCCCC

CTTCCCCCTGGCACCCTCCT

CTCGGTCACTCTGTTCCC

CCAAGAGCACCTCTGGGGG

ACCCTCGAGTGAGGAGC

CACAGCGGCCCTGGGCTGC

TTCAAGCCAACAAGGCC

CTGGTCAAGGACTACTTCC

ACACTGGTGTGTCTCATA

CCGAACCTGTGACGGTCTC

AGTGACTTCTACCCGGG

GTGGAACTCAGGCGCCCTG

AGCCGTGACAGTGGCCT

ACCAGCGGCGTGCACACCT

GGAAGGCAGATAGCAGC

TCCCGGCTGTCCTACAGTCC

CCCGTCAAGGCGGGAGT

TCANGACTCTACTCCCTCAG

GGAGACCACCACACCCT

CAGCGTGGTGACCGTGCCC

CCAAACAAAGCAACAAC

TCCAGCAGCTTGGGCACCC

AAGTACGCGGCCAGCAG

AGACCTACATCTGCAACGT

CTACCTGAGCCTGACGC

GAATCACAAGCCCAGCAAC

CTGAGCAGTGGAAGTCC

ACCAAAGGTGGACAAGAGA

CACAGAAGCTACAGCTG

GTTGAGCCCAAATCTTGTG

CCAGGTCACGCATGAAG

ACAAAACTCACACATGCCC

GGAGCACCGTGGNNAAG

ACCGTGCCCAGCACCTGAA

ACAGTGGNCCCTACAGA

CTCCTGGGGGGANCGTCAG

ATGTTCATAGAAGCTTG

TCTTCCTCTTCCCCCCAAAA

GCCGCCATGGCCCAACT

CCCAAGGACACCNTCATGA

TGTTTATTGCAGCTTATA

TCTCCCNGNACCCCTGAGG

ATGGTTACAAATAAAGC

TCNCNTGCGTGGNGGNNGN

AATAGCATCACAAATTT

NGTGANCCACGAAGANCCT

CACAAATAANCATTTTTT

GANGTCAAGTTNANTGNNN

CACTGCATCTANTTGNGT

CNNGGNNGNCNNNNNGTGC

TNNTCCAANCTCATCAAT

ATANNNNANANNAAGCNN

GNATCTNNCATGTCTGG

NGGANGANNAGTACAACN

NTCGGGAAN (SEQ

GCACGTNCNNNNNGNNAGC

ID NO: 3440)

NTCNNCACCNNCCNNNACC

NNNNACNNGNNNNANN

(SEQ ID NO: 3438)

V-C012
NNNNNNNNNNNTATGNATC
CAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNNNNNNNNTG
CAGTCTGCCCTGACTCAGCC
COV107_

NTACACATACGATTTAGGT
CTGGGGGAGGCGTGGTCCA
P1_B10
NNTCNACACATACGATT
TGCCTCCGTGTCTGGGTCTC
P1_B10

GACACTATAGAATAACATC
GCCTGGGAGGTCCCTGAGA

TAGGTGACACTATAGAA
CTGGACAGTCGATCACCATC

CACTTTGCCTTTCTCTCCAC
CTCTCCTGTGCAGCCTCTGG

TAACATCCACTTTGCCTT
TCCTGCACCGGAACCAGCA

AGGTGTCCACTCCCAGGTC
ATTCACCTTCAGTAGCCATG

TCTCTCCACAGGTGTCCA
GTGACGTTGGTGGTTATAAC

CAACTGCACCTCGGTTCTAT
CTATGCACTGGGTCCGCCA

CTCCCAGGTCCAACTGC
TATGTCTCCTGGTACCAACA

CGATTGAATTCCACCATGG
GGCTCCAGGCAAGGGGCTG

ACCTCGGTTCTATCGATT
ACACCCAGGCAAAGCCCCC

GATGGTCATGTATCATCCTT
GAGTGGGTGGCAGTTATAT

GAATTCCACCATGGGAT
AAACTCATGATTTATGATGT

TTTCTAGTAGCAACTGCAA
CATATGATGGAAGCAATAA

GGTCATGTATCATCCTTT
CAGTAATCGGCCCTCAGGG

CCGGTGTACATTCTCAGGT
ATACTACGCAGACTCCGTG

TTCTAGTAGCAACTGCA
GTTTCTAATCGCTTCTCTGG

GCAGCTGGTGGAGTCTGGG
AAGGGCCGATTCACCATCT

ACCGGTTCCTGGCCCAGT
CTCCAAGTCTGGCAACACGG

GGAGGCGTGGTCCAGCCTG
CCAGAGACAATTCCAAGAA

CTGCCCTGACTCAGCCTG
CCTCCCTGACCATCTCTGGG

GGAGGTCCCTGAGACTCTC
CACGCTGTATCTGCAAATG

CCTCCGTGTCTGGGTCTC
CTCCAGGCTGAGGACGAGG

CTGTGCAGCCTCTGGATTCA
AACAGCCTGAGAGCTGAGG

CTGGACAGTCGATCACC
CTGATTATTACTGCAGCTCA

CCTTCAGTAGCCATGCTATG
ACACGGCTGTGTATTACTGT

ATCTCCTGCACCGGAAC
TATACAAGCAGCAGCACTTG

CACTGGGTCCGCCAGGCTC
GCGAGAGAGGATTACTATG

CAGCAGTGACGTTGGTG
GGTGTTCGGCGGAGGGACC

CAGGCAAGGGGCTGGAGTG
ATAGTAGTGGTTCTTTTGAC

GTTATAACTATGTCTCCT
AAGCTGACCGTCCTAG

GGTGGCAGTTATATCATAT
TACTGGGGCCAGGGAACCC

GGTACCAACAACACCCA
(SEQ ID NO: 3445)

GATGGAAGCAATAAATACT
TGGTCACCGTCTCCTCAG

GGCAAAGCCCCCAAACT

ACGCAGACTCCGTGAAGGG
(SEQ ID NO: 3443)

CATGATTTATGATGTCAG

CCGATTCACCATCTCCAGA

TAATCGGCCCTCAGGGG

GACAATTCCAAGAACACGC

TTTCTAATCGCTTCTCTG

TGTATCTGCAAATGAACAG

GCTCCAAGTCTGGCAAC

CCTGAGAGCTGAGGACACG

ACGGCCTCCCTGACCATC

GCTGTGTATTACTGTGCGA

TCTGGGCTCCAGGCTGA

GAGAGGATTACTATGATAG

GGACGAGGCTGATTATT

TAGTGGTTCTTTTGACTACT

ACTGCAGCTCATATACA

GGGGCCAGGGAACCCTGGT

AGCAGCAGCACTTGGGT

CACCGTCTCCTCAGCGTCG

GTTCGGCGGAGGGACCA

ACCAAGGGCCCATCGGTCT

AGCTGACCGTCCTAGGT

TCCCCCTGGCACCCTCCTCC

CAGCCCAAGGCTGCCCC

AAGAGCACCTCTGGGGGCA

CTCGGTCACTCTGTTCCC

CAGCGGCCCTGGGCTGCCT

ACCCTCGAGTGAGGAGC

GGTCAAGGACTACTTCCCC

TTCAAGCCAACAAGGCC

GAACCTGTGACGGTCTCGT

ACACTGGTGTGTCTCATA

GGAACTCAGGCGCCCTGAC

AGTGACTTCTACCCGGG

CAGCGGCGTGCACACCTTC

AGCCGTGACAGTGGCCT

CCGGCTGTCCTACAGTCCTC

GGAAGGCAGATAGCAGC

AGGACTCTACTCCCTCAGC

CCCGTCAAGGCGGGAGT

AGCGTGGTGACCGTGCCCT

GGAGACCACCACACCCT

CCAGCAGCTTGGGCACCCA

CCAAACAAAGCAACAAC

GACCTACATCTGCAACGTG

AAGTACGCGGCCAGCAG

AATCACAAGCCCAGCAACA

CTACCTGAGCCTGACGC

CCAAGGTGGACAAGAGAGT

CTGAGCAGTGGAAGTCC

TGAGCCCAAATCTTGTGAC

CACAGAAGCTACAGCTG

AAAACTCACACATGCCCAC

CCAGGTCACGCATGAAG

CGTGCCCAGCACCTGAACT

GGAGCACCGTGGAGAAG

CCTGGGGGGACCGTCAGTC

ACAGTGGCCCCTACAGA

TTCCTCTTCCCCCCAAAACC

ATGTTCATAGAAGCTTG

CAAGGACACCCTCATGATC

GCCGCCATGGCCCAACT

TCCCGGACCCCTGAGGTTA

TGTTTATTGCAGCTTATA

CATGCGTGGNGGNGGNCGT

ATGGNTACAAATAAAGC

GAGCCACGAANACCCTGAN

AATAGCATCACAAATTT

NCAGTTCANCTGGNACNNG

CACAAATAAAGCATTTTT

GNNGGCGTNNNNTGCATNA

TTCACTGCATTCTANTTG

TGNNANAANAAGCCNNNG

TGGTTTGTCCAAACTCAT

GGAGGANCAGTANANAGC

CAATGTATCTTATCATGT

ACGTACCNNGNNNNAGCGT

CTGGATCGGGAATTAAN

CNCNCGTCNGCACANNACT

TNNNGCANCACCATGNN

GGNNNANGGNNAGNANTA

NTGAANTAACCTCNGAA

NNANNNCNNGNNNNNCNN

GANNACTTNNNNGNACC

NNANNNNNN (SEQ

TTCNGAGNNNANNNNNN

ID NO: 3442)

CTGNNNNNNNNGTCANT

NGGNNNNNGNANGTCCC

NNGNNCCCNNNAGGCAN

ANNNNNCNAAGCATNCA

TCTCANNNNNCANCANN

ANNNNN (SEQ ID NO:

3444)

V-C013
NNNNNNCNNNNTGNATCNT
CAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNNNTATGNAT
GACATCCAGATGACCCAGTC
COV107_

ACACNTACGATTTAGGTGA
CTGGGGGAGGCGTGGTCCA
P1_D2
CNTACACATACGATTTA
TCCTTCCACCCTGTCTGCAT
P1_D2

CACTATAGAATAACATCCA
GCCTGGGAGGTCCCTGAGA

GGTGACACTATAGAATA
CTGTAGGAGACAGAGTCAC

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCGTCTGG

ACATCCACTTTGCCTTTC
CATCACTTGCCGGGCCAGTC

GTGTCCACTCCCAGGTCCA
ATTCACCTTCAGTAACTTTG

TCTCCACAGGTGTCCACT
AGAGTATGAGTAGCTGGTTG

ACTGCACCTCGGTTCTATCG
GCATGCACTGGGTCCGCCA

CCCAGGTCCAACTGCAC
GCCTGGTATCAGCAGAAAC

ATTGAATTCCACCATGGGA
GGCTCCAGGCAAGGGGCTG

CTCGGTTCTATCGATTGA
CAGGGAACGCCCCTAAGCT

TGGTCATGTATCATCCTTTT
GAGTGGGTGGCAGTTATAT

ATTCCACCATGGGATGG
CCTGATCTATAAGGCGTCTA

TCTAGTAGCAACTGCAACC
GGTATGATGGAAGTAATAA

TCATGTATCATCCTTTTT
GTTTAGAAAGTGGGGTCCCA

GGTGTACATTCTCAGGTGC
ATACTATGCAGACTCCGTG

CTAGTAGCAACTGCAAC
TCAAGGTTCAGCGGCAGTG

AGCTGGTGGAGTCTGGGGG
AAGGGCCGATTCACCATCT

CGGTGTACATTCTGACAT
GATCTGGGACAGAATTCACT

AGGCGTGGTCCAGCCTGGG
CCAGAGACAATTCCAAGAA

CCAGATGACCCAGTCTC
CTCACCATCAGCAGCCTGCA

AGGTCCCTGAGACTCTCCT
CACGCTGTATCTGCAAATG

CTTCCACCCTGTCTGCAT
GCCTGATGATTTTGCAACTT

GTGCAGCGTCTGGATTCAC
AACAGCCTGAGAGCCGAGG

CTGTAGGAGACAGAGTC
ATTACTGCCAACAGCATAAT

CTTCAGTAACTTTGGCATGC
ACACGGCTGTGTATTACTGT

ACCATCACTTGCCGGGC
AGTTCCCCGCTCACTTTCGG

ACTGGGTCCGCCAGGCTCC
GCGAGAGGAGTAAACCCCG

CAGTCAGAGTATGAGTA
CGGAGGGACCAAGGTGGAG

AGGCAAGGGGCTGGAGTGG
ACGATATTTTGACTGGCGT

GCTGGTTGGCCTGGTATC
ATCAAAC (SEQ ID

GTGGCAGTTATATGGTATG
AGATGCTTTTGATATCTGGG

AGCAGAAACCAGGGAAC
NO: 3449)

ATGGAAGTAATAAATACTA
GCCAAGGGACAATGGTCAC

GCCCCTAAGCTCCTGATC

TGCAGACTCCGTGAAGGGC
CGTCTCTTCAG

TATAAGGCGTCTAGTTTA

CGATTCACCATCTCCAGAG
(SEQ ID NO: 3447)

GAAAGTGGGGTCCCATC

ACAATTCCAAGAACACGCT

AAGGTTCAGCGGCAGTG

GTATCTGCAAATGAACAGC

GATCTGGGACAGAATTC

CTGAGAGCCGAGGACACGG

ACTCTCACCATCAGCAG

CTGTGTATTACTGTGCGAG

CCTGCAGCCTGATGATTT

AGGAGTAAACCCCGACGAT

TGCAACTTATTACTGCCA

ATTTTGACTGGCGTAGATG

ACAGCATAATAGTTCCC

CTTTTGATATCTGGGGCCAA

CGCTCACTTTCGGCGGA

GGGACAATGGTCACCGTCT

GGGACCAAGGTGGAGAT

CTTCAGCGTCGACCAAGGG

CAAACGTACGGTGGCTG

CCCATCGGTCTTCCCCCTGG

CACCATCTGTCTTCATCT

CACCCTCCTCCAAGAGCAC

TCCCGCCATCTGATGAGC

CTCTGGGGGCACAGCGGCC

AGTTGAAATCTGGAACT

CTGGGCTGCCTGGTCAAGG

GCCTCTGTTGTGTGCCTG

ACTACTTCCCCGAACCTGTG

CTGAATAACTTCTATCCC

ACGGTCTCGTGGAACTCAG

AGAGAGGCCAAAGTACA

GCGCCCTGACCAGCGGCGT

GTGGAAGGTGGATAACG

GCACACCTTCCCGGCTGTCC

CCCTCCAATCGGGTAACT

TACAGTCCTCAGGACTCTA

CCCAGGAGAGTGTCACA

CTCCCTCAGCAGCGTGGTG

GAGCAGGACAGCAAGGA

ACCGTGCCCTCCAGCAGCT

CAGCACCTACAGCCTCA

TGGGCACCCAGACCTACAT

GCAGCACCCTGACGCTG

CTGCAACGTGAATCACAAG

AGCAAAGCAGACTACGA

CCCAGCAACACCAAGGTGG

GAAACACAAAGTCTACG

ACAAGAGAGTTGAGCCCAA

CCTGCGAAGTCACCCAT

ATCTTGTGACAAAACTCAC

CAGGGCCTGAGCTCGCC

ACATGCCCACCGTGCCCAG

CGTCACAAAGAGCTTCA

CACCTGAACTCCTGGGGGG

ACAGGGGANAGTGTTAG

ACCGTCAGTCTTCCTCTTCC

AAGCTTGGCCGCCATGG

CCCCAAAACCCAAGGACAC

CCCAACTTGTTTATTGCA

CCTCATGATCTCCCGGACCC

GCTTATAATGGNTACAA

CTGAGGTCACATGCGTGGN

ATAAAGCAATAGCATCA

GGNNNACGTGANCCACGAA

CAAATTTCACNAATAAA

GACCCTNAGGTCAAGTTCA

GCATTTTTTTCACTGCAT

ACTGGNACGTNNNGGCNTN

TCTANTTGNGGNTTNTCC

NNGTGCATNANGNCCAAGA

AAACTCATNANNNATNT

CNAAGCCGCGGNGANCAGT

NNCATGTCTGGNTCGNN

ACAACANCNNNTACCGTGN

NNANTNGNGCAGCNCNT

NGNNANNNTCNTCACCNNC

GNNNGAANNNCNCTGAA

NNNACCANNANTNNNTNAN

GAGANNNNNNNACTNTG

NNNNGNNTNNNNNNCNNG

AGNGAANANNTNNNNNN

NNNNNNNAANNNCNTCCNA

NGAATGNNNNNNTCANT

NNNCCATNNNNN (SEQ ID

NGGGNNNNNNAANTCCC

NO: 3446)

NNGNNNCCCCNNNNNNN

(SEQ ID NO: 3448)

V-C014
NNNNNNNNNNNNTGTNTNN
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNNNNNNTATG
CAGTCTGTGCTGACTCAGCC
COV107_

ACACATACGATTTAGGTGA
CTGGAGGAGGGTTGATCCA
P1_G1
TATCATACACATACGATT
GCCCTCAGTGTCTGGGGCCC
P1_G1

CACTATAGAATAACATCCA
GCCTGGGGGGTCCCTGAAA

TAGGTGACACTATAGAA
CAGGGCAGAGGGTCACCAT

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGTAGTCTCTGG

TAACATCCACTTTGCCTT
CTCCTGCACTGGGACCAGTT

GTGTCCACTCCCAGGTCCA
GTTCACCGTCAGTAAGAAC

TCTCTCCACAGGTGTCCA
CCAACATCGGGGCAGGTTAT

ACTGCACCTCGGTTCTATCG
TACATCAGTTGGGTCCGCC

CTCCCAGGTCCAACTGC
GATGTGCACTGGTACCAGCA

ATTGAATTCCACCATGGGA
AGGCTCCAGGCAAGGGGCT

ACCTCGGTTCTATCGATT
ACTTCCTGGAAGAGCCCCCA

TGGTCATGTATCATCCTTTT
GGAATGGGTCTCAGTTATTT

GAATTCCACCATGGGAT
AAGTCCTCATCTCTGGAAAC

TCTAGTAGCAACTGCAACC
TTGCCGGTGGTAGTACATTC

GGTCATGTATCATCCTTT
AACATTCGGCCCTCAGAGGT

GGTGTACATTCTCAGGTGC
TACGCAGACTCCGTTAAGG

TTCTAGTAGCAACTGCA
CCCTGACCGATTCTCTGGCT

AGCTGGTGGAGTCTGGAGG
GCCGATTCGCCATCTCCAG

ACCGGTTCCTGGGCCCA
CCAGGTCTGGCACCTCAGCC

AGGGTTGATCCAGCCTGGG
AGACAACTCCAACAACACG

GTCTGTGCTGACTCAGCC
TCCCTGGCCATCACTAGTCT

GGGTCCCTGAAACTCTCCT
CTGTTTCTTCAAATGAACAG

GCCCTCAGTGTCTGGGG
CCAGCCTGAGGATGAGGCT

GTGTAGTCTCTGGGTTCACC
CCTGAGAGTCGAGGACACG

CCCCAGGGCAGAGGGTC
CAATATTACTGTCAGTCTTA

GTCAGTAAGAACTACATCA
GCCATTTATTACTGTGCGAG

ACCATCTCCTGCACTGGG
TGACAGCAGTCTCTATGCGG

GTTGGGTCCGCCAGGCTCC
AGGGGACGGGGAGTTATTC

ACCAGTTCCAACATCGG
TGTTCGGCGGAGGGACCAA

AGGCAAGGGGCTGGAATGG
TTTGACCAATGGGGCCAGG

GGCAGGTTATGATGTGC
GCTGACCGTCCTA (SEQ

GTCTCAGTTATTTTTGCCGG
GAACCCTGGTCACCGTCTC

ACTGGTACCAGCAACTT
ID NO: 3453)

TGGTAGTACATTCTACGCA
CTCAG (SEQ ID NO:

CCTGGAAGAGCCCCCAA

GACTCCGTTAAGGGCCGAT
3451)

AGTCCTCATCTCTGGAAA

TCGCCATCTCCAGAGACAA

CAACATTCGGCCCTCAG

CTCCAACAACACGCTGTTTC

AGGTCCCTGACCGATTCT

TTCAAATGAACAGCCTGAG

CTGGCTCCAGGTCTGGC

AGTCGAGGACACGGCCATT

ACCTCAGCCTCCCTGGCC

TATTACTGTGCGAGAGGGG

ATCACTAGTCTCCAGCCT

ACGGGGAGTTATTCTTTGA

GAGGATGAGGCTCAATA

CCAATGGGGCCAGGGAACC

TTACTGTCAGTCTTATGA

CTGGTCACCGTCTCCTCAGC

CAGCAGTCTCTATGCGGT

GTCGACCAAGGGCCCATCG

GTTCGGCGGAGGGACCA

GTCTTCCCCCTGGCACCCTC

AGCTGACCGTCCTACGTC

CTCCAAGAGCACCTCTGGG

AGCCCAAGGCTGCCCCC

GGCACAGCGGCCCTGGGCT

TCGGTCACTCTGTTCCCA

GCCTGGTCAAGGACTACTT

CCCTCGAGTGAGGAGCT

CCCCGAACCTGTGACGGTC

TCAAGCCAACAAGGCCA

TCGTGGAACTCAGGCGCCC

CACTGGTGTGTCTCATAA

TGACCAGCGGCGTGCACAC

GTGACTTCTACCCGGGA

CTTCCCGGCTGTCCTACAGT

GCCGTGACAGTGGCCTG

CCTCAGGACTCTACTCCCTC

NAAGGCAGATAGCAGCC

AGCAGCGTGGTGACCGTGC

CCGTCAAGGCGGGAGTG

CCTCCAGCAGCTTGGGCAC

GAGACCACCACACCCTC

CCAGACCTACATCTGCAAC

CAAACAAAGCAACAACA

GTGAATCACAAGCCCAGCA

AGTACGCGGCCAGCAGC

ACACCAAGGTGGACAAGAG

TACCTGAGCCTGACGCCT

AGTTGAGCCCAAATCTTGT

GAGCAGTGGAAGTCCCA

GACAAAACTCACACATGCC

CAGAAGCTACAGCTGCC

CACCGTGCCCAGCACCTGA

AGGTCACGCATGAAGGG

ACTCCTGGGGGGANCGTCA

AGCACCGTGNANAAGAC

GTCTTCCTCTTCCCCCCAAA

AGTGGCCCCTACAGAAT

CCCNAGGACACCCTCATGA

GTTCATAGAAGCTTGGN

TCTCCCGGACCCCTGANTC

CGCCATGGCCCAACTTGT

ACATGCGTGGTGGTGGACG

TTATTGCAGCTTANNATG

TGAGCCACGAAGACCCTGA

GTTACAAANTAAAGCAA

GTCAAGTTCANTGGNACNN

TAGCATCACAAATTTCAC

NGNNGGCNNNGNGGTGCAT

AAATAAANNCATTTTTTT

AATGCCANANNAAGCCNNN

CACTGCATTCTANTTGNN

GGANGANCANNANANAGC

GTTNGNCCAAACTCNTC

ACNTACCGNGNNNNAGCGT

AATGNNTCTTATCATGNC

CCTNNNCNNCNNNNCNGNC

TGGATCGGNNANTNANT

TGNNNANGNNNNNNACNN

TCGGNNCAGCNNC

NNNCANGGNNNCANCNAN

(SEQ ID NO: 3452)

CCNTNCCNNCNNCNNTCNA

NAAAANNANNNNNN (SEQ

ID NO: 3450)

V-C015
NNNNNNNNTATGTATNNTA
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNCNNATGTATCN
GATATTGTGATGACTCAGTC
COV107_

CACATACGATTTAGGTGAC
CTGGGGGAGGCTTGATAAA
P2_B3
TACACATACGATTTAGGT
TCCACTCTCCCTGTCCGTCA
P2_B3

ACTATAGAATAACATCCAC
GCCAGGGCGGTCCCTGAGA

GACACTATAGAATAACA
CCCCTGGAGAGCCGGCCTCC

TTTGCCTTTCTCTCCACAGG
CTCTCTTGTACAGCCTCTGG

TCCACTTTGCCTTTCTCT
ATCTCCTGCAGGTCTAGTCA

TGTCCACTCCCAGGTCCAA
ATTCACCTTTGGTGATTATG

CCACAGGTGTCCACTCCC
GAGCCTCCTGCATAGTAATG

CTGCACCTCGGTTCTATCGA
CTATGACCTGGTTCCGCCA

AGGTCCAACTGCACCTC
GAAACAACTATTTCGATTGG

TTGAATTCCACCATGGGAT
GGCTCCAGGGAAGGGGCTG

GGTTCTATCGATTGAATT
TACCTGCAGAAGCCAGGGC

GGTCATGTATCATCCTTTTT
GAGTGGGTAGGTTTCATTA

CCACCATGGGATGGTCA
AGTCTCCACAGCTCCTGATC

CTAGTAGCAACTGCAACCG
GAAGTAAAGCTTATGGTGG

TGTATCATCCTTTTTCTA
TATTTGGGTTCTAATCGGGC

GGTACATTCTCAGGTGCAG
GACAACAGGATACGCCGCG

GTAGCAACTGCAACCGG
CTCCGGGGTCCCTGACAGGT

CTGGTGGAGTCTGGGGGAG
TCTGTGAAATACAGATTTA

TGTACATGGGGATATTGT
TCAGTGGCAGTGGATCAGG

GCTTGATAAAGCCAGGGCG
CCATCTCAAGAGATGATTC

GATGACTCAGTCTCCACT
CACAGATTTTACACTGAAGA

GTCCCTGAGACTCTCTTGTA
CAAAAGCATCGCCTATCTG

CTCCCTGTCCGTCACCCC
TCAGCAGAGTGGAGGCTGA

CAGCCTCTGGATTCACCTTT
CAAATGGACAGCCTGAAAA

TGGAGAGCCGGCCTCCA
GGATGTTGGGGTTTATTACT

GGTGATTATGCTATGACCT
CCGAGGACACAGCCGTGTA

TCTCCTGCAGGTCTAGTC
GCATGCAAGTTCTACAAATT

GGTTCCGCCAGGCTCCAGG
TTACTGTACTAGGTGGGAC

AGAGCCTCCTGCATAGT
CCGTACACTTTTGGCCAGGG

GAAGGGGCTGGAGTGGGTA
GGGTGGAGTCAACATGACT

AATGGAAACAACTATTT
GACCAAGCTGGAGATCAA

GGTTTCATTAGAAGTAAAG
ATTGGGGCCAGGGAACCCT

CGATTGGTACCTGCAGA
(SEQ ID NO: 3457)

CTTATGGTGGGACAACAGG
GGTCACCGTCTCCTCAG

AGCCAGGGCAGTCTCCA

ATACGCCGCGTCTGTGAAA
(SEQ ID NO: 3455)

CAGCTCCTGATCTATTTG

TACAGATTTACCATCTCAA

GGTTCTAATCGGGCCTCC

GAGATGATTCCAAAAGCAT

GGGGTCCCTGACAGGTT

CGCCTATCTGCAAATGGAC

CAGTGGCAGTGGATCAG

AGCCTGAAAACCGAGGACA

GCACAGATTTTACACTG

CAGCCGTGTATTACTGTACT

AAGATCAGCAGAGTGGA

AGGTGGGACGGGTGGAGTC

GGCTGAGGATGTTGGGG

AACATGACTATTGGGGCCA

TTTATTACTGCATGCAAG

GGGAACCCTGGTCACCGTC

TTCTACAAATTCCGTACA

TCCTCAGCGTCGACCAAGG

CTTTTGGCCAGGGGACC

GCCCATCGGTCTTCCCCCTG

AAGCTGGAGATCAAACG

GCACCCTCCTCCAAGAGCA

TACGGTGGCTGCACCAT

CCTCTGGGGGCACAGCGGC

CTGTCTTCATCTTCCCGC

CCTGGGCTGCCTGGTCAAG

CATCTGATGAGCAGTTG

GACTACTTCCCCGAACCTGT

AAATCTGGAACTGCCTCT

GACGGTCTCGTGGAACTCA

GTTGTGTGCCTGCTGAAT

NGCGCCCTGACCAGCGGCG

AACTTCTATCCCAGAGA

TGCACACCTTCCCGGCTGTC

GGCCAAAGTACAGTGGA

CTACAGTCCTCNNNCTCTAC

AGGTGGATAACGCCCTC

TCCCTCAGCAGCGTGGTGA

CAATCGGGTAACTCCCA

CCGTGCCCTCCAGCAGCTT

GGAGAGTGTCACAGAGC

GGGCACCCAGACCTACATC

AGGACAGCAAGGACAGC

TGCAACGTGAATCACAAGC

ACCTACAGCCTCAGCAG

CCAGCANNNCCNNNNNNNN

CACCCTGACGCTGAGCA

ANANANTTGAGCCCNAATC

AAGCAGACTACGAGAAA

TNNTGANNAACTCANNCAT

CACAAAGTCTACGCCTG

GCCCANCGNGCCCAGCACC

CGAAGTCACCCATCNGG

TGACTNCTGGGGGGANCGT

NCNTGAGCTCGCCCGTC

CAGTCTCNNTCCCCNNAAN

ACAAAGAGCTTCAACNG

CNNNNNNNCCNTCATGATN

GGGANANTGTTAGAAGC

NNCNNACCCTGAGTCACAT

TTGGNCGCCATGGCCCA

GNNNNGGTGGNNGANNTG

ACTTGTTTATTGCAGCTT

ANCCNCNANANCCTGAGNC

ATNATGGNTACAAATAA

AGTCANTGNANNGNNNGGN

AGCAATAGCATCACAAA

NNGNNNNNNCNNNANGCN

TTTCANAATAAAGCATTT

NANNNANNNNNNGNNNNN

TTTTCACTGCATNTANTN

NNNNNTNCANNNNGCNNGT

NGGNNNTCCAANCTCAT

NCNNNNGTNNNNNNNNNC

CNATGNATNTATCATGTC

NGTNCNNNNNNNNNNTGGN

TGGNTCNGNATTANTTC

NNANGNNNNNNNNNNANN

GNNNNAGCNNCANN

NNNNNGNNNNNCNNNANN

(SEQ ID NO: 3456)

NNNCNNNNCCCCCNNNNNN

NNA (SEQ ID NO:

3454)

V-C016
NNNNNNNNNNATGTATCAT
CAGGTGCAGCTGGTGGAGT
COV107_
NNNNCNTTATGNNTCNA
AATTTTATGCTGACTCAGCC
COV107_

ACACNTACGATTTAGGTGA
CTGGGGGAGGCGTGGTCCA
P2_C6
CNCATACGATTTAGGTG
CCACTCTGTGTCGGAGTCTC
P2_C6

CACTATAGAATAACATCCA
GCCTGGGAGGTCCCTGAGA

ACACTATAGAATAACAT
CGGGGAAGACGGTAACCAT

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCCTCTGG

CCACTTTGCCTTTCTCTC
CTCCTGCACCGGCAGCAGTG

GTGTCCACTCCCAGGTCCA
ATTCACCTACAGTACCTATG

CACAGGTGTCCACTCCC
GCAGCATTGCCAGCAACTAT

ACTGCACCTCGGTTCTATCG
CTATGCACTGGGTCCGCCA

AGGTCCAACTGCACCTC
GTGCAGTGGTACCAGCAGC

ATTGAATTCCACCATGGGA
GGCTCCAGGCAAGGGGCTG

GGTTCTATCGATTGAATT
GCCCGGGCAGTGCCCCCACC

TGGTCATGTATCATCCTTTT
GAGTGGGTGGCATTTATAT

CCACCATGGGATGGTCA
ACTGTGATCTATGAGGATAA

TCTAGTAGCAACTGCAACC
CATATGATGGAAGCAATAA

TGTATCATCCTTTTTCTA
CCAAAGACCCTGTGGGGTCC

GGTGTACATTCTCAGGTGC
ATACTACGCAGACTCCGTG

GTAGCAATGCAACCGGT
CTGATCGGTTCTCTGGCTCC

AGCTGGTGGAGTCTGGGGG
AAGGGCCGATTCACCATCT

TCTTGGGCCAATTTTATG
ATCGACAGGTCCTCCAACTC

AGGCGTGGTCCAGCCTGGG
CCAGAGACAATTCCAAGAA

CTGACTCAGCCCCACTCT
TGCCTCCCTCACCATCTCTG

AGGTCCCTGAGACTCTCCT
CACGCTGTATCTGCAAATG

GTGTCGGAGTCTCCGGG
GACTGAAGACTGAGGACGA

GTGCAGCCTCTGGATTCAC
AACAGCCTGAGAGCTGAGG

GAAGACGGTAACCATCT
GGCTGACTACTACTGTCAGT

CTACAGTACCTATGCTATGC
ACACGGCTGTGTATTACTGT

CCTGCACCGGCAGCAGT
CTTATGATAGCGGCAATCAT

ACTGGGTCCGCCAGGCTCC
GCGAGAGATTTCTACCATA

GGCAGCATTGCCAGCAA
TGGGTGGTATTCGGCGGAG

AGGCAAGGGGCTGGAGTGG
ACTGGTTCGACCCCTGGGG

CTATGTGCAGTGGTACC
GGACCAGGCTGACCGTCCTA

GTGGCATTTATATCATATGA
CCAGGGAACCCTGGTCACC

AGCAGCGCCCGGGCAGT
G (SEQ ID NO: 3461)

TGGAAGCAATAAATACTAC
GTCTCCTCAG (SEQ ID

GCCCCCACCACTGTGATC

GCAGACTCCGTGAAGGGCC
NO: 3459)

TATGAGGATAACCAAAG

GATTCACCATCTCCAGAGA

ACCCTCTGGGGTCCCTGA

CAATTCCAAGAACACGCTG

TCGGTTCTCTGGCTCCAT

TATCTGCAAATGAACAGCC

CGACAGGTCCTCCAACT

TGAGAGCTGAGGACACGGC

CTGCCTCCCTCACCATCT

TGTGTATTACTGTGCGAGA

CTGGACTGAAGACTGAG

GATTTCTACCATAACTGGTT

GACGAGGCTGACTACTA

CGACCCCTGGGGCCAGGGA

CTGTCAGTCTTATGATAG

ACCCTGGTCACCGTCTCCTC

CGGCAATCATTGGGTGG

AGCGTCGACCAAGGGCCCA

TATTCGGCGGAGGGACC

TCGGTCTTCCCCCTGGCACC

AGGCTGACCGTCCTAGG

CTCCTCCAAGAGCACCTCT

TCAGCCCAAGGCTGCCC

GGGGGCACAGCGGCCCTGG

CCTCGGTCACTCTGTTCC

GCTGCCTGGTCAAGGACTA

CGCCCTCGAGTGAGGAG

CTTCCCCGAACCTGTGACG

CTTCAAGCCAACAAGGC

GTCTCGTGGAACTCAGGCG

CACACTGGTGTGTCTCAT

CCCTGACCAGCGGCGTGCA

AAGTGACTTCTACCCGG

CACCTTCCCGGCTGTCCTAC

GAGCCGTGACAGTGGCC

AGTCCTCANGACTCTACTCC

TGGANGGCAGATAGCAG

CTCAGCAGCGTGGTGACCG

CCCCGTCAAGGCGGGAG

TGCCCTCCAGCAGCTTGGG

TGGAGACCACCACACCC

CACCCAGACCTACATCTGC

TCCAAACAAAGCAACNA

AACGTGAATCACAAGCCCA

CAAGTACGCNGNCNNNC

GCAACACCAAGGTGGACAA

ANN (SEQ ID NO:

GAGAGTTGAGCCCAAATCT

3460)

TGTGACAAAACTCACACAT

GCCCACCGTGCCCAGCACC

TGAACTCCTGGGGGGACCG

TCAGTCTTCCTCTTCCCCCC

AAAACCCNNNNNNNCCTCA

TGATCTCCCGGACCCCTGA

GTCACATGCGTGNNNNNNG

TGAGCCACGANANCCTGAG

NCAGTTCAACTGGNACNNN

GNNGGCNNGGNNNTGCAN

NATGCCNAGACNNAAGCCN

N (SEQ ID NO: 3458)

V-C017
NNNNNNNNNATGTATCNTA
CAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNCNNATGTATCN
CAGTCTGTGCTGACTCAGCC
COV107_

CACATACGATTTAGGTGAC
CTGGGGGAGGCGTGGTCCA
P2_H5
TACACATACGATTTAGGT
GCCCTCAGTGTCTGCGGCCC
P2_H5

ACTATAGAATAACATCCAC
GCCTGGGAGGTCCCTGAGA

GACACTATAGAATAACA
CAGGACAGAAGGTCACCAT

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
CTCCTGCTCTGGAAGCAGCT

TGTCCACTCCCAGGTCCAA
ATTCACCTTCAGTACCTATG

CCACAGGTGTCCACTCCC
CCAACATTGGGAATAATTTG

CTGCACCTCGGTTCTATCGA
CTATGCACTGGGTCCGCCA

AGGTCCAACTGCACCTC
GTATCCTGGTACCAGCAGCT

TTGAATTCCACCATGGGAT
GGCTCCAGGCGAGGGGCTG

GGTTCTATCGATTGAATT
CCCAGGAACAGCCCCCAAA

GGTCATGTATCATCCTTTTT
GAGTGGGTGGCAGTTATTT

CCACCATGGGATGGTCA
CTCCTCATCTATGAAAATAA

CTAGTAGCAATGCAACCGG
CATATGATGGAAGCAATAC

TGTATCATCCTTTTTCTA
TAAGCGACCCTCAGGGATTC

TGTACATTCTCAGGTGCAG
ATACTACGCAGACTCCGTG

GTAGCAACTGCAACCGG
CTGACCGATTCTCTGGCTCC

CTGGTGGAGTCTGGGGGAG
AAGGGCCGATTCACCATCT

TTCCTGGGCCCAGTCTGT
AAGTCTGGCACGTCAGCCAC

GCGTGGTCCAGCCTGGGAG
CCAGAGACAATTCCAAGAA

GCTGACTCAGCCGCCCTC
CCTGGGCATCACCGGACTCC

GTCCCTGAGACTCTCCTGTG
CACGCTGTATCTGCAAATG

AGTGTCTGCGGCCCCAG
AGACTGGGGACGAGGCCGA

CAGCCTCTGGATTCACCTTC
AACAGCCTGAGAGCTGAAG

GACAGAAGGTCACCATC
TTATTACTGCGGAGCATGGG

AGTACCTATGCTATGCACT
ACACGGCTGTGTATTACTGT

TCCTGCTCTGGAAGCAG
ATAGCAGCCTGAGTGCTGGC

GGGTCCGCCAGGCTCCAGG
GCGAGAGATCCCATATGGT

CTCCAACATTGGGAATA
GGGGTTTATGTCTTCGGAAC

CGAGGGGCTGGAGTGGGTG
TCGGGGAGTTATTATCTCCT

ATTTGGTATCCTGGTACC
TGGGACCAAGGTCACCGTCC

GCAGTTATTTCATATGATGG
CCTTTTGTTCACTTTGACTA

AGCAGCTCCCAGGAACA
TAG (SEQ ID NO:

AAGCAATACATACTACGCA
CTGGGGCCAGGGAACCCTG

GCCCCCAAACTCCTCATC
3465)

GACTCCGTGAAGGGCCGAT
GTCACCGTCTCCTCAG (SEQ

TATGAAAATAATAAGCG

TCACCATCTCCAGAGACAA
ID NO: 3463)

ACCCTCAGGGATTCCTG

TTCCAAGAACACGCTGTAT

ACCGATTCTCTGGCTCCA

CTGCAAATGAACAGCCTGA

AGTCTGGCACGTCAGCC

GAGCTGAAGACACGGCTGT

ACCCTGGGCATCACCGG

GTATTACTGTGCGAGAGAT

ACTCCAGACTGGGGACG

CCCATATGGTTCGGGGAGT

AGGCCGATTATTACTGC

TATTATCTCCTCCTTTTGTT

GGAGCATGGGATAGCAG

CACTTTGACTACTGGGGCC

CCTGAGTGCTGGCGGGG

AGGGAACCCTGGTCACCGT

TTTATGTCTTCGGAACTG

CTCCTCAGCGTCGACCAAG

GGACCAAGGTCACCGTC

GGCCCATCGGTCTTCCCCCT

CTAGGTCAGCCCAAGGC

GGCACCCTCCTCCAAGAGC

CAACCCCACTGTCACTCT

ACCTCTGGGGGCACAGCGG

GTTCCCACCCTCGAGTGA

CCCTGGGCTGCCTGGTCAA

GGAGCTTCAAGCCAACA

GGACTACTTCCCCGAACCT

AGGCCACACTGGTGTGT

GTGACGGTCTCGTGGAACT

CTCATAAGTGACTTCTAC

CAGGCGCCCTGACCAGCGG

CCGGGAGCCGTGACAGT

CGTGCACACCTTCCCGGCT

GGCCTGGAAGGCAGATA

GTCCTACAGTCCTCAGGAC

GCAGCCCCGTCAAGGCG

TCTACTCCCTCAGCAGCGTG

GGAGTGGAGACCACCAC

GTGACCGTGCCCTCCAGCA

ACCCTCCAAACAAAGCA

GCTTGGGCACCCAGACCTA

ACAACAAGTACGCGGCC

CATCTGCAACGTGAATCAC

AGCAGCTACCTGAGCCT

AAGCCCAGCAACACCNANG

GACGCCTGAGCAGTGGA

TGGACAAGAGAGTTGAGCC

AGTCCCACAGAAGCTAC

CAAATCTTGTGACAAAACT

AGCTGCCAGGTCACGCA

CACACATGCCCACCGTGCC

TGAAGGGAGCANCGTGN

CAGCACCTGAACTCCTGGG

NANANAGTNNCCCTACN

GGGACCGTCAGTCTTCCTCT

GAATGNTCATNNNANCT

TCCCCCCAAAACCCNAGGA

TGGNGCATGGCCCANTT

NACCCTCATGATCTCCCNG

GTTNANTGCAGCTTATA

ACCCCNGAGTCACNNGCCG

ATGGTNCAANNAAGCAT

NNGNNGGNGGACGTGAGCC

AGCATCACAAANTTCAC

NNGA (SEQ ID NO:

AAATAAGCATTTTTTNNC

3462)

TGCATCTANNNNGTTGN

CNAACTCNTCANGNNNC

TTANCATGNCNGNTCGG

NANNNNGNNCANNNCNT

NNNGAANNNACCNNTNA

NNNANTNNNNNGNACTN

NGANGNGAANANCNNN

NNNNNNNGGNGNNANN

NNGGNNNAAGNNNCCNN

GNNCCNNNGNNANNNNN

NNNNNNGNN (SEQ ID

NO: 3464)

V-C018
NNNNNNNNNNNNTGNATCN
CAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNNCNTATGNN
CAGTCTGTGCTGACTCAGTC
COV107_

ACACATACGATTTAGGTGA
CTGGGGGAGGCGTGGTCCA
P2_E1
NNNACACNTACGATTTA
GCCCTCTGCCTCTGCCTCCC
P2_E1

CACTATAGAATAACATCCA
GCCTGGGAGGTCCCTGAGA

GGTGACACTATAGAATA
TGGGAGCCTCGGTCAAGCTC

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
ACCTGCACTCTGAGCAGTGG

GTGTCCACTCCCAGGTCCA
ATTCACCTTCAGTAACTATG

TCTCCACAGGTGTCCACT
GCACAGCAGCTACGCCATC

ACTGCACCTCGGTTCTATCG
CTATGCACTGGGTCCGCCA

CCCAGGTCCAACTGCAC
GCATGGCATCAGCAGCAGC

ATTGAATTCCACCATGGGA
GGCTCCAGGCAAGGGGCTG

CTCGGTTCTATCGATTGA
CAGAGAAGGGCCCTCGGTA

TGGTCATGTATCATCCTTTT
GAGTGGGTGGCAGTTATAT

ATTCCACCATGGGATGG
CTTGATGAAGCTTAACACTG

TCTAGTAGCAACTGCAACC
CATATGATGGAAGCAATAN

TCATGTATCATCCTTTTT
ATGGCAGCCACAGCAAGGG

GGTGTACATTCTCAGGTGC
ATACTACGCAGACTCCGTG

CTAGTAGCAACTGCAAC
GGACGGGATCCCTGATCGCT

AGCTGGTGGAGTCTGGGGG
AAGGGCCGATTCACCATCT

CGGTTCTCTCTCCCAGCC
TCTCAGGCTCCAGCTCTGGG

AGGCGTGGTCCAGCCTGGG
CCAGAGACAATTCCAAGAA

TGTGCTGACTCAATCGCC
GCTGAGCGCTACCTCACCAT

AGGTCCCTGAGACTCTCCT
CACGCTGTATCTGCAAATG

CTCTGCCTCTGCCTCCCT
CTCCAGCCTCCAGTCTGAGG

GTGCAGCCTCTGGATTCAC
AACAGCCTGAGAGCTGAGG

GGGAGCCTCGGTCAAGC
ATGAGGCTGACTATTACTGT

CTTCAGTAACTATGCTATGC
ACACGGCTATTTATTACTGT

TCACCTGCACTCTGAGCA
CAGACCTGGGGCACTGGCA

ACTGGGTCCGCCAGGCTCC
GCGAGTGGATATACTGGCT

GTGGGCACAGCAGCTAC
TTCTCGTATTCGGCGGAGGG

AGGCAAGGGGCTGGAGTGG
ACGATTATTTTGTGCGGGG

GCCATCGCATGGCATCA
ACCAAGCTGACCGTCCTAG

GTGGCAGTTATATCATATG
GGACTACTACGGTCTGGAC

GCAGCAGCCAGAGAAGG
(SEQ ID NO: 3469)

ATGGAAGCAATAAATACTA
GTCTGGGGCCAAGGGACCA

GCCCTCGGTACTTGATGA

CGCAGACTCCGTGAAGGGC
CGGTCACCGTCTCCTCA

AGCTTAACACTGATGGC

CGATTCACCATCTCCAGAG
(SEQ ID NO: 3467)

AGCCACAGCAAGGGGGA

ACAATTCCAAGAACACGCT

CGGGATCCCTGATCGCTT

GTATCTGCAAATGAACAGC

CTCAGGCTCCAGCTCTGG

CTGAGAGCTGAGGACACGG

GGCTGAGCGCTACCTCA

CTATTTATTACTGTGCGAGT

CCATCTCCAGCCTCCAGT

GGATATACTGGCTACGATT

CTGAGGATGAGGCTGAC

ATTTTGTGCGGGGGGACTA

TATTACTGTCAGACCTGG

CTACGGTCTGGACGTCTGG

GGCACTGGCATTCTCGTA

GGCCAAGGGACCACGGTCA

TTCGGCGGAGGGACCAA

CCGTCTCCTCAGCGTCGACC

GCTGACCGTCCTAGGTC

AAGGGCCCATCGGTCTTCC

AGCCCAAGGCTGCCCCC

CCCTGGCACCCTCCTCCAA

TCGGTCACTCTGTTCCCG

GAGCACCTCTGGGGGCACA

CCCTCGAGTGAGGAGCT

GCGGCCCTGGGCTGCCTGG

TCAAGCCAACAAGGCCA

TCAAGGACTACTTCCCCGA

CACTGGTGTGTCTCATAA

ACCTGTGACGGTCTCGTGG

GTGACTTCTACCCGGGA

AACTCAGGCGCCCTGACCA

GCCGTGACAGTGGCCTG

GCGGCGTGCACACCTTCCC

GAAGGCAGATAGCAGCC

GGCTGTCCTACAGTCCTCA

CCGTCAAGGCGGGAGTG

GGACTCTACTCCCTCAGCA

GAGACCACCACACCCTC

GCGTGGTGACCGTGCCCTC

CAAACAAAGCAACAACA

CAGCAGCTTGGGCACCCAG

AGTACGCGGCCAGCAGC

ACCTACATCTGCAACGTGA

TACCTGAGCCTGACGCCT

ATCACAAGCCCAGCAACAC

GAGCAGTGNAAGTCCCA

CAAGGTGGACAAGAGAGTT

CAGAAGCTACAGCTGCC

GAGCCCAAATCTTGTGACA

AGGTCACGCATGAANGG

AAACTCACACATGCCCACC

AGCACCGTGGAGAAGAC

GTGCCCAGCACCTGAACTC

AGTGGCCCCTACAGAAT

CTGGGGGGACCGTCAGTCT

GTTCATAGAAGCTTGGG

TCCTCTTCCCCCCAAAACCC

CCGCCATGGNCCAACTT

AAGGACACCCTCATGATCT

GTTTATTGCAGCTTATAA

CCCGGACCCCTGAGGTNNC

TGGTTACAAATAAAGCA

ATGCGTGGNGGTGGNNGTG

ATAGCATCACAAATTTC

ANCCACNANACCCTGANGT

ACAAATAAAGCATTTTTT

CAAGTTCAACTGGNACGTN

TCACTGCATTCTANTTNG

NNGGCGTGAAGGTGCATAA

TGGNTTGTCCAAACTCAT

TGNCNANNANNANCCGCNG

CAATGNATCTTATCATGT

GNAGGAGCAGNANANNNN

CTGGNTCGGGAANTAAT

CNNNNNCNNGNNNNNCAN

TCGNNGCANCANCATNN

CNNCNTCNNCNNNNNNCAN

NTGAAATACNTCTNAAN

NNNNNTNNNNNNNNNNNN

NAGNNNTGNNNGGTACC

NANTACNANNNNAGNNNN

TTCTGAGGNNNANGAAN

CANNAANNCNTCCCNNNCC

CANCTNNGGNNNNNNNN

NCATNNNNAAAANNCNTNN

NNCANTNNGNNNNNNNN

NNCAANN (SEQ ID

NCCCNNNNCCCNNNNCC

NO: 3466)

NNANNATGCAAAGCATG

CATNTNNNNNNCNGNNN

NNNNNNNNAANNNCNCA

GNNNNCNCNNNNGGNNN

ANNNNNNNNAANNNN

(SEQ ID NO: 3468)

V-C019
NNNNNNNNNNNNNNNNTG
CAGGTGCAGCTGGTGCAGT
COV107_
NNNNNNNNNNNATGTAT
CAGTCTGCCCTGACTCAGCC
COV107_

TATCNNCACNTACGATTTA
CTGGGGCTGAGGTGAAGAA
P1_H7
CNTACACATACGATTTA
TGCCTCCGTGTCTGGGTCTC
P1_H7

GGTGACACTATAGAATAAC
GCCTGGGGCCTCAGTGAAG

GGTGACACTATAGAATA
CTGGACAGTCGATCACCATC

ATCCACTTTGCCTTTCTCTC
GTTTCCTGCAAGGCATCTG

ACATCCACTTTGCCTTTC
TCCTGCACTGGAACCAGCAG

CACAGGTGTCCACTCCCAG
GATACACCTTCACCAGCTA

TCTCCACAGGTGTCCACT
TGACGTTGGTGGTTATAAGT

GTCCAACTGCACCTCGGTTC
CTATATGCACTGGGTGCGA

CCCAGGTCCAACTGCAC
ATGTCTCCTGGTACCAACGG

TATCGATTGAATTCCACCAT
CAGGCCCCTGGACAAGGGC

CTCGGTTCTATCGATTGA
CACCCAGGCAAAGCCCCCA

GGGATGGTCATGTATCATC
TTGAGTGGATGGGAATAAT

ATTCCACCATGGGATGG
AACTCATGATATATGATGTC

CTTTTTCTAGTAGCAACTGC
CAACCCTAGTGGTGGTAGC

TCATGTATCATCCTTTTT
AGTAATCGGCCCTCAGGGGT

AACCGGTGTACATTCCCAG
ACAAGCTACGCACAGAAGT

CTAGTAGCAACTGCAAC
TTCTAATCGCTTCTCTGGCT

GTCCAGCTGGTACAGTCTG
TACAGGGCAGAGTCACCAT

CGGTTCCTGGGCCCAGTC
CCAAGTCTGGCAACACGGC

GGGCTGAGGTGAAGAAGCC
GACCAGGGACACGTCCACG

TGCCCTGACTCAGCCTGC
CTCCCTGACCATCTCTGGGC

TGGGGCCTCAGTGAAGGTT
AGCACAGTCTACATGGAGC

CTCCGTGTCTGGGTCTCC
TCCAGGCTGAGGACGAGGC

TCCTGCAAGGCATCTGGAT
TGAGCAGCCTGAGATCTGA

TGGACAGTCGATCACCA
TGATTATTACTGCAGCTCAT

ACACCTTCACCAGCTACTAT
GGACACGGCCGTGTATTAC

TCTCCTGCACTGGAACCA
ACACAAGCAGCAGCACTTCT

ATGCACTGGGTGCGACAGG
TGTGCGAGAGCCAATCATG

GCAGTGACGTTGGTGGT
GTGGTGTTCGGCGGAGGGA

CCCCTGGACAAGGGCTTGA
AAACAACTATGGACACTTA

TATAAGTATGTCTCCTGG
CCCAGCTGACCGTCCTAG

GTGGATGGGAATAATCAAC
CTACTACTACTACTACATGG

TACCAACGGCACCCAGG
(SEQ ID NO: 3473)

CCTAGTGGTGGTAGCACAA
ACGTCTGGGGCAAAGGGAC

CAAAGCCCCCAAACTCA

GCTACGCACAGAAGTTACA
CACGGTCACCGTCTCCTCA

TGATATATGATGTCAGTA

GGGCAGAGTCACCATGACC
(SEQ ID NO: 3471)

ATCGGCCCTCAGGGGTTT

AGGGACACGTCCACGAGCA

CTAATCGCTTCTCTGGCT

CAGTCTACATGGAGCTGAG

CCAAGTCTGGCAACACG

CAGCCTGAGATCTGAGGAC

GCCTCCCTGACCATCTCT

ACGGCCGTGTATTACTGTG

GGGCTCCAGGCTGAGGA

CGAGAGCCAATCATGAAAC

CGAGGCTGATTATTACTG

AACTATGGACACTTACTAC

CAGCTCATACACAAGCA

TACTACTACTACATGGACG

GCAGCACTTCTGTGGTGT

TCTGGGGCAAAGGGACCAC

TCGGCGGAGGGACCCAG

GGTCACCGTCTCCTCAGCGT

CTGACCGTCCTAGGTCA

CGACCAAGGGCCCATCGGT

GCCCAAGGCTGCCCCCT

CTTCCCCCTGGCACCCTCCT

CGGTCACTCTGTTCCCGC

CCAAGAGCACCTCTGGGGG

CCTCGAGTGAGGAGCTT

CACAGCGGCCCTGGGCTGC

CAAGCCAACAAGGCCAC

CTGGTCAAGGACTACTTCC

ACTGGTGTGTCTCATAAG

CCGAACCTGTGACGGTCTC

TGACTTCTACCCGGGAG

GTGGAACTCAGGCGCCCTG

CCGTGACAGTGGCCTGG

ACCAGCGGCGTGCACACCT

AAGGCAGATAGCAGCCC

TCCCGGCTGTCCTACAGTCC

CGTCAAGGCGGGAGTGG

TCANGACTCTACTCCCTCAG

AGACCACCACACCCTCC

CAGCGTGGTGACCGTGCCC

AAACAAAGCAACAACAA

TCCAGCAGCTTGGGCACCC

GTACGCGGCCAGCAGCT

AGACCTACATCTGCAACGT

ACCTGAGCCTGACGCCT

GAATCACAAGCCCAGCAAC

GAGCAGTGGAAGTCCCA

ACCNANGTGGACAAGAGAG

CAGAAGCTACAGCTGCC

TTGAGCCCAAATCTTGTGA

AGGTCACGCATGAAGGG

CAAAACTCACACATGCCCA

AGCACCGNGGNGAAGAC

CCGTGCCCAGCACCTGAAC

AGTGGCCCCTACAGAAT

TCCTGGGGGGACCGTCAGT

GTTCATAGAAGCTTGGN

CTTCCTCTTCCCCCCNAAAC

CGCCATGGCCCAACTTGT

CCNNNGACACCCTCATGAT

TTATTGCAGCTTATAATG

CTCCCGGACCCCTGAGGTC

GTTACAAATAAAGCAAT

ACATGCGTGGNNGNNGACG

AGCATCACAAATTTCAC

TGAGCCACGAANACCCTGA

AAATAANCATTTTTTTCA

NNCAAGTTCAACTGGNACN

CTGCATNTANTGNNGNT

TNNNGGNNNNNNNGNGCAT

NNTCCAAACTCATCNAT

NANGNNANAANAAGCNNN

GNATNTNTCATGTCTGG

NGGGAGGANCANNANNAA

NTCGGGNANTNANTCGN

CAGCNNNNNACCNNNGNN

NNNNAGCANNATNN

NGNCNNNCNNNCCNTCACC

(SEQ ID NO: 3472)

NN (SEQ ID NO: 3470)

V-C020
NNNNNNNNNNATGNNTCNA
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNNNTATGNAT
GACATCCAGATGACCCAGTC
COV107_

CACATACGATTTAGGTGAC
CTGGAGGAGGCTTGATCCA
P2_C8
CNTACACATACGATTTA
TCCATCCTCCCTGTCTGCAT
P2_C8

ACTATAGAATAACATCCAC
GCCTGGGGGGTCCCTGAGA

GGTGACACTATAGAATA
CTGTAGGAGACACAGTCAC

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CATCACTTGCCAGGCGAGTC

TGTCCACTCCCAGGTCCAA
GTTCACCGTCAGTAGCAAC

TCTCCACAGGTGTCCACT
AGGACATTAGCAAGTATTTA

CTGCACCTCGGTTCTATCGA
TACATGACCTGGGTCCGCC

CCCAGGTCCAACTGCAC
AATTGGTATCAGCAGAAAC

TTGAATTCCACCATGGGAT
AGGCTCCAGGGAAGGGGCT

CTCGGTTCTATCGATTGA
CAGGGAAAGCCCCTAAGCT

GGTCATGTATCATCCTTTTT
GGAGTGGGTCTCACTTATTT

ATTCCACCATGGGATGG
CCTGATCTACGATGCATCCA

CTAGTAGCAACTGCAACCG
ATCCCGGTGGTAGCACATA

TCATGTATCATCCTTTTT
ATTTGGAAACAGGGGTCCC

GTGTACATTCTGAGGTGCA
CTACGCAGACTCCGTGAAG

CTAGTAGCAACTGCAAC
ATCAAGGTTCAGTGGAAGT

GCTGGTGGAGTCTGGAGGA
GGCCGATTCACCATCTCCA

CGGTGTACATTGTGCCAT
GGATCTGGGACAGATTTTAC

GGCTTGATCCAGCCTGGGG
GAGACAATTCCAAGAACAC

CCGGATGACCCAGTCTC
TTTCACCATCAGCAGCCTGC

GGTCCCTGAGACTCTCCTGT
GCTGTATCTTCAAATGAAC

CATCCTCCCTGTCTGCAT
AGCCTGAAGATATTGCAAC

GCAGCCTCTGGGTTCACCG
AGCCTGAGAGCCGAGGACA

CTGTAGGAGACACAGTC
ATATTACTGTCAACAGTATG

TCAGTAGCAACTACATGAC
CGGCCGTCTATTACTGTGCG

ACCATCACTTGCCAGGC
ATAATCTCCCTCAGACTTTC

CTGGGTCCGCCAGGCTCCA
AGAGAGGGTATGGGTATGG

GAGTCAGGACATTAGCA
GGCGGAGGGACCAAGGTGG

GGGAAGGGGCTGGAGTGGG
CAGCAGCTGGTACGTGGGG

AGTATTTAAATTGGTATC
AGATCAAAC (SEQ ID

TCTCACTTATTTATCCCGGT
CCAGGGAACCCTGGTCACC

AGCAGAAACCAGGGAAA
NO: 3477)

GGTAGCACATACTACGCAG
GTCTCCTCAG (SEQ ID

GCCCCTAAGCTCCTGATC

ACTCCGTGAAGGGCCGATT
NO: 3475)

TACGATGCATCCAATTTG

CACCATCTCCAGAGACAAT

GAAACAGGGGTCCCATC

TCCAAGAACACGCTGTATC

AAGGTTCAGTGGAAGTG

TTCAAATGAACAGCCTGAG

GATCTGGGACAGATTTT

AGCCGAGGACACGGCCGTC

ACTTTCACCATCAGCAGC

TATTACTGTGCGAGAGAGG

CTGCAGCCTGAAGATAT

GTATGGGTATGGCAGCAGC

TGCAACATATTACTGTCA

TGGTACGTGGGGCCAGGGA

ACAGTATGATAATCTCCC

ACCCTGGTCACCGTCTCCTC

TCAGACTTTCGGCGGAG

AGCGTCGACCAAGGGCCCA

GGACCAAGGTGGAGATC

TCGGTCTTCCCCCTGGCACC

AAACGTACGGTGGCTGC

CTCCTCCAAGAGCACCTCT

ACCATCTGTCTTCATCTT

GGGGGCACAGCGGCCCTGG

CCCGCCATCTGATGAGC

GCTGCCTGGTCAAGGACTA

AGTTGAAATCTGGAACT

CTTCCCCGAACCTGTGACG

GCCTCTGTTGTGTGCCTG

GTCTCGTGGAACTCAGGCG

CTGAATAACTTCTATCCC

CCCTGACCAGCGGCGTGCA

AGAGAGGCCAAAGTACA

CACCTTCCCGGCTGTCCTAC

GTGGAAGGTGGATAACG

AGTCCTCAGGACTCTACTCC

CCCTCCAATCGGGTAACT

CTCAGCAGCGTGGTGACCG

CCCAGGAGAGTGTCACA

TGCCCTCCAGCAGCTTGGG

GAGCAGGACAGCAAGGA

CACCCAGACCTACATCTGC

CAGCACCTACAGCCTCA

AACGTGAATCACAAGCCCA

GCAGCACCCTGACGCTG

GCAACACCAAGGTGGACAA

AGCAAAGCAGACTACGA

GAGAGTTGAGCCCAAATCT

GAAACACAAAGTCTACG

TGTGACAAAACTCACACAT

CCTGCGAAGTCACCCAT

GCCCACCGTGCCNNNNCTG

CAGGGCCTGAGCTCGCC

AACNTCTGNNNNGGNNGGN

CGTCACAAAGAGCTTCA

NNNNNTTCCTNNTTCCTCCN

ACAGGGGAGAGTGTTAG

TNCCCCCNAAGNCNNNGNG

AAGCTTGGCCCGCCATG

AANNCNTNNNNGNNTNNCN

GCCCAACTTGTTTATTGC

CGAANCCNNTNNNNNNNNN

AGCTTATAATGGTTACA

NNNNNGGNNGNNNNACNN

AATAAAGCAATAGCATC

NANCCNNNNANNNNCNNN

ACAAATTTCACAAATAA

NNNNNANNNNNNNNNNNN

AGCATTTTTTTCACTGCA

NGNGGANNGNNNNGNNNG

TTCTAGTTGNNGTTTGTC

TNNNTNNNNCNNNNNNNNC

CAAACTCATCAATGTATC

NNNGNNNNNNNNTNNNNN

TTATCATGTCTGGATCGG

NNNCNNGTNNNNNNGNNA

GNATNNNCGGCGCAGCA

NNNCNNNCNCCGTCNGCNC

NCATGGCCTGAANNNAC

NNACTNNNNN (SEQ

CTNNGAAGANGANNNNG

ID NO: 3474)

NNAGGNACNTNNTGAGN

NNNN (SEQ ID NO:

3476)

V-C021
NNNNNNNNNNNATGNATCA
CAGGTGCAGCTGGTGCAGT
COV107_
NNNNNNNNNNATGTATC
CAGTCTGTGCTGACTCAGCC
COV107_

TACACATACGATTTAGGTG
CTGGGGCTGAGGTGAAGAA
P2_H10
NTACACATACGATTTAG
TGCCTCCGTGTCTGGGTCTC
P2_H10

ACACTATAGAATAACATCC
GCCTGGGGCCTCAGTGAAG

GTGACACTATAGAATAA
CTGGACAGTCGATCACCATC

ACTTTGCCTTTCTCTCCACA
GTCTCCTGCAAGGCTTCTGG

CATCCACTTTGCCTTTCT
TCCTGCACTGGAACCAGCAG

GGTGTCCACTCCCAGGTCC
ATACACCTTCACCGGCTACT

CTCCACAGGTGTCCACTC
TGATGTTGGGAGTTATAACC

AACTGCACCTCGGTTCTATC
ATATGCACTGGGTGCGACA

CCAGGTCCAACTGCACC
TTGTCTCCTGGTACCAACAG

GATTGAATTCCACCATGGG
GGCCCCTGGACAAGGGCTT

TCGGTTCTATCGATTGAA
CACCCAGGCAAAGCCCCCA

ATGGTCATGTATCATCCTTT
GAGTGGATGGGATGGATCA

TTCCACCATGGGATGGTC
AACTCATGATTTATGAGGGC

TTCTAGTAGCAACTGCAAC
GCCCTGTCAGTGGTGGCAC

ATGTATCATCCTTTTTCT
AGTAAGCGGCCCTCAGGGG

CGGTGTACATTCCCAGGTG
AAACTATGCACAGAAGTTT

AGTAGCAACTGCAACCG
TTTCTAATCGCTTCTCTGGCT

CAGCTGGTGCAGTCTGGGG
CAGGGCAGGGTCACCATGA

GTTCCTGGGCCCAGTCTG
CCAAGTCTGGCAACACGGC

CTGAGGTGAAGAAGCCTGG
CCAGGGACACGTCCATCAG

CCCTGACTCAGCCTGCCT
CTCCCTGACAATCTCTGGAC

GGCCTCAGTGAAGGTCTCC
CACAGCCTACATGGAGCTG

CCGTGTCTGGGTCTCCTG
TCCAGGCTGAGGACGAGGC

TGCAAGGCTTCTGGATACA
AGCAGGCTGAGATCTGACG

GACAGTCGATCACCATC
TGATTATTACTGCTGCTCAT

CCTTCACCGGCTACTATATG
ACACGGCCGTGTATTACTG

TCCTGCACTGGAACCAG
ATGCAGGTAGTAGCACTTTG

CACTGGGTGCGACAGGCCC
TGCGAGAGCCCCACTGTTC

CAGTGATGTTGGGAGTT
GTATTCGGCGGAGGGACCA

CTGGACAAGGGCTTGAGTG
CCCACAGGGGTGCTAGCTG

ATAACCTTGTCTCCTGGT
AGCTGACCGTCCTAG (SEQ

GATGGGATGGATCAGCCCT
GGGACTACTACTACTACGG

ACCAACAGCACCCAGGC
ID NO: 3481)

GTCAGTGGTGGCACAAACT
TATGGACGTCTGGGGCCAA

AAAGCCCCCAAACTCAT

ATGCACAGAAGTTTCAGGG
GGGACCACGGTCACCGTCT

GATTTATGAGGGCAGTA

CAGGGTCACCATGACCAGG
CCTCA (SEQ ID NO:

AGCGGCCCTCAGGGGTT

GACACGTCCATCAGCACAG
3479)

TCTAATCGCTTCTCTGGC

CCTACATGGAGCTGAGCAG

TCCAAGTCTGGCAACAC

GCTGAGATCTGACGACACG

GGCCTCCCTGACAATCTC

GCCGTGTATTACTGTGCGA

TGGACTCCAGGCTGAGG

GAGCCCCACTGTTCCCCAC

ACGAGGCTGATTATTACT

AGGGGTGCTAGCTGGGGAC

GCTGCTCATATGCAGGT

TACTACTACTACGGTATGG

AGTAGCACTTTGGTATTC

ACGTCTGGGGCCAAGGGAC

GGCGGAGGGACCAAGCT

CACGGTCACCGTCTCCTCA

GACCGTCCTAGGTCAGC

GCGTCGACCAAGGGCCCAT

CCAAGGCTGCCCCCTCG

CGGTCTTCCCCCTGGCACCC

GTCACTCTGTTCCCACCC

TCCTCCAAGAGCACCTCTG

TCGAGTGAGGAGCTTCA

GGGGCACAGCGGCCCTGGG

AGCCAACAAGGCCACAC

CTGCCTGGTCAAGGACTAC

TGGTGTGTCTCATAAGTG

TTCCCCGAACCTGTGACGG

ACTTCTACCCGGGAGCC

TCTCGTGGAACTCAGGCGC

GTGACAGTGGCCTGGAA

CCTGACCAGCGGCGTGCAC

GGCAGATAGCAGCCCCG

ACCTTCCCGGCTGTCCTACA

TCAAGGCGGGAGTGGAG

GTCCTCAGGACTCTACTCCC

ACCACCACACCCTCCAA

TCAGCAGCGTGGTGACCGT

ACAAAGCAACAACAAGT

GCCCTCCAGCAGCTTGGGC

ACGCGGCCAGCAGCTAC

ACCCAGACCTACATCTGCA

CTGAGCCTGACGCCTGA

ACGTGAATCACAAGCCCAG

GCAGTGGAAGTCCCACA

CAACACCAAGGTGGACAAG

GAAGCTACAGCTGCCAG

AGAGTTGAGCCCAAATCTT

GTCACGCATGAAGGGAG

GTGACAAAACTCACACATG

CACCGTGGAGAAGACAG

CCCACCGTGCCCAGCACCT

TGGCCCCTACAGAATGTT

GAACTCCTGGGGGGACCGT

CATAGAAGCTTGGCCGC

CAGTCTTCCTCTTCCCCCCA

CATGGCCCAACTTGTTTA

AAACCCAAGGACACCCTCA

TTGCAGCTTATAATGGTT

TGATCTCCCGGACCCCTGA

ACAAATAAAGCAATAGC

NNCACATGCGTGGNGGNNG

ATCACAAATTTCACAAA

ACGTGAGCCACGAANACCC

TAAAGCATTTTTTTCACT

TGAGGTCAAGTTCAACTGG

GCATTCTANTTGTGGTTT

NACGNNGNNGGCNNGN

GTCCAAACTCATCAATGT

(SEQ ID NO: 3478)

ATCTTATCATGTCTGGNT

CGGGAATTAATTCGNCG

CAGCACCATGNNNTGAA

ATANCTCTGAAAGAGNA

NTTGGNNNNNACCTTCT

GAGCNGAAAGAACCATC

TGNNGGAANNNGNNNN

(SEQ ID NO: 3480)

V-C022
NNNNNNNNNNNANNNNTC
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNNNNTGNNNN
GACATCCAGTTGACCCAGTC
COV107_

NTACACATACGATTTAGGT
CTGGAGGAGGCTTGATCCA
P1_B3
NTACACATACGATTTAG
TCCATCCTTCCTGTCTGCAT
P1_B3

GACACTATAGAATAACATC
GCCTGGGGGGTCCCTGAGA

GTGACACTATAGAATAA
CTGTAGGAGACAGAGTCAC

CACTTTGCCTTTCTCTCCAC
CTCTCCTGTGCAGCCTCTGG

CATCCACTTTGCCTTTCT
CATCACTTGCCGGGCCAGTC

AGGTGTCCACTCCCAGGTC
GCTCACCGTCAGTAGCAAC

CTCCACAGGTGTCCACTC
AGGGCATTAGCAGTTATTTA

CAACTGCACCTCGGTTCTAT
TACATGAGCTGGGTCCGCC

CCAGGTCCAACTGCACC
GCCTGGTATCAGCAAAAAC

CGATTGAATTCCACCATGG
AGGCTCCAGGGAAGGGGCT

TCGGTTCTATCGATTGAA
CAGGGAAAGCCCCTAAGCT

GATGGTCATGTATCATCCTT
GGAGTGGGTCTCAGTTCTTT

TTCCACCATGGGATGGTC
CCTGATCTATGCTGCATCCA

TTTCTAGTAGCAACTGCAA
ATAGCGGTGGTAGCTCATT

ATGTATCATCCTTTTTCT
CTTTGCAAAGTGGGGTCCCA

CCGGTGTACATTCTGAGGT
CTACGCAGACTCCGTGAAG

AGTAGCAACTGCAACCG
TCAAGGTTCAGCGGCAGTG

GCAGCTGGTGGAGTCTGGA
GGCCGATTCACCATCTCCA

GTGTACATTCAGACATCC
GATCTGGGACAGAATTCACT

GGAGGCTTGATCCAGCCTG
GAGACAATTCCAAGAACAC

AGTTGACCCAGTCTCCAT
CTCACAATCAGCAGCCTGCA

GGGGGTCCCTGAGACTCTC
GCTGTATCTTCAAATGAAC

CCTTCCTGTCTGCATCTG
GCCTGAAGATTTTGCAACTT

CTGTGCAGCCTCTGGGCTC
AGCCTGAGAGCCGAAGACA

TAGGAGACAGAGTCACC
ATTACTGTCAACAGCTTAAT

ACCGTCAGTAGCAACTACA
CGGCCGTGTATTACTGTGC

ATCACTTGCCGGGCCAG
AGTGACTCGTACACTTTTGG

TGAGCTGGGTCCGCCAGGC
GAGAGAAAGTGGGGATACA

TCAGGGCATTAGCAGTT
CCAGGGGACCAAGCTGGAG

TCCAGGGAAGGGGCTGGAG
ACTATGGCCTTTGACTACTG

ATTTAGCCTGGTATCAGC
ATCAAAC (SEQ ID

TGGGTCTCAGTTCTTTATAG
GGGCCAGGGAACCCTGGTC

AAAAACCAGGGAAAGCC
NO: 3485)

CGGTGGTAGCTCATTCTAC
ACCGTCTCCTCAG (SEQ

CCTAAGCTCCTGATCTAT

GCAGACTCCGTGAAGGGCC
ID NO: 3483)

GCTGCATCCACTTTGCAA

GATTCACCATCTCCAGAGA

AGTGGGGTCCCATCAAG

CAATTCCAAGAACACGCTG

GTTCAGCGGCAGTGGAT

TATCTTCAAATGAACAGCC

CTGGGACAGAATTCACT

TGAGAGCCGAAGACACGGC

CTCACAATCAGCAGCCT

CGTGTATTACTGTGCGAGA

GCAGCCTGAAGATTTTG

GAAAGTGGGGATACAACTA

CAACTTATTACTGTCAAC

TGGCCTTTGACTACTGGGG

AGCTTAATAGTGACTCGT

CCAGGGAACCCTGGTCACC

ACACTTTTGGCCAGGGG

GTCTCCTCAGCGTCGACCA

ACCAAGCTGGAGATCAA

AGGGCCCATCGGTCTTCCC

ACGTACGGTGGCTGCAC

CCTGGCACCCTCCTCCAAG

CATCTGTCTTCATCTTCC

AGCACCTCTGGGGGCACAG

CGCCATCTGATGAGCAG

CGGCCCTGGGCTGCCTGGT

TTGAAATCTGGAACTGC

CAAGGACTACTTCCCCGAA

CTCTGTTGTGTGCCTGCT

CCTGTGACGGTCTCGTGGA

GAATAACTTCTATCCCAG

ACTCAGGCGCCCTGACCAG

AGAGGCCAAAGTACAGT

CGGCGTGCACACCTTCCCG

GGAAGGTGGATAACGCC

GCTGTCCTACAGTCCTCAN

CTCCAATCGGGTAACTCC

GACTCTACTCCCTCAGCAG

CAGGAGAGTGTCACAGA

CGTGGTGACCGTGCCCTCC

GCAGGACAGCAAGGACA

AGCAGCTTGGGCACCCAGA

GCACCTACAGCCTCAGC

CCTACATCTGCAACGTGAA

AGCACCCTGACGCTGAG

TCACAAGCCCAGCAACACC

CAAAGCAGACTACGAGA

AAGGTGGACAAGANAGTTG

AACACAAAGTCTACGCC

AGCCCAAATCTTGTGACAA

TGCGAAGTCACCCATCA

AACTCACACATGCCCACCG

GGGCCTGAGCTCGCCCG

TGCCCAGCACCTGAACTCC

TCACAAAGAGCTTCAAC

TGGGGGGACCGTCAGTCTT

ANGGGGANANTGTNANA

CCNCNTCCCCCCAAAACCC

ANCTNGGCCGCNNNNNG

AAGGACACCCTCATGATCT

NCCACNTTGTNTNTNGN

CCNGGACCCCNGAGGTCAC

GNCNNNTNNTANNNTGN

ATGCGNNGGTGGNTGGNNG

NNACAAATANAACANAT

NGAGCCACGANNANCCTGA

CATCANNNNNTTTNNNA

GGTCAAGTTCAACTGGNAC

ANANNNNTTTTTTNNNN

GTGGACGGNNGNNGNNNN

CAGNCNAGNNGNNGTTG

NCATAATGCCAAGACCAAA

GTNNNNNTNNTCATNNN

GCNN (SEQ ID NO:

NNNANNNNTGNCTGNAT

3482)

GGATNANNNNNNNCNNN

NNNNNNNNNNNNNNNN

AACTANNNTNNNNANNA

NNTANNTNNNTANNTNC

NNNNNNANGANGAANN

N (SEQ ID NO:

3484)

V-C023
NNNNNNNNNNNTANNNNN
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNCNNNTGNATC
GACATCCAGTTGACCCAGTC
COV107_

TCNTACNNATACGATTTAG
CTGGAGGAGGCTTGATCCA
P1_B6
NTACACATACGATTTAG
TCCATCCTTCCTGTCTGCAT
P1_B6

GTGACACTATAGAATAACA
GCCTGGGGGGTCCCTGAGA

GTGACACTATAGAATAA
CTGTAGGAGACAGAGTCAC

TCCACTTTGCCTTTCTCTCC
CTCTCCTGTGCAGCCTCTGG

CATCCACTTTGCCTTTCT
CATCACTTGCCGGGCCAGTC

ACAGGTGTCCACTCCCAGG
GGTCACCGTCAGTAGGAAC

CTCCACAGGTGTCCACTC
AGGGCATTAGCAGTTATTTA

TCCAACTGCACCTCGGTTCT
TACATGAGCTGGGTCCGCC

CCAGGTCCAACTGCACC
GCCTGGTATCAGCAAAAAC

ATCGATTGAATTCCACCAT
AGGCTCCAGGGAAGGGGCT

TCGGTTCTATCGATTGAA
CAGGGAAAGCCCCTAAGCT

GGGATGGTCATGTATCATC
GGAGTGGGTCTCAGTTATTT

TTCCACCATGGGATGGTC
CCTGATCTATGCTGCATCCA

CTTTTTCTAGTAGCAACTGC
ATAGCGGTGGTAGCACATA

ATGTATCATCCTTTTTCT
CTTTGCAAAGTGGGGTCCCA

AACCGGTGTACATTCTGAG
CTACGCAGACTCCGTGAAG

AGTAGCAACTGCAACCG
TCAAGGTTCAGCGGCAGTG

GTGCAGCTGGTGGAGTCTG
GGCCGATTCACCATCTCCA

GTGTACATTCAGACATCC
GATCTGGGACAGAATTCACT

GAGGAGGCTTGATCCAGCC
GAGACAATTCCAAGAACAC

AGTTGACCCAGTCTCCAT
CTCACAATCAGCAGCCTGCA

TGGGGGGTCCCTGAGACTC
GCTGTATCTTCAAATGAAC

CCTTCCTGTCTGCATCTG
GCCTGAAGATTTTGCAACTT

TCCTGTGCAGCCTCTGGGGT
AGCCTGAGAGCCGAGGACA

TAGGAGACAGAGTCACC
ATTACTGTCAACAGCTTAAT

CACCGTCAGTAGGAACTAC
CGGCCGTGTATTACTGTGC

ATCACTTGCCGGGCCAG
AGTTACCCTCCAGCCTTCGG

ATGAGCTGGGTCCGCCAGG
GAGAGATCTATCTGCTGCTT

TCAGGGCATTAGCAGTT
CCAAGGGACACGACTGGAG

CTCCAGGGAAGGGGCTGGA
TTGATATCTGGGGCCAAGG

ATTTAGCCTGGTATCAGC
ATTAAAC (SEQ ID

GTGGGTCTCAGTTATTTATA
GACAATGGTCACCGTCTCTT

AAAAAccAGGGAAAGcc
NO: 3489)

GCGGTGGTAGCACATACTA
CAG (SEQ ID NO:

CCTAAGCTCCTGATCTAT

CGCAGACTCCGTGAAGGGC
3487)

GCTGCATCCACTTTGCAA

CGATTCACCATCTCCAGAG

AGTGGGGTCCCATCAAG

ACAATTCCAAGAACACGCT

GTTCAGCGGCAGTGGAT

GTATCTTCAAATGAACAGC

CTGGGACAGAATTCACT

CTGAGAGCCGAGGACACGG

CTCACAATCAGCAGCCT

CCGTGTATTACTGTGCGAG

GCAGCCTGAAGATTTTG

AGATCTATCTGCTGCTTTTG

CAACTTATTACTGTCAAC

ATATCTGGGGCCAAGGGAC

AGCTTAATAGTTACCCTC

AATGGTCACCGTCTCTTCAG

CAGCCTTCGGCCAAGGG

CGTCGACCAAGGGCCCATC

ACACGACTGGAGATTAA

GGTCTTCCCCCTGGCACCCT

ACGTACGGTGGCTGCAC

CCTCCAAGAGCACCTCTGG

CATCTGTCTTCATCTTCC

GGGCACAGCGGCCCTGGGC

CGCCATCTGATGAGCAG

TGCCTGGTCAAGGACTACT

TTGAAATCTGGAACTGC

TCCCCGAACCTGTGACGGT

CTCTGTTGTGTGCCTGCT

CTCGTGGAACTCAGGCGCC

GAATAACTTCTATCCCAG

CTGACCAGCGGCGTGCACA

AGAGGCCAAAGTACAGT

CCTTCCCGGCTGTCCTACAG

GGAAGGTGGATAACGCC

TCCTCAGGACTCTACTCCCT

CTCCAATCGGGTAACTCC

CAGCAGCGTGGTGACCGTG

CAGGAGAGTGTCACAGA

CCCTCCAGCAGCTTGGGCA

GCAGGACAGCAAGGACA

CCCAGACCTACATCTGCAA

GCACCTACAGCCTCAGC

CGTGAATCACAAGCCCAGC

AGCACCCTGACGCTGAG

AACACCAANGTGGACAAGA

CAAAGCAGACTACGAGA

GAGTTGAGCCCAAATCTTG

AACACAAAGTCTACGCC

TGACAAAACTCACACATGC

TGCGAAGTCACCCATCA

CCNCCGTGCCCAGCACCTG

GGGCCTGAGCTCGCCCG

NACTCCTGGGGGNNNNTCA

TCACAAAGAGCTTCAAC

GTCTTNNNCTNNNCCCCAA

AGGGGAGAGTGTTAGAA

AANCCNNNGNNNNCCNCNN

GCTTGGNCCGCCATGGC

NNNNTCCNCNANNCCNNNN

CCAACTTGTTTATTGCAG

GNCCCANNNGNGNNNNNN

CTTATAATGGTTACAAAT

NNNNNNGNCCNNGAACCN

AAAGCAATAGCATCACA

NCNNNNNNNNNNNNNNNN

AATTTCACAAATAAAGC

GTTNNNNGGNNCNTGGANN

ATTTTTTTCACTGCATTC

GNNNNNNANGNNNNNNAT

TANTTGNNGTTTGTCCAA

GNCNNANNAGNCNNNGNA

NCTCATCAATGTATNTNN

NNNCANTACANNNGNNCGT

CATGTCTGGNTCGGGAA

ACNNNNNGNCAGCGTCNTC

TTNNNNNNGCAGCNCNT

NCGTCNTGCACNNNACTGG

NNNTGAANNACNNTGAA

NNNANNGNNN (SEQ ID

NAGNNTTGNNNNGTACC

NO: 3486)

TTCTGAGNGAANNNNTC

TNNNGANN (SEQ ID

NO: 3488)

V-C024
NNNNNNNNTATGTATNNTA
GAGGTGCAGCTGGTGGAGT
COV107_
NNNNNNNNNNNTGNNTC
GAAATTGTGTTGACACAGTC
COV107_

CACATACGATTTAGGTGAC
CTGGGGGAGGCTTGGTACA
P1_A2
NTACACATACGATTTAG
TCCAGCCACCCTGTCTTTGT
P1_A2

ACTATAGAATAACATCCAC
GCCTGGGGGGTCCCTGAGA

GTGACACTATAGAATAA
CTCCAGGGGAAAGAGCCAC

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

CATCCACTTTGCCTTTCT
CCTCTCCTGCAGGGCCAGTC

TGTCCACTCCCAGGTCCAA
ATTCACCTTCAGTGGCTATA

CTCCACAGGTGTCCACTC
AGAGTTTTAGCAGCTACTTA

CTGCACCTCGGTTCTATCGA
GCATGAACTGGGTCCGCCA

CCAGGTCCAACTGCACC
GCCTGGTACCAACAGAAAC

TTGAATTCCACCATGGGAT
GGCTCCAGGGAAGGGGCCG

TCGGTTCTATCGATTGAA
CTGGCCAGGCTCCCAGGCTC

GGTCATGTATCATCCTTTTT
GAGTGGGTTTCATACATTA

TTCCACCATGGGATGGTC
CTCATCTATGATGCATCCAA

CTAGTAGCAACTGCAACCG
GTAGGAGTAGTAGTACCAT

ATGTATCATCCTTTTTCT
CAGGGCCACTGGCATCCCA

GTGTACATTCTGAGGTGCA
ATACTACGCAGACTCTGTG

AGTAGCAACTGCAACCG
GCCAGGTTCAGTGGCAGTG

GCTGGTGGAGTCTGGGGGA
AAGGGCCGATTCACCATCT

GTGTACATTCAGAAATT
GGTCTGGGACAGACTTCACT

GGCTTGGTACAGCCTGGGG
CCAGAGACAATGCCAAGAA

GTGTTGACACAGTCTCCA
CTCACCATCAGCAGCCTAGA

GGTCCCTGAGACTCTCCTGT
CTCACTGTATCTGCAAATG

GCCACCCTGTCTTTGTCT
GCCTGAAGATTTTGCAGTTT

GCAGCCTCTGGATTCACCTT
AACAGCCTGAGAGACGAGG

CCAGGGGAAAGAGCCAC
ATTACTGTCAGCAGCGTAAC

CAGTGGCTATAGCATGAAC
ACACGGCTGTGTATTACTGT

CCTCTCCTGCAGGGCCA
AACTGGCCTCCCGAGTGGAC

TGGGTCCGCCAGGCTCCAG
GCGAGAGAAGGGGCTAGA

GTCAGAGTTTTAGCAGCT
GTTCGGCCAAGGGACCAAG

GGAAGGGGCCGGAGTGGGT
GTGGGAGCTACATATGACA

ACTTAGCCTGGTACCAA
GTGGAAATCAAAC (SEQ

TTCATACATTAGTAGGAGT
CGTACTACTTTGACTACTGG

CAGAAACCTGGCCAGGC
ID NO: 3493)

AGTAGTACCATATACTACG
GGCCAGGGAACCCTGGTCA

TCCCAGGCTCCTCATCTA

CAGACTCTGTGAAGGGCCG
CCGTCTCCTCAG (SEQ

TGATGCATCCAACAGGG

ATTCACCATCTCCAGAGAC
ID NO: 3491)

CCACTGGCATCCCAGCC

AATGCCAAGAACTCACTGT

AGGTTCAGTGGCAGTGG

ATCTGCAAATGAACAGCCT

GTCTGGGACAGACTTCA

GAGAGACGAGGACACGGCT

CTCTCACCATCAGCAGCC

GTGTATTACTGTGCGAGAG

TAGAGCCTGAAGATTTT

AAGGGGCTAGAGTGGGAGC

GCAGTTTATTACTGTCAG

TACATATGACACGTACTAC

CAGCGTAACAACTGGCC

TTTGACTACTGGGGCCAGG

TCCCGAGTGGACGTTCG

GAACCCTGGTCACCGTCTC

GCCAAGGGACCAAGGTG

CTCAGCGTCGACCAAGGGC

GAAATCAAACGTACGGT

CCATCGGTCTTCCCCCTGGC

GGCTGCACCATCTGTCTT

ACCCTCCTCCAAGAGCACC

CATCTTCCCGCCATCTGA

TCTGGGGGCACAGCGGCCC

TGAGCAGTTGAAATCTG

TGGGCTGCCTGGTCAAGGA

GAACTGCCTCTGTTGTGT

CTACTTCCCCGAACCTGTGA

GCCTGCTGAATAACTTCT

CGGTCTCGTGGAACTCAGG

ATCCCAGAGAGGCCAAA

CGCCCTGACCAGCGGCGTG

GTACAGTGGAAGGTGGA

CACACCTTCCCGGCTGTCCT

TAACGCCCTCCAATCGG

ACAGTCCTCAGGACTCTAC

GTAACTCCCAGGAGAGT

TCCCTCAGCAGCGTGGTGA

GTCACAGAGCAGGACAG

CCGTGCCCTCCAGCAGCTT

CAAGGACAGCACCTACA

GGGCACCCAGACCTACATC

GCCTCAGCAGCACCCTG

TGCAACGTGAATCACAAGC

ACGCTGAGCAAAGCAGA

CCAGCAACACCAAGGTGGA

CTACGAGAAACACAAAG

CAAGAGAGTTGAGCCCAAA

TCTACGCCTGCGAAGTC

TCTTGTGACAAAACTCACA

ACCCATCAGGGCCTGAG

CATGCCCACCGTGCCCAGC

CTCGCCCGTCACAAAGA

ACCTGAACTCCTGGGGGGA

GCTTCAACAGGGGAGAG

CCGTCAGTCTTCCTCTTCCC

TGTTAGAAGCTTGGCCG

CCCAAAACCCAAGGACACC

CCATGGCCCAACTTGTTT

CTCATGATCTCCCGGACCCC

ATTGCAGCTTATAATGGT

TGNNNCACATGCGTGGTGG

TACAAATAAAGCAATAG

TGGNCGTGAGCCACGANAC

CATCACAAATTTCACAA

CCTGNNNCAAGTTCAACTG

ATAAAGCATTTTTTTCAC

GTACGNNGNCGGGCGNNGA

TGCATTCTAGTTGTGGTT

GGTGCATNATGCCAANANA

TGTCCAAACTCATCAATG

AGCCGCGGGNAGGAGCAGT

TATCTTATCATGTCTGGA

ANAACAGCNCGTACCGNNN

TCGGGAANTAATTNNNG

NNGNNAGNNN (SEQ ID

CANCANCATGGNNTGAA

NO: 3490)

ATAACCTCTGAAANANA

ACTTGGNNNGGTACCTN

CTGNANGCGGAAANAAN

CATCNNNN (SEQ ID

NO: 3492)

V-C025
NNNNNNNNNNATGTATCAT
CAAATGCAGCTGGTGCAGT
COV107_
NNNNNNNNCNNTANGTA
GAAATTGTGTTGACGCAGTC
COV107_

ACACATACGATTTAGGTGA
CTGGGCCTGAGGTGAAGAA
P2_G9
TCATACACATACGATTTA
TCCAGGCACCCTGTCTTTGT
P2_G9

CACTATAGAATAACATCCA
GCCTGGGACCTCAGTGAAG

GGTGACACTATAGAATA
CTCCAGGGGAAAGAGCCAC

CTTTGCCTTTCTCTCCACAG
GTCTCCTGCAAGGCTTCTGG

ACATCCACTTTGCCTTTC
CCTCTCCTGCAGGGCCAGTC

GTGTCCACTCCCAGGTCCA
ATTCACCTTTACTAGCTCTG

TCTCCACAGGTGTCCACT
AGAGTGTTAGCAGCAGCTA

ACTGCACCTCGGTTCTATCG
CTGTGCAGTGGGTGCGACA

CCCAGGTCCAACTGCAC
CTTAGCCTGGTACCAGCAGA

ATTGAATTCCACCATGGGA
GGCTCGTGGACAACGCCTT

CTCGGTTCTATCGATTGA
AACCTGGCCAGGCTCCCAG

TGGTCATGTATCATCCTTTT
GAGTGGATAGGATGGATCG

ATTCCACCATGGGATGG
GCTCCTCATCTATGGTGCAT

TCTAGTAGCAACTGCAACC
TCGTTGGCAGTGGTAACAC

TCATGTATCATCCTTTTT
CCAGCAGGGCCACTGGCAT

GGTGTACATTCCCAGGTGC
AAACTACGCACAGAAGTTC

CTAGTAGCAACTGCAAC
CCCAGACAGGTTCAGTGGC

AGCTGGTGCAGTCTGGGCC
CAGGAAAGAGTCACCATTA

CGGTGTACATTCAGAAA
AGTGGGTCTGGGACAGACTT

TGAGGTGAAGAAGCCTGGG
CCAGGGACATGTCCACAAG

TTGTGTTGACGCAGTCTC
CACTCTCACCATCAGCAGAC

ACCTCAGTGAAGGTCTCCT
CACAGCCTACATGGAGCTG

CAGGCACCCTGTCTTTGT
TGGAGCCTGAAGATTTTGCA

GCAAGGCTTCTGGATTCAC
AGCAGCCTGAGATCCGAGG

CTCCAGGGGAAAGAGCC
GTGTATTACTGTCAGCAGTA

CTTTACTAGCTCTGCTGTGC
ACACGGCCGTGTATTACTG

ACCCTCTCCTGCAGGGCC
TGGTAGCTCACCGTGGACGT

AGTGGGTGCGACAGGCTCG
TGCGGCACCTTATTGTAGTG

AGTCAGAGTGTTAGCAG
TCGGCCAAGGGACCAAGGT

TGGACAACGCCTTGAGTGG
GTGGTAGCTGCTCTGATGCT

CAGCTACTTAGCCTGGTA
GGAAATCAAAC (SEQ ID

ATAGGATGGATCGTCGTTG
TTTGATATCTGGGGCCAAG

CCAGCAGAAACCTGGCC
NO: 3497)

GCAGTGGTAACACAAACTA
GGACAATGGTCACCGTCTC

AGGCTCCCAGGCTCCTC

CGCACAGAAGTTCCAGGAA
TTCAG (SEQ ID NO:

ATCTATGGTGCATCCAGC

AGAGTCACCATTACCAGGG
3495)

AGGGCCACTGGCATCCC

ACATGTCCACAAGCACAGC

AGACAGGTTCAGTGGCA

CTACATGGAGCTGAGCAGC

GTGGGTCTGGGACAGAC

CTGAGATCCGAGGACACGG

TTCACTCTCACCATCAGC

CCGTGTATTACTGTGCGGC

AGACTGGAGCCTGAAGA

ACCTTATTGTAGTGGTGGTA

TTTTGCAGTGTATTACTG

GCTGCTCTGATGCTTTTGAT

TCAGCAGTATGGTAGCT

ATCTGGGGCCAAGGGACAA

CACCGTGGACGTTCGGC

TGGTCACCGTCTCTTCAGCG

CAAGGGACCAAGGTGGA

TCGACCAAGGGCCCATCGG

AATCAAACGTACGGTGG

TCTTCCCCCTGGCACCCTCC

CTGCACCATCTGTCTTCA

TCCAAGAGCACCTCTGGGG

TCTTCCCGCCATCTGATG

GCACAGCGGCCCTGGGCTG

AGCAGTTGAAATCTGGA

CCTGGTCAAGGACTACTTC

ACTGCCTCTGTTGTGTGC

CCCGAACCTGTGACGGTCT

CTGCTGAATAACTTCTAT

CGTGGAACTCAGGCGCCCT

CCCAGAGAGGCCAAAGT

GACCAGCGGCGTGCACACC

ACAGTGGAAGGTGGATA

TTCCCGGCTGTCCTACAGTC

ACGCCCTCCAATCGGGT

CTCAGGACTCTACTCCCTCA

AACTCCCAGGAGAGTGT

GCAGCGTGGTGACCGTGCC

CACAGAGCAGGACAGCA

CTCCAGCAGCTTGGGCACC

AGGACAGCACCTACAGC

CAGACCTACATCTGCAACG

CTCAGCAGCACCCTGAC

TGAATCACAAGCCCAGCAA

GCTGAGCAAAGCAGACT

CACCNNGTGGACAAGAGAG

ACGAGAAACACAAAGTC

TTGAGNCCAAATCNTGTGN

TACGCCTGCGAAGTCAC

NNAACTNANACNTNNNCNN

CCATCAGGGCCTGAGCT

NCCNNCNNGNCCAGNACCN

CGCCCGTCACAAAGAGC

NNNNNNNCGGGGGGGNNN

TTCAACAGGGGAGAGTG

NNNNCATTTNNNNNNNNNN

TTAGAAGCTTGGCCGCC

NNAAACCCAGGGACNCCCT

ATGGCCCAACTTGTTTAT

CANTGATCTCCNNNNNCCC

TGCAGCTTATAATGGTTA

NNGANGTCACNTGNNGTGG

CAAATAAAGCAATAGCA

TGGTGNNCGTGANCCANNA

TCACAAATTTCACNATA

NANNNGNNNCANTNAACTN

AAGCATTTTTTTCACTGC

NNCGTGNNGNNNTNNNNTG

ATTCTANTTGTGGTTTGT

CATANGCANANNNCNCGGG

CCANCTCATCAATGTATC

ANGNNCANTANACAGCNCG

TNATCATGTCTGGATCGG

TACGNGNNGNCANNNTCNT

GANTNANTNNNGCAGCA

CNNNGNCNN (SEQ ID

NCATGGNNTGAAATACN

NO: 3494)

TCTGAANNAGGANTTGG

NTANGTACCTNNNGAGN

GAANNNANCATNNNNNG

N (SEQ ID NO: 3496)

V-C026
NNNNNNNNNNNCNNNNTGT
CAGGTGCAGCTGCAGGAGT
COV107_
NNNNNNNNNNNNTGTAT
AATTTTATGCTGACTCAGCC
COV107_

ATCNTACACATACGATTTA
CGGGCCCAGGACTGGTGAA
P2_C4
CNTACACATACGATTTA
CCACTCTGTGTCGGAGTCTC
P2_C4

GGTGACACTATAGAATAAC
GCCTTCGGAGACCCTGTCC

GGTGACACTATAGAATA
CGGGGAAGACGGTAACCAT

ATCCACTTTGCCTTTCTCTC
CTCTCCTGCGCTGTCTCTGG

ACATCCACTTTGCCTTTC
CTCCTGCACCGGCAGCAGTG

CACNNNNNNCCACTCCCAG
TGGCTCCATCGGTAGTTACT

TCTCCACAGGTGTCCACT
GCAGCATTGCCAGCAACTAT

GTCCAACTGCACCTCGGTTC
TCTGGAGCTGGATCCGGCA

CCCAGGTCCAACTGCAC
GTGCAGTGGTACCAGCAGC

TATCGATTGAATTCCACCAT
GCCCCCAGGGAAGGGACTG

CTCGGTTCTATCGATTGA
GCCCGGGCAGTGCCCCCACC

GGGATGGTCATGTATCATC
GAGTGGATTGGATATCTCC

ATTCCACCATGGGATGG
ACTGTGATCAATGAAGATA

CTTTTTCTAGTAGCAACTGC
ATTACAGTGGGAGCACCAA

TCATGTATCATCCTTTTT
ACCAAAGACCCTCTGGGGTC

AACCGGTGTACATTCCCAG
CTACAACCCCTCCCTGAAG

CTAGTAGCAACTGCAAC
CCTGATCGGTTCTCTGGCTC

GTGCAGCTGCAGGAGTCGG
AGTCGAGTCACCATATCAG

CGGTTCTTGGGCCAATTT
CATCGACAGCTCCTCCAACT

GCCCAGGACTGGTGAAGCC
TAGACACGTCCAAGAATCA

TATGCTGACTCAGCCCCA
CTGCCTCCCTCACCATCTCT

TTCGGAGACCCTGTCCCTCT
GTTCTCCCTGAAGCTGAGCT

CTCTGTGTCGGAGTCTCC
GGACTGAAGACTGAGGACG

CCTGCGCTGTCTCTGGTGGC
CTGTGACCGCTGCGGACAC

GGGGAAGACGGTAACCA
AGGCTGACTACTACTGTCAG

TCCATCGGTAGTTACTTCTG
GGCCGTGTATTACTGTGCG

TCTCCTGCACCGGCAGC
TCTTATGATAGCAGCAATTT

GAGCTGGATCCGGCAGCCC
AGATTGCAGTGGCTACGCG

AGTGGCAGCATTGCCAG
GGTATTCGGCGGAGGGACC

CCAGGGAAGGGACTGGAGT
GAGCTTTTGATATCTGGGG

CAACTATGTGCAGTGGT
AAGCTGACCGTCCTAG

GGATTGGATATCTCCATTAC
CCAAGGGACAATGGTCACC

ACCAGCAGCGCCCGGGC
(SEQ ID NO: 3501)

AGTGGGAGCACCAACTACA
GTCTCTTCAG (SEQ ID

AGTGCCCCCACCACTGT

ACCCCTCCCTGAAGAGTCG
NO: 3499)

GATCAATGAAGATAACC

AGTCACCATATCAGTAGAC

AAAGACCCTCTGGGGTC

ACGTCCAAGAATCAGTTCT

CCTGATCGGTTCTCTGGC

CCCTGAAGCTGAGCTCTGT

TCCATCGACAGCTCCTCC

GACCGCTGCGGACACGGCC

AACTCTGCCTCCCTCACC

GTGTATTACTGTGCGAGATT

ATCTCTGGACTGAAGAC

GCAGTGGCTACGCGGAGCT

TGAGGACGAGGCTGACT

TTTGATATCTGGGGCCAAG

ACTACTGTCAGTCTTATG

GGACAATGGTCACCGTCTC

ATAGCAGCAATTTGGTA

TTCAGCGTCGACCAAGGGC

TTCGGCGGAGGGACCAA

CCATCGGTCTTCCCCCTGGC

GCTGACCGTCCTAGGTC

ACCCTCCTCCAAGAGCACC

AGCCCAAGGCTGCCCCC

TCTGGGGGCACAGCGGCCC

TCGGTCACTCTGTTCCCG

TGGGCTGCCTGGTCAAGGA

CCCTCGAGTGAGGAGCT

CTACTTCCCCGAACCTGTGA

TCAAGCCAACAAGGCCA

CGGTCTCGTGGAACTCAGG

CACTGGTGTGTCTCATAA

CGCCCTGACCAGCGGCGTG

GTGACTTCTACCCGGGA

CACACCTTCCCGGCTGTCCT

GCCGTGACAGTGGCCTG

ACAGTCCTCNNACTCTACTC

GAAGGCAGATAGCAGCC

CCTCAGCAGCGTGGTGACC

CCGTCAAGGCGGGAGTG

GTGCCCTCCAGCAGCTTGG

GAGACCACCACACCCTC

GCACCCAGACCTACATCTG

CAAACAAAGCAACAACA

CAACGTGAATCACAAGCCC

AGTACGCGGCCAGCAGC

AGCAACACCAAGGTGGANN

TACCTGAGCCTGACGCCT

GAGAGTTGAGCCCAAATCT

GAGCAGTGGAAGTCCCA

TGTGACAAAACTCACACAT

CAGAAGCTACAGCTGCC

GCCCACCGNGCCCAGCACC

AGGTCACGCATGNANGG

TGACTCCTGGGGGGACCGT

GAGCACCGTGGAGAAGA

CAGTCTTCCTCTTCCCCCAA

CAGTGGCCCCTACAGAA

AACNCNNGGANNNCCCNNA

TGTTCATAGAAGCTTGGC

TGATCTCCCNNANCCCTGA

CGCCATGGCCCAACTTGT

GNCACATGNNNNNGGTGGG

TTATTGCAGCTTATAATG

NGNNGTGAGCCACNANACC

GTTACAAATAAAGCAAT

CNNGAGNTNAGTTCNANTT

AGCATCACAAATTTCAC

GGNNCGNNGNANGGCGNG

AAATAAGCATTTTTTTCA

NAGGNNNNNTAATGNCANN

CTGCATTCTAGTTGNNGG

NNNNAAGNNNN (SEQ ID

NTTGTCCAAACTCATCAA

NO: 3498)

TGNNTCTNATCATGTCTG

GATCGGGAATTNNNCGN

NNAGCACCATNNNTNAA

ANNACNTCTGAANAGNN

NTGGTNAGGTACCTTCTN

NNNNAAANAANCATCTN

NNGNAANGN (SEQ ID

NO: 3500)

V-C027
NNNNNNNNNNNTATGNATN
CAGGTGCAGCTGGTGCAGT
COV107_
NNNNNNNNNNNNNNNTC
CAGTCTGTGCTGACTCAGCC
COV107_

ATACACATACGATTTAGGT
CTGGGGCTGAGGTGAAGAA
P1_C3
ATACACATACGATTTAG
ACCCTCAGCGTCTGGGACCC
P1_C3

GACACTATAGAATAACATC
GCCTGGGGCCTCAGTGAAG

GTGACACTATAGAATAA
CCGGGCAGAGGGTCACCAT

CACTTTGCCTTTCTCTCCAC
GTCTCCTGCAAGGCTTCTGG

CATCCACTTTGCCTTTCT
CTCTTGTTCTGGAAGCAGCT

AGGTGTCCACTCCCAGGTC
ATACACCTTCACCGGCTACT

CTCCACAGGTGTCCACTC
CCAACATCGGAAGTAATACT

CAACTGCACCTCGGTTCTAT
ATATGCACTGGGTGCGACA

CCAGGTCCAACTGCACC
GTAAACTGGTACCAGCAGCT

CGATTGAATTCCACCATGG
GGCCCCTGGACAAGGGCTT

TCGGTTCTATCGATTGAA
CCCAGGAACGGCCCCCAAA

GATGGTCATGTATCATCCTT
GAGTGGATGGGATGGATCA

TTCCACCATGGGATGGTC
CTCCTCATCTATAGTAATAA

TTTCTAGTAGCAACTGCAA
ACCCTAACAGTGGTGGCAC

ATGTATCATCCTTTTTCT
TCAGCGGCCCTCAGGGGTCC

CCGGTGTACATTCCCAGGT
AAACTATGCACAGAAGTTT

AGTAGCAACTGCAACCG
CTGACCGATTCTCTGGCTCC

GCAGCTGGTGCAGTCTGGG
CAGGGCAGGGTCACCATGA

GTTCCTGGGCCCAGTCTG
AAGTCTGGCACCTCAGCCTC

GCTGAGGTGAAGAAGCCTG
CCAGGGACACGTCCATCAG

TGCTGACTCAGCCACCCT
CCTGGCCATCAGTGGGCTCC

GGGCCTCAGTGAAGGTCTC
CACAGCCTACATGGAGCTG

CAGCGTCTGGGACCCCC
AGTCTGAGGATGAGGCTGA

CTGCAAGGCTTCTGGATAC
AGCAGGCTGAGATCTGACG

GGGCAGAGGGTCACCAT
TTATTACTGTGCAGCATGGG

ACCTTCACCGGCTACTATAT
ACACGGCCGTGTATTACTG

CTCTTGTTCTGGAAGCAG
ATGACAGCCTGAATGGCGT

GCACTGGGTGCGACAGGCC
TGCGACGGCGCACCCCCGG

CTCCAACATCGGAAGTA
GGTATTCGGCGGAGGGACC

CCTGGACAAGGGCTTGAGT
AGGATCCAAGGGGTATTTT

ATACTGTAAACTGGTAC
AAGCTGACCGTCCTAG

GGATGGGATGGATCAACCC
TTTTGGGGCCGGGCGTCTG

CAGCAGCTCCCAGGAAC
(SEQ ID NO: 3505)

TAACAGTGGTGGCACAAAC
GGGCCAAGGGACCACGGTC

GGCCCCCAAACTCCTCAT

TATGCACAGAAGTTTCAGG
ACCGTCTCCTCA (SEQ

CTATAGTAATAATCAGC

GCAGGGTCACCATGACCAG
ID NO: 3503)

GGCCCTCAGGGGTCCCT

GGACACGTCCATCAGCACA

GACCGATTCTCTGGCTCC

GCCTACATGGAGCTGAGCA

AAGTCTGGCACCTCAGC

GGCTGAGATCTGACGACAC

CTCCCTGGCCATCAGTGG

GGCCGTGTATTACTGTGCG

GCTCCAGTCTGAGGATG

ACGGCGCACCCCCGGAGGA

AGGCTGATTATTACTGTG

TCCAAGGGGTATTTTTTTTG

CAGCATGGGATGACAGC

GGGCCGGGCGTCTGGGGCC

CTGAATGGCGTGGTATTC

AAGGGACCACGGTCACCGT

GGCGGAGGGACCAAGCT

CTCCTCAGCGTCGACCAAG

GACCGTCCTAGGTCAGC

GGCCCATCGGTCTTCCCCCT

CCAAGGCTGCCCCCTCG

GGCACCCTCCTCCAAGAGC

GTCACTCTGTTCCCACCC

ACCTCTGGGGGCACAGCGG

TCGAGTGAGGAGCTTCA

CCCTGGGCTGCCTGGTCAA

AGCCAACAAGGCCACAC

GGACTACTTCCCCGAACCT

TGGTGTGTCTCATAAGTG

GTGACGGTCTCGTGGAACT

ACTTCTACCCGGGAGCC

CAGGCGCCCTGACCAGCGG

GTGACAGTGGCCTGGAA

CGTGCACACCTTCCCGGCT

GGCAGATAGCAGCCCCG

GTCCTACAGTCCTCANGAC

TCAAGGCGGGAGTGGAG

TCTACTCCCTCAGCAGCGTG

ACCACCACACCCTCCAA

GTGACCGTGCCCTCCAGCA

ACAAAGCAACAACAAGT

GCTTGGGCACCCAGACCTA

ACGCGGCCAGCAGCTAC

CATCTGCAACGTGAATCAC

CTGAGCCTGACGCCTGA

AAGCCCAGCAACACCNAAG

GCAGTGGAAGTCCCACA

TGGACAAGANAGTTGAGCC

GAAGCTACAGCTGCCAG

CAAATCTTGTGACAAAACT

GTCACGCATGAAGGGAG

CACACATGCCCACCGTGCC

CACCGTGGAGAAGACAG

CAGCACCTGAACTCCTGGG

TGGCCCCTACAGAATGTT

GGGANCGTCAGTCTTCCTCT

CATAGAAGCTTGGCCGC

TCCCCCNAAANCCCAANGA

CATGGCCCAACTTGTTTA

CACCCTCATGATNTCCCNN

TTGCAGCTTATAATGGTT

ACCCCTGAGGTCNNATNCG

ACAAATAAAGCAATAGC

TGGNNNNNGNNGTGANCCA

ATCACAAATTTCACAAA

CNANACCCNGANNCAGTTC

TAAAGCATTTTTTTCACT

AACTGGNACNTNNNGGCGN

GCATTCTANTTGTGGTTT

NNNNTGCANNANNCNANA

GTCCAAACTCATCAATGT

N (SEQ ID NO: 3502)

ATCTTATCNTGTCTGGAT

CGGGAATTANTTCGGCG

CANCACCNTGGCCTGAA

TANCCTCTGAAANANNA

ACTTGNNTANNGNACCT

TCTGNNNGNNANNTANN

NAANNNNNNNAANNNN

NGTCTNNNNNNNNNNNN

NGNNANNTNNNNNNNNN

N (SEQ ID NO:

3504)

V-C028
NNNNNNNNNNNTATGTATC
GAGGTGCAGCTGTTGGAGT
COV072_
NNNNNNNNCNNNNNGTA
GAAATTGTGTTGACGCAGTC
COV072_

NTACACATACGATTTAGGT
CTGGGGGAGGCTTGGTACA
P2_B12
TCNTACACATACGATTTA
TCCAGGCACCCTGTCTTTGT
P2_B12

GACACTATAGAATAACATC
GCCTGGGGGGTCCCTGAGA

GGTGACACTATAGAATA
CTCCAGGGGAAAGAGCCAC

CACTTTGCCTTTCTCTCCAC
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CCTCTCCTGCAGGGCCAGTC

AGGTGTCCACTCCCAGGTC
ATTCACCTTTAGCACCTATG

TCTCCACAGGTGTCCACT
AGAGTGTTAACAGCAGGCA

CAACTGCACCTCGGTTCTAT
CCATGAGTTGGGTCCGCCA

CCCAGGTCCAACTGCAC
GTTAGCCTGGTACCAGCAGA

CGATTGAATTCCACCATGG
GGCTCCAGGGAAGGGGCTG

CTCGGTTCTATCGATTGA
AACCTGGCCAGGCTCCCAG

GATGGTCATGTATCATCCTT
GAGTGGGTCTCAACTATTA

ATTCCACCATGGGATGG
GCTCCTCATCTATGGTGCGT

TTTCTAGTAGCAACTGCAA
CTGGTAGTGGTCGTGACAC

TCATGTATCATCCTTTTT
CCAGCAGGGCCACTGGCAT

CCGGTGTACATTCTGAGGT
ATACTACGCAGACTCCGTG

CTAGTAGCAACTGCAAC
CCCAGAGAGGTTCAGTGGC

GCAGCTGTTGGAGTCTGGG
AAGGGCCGGTTCACCATCT

CGGTGTACATTCAGAAA
AGTGGATCTGGGACAGACTT

GGAGGCTTGGTACAGCCTG
CCAGAGACAATTCCAAGAA

TTGTGTTGACGCAGTCTC
CACTCTCACCATCAGCAGAC

GGGGGTCCCTGAGACTCTC
CACGCTGTTTCTGCAACTGA

CAGGCACCCTGTCTTTGT
TGGAGTCTGAAGATTTTGCA

CTGTGCAGCCTCTGGATTCA
ACAGCCTGAGAGCCGAGGA

CTCCAGGGGAAAGAGCC
GTGTATCACTGTCAGCAATA

CCTTTAGCACCTATGCCATG
CGCGGCCGTGTATTCCTGTG

ACCCTCTCCTGCAGGGCC
TGGTAGCTCAAGGGCGCTCA

AGTTGGGTCCGCCAGGCTC
CGAACCACCCTCTGGCATC

AGTCAGAGTGTTAACAG
CTTTCGGCGGAGGGACCAA

CAGGGAAGGGGCTGGAGTG
AGGCGACGACTACTACCAC

CAGGCAGTTAGCCTGGT
GGTGGAGATCAAAC (SEQ

GGTCTCAACTATTACTGGTA
TACTACATGGACGTCTGGG

ACCAGCAGAAACCTGGC
ID NO: 3509)

GTGGTCGTGACACATACTA
GCAAAGGGACCACGGTCAC

CAGGCTCCCAGGCTCCTC

CGCAGACTCCGTGAAGGGC
CGTCTCCTCA (SEQ ID

ATCTATGGTGCGTCCAGC

CGGTTCACCATCTCCAGAG
NO: 3507)

AGGGCCACTGGCATCCC

ACAATTCCAAGAACACGCT

AGAGAGGTTCAGTGGCA

GTTTCTGCAACTGAACAGC

GTGGATCTGGGACAGAC

CTGAGAGCCGAGGACGCGG

TTCACTCTCACCATCAGC

CCGTGTATTCCTGTGCGAAC

AGACTGGAGTCTGAAGA

CACCCTCTGGCATCAGGCG

TTTTGCAGTGTATCACTG

ACGACTACTACCACTACTA

TCAGCAATATGGTAGCT

CATGGACGTCTGGGGCAAA

CAAGGGCGCTCACTTTC

GGGACCACGGTCACCGTCT

GGCGGAGGGACCAAGGT

CCTCAGCGTCGACCAAGGG

GGAGATCAAACGTACGG

CCCATCGGTCTTCCCCCTGG

TGGCTGCACCATCTGTCT

CACCCTCCTCCAAGAGCAC

TCATCTTCCCGCCATCTG

CTCTGGGGGCACAGCGGCC

ATGAGCAGTTGAAATCT

CTGGGCTGCCTGGTCAAGG

GGAACTGCCTCTGTTGTG

ACTACTTCCCCGAACCTGTG

TGCCTGCTGAATAACTTC

ACGGTCTCGTGGAACTCAG

TATCCCAGAGAGGCCAA

GCGCCCTGACCAGCGGCGT

AGTACAGTGGAAGGTGG

GCACACCTTCCCGGCTGTCC

ATAACGCCCTCCAATCG

TACAGTCCTCAGGACTCTA

GGTAACTCCCAGGAGAG

CTCCCTCAGCAGCGTGGTG

TGTCACAGAGCAGGACA

ACCGTGCCCTCCAGCAGCT

GCAAGGACAGCACCTAC

TGGGCACCCAGACCTACAT

AGCCTCAGCAGCACCCT

CTGCAACGTGAATCACAAG

GACGCTGAGCAAAGCAG

CCCAGCAACACCNAAGGTG

ACTACGAGAAACACAAA

GACAAGAGAGTTGAGCCCA

GTCTACGCCTGCGAAGT

AATCTTGTGACAAAACTCA

CACCCATCAGGNCCTGA

CACATGCCCACCGTGCCCA

GCTCGCCCGTCACAAAG

GCACCTGAACTNCTGGGGG

AGCTTCAACAGGGGANA

GACCGTCAGTCTTCCTCTTC

GTGTTAGAAGCTTGGNC

CCCCCAAAACCCNANGACA

GCCATGGCCCAACTTGTT

CCCTCATGATCTNCNNGAC

TANTGCAGCTTANNTGG

CCNNGAGTCACATGCCGTG

TTACAAATAAAGCAATA

GNGGNGGNNGTGANCCACN

GCATCACAAATTTCACA

ANGACCNTGAGTCAGTTCA

AATAAAGCATTTTTTTCA

NTNNNCNTGNNGGCGTGNN

CTGCATTCTANTGNGGNT

NGCANNANGCNANNNANN

TGTCCNAACTCATCAAN

ANCNNNNGGAGGANCANT

NNNNCTTATCATGTCTGG

ACNANNNNCNNNNNCNNN

NTCGGGAATTAATTCCG

NNNNNNANNCNNN (SEQ

NNNN (SEQ ID NO:

ID NO: 3506)

3508)

V-C029
NNNNNNNNNNTTATGTATC
CAGGTGCAGCTGGTGGAGT
COV072_
GNNNNNNNNNNNTTATN
GACATCCAGATGACCCAGTC
COV072_

NTACACATACGATTTAGGT
CTGGGGGAGGCGTGGTCCA
P2_C7
NNATCNTACACATACGA
TCCATCCTCCCTGTCTGCAT
P2_C7

GACACTATAGAATAACATC
GCCTGGGAGGTCCCTGAGA

TTTAGGTGACACTATAG
CTGTAGGAGACAGAGTCAC

CACTTTGCCTTTCTCTCCAC
CTCTCCTGTGCAGCCTCTGG

AATAACATCCACTTTGCC
CATCACTTGCCAGGCGAGTC

AGGTGTCCACTCCCAGGTC
ATTCACCTTCAGTAGCTATG

TTTCTCTCCACAGGTGTC
AGGACATTAGCAACTATTTA

CAACTGCACCTCGGTTCTAT
GCATGAACTGGGTCCGCCA

CACTCCCAGGTCCAACT
AATTGGTATCAGCAGAAAC

CGATTGAATTCCACCATGG
GGCTCCAGGCAAGGGGCTG

GCACCTCGGTTCTATCGA
CAGGGAAAGCCCCTAAGCT

GATGGTCATGTATCATCCTT
GAGTGGGTGGCAGTTATAT

TTGAATTCCACCATGGG
CCTGATCTACGATGCATCCA

TTTCTAGTAGCAACTGCAA
CATATGATGGAAGTAATAC

ATGGTCATGTATCATCCT
ATTTGGAAACAGGGGTCCC

CCGGTGTACATTCTCAGGT
ATACTATACAGACTCCGTG

TTTTCTAGTAGCAACTGC
ATCAAGGTTCAGTGGAAGT

GCAGCTGGTGGAGTCTGGG
AAGGGCCGATTCACCATCT

AACCGGTGTACATTCTG
GAATCTGGGACAGATTTTAC

GGAGGCGTGGTCCAGCCTG
CCAGAGACAATTCCAAGAA

ACATCCAGATGACCCAG
TTTCACCATCAGCAGCCTGC

GGAGGTCCCTGAGACTCTC
CACGCTGTATCTGCAAATG

TCTCCATCCTCCCTGTCT
AGCCTGAAGATATTGCAAC

CTGTGCAGCCTCTGGATTCA
AACAGCCTGAGAGTTGACG

GCATCTGTAGGAGACAG
ATATTACTGTCAACAGTATG

CCTTCAGTAGCTATGGCAT
ACACGGCTACATATTACTG

AGTCACCATCACTTGCCA
ATAATCTCCCGATCACCTTC

GAACTGGGTCCGCCAGGCT
TGCGAAAGGGCCCCGGTTT

GGCGAGTCAGGACATTA
GGCCAAGGGACACGACTGG

CCAGGCAAGGGGCTGGAGT
GGCTGGAGCTATAGAGGGG

GCAACTATTTAAATTGGT
AGATTAAAC (SEQ ID

GGGTGGCAGTTATATCATA
GGTCTGGTTTTGATATCTGG

ATCAGCAGAAACCAGGG
NO: 3513)

TGATGGAAGTAATACATAC
GGCCAAGGGACAATGGTCA

AAAGCCCCTAAGCTCCT

TATACAGACTCCGTGAAGG
CCGTCTCTTCAG (SEQ

GATCTACGATGCATCCA

GCCGATTCACCATCTCCAG
ID NO: 3511)

ATTTGGAAACAGGGGTC

AGACAATTCCAAGAACACG

CCATCAAGGTTCAGTGG

CTGTATCTGCAAATGAACA

AAGTGAATCTGGGACAG

GCCTGAGAGTTGACGACAC

ATTTTACTTTCACCATCA

GGCTACATATTACTGTGCG

GCAGCCTGCAGCCTGAA

AAAGGGCCCCGGTTTGGCT

GATATTGCAACATATTAC

GGAGCTATAGAGGGGGGTC

TGTCAACAGTATGATAA

TGGTTTTGATATCTGGGGCC

TCTCCCGATCACCTTCGG

AAGGGACAATGGTCACCGT

CCAAGGGACACGACTGG

CTCTTCAGCGTCGACCAAG

AGATTAAACGTACGGTG

GGCCCATCGGTCTTCCCCCT

GCTGCACCATCTGTCTTC

GGCACCCTCCTCCAAGAGC

ATCTTCCCGCCATCTGAT

ACCTCTGGGGGCACAGCGG

GAGCAGTTGAAATCTGG

CCCTGGGCTGCCTGGTCAA

AACTGCCTCTGTTGTGTG

GGACTACTTCCCCGAACCT

CCTGCTGAATAACTTCTA

GTGACGGTCTCGTGGAACT

TCCCAGAGAGGCCAAAG

CAGGCGCCCTGACCAGCGG

TACAGTGGAAGGTGGAT

CGTGCACACCTTCCCGGCT

AACGCCCTCCAATCGGG

GTCCTACAGTCCTCAGGAC

TAACTCCCAGGAGAGTG

TCTACTCCCTCAGCAGCGTG

TCACAGAGCAGGACAGC

GTGACCGTGCCCTCCAGCA

AAGGACAGCACCTACAG

GCTTGGGCACCCAGACCTA

CCTCAGCAGCACCCTGA

CATCTGCAACGTGAATCAC

CGCTGAGCAAAGCAGAC

AAGCCCAGCAACACCAAGG

TACGAGAAACACAAAGT

TGGACAAGAGAGTTGAGCC

CTACGCCTGCGAAGTCA

CAAATCTTGTGACAAAACT

CCCATCAGGGCCTGAGC

CACACATGCCCACCGTGCC

TCGCCCGTCACAAAGAG

CAGCACCTGAACTCCTGGG

CTTCAACAGGGGAGAGT

GGGACCGTCAGTCTTCCTCT

GTTAGAAGCTTGGNCGC

TCCCCCCAAAACCCAAGGA

CATGGCCCAACTTGTTTA

CACCCTCATGATCTCCCGG

TTGCAGCTTATAATGGTT

ACCCCTGAGGTCACATGCG

ACAAATAAAGCAATAGC

TGGNGGNNGACGTGAGCCA

ATCACAAATTTCNNNAA

CGAANANCCTGAGGTCAAG

TAAAGCATTTTTTTCACT

TTCAACTGGNACGNNGNNG

GCATTCTAGTTGTGGTTT

GCGTNNNNTGCATNANGCC

GTCCAAACTCATCAATGT

ANACAAAGCCNNNGGGAN

ATCTTATCATGTCTGGNT

GNANCAGTACACAGCNNNT

CGGGAATTNANTCGGCG

ACCGNGNGGNCAGCNNCCN

CAGCNNCCANGN (SEQ

NNNCCGNCNN (SEQ ID

ID NO: 3512)

NO: 3510)

V-C030
NNNNNNNNNNNNNNNTGN
CAGGTGCAGCTGGTGCAGT
COV072_
NNNNNNNNNNNNNNNN
TCCTATGTGCTGACTCAGCC
COV072_

NNNNTACACATACGATTTA
CTGGGGCTGAGGTGAAGAA
P3_E1
GTATCNTACNCNTACGA
ACCCTCAGTGTCAGTGGCCC
P3_E1

GGTGACACTATAGAATAAC
GCCTGGGGCCTCAGTGAAG

TTTAGGTGACACTATAG
CAGGAAAGACGGCCAGGAT

ATCCACTTTGCCTTTCTCTC
GTTTCCTGCAAGGCATCTG

AATAACATCCACTTTGCC
TACCTGTGGGGGAAACAAC

CACNGGTGTCCACTCCCAG
GATACACCTTCACCAACTA

TTTCTCTCCACNGGTGTC
ATTGGAAGTAAAAGTGTGC

GTCCAACTGCACCTCGGTTC
CTATATGCACTGGGTGCGA

CACTCCCAGGTCCAACT
ACTGGTACCAGCAGAAGCC

TATCGATTGAATTCCACCAT
CAGGCCCCTGGACAAGGGC

GCAACCGGTTCTGTGAC
AGGCCAGGCCCCTGTGCTGG

GGGATGGTCATGTATCATC
TTGAGTGGATGGGAATAAT

CTCCTATGAGCTGACAC
TCATCTATTATGATAGCGAC

CTTTTTCTAGTAGCAACTGC
CAACCCTAGTGGTGGTAGC

AGCCACCCTCAGTGTCA
CGGCCCTCAGGGATCCCTGA

AACCGGTGTACATTCCCAG
ACAGGCTACGCACAGAAGT

GTGGCCCCAGGAAAGAC
GCGATTCTCTGGCTCCAACT

GTGCAGCTGGTGCAGTCTG
TCCAGGGCAGAGTCACCAT

GGCCAGGATTACCTGTG
CTGGGAACACGGCCACCCT

GGGCTGAGGTGAAGAAGCC
GACCAGGGACACGTCCACG

GGGGAAACAACATTGGA
GACCATCAGCAGGGTCGAA

TGGGGCCTCAGTGAAGGTT
AGCACAGTCTACATGGAGC

AGTAAAAGTGTGCACTG
GCCGGGGATGAGGCCGACT

TCCTGCAAGGCATCTGGAT
TGAGCAGCCTGAGATCTGA

GTACCAGCAGAAGCCAG
ATTACTGTCAGGTGTGGGAT

ACACCTTCACCAACTACTAT
GGACACGGCCGTGTATTAC

GCCAGGCCCCTGTGCTG
AGTAGTAGTGATCATCCGGG

ATGCACTGGGTGCGACAGG
TGTGCGAGATCCCGACCGA

GTCATCTATTATGATAGC
GGTGGTATTCGGCGGAGGG

CCCCTGGACAAGGGCTTGA
CTCCTGACTGGTACTTCGAT

GACCGGCCCTCAGGGAT
ACCAAGCTGACCGTCCTAG

GTGGATGGGAATAATCAAC
CTCTGGGGCCGTGGCACCC

CCCTGAGCGATTCTCTGG
(SEQ ID NO: 3517)

CCTAGTGGTGGTAGCACAG
TGGTCACTGTCTCCTCAG

CTCCAACTCTGGGAACA

GCTACGCACAGAAGTTCCA
(SEQ ID NO: 3515)

CGGCCACCCTGACCATC

GGGCAGAGTCACCATGACC

AGCAGGGTCGAAGCCGG

AGGGACACGTCCACGAGCA

GGATGAGGCCGACTATT

CAGTCTACATGGAGCTGAG

ACTGTCAGGTGTGGGAT

CAGCCTGAGATCTGAGGAC

AGTAGTAGTGATCATCC

ACGGCCGTGTATTACTGTG

GGGGGTGGTATTCGGCG

CGAGATCCCGACCGACTCC

GAGGGACCAAGCTGACC

TGACTGGTACTTCGATCTCT

GTCCTAGGTCAGCCCAA

GGGGCCGTGGCACCCTGGT

GGCTGCCCCCTCGGTCAC

CACCGTCTCCTCAGCGTCG

TCTGTTCCCACCCTCGAG

ACCAAGGGCCCATCGGTCT

TGAGGAGCTTCAAGCCA

TCCCCCTGGCACCCTCCTCC

ACAAGGCCACACTGGTG

AAGAGCACCTCTGGGGGCA

TGTCTCATAAGTGACTTC

CAGCGGCCCTGGGCTGCCT

TACCCGGGAGCCGTGAC

GGTCAAGGACTACTTCCCC

AGTGGCCTGGAAGGCAG

GAACCTGTGACGGTCTCGT

ATAGCAGCCCCGTCAAG

GGAACTCAGGCGCCCTGAC

GCGGGAGTGGAGACCAC

CAGCGGCGTGCACACCTTC

CACACCCTCCAAACAAA

CCGGCTGTCCTACAGTCCTC

GCAACAACAAGTACGCG

AGGACTCTACTCCCTCAGC

GCCAGCAGCTACCTGAG

AGCGTGGTGACCGTGCCCT

CCTGACGCCTGAGCAGT

CCAGCAGCTTGGGCACCCA

GGAAGTCCCACAGAAGC

GACCTACATCTGCAACGTG

TACAGCTGCCAGGTCAC

AATCACAAGCCCAGCAACA

GCATGAANNGGAGCACC

CCNAGGTGGANAGAGAGTT

GTGGAGAAGACAGTGGC

GAGCCCAAATCTTGTGACA

CCCTACAGAATGTTCATA

AACTCACACATGCCCACCG

GAAGCTTGGCCGCCATG

TGCCCAGCACCTGAACTCC

GCCCAACTTGTTTATTGC

TGGGGGGACCGTCAGTCTT

AGCTTATAATGGTTACA

CCTCNTCCCCCCAAAACCC

AATAAAGCAATAGCATC

ANGGANACCCNTCATGATC

ACAANNTTCACAAATAA

TCCNNNACCCTGAGNCNCN

AGCATTTTTTTCACTGCA

NTGCGTGNNNGACNNNNAN

TTCTANTTGTGGTTTGTC

CCACNAANACCCTGAGNCA

CAACTCATCANGTATCTT

NNTCAACTGGNNCGNNGNN

ATCATGTCTGGATCGGN

(SEQ ID NO: 3514)

ATTAATTCGGCGCANCA

NCATGGCCTGAAATAAC

CTCTGAAANANGAANTT

GGNNAGGNACCTTCNGA

NGCNGAAAGAANCNTNN

(SEQ ID NO: 3516)

V-C031
NNNNNNNNNNNNNGNATN
CAGGTGCAGCTGGTGCAGT
COV072_
NNNNNNNNNNNNNANN
GAAATAGTGATGACGCAGT
COV072_

NTACACATACGATTTAGGT
CTGGGTCTGAGGTGAAGAA
P3_B5
NNNNNNTACACNTACGA
CTCCAGCCACCCTGTCTGTG
P3_B5

GACACTATAGAATAACATC
GCCTGGGTCCTCGGTGAAG

TTTAGGTGACACTATAG
TCTCCAGGGGAAAGAGCCA

CACTTTGCCTTTCTCTCCAC
GTCTCCTGCAAGGCTTCTGG

AATAACATCCACTTTGCC
CCCTCTCCTGCAGGGCCAGT

AGGTGTCCACTCCCAGGTC
AGGCACCTTCAGCAGCTAT

TTTCTCTCCACAGGTGTC
CAGAGTGTTAGCAGCAACTT

CAACTGCACCTCGGTTCTAT
GCTTTCAGCTGGGTGCGAC

CACTCCCAGGTCCAACT
AGCCTGGTACCAGCAGAAA

CGATTGAATTCCACCATGG
AGGCCCCTGGACAAGGGCT

GCACCTCGGTTCTATCGA
CCTGGCCAGGCTCCCAGGCT

GATGGTCATGTATCATCCTT
TGAGTGGATGGGAAGGATC

TTGAATTCCACCATGGG
CCTCATCTATGGTGCATCCA

TTTCTAGTAGCAACTGCAA
ATCCCTATCCTTGCTTTAGC

ATGGTCATGTATCATCCT
CCAGGGCCACTGGTATCCCA

CCGGTGTACATTCCCAGGT
AAACTACGCACAGAAGTTC

TTTTCTAGTAGCAACTGC
GCCAGGTTCAGTGGCAGTG

GCAGCTGGTGCAGTCTGGG
CAGGGCAGAGTCACGATTA

AACCGGTGTACATTCAG
GGTCTGGGACAGAGTTCACT

TCTGAGGTGAAGAAGCCTG
CCGCGGACAAATCCACGAG

AAATAGTGATGACGCAG
CTCACCATCAGCAGCCTGCA

GGTCCTCGGTGAAGGTCTC
CACAGCCTACATGGAGCTG

TCTCCAGCCACCCTGTCT
GTCTGAAGATTTTGCAGTTT

CTGCAAGGCTTCTGGAGGC
AGCAGCCTGAGATCTGAGG

GTGTCTCCAGGGGAAAG
ATTACTGTCAGCAGTATAAT

ACCTTCAGCAGCTATGCTTT
ACACGGCCGTGTATTACTG

AGCCACCCTCTCCTGCAG
AACTGGCCGATCACCTTCGG

CAGCTGGGTGCGACAGGCC
TGCGAGAGTCAATCAAGCA

GGCCAGTCAGAGTGTTA
CCAAGGGACACGACTGGAG

CCTGGACAAGGGCTTGAGT
GTAACTACTCCCTTCTCCAT

GCAGCAACTTAGCCTGG
ATTAAAC (SEQ ID

GGATGGGAAGGATCATCCC
GGACGTCTGGGGCCAAGGG

TACCAGCAGAAACCTGG
NO: 3521)

TATCCTTGCTTTAGCAAACT
ACCACGGTCACCGTCTCCTC

CCAGGCTCCCAGGCTCCT

ACGCACAGAAGTTCCAGGG
A (SEQ ID NO: 3519)

CATCTATGGTGCATCCAC

CAGAGTCACGATTACCGCG

CAGGGCCACTGGTATCC

GACAAATCCACGAGCACAG

CAGCCAGGTTCAGTGGC

CCTACATGGAGCTGAGCAG

AGTGGGTCTGGGACAGA

CCTGAGATCTGAGGACACG

GTTCACTCTCACCATCAG

GCCGTGTATTACTGTGCGA

CAGCCTGCAGTCTGAAG

GAGTCAATCAAGCAGTAAC

ATTTTGCAGTTTATTACT

TACTCCCTTCTCCATGGACG

GTCAGCAGTATAATAAC

TCTGGGGCCAAGGGACCAC

TGGCCGATCACCTTCGGC

GGTCACCGTCTCCTCAGCGT

CAAGGGACACGACTGGA

CGACCAAGGGCCCATCGGT

GATTAAACGTACGGTGG

CTTCCCCCTGGCACCCTCCT

CTGCACCATCTGTCTTCA

CCAAGAGCACCTCTGGGGG

TCTTCCCGCCATCTGATG

CACAGCGGCCCTGGGCTGC

AGCAGTTGAAATCTGGA

CTGGTCAAGGACTACTTCC

ACTGCCTCTGTTGTGTGC

CCGAACCTGTGACGGTCTC

CTGCTGAATAACTTCTAT

GTGGAACTCANGCGCCCTG

CCCAGAGAGGCCAAAGT

ACCAGCGGCGTGCACACCT

ACAGTGGAAGGTGGATA

TCCCGGCTGTCCTACAGTCC

ACGCCCTCCAATCGGGT

TCAGGACTCTACTCCCTCAG

AACTCCCAGGAGAGTGT

CAGCGTGGTGACCGTGCCC

CACAGAGCAGGACAGCA

TCCAGCAGCTTGGGCACCC

AGGACAGCACCTACAGC

AGACCTACATCTGCAACGT

CTCAGCAGCACCCTGAC

GAATCACAAGCCCAGCAAC

GCTGAGCAAAGCAGACT

ACCAAGGTGGACAAGAGAG

ACGAGAAACACAAAGTC

TTGAGCCCAAATCTTGTGA

TACGCCTGCGAAGTCAC

CAAAACTCACACATGCCCA

CCATCAGGGCCTGAGCT

CCGTGCCCAGCACCTGAAC

CGCCCGTCACAAAGAGC

TNCTGGGGGGACCGTCAGT

TTCAACNGGGGAGANTG

CTTCNTCTTCCCCCCAAANC

TTAGAAGCTTGGCCGCC

CNAGGANNCCCTCATGATC

ATGGCCCAACTTGTTTAT

TCNNNACCCNGAGTCNACA

TGCAGCTTATAATGGTTA

TGCGTGGNGGTGNNGTGAN

CAAATAAGCAATAGCAT

CNNCNAANNNCCNGAGGTC

CACAAATTTCACAAATA

AAGTTCAACTGGNNNCNTN

AAGCATTTTTTCACTGCA

(SEQ ID NO: 3518)

TTCTANTNNNNNNTNGN

CCAAACTCATCAATGNN

NTCTTATCATGTCNGGNT

CGGNAATTAANTN

(SEQ ID NO: 3520)

V-C032
NNNNNNNNNNNNNTGTATC
CAGGTGCAGCTGCAGGAGT
COV072_
NNNNNNNNNNNNNNNN
CAGTCTGTGCTGACTCAGCC
COV072_

ATACACATACGATTTAGGT
CGGGCCCAGGACTGGTGAA
P3_C1
NTNNTNNNNTACNNNTA
TGCCTCCGTGTCTGGGTCTC
P3_C1

GACACTATAGAATAACATC
GCCTTCGGGGACCCTGTCC

CNATTTAGGTGACACTAT
CTGGACAGTCGATCACCATC

CACTTTGCCTTTCTCTCCAC
CTCACCTGCGCTGTCTCTGG

AGAATAACATCCACTTT
TCCTGCACTGGAACCAGCAG

NGGTGTCCACTCCCAGGTC
TGGCTCCATCAGCAGTAAT

GCCTTTCTCTCCCCNGGT
TGACGTTGGTGGTTATAACT

CAACTGCACCTCGGTTCTAT
AACTGGTGGAGTTGTGTCC

GTCCACTCCCAGGTCCA
ATGTCTCCTGGTACCAACAA

CGATTGAATTCCACCATGG
GCCAGCCCCCAGGGAAGGG

ACTGCACCTCGGTTCTAT
CACCCAGGCAAAGCCCCCA

GATGGTCATGTATCATCCTT
GCTGGAGTGGATTGGGGAA

CGATTGAATTCCACCATG
AACTCATGATTTATGATGTC

TTTCTAGTAGCAACTGCAA
ATCTATCATAGTGGGAGCA

GGATGGTCATGTATCATC
AGTAATCGGCCCTCAGGGGT

CCGGTGTACATTCCCAGGT
CCAACTACAACCCGTCCCT

CTTTTTCTAGTAGCAACT
TTCTAATCGCTTCTCTGGCT

GCAGCTGCAGGAGTCGGGC
CAAGAGTCGAGTCACCATA

GCAACCGGTTCCTGGGC
CCAAGTCTGGCAACACGGC

CCAGGACTGGTGAAGCCTT
TCAGTAGACAAGTCCAAGA

CCAGTCTGCCCTGACTCA
CTCCCTGACCATCTCTGGGC

CGGGGACCCTGTCCCTCAC
ACCAGTTCTCCCTGAAGCT

GCCTGCCTCCGTGTCTGG
TCCAGGCTGAGGACGAGGC

CTGCGCTGTCTCTGGTGGCT
GAGCTCTGTGACCGCCGCG

GTCTCCTGGACAGTCGAT
TGATTATTACTGCAGCTCAT

CCATCAGCAGTAATAACTG
GACACGGCCGTGTATTACT

CACCATCTCCTGCACTGG
ATACAAGCAGCAGCACTCTT

GTGGAGTTGTGTCCGCCAG
GTGCGAGAGGGGGGGATAC

AACCAGCAGTGACGTTG
TTGTTCGGCGGAGGGACCA

CCCCCAGGGAAGGGGCTGG
AGCTATGGGCCCCGAATAC

GTGGTTATAACTATGTCT
AGCTGACCGTCCTAG

AGTGGATTGGGGAAATCTA
TTTGACTACTGGGGCCAGG

CCTGGTACCAACAACAC
(SEQ ID NO: 3525)

TCATAGTGGGAGCACCAAC
GAACCCTGGTCACCGTCTC

CCAGGCAAAGCCCCCAA

TACAACCCGTCCCTCAAGA
CTCAG (SEQ ID NO:

ACTCATGATTTATGATGT

GTCGAGTCACCATATCAGT
3523)

CAGTAATCGGCCCTCAG

AGACAAGTCCAAGAACCAG

GGGTTTCTAATCGCTTCT

TTCTCCCTGAAGCTGAGCTC

CTGGCTCCAAGTCTGGC

TGTGACCGCCGCGGACACG

AACACGGCCTCCCTGAC

GCCGTGTATTACTGTGCGA

CATCTCTGGGCTCCAGGC

GAGGGGGGGATACAGCTAT

TGAGGACGAGGCTGATT

GGGCCCCGAATACTTTGAC

ATTACTGCAGCTCATATA

TACTGGGGCCAGGGAACCC

CAAGCAGCAGCACTCTT

TGGTCACCGTCTCCTCAGCG

TTGTTCGGCGGAGGGAC

TCGACCAAGGGCCCATCGG

CAAGCTGACCGTCCTAG

TCTTCCCCCTGGCACCCTCC

GTCAGCCCAAGGCTGCC

TCCAAGAGCACCTCTGGGG

CCCTCGGTCACTCTGTTC

GCACAGCGGCCCTGGGCTG

CCACCCTCGAGTGAGGA

CCTGGTCAAGGACTACTTC

GCTTCAAGCCAACAAGG

CCCGAACCTGTGACGGTCT

CCACACTGGTGTGTCTCA

CGTGGAACTCAGGCGCCCT

TAAGTGACTTCTACCCGG

GACCAGCGGCGTGCACACC

GAGCCGTGACAGTGGCC

TTCCCGGCTGTCCTACAGTC

TGNAAGGCAGATANCAG

CTCAGGACTCTACTCCCTCA

CCCCGTCAAGGCGGGAN

GCAGCGTGGTGACCGTGCC

TGGAGACCACCACACCC

CTCCAGCAGCTTGGGCACC

TCCAAACAAAGCAACAA

CAGACCTACATCTGCAACG

CAAGTACGCGGGCCAGC

TGAATCACAAGCCCAGCAA

AGCTACCTGANCCNTGA

CACCAAGGTGGACAAGAGA

CGCCTGAGCANTGGAAG

GTTGAGCCCAAATCTTGTG

TCCCACAGAAGCNTACA

ACAAAACTCACACATGCCC

GCTGCCANGTCACGCAT

ACCGTGCCCAGCACCTGAA

GAAGGGAGCACCGNGNA

CTCCTGGGGGGACCGTCAG

GAGANANTGGCNCCTAC

TCTTCCTCTTCCCCCCAAAA

AGAATGTTCATANAANC

NCCNAAGGACACCCTCATG

TTGGCCGCCCANGGCCC

ATCTCCCNGACCCNTGAGG

AACTTGTTATTGNNGCTT

TCNACATGCGTGGTGGNGG

ATNN (SEQ ID NO:

NCGTGANCCACNAAGACCC

3524)

TGNNNGTCAAGTTCAACTG

GNTACGTGGNANGGGNGNN

NNNGGNNCANN (SEQ ID

NO: 3522)

V-C033
NNNNNNNNNNNNNNNGNN
CAGGTGCAGCTGGTGGAGT
COV072_
GNNNNNNNNNNNNGTAT
GACATCCAGATGACCCAGTC
COV072_

TNNTACACATACGATTTAG
CTGGGGGAGGCGTGGTCCA
P3_E5
CNNNCNCATACGATTTA
TCCATCCTCCCTGTCTGCAT
P3_E5

GTGACACTATAGAATAACA
GCCTGGGAGGTCCCTGAGA

GGTGACACTATAGAATA
CTGTAGGAGACAGAGTCAC

TCCACTTTGCCTTTCTCTCC
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CATCACTTGCCGGGCAAGTC

ACNGNTGTCCACTCCCAGG
ATTCACCTTCAGTAGCTATG

TCTCCACNGGTGTCCACT
AGAGCATTAGCAGCTATTTA

TCCAACTGCACCTCGGTTCT
CTATGCACTGGGTCCGCCA

CCCAGGTCCAACTGCAC
AATTGGTATCAGCAGAAAC

ATCGATTGAATTCCACCAT
GGCTCCAGGCAAGGGGCTG

CTCGGTTCTATCGATTGA
CAGGGAAAGCCCCTAAGCT

GGGATGGTCATGTATCATC
GAGTGGGTGGCAGTTATAT

ATTCCACCATGGGATGG
CCTGATCTATGCTGCATCCA

CTTTTTCTAGTAGCAACTGC
TATATGATGGAAGCAATAA

TCATGTATCATCCTTTTT
GTTTGCAAAGTGGGGTCCCA

AACCGGTGTACATTCTCAG
ATACTACGCAGACTCCGTG

CTAGTAGCAACTGCAAC
TCAAGGTTCAGTGGCAGTGG

GTGCAGCTGGTGGAGTCTG
AAGGGCCGATTCACCATCT

CGGTGTACATTCTGACAT
ATCTGGGACAGATTTCACTC

GGGGAGGCGTGGTCCAGCC
CCAGAGACAATTCCAAGAA

CCAGATGACCCAGTCTC
TCACCATCAGCAGTCTGCAA

TGGGAGGTCCCTGAGACTC
CACGCTGTATCTGCAAATG

CATCCTCCCTGTCTGCAT
CCTGAAGATTTTGCAACTTA

TCCTGTGCAGCCTCTGGATT
AACAGCCTGAGAGCTGAGG

CTGTAGGAGACAGAGTC
CTACTGTCAACAGAGTTACA

CACCTTCAGTAGCTATGCTA
ACACGGCTGTGTATTACTGT

ACCATCACTTGCCGGGC
GTACCCCTCCGTGGACGTTC

TGCACTGGGTCCGCCAGGC
GCGAGAGATTCGGACGTAG

AAGTCAGAGCATTAGCA
GGCCAAGGGACCAAGGTGG

TCCAGGCAAGGGGCTGGAG
ATACATCTATGGTTACTTGG

GCTATTTAAATTGGTATC
AAATCAAAC (SEQ ID

TGGGTGGCAGTTATATTAT
TTCGACTACTGGGGCCAGG

AGcAGAAAccAGGGAAA
NO:3 529)

ATGATGGAAGCAATAAATA
GAACCCTGGTCACCGTCTC

GCCCCTAAGCTCCTGATC

CTACGCAGACTCCGTGAAG
CTCAG (SEQ ID NO:

TATGCTGCATCCAGTTTG

GGCCGATTCACCATCTCCA
3527)

CAAAGTGGGGTCCCATC

GAGACAATTCCAAGAACAC

AAGGTTCAGTGGCAGTG

GCTGTATCTGCAAATGAAC

GATCTGGGACAGATTTC

AGCCTGAGAGCTGAGGACA

ACTCTCACCATCAGCAGT

CGGCTGTGTATTACTGTGCG

CTGCAACCTGAAGATTTT

AGAGATTCGGACGTAGATA

GCAACTTACTACTGTCAA

CATCTATGGTTACTTGGTTC

CAGAGTTACAGTACCCC

GACTACTGGGGCCAGGGAA

TCCGTGGACGTTCGGCC

CCCTGGTCACCGTCTCCTCA

AAGGGACCAAGGTGGAA

GCGTCGACCAAGGGCCCAT

ATCAAACGTACGGTGGC

CGGTCTTCCCCCTGGCACCC

TGCACCATCTGTCTTCAT

TCCTCCAAGAGCACCTCTG

CTTCCCGCCATCTGATGA

GGGGCACAGCGGCCCTGGG

GCAGTTGAAATCTGGAA

CTGCCTGGTCAAGGACTAC

CTGCCTCTGTTGTGTGCC

TTCCCCGAACCTGTGACGG

TGCTGAATAACTTCTATC

TCTCGTGGAACTCAGGCGC

CCAGAGAGGCCAAAGTA

CCTGACCAGCGGCGTGCAC

CAGTGGAAGGTGGATAA

ACCTTCCCGGCTGTCCTACA

CGCCCTCCAATCGGGTA

GTCCTCAGGACTCTACTCCC

ACTCCCAGGAGAGTGTC

TCAGCAGCGTGGTGACCGT

ACAGAGCANGACAGCAA

GCCCTCCAGCAGCTTGGGC

GGACAGCACCTACAGCC

ACCCAGACCTACATCTGCA

TCAGCAGCACCCTGACG

ACGTGAATCACAAGCCCAG

CTGAGCAAAGCAGACTA

CAACACCNAAGGTGGACAA

CGAGAAACACAAAGTCT

GAGAGTTGANCCCAAATCT

ACGCCTGCGAAGTCACC

TGTGACAAAACTCACACAT

CATCNGGGCCTGAGCTC

GCCCACCGTGCCCAGCACC

GCCCGTCACAAAGAGCT

TGAACTCCTGGGGGGACCG

TCAACAGGGGAGAGTGT

TCAGTCTTCCTCTTCCCCCN

TAGAAGCTTGGCCGCCA

NAAACCCANGGANACCCNC

TGGNCCAACTTGTTTATT

ATGATCTCCCNGACCCCTG

GCAGCTTATNATGGTTAC

AGNCACNTGNNNTGGNGGN

AAATAAGCAATAGCATC

GGANNNNGANCCNCGAAG

ACAAATTTCACAAATAA

ACCCTGGAGGTNAGTTCAA

AGCATTTTTTNNNNCTGC

CTGGNNCNNNGGAANGNN

ATNCTAGTTGNNGGTTN

NNNNN (SEQ ID NO:

GTCCAAACTN (SEQ ID

3526)

NO: 3528)

V-C034
NNNNNNNNCNNNNTGTATC
GAGGTGCAGCTGTTGGAGT
COV072_
NNNNNNNNNNNNTGTAT
TCCTATGTGCTGACTCAGCC
COV072_

NTACACATACGATTTAGGT
CTGGGGGAGGCTTGGTACA
P3_H9
CATACACATACGATTTA
ACCCTCAGTGTCAGTGGCCC
P3_H9

GACACTATAGAATAACATC
GCCTGGGGGGTCCCTGAGA

GGTGACACTATAGAATA
CAGGAAAGACGGCCAGGAT

CACTTTGCCTTTCTCTCCAC
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
TACCTGTGGGGGAAACAAC

AGGTGTCCACTCCCAGGTC
ATTCACCTTTAGCAACTATG

TCTCCACAGGTGTCCACT
ATTGGAAGTAAAAGTGTGC

CAACTGCACCTCGGTTCTAT
CCATGAGCTGGGTCCGCCA

CCCAGGTCCAACTGCAC
ACTGGTACCAGCAGAAGCC

CGATTGAATTCCACCATGG
GGCTCCAGGGAAGGGGCTG

CTCGGTTCTATCGATTGA
AGGCCAGGCCCCTGTGCTGG

GATGGTCATGTATCATCCTT
GAGTGGGTCTCAGCTATTA

ATTCCACCATGGGATGG
TCATCTATTATGATAGCGAC

TTTCTAGTAGCAACTGCAA
GTGGTAGTGATGGTAGCAC

TCATGTATCATCCTTTTT
CGGCCCTCAGGGATCCCTGA

CCGGTGTACATTCTGAGGT
ATACTACGCAGGCTCCGTG

CTAGTAGCAACTGCAAC
GCGATTCTCTGGCTCCAACT

GCAGCTGTTGGAGTCTGGG
AAGGGCCGGTTCACCATCT

CGGTTCTGTGACCTCCTA
CTGGGAACACGGCCACCCT

GGAGGCTTGGTACAGCCTG
CCAGAGACAATTCCAAGAA

TGAGCTGACACAGCCAC
GACCATCAGCAGGGTCGAA

GGGGGTCCCTGAGACTCTC
CACACTGTATCTGCAAATG

CCTCAGTGTCAGTGGCCC
GCCGGGGATGAGGCCGAAT

CTGTGCAGCCTCTGGATTCA
AACAGCCTGAGAGCCGAGG

CAGGAAAGACGGCCAGG
ATCACTGTCAGGTGTGGGAT

CCTTTAGCAACTATGCCATG
ACACGGCCGTATATTACTG

ATTACCTGTGGGGGAAA
AGTAGTAGTGATCGTCCGGG

AGCTGGGTCCGCCAGGCTC
TGCGAAAGATCCCCTTATA

CAACATTGGAAGTAAAA
GGTGGTTTTCGGCGGAGGG

CAGGGAAGGGGCTGGAGTG
ACTGGACCTACCTATCAAT

GTGTGCACTGGTACCAG
ACCAAGCTGACCGTCCTAG

GGTCTCAGCTATTAGTGGT
ACTTTCACTACTGGGGCCA

CAGAAGCCAGGCCAGGC
(SEQ ID NO: 3533)

AGTGATGGTAGCACATACT
GGGAACCCTGGTCACCGTC

CCCTGTGCTGGTCATCTA

ACGCAGGCTCCGTGAAGGG
TCCTCAG (SEQ ID

TTATGATAGCGACCGGC

CCGGTTCACCATCTCCAGA
NO: 3531)

CCTCAGGGATCCCTGAG

GACAATTCCAAGAACACAC

CGATTCTCTGGCTCCAAC

TGTATCTGCAAATGAACAG

TCTGGGAACACGGCCAC

CCTGAGAGCCGAGGACACG

CCTGACCATCAGCAGGG

GCCGTATATTACTGTGCGA

TCGAAGCCGGGGATGAG

AAGATCCCCTTATAACTGG

GCCGAATATCACTGTCA

ACCTACCTATCAATACTTTC

GGTGTGGGATAGTAGTA

ACTACTGGGGCCAGGGAAC

GTGATCGTCCGGGGGTG

CCTGGTCACCGTCTCCTCAG

GTTTTCGGCGGAGGGAC

CGTCGACCAAGGGCCCATC

CAAGCTGACCGTCCTAG

GGTCTTCCCCCTGGCACCCT

GTCAGCCCAAGGCTGCC

CCTCCAAGAGCACCTCTGG

CCCTCGGTCACTCTGTTC

GGGCACAGCGGCCCTGGGC

CCACCCTCGAGTGAGGA

TGCCTGGTCAAGGACTACT

GCTTCAAGCCAACAAGG

TCCCCGAACCTGTGACGGT

CCACACTGGTGTGTCTCA

CTCGTGGAACTCAGGCGCC

TAAGTGACTTCTACCCGG

CTGACCAGCGGCGTGCACA

GAGCCGTGACAGTGGCC

CCTTCCCGGCTGTCCTACAG

TGGAAGGCAGATAGCAG

TCCTCNNACTCTACTCCCTC

CCCCGTCAAGGCGGGAG

AGCAGCGTGGTGACCGTGC

TGGAGACCACCACACCC

CCTCCAGCAGCTTGGGCAC

TCCAAACAAAGCAACAA

CCAGACCTACATCTGCAAC

CAAGTACGCGGCCAGCA

GTGAATCACAAGCCCAGCA

GCTACCTGAGCCTGACG

ACACCNAAGGTGGACAAGA

CCTGAGCAGTGGAAGTC

NAGTTGAGCCCAAATCTTG

CCACAGAAGCTACAGCT

TGACAAAACTCACACATGC

GCCAGGTCACGCATGAA

CCACCGTGCCCAGCACCTG

GGGAGCACCGTGGAGAA

AACTNCTGGGGGGGACCGT

GACAGTGGCCCCTACAG

CAGTCTTCCTCTTCCCCCNA

AATGTTCATAGAAGCTT

AANCCNAGGANACCCTCAT

GGCCGCCATGGNCCAAC

GATCTCCCNNACCCCNGAA

TTGTTTATTGCAGCTTAN

GGTCNCATGCNTGGNNGGT

NATGGTTACAAATAAAG

GGACGTGAGCCNCGAANNA

CAATAGCATCACAAATT

NCCNN (SEQ ID NO:

TCACAAANAAAGCATTT

3530)

TTTTCACTGCATCTANTG

TGGNTNNTCCNAACNCA

TCNATGNNNNNTNNCAT

GTCTGGATCN (SEQ ID

NO: 3532)

V-C035
NNNNNNNNNNNTGTATCNT
CAGGTGCAGCTGGTGGAGT
COV072_
NNNNNNNNNNNNTNTGT
GACATCCAGATGACCCAGTC
COV072_

ACACATACGATTTAGGTGA
CTGGGGGAGGCGTGGTCCA
P3_D9
ATCNTACNCNTACGATTT
TCCTTCCACCCTGTCTGCAT
P3_D9

CACTATAGAATAACATCCA
GCCTGGGAGGTCCCTGAGA

AGGTGACACTATAGAAT
CTGTAGGAGACAGAGTCAC

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCCTCTGG

AACATCCACTTTGCCTTT
CATCACTTGCCGGGCCAGTC

GTGTCCACTCCCAGGTCCA
ATTCACCTTCAGTAGCTATG

CTCTCCACAGGTGTCCAC
AGAGTATTAGTAACTGGTTG

ACTGCACCTCGGTTCTATCG
CTATGCACTGGGTCCGCCA

TCCCAGGTCCAACTGCA
GCCTGGTTTCAGCAGAAACC

ATTGAATTCCACCATGGGA
GGCTCCAGGCAAGGGGCTG

CCTCGGTTCTATCGATTG
AGGGAAAGCCCCTAAGCTC

TGGTCATGTATCATCCTTTT
GAGTGGGTGGCAGTTATAC

AATTCCACCATGGGATG
CTGATCTATGAGGCGTNTAG

TCTAGTAGCAACTGCAACC
CATTTGATGGAAGAAATAA

GTCATGTATCATCCTTTT
TTTAGAAAGTGGGGTCCCAT

GGTGTACATTCTCAGGTGC
GTACTACGCAGACTCCGTG

TCTAGTAGCAACTGCAA
CAAGGTTCAGCGGCAGTGG

AGCTGGTGGAGTCTGGGGG
ACGGGCCGATTCACCATCT

CCGGTGTACATTCTGACA
ATCTGGGACAGAATTCACTC

AGGCGTGGTCCAGCCTGGG
CCAGAGACAATTCCAAGAA

TCCAGATGACCCAGTCTC
TCACCATCAGCAGCCTGCAG

AGGTCCCTGAGACTCTCCT
CACACTGTATCTGCAAATG

CTTCCACCCTGTCTGCAT
CCTGATGATTTTGCAACTTA

GTGCAGCCTCTGGATTCAC
AACAGCCTGAGAGCTGAGG

CTGTAGGAGACAGAGTC
TTACTGCCAACAGTATAATA

CTTCAGTAGCTATGCTATGC
ACACGGCTGTGTATTACTGT

ACCATCACTTGCCGGGC
GTTATCCGTGGACGTTCGGC

ACTGGGTCCGCCAGGCTCC
GCGAGTAGTAGTGGTTATC

CAGTCAGAGTATTAGTA
CAAGGGACCAAGGTGGAAA

AGGCAAGGGGCTGGAGTGG
TTTTCCACTCTGACTACTGG

ACTGGTTGGCCTGGTTTC
TCAAAC (SEQ ID NO:

GTGGCAGTTATACCATTTG
GGCCAGGGAACCCTGGTCA

AGCAGAAACCAGGGAAA
3537)

ATGGAAGAAATAAGTACTA
CCGTCTCCTCAG (SEQ ID

GCCCCTAAGCTCCTGATC

CGCAGACTCCGTGACGGGC
NO: 3535)

TATGAGGCGTCTAGTTTA

CGATTCACCATCTCCAGAG

GAAAGTGGGGTCCCATC

ACAATTCCAAGAACACACT

AAGGTTCAGCGGCAGTG

GTATCTGCAAATGAACAGC

GATCTGGGACAGAATTC

CTGAGAGCTGAGGACACGG

ACTCTCACCATCAGCAG

CTGTGTATTACTGTGCGAGT

CCTGCAGCCTGATGATTT

AGTAGTGGTTATCTTTTCCA

TGCAACTTATTACTGCCA

CTCTGACTACTGGGGCCAG

ACAGTATAATAGTTATCC

GGAACCCTGGTCACCGTCT

GTGGACGTTCGGCCAAG

CCTCAGCGTCGACCAAGGG

GGACCAAGGTGGAGATC

CCCATCGGTCTTCCCCCTGG

AAACGTACGGTGGCTGC

CACCCTCCTCCAAGAGCAC

ACCATCTGTCTTCATCTT

CTCTGGGGGCACAGCGGCC

CCCGCCATCTGATGAGC

CTGGGCTGCCTGGTCAAGG

AGTTGAAATCTGGAACT

ACTACTTCCCCGAACCTGTG

GCCTCTGTTGTGTGCCTG

ACGGTCTCGTGGAACTCAG

CTGAATAACTTCTATCCC

GCGCCCTGACCAGCGGCGT

AGAGAGGCCAAAGTACA

GCACACCTTCCCGGCTGTCC

GTGGAAGGTGGATAACG

TACAGTCCTCANGACTCTA

CCCTCCAATCGGGTAACT

CTCCCTCAGCAGCGTGGTG

CCCAGGAGAGTGTCACA

ACCGTGCCCTCCAGCAGCT

GAGCAGGACAGCAAGGA

TGGGCACCCAGACCTACAT

CAGCACCTACAGCCTCA

CTGCAACGTGAATCACAAG

GCAGCACCCTGACGCTG

CCCAGCAACACCNAAGGTG

AGCAAAGCAGACTACGA

GACAAGANAGTTGAGCCCA

GAAACACAAAGTCTACG

AATCTTGTGACAAAACTCA

CCTGCGAAGTCACCCAT

CACATGCCCACCGTGCCCA

CNGGGCCTGAGCTCGCC

GCACCTGAACTCCTGGGGG

CGTCACAAAGAGCTTCA

GACCGTCAGTCTTCCTCTTC

ACAGGGGAGAGTGTTAG

CCCCCAAAACCCANNNNAC

AAGCTTGGCCGCCATGG

CCNCATGATCTCCCNNACC

CCCAACTTGTTTATTGCA

CCTGANNCNCATGNNNGGN

GCTTATAATGGNTACAA

GGNNNCGTGAGCCACNAAG

ATAAAGCAATAGCATCA

ACCNTGNNNCAGTTCAACT

CAATTTCACAAATAAAG

GGNACNNNGNNGNNNNGG

CATTTTTTTCACTGCATT

NNGTGCATAATGNCAANAA

CTAGTTGTGGTTTGTCCA

NNAAGCCNCGGGANNANC

ANCTCATNANGNATNNN

ANTANNANNGCNNCGTACC

NCATGTCTNGNTCGGGN

GNNNNNNGNNNNNNNGTN

NNNTCGNNGCAGCACCA

NNNNNCGNCCNGCACNNNN

NGGNCNNGAANNNACCN

GNAANNNNNNTNN (SEQ

CNNANNAN (SEQ ID

ID NO: 3534)

NO: 3536)

V-C036
NNNNNNNNNNATGNATCNT
GAGGTGCAGCTGGTGCAGT
COV072_
NNNNNNNNNTATGTATC
CAGTCTGTGCTGACTCAGCC
COV072_

ACACNTACGATTTAGGTGA
CTGGAGTAGAGGTGAAAAA
P2_B10
NTACNCATACGATTTAG
TCCCTCCGTGTCCGGGTCTC
P2_B10

CACTATAGAATAACATCCA
GTCGGGGGAGTCTCTGAAG

GTGACACTATAGAATAA
CTGGACAGTCAGTCACCATC

CTTTGCCTTTCTCTCCACAG
ATCTCCTGTAAGGGCTCTG

CATCCACTTTGCCTTTCT
TCCTGCACTGGAACCAGCAG

GTGTCCACTCCCAGGTCCA
GATACAACTTTGCCACCTCC

CTCCACAGGTGTCCACTC
TGACGTTGGTAGTTATAACC

ACTGCACCTCGGTTCTATCG
TGGCTCGGCTGGGTGCGCC

CCAGGTCCAACTGCACC
GTGTCTCTTGGTACCAGCAG

ATTGAATTCCACCATGGGA
AGATGCCCGGCAAAGGCCT

TCGGTTCTATCGATTGAA
CCCCCAGGCACAGCCCCCA

TGGTCATGTATCATCCTTTT
GGAGTGGATGGGGATCATC

TTCCACCATGGGATGGTC
AACTCATGATTTATGAGGTC

TCTAGTAGCAACTGCAACC
TATCCTGGTGACTCTGATAC

ATGTATCATCCTTTTTCT
AATAATCGGCCCTCAGGGGT

GGTGTACATTCCGAGGTGC
CAGATACAGCCCGTCCTTC

AGTAGCAACTGCAACCG
CCCTGATCGCTTCTCTGGGT

AGCTGGTGCAGTCTGGAGT
CAAGGCCAGGTCACCATCT

GTTCCTGGGCCCAGTCTG
CCAAGTCTGGCAACACGGC

AGAGGTGAAAAAGTCGGGG
CAGCCGACAAGTCCATCAG

CCCTGACTCAGCCTCCCT
CTCCCTGACCATCTCTGGGC

GAGTCTCTGAAGATCTCCT
CACCGCCTACCTGCAGTGG

CCGTGTCCGGGTCTCCTG
TCCAGGCTGAAGACGAGGC

GTAAGGGCTCTGGATACAA
AGCAGCCTGAAGGCCTCGG

GACAGTCAGTCACCATC
TGATTATTACTGCAGCTCAT

CTTTGCCACCTCCTGGCTCG
ACACCGCCATGTATTACTGT

TCCTGCACTGGAACCAG
ATACAAGCAGTAGCAATTTC

GCTGGGTGCGCCAGATGCC
GCGAGACTCACATATACCA

CAGTGACGTTGGTAGTT
GATGTCTTCGGAACTGGGAC

CGGCAAAGGCCTGGAGTGG
GTGGCTGGTACTGGGGCCA

ATAACCGTGTCTCTTGGT
CAAGGTCACCGTCCTAG

ATGGGGATCATCTATCCTG
GGGAACCCTGGTCACCGTC

ACCAGCAGCCCCCAGGC
(SEQ ID NO: 3541)

GTGACTCTGATACCAGATA
TCGTCAG (SEQ ID NO:

ACAGCCCCCAAACTCAT

CAGCCCGTCCTTCCAAGGC
3539)

GATTTATGAGGTCAATA

CAGGTCACCATCTCAGCCG

ATCGGCCCTCAGGGGTC

ACAAGTCCATCAGCACCGC

CCTGATCGCTTCTCTGGG

CTACCTGCAGTGGAGCAGC

TCCAAGTCTGGCAACAC

CTGAAGGCCTCGGACACCG

GGCCTCCCTGACCATCTC

CCATGTATTACTGTGCGAG

TGGGCTCCAGGCTGAAG

ACTCACATATACCAGTGGC

ACGAGGCTGATTATTACT

TGGTACTGGGGCCAGGGAA

GCAGCTCATATACAAGC

CCCTGGTCACCGTCTCCTCA

AGTAGCAATTTCGATGTC

GCGTCGACCAAGGGCCCAT

TTCGGAACTGGGACCAA

CGGTCTTCCCCCTGGCACCC

GGTCACCGTCCTAGGTC

TCCTCCAAGAGCACCTCTG

AGCCCAAGGCCAACCCC

GGGGCACAGCGGCCCTGGG

ACTGTCACTCTGTTCCCG

CTGCCTGGTCAAGGACTAC

CCCTCGAGTGAGGAGCT

TTCCCCGAACCTGTGACGG

TCAAGCCAACAAGGCCA

TCTCGTGGAACTCAGGCGC

CACTGGTGTGTCTCATAA

CCTGACCAGCGGCGTGCAC

GTGACTTCTACCCGGGA

ACCTTCCCGGCTGTCCTACA

GCCGTGACAGTGGCCTG

GTCCTCNNACTCTACTCCCT

GAAGGCAGATAGCAGCC

CAGCAGCGTGGTGACCGTG

CCGTCAAGGCGGGAGTG

CCCTCCAGCAGCTTGGGCA

GAGACCACCACACCCTC

CCCAGACCTACATCTGCAA

CAAACAAAGCAACAACA

CGTGAATCACAAGCCCAGC

AGTACGCGGCCAGCAGC

AACACCNANGTGGACAAGA

TACCTGAGCCTGACGCCT

NAGTTGAGCCCAAATCTTG

GAGCAGTGGAAGTCCCA

TGACAAAACTCACACATGC

CAGAAGCTACAGCTGCC

CCACCGTGCCCAGCACCTG

AGGTCACGCATGANGGN

AACTCCTGGGGGGACCGTC

NCACCGTGGANAANACA

AGTCTTCCNCTTCCCCCCAA

GTGGNCCCTACAGAATG

ANCNNNNNCACCCTCATGA

TTCATAGAAGCTTGGCC

TCTCCCNGACCCCTGAGTC

GCCATGGCCCAACTTGTT

ACATGCGTGNGNNNNGTGA

TATTGCAGCTTANNATG

NCCACGANACCCTGNNNCA

GNTACAAATAAAGCAAT

GTCANTNNNCGTGNNGGCG

AGCATCACAAATTTCAC

TGNNNGCNTANNCNNAANN

NAATAAAGCATTTTTTNN

AGCNCNGGANNNNNANTAC

ACTGCATTCTANTNNNN

NANNNNNNGTACNNNNNG

NNTNGNCNAACTCATNA

NNAGCGTCCNNCNNNNTCN

NGNATCTNATCATGNNC

NNNCNNNNTNNNGAANNN

TGGNTCGGGNNNNNGNN

ANGGANNNCAANNNGCAN

CANCNNNTNNNNANNAC

GGNNNN (SEQ ID NO:

NNTGAANAGACNNNGNN

3538)

GNACTNCTGNNGNGGAA

NNAACATNNNNNNNGAA

N (SEQ ID NO:

3540)

V-C037
NNNNNNNNNNNATGNATCN
GAGGTGCAGCTGGTGCAGT
COV072_
NNNNNNNNNNATGTATC
CAGTCTGCCCTGACTCAGCC
COV072_

TACACNTACGATTTAGGTG
CTGGAGTAGAGGTGAAAAA
P2_D6
NTACACNTACGATTTAG
TCCCTCCGTGTCCGGGTCTC
P2_D6

ACACTATAGAATAACATCC
GTCGGGGGAGTCTCTGAAG

GTGACACTATAGAATAA
CTGGACAGTCAGTCACCATC

ACTTTGCCTTTCTCTCCACA
ATCTCCTGTAAGGGCTCTG

CATCCACTTTGCCTTTCT
TCCTGCACTGGAACCAGCAG

GGTGTCCACTCCCAGGTCC
GATACAACTTTGCCACCTCC

CTCCACAGGTGTCCACTC
TGACGTTGGTAGTTATAACC

AACTGCACCTCGGTTCTATC
TGGCTCGGCTGGGTGCGCC

CCAGGTCCAACTGCACC
GTGTCTCTTGGTACCAGCAG

GATTGAATTCCACCATGGG
AGATGCCCGGCAAAGGCCT

TCGGTTCTATCGATTGAA
CCCCCAGGCACAGCCCCCA

ATGGTCATGTATCATCCTTT
GGAGTGGATGGGGATCATC

TTCCACCATGGGATGGTC
AACTCATGATTTATGAGGTC

TTCTAGTAGCAACTGCAAC
TATCCTGGTGACTCTGATAC

ATGTATCATCCTTTTTCT
AATAATCGGCCCTCAGGGGT

CGGTGTACATTCCGAGGTG
CAGATACAGCCCGTCCTTC

AGTAGCAACTGCAACCG
CCCTGATCGCTTCTCTGGGT

CAGCTGGTGCAGTCTGGAG
CAAGGCCAGGTCACCATTT

GTTCCTGGGCCCAGTCTG
CCAAGTCTGGCAACACGGC

TAGAGGTGAAAAAGTCGGG
CAGCCGACAAGTCCATCAG

CCCTGACTCAGCCTCCCT
CTCCCTGACCATCTCTGGGC

GGAGTCTCTGAAGATCTCC
CACCGCCTACCTGCAGTGG

CCGTGTCCGGGTCTCCTG
TCCAGGCTGAAGACGAGGC

TGTAAGGGCTCTGGATACA
AGCAGCCTGAAGGCCTCGG

GACAGTCAGTCACCATC
TGATTATTACTGCAGCTCAT

ACTTTGCCACCTCCTGGCTC
ACACCGCCATGTATTACTGT

TCCTGCACTGGAACCAG
ATACAAGCAGTAGCAATTTC

GGCTGGGTGCGCCAGATGC
GCGAGACTCATATATACCA

CAGTGACGTTGGTAGTT
GATGTCTTCGGAACTGGGAC

CCGGCAAAGGCCTGGAGTG
GTGGCTGGTACTGGGGCCA

ATAACCGTGTCTCTTGGT
CAAGGTCACCGTCCTAG

GATGGGGATCATCTATCCT
GGGAACCCTGGTCACCGTC

ACCAGCAGCCCCCAGGC
(SEQ ID NO: 3545)

GGTGACTCTGATACCAGAT
TCCTCAG (SEQ ID

ACAGCCCCCAAACTCAT

ACAGCCCGTCCTTCCAAGG
NO: 3543)

GATTTATGAGGTCAATA

CCAGGTCACCATTTCAGCC

ATCGGCCCTCAGGGGTC

GACAAGTCCATCAGCACCG

CCTGATCGCTTCTCTGGG

CCTACCTGCAGTGGAGCAG

TCCAAGTCTGGCAACAC

CCTGAAGGCCTCGGACACC

GGCCTCCCTGACCATCTC

GCCATGTATTACTGTGCGA

TGGGCTCCAGGCTGAAG

GACTCATATATACCAGTGG

ACGAGGCTGATTATTACT

CTGGTACTGGGGCCAGGGA

GCAGCTCATATACAAGC

ACCCTGGTCACCGTCTCCTC

AGTAGCAATTTCGATGTC

AGCGTCGACCAAGGGCCCA

TTCGGAACTGGGACCAA

TCGGTCTTCCCCCTGGCACC

GGTCACCGTCCTAGGTC

CTCCTCCAAGAGCACCTCT

AGCCCAAGGCCAACCCC

GGGGGCACAGCGGCCCTGG

ACTGTCACTCTGTTCCCG

GCTGCCTGGTCAAGGACTA

CCCTCGAGTGAGGAGCT

CTTCCCCGAACCTGTGACG

TCAAGCCAACAAGGCCA

GTCTCGTGGAACTCANGCG

CACTGGTGTGTCTCATAA

CCCTGACCAGCGGCGTGCA

GTGACTTCTACCCGGGA

CACCTTCCCGGCTGTCCTAC

GCCGTGACAGTGGCCTG

AGTCCTCAGGACTCTACTCC

GAAGGCAGATAGCAGCC

CTCAGCAGCGTGGTGACCG

CCGTCAAGGCGGGAGTG

TGCCCTCCAGCAGCTTGGG

GAGACCACCACACCCTC

CACCCAGACCTACATCTGC

CAAACAAAGCAACAACA

AACGTGAATCACAAGCCCA

AGTACGCGGCCAGCAGC

GCAACACCAAAGGTGGANA

TACCTGAGCCTGACGCCT

AGANAGTTGAGCCCAAATC

GAGCAGTGGAAGTCCCA

TTGTGACAAAACTCACACA

CAGAAGCTACAGCTGCC

TGCCCACCGNGCCCAGCAC

AGGTCACGCATGAAGGG

CTGAACTNCTGGGGGGACC

AGCACCGTGGAGAAGAC

GTCAGTCTTCCTCTTCCCCC

AGTGGCCCCTACAGAAT

CAAAACCCNNNCACCCTCA

GTTCATAGAAGCTTGGN

TGATCTCCCNGACCCCNGA

CGCCATGGCCCAACTTGT

GTCACATGCGTGNGNGNCG

TTATTGCAGCTTATAATG

TGANCCACGANANCCTGAG

GNTACAAATAAAGCAAT

TCAGTNACTNNNCNNNNNG

AGCATCACAAATTTCAC

GNNNGGANNNGCATANNC

AAATAAAGCATTTTTTTC

NNAANNAGCNNNGNAGAG

ACTGCATTCTANTTGTGG

CANTANANAGCNNNTNCGN

TTTNTCCNAACTCATCAN

GNNNGNCANCGTCNNNNNN

GTATCTNNCATGTCTGGA

CNNN (SEQ ID NO:

TCGGGAATTANNCGNCG

3542)

CAGCNNNTGGCCTGAAA

NNACNCTGAAAGAGANN

NNNNGNNCTNCTGAGNG

AAANANNTCNGNNGAAN

GNNNNGNTCANTNNGGN

NNNNGNANGTCCAGNNN

CCCNNCAGNNNNNANNN

TGNNNGCATNCANNNNN

NNNNCNGCNNNNNGNNN

NNGGNNNNNN (SEQ

ID NO: 3544)

V-C038
NNNNNNNNNNNATGTATCN
GAGGTGCAGCTGGTGGAGT
COV072_
NNNNNNNNNNNNNTGTA
AATTTTATGCTGACTCAGCC
COV072_

TACACATACGATTTAGGTG
CTGGGGGAGGCTTGGTCCA
P2_C9
TCNTACACATACGATTTA
CCACTCTGTGTCGGAGTCTC
P2_C9

ACACTATAGAATAACATCC
GCCTGGGGGGTCCCTGAGA

GGTGACACTATAGAATA
CGGGGAAGACGGTAACCAT

ACTTTGCCTTTCTCTCCACA
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CTCCTGCACCGGCAGCAGTG

GGTGTCCACTCCCAGGTCC
ATTCACCTTTAGTACCTATT

TCTCCACAGGTGTCCACT
GCAGCATTGCCAGCAACTAT

AACTGCACCTCGGTTCTATC
GGATGAGCTGGGTCCGCCA

CCCAGGTCCAACTGCAC
GTGCAGTGGTACCAGCAGC

GATTGAATTCCACCATGGG
GCCTCCAGGGAAGGGGCTG

CTCGGTTCTATCGATTGA
GCCCGGGCAGTGCCCCCACC

ATGGTCATGTATCATCCTTT
GAGTGGGTGGCCAACATAA

ATTCCACCATGGGATGG
ACTGTGATCTATGAGGATAA

TTCTAGTAGCAACTGCAAC
AGCAAGATGGAAGTGAGAA

TCATGTATCATCCTTTTT
CCAAAGACCCTCTGGGGTCC

CGGTGTACATTCTGAGGTG
ATACTATGTGGATTCTGTGA

CTAGTAGCAACTGCAAC
CTGATCGGTTCTCTGGCTCC

CAGCTGGTGGAGTCTGGGG
AGGGCCGATTCACCATCTC

CGGTTCTTGGGCCAATTT
ATCGACAGCTCCTCCAACTC

GAGGCTTGGTCCAGCCTGG
CAGAGACAACGCCAAGAAC

TATGCTGACTCAGCCCCA
TGCCTCCCTCACCATCTCTG

GGGGTCCCTGAGACTCTCC
TCACTGTATCTGCAAATGA

CTCTGTGTCGGAGTCTCC
GACTGAAGACTGAGGACGA

TGTGCAGCCTCTGGATTCAC
ACAGCCTGAGAGCCGACGA

GGGGAAGACGGTAACCA
GGCTGACTACTACTGTCAGT

CTTTAGTACCTATTGGATGA
CACGGCCGTGTATTACTGT

TCTCCTGCACCGGCAGC
CTTATGATAGCAGCAATTGG

GCTGGGTCCGCCAGCCTCC
GCCGGGGGGACATGGCTAC

AGTGGCAGCATTGCCAG
GTGTTCGGCGGAGGGACCA

AGGGAAGGGGCTGGAGTGG
GATCCTCTTTTGACTACTGG

CAACTATGTGCAGTGGT
AGCTGACCGTCCTA (SEQ

GTGGCCAACATAAAGCAAG
GGCCAGGGAACCCTGGTCA

ACCAGCAGCGCCCGGGC
ID NO: 3549)

ATGGAAGTGAGAAATACTA
CCGTCTCCTCAG (SEQ ID

AGTGCCCCCACCACTGT

TGTGGATTCTGTGAAGGGC
NO: 3547)

GATCTATGAGGATAACC

CGATTCACCATCTCCAGAG

AAAGACCCTCTGGGGTC

ACAACGCCAAGAACTCACT

CCTGATCGGTTCTCTGGC

GTATCTGCAAATGAACAGC

TCCATCGACAGCTCCTCC

CTGAGAGCCGACGACACGG

AACTCTGCCTCCCTCACC

CCGTGTATTACTGTGCCGG

ATCTCTGGACTGAAGAC

GGGGACATGGCTACGATCC

TGAGGACGAGGCTGACT

TCTTTTGACTACTGGGGCCA

ACTACTGTCAGTCTTATG

GGGAACCCTGGTCACCGTC

ATAGCAGCAATTGGGTG

TCCTCAGCGTCGACCAAGG

TTCGGCGGAGGGACCAA

GCCCATCGGTCTTCCCCCTG

GCTGACCGTCCTACGTCA

GCACCCTCCTCCAAGAGCA

GCCCAAGGCTGCCCCCT

CCTCTGGGGGCACAGCGGC

CGGTCACTCTGTTCCCGC

CCTGGGCTGCCTGGTCAAG

CCTCGAGTGAGGAGCTT

GACTACTTCCCCGAACCTGT

CAAGCCAACAAGGCCAC

GACGGTCTCGTGGAACTCA

ACTGGTGTGTCTCATAAG

GGCGCCCTGACCAGCGGCG

TGACTTCTACCCGGGAG

TGCACACCTTCCCGGCTGTC

CCGTGACAGTGGCCTGG

CTACAGTCCTCANGACTCT

AAGGCAGATAGCAGCCC

ACTCCCTCAGCAGCGTGGT

CGTCAAGGCGGGAGTGG

GACCGTGCCCTCCAGCAGC

AGACCACCACACCCTCC

TTGGGCACCCAGACCTACA

AAACAAAGCAACAACAA

TCTGCAACGTGAATCACAA

GTACGCGGCCAGCAGCT

GCCCAGCAACACCNAAGGT

ACCTGAGCCTGACGCCT

GGACNAGAGAGTTGAGCCC

GAGCAGTGGAAGTCCCA

AAATCTTGTGACNAAACTC

CAGAAGCTACAGCTGCC

ACACATGCCCACCGTGCCC

AGGTCACGCATGAAGGG

AGCACCTGAACTCCTGGGG

AGCACCGTGGANAAGAC

GGACCGTCAGTCTTCCTCNT

AGTGGCCCCTACAGAAT

CCCCCAAACCCAAGGACAC

GTTCATAGAAGCTTGGC

CCTCATGATCTCCCGGACCC

CGCCATGGCCCAACTTGT

TGANTCACATGCNTGGTGG

TTATTGCAGCTTATAATG

TGGANGTGAGCCACNANNN

GTTACNAATAAAGCAAT

CNTGAGGTCANTCANTGGN

ANCATCACAAATTTCAC

ACGNNGNNGGCNNNGAGG

AAATAAAGCATTTTTTTC

TGCATAANNCNNNNNNAAG

ACTGCATTCTANTNGNG

CNNNGGNAGGANCNNTACA

GTTTGTCCAANCTCATCA

ANNNNCNCGTACNNNNNNN

NGNATNNNNNATGTCTG

NANNNGTCNTNNNCGTNNN

GATCGGNATTNNNGNNN

NNNNCNNNAANNNNNNTG

NNNNCNNCNTGGCCTGA

AANNG (SEQ ID NO:

AANNACCTCTGAAAGAN

3546)

NNTNNNNGNANNNNGAG

NNNANNNNTCNGNNNNG

NNNNGTCANTNGGGTGN

NGAANNNCCAGNTNCCC

NNCAGNNNANNNNTGNA

AGCATGNATNTCNNNNN

CANNNNNNNNNGNGNN

(SEQ ID NO: 3548)

V-C039
NNNNNNNNNNATGNATCNT
CAGGTGCAGCTGGTGGAGT
COV072_
NNNNNNNNNNNTATGNA
GACATCCAGATGACCCAGTC
COV072_

ACACATACGATTTAGGTGA
CTGGGGGAGGCGTGGTCCA
P2_F3
TCNTACACNTACGATTTA
TCCATCCTCCCTGTCTGCAT
P2_F3

CACTATAGAATAACATCCA
GCCTGGGAGGTCCCTGAGA

GGTGACACTATAGAATA
CTGTAGGAGACAGAGTCAC

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CATCACTTGCCAGGCGAGTC

GTGTCCACTCCCAGGTCCA
ATTCACCTTCAGTAGCTATG

TCTCCACAGGTGTCCACT
AGGACATTAGCAACTATTTA

ACTGCACCTCGGTTCTATCG
CCATGCACTGGGTCCGCCA

CCCAGGTCCAACTGCAC
AATTGGTATCAGCAGAAAC

ATTGAATTCCACCATGGGA
GGCTCCAGGCAAGGGGCTG

CTCGGTTCTATCGATTGA
CAGGGAAAGCCCCTAAGCT

TGGTCATGTATCATCCTTTT
GAGTGGGTGGCAGTTATAT

ATTCCACCATGGGATGG
CCTGATCTACGATGCATCCA

TCTAGTAGCAACTGCAACC
CATATGATGGAAGTAATAA

TCATGTATCATCCTTTTT
ATTTGGAAACAGGGGTCCC

GGTGTACATTCTGAGGTGC
ATACTCTGCAGACTCCGTG

CTAGTAGCAACTGCAAC
ATCAAGGTTCAGTGGAAGT

AGCTGGTGGAGTCTGGGGG
AAGGGCCGATTCACCATCT

CGGTGTACATTCTGACAT
GGATCTGGGACAGATTTTAC

AGGCGTGGTCCAGCCTGGG
CCAGAGACAATTCCAAGAA

CCAGATGACCCAGTCTC
TTTCACCATCAGCAGCCTGC

AGGTCCCTGAGACTCTCCT
CACGCTGTATCTGCAAATG

CATCCTCCCTGTCTGCAT
AGCCTGAAGATATTGCAAC

GTGCAGCCTCTGGATTCAC
AACAGCCTGAGAGCTGAGG

CTGTAGGAGACAGAGTC
ATATTACTGTCAACAGTATG

CTTCAGTAGCTATGCCATGC
ACACGGCTGTGTATTACTGT

ACCATCACTTGCCAGGC
ATAATCTCCCGCTCACTTTC

ACTGGGTCCGCCAGGCTCC
GCGAAAGGGGGGGCCTACA

GAGTCAGGACATTAGCA
GGCGGAGGGACCAAGGTGG

AGGCAAGGGGCTGGAGTGG
GCTACTACTACTACATGGA

ACTATTTAAATTGGTATC
AGATCAAAC (SEQ ID

GTGGCAGTTATATCATATG
CGTCTGGGGCAAAGGGACC

AGCAGAAACCAGGGAAA
NO: 3553)

ATGGAAGTAATAAATACTC
ACGGTCACCGTCTCCTCA

GCCCCTAAGCTCCTGATC

TGCAGACTCCGTGAAGGGC
(SEQ ID NO: 3551)

TACGATGCATCCAATTTG

CGATTCACCATCTCCAGAG

GAAACAGGGGTCCCATC

ACAATTCCAAGAACACGCT

AAGGTTCAGTGGAAGTG

GTATCTGCAAATGAACAGC

GATCTGGGACAGATTTT

CTGAGAGCTGAGGACACGG

ACTTTCACCATCAGCAGC

CTGTGTATTACTGTGCGAA

CTGCAGCCTGAAGATAT

AGGGGGGGCCTACAGCTAC

TGCAACATATTACTGTCA

TACTACTACATGGACGTCT

ACAGTATGATAATCTCCC

GGGGCAAAGGGACCACGGT

GCTCACTTTCGGCGGAG

CACCGTCTCCTCAGCGTCG

GGACCAAGGTGGAAATC

ACCAAGGGCCCATCGGTCT

AAACGTACGGTGGCTGC

TCCCCCTGGCACCCTCCTCC

ACCATCTGTCTTCATCTT

AAGAGCACCTCTGGGGGCA

CCCGCCATCTGATGAGC

CAGCGGCCCTGGGCTGCCT

AGTTGAAATCTGGAACT

GGTCAAGGACTACTTCCCC

GCCTCTGTTGTGTGCCTG

GAACCTGTGACGGTCTCGT

CTGAATAACTTCTATCCC

GGAACTCANGCGCCCTGAC

AGAGAGGCCAAAGTACA

CAGCGGCGTGCACACCTTC

GTGGAAGGTGGATAACG

CCGGCTGTCCTACAGTCCTC

CCCTCCAATCGGGTAACT

NNNCTCTACTCCCTCAGCA

CCCAGGAGAGTGTCACA

GCGTGGTGACCGTGCCCTC

GAGCAGGACAGCAAGGA

CAGCAGCTTGGGCACCCAG

CAGCACCTACAGCCTCA

ACCTACATCTGCAACGTGA

GCAGCACCCTGACGCTG

ATCACAAGCCCAGCAACAC

AGCAAAGCAGACTACGA

CAAGGTGGACAAGAGAGTT

GAAACACAAAGTCTACG

GAGCCCAAATCTTGTGANN

CCTGCGAAGTCACCCAT

AAACTCACACATGCCCACC

CNGGCCTGAGCTCGCCC

GTGCCCAGCANCTGAACTN

GTCACAAAGAGCTTCAA

CTGGGGGGACCGTCAGTCT

CAGGGGAGAGTGTTAGA

TCCTCNTCCCCCNAANCCN

AGCTTGGCCGCCATGGN

AGGACACCCNNCATGATCT

CCAACTTGNTTATTGCAG

NCCNNACCNNGAGTCACAT

CTTATNATGGTTACAATA

GCGTGNNNNNNGTNAGCAC

AAGCAATAGCATCACAA

GANANCCTGAGTCAGTCAN

ATTTCACAAATAAAGCA

TGGNACNNNGNNGGNNNN

TTTTTTTCACTGCATTCT

GNNNNGCNTANNCNNANN

ANTNGNNGGTTNGTCCA

NCNNNGGNAGNANCNNTAC

ANCTCATCAATGNATNN

ANNNNNCGTACNNNNNGNC

NNCATGTCTGGNTCGGG

AGCNNNNTNNNCGTCNNNN

ANTNNNNGNGCAGCNNC

CCNNGNNNGNNNNAANGG

NTGGCNTGAANNNNNTC

NA (SEQ ID NO:

TGAAGAGANTNNNAGNA

3550)

CNNTGAGNGNNNCNTNN

NNNNNNNNNNNNNNNTC

AGTNGNNNNNNGAANNN

(SEQ ID NO: 3552)

V-C040
NNNNNNNNNATGNATCNTA
GAGGTGCAGCTGGTGGAGT
COV072_
NNNNNNNNNNNNNGNAT
GACATCCAGTTGACCCAGTC
COV072_

CACATACGATTTAGGTGAC
CTGGGGGAGGCTTGGTCCA
P2_C12
CNTACACATACGATTTA
TCCATCCTTCCTGTCTGCAT
P2_C12

ACTATAGAATAACATCCAC
GCCTGGGGGGTCCCTGAGA

GGTGACACTATAGAATA
CTGTAGGAGACAGAGTCAC

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CATCACTTGCCGGGCCAGTC

TGTCCACTCCCAGGTCCAA
AGTCACCGTCAGTAGCAAC

TCTCCACAGGTGTCCACT
AGGGCATTAGCAGTTATTTA

CTGCACCTCGGTTCTATCGA
TACATGAGCTGGGTCCGCC

CCCAGGTCCAACTGCAC
GCCTGGTATCAGCAAAAAC

TTGAATTCCACCATGGGAT
AGGCTCCAGGGAAGGGGCT

CTCGGTTCTATCGATTGA
CAGGGAAAGCCCCTAAGCT

GGTCATGTATCATCCTTTTT
GGAGTGGGTCTCACTTATTT

ATTCCACCATGGGATGG
CCTGATCTATGCTGCATCCA

CTAGTAGCAACTGCAACCG
ATAGCGGTGGTAGCACATT

TCATGTATCATCCTTTTT
CTTTGCAAAGTGGGGTCCCA

GTGTACATTCTGAGGTGCA
CTACGCAGACTCCGTGAAG

CTAGTAGCAACTGCAAC
TCAAGGTTCAGCGGCAGTG

GCTGGTGGAGTCTGGGGGA
GGCAGATTCACCATCTCCA

CGGTGTACATTCAGACA
GATCTGGGACAGAATTCACT

GGCTTGGTCCAGCCTGGGG
GAGACAATTCCGAGAACAC

TCCAGTTGACCCAGTCTC
CTCACAATCAGCAGCCTGCA

GGTCCCTGAGACTCTCCTGT
GCTGTATCTTCAAATGAAC

CATCCTTCCTGTCTGCAT
GCCTGAAGATTTTGCAACTT

GCAGCCTCTGGAGTCACCG
ACCCTGAGAGCCGAGGACA

CTGTAGGAGACAGAGTC
ATTACTGTCAACAGCTTAAT

TCAGTAGCAACTACATGAG
CGGCTGTGTATTACTGTGCG

ACCATCACTTGCCGGGC
AGTTACTCTTACACTTTTGG

CTGGGTCCGCCAGGCTCCA
AGAGATCTGTATTACTACG

CAGTCAGGGCATTAGCA
CCAGGGGACCAAGCTGGAG

GGGAAGGGGCTGGAGTGGG
GTATGGACGTCTGGGGCCA

GTTATTTAGCCTGGTATC
ATCAAAC (SEQ ID NO:

TCTCACTTATTTATAGCGGT
AGGGACCACGGTCACCGTC

AGCAAAAACCAGGGAAA
3557)

GGTAGCACATTCTACGCAG
TCCTCA (SEQ ID NO:

GCCCCTAAGCTCCTGATC

ACTCCGTGAAGGGCAGATT
3555)

TATGCTGCATCCACTTTG

CACCATCTCCAGAGACAAT

CAAAGTGGGGTCCCATC

TCCGAGAACACGCTGTATC

AAGGTTCAGCGGCAGTG

TTCAAATGAACACCCTGAG

GATCTGGGACAGAATTC

AGCCGAGGACACGGCTGTG

ACTCTCACAATCAGCAG

TATTACTGTGCGAGAGATC

CCTGCAGCCTGAAGATTT

TGTATTACTACGGTATGGA

TGCAACTTATTACTGTCA

CGTCTGGGGCCAAGGGACC

ACAGCTTAATAGTTACTC

ACGGTCACCGTCTCCTCAG

TTACACTTTTGGCCAGGG

CGTCGACCAAGGGCCCATC

GACCAAGCTGGAGATCA

GGTCTTCCCCCTGGCACCCT

AACGTACGGTGGCTGCA

CCTCCAAGAGCACCTCTGG

CCATCTGTCTTCATCTTC

GGGCACAGCGGCCCTGGGC

CCGCCATCTGATGAGCA

TGCCTGGTCAAGGACTACT

GTTGAAATCTGGAACTG

TCCCCGAACCTGTGACGGT

CCTCTGTTGTGTGCCTGC

CTCGTGGAACTCAGGCGCC

TGAATAACTTCTATCCCA

CTGACCAGCGGCGTGCACA

GAGAGGCCAAAGTACAG

CCTTCCCGGCTGTCCTACAG

TGGAAGGTGGATAACGC

TCCTCAGGACTCTACTCCCT

CCTCCAATCGGGTAACTC

CAGCAGCGTGGTGACCGTG

CCAGGAGAGTGTCACAG

CCCTCCAGCAGCTTGGGCA

AGCANGACAGCAAGGAC

CCCAGACCTACATCTGCAA

AGCACCTACAGCCTCAG

CGTGAATCACAAGCCCAGC

CAGCACCCTGACGCTGA

AACACCNANGTGGACAAGA

NCAAAGCAGACTACGAG

NAGTTGAGCCCAAATCTTG

AAACACAAAGTCTACGC

TGACAAAACTCACACATGC

CTGCGAAGTCACCCATC

CCACCGTGCCCAGCACCTG

AGGGCCTGAGCTCGCCC

AACTCCTGGGGGGACCGTC

GTCACAAAGAGCTTCAA

AGTCTTCCTCTTCCCCCCAA

CAGGGGAGAGTGTTAGA

AANCCAAGGACACCCTNAT

AGCTTGGCCGCCATGGC

GATCNCCCNGACCCCNGAN

CCAACTTGTTTATTGCAG

TCACATGCGTGGNGNNGAC

CTTATAATGGNTACAAA

GTGAGCCACGANACCCNGA

TAAAGCAATAGCATCAC

GTCAGTTCAACTGGNACGN

AAATTTCACAAATAAAG

NGNNGGNNNNGGAGGTGC

CATTTTTTTCACTGCATT

ANANNCNNNAANAAGCCN

CTANTTGNGGNTTGNCC

NNGGNAGGANNAGTANAN

AAACTCATNNNGNATNT

NGNNCGTACNNNNNNNNCA

NTCATGTCTGNATCNGN

NCGTCNNCNNCNNNNNNNC

NNTNATTCGNCGCAGCN

AGNNTNNNGAANGGCNNG

CNTNNNNAANNACNCTG

NNNNNNNANNGCAANGNN

AANAGNNNNNNNNACN

NNNCNNNNAANNNNNN

NNGAGNGAANAACNTNN

(SEQ ID NO: 3554)

TGNGANNNNNNNTCAGT

NGGNNGNNGAAAGTCCC

NNGNTNCCNANCAGNAN

ANNNTGNNNCANGCATT

NNCANNNNNNNCNNCNG

NNNNGGAAANTCNNNNN

NNNN (SEQ ID NO:

3556)

V-C041
NNNNNNNNNATGTATCNTA
CAGGTGCAGCTGGTGGAGT
COV072_
NNNNNNNNNNTATGNAT
AATTTTATGCTGACTCAGCC
COV072_

CACNTACGATTTAGGTGAC
CTGGGGGAGGCGTGGTCCA
P3_H7
CNTACACATACGATTTA
CCACTCTGTGTCGGAGTCTC
P3_H7

ACTATAGAATAACATCCAC
GCCTGGGAGGTCCCTGAGA

GGTGACACTATAGAATA
CGGGGAAGACGGTAACCAT

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CTCCTGCACCGGCAGCAGTG

TGTCCACTCCCAGGTCCAA
ATTCACCTTCAGTAGCTATG

TCTCCACAGGTGTCCACT
GCAGCATTGCCAGCAACTAT

CTGCACCTCGGTTCTATCGA
CTATGTTCTGGGTCCGCCAG

CCCAGGTCCAACTGCAC
GTGCAGTGGTACCAGCAGC

TTGAATTCCACCATGGGAT
GCTCCAGGCAAGGGGCTGG

CTCGGTTCTATCGATTGA
GCCCGGGCAGTGCCCCCACC

GGTCATGTATCATCCTTTTT
AGTGGGTGGCAGTTATATC

ATTCCACCATGGGATGG
ACTGTGATCTATGAGGATAA

CTAGTAGCAACTGCAACCG
ATATGATGGAAGCAATAAA

TCATGTATCATCCTTTTT
CCAAAGACCCTCTGGGGTCC

GTGTACATTCTGAGGTGCA
TACTACGCAGACTCCGTGA

CTAGTAGCAACTGCAAC
CTGATCGGTTCTCTGGCTCC

GCTGGTGGAGTCTGGGGGA
AGGGCCGATTCACCATCTC

CGGTTCTTGGGCCAATTT
ATCGACAGCTCCTCCAACTC

GGCGTGGTCCAGCCTGGGA
CAGAGACAATTCCAAGAAC

TATGCTGACTCAGCCCCA
TGCCTCCCTCACCATCTCTG

GGTCCCTGAGACTCTCCTGT
ACGCTGTATCTGCAAATGA

CTCTGTGTCGGAGTCTCC
GACTGAAGACTGAGGACGA

GCAGCCTCTGGATTCACCTT
ACAGCCTGAGAGCTGAGGA

GGGGAAGACGGTAACCA
GGCTGACTACTACTGTCAGT

CAGTAGCTATGCTATGTTCT
CACGGCTGTGTATTACTGTG

TCTCCTGCACCGGCAGC
CTTATGATAGCAGCAATTGG

GGGTCCGCCAGGCTCCGGG
CGAGGGCGGATTTAGGATA

AGTGGCAGCATTGCCAG
GTGTTCGGCGGAGGGACCA

CAAGGGGCTGGAGTGGGTG
TTGTACTAATGGTGTATGCT

CAACTATGTGCAGTGGT
AGCTGACCGTCCTAG (SEQ

GCAGTTATATCATATGATG
ATGTTGACTACTGGGGCCA

ACCAGCAGCGCCCGGGC
ID NO: 310)

GAAGCAATAAATACTACGC
GGGAACCCTGGTCACCGTC

AGTGCCCCCACCACTGT

AGACTCCGTGAAGGGCCGA
TCCTCA (SEQ ID NO:

GATCTATGAGGATAACC

TTCACCATCTCCAGAGACA
3559)

AAAGACCCTCTGGGGTC

ATTCCAAGAACACGCTGTA

CCTGATCGGTTCTCTGGC

TCTGCAAATGAACAGCCTG

TCCATCGACAGCTCCTCC

AGAGCTGAGGACACGGCTG

AACTCTGCCTCCCTCACC

TGTATTACTGTGCGAGGGC

ATCTCTGGACTGAAGAC

GGATTTAGGATATTGTACT

TGAGGACGAGGCTGACT

AATGGTGTATGCTATGTTG

ACTACTGTCAGTCTTATG

ACTACTGGGGCCAGGGAAC

ATAGCAGCAATTGGGTG

CCTGGTCACCGTCTCCTCAG

TTCGGCGGAGGGACCAA

CGTCGACCAAGGGCCCATC

GCTGACCGTCCTAGGTC

GGTCTTCCCCCTGGCACCCT

AGCCCAAGGCTGCCCCC

CCTCCAAGAGCACCTCTGG

TCGGTCACTCTGTTCCCG

GGGCACAGCGGCCCTGGGC

CCCTCGAGTGAGGAGCT

TGCCTGGTCAAGGACTACT

TCAAGCCAACAAGGCCA

TCCCCGAACCTGTGACGGT

CACTGGTGTGTCTCATAA

CTCGTGGAACTCANGCGCC

GTGACTTCTACCCGGGA

CTGACCAGCGGCGTGCACA

GCCGTGACAGTGGCCTG

CCTTCCCGGCTGTCCTACAG

GAAGGCAGATAGCAGCC

TCCTCAGGACTCTACTCCCT

CCGTCAAGGCGGGAGTG

CAGCAGCGTGGTGACCGTG

GAGACCACCACACCCTC

CCCTCCAGCAGCTTGGGCA

CAAACAAAGCAACAACA

CCCAGACCTACATCTGCAA

AGTACGCGGCCAGCAGC

CGTGAATCACAAGCCCAGC

TACCTGAGCCTGACGCCT

AACACCANNNGGACAAGA

GAGCAGTGGAAGTCCCA

NAGTTGAGCCCAAATCTTG

CAGAAGCTACAGCTGCC

TGACAAAACTCACACATGC

AGGTCACGCATGAAGGG

CCACCGTGCCCAGCACCTG

AGCACCGTGGNNAAGAC

ACTCCTGGGGGGACCGTCA

AGTGGCCCCTACAGAAT

GTCTTCNNNTCCCCCAAAA

GTTCATAGAAGCTTGGC

NCCAANNNANCCNTCATGA

CGCCATGGCCCAACTTGT

TCTNCCNNCCNNGAGTCAC

TTATTGCAGCTTATAATG

NTGNNGTGGNGNNNGNNGT

GTTACAAATAAAGCANA

GANCNCNANANCCTGAGTC

GCATCACAAATTTCACA

AGTCACTNNNCNTGNNNNN

AATAAAGCATTTTTTTCA

NNNGANNNGCNNANNCNN

CTGCATNCTANTNGNGG

NNNNANCNNNGANNANAG

TTTGTCCAAACTCATCNN

TNCANNGNNCNNNCNNNNN

NNATNNNTCATGTCTGG

NGNCANCNNNNNNNNNNC

ATCGGGAATNNNTNGNC

CGTNNNNNNNCNNNNGNA

GCANCNCNTGCCTGANN

ANNNGGCNNNNN (SEQ

ACCTCTGAANANNNTNN

ID NO: 3558)

NGTACTNCNGAGNGAAA

NNANNTCTGNGNNNNNN

GTCAGTTNGGGNGNNNN

NNCCNGNTNCCCNNNNN

GNANANNNTGCAAGCAT

GCNTNNTNNNTNANTCA

NN (SEQ ID NO:

3560)

V-C042

GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNNNTNNNGNN
GACATCGTGATGACCCAGTC
COV047_

CTGGGGGAGGCTTGGTCCA
P5_H7
TNNTACNCATACGATTTA
TCCAGACTCCCTGGCTGTGT
P5_H7

GCCGGGGGGGTCCCTGAGA

GGTGACACTATAGAATA
CTNTGGGCGAGAGGGCCAC

CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CATCAACTGCAAGTCCAGCC

ATTCAGTGTCAGCACGAAG

TCTCCACAGGTGTCCACT
AGAGTGTTTTATACAGCTCC

TACATGACATGGGTCCGTC

CCCAGGTCCAACTGCAC
AACAATAAGAACTACTTAG

AGGCTCCAGGGAAGGGACT

CTCGGTTCTATCGATTGA
CTTGGTACCAGCAGAAACC

GGAGTGGGTCTCAGCTCTTT

ATTCCACCATGGGATGG
AGGACAGCCTCCTAAGCTGC

ACAGCGGTGGTAGTGATTA

TCATGTATCATCCTTTTT
TCATTTACTGGGCATCTACC

CTACGCAGACTCCGTGAAG

CTAGTAGCAACTGCAAC
CGGGAATCCGGGGTCCCTG

GGCAGATTCACCATCTCCA

CGGTGTACATTCGGACA
ACCGATTCAGTGGCAGCGG

GAGACAATTCCAAGAACAC

TCGTGATGACCCAGTCTC
GTCTGGGACAGATTTCACTC

TTTATATCTTCAAATGAGCA

CAGACTCCCTGGCTGTGT
TCACCATCAGCAGCCTGCAG

GCTTGAGAGTCGAGGACAC

CTCTGGGCGAGAGGGCC
GCTGAAGATGTGGCAGTTTA

GGGTGTTTATTACTGTGCCA

ACCATCAACTGCAAGTC
TTACTGTCAGCAATATTATA

GAGACTCGTCGGAAGTCCG

CAGCCAGAGTGTTTTATA
GTACTCCGCTCACTTTCGGC

TGACCACCCCGGGCACCCA

CAGCTCCAACAATAAGA
GGAGGGACCAAGGTGGAGA

GGGCGCTCGGTGGGGGCTT

ACTACTTAGCTTGGTACC
TCAAAC (SEQ ID NO:

TTGATATTTGGGGCCAAGG

AGCAGAAACCAGGACAG
3564)

GACAATGGTC (SEQ ID

CCTCCTAAGCTGCTCATT

NO: 3562)

TACTGGGCATCTACCCG

GGAATCCGGGGTCCCTG

ACCGATTCAGTGGCAGC

GGGTCTGGGACAGATTT

CACTCTCACCATCAGCA

GCCTGCAGGCTGAAGAT

GTGGCAGTTTATTACTGT

CAGCAATATTATAGTACT

CCGCTCACTTTCGGCGGA

GGGACCAAGGTGGAGAT

CAAACGTACGGTGGCTG

CACCATCTGTCTTCATCT

TCCCGCCATCTGATGAGC

AGTTGAAATCTGGAACT

GCCTCTGTTGTGTGCCTG

CTGAATAACTTCTATCCC

AGAGAGGCCAAAGTACA

GTGGAAGGTGGATAACG

CCCTCCAATCGGGTAACT

CCCAGGAGAGTGTCACA

GAGCAGGACAGCAAGGA

CAGCACCTACAGCCTCA

GCAGCACCCTGACGCTG

AGCAAAGCAGACTACGA

GAAACACAAAGTCTACG

CCTGCGAAGTCACCCAT

CANGGCCTGAGCTCGCC

CGTCACAAAGAGCTTCA

ACAGGGGAGAGTGTTAG

AAGCTTGGCCGCCATGG

CCCAACTTGTTTATTGCA

GCTTATAATGGTTACAA

ATAAAGCAATAGCATCA

CAAATTTCACAAATAAA

GCATTTTTTTCACTGCAT

TCTANTTGTGGTTTGTCC

AAACTCATCAATGTATCT

NATCATGTCTGGATCGG

GAATTNATTCGGCGCAG

CANCATGGNCCTGAAAT

AACCTNNNAAAGANNAC

TTGNTTAGNACNTNCTG

ANNNNANNACATCNNNN

GAATGNNNGTCANNNNN

NGGNNGAAAGTCCCNNN

CTCCCCNNCNGNNANNN

TGCNNANNNNNNNNNNN

NNNNCAGCACNGNNNGA

ANNNNNNNNNNNNNNN

GCNAANNNNCANCANNN

ANNNNNNNNNNNNNNN

ANC (SEQ ID NO:

3563)

V-C043
NNNNNNNNNNATGNATCNT
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNCCNNNNNNT
CAGTCTGTGCTGACTCAGCC
COV047_

ACACATACGATTTAGGTGA
CTGGGGGAGGCTTGGTCCA
P5_E9
ANNNTACNCATACGATT
TGCCTCCGTGTCTGGGTCTC
P5_E9

CACTATAGAATAACATCCA
GCCGGGGGGGTCCCTGAGA

TAGGTGACACTATAGAA
CTGGACAGTCGATCACCATC

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCCTCTGG

TAACATCCACTTTGCCTT
TCCTGCACTGGAACCAGCAA

GTGTCCACTCCCAGGTCCA
ATTCAGTGTCAGCACCAAG

TCTCTCCACAGGTGTCCA
TGATGTTGGGAGTTATACCC

ACTGCACCTCGGTTCTATCG
TACATGACATGGGTCCGTC

CTCCCAGGTCCAACTGC
TTGTCTCCTGGTACCAACAG

ATTGAATTCCACCATGGGA
AGGCTCCAGGGAAGGGGCT

ACCTCGGTTCTATCGATT
TACCCAGGCAAAGCCCCCA

TGGTCATGTATCATCCTTTT
GGAGTGGGTCTCAGTTCTTT

GAATTCCACCATGGGAT
AACTCTTAATTTTTGAGGGC

TCTAGTAGCAACTGCAACC
ACAGCGGTGGTAGTGATTA

GGTCATGTATCATCCTTT
ACTAAGCGGTCCTCAGGGAT

GGTGTACATTCTGAGGTGC
CTACGCAGACTCCGTGAAG

TTCTAGTAGCAACTGCA
TTCTAATCGCTTCTCTGGTTC

AGCTGGTGGAGTCTGGGGG
GGCAGATTCACCATCTCCA

ACCGGTTCCTGGGCCCA
CAAGTCTGGCAACACGGCCT

AGGCTTGGTCCAGCCGGGG
GAGACAATTCCAAGAACGC

GTCTGCCCTGACTCAGCC
CCCTGACAATCTCTGGGCTC

GGGTCCCTGAGACTCTCCT
TTTATATCTTCAAATGAACA

TGCCTCCGTGTCTGGGTC
CAGGGTGAAGACGAGGCTG

GTGCAGCCTCTGGATTCAG
GCTTGAGAGTCGAGGACAC

TCCTGGACAGTCGATCA
ATTATTATTGCTGCTCATAT

TGTCAGCACCAAGTACATG
GGGTGTTTATTACTGTGCCA

CCATCTCCTGCACTGGAA
GCAGGTGCTAGCACTTTCGT

ACATGGGTCCGTCAGGCTC
GAGACTCGTCGGAAGTCCG

CCAGCAATGATGTTGGG
GTTCGGCGGAGGGACCAAG

CAGGGAAGGGGCTGGAGTG
TGACCACCCCGGGCACCCA

AGTTATACCCTTGTCTCC
CTGACCGTCCTAG (SEQ

GGTCTCAGTTCTTTACAGCG
GGGCGCTCGGTGGGGGCTT

TGGTACCAACAGTACCC
ID NO: 3568)

GTGGTAGTGATTACTACGC
TTGATATCTGGGGCCAAGG

AGGCAAAGCCCCCAAAC

AGACTCCGTGAAGGGCAGA
GACAATGGTCACCGTCTCTT

TCTTAATTTTTGAGGGCA

TTCACCATCTCCAGAGACA
CAG (SEQ ID NO:

CTAAGCGGTCCTCAGGG

ATTCCAAGAACGCTTTATAT
3566)

ATTTCTAATCGCTTCTCT

CTTCAAATGAACAGCTTGA

GGTTCCAAGTCTGGCAA

GAGTCGAGGACACGGGTGT

CACGGCCTCCCTGACAA

TTATTACTGTGCCAGAGACT

TCTCTGGGCTCCAGGGTG

CGTCGGAAGTCCGTGACCA

AAGACGAGGCTGATTAT

CCCCGGGCACCCAGGGCGC

TATTGCTGCTCATATGCA

TCGGTGGGGGCTTTTGATAT

GGTGCTAGCACTTTCGTG

CTGGGGCCAAGGGACAATG

TTCGGCGGAGGGACCAA

GTCACCGTCTCTTCAGCGTC

GCTGACCGTCCTAGGTC

GACCAAGGGCCCATCGGTC

AGCCCAAGGCTGCCCCC

TTCCCCCTGGCACCCTCCTC

TCGGTCACTCTGTTCCCA

CAAGAGCACCTCTGGGGGC

CCCTCGAGTGAGGAGCT

ACAGCGGCCCTGGGCTGCC

TCAAGCCAACAAGGCCA

TGGTCAAGGACTACTTCCC

CACTGGTGTGTCTCATAA

CGAACCTGTGACGGTCTCG

GTGACTTCTACCCGGGA

TGGAACTCAGGCGCCCTGA

GCCGTGACAGTGGCCTG

CCAGCGGCGTGCACACCTT

GAAGGCAGATAGCAGCC

CCCGGCTGTCCTACAGTCCT

CCGTCAAGGCGGGAGTG

CAGGACTCTACTCCCTCAG

GAGACCACCACACCCTC

CAGCGTGGTGACCGTGCCC

CAAACAAAGCAACAACA

TCCAGCAGCTTGGGCACCC

AGTACGCGGCCAGCAGC

AGACCTACATCTGCAACGT

TACCTGAGCCTGACGCCT

GAATCACAAGCCCAGCAAC

GAGCAGTGGAAGTCCCA

ACCAANGTGGACAAGAGAG

CAGAAGCTACAGCTGCC

TTGAGCCCAAATCTTGTGA

AGGTCACGCATGAAGGG

NNNAANTNANNCNNGNCCA

AGCACCGTGGAGAAGAC

TGNNCCGNCCGNGCCCAGN

AGTGGCCCCTACAGAAT

ACTNGNANNNCNNGGGGG

GTTCATAGAAGCTTGGC

GANCNNTCANNNTTNCNTC

CGCCATGGCCCAACTTGT

TTCCCCCCAAAACCCANGG

TTATTGCAGCTTATAATG

ACACCNNCATGATCTCCCG

GTTACAAATAAAGCAAT

GACCCNTGAGTCANNNTGG

AGCATCACAAATTTCAC

CGATTTTTGGAGTGGTTATT

AGCTCATATACAAGCAG

CTAGAGACCGTTACTACTTT

CACCACTCGAGTCTTCGG

GACTACTGGGGCCAGGGAA

AACTGGGACCAGGGTCA

CCCTGGTCACCGTCTCCTCA

CCGTCCTAGGTCAGCCC

GCGTCGACCAAGGGCCCAT

AAGGCCAACCCCACTGT

CGGTCTTCCCCCTGGCACCC

CACTCTGTTCCCACCCTC

TCCTCCAAGAGCACCTCTG

GAGTGAGGAGCTTCAAG

GGGGCACAGCGGCCCTGGG

CCAACAAGGCCACACTG

CTGCCTGGTCAAGGACTAC

GTGTGTCTCATAAGTGAC

TTCCCCGAACCTGTGACGG

TTCTACCCGGGAGCCGT

TCTCGTGGAACTCANGCGC

GACAGTGGCCTGGAAGG

CCTGACCAGCGGCGTGCAC

CAGATAGCAGCCCCGTC

ACCTTCCCGGCTGTCCTACA

AAGGCGGGAGTGGAGAC

GTCCTCANGACTCTACTCCC

CACCACACCCTCCAAAC

TCAGCAGCGTGGTGACCGT

AAAGCAACAACAAGTAC

GCCCTCCAGCAGCTTGGGC

GCGGCCAGCAGCTACCT

ACCCAGACCTACATCTGCA

GAGCCTGACGCCTGAGC

ACGTGAATCACAAGCCCAG

AGTGGAAGTCCCACAGA

CAACACCNAAGGTGGACAA

AGCTACAGCTGCCAGGT

GANAGTTGAGCCCAAATCT

CACGCATGAAGGGAGCA

TGTGACAAAACTCACACAT

CCGTGGAGAAGACAGTG

GCCCACCGTGCCCAGCACC

GCCCCTACAGAATGTTC

TGACTCCTGGGGGGACCGT

ATAGAAGCTTGGCCGCC

CAGTCTTCCTCTTCCCCCCA

ATGGCCCAACTTGTTTAT

AACCCAAGGACACCCTCAT

TGCAGCTTATAATGGTTA

GATCTCCCGGACCCCTGAG

CAAATAAAGCAATAGCA

TCACATGNCGNGGNGGNGG

TNNNNAATTTCACAAAT

NCGTGNNCCACNAANANCC

AAAGCATTTTTTTCACTG

TGAGNNAGTTCAACTGGNA

CATTCTAGTTGTGGTTTG

CGTNNNGGNNNNGNNNNN

TCCAAACTCATCNATGN

GCANNNNNNNNNANNAAA

ANNTTATCATGNNCTGG

NNNNCNGGNAGGANNANN

ATNGGGNATNANTNNNN

ANNANNANCNCNTNCNNNN

NNAGCNNCNTGGNNTGN

NGNNCNNNCGNNNNNNNC

AANNCNNNTNAANNNGA

NNCNNNNCNNNNNNNNNN

NTTGGNNNNGTANCTTN

NNANNGNNNNNNNNNANA

NNNNNNNNGGNANNACC

NANNNNANNNNNNNNNNN

NTNNNGNGNNGNGNNTC

NNNNNNNNNNNNNNNNNN

AGTNNNNNNGANNNCCN

NCNNNNNCNNNNCNNNNG

NGNNNCCNNNNGNNNNN

NNGNANNCNTGCANNNN

CGNNGGNNGNGGNCGTGA

AAATAAAGCATTTTTTTC

GCCANNAANANNCTGANNC

ACTGCATNCCNANTTGT

ANNNANTGNNNCNNNGNN

GGTTTGTCCAAACTCATC

GGGCNNGGNNGGTNCATAA

AATGTATCTTATCATGTC

NGNNANANAAGCNNNNGG

TGGATCGGGAATTAANT

NNNGNANCANNACANNNN

TNNGCGCANCACCATGN

NNNTACCGNNNNNNANCNN

NNTGAAATNACCTCTGA

CNNNNNNCGTCNNNNNNCN

AAGANGAACTNNNNTAN

GNNNNNNNNNNNGNNAGG

GTACCTTCTGNNNNNAA

NNNNNNNNNNNNNNNNNA

GNANNTCNNNGNNTGNN

NNNANNNNCTNCNNNNCCC

NNNNCNNNNGGGNGNN

ATNNGNANNNNNNTNNNN

GNANNTCCCAGNNNCCC

NNNNNANNGNCNNNCCNC

NNNNGNANANNNATGNN

NNNNNNNNNNNNNNN

NNATNCATNNNNNNNNC

(SEQ ID NO: 3565)

ANCANNNNNNGNNNNN

NNNCCNNNNNCCNNNGN

NANNTGCANNNNANGNN

ANNNNNNNTNNNNNNNN

NNNNCANANNNCNNNNN

CCNNNN (SEQ ID NO:

3567)

V-C044
ANNNNNNNNATGNATCNTA
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNNNNNNNTGN
CAGTCTGTGCTGACTCAGCC
COV047_

CACATACGATTTAGGTGAC
CTGGAGGAGGCTTGATCCA
P3_D7
NTNNTANNCATACGATT
TGCCTCCGTGTCTGGGTCTC
P3_D7

ACTATAGAATAACATCCAC
GCCTGGGGGGTCCCTGAGA

TAGGTGACACTATAGAA
CTGGACAGTCGATCACCATC

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

TAACATCCACTTTGCCTT
TCCTGCACTGGAACCAGCAG

TGTCCACTCCCAGGTCCAA
GTTCACCGTCAGTAACAAC

TCTCTCCACAGGTGTCCA
TGACGTTGGTGGTTATAACT

CTGCACCTCGGTTCTATCGA
TACATGAGCTGGGTCCGCC

CTCCCAGGTCCAACTGC
ATGTCTCCTGGTACCAACAA

TTGAATTCCACCATGGGAT
AGGCTCCAGGGAAGGGGCT

ACCTCGGTTCTATCGATT
CACCCAGGCAAAGCCCCCA

GGTCATGTATCATCCTTTTT
GGAGTGGGTCTCAGTTATTT

GAATTCCACCATGGGAT
AACTCATGATTTATGATGTC

CTAGTAGCAACTGCAACCG
ATAGCGGTGGTAGCACATA

GGTCATGTATCATCCTTT
AGTAATCGGCCCTCAGGGGT

GTGTACATTCTGAGGTGCA
CTACGCAGACTCCGTGAAG

TTCTAGTAGCAACTGCA
TTCTAATCGCTTCTCTGGCT

GCTGGTGGAGTCTGGAGGA
GGCCGATTCACCATCTCCA

ACCGGTTCCTGGGCCCA
CCAAGTCTGGCAACACGGC

GGCTTGATCCAGCCTGGGG
GAGACAAATCCAAGAACAC

GTCTGCCCTGACTCAGCC
CTCCCTGACCATCTCTGGGC

GGTCCCTGAGACTCTCCTGT
GCTGTATCTTCAAATGAAC

TGCCTCCGTGTCTGGGTC
TCCAGGCTGAGGACGAGGC

GCAGCCTCTGGGTTCACCG
AGGCTGAGAGCCGAGGACA

TCCTGGACAGTCGATCA
TGATTATTACTGCAGCTCAT

TCAGTAACAACTACATGAG
CGGCCGTGTATTATTGTGCG

CCATCTCCTGCACTGGAA
ATACAAGCAGCAGCACTCG

CTGGGTCCGCCAGGCTCCA
AGAGAAGGGGAGGTAGAA

CCAGCAGTGACGTTGGT
AGTCTTCGGAACTGGGACCA

GGGAAGGGGCTGGAGTGGG
GGGTATAACGATTTTTGGA

GGTTATAACTATGTCTCC
AGGTCACCGTCCTAG (SEQ

TCTCAGTTATTTATAGCGGT
GTGGTTATTCTAGAGACCG

TGGTACCAACAACACCC
ID NO: 3572)

GGTAGCACATACTACGCAG
TTACTACTTTGACTACTGGG

AGGCAAAGCCCCCAAAC

ACTCCGTGAAGGGCCGATT
GCCAGGGAACCCTGGTCAC

TCATGATTTATGATGTCA

CACCATCTCCAGAGACAAA
CGTCTCCTCAG (SEQ

GTAATCGGCCCTCAGGG

TCCAAGAACACGCTGTATC
ID NO: 3570)

GTTTCTAATCGCTTCTCT

TTCAAATAAACAGGCTGAG

GGCTCCAAGTCTGGCAA

AGCCGAGGACACGGCCGTG

CACGGCCTCCCTGACCAT

TATTATTGTGCGAGAGAAG

CTCTGGGCTCCAGGCTG

GGGAGGTAGAAGGGTATAA

AGGACGAGGCTGATTAT

CGATTTTTGGAGTGGTTATT

TACTGCAGCTCATATACA

CTAGAGACCGTTACTACTTT

AGCAGCAGCACTCGAGT

GACTACTGGGGCCAGGGAA

CTTCGGAACTGGGACCA

CCCTGGTCACCGTCTCCTCA

AGGTCACCGTCCTAGGT

GCGTCGACCAAGGGCCCAT

CAGCCCAAGGCCAACCC

CGGTCTTCCCCCTGGCACCC

CACTGTCACTCTGTTCCC

TCCTCCAAGAGCACCTCTG

ACCCTCGAGTGAGGAGC

GGGGCACAGCGGCCCTGGG

TTCAAGCCAACAAGGCC

CTGCCTGGTCAAGGACTAC

ACACTGGTGTGTCTCATA

TTCCCCGAACCTGTGACGG

AGTGACTTCTACCCGGG

TCTCGTGGAACTCAGGCGC

AGCCGTGACAGTGGCCT

CCTGACCAGCGGCGTGCAC

GGAAGGCAGATAGCAGC

ACCTTCCCGGCTGTCCTACA

CCCGTCAAGGCGGGAGT

GTCCTCANGACTCTACTCCC

GGAGACCACCACACCCT

TCANCAGCGTGGGGANNCN

CCAAACAAAGCAACAAC

GNNCNCCTCCANCANTTTG

AAGTACGCGGCCAGCAG

GGCNNCCNNAAANCTANNT

CTACCTGAGCCTGACGC

TNNGCAACGTNAANTCAAN

CTGAGCAGTGGAAGTCC

ANCCCAGCANCNNCCAAGG

CACAGAAGCTACAGCTG

NGNNNANAAAANTTGANCC

CCAGGTCACGCATGAAG

CAAATCTTGNGACAAAACT

GGAGCACCGTGGAGAAG

CACACATGCCCCANCGTGC

ACAGTGGCCCCTACAGA

CCAGCNCNGACTNCTGGGG

ATGTTCATAGAAGCTTG

GGACNTCAGTNTCNNTNCC

GCCGCCATGGCCCAACT

CNNAANCNNNNNNCCTNAT

TGTTTATTGCAGCTTATA

GATCNCCNNCCCNGAGTCA

ATGGTTACAAATAAAGC

NNTGNNNGTGNNGNNNTGA

AATAGCATCACAAATTT

NCNNGANACCNGAGNCAGT

CACAAATAAAGCATTTTT

CACTNNNCNTGNNGNNNNN

TTCACTGCATTCTAGTTG

NNGNNCANANNCNNANNA

TGGTTTGTCCAAACTCAT

NCNNNNNNNNNNCANNNN

CAATGTATCTTATCATGT

NNGTNCNNGNNGTNNNNTC

CTGGNTCGGGAATTAAT

NNNCGTCNNNNNNGNANTG

TCNGNGNCANCNCCATG

NNNNNNNNNNNNNNNNNN

GCCTGAAATAACNNNTG

NNNNNNNNNANCNNCNNN

AAAGANNNCTTGGTNGN

CNNNNAANNNNNNNCNAN

ACCTTCTGAGNGNAANN

NCNNNNNNNNN (SEQ

ANNNTCTGNNGAANNNN

ID NO: 3569)

NNTCAGTTNGGNNNNNN

AAGTCCCCNGNNNCCCN

NNNGNNNAANNNNGCA

AGCATGCATCTCANNNN

NAGCANNNNNNNNNNCC

NNGNTCCNNNNGNNNNT

GCNNNNNNNNNANNNN

NNNNNNNCNNNNNNNN

NCNNNCCCCNTANN

(SEQ ID NO: 3571)

V-C045
NNNNNNNNNATGNNTCNTA
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNCNNTATGNATN
CAGTCTGTGCTGACTCAGCC
COV047_

CACATACGATTTAGGTGAC
CTGGAGGAGGCTTGATCCA
P5_E1
NTACACATACGATTTAG
TGCCTCCGTGTCTGGGTCTC
P5_E1

ACTATAGAATAACATCCAC
GCCTGGGGGGTCCCTGAGA

GTGACACTATAGAATAA
CTGGACAGTCGATCACCATC

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

CATCCACTTTGCCTTTCT
TCCTGCACTGGAACCAGCAG

TGTCCACTCCCAGGTCCAA
GTTCAGCGTCAGTAGCAAC

CTCCACAGGTGTCCACTC
TGACGTTGGTGGTTATAACT

CTGCACCTCGGTTCTATCGA
TACATGAGCTGGGTCCGCC

CCAGGTCCAACTGCACC
ATGTCTCCTGGTACCAACAA

TTGAATTCCACCATGGGAT
AGGCTCCAGGGAAGGGGCT

TCGGTTCTATCGATTGAA
CACCCAGGCAAAGCCCCCA

GGTCATGTATCATCCTTTTT
GGAGTGGGTCTCAGTTATTT

TTCCACCATGGGATGGTC
AACTCATGATTTATGATGTC

CTAGTAGCAACTGCAACCG
ATAGCGGTGGTAGTACATA

ATGTATCATCCTTTTTCT
AGTAATCGGCCCTCAGGGGT

GTGTACATTCTGAGGTGCA
CTACGCAGACTCCGTGAAG

AGTAGCAACTGCAACCG
TTCTAATCGCTTCTCTGGCT

GCTGGTGGAGTCTGGAGGA
GGCCGATTCACCATCTCCA

GTTCCTGGGCCCAGTCTG
CCAAGTCTGGCAACACGGC

GGCTTGATCCAGCCTGGGG
GAGACAATTCCAAGAACAC

CCCTGACTCAGCCTGCCT
CTCCCTGACCATCTCTGGGC

GGTCCCTGAGACTCTCCTGT
GCTGTATCTTCAAATGAAC

CCGTGTCTGGGTCTCCTG
TCCAGGCTGAGGACGAGGC

GCAGCCTCTGGGTTCAGCG
AGCCTGAGAGCCGAGGACA

GACAGTCGATCACCATC
TGATTATTACTGCAGCTCAT

TCAGTAGCAACTACATGAG
CGGCCGTGTATTACTGTGC

TCCTGCACTGGAACCAG
ATACAAGCAGCACCACTCG

CTGGGTCCGCCAGGCTCCA
GAGAGAAGGGGAGGTAGA

CAGTGACGTTGGTGGTT
AGTCTTCGGAACTGGGACCA

GGGAAGGGGCTGGAGTGGG
AGGGTATTACGATTTTTGG

ATAACTATGTCTCCTGGT
GGGTCACCGTCCTAG (SEQ

TCTCAGTTATTTATAGCGGT
AGTGGTTATTCTAGAGACC

ACCAACAACACCCAGGC
ID NO: 3576)

GGTAGTACATACTACGCAG
GTTACTACTTTGACTACTGG

AAAGCCCCCAAACTCAT

ACTCCGTGAAGGGCCGATT
GGCCAGGGAACCCTGGTCA

GATTTATGATGTCAGTAA

CACCATCTCCAGAGACAAT
CCGTCTCCTCAG (SEQ

TCGGCCCTCAGGGGTTTC

TCCAAGAACACGCTGTATC
ID NO: 315)

TAATCGCTTCTCTGGCTC

TTCAAATGAACAGCCTGAG

CAAGTCTGGCAACACGG

AGCCGAGGACACGGCCGTG

CCTCCCTGACCATCTCTG

TATTACTGTGCGAGAGAAG

GGCTCCAGGCTGAGGAC

GGGAGGTAGAAGGGTATTA

GAGGCTGATTATTACTGC

NNANNNGNNNN (SEQ ID

ATNNNCNNNNNGNNNNN

NO: 3573)

NNAGNNNNNNNNNANG

NNAANNNNAANCNNNN

NNNNNNANNN (SEQ

ID NO: 3575)

V-C046
NNNNNNNNNATGNATCNTA
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNATGTATCNT
CAGTCTGCCCTGACTCAGCC
COV047_

CACATACGATTTAGGTGAC
CTGGGGGAGGCCTGGTCAA
P3_F12
ACACATACGATTTAGGT
TGCCTCCGTGTCTGGGTCTC
P3_F12

ACTATAGAATAACATCCAC
GCCTGGGGGGTCCCTGAGA

GACACTATAGAATAACA
CTGGACAGTCGATCACCATC

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
TCCTGCACTGGAACCAGCAG

TGTCCACTCCCAGGTCCAA
ACTCACCTTCACTGCCTATA

CCACAGGTGTCCACTCCC
TGACATTGGTGTTTATAACT

CTGCACCTCGGTTCTATCGA
GAATGAATTGGGTCCGCCA

AGGTCCAACTGCACCTC
ATATCTCCTGGAGCCAACAA

TTGAATTCCACCATGGGAT
GGCTCCAGGGAAGGGGCTG

GGTTCTATCGATTGAATT
CACCCAGGCAAAGCCCCCA

GGTCATGTATCATCCTTTTT
GAGTGGCTCTCATCAATTA

CCACCATGGGATGGTCA
AAGTCATGATTTATGATGTC

CTAGTAGCAACTGCAACCG
GTAATACAAATGGCGACAT

TGTATCATCCTTTTTCTA
ACTAATCGGCCCTCAGGGGT

GTGTACATTCTGAGGTGCA
ATACTATGCAGACTCAGTG

GTAGCAACTGCAACCGG
TTCTAATCGCTTCTCTGGCT

GCTGGTGGAGTCTGGGGGA
AAGGGCCGATTCACCATCT

TTCCTGGGCCCAGTCTGC
CCAAGTCTGGCAACACGGC

GGCCTGGTCAAGCCTGGGG
CCAGAGACAACGCCAAGAA

CCTGACTCAGCCTGCCTC
CTCCCTGACCATCTCTGGGC

GGTCCCTGAGACTCTCCTGT
TTCTCTGTATCTGCAAATGA

CGTGTCTGGGTCTCCTGG
TCCAGGCTGAGGACGAGGC

GCAGCCTCTGGACTCACCTT
ACAGCCTGAGGGCCGACGA

ACAGTCGATCACCATCTC
TGATTATTATTGCAGCTCAT

CACTGCCTATAGAATGAAT
CACGGCTGTATATTACTGTG

CTGCACTGGAACCAGCA
ATAGAGGCAGCAGCACTCC

TGGGTCCGCCAGGCTCCAG
CGAGAGATGTTGCATCTAA

GTGACATTGGTGTTTATA
CTATGTCTTCGGAACTGGGA

GGAAGGGGCTGGAGTGGCT
CTACGCTTACTTTGACCTTT

ACTATATCTCCTGGAGCC
CCAAGGTCACCNTCCTAG

CTCATCAATTAGTAATACA
GGGGCCAGGGAACCCTGGT

AACAACACCCAGGCAAA
(SEQ ID NO: 3580)

AATGGCGACATATACTATG
CACCGTCTCCTCAG (SEQ

GCCCCCAAAGTCATGAT

CAGACTCAGTGAAGGGCCG
ID NO: 3578)

TTATGATGTCACTAATCG

ATTCACCATCTCCAGAGAC

GCCCTCAGGGGTTTCTAA

AACGCCAAGAATTCTCTGT

TCGCTTCTCTGGCTCCAA

ATCTGCAAATGAACAGCCT

GTCTGGCAACACGGCCT

GAGGGCCGACGACACGGCT

CCCTGACCATCTCTGGGC

GTATATTACTGTGCGAGAG

TCCAGGCTGAGGACGAG

ATGTTGCATCTAACTACGCT

GCTGATTATTATTGCAGC

TACTTTGACCTTTGGGGCCA

TCATATAGAGGCAGCAG

GGGAACCCTGGTCACCGTC

CACTCCCTATGTCTTCGG

TCCTCAGCGTCGACCAAGG

AACTGGGACCAAGGTCA

GCCCATCGGTCTTCCCCCTG

CCGTCCTAGGTCAGCCC

GCACCCTCCTCCAAGAGCA

AAGGCCAACCCCACTGT

CCTCTGGGGGCACAGCGGC

CACTCTGTTCCCACCCTC

CCTGGGCTGCCTGGTCAAG

GAGTGAGGAGCTTCAAG

GACTACTTCCCCGAACCTGT

CCAACAAGGCCACACTG

GACGGTCTCGTGGAACTCA

GTGTGTCTCATAAGTGAC

GGCGCCCTGACCAGCGGCG

TTCTACCCGGGAGCCGT

TGCACACCTTCCCGGCTGTC

GACAGTGGCCTGGAAGG

CTACAGTCCTCAGGANTCT

CAGATAGCAGCCCCGTC

ACTCCCTCAGCAGCGTGGT

AAGGCGGGAGTGGAGAC

GACCGTGCCCTCCAGCAGC

CACCACACCCTCCAAAC

TTGGGCACCCAGACCTACA

AAAGCAACAACAAGTAC

TCTGCAANGTGAANNNCAA

GCGGCCAGCAGCTACCT

NCCCANNAACACCNNANGN

GAGCCTGACGCCTGAGC

GNGANANNAGANNNNAGA

AGTGGAAGTCCCACAGA

NCCNANATTNNTGAGANAA

AGCTACAGCTGCCAGGT

AACTCACACATGCCCCACC

CACGCATGAAGGGAGCA

GTGCCCAGCANCTGAACTC

CCGTGGAGAAGACAGTG

CTGGGGGGACCGTCAGTCT

GCCCCTACAGAATGNTC

TCCTCNTCCCCCAAACCCA

ATAGAAGCTTGGCCGCC

NNNCACCTCATGATCTCCN

ATGGCCCAACTTGTTTAT

GACCNNGANNCACNTGCGT

TGCANCTTATNATGGTTA

NNNNNNCGTGAGCCACGAN

CGNATANAGCAATAGCA

ACCNGANTCAGTCACTNNN

TCACNNTCNCACATTTCN

CNNGNNGGCGTNNNNNCAT

NANANNAANCTTTNTTT

ANGCNNACAAGCNCGGGA

NTNNCTGCATTCTANTTN

GNNNAGTNNNANNGNNNG

NNGNNNNGNNCNAACNT

TNCNNGNNGNCANCNTCNN

CNNNNNNNGNNTNCNTA

NCNTCCTGNNNNGNNNGNN

NNNNGGNNNGNNNCNN

TNNNTGNNNNNNNTANNNN

NANNNANNNNNNCANCA

NNNNGNNTCNNNNNANNN

CNTGNNNTGAAATNACN

NNNNNNNNNNNNNNNNNN

NCTGAAGAGANTNNNNN

CAANNNNNGNNNNNNNNA

GTACTNCTGAGNNNANA

NNCNNGNNTANCCNNNN

CNTCNGNGANGNNNNNC

(SEQ ID NO: 3577)

ANTNGGNNNNNNNNCCC

CNGNTNCCNNCAGNNNA

ANNNNGNANCATGCATN

NNATNNNNCNNNNNNGN

NNNGANNCCNNNNNNNN

NNNNGNNNNNNNTNNNN

ANNNNNNNNNNNNNNNN

(SEQ ID NO: 3579)

V-C047
NNNNNNNNNNNNTATGNN
GAGGTGCAGCTGGTGCAGT
COV047_
NNNNNNNNTTANGNATC
CAGTCTGTGCTGACTCAGGA
COV047_

NNNACACATACGATTTAGG
CTGGAGCAGAGGTGAAAAA
P3_H7
NTACACATACGATTTAG
GCCCTCACTGACTGTGTCCC
P3_H7

TGACACTATAGAATAACAT
GCCCGGGGAGTCTCTGAAG

GTGACACTATAGAATAA
CAGGAGGGACAGTCACTCT

CCACTTTGCCTTTCTCTCCA
ATCTCCTGTAAGGGTTCTGG

CATCCACTTTGCCTTTCT
CACCTGTGGCTCCAGCACTG

CAGGTGTCCACTCCCAGGT
ATACAGATTTACCAACTAC

CTCCACAGGTGTCCACTC
GAGCTGTCACCAGTGGTCAT

CCAACTGCACCTCGGTTCTA
TGGATCGGCTGGGTGCGCC

CCAGGTCCAACTGCACC
TATCCCTACTGGTTCCAGCA

TCGATTGAATTCCACCATG
AGATGCCCGGGAAAGGCCT

TCGGTTCTATCGATTGAA
GAAGTCTGGCCAAGCCCCC

GGATGGTCATGTATCATCCT
GGAGTGGATGGGGATCATC

TTCCACCATGGGATGGTC
AGGACACTGATTTATGAAAC

TTTTCTAGTAGCAACTGCAA
TATCCTGGTGACTCTGATAC

ATGTATCATCCTTTTTCT
AAGCATCAAACACTCCTGG

CCGGTGTACATTCCGAGGT
CAGATACAGCCCGTCCTTC

AGTAGCAACTGCAACCG
ACCCCTGCCCGGTTCTCAGG

GCAGCTGGTGCAGTCTGGA
CAAGGCCAGGTCACCATCT

GTTCCAATTCCCAGGCTG
CTCCCTCCTTGGGGGCAAAG

GCAGAGGTGAAAAAGCCCG
CAGCCGACAAGTCCATCAC

TGGTGACCCAGGAGCCC
CTGCCCTGACCCTTTCGGGT

GGGAGTCTCTGAAGATCTC
CACCGCCTACCTGCAGTGG

TCACTGACTGTGTCCCCA
GCGCAGCCTGAGGATGAGG

CTGTAAGGGTTCTGGATAC
AGCAGCCTGAAGGCCTCGG

GGAGGGACAGTCACTCT
CTGATTATTACTGCTTGCTC

AGATTTACCAACTACTGGA
ACACCGCCATGTATTACTGT

CACCTGTGGCTCCAGCA
TCCTATAGTGGTGCTCGGCC

TCGGCTGGGTGCGCCAGAT
GCGAGACTCAGTGACCGCT

CTGGAGCTGTCACCAGT
GGTGTTCGGCGGAGGGACC

GCCCGGGAAAGGCCTGGAG
GGTACAGTCCGTTCGACCC

GGTCATTATCCCTACTGG
AAGCTGACCGTCCTAG

TGGATGGGGATCATCTATC
CTGGGGCCAGGGAACCCTG

TTCCAGCAGAAGTCTGG
(SEQ ID NO: 3584)

CTGGTGACTCTGATACCAG
GTCACCGTCTCCTCAG

CCAAGCCCCCAGGACAC

ATACAGCCCGTCCTTCCAA
(SEQ ID NO: 3582)

TGATTTATGAAACAAGC

GGCCAGGTCACCATCTCAG

ATCAAACACTCCTGGAC

CCGACAAGTCCATCACCAC

CCCTGCCCGGTTCTCAGG

CGCCTACCTGCAGTGGAGC

CTCCCTCCTTGGGGGCAA

AGCCTGAAGGCCTCGGACA

AGCTGCCCTGACCCTTTC

CCGCCATGTATTACTGTGCG

GGGTGCGCAGCCTGAGG

AGACTCAGTGACCGCTGGT

ATGAGGCTGATTATTACT

ACAGTCCGTTCGACCCCTG

GCTTGCTCTCCTATAGTG

GGGCCAGGGAACCCTGGTC

GTGCTCGGCCGGTGTTCG

ACCGTCTCCTCAGCGTCGA

GCGGAGGGACCAAGCTG

CCAAGGGCCCATCGGTCTT

ACCGTCCTAGGTCAGCC

CCCCCTGGCACCCTCCTCCA

CAAGGCTGCCCCCTCGG

AGAGCACCTCTGGGGGCAC

TCACTCTGTTCCCACCCT

AGCGGCCCTGGGCTGCCTG

CGAGTGAGGAGCTTCAA

GTCAAGGACTACTTCCCCG

GCCAACAAGGCCACACT

AACCTGTGACGGTCTCGTG

GGTGTGTCTCATAAGTG

GAACTCAGGCGCCCTGACC

ACTTCTACCCGGGAGCC

AGCGGCGTGCACACCTTCC

GTGACAGTGGCCTGGAA

CGGCTGTCCTACAGTCCTCA

GGCAGATAGCAGCCCCG

GGACTCTACTCCCTCAGCA

TCAAGGCGGGAGTGGAG

GCGTGGTGACCGTGCCCTC

ACCACCACACCCTCCAA

CAGCAGCTTGGGCACCCAG

ACAAAGCAACAACAAGT

ACCTACATCTGCAACGTGA

ACGCGGCCAGCAGCTAC

ATCACAAGCCCAGCAACAC

CTGAGCCTGACGCCTGA

CAAGGTGGACAAGAGAGTT

GCAGTGGAAGTCCCACA

GAGCCCAAATCTTGTGACA

GAAGCTACAGCTGCCAG

AAACTCACACATGCCCACC

GTCACGCATGAAGGGAG

GTGCCCAGCACCTGAACTC

CACCGTGGAGAAGACAG

CTGGGGGGACCGTCAGTCT

TGGCCCCTACAGAATGTT

TCCTCTTNCCCCCNAAACCC

CATAGAAGCTTGGCCGC

AAGGACACCCTCNTGATCT

CATGGCCCAACTTGTTTA

CCCGGACCCCTGANGTCAC

TTGCAGCTTATAATGGTT

ATGCGTGGTGGTGGANGTG

ACAAATAAAGCAATAGC

AGCCACGAANANCCTGANG

ATCACAAATTTCACAAA

NCAGGTCAACTGNTNNGTN

TAAAGCATTTTTTTCACT

GACGGCGNGGANNTGNNN

GCATTCTANTTGTGGTTN

NTGNCAAGACNAANNNNAC

NNCCAAACTCATCAATG

ANGNNNNNNNNGGANNNN

TATNNNATCATGTNTGG

NNNANGNNNNGNNNNNNN

NNCGGGAATNANNNNNT

CNGGGNNNNNNNNNNNCN

NNNNNCNNCNNNNNNNN

NCCCCNNNNCNNGNNCNGA

NNNNNNNNNNNNNNNA

ANNNNAGNNNNNNNNGNN

NNNNNNNNAANNNANN

NGATNNNNNNNTNNNNGN

NANNNNNNNNNNNNCN

NNNNCNNNNNCCCNTNCNN

NNNNGNANGCNNAAAN

NNCNCNNTCNANAANNNNN

NANCATNNTGNNNGNAN

NNNNNNNCCNAANNNNGC

NNNNNGNNANTNNGGNN

NNNCCCNNCNNNAANNNN

NNNANNTCCCNGNTCCC

NNNGNNNGNNNNNCN

ANNNGNANAANTNTNNN

(SEQ ID NO: 3581)

NCNNNNNTNNNNNNNCA

NNNNNNNNGNNNNNCN

NNNNNNNNGNNNNNNN

NANAGNNATNNNNNNNN

NNNNNNNNNNNNNNCN

NCNN (SEQ ID NO:

3583)

V-C048
NNNNNNNNNNNTGNATCNT
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNCNNATGNATNNT
GAAATAGTGATGACGCAGT
COV047_

ACACATACGATTTAGGTGA
CTGGGGGAGGCTTGGTCCA
P3_B12
ACACATACGATTTAGGT
CTCCAGCCACCCTGTCTGTG
P3_B12

CACTATAGAATAACATCCA
GCCTGGGGGGTCCCAGAGA

GACACTATAGAATAACA
TCTCCAGGGGAAAGAGCCA

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
CCCTCTCCTGCAGGGCCAGT

GTGTCCACTCCCAGGTCCA
ATTCACCGTCAGTAGCAAT

CCACAGGTGTCCACTCCC
CAGAGTGTTAGCAGCCACTT

ACTGCACCTCGGTTCTATCG
TACATGAGCTGGATCCGCC

AGGTCCAACTGCACCTC
AGCCTGGTACCAGCAGAAA

ATTGAATTCCACCATGGGA
AGGCTCCAGGGAAGGGGCT

GGTTCTATCGATTGAATT
CCTGGCCAGGCTCCCAGGCT

TGGTCATGTATCATCCTTTT
GGAGTGGGTCTCAGTTATTT

CCACCATGGGATGGTCA
CCTCATCTATGGTGCATCCA

TCTAGTAGCAACTGCAACC
ATAGCGGTGGTAGCGCATA

TGTATCATCCTTTTTCTA
CCAGGGCCACTGGTATCCCA

GGTGTACATTCTGAGGTGC
CTACGTAGACTCCGTGAAG

GTAGCAACTGCAACCGG
ACCAGGTTCAGTGGCAGTG

AGCTGGTGGAGTCTGGGGG
GGCAGATTCACCATCTCCA

TGTACATTCAGAAATAG
GGTCTGGGACAGAGTTCACT

AGGCTTGGTCCAGCCTGGG
GAGACAATTCCAAGAACAC

TGATGACGCAGTCTCCA
CTCACCATCAGCAGCCTGCA

GGGTCCCAGAGACTCTCCT
CCTGTATCTTCAAATGAAC

GCCACCCTGTCTGTGTCT
GTCTGAAGATTTTGCAGTTT

GTGCAGCCTCTGGATTCAC
AGCCTGAGACCCGAGGACA

CCAGGGGAAAGAGCCAC
ATTACTGCCAGCAGTATAAT

CGTCAGTAGCAATTACATG
CGGCTGTGTATTACTGTGCG

CCTCTCCTGCAGGGCCA
AACTGGCCTCCGCTCACTTT

AGCTGGATCCGCCAGGCTC
AGAATCGCAAACTACATGG

GTCAGAGTGTTAGCAGC
CGGCGGAGGGACCAAGGTG

CAGGGAAGGGGCTGGAGTG
ACGTCTGGGGCAAAGGGAC

CACTTAGCCTGGTACCA
GAGATCAAAC (SEQ ID

GGTCTCAGTTATTTATAGCG
CACGGTCACCGTCTCCTCA

GCAGAAACCTGGCCAGG
NO: 3588)

GTGGTAGCGCATACTACGT
(SEQ ID NO: 3586)

CTCCCAGGCTCCTCATCT

AGACTCCGTGAAGGGCAGA

ATGGTGCATCCACCAGG

TTCACCATCTCCAGAGACA

GCCACTGGTATCCCAAC

ATTCCAAGAACACCCTGTA

CAGGTTCAGTGGCAGTG

TCTTCAAATGAACAGCCTG

GGTCTGGGACAGAGTTC

AGACCCGAGGACACGGCTG

ACTCTCACCATCAGCAG

TGTATTACTGTGCGAGAAT

CCTGCAGTCTGAAGATTT

CGCAAACTACATGGACGTC

TGCAGTTTATTACTGCCA

TGGGGCAAAGGGACCACGG

GCAGTATAATAACTGGC

TCACCGTCTCCTCAGCGTCG

CTCCGCTCACTTTCGGCG

ACCAAGGGCCCATCGGTCT

GAGGGACCAAGGTGGAG

TCCCCCTGGCACCCTCCTCC

ATCAAACGTACGGTGGC

AAGAGCACCTCTGGGGGCA

TGCACCATCTGTCTTCAT

CAGCGGCCCTGGGCTGCCT

CTTCCCGCCATCTGATGA

GGTCAAGGACTACTTCCCC

GCAGTTGAAATCTGGAA

GAACCTGTGACGGTCTCGT

CTGCCTCTGTTGTGTGCC

GGAACTCAGGCGCCCTGAC

TGCTGAATAACTTCTATC

CAGCGGCGTGCACACCTTC

CCAGAGAGGCCAAAGTA

CCGGCTGTCCTACAGTCCTC

CAGTGGAAGGTGGATAA

AGGACTCTACTCCCTCAGC

CGCCCTCCAATCGGGTA

AGCGTGGTGACCGTGCCCT

ACTCCCAGGAGAGTGTC

CCAGCAGCTTGGGCACCCA

ACAGAGCAGGACAGCAA

GACCTACATCTGCAACGTG

GGACAGCACCTACAGCC

AATCACAAGCCCAGCAACA

TCAGCAGCACCCTGACG

CCAAGGTGGACAAGAGAGT

CTGAGCAAAGCAGACTA

TGAGCCCAAATCTTGTGAC

CGAGAAACACAAAGTCT

AAAACTNNNNNNNNNCCCC

ACGCCTGCGAAGTCACC

CGNNNCCNNNNCNCNNNNN

CATCAGGGCCTGAGCTC

CNNCNGGGGGNGANNNNN

GCCCGTCACAAAGAGCT

NANTNTTCTNNTNCCCCCA

TCAACAGGGGAGAGTGT

AANCCNAGGNNNNCCNNN

TAGAAGCTTGGCCGCCA

NNNNNNTTNNNCNNGNCCC

TGGNNCCANNTNNNTNT

NNNNNGNNNNNTGNGNGN

ATNNCAGNNNANAATGN

GNNGGGNNNNNGNGNNCN

NTNCAAATAAAGCNATA

AAAAANNCNCNNGAGNNN

NCATCACANATTTCACA

NNNTTNNNNNNNGNNNNN

AATAAAGCATTTTTTTCA

NNANNNNNNGNANGNNNN

CTGCNTNCTAGTGTGGNT

NTNANNNNNANANNNNCN

TGTNNNCANNNCNNNNN

GNNNNNANGNNNNNNNAC

NNNNNNNNNNNNNNNN

AACNNNNCNTNCGNGNNNN

NCNNNNNNNNNNNNNN

NGNNNCTNNNNNTCNNNNC

NNNNNNCGCANCACNNG

NNNACTNNNGNANGNANG

NNNTNAAANTNNCTNNN

NANNNNNNNANNNNNANN

NAANNNNNNNNNNNGN

NNNNCNNNNNNTNNNNCNT

NNCNNNGAGGNNAANN

NNANNNNNNNNNNANNNN

ANCNNNNNNNNNNNGTC

NNNNNCNNNNNNNNNNGN

ANTNNGNNGNNNNNNNN

GNANNNNN (SEQ ID

NNCCNNNNGNNNANNNG

NO: 3585)

NNANCNTNNNTNANNNN

CNNNNNNNNNNNNCCNN

NNNNANGNANNGNANCN

(SEQ ID NO: 3587)

V-C049
NNNNNNNNNNNNNNNNNN
CAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNNATGNATCN
GACATCCAGATGACCCAGTC
COV047_

TCNTACACATACGATTTAG
CTGGGGGAGGCGTGGTCCA
P5_F8
TACACNTACGATTTAGGT
TCCATCCTCCCTGTCTGCAT
P5_F8

GTGACACTATAGAATAACA
GCCTGGGAGGTCCCTGAGA

GACACTATAGAATAACA
CTGTAGGAGACAGAGTCAC

TCCACTTTGCCTTTCTCTCC
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
CATCACTTGCCGGGCAAGTC

ACAGGTGTCCACTCCCAGG
ATTCACCTTCAGTACCTATG

CCACAGGTGTCCACTCCC
AGAGCATTAGCAGTTATTTA

TCCAACTGCACCTCGGTTCT
GCATGCACTGGGTCCGCCA

AGGTCCAACTGCACCTC
AATTGGTATCAGCAGAAAC

ATCGATTGAATTCCACCAT
GGCTCCAGGCAAGGGGCTG

GGTTCTATCGATTGAATT
CAGGGAAAGTCCCTAAGCT

GGGATGGTCATGTATCATC
GAGTGGGTGGCCGTTATAT

CCACCATGGGATGGTCA
CCTGATCTATGCTGCATCCA

CTTTTTCTAGTAGCAACTGC
CATATGATGGAAGTAATAA

TGTATCATCCTTTTTCTA
GTTTGCAAAGTGGGGTCCCA

AACCGGTGTACATTCTCAG
ATACTTTGCAGACTCCGTG

GTAGCAACTGCAACCGG
TCAAGGTTCAGTGGCAGTGG

GTGCAGCTGGTGGAGTCTG
AAGGGCCGATTCACCATCT

GTACATTCTGACATCCAG
ATCTGGGACAGACTTCACTC

GGGGAGGCGTGGTCCAGCC
CCAGAGACAATTCCAAGAA

ATGACCCAGTCTCCATCC
TCACCATCAGCAGTCTGCAA

TGGGAGGTCCCTGAGACTC
CACGCTTTATTTGCAAATGA

TCCCTGTCTGCATCTGTA
CCTGAAGATTTTGCAACTTA

TCCTGTGCAGCCTCTGGATT
ACAGCCTGAGACCTGAGGA

GGAGACAGAGTCACCAT
CTACTGTCAACAGAGTTACA

CACCTTCAGTACCTATGGC
CACGGCTGTATATTACTGTG

CACTTGCCGGGCAAGTC
GAACCCCGCTCACTTTCGGC

ATGCACTGGGTCCGCCAGG
CGAAAGTGGGGATGGAGTA

AGAGCATTAGCAGTTAT
GGAGGGACCAAGGTGGAGA

CTCCAGGCAAGGGGCTGGA
CAGCAGTGGCTGGTACGGG

TTAAATTGGTATCAGCA
TCAAAC (SEQ ID NO:

GTGGGTGGCCGTTATATCA
GAAGAAATTGACTTCTGGG

GAAACCAGGGAAAGTCC
3592)

TATGATGGAAGTAATAAAT
GCCAGGGAACCCTGGTCAC

CTAAGCTCCTGATCTATG

ACTTTGCAGACTCCGTGAA
CGTCTCCTCAG (SEQ ID

CTGCATCCAGTTTGCAAA

GGGCCGATTCACCATCTCC
NO: 3590)

GTGGGGTCCCATCAAGG

AGAGACAATTCCAAGAACA

TTCAGTGGCAGTGGATCT

CGCTTTATCTGCAAATGAA

GGGACAGACTTCACTCT

CAGCCTGAGACCTGAGGAC

CACCATCAGCAGTCTGC

ACGGCTGTATATTACTGTGC

AACCTGAAGATTTTGCA

GAAAGTGGGGATGGAGTAC

ACTTACTACTGTCAACAG

AGCAGTGGCTGGTACGGGG

AGTTACAGAACCCCGCT

AAGAAATTGACTTCTGGGG

CACTTTCGGCGGAGGGA

CCAGGGAACCCTGGTCACC

CCAAGGTGGAGATCAAA

GTCTCCTCAGCGTCGACCA

CGTACGGTGGCTGCACC

AGGGCCCATCGGTCTTCCC

ATCTGTCTTCATCTTCCC

CCTGGCACCCTCCTCCAAG

GCCATCTGATGAGCAGT

AGCACCTCTGGGGGCACAG

TGAAATCTGGAACTGCC

CGGCCCTGGGCTGCCTGGT

TCTGTTGTGTGCCTGCTG

CAAGGACTACTTCCCCGAA

AATAACTTCTATCCCAGA

CCTGTGACGGTCTCGTGGA

GAGGCCAAAGTACAGTG

ACTCAGGCGCCCTGACCAG

GAAGGTGGATAACGCCC

CGGCGTGCACACCTTCCCG

TCCAATCGGGTAACTCCC

GCTGTCCTACAGTCCTCAG

AGGAGAGTGTCACAGAG

GACTCTACTCCCTCAGCAG

CAGGACAGCAAGGACAG

CGTGGTGACCGTGCCCTCC

CACCTACAGCCTCAGCA

AGCAGCTTGGGCACCCAGA

GCACCCTGACGCTGAGC

CCTACATCTGCAACGTGAA

AAAGCAGACTACGAGAA

TCACAAGCCCAGCAACACC

ACACAAAGTCTACGCCT

AAGGTGGACAAGAGAGTTG

GCGAAGTCACCCATCAG

AGCCCAAATCTTGTGACAA

GGCCTGAGCTCGCCCGT

AACTCACACATGCCCACCG

CACAAAGAGCTTCAACA

TGCCCAGCACCTGANNTCC

GGGGAGAGTGTTAGAAG

TGGGGGGACCGTCAGTCTT

CTTGGCCGCCATGGCCC

CCTCTTCCCCCCAAAACCN

AACTTGTTTATTGCAGCT

NNGACACCCTCATGATCNN

TATAATGGTTACAAATA

CCGGACCCCTGAGGTCACA

AAGCAATAGCATCACAA

TGCGTGGTGGNNGGACGTG

ATTTCACAAATAAAGCA

AGCCACGAANANCCTGAGG

TTTTTTTCACTGCATTCT

TCAAGTTCAACTGGNACNT

AGTTGTGGNTTGTCCAA

NNCGGCGNNGGNANGGNN

ACTCATCAATGNATCTTA

CATANATGNNCNNNNNNNN

TCATGTCTGNNTCGGGA

NNNCNNNGGGNAGNANCA

ATTNATTCNGCGCAGCN

GTTACAANCAGCNNCNTAC

NNTNNNNGAANNNANNC

NNGNTNGTGGTCANCNTCC

TGAAANAGNACTNNNNN

TCNCGTCNGCNNCANNNAN

NNACNNNGAGNGAANN

TGNNTTNAANNGNNAGGAN

ACNTCTGNNNNGNNNGT

NNCNAGNGNANGGGTNNN

CANTNGGNNNNGAAGTC

CANNAANNCCNTNCCNNNC

CCAGNTCCCNNCNGNNN

CCCATTNNANAAAANNCNN

AANNATGCAANNNNGCA

TNNNNNNNNNNNNNGGNN

NNNNNNNNNNCANNNNC

NAANCNNCNNNNAANNNN

NNNNNNNNNANNNNNN

NGGNGNNACNNNNNNNNC

NNNCNNNNGNNAAANNT

CCCNCNNNNNNCCNNGNNN

GNANNNNNNNNNNNNN

NNNN (SEQ ID NO:

NNNNNNNNNNNNNNCNC

3589)

CCNANTNGNNNNN

(SEQ ID NO: 3591)

V-C050
NNNNNNNNNNATGNATNNT
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNNATGNATCN
CAGTCTGTGCTGACTCAGCC
COV047_

ACNCATACGATTTAGGTGA
CCGGGGGAGGCTTAGTTCA
P3_C1
TACACATACGATTTAGGT
TGCCTCCGTGTCTGGGTCTC
P3_C1

CACTATAGAATAACATCCA
GCCTGGGGGGTCCCTGAGA

GACACTATAGAATAACA
CTGGACAGTCGATCACCATC

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGTAGCCTCTGG

TCCACTTTGCCTTTCTCT
TCCTGCACTGGAACCAGCAG

GTGTCCACTCCCAGGTCCA
ATTCACCTTCAGTAGCTACT

CCACAGGTGTCCACTCCC
TGACGTTGGTTATTATAACT

ACTGCACCTCGGTTCTATCG
GGATGCACTGGGTCCGCCA

AGGTCCAACTGCACCTC
TTGTCTCCTGGTACCAACAA

ATTGAATTCCACCATGGGA
AGTCCCAGGGAAGGGGCCG

GGTTCTATCGATTGAATT
CACCCAGGCAAAGCCCCCA

TGGTCATGTATCATCCTTTT
GTGTGGGTCTCACATATTA

CCACCATGGGATGGTCA
AACTCATGATTTATGAGGTC

TCTAGTAGCAACTGCAACC
ACAGTGAAGGGAGTAGCAC

TGTATCATCCTTTTTCTA
AGTAATCGGCCCTCTGGGGT

GGTGTACATTCTGAGGTGC
AAACTACGCGGACTCCGTG

GTAGCAACTGCAACCGG
TTCTAATCGCTTCTCTGGCT

AGCTGGTGGAGTCCGGGGG
AGGGGCCGATTCACCATCT

TTCCTGGGCCCAGTCTGC
CCAAGTCTGGCAACACGGC

AGGCTTAGTTCAGCCTGGG
CCAGAGACAACGCCAAGGA

CCTGACTCAGCCTGCCTC
CTCCCTGATCATCTCTGGGC

GGGTCCCTGAGACTCTCCT
CACGCTATATCTTCAAATG

CGTGTCTGGGTCTCCTGG
TCCAGGCTGAGGACGAGGC

GTGTAGCCTCTGGATTCACC
AACAATCTGAGAGCCGAGG

ACAGTCGATCACCATCTC
TGATTATTACTGCAGCTCAT

TTCAGTAGCTACTGGATGC
ACACGGCTGTATATTACTGT

CTGCACTGGAACCAGCA
ATAGAAGCAGCAGCACTCT

ACTGGGTCCGCCAAGTCCC
GCAAGACCGACGGCTGTAG

GTGACGTTGGTTATTATA
GGTGTTCGGCGGGGGGACC

AGGGAAGGGGCCGGTGTGG
CAGCAGCTGGCAATTACTT

ACTTTGTCTCCTGGTACC
AAGCTGACCGTCCTAG

GTCTCACATATTAACAGTG
CTACTACTACGGTATGGAC

AACAACACCCAGGCAAA
(SEQ ID NO: 3596)

AAGGGAGTAGCACAAACTA
GTCTGGGGCCAAGGGACCA

GCCCCCAAACTCATGATT

CGCGGACTCCGTGAGGGGC
CGGTCACCGTCTCTTCA

TATGAGGTCAGTAATCG

CGATTCACCATCTCCAGAG
(SEQ ID NO: 3594)

GCCCTCTGGGGTTTCTAA

ACAACGCCAAGGACACGCT

TCGCTTCTCTGGCTCCAA

ATATCTTCAAATGAACAAT

GTCTGGCAACACGGCCT

CTGAGAGCCGAGGACACGG

CCCTGATCATCTCTGGGC

CTGTATATTACTGTGCAAG

TCCAGGCTGAGGACGAG

ACCGACGGCTGTAGCAGCA

GCTGATTATTACTGCAGC

GCTGGCAATTACTTCTACTA

TCATATAGAAGCAGCAG

CTACGGTATGGACGTCTGG

CACTCTGGTGTTCGGCGG

GGCCAAGGGACCACGGTCA

GGGGACCAAGCTGACCG

CCGTCTCCTCAGCGTCGACC

TCCTAGGTCAGCCCAAG

AAGGGCCCATCGGTCTTCC

GCTGCCCCCTCGGTCACT

CCCTGGCACCCTCCTCCAA

CTGTTCCCACCCTCGAGT

GAGCACCTCTGGGGGCACA

GAGGAGCTTCAAGCCAA

GCGGCCCTGGGCTGCCTGG

CAAGGCCACACTGGTGT

TCAAGGACTACTTCCCCGA

GTCTCATAAGTGACTTCT

ACCTGTGACGGTCTCGTGG

ACCCGGGAGCCGTGACA

AACTCAGGCGCCCTGACCA

GTGGCCTGGAAGGCAGA

GCGGCGTGCACACCTTCCC

TAGCAGCCCCGTCAAGG

GGCTGTCCTACAGTCCTCA

CGGGAGTGGAGACCACC

GGACTCTACTCCCTCAGCA

ACACCCTCCAAACAAAG

GCGTGGTGACCGTGCCCTC

CAACAACAAGTACGCGG

CAGCAGCTTGGGCACCCAG

CCAGCAGCTACCTGAGC

ACCTACATCTGCAACGTGA

CTGACGCCTGAGCAGTG

ATCACAAGCCCAGCAACAC

GAAGTCCCACAGAAGCT

CNAAGTGGACAAGAGAGTT

ACAGCTGCCAGGTCACG

GAGCCCAAATCTTGTGACA

CATGAAGGGAGCACCGT

AAACTCACACATGCCCACC

GGAGAAGACAGTGGCCC

GTGCCCAGCACCTGAACTC

CTACAGAATGTTCATAG

NTGGGGGGGACNNTCAGTC

AAGCTTGGCCGCCATGG

TTCNTCTTCNNCCCNNNAA

CNCAACNNGTTTNTTNN

NNCAANNGANANNNTCNTG

NGCTNNTTATGATGGNT

ATNNNNNCTNNCCNNNGNN

ACNAATAAAGCAATAGC

GNNNNNTGNNNTGGTGGNG

ATCACNANTTTCACAAA

GGNNGNGANNNNNNAACN

TAAAGCATTTTTTTCACT

ANCCAANNNNNNCNNGNN

GCATTCTANTTGTGNNTG

NNNANNTNNNNNNNNNGN

TCCNAACTCATCATGTAT

NNNNNNNNNNNNNNNNNN

NTNTCATGNCTGGNTCG

NNNCNNNANNNCNNANAN

GNANTAANNNNGCAGCN

NAANNNNNGGNANNAANA

CATGNCTGNNNNNNNCN

NNNCNANNNNNNGTNCNN

NANNANANNNNNNGTAC

NNNNNNNNNNNNCTNNCCN

TCNNNNNGANNNNNCNN

NNCNNNNNNNNNNANNGN

NGANGANGNNGNNNNTN

NNANGGNNANGNNNNNNN

GGNGNNNNANNNNNCN

ANNNNNNNNANANNNNNN

NNCNNCNNNNGNNNNNN

NANCATGNANNNTTNANCN

NNNCNNNCNTNCNNNNN

NNNNNNNNCNNNNNNN

NNNNNNNNNNNNNNNN

(SEQ ID NO: 3593)

NNNNCNNNGNCCNNNNN

GNNNNNTGNNNNNNNN

(SEQ ID NO: 3595)

V-C051
NNNNNNCNNATGNATCNTA
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNNNNATGNAT
AATTTTATGCTGACTCAGCC
COV047_

CACATACGATTTAGGTGAC
CTGGGGGAGGCCTGGTCAA
P5_B12
CNTACNCATACGATTTA
CCACTCTGTGTCGGAGTCTC
P5_B12

ACTATAGAATAACATCCAC
GCCTGGGGGGTCCCTGAGA

GGTGACACTATAGAATA
CGGGGAAGACGGTAACCAT

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

ACATCCACTTTGCCTTTC
CTCCTGCACCGGCAGCAGTG

TGTCCACTCCCAGGTCCAA
ATTCACCTTCAGTAGCTATA

TCTCCACAGGTGTCCACT
GCAGCATTGCCAGCAACTAT

CTGCACCTCGGTTCTATCGA
ACATGAACTGGGTCCGCCA

CCCAGGTCCAACTGCAC
GTGCAGTGGTACCAGCAGC

TTGAATTCCACCATGGGAT
GGCTCCAGGGAAGGGGCTG

CTCGGTTCTATCGATTGA
GCCCGGGCAGTGCCCCCACC

GGTCATGTATCATCCTTTTT
GAGTGGGTCTCATGCATTA

ATTCCACCATGGGATGG
ACTGTGATCTATGAGGATAA

CTAGTAGCAACTGCAACCG
GTAGTAGTAGTAGTTACAT

TCATGTATCATCCTTTTT
CCAAAGACCCTCTGGGGTCC

GTGTACATTCTGAGGTGCA
ATACTACGCAGACTCAGTG

CTAGTAGCAACTGCAAC
CTGATCGGTTCTCTGGCTCC

GCTGGTGGAGTCTGGGGGA
AAGGGCCGATTCACCATCT

CGGTTCTTGGGCCAATTT
ATCGACAGCTCCTCCAACTC

GGCCTGGTCAAGCCTGGGG
CCAGAGACAACGCCAAGAA

TATGCTGACTCAGCCCCA
TGCCTCCCTCACCATCTCTG

GGTCCCTGAGACTCTCCTGT
CTCACTGTATCTGCAAATG

CTCTGTGTCGGAGTCTCC
GACTGAAGACTGAGGACGA

GCAGCCTCTGGATTCACCTT
AACAGCCTGAGAGCCGAGG

GGGGAAGACGGTAACCA
GGCTGACTACTACTGTCAGT

CAGTAGCTATAACATGAAC
ACACGGCTGTGTATTACTGT

TCTCCTGCACCGGCAGC
CTTATGATAGCAGCAATTAT

TGGGTCCGCCAGGCTCCAG
GCGAGAGAGAGGGGGTATG

AGTGGCAGCATTGCCAG
TGGGTGTTCGGCGGAGGGA

GGAAGGGGCTGGAGTGGGT
ACGGTGGTAAAACCCCCCC

CAACTATGTGCAGTGGT
CCAAGCTGACCGTCCTAG

CTCATGCATTAGTAGTAGT
ATTTCTTGGGGGCCAGGGA

ACCAGCAGCGCCCGGGC
(SEQ ID NO: 3600)

AGTAGTTACATATACTACG
ACCCTGGTCACCGTCTCCTC

AGTGCCCCCACCACTGT

CAGACTCAGTGAAGGGCCG
AG (SEQ ID NO: 3598)

GATCTATGAGGATAACC

ATTCACCATCTCCAGAGAC

AAAGACCCTCTGGGGTC

AACGCCAAGAACTCACTGT

CCTGATCGGTTCTCTGGC

ATCTGCAAATGAACAGCCT

TCCATCGACAGCTCCTCC

GAGAGCCGAGGACACGGCT

AACTCTGCCTCCCTCACC

GTGTATTACTGTGCGAGAG

ATCTCTGGACTGAAGAC

AGAGGGGGTATGACGGTGG

TGAGGACGAGGCTGACT

TAAAACCCCCCCATTTCTTG

ACTACTGTCAGTCTTATG

GGGGCCAGGGAACCCTGGT

ATAGCAGCAATTATTGG

CACCGTCTCCTCAGCGTCG

GTGTTCGGCGGAGGGAC

ACCAAGGGCCCATCGGTCT

CAAGCTGACCGTCCTAG

TCCCCCTGGCACCCTCCTCC

GTCAGCCCAAGGCTGCC

AAGAGCACCTCTGGGGGCA

CCCTCGGTCACTCTGTTC

CAGCGGCCCTGGGCTGCCT

CCGCCCTCGAGTGAGGA

GGTCAAGGACTACTTCCCC

GCTTCAAGCCAACAAGG

GAACCTGTGACGGTCTCGT

CCACACTGGTGTGTCTCA

GGAACTCAGGCGCCCTGAC

TAAGTGACTTCTACCCGG

CAGCGGCGTGCACACCTTC

GAGCCGTGACAGTGGCC

CCGGCTGTCCTACAGTCCTC

TGGAAGGCAGATAGCAG

AGGACTCTACTCCCTCAGC

CCCCGTCAAGGCGGGAG

AGCGTGGTGACCGTGCCCT

TGGAGACCACCACACCC

CCAGCAGCTTGGGCACCCA

TCCAAACAAAGCAACAA

GACCTACATCTGCAACGTG

CAAGTACGCGGCCAGCA

AATCACAAGCCCAGCAACA

GCTACCTGAGCCTGACG

CCNANNTGGACAAGAGAGT

CCTGAGCAGTGGAAGTC

TGAGCCCCAATCTTGTGAC

CCACAGAAGCTACAGCT

AAAACTCACACATGCCCAC

GCCAGGTCACGCATGAA

CGTGCCCANCACCTGNANT

GGGAGCACCGTGGAGAA

CNNNNGGGGGAGGGNNNG

GACAGTGGCCCCTACAG

TCTTNTTNTTNNTCNNCCCN

AATGTTCATAGAAGCTT

NCCNAAANNNNAGGANNN

GGCCGCCATGGCCCNAC

NCNTNNTNNTTNNCCCGGA

TNGTTGNTTATNGCANCT

CCNNTGANGNTNNCNNGGN

TATGNTGGTTANNAATA

GTGGGGGGNGGNNNNTGN

AAGCAATATCATCACAN

NNNACNAANNCCCNGNAG

NTTTCACAAATAAAGCA

GTCAAGTTCAACTGGNACG

ttttntttcnntgcnntc

TGGNCGGNNTNNNNTGCNN

TANNNNNGGNTTGTCNN

NNNNCAANAANNAAGCCG

ACTCNTCAATGTATCTNN

CNGGANGNNNNNTANANA

TCATGNCNGGNTCGNGA

GCACNNACCGNNGNGNNN

ATTAANTCNNCNCNNCN

NNCNNCNTCNCCGTCNGNN

CNTGNNNNNNNNNNAAN

NNNNNTNNNNANNGNANN

NNNNNGNANNNNNNAN

NNNANNNNNNNNNNNNAN

GTAGNNNNNNNNNNCNN

ANCNTNCNNNNCCNNNGNN

NNNNGNNGNNNACNAN

NACNNNCAANNNCANNNN

NNNCNGANNNNGGTNNG

NNNCNNNNANNNNNNNTA

TNAGNTAGGGGNGNNGN

NNNNCNNNNCCCNCNCNNN

NNNNNNCNNNCNNNNNN

(SEQ ID NO: 3597)

NNAGNNNNANNNATGNN

NNNNTNCANNNNNNNNC

NNNNNNNNNNNNNANN

CCNANNNNNNNNNNGNN

NNNGNANNNNNNNANTN

NNNNNNNANNNNTNNNN

CNNNNNNNNNNNN

(SEQ ID NO: 3599)

V-C052
NNNNNNNNNTGNATCNTAC
CAGGTTCAGCTGGTGCAGT
COV047_
NNNNNNNNNATGNATNN
GACATCCAGATGACCCAGTC
COV047_

ACATACGATTTAGGTGACA
CTGGAGCTGAGGTGAAGAA
P3_A10
TACACATACGATTTAGGT
TCCATCCTCCCTGTCTGCAT
P3_A10

CTATAGAATAACATCCACT
GCCTGGGGCCTCAGTGAAG

GACACTATAGAATAACA
CTGTAGGAGACAGAGTCAC

TTGCCTTTCTCTCCACAGGT
GTCTCCTGCAAGGCTTCTGG

TCCACTTTGCCTTTCTCT
CATCACTTGCCGGGCGAGTC

GTCCACTCCCAGGTCCAAC
TTACACCTTTACCAGCTACG

CCACAGGTGTCCACTCCC
AGGGCATAAGCAATTACTTA

TGCACCTCGGTTCTATCGAT
GTATCAGCTGGGTGCGACA

AGGTCCAACTGCACCTC
GCCTGGTATCAGCAGAGAC

TGAATTCCACCATGGGATG
GGCCCCTGGACAAGGGCTT

GGTTCTATCGATTGAATT
CAGGGAAAGTTCCTAAGCTC

GTCATGTATCATCCTTTTTC
GAGTGGATGGGATGGATCA

CCACCATGGGATGGTCA
CTGATCTTTGCTGCATCCAC

TAGTAGCAACTGCAACCGG
GCGCTTACAATGGTAACAC

TGTATCATCCTTTTTCTA
TTTGCAATCAGGGGTCCCAT

TGTACATTCCCAGGTTCAGC
AAACTATGCACAGAAGCTC

GTAGCAACTGCAACCGG
CTCGGTTCAGTGGCAGTGGA

TGTGCAGTCTGGAGCTGAG
CAGGGCAGAGTCACCATGA

TGTACATTCTGACATCCA
TCTGGGACAGATTTCACTCT

GTGAAGAAGCCTGGGGCCT
CCACAGACACATCCACGAG

GATGACCCAGTCTCCATC
CACCATCAGCAGCCTGCAGC

CAGTGAAGGTCTCCTGCAA
CACAGCCTACATGGAGCTG

CTCCCTGTCTGCATCTGT
CTGAAGATGTTGCAACTTAT

GGCTTCTGGTTACACCTTTA
AGGAGCCTGAGATCTGACG

AGGAGACAGAGTCACCA
TACTGTCAAAAGTATAACAG

CCAGCTACGGTATCAGCTG
ACACGGCCGTGTTTTACTGT

TCACTTGCCGGGCGAGT
TGCCCCTCGGACGTTCGGCC

GGTGCGACAGGCCCCTGGA
GCGAGAGATCGGGGGGGGC

CAGGGCATAAGCAATTA
AAGGGACCAAGGTGGAAAT

CAAGGGCTTGAGTGGATGG
ACGATTTTTGGAGTGGTTAT

CTTAGCCTGGTATCAGCA
CAAAC (SEQ ID NO:

GATGGATCAGCGCTTACAA
GGGTTCTACTACTACTACG

GAGACCAGGGAAAGTTC
3604)

TGGTAACACAAACTATGCA
GTATGGACGTCTGGGGCCA

CTAAGCTCCTGATCTTTG

CAGAAGCTCCAGGGCAGAG
AGGGACCACGGTCACCGTC

CTGCATCCACTTTGCAAT

TCACCATGACCACAGACAC
TCCTCA (SEQ ID NO:

CAGGGGTCCCATCTCGG

ATCCACGAGCACAGCCTAC
3602)

TTCAGTGGCAGTGGATCT

ATGGAGCTGAGGAGCCTGA

GGGACAGATTTCACTCTC

GATCTGACGACACGGCCGT

ACCATCAGCAGCCTGCA

GTTTTACTGTGCGAGAGAT

GCCTGAAGATGTTGCAA

CGGGGGGGGCACGATTTTT

CTTATTACTGTCAAAAGT

GGAGTGGTTATGGGTTCTA

ATAACAGTGCCCCTCGG

CTACTACTACGGTATGGAC

ACGTTCGGCCAAGGGAC

GTCTGGGGCCAAGGGACCA

CAAGGTGGAAATCAAAC

CGGTCACCGTCTCCTCAGC

GTACGGTGGCTGCACCA

GTCGACCAAGGGCCCATCG

TCTGTCTTCATCTTCCCG

GTCTTCCCCCTGGCACCCTC

CCATCTGATGAGCAGTT

CTCCAAGAGCACCTCTGGG

GAAATCTGGAACTGCCT

GGCACAGCGGCCCTGGGCT

CTGTTGTGTGCCTGCTGA

GCCTGGTCAAGGACTACTT

ATAACTTCTATCCCAGAG

CCCCGAACCTGTGACGGTC

AGGCCAAAGTACAGTGG

TCGTGGAACTCANGCGCCC

AAGGTGGATAACGCCCT

TGACCAGCGGCGTGCACAC

CCAATCGGGTAACTCCC

CTTCCCGGCTGTCCTACAGT

AGGAGAGTGTCACAGAG

CCTCANGACTCTACTCCCTC

CAGGACAGCAAGGACAG

AGCAGCGTGGTGACCGTGC

CACCTACAGCCTCAGCA

CCTNCCNNNNNNTTGGGNC

GCACCCTGACGCTGAGC

NCNNACANNTATNTGTGNN

AAAGCAGACTACGAGAA

ANGNGAANTCACAANCCCC

ACACAAAGTCTACGCCT

ANCAACACNNNGNNNNAA

GCGAAGTCACCCATCAG

GANAGTTGAGCCCAAATCT

GGCCTGAGCTCGCCCGT

TGTGANAAACTCACACATG

CACAAAGAGCTTCAACA

CCCACCGTGCCCAGCACCT

GGGGGAGAGTGTTAGAA

GACTCNGGGGGGACGTCAG

GCTTGGCCGCCATGGCC

TCTTCNNTCCCCCNNNCCN

CAACTTGTTTATTGCAGC

NNNNCCCTCATGATCTCCG

TTATAATGGNTACAAAT

ACCCTGAGTCANNTGCGTG

AAAGCAATAGCATCACA

NGNGNCGTGANCNCNANAN

AATTTCACAAATAAAGC

CNTGANGNCAGTCANTGNA

ATTTTTTTCACTGCATTC

CNTGNNGGNNNNNNGNNC

TAGTTGTGGTTTGTCCAA

NTANNCANANNANCNNNG

ACTCATCAATGTATNTNT

GAGNNNANTNNANNNNNN

CATGTCTGGATCGGNAN

GNNNCNNNNNGNNANCNN

TNANTNGNGCAGNNCNT

CNNNCNNNCNNNNNNNNN

NNNTGAAANACNCTGAA

NTGNNNNANNNNNNNNNN

NAGNNNTNNNNNNGTAC

NNNNNNNNNNNNNNNNAN

TNCTGAGNGNAGANNNN

NNNNNNNNNNNNNNNNNC

CNNNGANNNNNGTCANN

NTNNAANCNNNGGGNNNC

NNNNGGNGNANNNNCCN

NCNNNNA (SEQ ID

NNGCNNNCNNCNGNNNA

NO: 3601)

NNNNNNNAGCATGCNTN

CNNNNNNNNNNNNNNN

NGNAGNNNACNNNCNNN

NNNNGNNNNNNNNNNN

GCNANNNNNNCNNNNNN

TN (SEQ ID NO:

3603)

V-C053
NNNNNNNNTTATGTATCNT
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNCNNATGNATNN
CAGTCTGCCCTGACTCAGCC
COV047_

ACACATACGATTTAGGTGA
CTGGAGGAGGCTTGATCCA
P5_E10
TACACATACGATTTAGGT
TGCCTCCGTGTCTGGGTCTC
P5_E10

CACTATAGAATAACATCCA
GCCTGGGGGGTCCCTGAGA

GACACTATAGAATAACA
CTGGACAGTCGATCACCATC

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
TCCTGCACTGGAACCAGCAG

GTGTCCACTCCCAGGTCCA
GTTCACCGTCAGTAGCAAC

CCACAGGTGTCCACTCCC
TGATGTTGGGAGTTATAACC

ACTGCACCTCGGTTCTATCG
TACATGAGCTGGGTCCGCC

AGGTCCAACTGCACCTC
TTGTCTCCTGGTACCAACAG

ATTGAATTCCACCATGGGA
AGGCTCCAGGGAAGGGGCT

GGTTCTATCGATTGAATT
CACCCAGGCAAAGCCCCCA

TGGTCATGTATCATCCTTTT
GGAGTGGGTCTCAGTTATTT

CCACCATGGGATGGTCA
AACTCATGATTTATGAGGGC

TCTAGTAGCAACTGCAACC
ATAGCGGTTATAGCACATA

TGTATCATCCTTTTTCTA
AGTAAGCGGCCCTCAGGGG

GGTGTACATTCTGAGGTGC
CTACGTAGACTCCGTGAAG

GTAGCAACTGCAACCGG
TTTCTAATCGCTTCTCTGGCT

AGCTGGTGGAGTCTGGAGG
GGCCGATTCACCATCTCCA

TTCCTGGGCCCAGTCTGC
CCAAGTCTGGCAACACGGC

AGGCTTGATCCAGCCTGGG
GAGACAATTCCAAGAACAC

CCTGACTCAGCCTGCCTC
CTCCCTGACAATCTCTGGGC

GGGTCCCTGAGACTCTCCT
GCTGTATCTTCAAATGAAC

CGTGTCTGGGTCTCCTGG
TCCAGGCTGAGGACGAGGC

GTGCAGCCTCTGGGTTCAC
AGCCTGAGAGCCGAGGACA

ACAGTCGATCACCATCTC
TGATTATTACTGCTGCTCAT

CGTCAGTAGCAACTACATG
CGGCCGTGTATTACTGTGC

CTGCACTGGAACCAGCA
ATGCAGGTAGTAGCACTTGG

AGCTGGGTCCGCCAGGCTC
GAGAGTGGGGGGAGCACAT

GTGATGTTGGGAGTTAT
GTGTTCGGCGGAGGGACCA

CAGGGAAGGGGCTGGAGTG
AGTGGCTACGACGGATCCT

AACCTTGTCTCCTGGTAC
AGCTGACCGTCCTAG (SEQ

GGCCTCAGTTATTTATAGCG
TTGACTACTGGGGCCAGGG

CAACAGCACCCAGGCAA
ID NO: 3608)

GTTATAGCACATACTACGT
AACCCTGGTCACCGTCTCCT

AGCCCCCAAACTCATGA

AGACTCCGTGAAGGGCCGA
CAG (SEQ ID NO:

TTTATGAGGGCAGTAAG

TTCACCATCTCCAGAGACA
3606)

CGGCCCTCAGGGGTTTCT

ATTCCAAGAACACGCTGTA

AATCGCTTCTCTGGCTCC

TCTTCAAATGAACAGCCTG

AAGTCTGGCAACACGGC

AGAGCCGAGGACACGGCCG

CTCCCTGACAATCTCTGG

TGTATTACTGTGCGAGAGT

GCTCCAGGCTGAGGACG

GGGGGGAGCACATAGTGGC

AGGCTGATTATTACTGCT

TACGACGGATCCTTTGACT

GCTCATATGCAGGTAGT

ACTGGGGCCAGGGAACCCT

AGCACTTGGGTGTTCGG

GGTCACCGTCTCCTCAGCGT

CGGAGGGACCAAGCTGA

CGACCAAGGGCCCATCGGT

CCGTCCTAGGTCAGCCC

CTTCCCCCTGGCACCCTCCT

AAGGCTGCCCCCTCGGT

CCAAGAGCACCTCTGGGGG

CACTCTGTTCCCACCCTC

CACAGCGGCCCTGGGCTGC

GAGTGAGGAGCTTCAAG

CTGGTCAAGGACTACTTCC

CCAACAAGGCCACACTG

CCGAACCTGTGACGGTCTC

GTGTGTCTCATAAGTGAC

GTGGAACTCAGGCGCCCTG

TTCTACCCGGGAGCCGT

ACCAGCGGCGTGCACACCT

GACAGTGGCCTGGAAGG

TCCCGGCTGTCCTACAGTCC

CAGATAGCAGCCCCGTC

TCAGGACTCTACTCCCTCAG

AAGGCGGGAGTGGAGAC

CAGCGTGGTGACCGTGCCC

CACCACACCCTCCAAAC

TCCAGCAGCTTGGGCACCC

AAAGCAACAACAAGTAC

AGACCTACATCTGCAACGT

GCGGCCAGCAGCTACCT

GAATCACAAGCCCAGCAAC

GAGCCTGACGCCTGAGC

ACCAAGGTGGACAAGAGAG

AGTGGAAGTCCCACAGA

TTGAGCCCAAATCTTGTGA

AGCTACAGCTGCCAGGT

CAAAACTCACACATGCCCA

CACGCATGAAGGGAGCA

CCGTGCCCAGCACCTGAAC

CCGTGGAGAAGACAGTG

TCCTGGGGGGACCGTCAGT

GCCCCTACAGAATGTTC

CTTCCTCTTCCCCCCAAAAC

ATAGAAGCTTGGCCGNC

CCAANGACACCCTCATGAT

NNNGNCCNANNTTNGTT

CTCCCGGACCCCTGANNCA

ANNTNNNNNNTTANNNN

CATGCGTGGTGGNGGACGT

GNTTACANATAANGCNA

GAGCCACGAAGACCTGANN

TANTCATCACANATTTTC

CAAGTTCANTGGTACNTGG

ACANAATAANAGNNNTT

NNNGCNTGNNNGCATGATG

TTNTTNNCTGNNNTTCTA

NCNNNANNANNCNNNNNA

GTNGTGNGTTNTGNNNA

GANNNGTNNNNNANNANN

NNTCNNCNTCAGTGTAT

TANCNGGNNNNNNNCNGTG

CATNANNGTNTNNNNNA

NNNGNNCNNNNNTNCNCNN

TCGANNANTTANNTNNN

NNCTNNNNNNNANNNGGG

CGCANCNNNNNGNCNGN

NNNNANNGGNANNNNNNN

AANNNNCNNNTNNNNNN

NNNNNNANNGGNNTNNNN

NNNNNNNNAGNNCTNCT

NNANNNNNNNNNNCNNNN

GAGNNNNNNNCNTCNGN

NNNNANNNNNNNNNNNNN

GNNNGNNNNCAGTNGNN

NNNNNNNNAAANCNNNNN

CNNNNNNNCCNNNNCCN

GGNNNNNCCCN (SEQ

NCAGCNNANNNGCANNC

ID NO: 3605)

ATNNNTNNANNANNNNN

NNNNNNNNAGTCCNGNC

NNNGNNNNNNANNNNN

NNNNNNNNNN (SEQ

ID NO: 3607)

V-C054
NNNNNNNNNNNNNNNNNN
CAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNNNTGNATCN
GACATCCAGATGACCCAGTC
COV047_

NNNTACACNTACGATTTAG
CTGGGGGAGGCGTGGTCCA
P5_H7
TACACATACGATTTAGGT
TCCATCCTCCCTGTCTGCAT
P5_H7

GTGACACTATAGAATAACA
GCCTGGGAGGTCCCTGAGA

GACACTATAGAATAACA
CTGTAGGAGACAGAGTCAC

TCCACTTTGCCTTTCTCTCC
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
CATCACTTGCCAGGCGAGTC

ACAGGTGTCCACTCCCAGG
ATTCACCTTCAGTCGCTATG

CCACAGGTGTCCACTCCC
AGGGCATTAGCAACTATTTA

TCCAACTGCACCTCGGTTCT
GCATGCACTGGGTCCGCCA

AGGTCCAACTGCACCTC
AATTGGTATCAGCAGAAAC

ATCGATTGAATTCCACCAT
GGCTCCAGGCAAGGGGCTG

GGTTCTATCGATTGAATT
CAGGGAAAGCCCCTAAGCT

GGGATGGTCATGTATCATC
GAGTGGGTGGCAGTTATGT

CCACCATGGGATGGTCA
CCTGATCTACGATGCATCCA

CTTTTTCTAGTAGCAACTGC
CATATGATGGAAGTAGTAA

TGTATCATCCTTTTTCTA
ATTTGGAAACAGGGGTCCC

AACCGGTGTACATTCTCAG
ATACTATGCAGACTCCGTG

GTAGCAACTGCAACCGG
ATCAAGGTTCAGTGGAAGT

GTGCAGCTGGTGGAGTCTG
AAGGGCCGATTCACCATCT

TGTACATTCTGACATCCA
GGATCTGGGACAGATTTTAC

GGGGAGGCGTGGTCCAGCC
CCAGAGACAATTCCAAGAA

GATGACCCAGTCTCCATC
TTTCACCATCAGCAGCCTGC

TGGGAGGTCCCTGAGACTC
CACGCTGTGTCTGCAAATG

CTCCCTGTCTGCATCTGT
AGCCTGAAGATATTGCAAC

TCCTGTGCAGCCTCTGGATT
AACAGCCTGAGAGCTGAGG

AGGAGACAGAGTCACCA
ATATTACTGTCAACAGTATG

CACCTTCAGTCGCTATGGC
ACACGGCTGTGTATTACTGT

TCACTTGCCAGGCGAGT
ATAATCTCCCGATCACCTTC

ATGCACTGGGTCCGCCAGG
GCGAAACAGGCGGGCCCAT

CAGGGCATTAGCAACTA
GGCCAAGGGACACGACTGG

CTCCAGGCAAGGGGCTGGA
ATTGTAGTGGTGGTAGCTG

TTTAAATTGGTATCAGCA
AGATTAAAC (SEQ ID NO:

GTGGGTGGCAGTTATGTCA
CTACTCCGCGCCCTTTGACT

GAAAccAGGGAAAGccc
3612)

TATGATGGAAGTAGTAAAT
ACTGGGGCCAGGGAACCCT

CTAAGCTCCTGATCTACG

ACTATGCAGACTCCGTGAA
GGTCACCGTCTCCTCAG

ATGCATCCAATTTGGAA

GGGCCGATTCACCATCTCC
(SEQ ID NO: 3610)

ACAGGGGTCCCATCAAG

AGAGACAATTCCAAGAACA

GTTCAGTGGAAGTGGAT

CGCTGTGTCTGCAAATGAA

CTGGGACAGATTTTACTT

CAGCCTGAGAGCTGAGGAC

TCACCATCAGCAGCCTG

ACGGCTGTGTATTACTGTGC

CAGCCTGAAGATATTGC

GAAACAGGCGGGCCCATAT

AACATATTACTGTCAAC

TGTAGTGGTGGTAGCTGCT

AGTATGATAATCTCCCG

ACTCCGCGCCCTTTGACTAC

ATCACCTTCGGCCAAGG

TGGGGCCAGGGAACCCTGG

GACACGACTGGAGATTA

TCACCGTCTCCTCAGCGTCG

AACGTACGGTGGCTGCA

ACCAAGGGCCCATCGGTCT

CCATCTGTCTTCATCTTC

TCCCCCTGGCACCCTCCTCC

CCGCCATCTGATGAGCA

AAGAGCACCTCTGGGGGCA

GTTGAAATCTGGAACTG

CAGCGGCCCTGGGCTGCCT

CCTCTGTTGTGTGCCTGC

GGTCAAGGACTACTTCCCC

TGAATAACTTCTATCCCA

GAACCTGTGACGGTCTCGT

GAGAGGCCAAAGTACAG

GGAACTCAGGCGCCCTGAC

TGGAAGGTGGATAACGC

CAGCGGCGTGCACACCTTC

CCTCCAATCGGGTAACTC

CCGGCTGTCCTACAGTCCTC

CCAGGAGAGTGTCACAG

AGGACTCTACTCCCTCAGC

AGCAGGACAGCAAGGAC

AGCGTGGTGACCGTGCCCT

AGCACCTACAGCCTCAG

CCAGCAGCTTGGGCACCCA

CAGCACCCTGACGCTGA

GACCTACATCTGCAACGTG

GCAAAGCAGACTACGAG

AATCACAAGCCCAGCAACA

AAACACAAAGTCTACGC

CCAAGGTGGACAAGAGAGT

CTGCGAAGTCACCCATC

TGAGCCCAAATCTTGTGAC

AGGGCCTGAGCTCGCCC

AAAACTCACACATGCCCAC

GTCACAAAGAGCTTCAA

CGTGCCCAGCACCTGAACT

CAGGGGAGAGTGTTAGA

CCTGGGGGGACCGTCAGTC

AGCTTGGCCGCCATGGC

TTCCTCTTCCCCCCAAAACC

CCAACTTGTTTATTGCAG

CAANGACACCCTCNTGATC

CTTATAATGGTTACAAAT

TCCCGGACCCCTGAGGTCN

AAAGCAATAGCATCACA

NATGCGTGGTGGTGGNNGT

AATTTCACAAATAAAGC

GAGCCACGAAGACCCNGAN

ATTTTTTTCACTGCATTC

NCNAGTTCAACTGGNACGN

TNNNNTGTGGGNTTNTG

GGACGGNGNNNNGGNGCA

NNNNANNNNNNNNNNN

NNANGCCAAGACAAAGCCG

GTNTCATANCNNNTCGG

CGGGAGGANCNNT ANNAN

GGNNNGGGNNATTAATT

N_AGC_ACNN_ACCGNNNNGNC

CGNNGCAGCNNNTGNNN

AGCGNNCCNTNNNCGNCNG

GAAANANNNTGAAAGAG

NNCCNNNNACTNNNNAANG

NNNNNNNNNACTNNGAG

GCNNNNTACANNNCNNGNN

NGAANAACNNCNGNNNN

NTCCANNNANNNNNNNNN

GNNNNGTCAGTNGNNGN

NCNTNNNNAANCNNNNNN

NGAAAGTCNNNGNTCCN

NCAANNNNNNNNNNNNCC

NNNGNNNANNNATGNNA

CCCNNNNNNN (SEQ ID NO:

ANNNTNNNNNNNNTNNN

3609)

CNGCANCNGNNNNNNNA

NNNNNNNNNNNNNGGN

NNNNNANNNNNNNNNN

NNNNNNNNNNCCNNNNN

NNNNN (SEQ ID

NO: 3611)

V-CO55
NNNNNNNNNNNNTGNNNN
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNNATGTATCN
GAAATAGTGATGACGCAGT
COV047_

NTACANNTACGATTTAGGT
CTGGAGGAGGCTTGATCCA
P5_C3
TACACATACGATTTAGGT
CTCCAGCCACCCTGTCTGTG
P5_C3

GACACTATAGAATAACATC
GCCTGGGGGGTCCCTGAGA

GACACTATAGAATAACA
TCTCCAGGGGAAAGAGCCA

CACTTTGCCTTTCTCTCCAC
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
CCCTCTCCTGCAGGGCCAGT

NNGNGTCCACTCCCAGGTC
GTTCATCGTCAGTAGCAAC

CCACAGGTGTCCACTCCC
CAGAGTGTTAGCAGCAACTT

CAACTGCACCTCGGTTCTAT
TACATGAGCTGGGTCCGCC

AGGTCCAACTGCACCTC
AGCCTGGTACCAGCAGAAA

CGATTGAATTCCACCATGG
AGGCTCCAGGGAAGGGCCT

GGTTCTATCGATTGAATT
CCTGGCCAGGCTCCCAGGCT

GATGGTCATGTATCATCCTT
GGAGTGGGTCTCAGTTATTT

CCACCATGGGATGGTCA
CCTCATCTATGGTGCATCCA

TTTCTAGTAGCAACTGCAA
ATAGCGGTGGTAGCACATT

TGTATCATCCTTTTTCTA
CCAGGGCCACTGCTATCCCA

CCGGTGTACATTCTGAGGT
CTACGCAGACTCCGTGAAG

GTAGCAACTGCAACCGG
GCCAGGTTCAGTGGCAGTG

GCAGCTGGTGGAGTCTGGA
GGCCGATTCACCATCTCCA

TGTACATTCAGAAATAG
GGTCTGGGACAGAGTTCACT

GGAGGCTTGATCCAGCCTG
GAGACAATTCCAAGAACAC

TGATGACGCAGTCTCCA
CTCACCATCAGCAGCCTGCA

GGGGGTCCCTGAGACTCTC
GCTGTATCTTCAAATGAAC

GCCACCCTGTCTGTGTCT
GTCTGAAGATTTTGCAGTTT

CTGTGCAGCCTCTGGGTTCA
AGCCTGAGAGCCGAGGACA

CCAGGGGAAAGAGCCAC
ATTACTGTCAGCAGTATAAT

TCGTCAGTAGCAACTACAT
CGGCCGTGTATTACTGTGC

CCTCTCCTGCAGGGCCA
AACTGGCCTCGGACGTTCGG

GAGCTGGGTCCGCCAGGCT
GAGAGATTTTGGAGAGTTC

GTCAGAGTGTTAGCAGC
CCAAGGGACCAAGGTGGAA

CCAGGGAAGGGCCTGGAGT
TACTTTGACTACTGGGGCC

AACTTAGCCTGGTACCA
ATCAAAC (SEQ ID NO:

GGGTCTCAGTTATTTATAGC
AGGGAACCCTGGTCACCGT

GCAGAAACCTGGCCAGG
3616)

GGTGGTAGCACATTCTACG
CTCCTCAG (SEQ ID

CTCCCAGGCTCCTCATCT

CAGACTCCGTGAAGGGCCG
NO: 3614)

ATGGTGCATCCACCAGG

ATTCACCATCTCCAGAGAC

GCCACTGCTATCCCAGCC

AATTCCAAGAACACGCTGT

AGGTTCAGTGGCAGTGG

ATCTTCAAATGAACAGCCT

GTCTGGGACAGAGTTCA

GAGAGCCGAGGACACGGCC

CTCTCACCATCAGCAGCC

GTGTATTACTGTGCGAGAG

TGCAGTCTGAAGATTTTG

ATTTTGGAGAGTTCTACTTT

CAGTTTATTACTGTCAGC

GACTACTGGGGCCAGGGAA

AGTATAATAACTGGCCT

CCCTGGTCACCGTCTCCTCA

CGGACGTTCGGCCAAGG

GCGTCGACCAAGGGCCCAT

GACCAAGGTGGAGATCA

CGGTCTTCCCCCTGGCACCC

AACGTACGGTGGCTGCA

TCCTCCAAGAGCACCTCTG

CCATCTGTCTTCATCTTC

GGGGCACAGCGGCCCTGGG

CCGCCATCTGATGAGCA

CTGCCTGGTCAAGGACTAC

GTTGAAATCTGGAACTG

TTCCCCGAACCTGTGACGG

CCTCTGTTGTGTGCCTGC

TCTCGTGGAACTCAGGCGC

TGAATAACTTCTATCCCA

CCTGACCAGCGGCGTGCAC

GAGAGGCCAAAGTACAG

ACCTTCCCGGCTGTCCTACA

TGGAAGGTGGATAACGC

GTCCTCAGGACTCTACTCCC

CCTCCAATCGGGTAACTC

TCAGCAGCGTGGTGACCGT

CCAGGAGAGTGTCACAG

GCCCTCCAGCAGCTTGGGC

AGCAGGACAGCAAGGAC

ACCCAGACCTACATCTGCA

AGCACCTACAGCCTCAG

ACGTGAATCACAAGCCCAG

CAGCACCCTGACGCTGA

CAACACCAAGGTGGACAAG

GCAAAGCAGACTACGAG

AGAGTTGAGCCCAAATCTT

AAACACAAAGTCTACGC

GTGACAAAACTCACACATG

CTGCGAAGTCACCCATC

CCCACCGTGCCCAGCACCT

AGGGCCTGAGCTCGCCC

GAACTCCTGGGGGGANCGT

GTCACAAAGAGCTTCAA

CAGTCTTCCTCTTCCCCCCA

CAGGGGAGAGTGTTAGA

AAACCCAAGGACACCCTCA

AGCTTGGNCCGCCATGG

TGATCTCCCGGACCCCTGA

NNNCNNCNNNTTGTNTA

GGTCACATGCGTGGTGGNG

NNGCATCTTATNNTGNTT

GNACGTGANCCACGAAGAC

ACAAATAAGCAATANCA

CCTNNNGTCAGTTCAACTG

TCACNAATTTCACAAAT

GNACNNGGAANGGNNNTG

AAAGCATTTTTNTCACTG

GANGTGCNNNATGNCAAGA

CATNTANNNTGNTTGTCC

ANNAAGCCNCGGGNANGG

NAACTCNTNANGTATCT

ANCAGTACACAGCACGTAC

NNNNTGNNNNNNCNGNA

CGNNNNGGNCANCNNCCNN

NNNTNNNNCANNNCNTG

CNNCGTNCNNCACCANNNC

NNNGNAATANNCTGAAN

TNNNNANNNNANNNNNNA

AGAANTNNNGTACTCTN

CANNGCAGNNNNCANCAA

AGNGNNNNAANANCNN

ANCCCNNNNNCCCNNTNNN

NNNNNNNGNNNNNNNN

NNANNNNNNNNANNNNNN

GNNGNGNNANNNNNCN

NNNNNNNNNANNNNGGNN

NNNNCNNNNNNNNNNN

NANNCCNNNNNNNNTNNCC

NNNNNNANGNTNNNNNN

NNNNNNNN (SEQ ID

NNNNNCNGNNNNNNNCC

NO: 3613)

NNNNNNNNN (SEQ ID

NO: 3615)

V-C056
NNNNNNNNNNNNNNGNGN
CAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNCNNATGNATCN
TCCTATGTGCTGACTCAGCC
COV047_

TNNTNNNNNTACGATTTAN
CTGGGGGAGGCGTGGTCCA
P3_F4
TACACATACGATTTAGGT
ACCCTCGGTGTCAGTGGCCC
P3_F4

GTGACACTATANAATAACA
GCCTGGGAGGTCCCTGAGA

GACACTATAGAATAACA
CAGGACAGACGGCCAGGAT

TCCACTTTGCCTTTCTCTCC
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
TTCCTGTGGGGGAAACAAC

ACNGGTGTCCACTCCCAGG
ATTCACCTTCAGTAACTATG

CCACAGGTGTCCACTCCC
ATTGGAAGTAAAAATGTGC

TCCAACTGCACCTCGGTTCT
GCATGCACTGGGTCCGCCA

AGGTCCAACTGCACCTC
ACTGGTACCAGCAGAAGCC

ATCGATTGAATTCCACCAT
GGCTCCAGGCAAGGGGCTG

GGTTCTATCGATTGAATT
AGGCCAGGCCCCTGTGCTGG

GGGATGGTCATGTATCATC
GAGTGGGTGGCAGTTATAT

CCACCATGGGATGGTCA
TCGTCTATGATGATAGCGAC

CTTTTTCTAGTAGCAACTGC
CATATGATGGAAATAATAA

TGTATCATCCTTTTTCTA
CGGCCCTCAGGGATCCCTGA

AACCGGTGTACATTCTCAG
ATACTATGCAGACTCCGTG

GTAGCAACTGCAACCGG
GCGATTCTCTGGCTCCAACT

GTGCAGCTGGTGGAGTCTG
AAGGGCCGATTCACCATCT

TTCTGTGACCTCCTATGA
CTGGGAACACGGCCACCCT

GGGGAGGCGTGGTCCAGCC
CCAGAGACAATTCCAAGAA

GCTGACTCAGCCACCCTC
GACCATCAGCAGGGTCGAA

TGGGAGGTCCCTGAGACTC
CACGCTGTATCTGCAAATG

GGTGTCAGTGGCCCCAG
GCCGGGGATGAGGCCGACT

TCCTGTGCAGCCTCTGGATT
AACAGCCTGAGAGCTGAGG

GACAGACGGCCAGGATT
ATTACTGTCAGGTGTGGGAT

CACCTTCAGTAACTATGGC
ACACGGCTGTGTATTACTGT

TCCTGTGGGGGAAACAA
AGTAGTAGTGATCCTTGGGT

ATGCACTGGGTCCGCCAGG
GCGAAAGATCCTTTCCCCTT

CATTGGAAGTAAAAATG
GTTCGGCGGAGGGACCAAG

CTCCAGGCAAGGGGCTGGA
AGCAGTGGCTGGGACGGGC

TGCACTGGTACCAGCAG
CTGACCGTCCTAG (SEQ

GTGGGTGGCAGTTATATCA
TACTTTGACTACTGGGGCC

AAGccAGGccAGGcccc
ID NO: 3620)

TATGATGGAAATAATAAAT
AGGGAACCCTGGTCACCGT

TGTGCTGGTCGTCTATGA

ACTATGCAGACTCCGTGAA
CTCCTCAG (SEQ ID NO:

TGATAGCGACCGGCCCT

GGGCCGATTCACCATCTCC
3618)

CAGGGATCCCTGAGCGA

AGAGACAATTCCAAGAACA

TTCTCTGGCTCCAACTCT

CGCTGTATCTGCAAATGAA

GGGAACACGGCCACCCT

CAGCCTGAGAGCTGAGGAC

GACCATCAGCAGGGTCG

ACGGCTGTGTATTACTGTGC

AAGCCGGGGATGAGGCC

GAAAGATCCTTTCCCCTTAG

GACTATTACTGTCAGGTG

CAGTGGCTGGGACGGGCTA

TGGGATAGTAGTAGTGA

CTTTGACTACTGGGGCCAG

TCCTTGGGTGTTCGGCGG

GGAACCCTGGTCACCGTCT

AGGGACCAAGCTGACCG

CCTCAGCGTCGACCAAGGG

TCCTAGGTCAGCCCAAG

CCCATCGGTCTTCCCCCTGG

GCTGCCCCCTCGGTCACT

CACCCTCCTCCAAGAGCAC

CTGTTCCCGCCCTCGAGT

CTCTGGGGGCACAGCGGCC

GAGGAGCTTCAAGCCAA

CTGGGCTGCCTGGTCAAGG

CAAGGCCACACTGGTGT

ACTACTTCCCCGAACCTGTG

GTCTCATAAGTGACTTCT

ACGGTCTCGTGGAACTCAG

ACCCGGGAGCCGTGACA

GCGCCCTGACCAGCGGCGT

GTGGCCTGGAAGGCAGA

GCACACCTTCCCGGCTGTCC

TAGCAGCCCCGTCAAGG

TACAGTCCTCAGGACTCTA

CGGGAGTGGAGACCACC

CTCCCTCAGCAGCGTGGTG

ACACCCTCCAAACAAAG

ACCGTGCCCTCCAGCAGCT

CAACAACAAGTACGCGG

TGGGCACCCAGACCTACAT

CCAGCAGCTACCTGAGC

CTGCAACGTGAATCACAAG

CTGACGCCTGAGCAGTG

CCCAGCAACACCAAGGTGG

GAAGTCCCACAGAAGCT

ACAAGAGAGTTGAGCCCAA

ACAGCTGCCAGGTCACG

ATCTTGTGACAAAACTCAC

CATGAAGGGAGCACCGT

ACATGCCCACCGTGCCCAG

GGAGAAGACAGTGGCCC

CACCTGAACTCCTGGGGGG

CTACAGAATGTTCATAG

ACCGTCAGTCTTCCTCTTCC

AAGCTTGGCCGCCATGG

CCCCAAAACCCAAGGACAC

CCCAACTTGTTTATTGCA

CCTCNNTGATCTCCCNGNA

GCTTATAATGGTTACAA

CCCCTGAGGTCACATGCGT

ATAAAGCAATAGCATCA

GGTGGNGGACGTGAGCCAC

CAAATTTCACAAATAAA

GAANACCCTGAGNCAAGTT

GCATTTTTTTTCACTGCA

TCAACTGGNNACNTGGANG

TTCTAGTTGTGGTTTGNC

GCGNNNNNNGCATNANGCC

CAAACTCATCAATGTATC

NANNNAAAGCCNNNGAGG

TTATCATGTCTGGATCGG

ANCAGTANANNGCACGTNN

GAATNANTTCTGCNCAG

CCGNNNNNNANNNTCNTCN

CNCCATGGNCCTGGNNN

NCGNNCNNCACCNNNNTNN

TAGCACTGANNNNNNAN

NNANNNNAGNANNANANN

NNNGNNNNNGNNNNNN

NNAGNNNCNACAANNCNTN

NTTNNNNTNNNANNNNN

CCNNCNNNNNNNANNNNNT

ANCNNNNNNNNCNNTNN

NNANNNNANNNNNCCCNC

NNNNNNATGNNGTGTCA

NNNNNNNNNNNGNNNNNN

GNTNNGNNNNNNNANNN

N(SEQ ID NO: 3617)

TCCNCNGGNNNCCCNNN

AGNANANNNTNNNNNNC

NTNCATNTCNNNNNCNN

NANCNNGNNNNNNANN

NNCCNNNNNNCNNNNNG

NNNNNNNNNNNNNANN

NNNNNNNNNNNNNNNN

NNNNNNNNNNNNCNNA

ANC (SEQ ID NO:

3619)

V-C057
NNNNNNNNTATGTATCNTA
GAGGTGCAGCTGTTGGAGT
COV047_
NNNNNNNCNTATGNATC
GACATCGTGATGACCCAGTC
COV047_

CACNTACGATTTAGGTGAC
CTGGGGGAGGCTTGGTACA
P3_C5
NTACACATACGATTTAG
TCCAGACTCCCTGGCTGTGT
P3_C5

ACTATAGAATAACATCCAC
ACCTGGGGGGTCCCTGAGA

GTGACACTATAGAATAA
CNNTGGGCGAGAGGGCCAC

TTTGCCTTTCTCTCCACAGG
CTCTCCTGTGCAGCCTCTGG

CATCCACTTTGCCTTTCT
CATCAACTGCAAGTCCAGCC

TGTCCACTCCCAGGTCCAA
ATTCACCTTTAGCAGCTATG

CTCCACAGGTGTCCACTC
AGAATGTTTTATACAGCTCC

CTGCACCTCGGTTCTATCGA
CCATGAGCTGGGTCCGCCA

CCAGGTCCAACTGCACC
AACAATAAGAACTACTTAG

TTGAATTCCACCATGGGAT
GGCTCCAGGGAAGGGGCTG

TCGGTTCTATCGATTGAA
CTTGGTACCAGCAGAAACC

GGTCATGTATCATCCTTTTT
GAGTGGGTCTCAGCTACCA

TTCCACCATGGGATGGTC
AAGACAGCCTCCTAAACTGC

CTAGTAGCAACTGCAACCG
GTGATAGTGGTGGTACCAC

ATGTATCATCCTTTTTCT
TCATTTACTGGGCATCTACC

GTGTACATTCTGAGGTGCA
ATACTACGCAGACTCCGTG

AGTAGCAACTGCAACCG
CGGGAATCCGGGGTCCCTG

GCTGTTGGAGTCTGGGGGA
AAGGGGCGGTTCACCATCT

GTGTACATTCGGACATC
ACCGATTCAGTGGCAGCGG

GGCTTGGTACAACCTGGGG
CCAGAGACAATTCCAAGAA

GTGATGACCCAGTCTCC
GTCTGGGACAGATTTCACTC

GGTCCCTGAGACTCTCCTGT
CACGCTGTATCTGCAAATG

AGACTCCCTGGCTGTGTC
TCACCATCAGCAGCCTGCAG

GCAGCCTCTGGATTCACCTT
AATAGTCTGAGAGCCGAGG

TCTGGGCGAGAGGGCCA
GCCGAAGATGTGGCAGTTTA

TAGCAGCTATGCCATGAGC
ACACGGCCATATATTACTG

CCATCAACTGCAAGTCC
TTACTGTCAGCAATATTATA

TGGGTCCGCCAGGCTCCAG
TGCGAGGAGAGGAAATAGT

AGCCAGAATGTTTTATAC
CTCTTCGTTGGACGTTCGGC

GGAAGGGGCTGGAGTGGGT
GGGAGCTACCCTGACCCTG

AGCTCCAACAATAAGAA
CAAGGGACCAAGGTGGAAA

CTCAGCTACCAGTGATAGT
ACTACTGGGGCCAGGGAAC

CTACTTAGCTTGGTACCA
TCAAAC (SEQ ID NO:

GGTGGTACCACATACTACG
CCTGGTCACCNTCTCCTCAG

GCAGAAACCAAGACAGC
3624)

CAGACTCCGTGAAGGGGCG
(SEQ ID NO: 3622)

CTCCTAAACTGCTCATTT

GTTCACCATCTCCAGAGAC

ACTGGGCATCTACCCGG

AATTCCAAGAACACGCTGT

GAATCCGGGGTCCCTGA

ATCTGCAAATGAATAGTCT

CCGATTCAGTGGCAGCG

GAGAGCCGAGGACACGGCC

GGTCTGGGACAGATTTC

ATATATTACTGTGCGAGGA

ACTCTCACCATCAGCAG

GAGGAAATAGTGGGAGCTA

CCTGCAGGCCGAAGATG

CCCTGACCCTGACTACTGG

TGGCAGTTTATTACTGTC

GGCCAGGGAACCCTGGTCA

AGCAATATTATACTCTTC

CCGTCTCCTCAGCGTCGACC

GTTGGACGTTCGGCCAA

AAGGGCCCATCGGTCTTCC

GGGACCAAGGTGGAAAT

CCCTGGCACCCTCCTCCAA

CAAACGTACGGTGGCTG

GAGCACCTCTGGGGGCACA

CACCATCTGTCTTCATCT

GCGGCCCTGGGCTGCCTGG

TCCCGCCATCTGATGAGC

TCAAGGACTACTTCCCCGA

AGTTGAAATCTGGAACT

ACCTGTGACGGTCTCGTGG

GCCTCTGTTGTGTGCCTG

AACTCAGGCGCCCTGACCA

CTGAATAACTTCTATCCC

GCGGCGTGCACACCTTCCC

AGAGAGGCCAAAGTACA

GGCTGTCCTACAGTCCTCA

GTGGAAGGTGGATAACG

GGACTCTACTCCCTCAGCA

CCCTCCAATCGGGTAACT

GCGTGGTGACCGTGCCCTC

CCCAGGAGAGTGTCACA

CAGCAGCTTGGGCACCCAG

GAGCAGGACAGCAAGGA

ACCTACATCTGCAACGTGA

CAGCACCTACAGCCTCA

ATCACAAGCCCAGCAACAC

GCAGCACCCTGACGCTG

CAAGGTGGACAAGAGAGTT

AGCAAAGCAGACTACGA

GAGCCCAAATCTTGTGACA

GAAACACAAAGTCTACG

AAACTCACACATGCCCACC

CCTGCGAAGTCACCCAT

GTGCCCAGCACCTGAACTC

CAGGGCCTGAGCTCGCC

CTGGGGGGACCGTCAGTCT

CGTCACAAAGAGCTTCN

TCCTCTTCCCCCCAAAACCC

ANNNGGGGGAGAGTGTT

ANNNCACCCTCATGATCTC

AGAAGCTTGGNCCGCCA

CCGGACCCCTGAGGTCACA

TGGCCCAACTTGNTTTNT

TGCGTGGTGGTGGAGGTGA

TNGCAGNTNTATANNNN

GNCACGAGACCNNGAAGN

TNNCAAATAAAGCAATA

NNNNNNAGNNNNGNTNNA

GCATCACAAATTTCACA

GNTNGGNANNGNNANGGC

AATAAAGCATTTTTTTCA

NTNGNAGGTGCATAATGNN

CTGCATTCTAGTTGTGGT

NNNNAAANNCCNNNGGGA

TTGTCCAAACTCATCAAN

NGANCAGTACAANNGCACN

GNATNTNATCATGNCTG

NACCNNNNNGGNNNNNNN

GNTCGNNATNATTCGNG

NNNNNNNCNGTNCNNNNN

CAGCNNCATNNNCTGAA

NNN(SEQ ID NO:

TACNTCTGAANAGACTN

3621)

NNNNACTNNGAGNGAAG

ANNNCNNNGANGGNNN

GTCNNTNNNNNGGGGNA

NNNNNNCCNNNNNC

(SEQ ID NO: 3623)

V-C058
NNNNNNNNNNNTGNNTCNT
CAGGTGCAGCTGGTGCAGT
COV047_
NNNNNNNNNNNNNNTGT
GACATCCAGATGACCCAGTC
COV047_

ACACNTACGATTTAGGTGA
CTGGGGCTGAGGTGAAGAA
P5_F6
NTNNACNCNTACGATTT
TCCATCCTCCCTGTCTGCAT
P5_F6

CACTATAGAATAACATCCA
GCCTGGGGCCTCAGTGAAG

AGGTGACACTATAGAAT
CTGTAGGAGACAGAGTCAC

CTTTGCCTTTCTCTCCACAG
GTTTCCTGCAAGGCATCTG

AACATCCACTTTGCCTTT
CATCACTTGCCGGGCAAGTC

GTGTCCACTCCCAGGTCCA
GATACACCTTCATCAGCTA

CTCTCCACAGGTGTCCAC
AGAGCATTAGCAGCTATTTA

ACTGCACCTCGGTTCTATCG
CTATATGCACTGGGTGCGA

TCCCAGGTCCAACTGCA
AATTGGTATCAGCAGAAAC

ATTGAATTCCACCATGGGA
CAGGCCCCTGGACAAGGGC

CCTCGGTTCTATCGATTG
CAGGGAAAGCCCCTAAGCT

TGGTCATGTATCATCCTTTT
TTGAGTGGATGGGAATAAT

AATTCCACCATGGGATG
CCTGATCTATGCTGCATCCA

TCTAGTAGCAACTGCAACC
CAACCCTAGTGGTGGTAGC

GTCATGTATCATCCTTTT
GTTTGCAAAGTGGGGTCCCA

GGTGTACATTCCCAGGTGC
ACAAGCTACGCACAGAAGT

TCTAGTAGCAACTGCAA
TCAAGGTTCAGTGGCAGTGG

AGCTGGTGCAGTCTGGGGC
TCCAGGGCAGAGTCACCAT

CCGGTGTACATTCTGACA
ATCTGGGACAGATTTCACTC

TGAGGTGAAGAAGCCTGGG
GACCAGGGACACGTCCACG

TCCAGATGACCCAGTCTC
TCACCATCAGCAGTCTGCAA

GCCTCAGTGAAGGTTTCCT
AGCACAGTCTACATGGAGC

CATCCTCCCTGTCTGCAT
CCTGAAGATTTTGCAACTTA

GCAAGGCATCTGGATACAC
TGAGCAGCCTGAGATCTGA

CTGTAGGAGACAGAGTC
CTACTGTCAACAGAGTTACA

CTTCATCAGCTACTATATGC
GGACACGGCCGTGTATTAC

ACCATCACTTGCCGGGC
GTACCCCTCCGGAGGGCAGT

ACTGGGTGCGACAGGCCCC
TGTGCTAGGGCAAATGAGG

AAGTCAGAGCATTAGCA
TTTGGCCAGGGGACCAAGCT

TGGACAAGGGCTTGAGTGG
GAGCAGCTGTTTCATTTGAC

GCTATTTAAATTGGTATC
GGAGATCAAAC (SEQ ID

ATGGGAATAATCAACCCTA
TACTGGGGCCAGGGAACCC

AGCAGAAACCAGGGAAA
NO: 3628)

GTGGTGGTAGCACAAGCTA
TGGTCACCNTNTCCTCAG

GCCCCTAAGCTCCTGATC

CGCACAGAAGTTCCAGGGC
(SEQ ID NO: 3626)

TATGCTGCATCCAGTTTG

AGAGTCACCATGACCAGGG

CAAAGTGGGGTCCCATC

ACACGTCCACGAGCACAGT

AAGGTTCAGTGGCAGTG

CTACATGGAGCTGAGCAGC

GATCTGGGACAGATTTC

CTGAGATCTGAGGACACGG

ACTCTCACCATCAGCAGT

CCGTGTATTACTGTGCTAGG

CTGCAACCTGAAGATTTT

GCAAATGAGGGAGCAGCTG

GCAACTTACTACTGTCAA

TTTCATTTGACTACTGGGGC

CAGAGTTACAGTACCCC

CAGGGAACCCTGGTCACCG

TCCGGAGGGCAGTTTTG

TCTCCTCAGCGTCGACCAA

GCCAGGGGACCAAGCTG

GGGCCCATCGGTCTTCCCCC

GAGATCAAACGTACGGT

TGGCACCCTCCTCCAAGAG

GGCTGCACCATCTGTCTT

CACCTCTGGGGGCACAGCG

CATCTTCCCGCCATCTGA

GCCCTGGGCTGCCTGGTCA

TGAGCAGTTGAAATCTG

AGGACTACTTCCCCGAACC

GAACTGCCTCTGTTGTGT

TGTGACGGTCTCGTGGAAC

GCCTGCTGAATAACTTCT

TCAGGCGCCCTGACCAGCG

ATCCCAGAGAGGCCAAA

GCGTGCACACCTTCCCGGC

GTACAGTGGAAGGTGGA

TGTCCTACAGTCCTCAGGA

TAACGCCCTCCAATCGG

CTCTACTCCCTCAGCAGCGT

GTAACTCCCAGGAGAGT

GGTGACCGTGCCCTCCAGC

GTCACAGAGCAGGACAG

AGCTTGGGCACCCAGACCT

CAAGGACAGCACCTACA

ACATCTGCAACGTGAATCA

GCCTCAGCAGCACCCTG

CAAGCCCAGCAACACCAAN

ACGCTGAGCAAAGCAGA

GTGGACAAGAGAGTTGAGC

CTACGAGAAACACAAAG

CCAAATCTTGTGACAAAAC

TCTACGCCTGCGAAGTC

TCACACATGCCCACCGTGC

ACCCATCANGGCCTGAG

CCAGCACCTGAACTCCTGG

CTCGCCCGTCACAAAGA

GGGGGANCGTCAGTCTTNN

GCTTCAACAGGGGAGAG

TCTTNNNNNCNNAANANAA

TGTTAGAAGCTTGGCCG

NGNANANGNNCNNNNNNN

NCCATGNCCCAACTTGTT

NNNNNTNCCCGNNNNNNNG

TATTGCAGCTTATAATGG

NNGNNNCNTGGGGTGGNNG

TTACAAATAAAGCAATA

GTGNNNNNGANCNNNNAA

GCATCACAAATTTCACA

NANCCNNGANGTCAAGTTC

AATAAAGCATTTTTTTCA

AACTGGNACNGTNGNNGGG

CTGCATTCTAGTTGTGGT

CGTNNNNGCANNANGNCAA

TTGTCCAAACTCATCAAT

NANNAGCCNNNGGANGNN

GTATCTNATCATGTCTGG

CANTANANAGCNCGTACCG

NTCGGGAATTNATTCGN

NGNNNGNCAGCGTCCTNNN

CGCAGCANCATGNNNNA

NNCNGCNCANNACNGGNTG

ANNACTNNGANNNANNN

AANGGNANGGNANTNNNA

NNNNNNNNNNNNNNNN

NNNNNN (SEQ ID

NNNNTGAGCGAAAGAAC

NO: 3625)

ATCTGNNGANTNNGNGT

CANTTNNNNNGN (SEQ

ID NO: 3627)

V-CO59
NNNNNNNNNNNANGNNTC
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNTTATGTATN
CAGTCTGCCCTGACTCAGCC
COV047_

NTACACATACGATTTAGGT
CTGGGGGAGACTTGGTCCA
P5_G9
NNCNCATACGATTTAGG
TGCCTCCGTGTCTGGGTCTC
P5_G9

GACACTATAGAATAACATC
GCCTGGGGGGTCCCTGAGA

TGACACTATAGAATAAC
CTGGACAGTCGATCACCATC

CACTTTGCCTTTCTCTCCAC
CTCTCCTGTTCAGCCTCTGG

ATCCACTTTGCCTTTCTC
TCCTGCACTGGAACCAGCAG

AGGTGTCCACTCCCAGGTC
ATTCACCTTCAGTAGCTATG

TCCACAGGTGTCCACTCC
TGACATTGGTGATTATAACT

CAACTGCACCTCGGTTCTAT
CTATGCACTGGGTCCGCCA

CAGGTCCAACTGCACCT
ATGTCTCCTGGTACCAACAC

CGATTGAATTCCACCATGG
GGCTCCAGGGAAGGGACTG

CGGTTCTATCGATTGAAT
CACCCAGGCAAAGCCCCCA

GATGGTCATGTATCATCCTT
GAATATGTTTCAGTTATTAG

TCCACCATGGGATGGTC
AACTCATGATTTATGAAGTC

TTTCTAGTAGCAACTGCAA
TAATACTGGGGGTGACACA

ATGTATCATCCTTTTTCT
AGTAATCGGCCCTCAGGGGT

CCGGTGTACATTCTGAGGT
TACTACGCAGACTCCGTGA

AGTAGCAACTGCAACCG
TTCTAATCGCTTCTCTGGCT

GCAGCTGGTGGAGTCTGGG
AGGGCAGATTCACCATCTC

GTTCCTGGGCCCAGTCTG
CCAAGTCTGGCAACACGGC

GGAGACTTGGTCCAGCCTG
CAGAGACAATTCCAAGAAC

CCCTGACTCAGCCTGCCT
CTCCCTGACCATCTCTGGGC

GGGGGTCCCTGAGACTCTC
ACGTTGTATCTTCAAGTGA

CCGTGTCTGGGTCTCCTG
TCCAGGCTGAGGACGAGAC

CTGTTCAGCCTCTGGATTCA
GCAGTCTGAGACCTGAAGA

GACAGTCGATCACCATC
TGATTATTACTGCATCTCAT

CCTTCAGTAGCTATGCTATG
CACGGCTGTGTATTACTGTG

TCCTGCACTGGAACCAG
ATACAAGCAGCAGCACTCTT

CACTGGGTCCGCCAGGCTC
TGAAAGATCAAGGGGGCCG

CAGTGACATTGGTGATT
CCCTATGTCTTCGGAACTGG

CAGGGAAGGGACTGGAATA
GGGGTGGCCAAGTTACTAC

ATAACTATGTCTCCTGGT
GACCAAGGTCACCGTCCTAG

TGTTTCAGTTATTAGTAATA
TACTACCACTACATGGACG

ACCAACACCACCCAGGC
(SEQ ID NO: 3632)

CTGGGGGTGACACATACTA
TCTGGGGCAAAGGGACCAC

AAAGCCCCCAAACTCAT

CGCAGACTCCGTGAAGGGC
GGTCACCGTCTCCTCA

GATTTATGAAGTCAGTA

AGATTCACCATCTCCAGAG
(SEQ ID NO: 3630)

ATCGGCCCTCAGGGGTTT

ACAATTCCAAGAACACGTT

CTAATCGCTTCTCTGGCT

GTATCTTCAAGTGAGCAGT

CCAAGTCTGGCAACACG

CTGAGACCTGAAGACACGG

GCCTCCCTGACCATCTCT

CTGTGTATTACTGTGTGAAA

GGGCTCCAGGCTGAGGA

GATCAAGGGGGCCGGGGGT

CGAGACTGATTATTACTG

GGCCAAGTTACTACTACTA

CATCTCATATACAAGCA

CCACTACATGGACGTCTGG

GCAGCACTCTTCCCTATG

GGCAAAGGGACCACGGTCA

TCTTCGGAACTGGGACC

CCGTCTCCTCAGCGTCGACC

AAGGTCACCGTCCTAGG

AAGGGCCCATCGGTCTTCC

TCAGCCCAAGGCCAACC

CCCTGGCACCCTCCTCCAA

CCACTGTCACTCTGTTCC

GAGCACCTCTGGGGGCACA

CACCCTCGAGTGAGGAG

GCGGCCCTGGGCTGCCTGG

CTTCAAGCCAACAAGGC

TCAAGGACTACTTCCCCGA

CACACTGGTGTGTCTCAT

ACCTGTGACGGTCTCGTGG

AAGTGACTTCTACCCGG

AACTCAGGCGCCCTGACCA

GAGCCGTGACAGTGGCC

GCGGCGTGCACACCTTCCC

TGGAAGGCAGATAGCAG

GGCTGTCCTACAGTCCTCA

CCCCGTCAAGGCGGGAG

GGACTCTACTCCCTCAGCA

TGGAGACCACCACACCC

GCGTGGTGACCGTGCCCTC

TCCAAACAAAGCAACAA

CAGCAGCTTGGGCACCCAG

CAAGTACGCGGCCAGCA

ACCTACATCTGCAACGTGA

GCTACCTGAGCCTGACG

ATCACAAGCCCAGCAACAC

CCTGAGCAGTGGAAGTC

CAAGGTGGACAAGAGAGTT

CCACAGAAGCTACAGCT

GAGCCCAAATCTTGTGACA

GCCAGGTCACGCATGAA

AAACTCACACATGCCCACC

GGGAGCACCGTGGAGAA

GTGCCCAGCACCTGAACTC

GACAGTGGCCCCTACAG

CTGGGGGGACCGTCAGTCT

AATGTTCATAGAAGCTT

TCCTCTTCCCCCCAAAACCC

GGCCGCCATGGCCCAAC

AAGGACACCCTCATGATCT

TTGTTTATTGTNNCNNNN

CCCGGACCCCTGAGGTCAC

TATNNTGATTACNAAAT

ATGCGTGGGNGGNGGANNT

AAAGCAATAGCATCACA

GANCCACNANACCCTGAGN

AATTTCACAAATAAAGC

CAAGTTCAACTGGNACNNG

ATTTTTTTCACTGCATTC

GNNGGCGNNGAGGTGCATA

TAGTTGTGGTTNGTCCAA

ATGNNAANAANNAANNCG

ACTCATCNATGNNNNNN

CGGGAGGANCAGTACNANN

TTATCNTGNCTGGATCNG

NGCNNNTACCGNNNGGNNA

GAATNNNNNNNGCANCN

GNCNNNNNNNNNNCNNNN

CNTNNNNAAATNACCNN

NNNNNANTGNNNNAANGG

TGAANNNNNNANTNNNN

NN (SEQ ID NO:

NNGTACTNNNNNNNGNN

3629)

NNNNNAACNNNNNNNG

NANNNNNNNGTNNNNNT

NNNNNNNAANNNCCNNG

NNNNNNNNNGGNANNN

NTNNNNNAANNNNNN

(SEQ ID NO: 3631)

V-C060
NNNNNNNCNNATGTATCNT
CAGGTTCAGCTGGTGCAGT
COV107_
NNNNNNNTATGTATCNT
TCCTATGTGCTGACTCAGCC
COV107_

ACNCATACGATTTAGGTGA
CTGGAGCTGAGGTGAAGAA
P3_E5
ACACNTACGATTTAGGT
ACCCTCGGTGTCAGTGTCCC
P3_E5

CACTATAGAATAACATCCA
GCCTGGGGCCTCAGTGAAG

GACACTATAGAATAACA
CAGGACAGACGGCCAGGAT

CTTTGCCTTTCTCTCCACAG
GTCTCCTGCAAGGCTTCTGG

TCCACTTTGCCTTTCTCT
CACCTGCTCTGGAGATGCAT

GTGTCCACTCCCAGGTCCA
TTACACCTTTACCAGCTACG

CCACAGGTGTCCACTCCC
TGCCAAAGCAATATGCTTAT

ACTGCACCTCGGTTCTATCG
GTATCAGCTGGGTGCGACA

AGGTCCAACTGCACCTC
TGGTACCAGCAGAAGCCAG

ATTGAATTCCACCATGGGA
GGCCCCTGGACAAGGGCTT

GGTTCTATCGATTGAATT
GCCAGGCCCCTGTGCTGGTG

TGGTCATGTATCATCCTTTT
GAGTGGATGGGATGGATCA

CCACCATGGGATGGTCA
ATATATAAAGACAGTGAGA

TCTAGTAGCAACTGCAACC
GCGCTTACAATGGTAACAC

TGTATCATCCTTTTTCTA
GGCCCTCAGGGATCCCTGAG

GGTGTACATTCCCAGGTTC
AAACTATGCACAGAAGCTC

GTAGCAACTGCAACCGG
CGATTCTCTGGCTCCAGCTC

AGCTGGTGCAGTCTGGAGC
CAGGGCAGAGTCACCATGA

TTCTGTGACCTCCTATGA
AGGGACAACAGTCACGTTG

TGAGGTGAAGAAGCCTGGG
CCACAGACACATCCACGAG

GCTGACACAGCCACCCT
ACCATCAGTGGAGTCCAGG

GCCTCAGTGAAGGTCCCCT
CACAGCCTACATGGAGCTG

CGGTGTCAGTGTCCCCA
CAGAAGACGAGGCTGACTA

GCAAGGCTTCTGGTTACAC
AGGAGCCTGAGATCTGACG

GGACAGACGGCCAGGAT
TTACTGTCAATCAGCAGACA

CTTTACCAGCTACGGTATCA
ACACGGCCGTGTATTACTG

CACCTGCTCTGGAGATG
GCAGTGGTACTCTTTGGGTG

GCTGGGTGCGACAGGCCCC
TGCGAGAGTTCCCGCCTCG

CATTGCCAAAGCAATAT
TTCGGCGGAGGGACCAAGC

TGGACAAGGGCTTGAGTGG
TACGGTGACGACGATTACT

GCTTATTGGTACCAGCA
TGACCGTCCTAG (SEQ ID

ATGGGATGGATCAGCGCTT
ACTACTACTACGGTATGGA

GAAGCCAGGCCAGGCCC
NO: 3636)

ACAATGGTAACACAAACTA
CGTCTGGGGCCAAGGGACC

CTGTGCTGGTGATATATA

TGCACAGAAGCTCCAGGGC
ACGGTCACCGTCTCCTCA

AAGACAGTGAGAGGCCC

AGAGTCACCATGACCACAG
(SEQ ID NO: 339)

TCAGGGATCCCTGAGCG

ACACATCCACGAGCACAGC

ATTCTCTGGCTCCAGCTC

CTACATGGAGCTGAGGAGC

AGGGACAACAGTCACGT

CTGAGATCTGACGACACGG

TGACCATCAGTGGAGTC

CCGTGTATTACTGTGCGAG

CAGGCAGAAGACGAGGC

AGTTCCCGCCTCGTACGGT

TGACTATTACTGTCAATC

GACGACGATTACTACTACT

AGCAGACAGCAGTGGTA

ACTACGGTATGGACGTCTG

CTCTTTGGGTGTTCGGCG

GGGCCAAGGGACCACGGTC

GAGGGACCAAGCTGACC

ACCGTCTCCTCAGCGTCGA

GTCCTAGGTCAGCCCAA

CCAAGGGCCCATCGGTCTT

GGCTGCCCCCTCGGTCAC

CCCCCTGGCACCCTCCTCCA

TCTGTTCCCACCCTCGAG

AGAGCACCTCTGGGGGCAC

TGAGGAGCTTCAAGCCA

AGCGGCCCTGGGCTGCCTG

ACAAGGCCACACTGGTG

GTCAAGGACTACTTCCCCG

TGTCTCATAAGTGACTTC

AACCTGTGACGGTCTCGTG

TACCCGGGAGCCGTGAC

GAACTCAGGCGCCCTGACC

AGTGGCCTGGAAGGCAG

AGCGGCGTGCACACCTTCC

ATAGCAGCCCCGTCAAG

CGGCTGTCCTACAGTCCTCA

GCGGGAGTGGAGACCAC

GGACTCTACTCCCTCAGCA

CACACCCTCCAAACAAA

GCGTGGTGACCGTGCCCTC

GCAACAACAAGTACGCG

CAGCAGCTTGGGCACCCAG

GCCAGCAGCTACCTGAG

ACCTACATCTGCAACGTGA

CCTGACGCCTGAGCAGT

ATCACAAGCCCAGCAACAC

GGAAGTCCCACAGAAGC

CNANGTGGACAAGAGAGTT

TACAGCTGCCAGGTCAC

GAGCCCAAATCTTGTGACA

GCATGAAGGGAGCACCG

AAACTCACACATGCCCACC

TGGAGAAGACAGTGGCC

GTGCCCAGCACCTGAACTC

CCNANNNNNAATGTTCA

CTGGGGGGACCGTCAGTCT

TAGAAGCTTGGCCCGCC

TCCTCTTCCCCCCAAAACCC

ATGGCCCAACTTGTTTAT

AAGGNNNCCCTCATGATNN

TGCAGCTTATAATGGTTA

NCCCGNACCCCNGAGGTCA

CAAATAAAGCAATAGCA

CATGCGTGGNGGTGGACGT

TCACAAATTTCACAAAT

GANCCACGAANACCCTGAG

AAAGCATTTTTTTCACTG

NCAAGTTCAACTGGNACNN

CATTCTAGTTGTGGTTTG

GGNNGGCNNNNNNGCATA

TCCAAACTCATCAATGN

ANGNNANAANNAAGCCGN

NTCTTATCATGTCTGGNT

NGGNAGGANCANNNNNNN

CGGGNATTNATTTNGNN

NAGCNCGNNCCGNGNNNN

GCAGCNNNTGNNNGAAN

NCANNNTTCNNN (SEQ

NANNNTGAAAGAGNNTN

ID NO: 3633)

NNNNGNNCTTCTGAGNG

AANACNTCNNNNGANNN

NNGTCANTNNNNNGAAN

GTCCCAGNTCCCNNNNG

GNNNNTNNGNNNNNNNN

NNNTNNNCANTNNNTCA

NNNNNN (SEQ ID NO:

3635)

V-C061
NNNNNNNNCNNATGTATCN
CAGGTGCAGCTACAGCAGT
COV107_
NNNNNNNNNNNTATGNN
GAAATTGTGTTGACGCAGTC
COV107_

TACNCNTACGATTTAGGTG
GGGGCGCAGGACTGTTGAA
P1_G12
TCNTACNCATACGATTTA
TCCAGGCACCCTGTCTTTGT
P1_G12

ACACTATAGAATAACATCC
GCCTTCGGAGACCCTGTCTC

GGTGACACTATAGAATA
CTCCAGGGGAAAGAGCCAC

ACTTTGCCTTTCTCTCCACA
TCACCTGCGCTGTCTCTGGT

ACATCCACTTTGCCTTTC
CCTCTCCTGCAGGGCCAGTC

GGTGTCCACTCCCAGGTCC
GGGTCACTCAGTGGTTTCTA

TCTCCACAGGTGTCCACT
AGACTCTTACCGCCAACTAC

AACTGCACCTCGGTTCTATC
CTGGACCTGGATCCGCCAG

CCCAGGTCCAACTGCAC
TTAGCCTGGTACCAGCAGAA

GATTGAATTCCACCATGGG
CCCCCCGGAAAGGGGCTGG

CTCGGTTCTATCGATTGA
ACCTGGCCAGGCTCCCAGAC

ATGGTCATGTATCATCCTTT
AGTGGATTGGGGAAACCAA

ATTCCACCATGGGATGG
TCCTCATCTATGGTGCATCC

TTCTAGTAGCAACTGCAAC
TCATTTTGGAAGCACCGAC

TCATGTATCATCCTTTTT
AAGAGGGCCACTGGCATCC

CGGTGTACATTCCCAGGTG
TACAAGCCGTCCCTCAAGA

CTAGTAGCAACTGCAAC
CAGACAGGTTCAGTGGCAG

CAGCTACAGCAGTGGGGCG
GTCGAGTCACCATATCAGT

CGGTGTACATTCAGAAA
TGGGTCTGGGACAGACTTCA

CAGGACTGTTGAAGCCTTC
AGACATGTCCAGGAACCAA

TTGTGTTGACGCAGTCTC
CTCTCAGCATCAGCAGACTG

GGAGACCCTGTCTCTCACCT
TTTTCCCTGATTATGACCTC

CAGGCACCCTGTCTTTGT
GAGCCTGAAGATTTTGCAGT

GCGCTGTCTCTGGTGGGTC
TGTGACCGCCGCGGACACG

CTCCAGGGGAAAGAGCC
GTATTACTGTCAGCAGTATG

ACTCAGTGGTTTCTACTGGA
GCTGTGTATTACTGTGCGA

ACCCTCTCCTGCAGGGCC
GTACTACACCTCGGACTTTC

CCTGGATCCGCCAGCCCCC
GAAAGACCCTCCTCTTCAG

AGTCAGACTCTTACCGCC
GGCGGAGGGACCAAGGTGG

CGGAAAGGGGCTGGAGTGG
TGACTTTTCTCCTGGTGCTT

AACTACTTAGCCTGGTAC
AGATCAA (SEQ ID NO:

ATTGGGGAAACCAATCATT
TTGATATCTGGGGCCAAGG

CAGCAGAAACCTGGCCA
3640)

TTGGAAGCACCGACTACAA
GACAATGGTCGTAGTCTCTT

GGCTCCCAGACTCCTCAT

GCCGTCCCTCAAGAGTCGA
CAG (SEQ ID NO:

CTATGGTGCATCCAAGA

GTCACCATATCAGTAGACA
3638)

GGGCCACTGGCATCCCA

TGTCCAGGAACCAATTTTCC

GACAGGTTCAGTGGCAG

CTGATTATGACCTCTGTGAC

TGGGTCTGGGACAGACT

CGCCGCGGACACGGCTGTG

TCACTCTCAGCATCAGCA

TATTACTGTGCGAGAAAGA

GACTGGAGCCTGAAGAT

CCCTCCTCTTCAGTGACTTT

TTTGCAGTGTATTACTGT

TCTCCTGGTGCTTTTGATAT

CAGCAGTATGGTACTAC

CTGGGGCCAAGGGACAATG

ACCTCGGACTTTCGGCG

GTCACCGTCTCTTCAGCGTC

GAGGGACCAAGGTGGAA

GACCAAGGGCCCATCGGTC

ATCAAACGTACGGTGGC

TTCCCCCTGGCACCCTCCTC

TGCACCATCTGTCTTCAT

CAAGAGCACCTCTGGGGGC

CTTCCCGCCATCTGATGA

ACAGCGGCCCTGGGCTGCC

GCAGTTGAAATCTGGAA

TGGTCAAGGACTACTTCCC

CTGCCTCTGTTGTGTGCC

CGAACCTGTGACGGTCTCG

TGCTGAATAACTTCTATC

TGGAACTCAGGCGCCCTGA

CCAGAGAGGCCAAAGTA

CCAGCGGCGTGCACACCTT

CAGTGGAAGGTGGATAA

CCCGGCTGTCCTACAGTCCT

CGCCCTCCAATCGGGTA

CAGGACTCTACTCCCTCAG

ACTCCCAGGAGAGTGTC

CAGCGTGGTGACCGTGCCC

ACAGAGCAGGACAGCAA

TCCAGCAGCTTGGGCACCC

GGACAGCACCTACAGCC

AGACCTACATCTGCAACGT

TCAGCAGCACCCTGACG

GAATCACAAGCCCAGCAAC

CTGAGCAAAGCAGACTA

ACCAAGGTGGACAAGAGAG

CGAGAAACACAAAGTCT

TTGAGCCCAAATCTTGTGA

ACGCCTGCGAAGTCACC

CAAAACTCACACATGCCCA

CATCAGGGCCTGAGCTC

CCGTGCCCAGCACCTGAAC

GCCCGTCACAAAGAGCT

TCCTGGGGGGACCGTCAGT

TCAACAGGGGANANNNN

CTTCCTCTTCCCCCCAAAAC

NGAAGCTTNGGCCNCCN

CCAAGGACACCCTCATGAT

TGNGCCCNCNNNNTGTN

NNNCCGGACCCCTGANGTC

TNNNNNNNNTNNNNNNN

NNNTGCNTGGTGGTGGACG

NTNACAAATAAAGCAAT

TGAGCCACGANNACCCTGN

ANCATCNCANNTTCNCA

NNCAGTCANTGGNACGNNG

AAAAANNNNTTTTTTTNT

NNGGNNNGNAGGTNCATAA

CACTGCATNNNGTGNGN

TGNCAANANNAAGCCNNNG

TTGTCCAACTCATCATGN

GNAGGAGCAGNNNNANCA

NNCTNNCATGNCNGNTC

GCNNCGTACCCNNNNNNNN

GGNNTNNNGNGCANCAC

ANCNNN (SEQ ID NO:

NTNNNNANNNNNNNGNA

3637)

NNGANTGNNNGTACTNN

NNNNGNAANACNTCNGN

GANGNNNNCAGTNGGNG

NNGANGTCCCNGNNNN

(SEQ ID NO: 3639)

V-C062
NNNNNNNNNATGNATCNTA
CAGGTGCAGCTACAGCAGT
COV107_
NNNNNNNNNNNNATGNA
GAAATTGTGTTGACGCAGTC
COV107_

CACATACGATTTAGGTGAC
GGGGCGCAGGACTGTTGAA
P1_A11
TNNNCACNTACGATTTA
TCCAGGCACCCTGTCTTTGT
P1_A11

ACTATAGAATAACATCCAC
GCCTTCGGAGACCCTGTCC

GGTGACACTATAGAATA
CTCCAGGGGAAAGAGCCAC

TTTGCCTTTCTCTCCACAGG
CTCACCTGCGCTGTCTCTGG

ACATCCACTTTGCCTTTC
CCTCTCCTGCAGGGCCAGTC

TGTCCACTCCCAGGTCCAA
TGGGTCACTCAGTGGTTTCT

TCTCCACAGGTGTCCACT
AGACTCTTACCGCCAACTAC

CTGCACCTCGGTTCTATCGA
ACTGGACCTGGATCCGCCA

CCCAGGTCCAACTGCAC
TTAGCCTGGTACCAGCAGAA

TTGAATTCCACCATGGGAT
GCCCCCAGGAAAGGGGCTG

CTCGGTTCTATCGATTGA
ACCTGGCCAGGCTCCCAGAC

GGTCATGTATCATCCTTTTT
GAGTGGATTGGGGAAACCA

ATTCCACCATGGGATGG
TCCTCATCTATGGTGCATCC

CTAGTAGCAACTGCAACCG
ATCATTTTGGAAGCACCGA

TCATGTATCATCCTTTTT
AAGAGGGCCGCTGGCATCC

GTGTACATTCCCAGGTGCA
CTACAAGGCGTCCCTCAAG

CTAGTAGCAACTGCAAC
CAGACAGGTTCAGTGGCAG

GCTACAGCAGTGGGGCGCA
AGTCGAGTCACCATATCAG

CGGTGTACATTCAGAAA
TGGGTCTGGGACAGACTTCA

GGACTGTTGAAGCCTTCGG
TAGGCATGTCCAGGAACCA

TTGTGTTGACGCAGTCTC
CTCTCAGCATCACCAGACTG

AGACCCTGTCCCTCACCTGC
ATTTTCCCTGAAGGTGACTT

CAGGCACCCTGTCTTTGT
GAGCCTGAAGATTTTGCAGT

GCTGTCTCTGGTGGGTCACT
CTCTGACCGCCGCGGACAC

CTCCAGGGGAAAGAGCC
GTATTACTGTCAGCAGTATC

CAGTGGTTTCTACTGGACCT
GGCTGTGTATTACTGTGCG

ACCCTCTCCTGCAGGGCC
ATACTACACCTCGGACTTTC

GGATCCGCCAGCCCCCAGG
AGAAAGCCCCTCCTCTACA

AGTCAGACTCTTACCGCC
GGCGGAGGGACCAAGGTGG

AAAGGGGCTGGAGTGGATT
GTGACTTTTCTCCTGGTGCT

AACTACTTAGCCTGGTAC
AGATCAA (SEQ ID NO:

GGGGAAACCAATCATTTTG
TTTGATATCTGGGGCCAAG

CAGCAGAAACCTGGCCA
344)

GAAGCACCGACTACAAGGC
GGACAATGATCGTAGTCTC

GGCTCCCAGACTCCTCAT

GTCCCTCAAGAGTCGAGTC
TTCAG (SEQ ID NO:

CTATGGTGCATCCAAGA

ACCATATCAGTAGGCATGT
3642)

GGGCCGCTGGCATCCCA

CCAGGAACCAATTTTCCCT

GACAGGTTCAGTGGCAG

GAAGGTGACTTCTCTGACC

TGGGTCTGGGACAGACT

GCCGCGGACACGGCTGTGT

TCACTCTCAGCATCACCA

ATTACTGCGCGAGAAAGCC

GACTGGAGCCTGAAGAT

CCTCCTCTACAGTGACTTTT

TTTGCAGTGTATTACTGT

CTCCTGGTGCTTTTGATGTC

CAGCAGTATCATACTAC

TGGGGCCAAGGGACAATGG

ACCTCGGACTTTCGGCG

TCACCGTCTCTTCAGCGTCG

GAGGGACCAAGGTGGAG

ACCAAGGGCCCATCGGTCT

ATCAAACGTACGGTGGC

TCCCCCTGGCACCCTCCTCC

TGCACCATCTGTCTTCAT

AAGAGCACCTCTGGGGGCA

CTTCCCGCCATCTGATGA

CAGCGGCCCTGGGCTGCCT

GCAGTTGAAATCTGGAA

GGTCAAGGACTACTTCCCC

CTGCCTCTGTTGTGTGCC

GAACCTGTGACGGTCTCGT

TGCTGAATAACTTCTATC

GGAACTCAGGCGCCCTGAC

CCAGAGAGGCCAAAGTA

CAGCGGCGTGCACACCTTC

CAGTGGAAGGTGGATAA

CCGGCTGTCCTACAGTCCTC

CGCCCTCCAATCGGGTA

AGGACTCTACTCCCTCAGC

ACTCCCAGGAGAGTGTC

AGCGTGGTGACCGTGCCCT

ACAGAGCAGGACAGCAA

CCAGCAGCTTGGGCACCCA

GGACAGCACCTACAGCC

GACCTACATCTGCAACGTG

TCAGCAGCACCCTGACG

AATCACAAGCCCAGCAACA

CTGAGCAAAGCAGACTA

CCAAGGTGGACAAGAGAGT

CGAGAAACACAAAGTCT

TGAGCCCAAATCTTGTGAC

ACGCCTGCGAAGTCACC

AAAACTCACACATGCCCAC

CATCAGGGCCTGAGCTC

CGTGCCCAGCACCTGAACT

GCCCGTCACAAAGAGCT

CCTGGGGGGACCGTCAGTC

TCAACAGGGGAGAGTGT

TTCCTCTTCCCCCCAAAACC

TAGAAGCTTGGCCGCCA

CAAGGACNNCCTCATGATC

TGGCCCAACTTGTTTATT

TCCCGGACCCCTGNNNCAC

GCAGCTTATAATGGNTA

ATGCGTGNNNNGACGTGAG

CAAATAAAGCAATAGCA

CCACGAANANCCTGANTCA

TCACAAATTTCACAAAT

GTCANTGGNACGNNGNNGG

AAAGCATTTTTTTCACTG

CNNNNNNGCATANNCNNAN

CATTCTAGTTGTGGNTNG

AAGCNNNGGANGANCANT

TCCAAACTCATCAATGN

ANANAGCACGTACCGNGNN

ATCTTATCATGTCTGGAT

NCAGCGTCNTNNNGTCNGN

CGGNNNNNNCGNNNCAG

NCCNGANTGNNGAATGNN

CNNNNNNNNAANNNNN

(SEQ ID NO: 3641)

NNTGAANNNNCTNGNNG

TACTNCTGAGNGAANAA

CNTCNGNNNANNNNNNN

NCAGTAGGGNNNNNGAA

GTCCCNNGGNNC (SEQ

ID NO: 3643)

V-C063
NNNNNNNNTNTGNATCNTA
CAGGTGCAGCTACAGCAGT
COV107_
NNNNNNNNNTATGNATC
GAAATTGTGTTGACGCAGTC
COV107_

CACATACGATTTAGGTGAC
GGGGCGCAGGACTGTTGAA
P2_C7
NTACACATACGATTTAG
TCCAGGCACCCTGTCTTTGT
P2_C7

ACTATAGAATAACATCCAC
GCCTTCGGAGACCCTGTCC

GTGACACTATAGAATAA
CTCCAGGGGAAAGAGCCAC

TTTGCCTTTCTCTCCACAGG
CTCACCTGCGCTGTCTCTGG

CATCCACTTTGCCTTTCT
CCTCTCCTGCAGGGCCAGTC

TGTCCACTCCCAGGTCCAA
TGGGTCACTCAGTGGTTTCT

CTCCACAGGTGTCCACTC
AGACTGTTTCCGCCAACTAC

CTGCACCTCGGTTCTATCGA
ACTGGACCTGGATCCGCCA

CCAGGTCCAACTGCACC
TTAGCCTGGTACCAGCAGAA

TTGAATTCCACCATGGGAT
GCCCCCAGGAAAGGGGCTG

TCGGTTCTATCGATTGAA
AGCTGGCCAGGCTCCCAGA

GGTCATGTATCATCCTTTTT
GAGTGGATTGGGGAAACCA

TTCCACCATGGGATGGTC
CTCCTCATCTATGGTGCATC

CTAGTAGCAACTGCAACCG
ATCATTTTGGAAGCACCGA

ATGTATCATCCTTTTTCT
CAAGAGGGCCACTGGCATC

GTGTACATTCCCAGGTGCA
CTACAAGCCGTCCCTCAAG

AGTAGCAACTGCAACCG
CCAGACAGGTTCAGTGGCA

GCTACAGCAGTGGGGCGCA
AGTCGAGTCACCATATCAG

GTGTACATTCAGAAATT
GTGGGTCTGGGACAGACTTC

GGACTGTTGAAGCCTTCGG
TAGACATGTCCAGGAACCA

GTGTTGACGCAGTCTCCA
ACTCTCAGCATCAGCAGACT

AGACCCTGTCCCTCACCTGC
GTTCTCCCTGAAGGTGACCT

GGCACCCTGTCTTTGTCT
GGAGCCTGAAGATTTTGCTG

GCTGTCTCTGGTGGGTCACT
CTGTGACCGCCGCGGACAC

CCAGGGGAAAGAGCCAC
TGTATTACTGTCAGCAGTAT

CAGTGGTTTCTACTGGACCT
GGCTGTTTATTACTGTGCGA

CCTCTCCTGCAGGGCCA
GTTACTACACCTCGGACTTT

GGATCCGCCAGCCCCCAGG
GAAAGCCCCTCCTCCACAG

GTCAGACTGTTTCCGCCA
CGGCGGAGGGACCAAGGTG

AAAGGGGCTGGAGTGGATT
TGACTTATCTCCTGGTGCTT

ACTACTTAGCCTGGTACC
GAGATCAA (SEQ ID NO:

GGGGAAACCAATCATTTTG
TTGATATCTGGGGCCAAGG

AGCAGAAAGCTGGCCAG
3648)

GAAGCACCGACTACAAGCC
GACAATGGTCGCCGTCTCTT

GCTCCCAGACTCCTCATC

GTCCCTCAAGAGTCGAGTC
CAG (SEQ ID NO:

TATGGTGCATCCAAGAG

ACCATATCAGTAGACATGT
3646)

GGCCACTGGCATCCCAG

CCAGGAACCAGTTCTCCCT

ACAGGTTCAGTGGCAGT

GAAGGTGACCTCTGTGACC

GGGTCTGGGACAGACTT

GCCGCGGACACGGCTGTTT

CACTCTCAGCATCAGCA

ATTACTGTGCGAGAAAGCC

GACTGGAGCCTGAAGAT

CCTCCTCCACAGTGACTTAT

TTTGCTGTGTATTACTGT

CTCCTGGTGCTTTTGATATC

CAGCAGTATGTTACTAC

TGGGGCCAAGGGACAATGG

ACCTCGGACTTTCGGCG

TCACCGTCTCTTCAGCGTCG

GAGGGACCAAGGTGGAA

ACCAAGGGCCCATCGGTCT

ATCAAACGTACGGTGGC

TCCCCCTGGCACCCTCCTCC

TGCACCATCTGTCTTCAT

AAGAGCACCTCTGGGGGCA

CTTCCCGCCATCTGATGA

CAGCGGCCCTGGGCTGCCT

GCAGTTGAAATCTGGAA

GGTCAAGGACTACTTCCCC

CTGCCTCTGTTGTGTGCC

GAACCTGTGACGGTCTCGT

TGCTGAATAACTTCTATC

GGAACTCAGGCGCCCTGAC

CCAGAGAGGCCAAAGTA

CAGCGGCGTGCACACCTTC

CAGTGGAAGGTGGATAA

CCGGCTGTCCTACAGTCCTC

CGCCCTCCAATCGGGTA

AGGACTCTACTCCCTCAGC

ACTCCCAGGAGAGTGTC

AGCGTGGTGACCGTGCCCT

ACAGAGCAGGACAGCAA

CCAGCAGCTTGGGCACCCA

GGACAGCACCTACAGCC

GACCTACATCTGCAACGTG

TCAGCAGCACCCTGACG

AATCACAAGCCCAGCAACA

CTGAGCAAAGCAGACTA

CCAANGTGNACAAGAGAGT

CGAGAAACACAAAGTCT

TGAGCCCNNATCTTGTGAC

ACGCCTGCGAAGTCACC

ANAACTCACACATGCNCNC

CATCAGGGCCTGAGCTC

CGTGCNCNNCACCTGANNN

GCCCGTCACAAAGAGCT

CCNNNGGGGGANNNNNCA

TCAACAGGGGAGAGTGT

NNGTTCTTCTTCCTCCTCCC

TAGAAGCTTGGCCGCCA

CCCCAAAANCNNANGACAN

TGGCCCAACTTGTTTATT

CCTCATGATCTCCCNGACCC

GCAGCTTATAATGGTTAC

CTGAGGTCACATGCGTGGT

AAATAAAGCAATAGCAT

GGNGGACGTGAGCNACGAN

CACAAATTTCACAAATA

GACCCNGNNNCAANTTCAN

AAGCATTTTTTTCACTGC

TGGNACNNNGNCGGCGTGN

ATTCTAGTTGTGGTTTGT

AGNTGCANANGNNAANAN

CCAAACTCATCAATGTAT

AANNCNNNGGGNANNANC

CTTATCATGTCTGGNTCG

ANTANACAGCNCGNNNCNN

GGAATTAATTCGGCGCA

NNNNGGNNNNNNNCNTNN

GCNCNTGNNNTGNAATA

NCNNNCNNCNNNNNNGNA

NNNTGAAAGANNANNNN

NTNNNNNGNAATGNNNNN

NNNNANNNTGAGNGAAN

NNANNNN (SEQ ID

ACNTCTNNGANNNNNGT

NO: 3645)

CANTNGGNNGNNNNGTC

CCAGNNNCCCNNNNGNA

NAANNNTGNAAGNNNNN

NNNNNTNNNNNNCANNN

NN (SEQ ID NO:

3647)

V-C064
NNNNNNNNNNNNNNNTCNT
GAGGTGCAGCTGGTGGAGT
COV047_
NNNNNNNNTATGNATNN
CAGTCTGTGCTGACTCAGCC
COV047_

ACACATACGATTTAGGTGA
CTGGGGGAGGCTTGGTCCA
P4_A3
TACACATACGATTTAGGT
TGCCTCCGTGTCTGGGTCTC
P4_A3

CACTATAGAATAACATCCA
GCCGGGGGGGTCCCTGAGA

GACACTATAGAATAACA
CTGGACAGTCGATCACCATC

CTTTGCCTTTCTCTCCACAG
CTCTCCTGTGCAGCCTCTGG

TCCACTTTGCCTTTCTCT
TCCTGCACTGGAACCAGCAA

GTGTCCACTCCCAGGTCCA
ATTCAGTGTCAGCACCAAG

CCACAGGTGTCCACTCCC
TGATGTTGGGAGTTATACCC

ACTGCACCTCGGTTCTATCG
TACATGACATGGGTCCGTC

AGGTCCAACTGCACCTC
TTGTCTCCTGGTACCAACAG

ATTGAATTCCACCATGGGA
AGGCTCCAGGGAAGGGGCT

GGTTCTATCGATTGAATT
TACCCAGGCAAAGCCCCCA

TGGTCATGTATCATCCTTTT
GGAGTGGGTCTCAGTTCTTT

CCACCATGGGATGGTCA
AGCTCTTAATTTTTGAGGTC

TCTAGTAGCAACTGCAACC
ACAGCGGTGGTAGTGATTA

TGTATCATCCTTTTTCTA
ACTAAGCGGTCCTCAGGGAT

GGTGTACATTCTGAGGTGC
CTACGCAGACTCCGTGAAG

GTAGCAACTGCAACCGG
TTCTAATCGCTTCTCTGGTTC

AGCTGGTGGAGTCTGGGGG
GGCAGATTCACCATCTCCA

TTCCTGGGCCCAGTCTGC
CAAGTCTGGCAACACGGCCT

AGGCTTGGTCCAGCCGGGG
GAGACAATTCCAAGAACGC

CCTGACTCAGCCTGCCTC
CCCTGACAATCTCTGGGCTC

GGGTCCCTGAGACTCTCCT
TTTATATCTTCAAATGAACA

CGTGTCTGGGTCTCCTGG
CAGGGTGAAGACGAGGCTG

GTGCAGCCTCTGGATTCAG
GCTTGAGAGTCGAGGACAC

ACAGTCGATCACCATCTC
ATTATTATTGCTGCTCATAT

TGTCAGCACCAAGTACATG
GGGTGTTTATTACTGTGCCA

CTGCACTGGAACCAGCA
GCAGGTGCTAGCACTTTCGT

ACATGGGTCCGTCAGGCTC
GAGACTCGTCGGAAGTCCG

ATGATGTTGGGAGTTAT
GTTCGGCGGAGGGACCAAG

CAGGGAAGGGGCTGGAGTG
TGACCACCCCGGGCACCCA

ACCCTTGTCTCCTGGTAC
CTGACCGTCCTAG (SEQ

GGTCTCAGTTCTTTACAGCG
GGGCGCTCGGTGGGGGCTT

CAACAGTACCCAGGCAA
ID NO: 3651)

GTGGTAGTGATTACTACGC
TTGATATCTGGGGCCAAGG

AGCCCCCAAGCTCTTAAT

AGACTCCGTGAAGGGCAGA
GACAATGGTCACCGTCTCTT

TTTTGAGGTCACTAAGCG

TTCACCATCTCCAGAGACA
CAG (SEQ ID NO: 311)

GTCCTCAGGGATTTCTAA

ATTCCAAGAACGCTTTATAT

TCGCTTCTCTGGTTCCAA

CTTCAAATGAACAGCTTGA

GTCTGGCAACACGGCCT

GAGTCGAGGACACGGGTGT

CCCTGACAATCTCTGGGC

TTATTACTGTGCCAGAGACT

TCCAGGGTGAAGACGAG

CGTCGGAAGTCCGTGACCA

GCTGATTATTATTGCTGC

CCCCGGGCACCCAGGGCGC

TCATATGCAGGTGCTAG

TCGGTGGGGGCTTTTGATAT

CACTTTCGTGTTCGGCGG

CTGGGGCCAAGGGACAATG

AGGGACCAAGCTGACCG

GTCACCGTCTCTTCAGCGTC

TCCTAGGTCAGCCCAAG

GACCAAGGGCCCATCGGTC

GCTGCCCCCTCGGTCACT

TTCCCCCTGGCACCCTCCTC

CTGTTCCCACCCTCGAGT

CAAGAGCACCTCTGGGGGC

GAGGAGCTTCAAGCCAA

ACAGCGGCCCTGGGCTGCC

CAAGGCCACACTGGTGT

TGGTCAAGGACTACTTCCC

GTCTCATAAGTGACTTCT

CGAACCTGTGACGGTCTCG

ACCCGGGAGCCGTGACA

TGGAACTCAGGCGCCCTGA

GTGGCCTGGAAGGCAGA

CCAGCGGCGTGCACACCTT

TAGCAGCCCCGTCAAGG

CCCGGCTGTCCTACAGTCCT

CGGGAGTGGAGACCACC

CAGGACTCTACTCCCTCAG

ACACCCTCCAAACAAAG

CAGCGTGGTGACCGTGCCC

CAACAACAAGTACGCGG

TCCAGCAGCTTGGGCACCC

CCAGCAGCTACCTGAGC

AGACCTACATCTGCAACGT

CTGACGCCTGAGCAGTG

GAATCACAAGCCCNGCAAC

GAAGTCCCACAGAAGCT

ACCCAAGNGGACAANANA

ACAGCTGCCAGGTCACG

GATGAGNCCNNATNTTGTG

CATGAAGGGAGCACCGT

NNNAAAATNNNNNATGNNC

GGAGAAGACAGTGGCCC

TCCCCGNNNNNNNCNANNN

CTACAGAATGTTCATAG

NNNNNNGGGGGGGGGNAA

AAGCTTGGCCGCCATGG

CNTTNNTCTTTNNNNNNNC

CCCAACTTGTTTATTGCA

CCCCNAAAAANNNAANNN

GCTTATAATGGTTACAA

NNNCNNTNNTGNNNNNCNN

ATAAAGCAATAGCATCA

NNNCCNNNNANGTCNNNNN

CAAATTTCACAAATAAA

NGNGGNNGNNGNNNGTGA

GCATTTTTTTCACTGCAT

CCNNNNAAANNCCTNNNNG

TCTAGTTGTGGTTTGTCC

TCAANTTCAANNGGTNNNN

AAACTCATCAATGTATCT

GNANNN (SEQ ID NO:

TATCATGTCTGGATCGGG

3649)

AATTAATTCGGCGCAGC

ACCATGGNCTGAAATAN

CTCTGAAAGAGGACTTG

GNTAGGTACCTTCTGAN

CGGAAANNACCATCTGN

NGAATGNNTGTCANTTA

GGGTGNNGAAAGTCCCC

AGGNNNCCCNNNNNN

(SEQ ID NO: 3650)

V-C065
NNNNNNNNNNNNNNNNNN
CAGGTGCAGCTGGTGCAGT
COV072_
NNNNNNCNNNATGNATN
GAAATTGTGTTGACGCAGTC
COV072_

NNTACNCATACGATTTAGG
CTGGGGCTGAGGTGAAGAA
P3_D12
NTACNCATACGATTTAG
TCCAGGCACCCTGTCTTTGT
P3_D12

TGACACTATAGAATAACAT
GCCTGGGTCGTCGGTGAAG

GTGACACTATAGAATAA
CTCCAGGGGAAAGAGCCAC

CCACTTTGCCTTTCTCTCCA
GTCTCCTGCAAGGCTTCTGG

CATCCACTTTGCCTTTCT
CCTCTCCTGCAGGGCCAGTC

CAGGTGTCCACTCCCAGGT
AGGCACCTTCAGTAGCTAT

CTCCACAGGTGTCCACTC
AGAGTGTTAGCAGCACCTAC

CCAACTGCACCTCGGTTCTA
GCTATCAACTGGGTGCGAC

CCAGGTCCAACTGCACC
TTAGCCTGGTACCAGCAGAA

TCGATTGAATTCCACCATG
AGGCCCCTGGACAAGGGCT

TCGGTTCTATCGATTGAA
ACCTGGCCAGGCTCCCAGGC

GGATGGTCATGTATCATCCT
TGAGTGGATGGGAAGGATC

TTCCACCATGGGATGGTC
TCCTCATCTATGGTGCATCC

TTTTCTAGTAGCAACTGCAA
ATCCCTATCGTTGGTATAGC

ATGTATCATCCTTTTTCT
AGCAGGGCCACTGGCATCC

CCGGTGTACATTCCCAGGT
AAACTACGCACAGAAGTTC

AGTAGCAACTGCAACCG
CAGACAGGTTCAGTGGCAG

GCAGCTGGTGCAGTCTGGG
CAGGGCAGAGTCACGATTA

GTGTACATTCAGAAATT
TGGGTCTGGGACAGACTTCA

GCTGAGGTGAAGAAGCCTG
CGGCGGACAAATCCTCGAG

GTGTTGACGCAGTCTCCA
CTCTCACCATCAGCAGACTG

GGTCGTCGGTGAAGGTCTC
CACAGCCTACATGGAGCTG

GGCACCCTGTCTTTGTCT
GAGCCTGAAGATTTTGCAGT

CTGCAAGGCTTCTGGAGGC
AGCAGCCTGAGATCTGAGG

CCAGGGGAAAGAGCCAC
GTATTACTGTCAGCAGTATG

ACCTTCAGTAGCTATGCTAT
ACACGGCCGTGTATTACTG

CCTCTCCTGCAGGGCCA
GTAGCTCACCGTGGACGTTC

CAACTGGGTGCGACAGGCC
TGCGAGAGATCTCCTGGAC

GTCAGAGTGTTAGCAGC
GGCCAAGGGACCAAGGTGG

CCTGGACAAGGGCTTGAGT
CCCCAGCTAGATGATGCTTT

ACCTACTTAGCCTGGTAC
AAATCAAAC (SEQ ID

GGATGGGAAGGATCATCCC
TGATATCTGGGGCCAAGGG

CAGCAGAAACCTGGCCA
NO: 3655)

TATCGTTGGTATAGCAAAC
ACAATGGTCACCGTCTCTTC

GGCTCCCAGGCTCCTCAT

TACGCACAGAAGTTCCAGG
AG (SEQ ID NO: 3653)

CTATGGTGCATCCAGCA

GCAGAGTCACGATTACGGC

GGGCCACTGGCATCCCA

GGACAAATCCTCGAGCACA

GACAGGTTCAGTGGCAG

GCCTACATGGAGCTGAGCA

TGGGTCTGGGACAGACT

GCCTGAGATCTGAGGACAC

TCACTCTCACCATCAGCA

GGCCGTGTATTACTGTGCG

GACTGGAGCCTGAAGAT

AGAGATCTCCTGGACCCCC

TTTGCAGTGTATTACTGT

AGCTAGATGATGCTTTTGAT

CAGCAGTATGGTAGCTC

ATCTGGGGCCAAGGGACAA

ACCGTGGACGTTCGGCC

TGGTCACCGTCTCTTCAGCG

AAGGGACCAAGGTGGAA

TCGACCAAGGGCCCATCGG

ATCAAACGTACGGTGGC

TCTTCCCCCTGGCACCCTCC

TGCACCATCTGTCTTCAT

TCCAAGAGCACCTCTGGGG

CTTCCCGCCATCTGATGA

GCACAGCGGCCCTGGGCTG

GCAGTTGAAATCTGGAA

CCTGGTCAAGGACTACTTC

CTGCCTCTGTTGTGTGCC

CCCGAACCTGTGACGGTCT

TGCTGAATAACTTCTATC

CGTGGAACTCAGGCGCCCT

CCAGAGAGGCCAAAGTA

GACCAGCGGCGTGCACACC

CAGTGGAAGGTGGATAA

TTCCCGGCTGTCCTACAGTC

CGCCCTCCAATCGGGTA

CTCAGGACTCTACTCCCTCA

ACTCCCAGGAGAGTGTC

GCAGCGTGGTGACCGTGCC

ACAGAGCAGGACAGCAA

CTCCAGCAGCTTGGGCACC

GGACAGCACCTACAGCC

CAGACCTACATCTGCAACG

TCAGCAGCACCCTGACG

TGAATCACAAGCCCAGCAA

CTGAGCAAAGCAGACTA

CACCNNNTGGACAAGAGAG

CGAGAAACACAAAGTCT

TTGAGCCCAAATCTTGTGA

ACGCCTGCGAAGTCACC

CAAACTCACACATGCCCAC

CATCAGGGCCTGAGCTC

CGTGCCCAGCACCTGAACT

GCCCGTCACAAAGAGCT

CCTGGGGGGACCGTCAGTC

TCAACAGGGGAGAGTGT

TTCCTCTNNCCCCAAACCCA

TAGAAGCTTGGCCGCCA

ANGACNCCCTCATGATCNC

TGGCCCAACTTGTTTATT

CCNGANCCCTGANGNCNCN

GCAGCTTATAATGGTTAC

TGCGTGNNGGNGGANGNGN

AAATAAAGCAATAGCAT

GNNNNNANNANCCNNNNN

CACAAATTTCACAAATA

NNNCCNNGANNNNNAANN

AAGCATTTTTTTCACTGC

TCNNCTGGNTACNNNGGAC

ATTCTANTTGTGGTTTGN

NGCNNNGNNGGTGCATAAT

CCAAACTCATCAATGTAT

GCCANNANNAANCCNNGG

CTTATCATGTCTGGATCN

NAGNANNNNNNNNAACNG

GGNATTAATTCNGCGCA

NNCGTTNCNNNNNN (SEQ

NCACCATGNNCTGAAAT

ID NO: 3652)

NACCTCTGAAANAGGAA

CNTGNNNAAGGTACNNT

CTGAAGCCGNANNNNCA

TCNNNNGAANGNNGGTC

AAATNNNGGGGNNNGNA

ANGNNN (SEQ ID NO:

3654)

TABLE 16

Crystallographic data collection and refinement

statistics for C105 Fab structure (related to FIG. 21)

C105 Fab

(12-1, SSRL)

PDB ID
XXXX

Data collection^a

Space group
1222

Unit cell (Å)
67.4, 120.1, 123.3

α, β, γ (°)
90, 90, 90

Wavelength (Å)
1.0

Resolution (Å)
38.9-1.80 (1.84-1.80)

Unique Reflections
46,713 (2752)

Completeness (%)
100 (99.8)

Redundancy
6.8 (6.5)

CCl/2 (%)
98.8 (54.1)

<I/σI>
5.7 (1.2)

Mosaicity (°)
0.19

Rmerge (%)
18.1 (157)

Rpim (%)
7.9 (70.5)

Wilson B -factor
16.8

Refinement and Validation

Resolution (Å)
38.9-1.80

Number of atoms

Protein
3,132

Ligand
10

Waters
477

Rwork/Rfree (%)
18.7/21.6

R.m.s. deviations

Bond lengths (Å)
0.006

Bond angles (°)
0.853

MolProbity score
1.29

Clashscore (all atom)
4.2

Poor rotamers (%)
0

Ramachandran plot

Favored (%)
97.6

Allowed (%)
2.4

Disallowed (%)
0

Average B -factor (Å)
27.1

^aNumbers in parentheses correspond to the highest resolution shell

TABLE 16

Cryo-EM data collection and refinement statistics

for C105-S complex structure (related to FIG. 21).

C105
C105

SARS-CoV-2
SARS-CoV-2

P D B
S 2P
S 2P

E M D
(state 1)
(state 2)

Microscope
Titan Krios
Titan Krios

Camera
GatanK3
GatanK3

Summit
Summit

Magnification
105,000x
105,000x

Voltage (kV)
300
300

Recording mode
counting
counting

Dose rate (e−/pixel/s)
22.1
22.1

Electron dose (e−/Å²)
60
60

Defocus range (μm)
1.0-2.5
1.0-2.5

Pixel size (Å)
0.418
0.418

(super resolution);
(super resolution);

0.836 (binned)
0.836 (binned)

Micrographs collected
5,940
5,940

Micrographs used
5,336
5,336

Total extracted particles
71,289
71,289

Refined particles
37,615
14,119

Symmetry imposed
C1
C3

Nominal Resolution (Å)

FSC 0.5
3.90/3.60
4.30/3.90

(unmasked/masked)

FSC 0.143
3.40/3.20
3.70/3.50

(unmasked · masked)

Map sharpening B -factor

Refinement and Validation

Number of atoms

Protein
25,973

Ligand
711

MapCC (global/local)
0.86/0.84

R.m.s. deviations

Bond lengths (Å)
0.008

Bond angles (°)
0.812

MolProbity score
2.17

Clashscore (all atom)
13.6

Poor rotamers (%)
0.04

Ramachandran plot

Favored (%)
90.9

Allowed (%)
9

Disallowed (%)
461

TABLE 17

S protein mutations found in different

SARS-CoV-2 isolates (related to FIG. 22)

Frequency

Mutation
Count
(%)
Location

D614G
9688
63.2
S1 domain D

P1263L
115
0.7
S2 cytoplasmic tail

L5F
91
0.6
signal sequence

D936Y
88
0.6
S2 HR1

L54F
58
0.4
S1 domain A

G1124V
56
0.4
S2

N439K
38
0.2
S1 domain B (RBD)

H49Y
35
0.2
S1 domain A

L18F
31
0.2
S1 domain A

L8V
30
0.2
signal sequence

A831V
29
0.2
S2

D839Y
28
0.2
S2

V483A
28
0.2
S1 domain B (RBD)

Q675H
24
0.2
S1 domain D

S50L
24
0.2
S1 domain A

S943P
22
0.1
S2 HR1

A1078S
21
0.1
S2

R21I
19
0.1
S1 domain A

V367F
18
0.1
S1 domain B (RBD)

T29I
18
0.1
S1 domain A

List of SARS-CoV-2 spike mutations with a frequency ≥0.1% in a set of 15335 isolates downloaded from the Global Initiative for Sharing All Influenza Data (GISAID) SARS-CoV-2 sequence database on May 3, 2020 (Elbe and Buckland-Merrett, 2017; Shu and McCauley, 2017). The genomes were processed with the nextstrain augur pipeline (https://github.com/nextstrain/augur) (Hadfield et al., 2018), using MAFFT v7.464 (Katoh and Standley, 2013) for sequence alignment and FastTree (Price et al., 2010) to generate a phylogenetic tree. The resulting data were then analyzed with a custom Swift program.

REFERENCES

Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, L W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213-221.

Bell, J. M., Chen, M., Baldwin, P. R., and Ludtke, S. J. (2016). High resolution single particle refinement in EMAN2.1. Methods 100, 25-34.

Bianchi, M., Turner, H. L., Nogal, B., Cottrell, C. A., Oyen, D., Pauthner, M., Bastidas, R., Nedellec, R., McCoy, L. E., Wilson, I. A., et al. (2018). Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. Immunity 49, 288-300 e288.

Briney, B., Inderbitzin, A., Joyce, C., and Burton, D. R. (2019). Commonality despite exceptional diversity in the baseline human antibody repertoire. Nature 566, 393-397.

Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Tones, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. bioRxiv 10.1101/2020.05.12.088716.

Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020). Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell 10.1016/j.cell.2020.05.025. Chen, V. B., Arendall, W. B., 3rd, Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010). MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66, 12-21. Chen, X., Li, R., Pan, Z., Qian, C., Yang, Y., You, R., Zhao, J., Liu, P., Gao, L., Li, Z., et al. (2020). Human monoclonal antibodies block the binding of SARS-CoV-2 Spike protein to angiotensin converting enzyme 2. medRxiv 10.1101/2020.04.06.20055475

Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020). A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv 10.1101/2020.05.08.083964. Crawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, A. M., Veesler, D., Murphy, M., et al. (2020). Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays. bioRxiv 10.1101/2020.04.20.051219.

de Wit, E., van Doremalen, N., Falzarano, D., and Munster, V. J. (2016). SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14, 523-534.

Dunbar, J., Krawczyk, K., Leem, J., Baker, T., Fuchs, A., Georges, G., Shi, J., and Deane, C. M. (2014). SAbDab: the structural antibody database. Nucleic Acids Res 42, D1140-1146. Elbe, S., and Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall 1, 33-46.

Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010). Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501.

Fung, T. S., and Liu, D. X. (2019). Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol 73, 529-557.

Goddard, T. D., Huang, C. C., and Ferrin, T. E. (2007). Visualizing density maps with UCSF Chimera. J Struct Biol 157, 281-287.

Graham, R. L., Donaldson, E. F., and Baric, R. S. (2013). A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11, 836-848.

Gralinski, L. E., and Baric, R. S. (2015). Molecular pathology of emerging coronavirus infections. The Journal of pathology 235, 185-195.

Gristick, H. B., von Boehmer, L., West, A. P., Jr., Schamber, M., Gazumyan, A., Golijanin, J., Seaman, M. S., Fatkenheuer, G., Klein, F., Nussenzweig, M. C., et al. (2016). Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat Struct Mol Biol 23, 906-915.

Gui, M., Song, W., Zhou, H., Xu, J., Chen, S., Xiang, Y., and Wang, X. (2017). Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res 27, 119-129.

Guindon, S., Dufayard, J. F., Lefort, V., Anisimova, M., Hordijk, W., and Gascuel, O. (2010). New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59, 307-321.

Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., and Neher, R. A. (2018). Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121-4123.

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280 e278.

Hwang, W. C., Lin, Y., Santelli, E., Sui, J., Jaroszewski, L., Stec, B., Farzan, M., Marasco, W. A., and Liddington, R. C. (2006). Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem 281, 34610-34616.

Ju, B., Zhang, Q., Ge, X., Wang, R., Yu, J., Ge, J., Lan, J., Yuan, J., Wang, H., Zhao, J., et al. (2020). Potent human neutralizing antibodies elicited 1 by SARS-CoV-2 infection. bioRxiv 10.1101/2020.03.21.990770.

Kabsch, W. (2010). XDS. Acta Crystallogr D Biol Crystallogr 66, 125-132.

Kane, M., Zang, T. M., Rihn, S. J., Zhang, F., Kueck, T., Alim, M., Schoggins, J., Rice, C. M., Wilson, S. J., and Bieniasz, P. D. (2016). Identification of Interferon-Stimulated Genes with Antiretroviral Activity. Cell Host Microbe 20, 392-405.

Katoh, K., and Standley, D. M. (2013). MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30, 772-780.

Kirchdoerfer, R. N., Bhandari, M., Martini, O., Sewall, L. M., Bangaru, S., Yoon, K.-J., and Ward, A. B. (2020). Structure and immune recognition of the porcine epidemic diarrhea virus spike protein. bioRxiv 10.1101/2020.02.18.955195.

Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S., McLellan, J. S., and Ward, A. B. (2016). Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118-121.

Kirchdoerfer, R. N., Wang, N., Pallesen, J., Wrapp, D., Turner, H. L., Cottrell, C. A., Corbett, K. S., Graham, B. S., McLellan, J. S., and Ward, A. B. (2018). Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Scientific reports 8, 15701.

Klein, J. S., and Bjorkman, P. J. (2010). Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 6, e1000908.

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Foley, B., Giorgi, E. E., Bhattacharya, T., Parker, M. D., et al. (2020). Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv 10.1101/2020.04.29.069054. Landau, M., Mayrose, I., Rosenberg, Y., Glaser, F., Martz, E., Pupko, T., and Ben-Tal, N. (2005). ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures. Nucleic Acids Res 33, W299-302.

Lefranc, M. P., Giudicelli, V., Duroux, P., Jabado-Michaloud, J., Folch, G., Aouinti, S., Carillon, E., Duvergey, H., Houles, A., Paysan-Lafosse, T., et al. (2015). IMGT®, the international ImMunoGeneTics information System® 25 years on. Nucleic Acids Res 43, D413-422.

Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450-454.

Li, Z., Tomlinson, A. C., Wong, A. H., Zhou, D., Desforges, M., Talbot, P. J., Benlekbir, S., Rubinstein, J. L., and Rini, J. M. (2019). The human coronavirus HCoV-229E S-protein structure and receptor binding. Elife 8.

Mastronarde, D. N. (2005). Automated electron microscope tomography using robust prediction of specimen movements. J Struct Biol 152, 36-51.

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007). Phaser crystallographic software. J Appl Crystallogr 40, 658-674.

Neuman, B. W., Kiss, G., Kunding, A. H., Bhella, D., Baksh, M. F., Connelly, S., Droese, B., Klaus, J. P., Makino, S., Sawicki, S. G., et al. (2011). A structural analysis of M protein in coronavirus assembly and morphology. J Struct Biol 174, 11-22.

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020). Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 9, 680-686.

Nogal, B., Bianchi, M., Cottrell, C. A., Kirchdoerfer, R. N., Sewall, L. M., Turner, H. L., Zhao, F., Sok, D., Burton, D. R., Hangartner, L., et al. (2020). Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines. Cell reports 30, 37553765 e3757.

Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et a !. (2020). Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620.

Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA 114, E7348-E7357. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004). UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25, 1605-1612.

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020). Structural and functional analysis of a potent sarbecovirus neutralizing antibody. Nature 10.1038/s41586-020-2349-y.

Plotkin, S. A. (2001). Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 20, 63-75.

Plotkin, S. A. (2008). Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47, 401-409.

Plotkin, S. A. (2010). Correlates of protection induced by vaccination. Clin Vaccine Immunol 17, 1055-1065.

Prabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X., Ji, X., and Dimitrov, D. S. (2006). Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 281, 15829-15836.

Premkumar, L., Segovia-Chumbez, B., Jadi, R., Martinez, D. R., Raut, R., Markmann, A., Conraby, C., Barbtelt, L., Weiss, S. C., Park, Y. J., et al. (2020). The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies. medRxiv 10.1101/2020.05.06.20093377.

Price, M. N., Dehal, P. S., and Arkin, A. P. (2010). FastTree 2—approximately maximum-likelihood trees for large alignments. PLoS One 5, e9490.

Punjani, A., Rubinstein, J. L., Fleet, D. J., and Brubaker, M. A. (2017). cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 14, 290-296.

Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020). The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody dependent enhancement. 10.1101/2020.04.10.036418.

Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H., Muller, M. A., Dijkman, R., Muth, D., Demmers, J. A., Zaki, A., Fouchier, R. A., et al. (2013). Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254.

Reguera, J., Santiago, C., Mudgal, G., Ordono, D., Enjuanes, L., and Casasnovas, J. M. (2012). Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies. PLoS Pathog 8, e1002859.

Robbiani, D. F., Gaebler, C., Muecksch, F., Cetrulo Lorenzi, J. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Finkin, S., Hagglof, T., et al. (2020). Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals. bioRxiv 10.1101/2020.05.13.092619. Rockx, B., Corti, D., Donaldson, E., Sheahan, T., Stadler, K., Lanzavecchia, A., and Baric, R. (2008). Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol 82, 3220-3235.

Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Abbott, R. K., Callaghan, S., Garcia, E., He, W.-t., Hurtado, J., Limbo, O., et al. (2020). Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model. bioRxiv 10.1101/2020.05.11.088674. Rohou, A., and Grigorieff, N. (2015). CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol 192, 216-221.

Scharf, L., Wang, H., Gao, H., Chen, S., McDowall, A. W., and Bjorkman, P. J. (2015). Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. Cell 162, 1379-1390.

Schoofs, T., Barnes, C. O., Suh-Toma, N., Golijanin, J., Schommers, P., Gruell, H., West, A. P., Jr., Bach, F., Lee, Y. E., Nogueira, L., et al. (2019). Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity 50, 1513-1529 e1519.

Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020). Characterization of neutralizing antibodies 1 from a SARS-CoV-2 infected individual. bioRxiv 10.1101/2020.05.12.091298.

Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., and Li, F. (2020). Structural basis of receptor recognition by SARS-CoV-2. Nature 10.1038/s41586-0202179-y.

Shang, J., Zheng, Y., Yang, Y., Liu, C., Geng, Q., Tai, W., Du, L., Zhou, Y., Zhang, W., and Li, F. (2018). Cryo-Electron Microscopy Structure of Porcine Deltacoronavirus Spike Protein in the Prefusion State. J Virol 92.

Shu, Y., and McCauley, J. (2017). GISAID: Global initiative on sharing all influenza data—from vision to reality. Euro Surveill 22.

Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., Lopez, R., McWilliam, H., Remmert, M., Soding, J., et al. (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7, 539.

Terwilliger, T. C., Adams, P. D., Afonine, P. V., and Sobolev, O. V. (2018). A fully automatic method yielding initial models from high-resolution cryo-electron microscopy maps. Nat Methods 15, 905-908.

Tortorici, M. A., and Veesler, D. (2019). Structural insights into coronavirus entry. Adv Virus Res 105, 93-116.

Tortorici, M. A., Walls, A. C., Lang, Y., Wang, C., Li, Z., Koerhuis, D., Boons, G. J., Bosch, B. J., Rey, F. A., de Groot, R. J., et al. (2019). Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol 26, 481-489.

Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292 e286.

Walls, A. C., Tortorici, M. A., Bosch, B. J., Frenz, B., Rottier, P. J. M., DiMaio, F., Rey, F. A., and Veesler, D. (2016). Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114-117.

Walls, A. C., Tortorici, M. A., Snijder, J., Xiong, X., Bosch, B. J., Rey, F. A., and Veesler, D. (2017). Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci USA 114, 11157-11162.

Walls, A. C., Xiong, X., Park, Y. J., Tortorici, M. A., Snijder, J., Quispe, J., Cameroni, E., Gopal, R., Dai, M., Lanzavecchia, A., et al. (2019). Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion. Cell 176, 1026-1039 e1015.

Wan, Y., Shang, J., Graham, R., Baric, R. S., and Li, F. (2020). Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 94.

Wang, C., Li, W., Drabek, D., Okba, N. M. A., van Haperen, R., Osterhaus, A. D. M. E., van Kuppeveld, F. J. M., Haagmans, B. L., Grosveld, F., and Bosch, B.-J. (2020). A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications 11.

Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., Zhang, Y., Leung, K., Lees, C. R., Zhou, T., Yassine, H. M., Kanekiyo, M., et al. (2015). Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 6, 7712.

Widjaja, I., Wang, C., van Haperen, R., Gutierrez-Alvarez, J., van Dieren, B., Okba, N. M. A., Raj, V. S., Li, W., Fernandez-Delgado, R., Grosveld, F., et al. (2019). Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg Microbes Infect 8, 516-530.

Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G., McCoy, A., et al. (2011). Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67, 235-242.

Wrapp, D., and McLellan, J. S. (2019). The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation. Journal of Virology 93, e00923-00919.

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C. L., Abiona, O., Graham, B. S., and McLellan, J. S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263.

Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020a). Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. bioRxiv 10.1101/2020.03.30.20047365.

Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hu, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., et al. (2020b). A new coronavirus associated with human respiratory disease in China. Nature 579, 265-269.

Wu, H., Pfarr, D. S., Tang, Y., An, L. L., Patel, N. K., Watkins, J. D., Huse, W. D., Kiener, P. A., and Young, J. F. (2005). Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350, 126-144.

Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020c). A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 10.1126/science.abc2241.

Xiong, H., Wu, Y., Cao, J., Yang, R., Ma, J., Qiao, X., Yao, X., Zhang, B., Zhang, Y., Hou, W., et al. (2020). Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells. 10.1101/2020.04.08.026948.

Xiong, X., Tortorici, M. A., Snijder, J., Yoshioka, C., Walls, A. C., Li, W., McGuire, A. T., Rey, F. A., Bosch, B. J., and Veesler, D. (2018). Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections. J Virol 92.

Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., and Zhou, Q. (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444-1448.

Yuan, M., Wu, N. C., Zhu, X., Lee, C. D., So, R. T. Y., Lv, H., Mok, C. K. P., and Wilson, I. A. (2020). A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science 10.1126/science.abb7269.

Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi, Y., et al. (2017). Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun 8, 15092.

Zhou, G., and Zhao, Q. (2020). Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci 16, 1718-1723.

Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.

Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020). Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. bioRxiv 10.1101/2020.05.12.091462.

Number	Name	Date	Kind
8546543	Lazar	Oct 2013	B2
9676863	Lo	Jun 2017	B2
10407502	Waksal et al.	Sep 2019	B2
11053304	Glanville	Jul 2021	B1
20060121580	Ter Meulen	Jun 2006	A1

Number	Date	Country
63119088	Nov 2020	US
63038384	Jun 2020	US
63032112	May 2020	US
63021387	May 2020	US
63016569	Apr 2020	US

Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications

Abstract

Description

Claims

CROSS-REFERENCE TO RELATED APPLICATIONS

STATEMENT REGARDING FEDERALLY FUNDED RESEARCH

US Referenced Citations (5)

Non-Patent Literature Citations (15)

Related Publications (1)

Provisional Applications (5)